ATCC[®] Cell Biology Catalogue 2007



Your **Discoveries**Begin with **Us**.



ATCC[®] Cell Biology Catalogue 2007



Your **Discoveries**Begin with **Us**.

Table of Contents

| | Section I: General Information | 5 |
|-------------------------------------|---|-----|
| | | |
| | Introduction | 6 |
| | How to use the catalog | 8 |
| | Reviewing the product description online | 9 |
| | How to search the ATCC website | 10 |
| | Cell biology collections | 12 |
| | Placing an order | 13 |
| | Distributors | 14 |
| | Depositing with ATCC | 15 |
| | Section II: Cell Culture Bioproducts | 17 |
| | High-performance liquid media | 18 |
| | High-performance sera | 20 |
| | Media supplements and antibiotics | 21 |
| | Reagents, buffers, and stains | 22 |
| a land | Extracellular matrix products | 23 |
| | Hybridoma development and cryopreservation | 24 |
| | MTT Cell Proliferation Assay | 25 |
| | ELF® Phosphatase Detection Kit | 26 |
| | EL Thosphatase Detection Nit | |
| | Section III: Cell Line Indexes | 29 |
| | Alphanumeric | 30 |
| | Tissue source | 104 |
| | Species other than human, mouse and rat | 123 |
| | Hybridomas | 130 |
| | Tumor cell lines by disease | 153 |
| | Tumor cell lines from metastatic sites | 170 |
| | Tumor/normal matched cell line pairs | 176 |
| | Stem cells | 178 |
| W. W. W. Ale also also described to | Cell lines used as tools and models | 181 |
| | Neurobiology | 186 |
| | Genetic variant fibroblasts | 189 |
| | Immortalized cells | 192 |
| | Genes and bioactive compounds | 193 |
| | deries and bloactive compounds | 175 |
| | Section IV: Technical Information | 259 |
| | Getting started with an ATCC cell line | 260 |
| | Cell growth and propagation | 261 |
| | Complete growth media | 267 |
| | Culture vessels and surfaces | 272 |
| | Cryopreservation | 274 |
| | Contamination | 277 |
| (a) | Biosafety | 278 |
| | Glossary | 279 |
| Think I have | Formulations of media not available from ATCC | 282 |
| | References | 284 |
| | Cooperation partners | 285 |
| | Disclaimers | 286 |
| | Material Transfer Agreement | 287 |
| | 3 | |



Section I: General Information



Introduction

How to use the catalog

Reviewing the product description online

How to search the ATCC website

Cell biology collections

Placing an order

Distributors

Depositing with ATCC



Introduction

Choose ATCC cell lines with confidence

Every ATCC cell line and hybridoma comes with comprehensive authentication and quality assurance testing and is backed by dependable technical support. From the initial starter culture derived from the original depositor's ampule to the final distribution vials, continual testing for species confirmation and contamination is performed to deliver high-quality reagents with minimal passage numbers.

Each year, ATCC cultivates approximately 1,200 different cell lines and produces hundreds of thousands of vials for distribution.

Risks of over-subculturing

It is well known that cell characteristics can change when cell lines are cultivated for extended periods. ¹⁻⁶ It is also true that stocks of commonly used cell lines maintained in many laboratories have been passaged hundreds of times and should not be considered as true models of the original source material. Furthermore, cellular cross-contamination of cell lines occurs with alarming frequency.^{7,8} Finally, contamination of cell lines with mycoplasma can lead to detrimental effects including chromosomal aberrations, growth changes, alterations in gene expression, and changes in virus replication and antibody production.⁹

Inexplicable variations in experimental data may be a signal that the cell line has been subcultured too many times or is contaminated and needs to be replaced.

Comprehensive testing of cell lines at ATCC

The ATCC accessioning process ensures that problems associated with genetic instability, cell line selection, senescence, and transformation are avoided. When a culture arrives at ATCC for deposit, a preliminary freeze is done and is checked for contamination and the species is verified (Figure 1). Cells are further characterized with a selection of tests when appropriate:

- Testing for microbes, including mycoplasma, determines that the culture is free from contamination.
- Isoenzyme analysis, karyotyping, and immunological testing verify the species of origin.
- Morphologies of growing cells are recorded at low and high densities and are routinely made available to researchers on the ATCC website.
- Short tandem repeat (STR) profiling is used to confirm the identity of all human cell lines.
- The viability of the cell line is checked before and after freezing.
- Growth characteristics such as growth rates and cell density are recorded.
- Various specialized testing such as determining the immunoglobin subclass secreted by hybridomas or confirming expression of cellular markers by flow cytometry may be employed.
- Specific cytogenetic events may be confirmed by karyotyping (for example, translocations in leukemias or lymphomas).

ATCC maintains over 3,600 different cell lines and hybridomas and distributes research materials to more than 80 countries.




Figure 1. The general ATCC accessioning scheme. Cells deposited at ATCC undergo repeated quality testing before distribution. The seed stock method ensures that the number of passages is minimized.



Introduction

State-of-the-art bioproduction

A large number of frozen vials are prepared from depositor-supplied stock which are stored as seed stock and used for future production runs. Quality testing is applied to the seed stock and is repeated for each new distribution lot. This system avoids prolonged serial subculturing and minimizes the number of passages that the cells undergo.

All cryopreserved material at ATCC is meticulously stored in liquid nitrogen vapor. Both the temperature and the liquid nitrogen levels in the freezers are monitored continuously.

ATCC processes for accessioning, producing, storing, and distributing cell lines ensure that researchers consistently receive high-quality reagents.

Start with genuine ATCC cell cultures

Well-characterized reference cultures are the best starting materials for any research project. Cell lines from ATCC offer significant advantages:

- Systematic experimentation high-quality cells at the same passage level over the course of years.
- Comprehensive quality testing standard cells with an authenticated origin, documented history, and described characteristics.
- Reliable source a broad spectrum of cell lines that may otherwise be difficult to find and are available worldwide.

References

- Esquenet M et al. LNCaP prostatic adenocarncinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids. J. Steroid Biochem. Mol. Biol. 62(5-6): 391-399, 1997.
- Briske-Anderson MJ et al. Influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc. Soc. Exp. Biol. Med. 214(3): 248-257, 1997.
- 3. Chang-Liu CM and Woloschak GE. Effect of passage number on cellular response to DNA-damaging agents: cell survival and gene expression. Cancer Lett. 113(1-2): 77-86, 1997.
- 4.Yu H et al. Evidence for diminished functional expression of intestinal transporters in Caco-2 cell monolayers at high passages. Pharm. Res. 14(6): 757-762, 1997.
- Sambuy Y et al. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 21(1): 1-26. 2005.
- 6. Wenger SL et al. Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization. Biosci. Rep. 24(6):631-639, 2004.
- 7. Buehring GC et al. Cell line cross-contamination: how aware are mammalian cell culturists of the problems and how to monitor it? In Vitro Cell. Dev. Bio. Anim. 40(7): 211-215, 2004.
- Thompson EW et al. LCC15-MB cells are MDA-MB-435: A review of misidentified breast and prostate cell lines. Clin. Exp. Metastasis 21(6): 535-541, 2004.
- McGarrity GJ et al. Cell culture mycoplasmas. In: The Mycoplasmas, Vol IV. Razin S and Barile MF, eds. New York: Academic Press; pp. 353-390, 1985.



Figure 2. ATCC routinely uses the SelecTTM system for high-throughput automated cell culturing.



How to Use the Catalog

The ATCC 2007 Cell Biology Catalogue contains indexes arranged by cell line name, source and application. The catalogue number can be searched on the ATCC website to find complete, detailed and up-to-date information on the item.

Cell line indexes

- Alphanumeric lists all cell lines and hybridomas by name
- **Tissue source** lists nontumor cell lines by tissue source
- Species other than human, mouse and rat
- **Hybridomas** lists hybridomas by antigenic determinant
- Tumor cell lines by disease
- Tumor cell lines from metastatic sites
- Tumor/normal matched cell line pairs
- Stem cells lists germline-competent, pluripotent and nullipotent embryonic stem cell lines and feeder cell lines used to support stem cell growth
- Cell lines used as tools and models includes hybridoma fusion partners, differentiating lines and lines used as factor assay systems
- Neurobiology
- Genetic variant fibroblasts
- Immortalized cells
- Genes and bioactive compounds lists cell lines by gene product or by receptor with gene product

These indexes provide basic information such as ATCC number, source and morphology. For a complete description of the product, including associated protocols and price, use the ATCC website.



Reviewing the Product Description Online

After finding the catalogue number of a cell line of interest, go to **www.lgcpromochem.com/atcc.** From the homepage, click on "Search Catalog: Choose Option" in the upper right corner, and select "By ATCC Number" from the drop-down menu.

Enter the ATCC number of the cell line into the query window and click the search button. You will be taken directly to the description for that product.

The description includes important detailed information about the line and how to successfully propagate it (Figure 3). Specific characteristics are provided for each cell line:

Price — does not include shipping and handling.

Designation — the name of the cell line as given by the depositor or originator.

Depositor — the person or institution who submitted the cells to ATCC.

Biosafety Level — the ATCC suggested level for safe shipment of the item.

Shipped — the description of how the cells are shipped, either frozen or in a flask.

Medium and Serum — contains a link to the **Propagation** field.

Propagation — includes a detailed description of the recommended medium and supplements.

Growth Properties — indicates either adherent or suspension. **Organism** — identifies the source of the cells.

Morphology — describes the appearance of the cultured cell line. If a microscope icon appears in this field, click on it to view a photomicrograph of the cell line.

Source — describes the physiological source of the cells. This field will indicate whether the cells are normal or tumor, the type of cancer, and if the cell line is a hybridoma.

Cellular Products — lists the compounds produced by the cells, including proteins, hormones, and monoclonal antibodies. **Permits/Forms** — provides a link to information that will help determine which (if any) regulatory documents are necessary to receive the cell line.



Figure 3. The complete description of an ATCC cell line as found on the website.

The information in the **Propagation** field is critical. For best results right from the start, ATCC strongly recommends using the specified medium and method for cultivating the cells, especially when first initiating the culture. (For more information on propagating a cell line from ATCC, see page 260).

Read the formulations for recommended media carefully. Formulations vary among media suppliers, and other additives and supplements are sometimes needed. When the propagation information reads "adjusted to contain," it means that the base medium as sold by ATCC already contains ingredients in those amounts; if you are using a different supplier make sure to check the label. "Supplemented with" means that a substance must be added to the ATCC formulation of the basic medium.

Example: The propagation field for TIB-202 reads "RPMI-1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES and 1.0 mM sodium pyruvate and supplemented with 0.05 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%."This means that ATCC's RPMI-1640 medium (Catalogue No. 30-2001) contains 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES and 1.0 mM sodium pyruvate. To create this complete growth medium, add 0.05 mM 2-mercaptoethanol and 10% (v/v) fetal bovine serum to the RPMI-1640 base medium.



How to Search the ATCC Website

The ATCC website is the complete guide to ATCC products, services, and protocols. New items are continually added to the online catalog, making the website the most up-to-date resource for information. In addition to descriptions of each cell line, technical help and cell culture products can also be found here.

Here are some tips for using the ATCC website to help find the cells you need.

Search by ATCC catalogue number

To find a cell line by the ATCC catalogue number, start at the ATCC home page at **www.lgcpromochem.com/atcc.** Click on the "Search Catalog: Choose Option" field in the upper right corner of the page and choose "By ATCC Number" from the drop-down menu. The resulting search page finds ATCC products by catalogue number.

Search by keyword

The ATCC website's search engine will also locate cell lines by keyword searching. There are two ways of accessing the ATCC Cell Biology Collection search function from the homepage. 1) Click on the "Search Catalog: Choose Option" field in the upper right corner, and choose "Cell Lines and Hybridomas" from the drop-down menu; or 2) Click on "Cell Lines and Hybridomas" from the list running down the left side of the page.

Search by field

Enter search terms into the appropriate drop-down fields under the Field Search (Figure 4). Most of the fields are self-explanatory, such as Organism, Depositor and Gender. Source is one of the most commonly used fields and includes the source of the cells, the disease state (if any) and the word "hybridoma" if applicable.

TIP: The Cellular Products field is used to find cell lines that produce certain compounds, such as hormones or monoclonal antibodies.

TIP: Use the word "against" rather than "anti" when searching hybridomas: **against CD28**, not anti-CD28.

TIP: The Comments field is used when depositors provide information that does not easily fit into other fields. It is valuable when searching for particular functions or special characteristics, such as information regarding related cell lines or the parental line from which the cells were derived.

When the search results appear (Figure 5), choose one cell line to view by clicking on the linked ATCC number in the column at the left, or select several cell lines by checking the boxes on the right and choosing "View Selections." Your browser will then open the product description page (Figure 3).



Figure 4. The ATCC cell biology search page with field search and full-text search functions.

Full-text search

The full-text search is the broadest way to search the collection (Figure 4). By entering words or characters that describe the cell line, a list of all cell lines that contain an exact match of the terms anywhere within the description is provided. For example, enter the word **bovine** into the query window, the search engine will retrieve all records that contain the word "bovine".

TIP: Note that this type of search will retrieve cell lines that are of bovine origin and those that simply require bovine serum. If the search results in too many hits, try field searching.

Using wildcards

Both the field search and the full-text search will retrieve **exact** matches for search terms. If the exact spelling or abbreviation is unknown, use the wildcard symbol * to replace characters. For example, if the cell line name starts with MDA but you are unsure of the rest, search for **MDA***, and the search engine will find all cell lines that begin with those letters.



How to Search the ATCC Website




Figure 5. The ATCC online catalogue search results page.

Troubleshooting a search

If no hits are returned:

- Check the spelling. The search engine will return only exact matches. Try using the wildcard symbol * to find varieties of a term.
- Some cell lines are not a part of the general collection. A cell
 line may be in a confidential safety deposit or it may be a
 patented cell line which has not been accessioned into the
 general collection. Not all patent items are listed in the online
 catalog. Contact ATCC Technical Services department at
 tech@atcc.org if you have questions.
- The cell line may have been removed from the collection. When
 the identity of a cell line proves to be incorrect, ATCC notes
 these items on the "Misidentified Cell Lines" page. See the Cell
 Biology Search page for this link.

If too many hits are returned:

- Narrow the search by adding as many relevant terms to the correct field windows as possible. Only records which contain all the words will be retrieved.
- Use search operators to define the search. The "and not" symbol
 (^ or shift-6) can help eliminate unwanted results. For example,
 if human is entered in the Organism field and lung ^carcinoma in the Source field, the search will find cells from human
 lung that are not derived from carcinomas.
- Use the field search instead of the full-text search.

If you have trouble finding the cells you need, contact Technical Services by phone (see back cover for details) or by email at atcctech@lqcpromochem.com.

Other website resources

In addition to listing the cell lines available from ATCC, the website is also a resource for technical literature, material safety data sheets, media formulations and customer service information. A PDF version of this catalogue is also available online. The site is best viewed using Internet Explorer version 5.0 or higher, Netscape 4.8 or higher, Firefox 1.0 or higher, and Safari.

Cell culture media, sera, and reagents

ATCC distributes media, sera, and reagents to support the growth and maintenance of ATCC cell cultures. Media formulations have been specifically designed to promote proliferation and sustain long-term growth of ATCC cell lines. Likewise, all lots of serum provided by ATCC have been tested for growth-promoting properties against a variety of cell lines in the collection. ATCC also offers dissociation reagents, attachment factors, and hybridoma development products to assist in all areas of cell culture and development. For best results, use ATCC media, sera, and reagents!



Cell Biology Collections

General collection

The ATCC Cell Biology Collection is composed of several subcollections organized by how the cells were deposited. The prefixes to the catalogue numbers were originally assigned to designate the source of funding for the cell line's accession. Certified Cell Lines (CCL) and Cell Repository Lines (CRL) are part of the general collection. Cell lines acquired through contract-supported cell banks such as the Tumor Immunology Bank (TIB), the Human Tumor Cell Bank (HTB), and the Hybridoma Bank (HB) are also part of the general collection. Unless special funding is available for cell line additions, most cell lines are accessioned as CRLs. When this series of numbers is used up, the prefix CBA (Cell Biology A) will be used, followed by CBB, etc.

Patented cell line collection

Hundreds of cell lines have been deposited into the ATCC Patent Depository. As part of the legal requirements for the patent process, these cell lines become available to researchers when the patent first issues. These products are noted with a dagger symbol (†) throughout the catalogue and they may not be used in a manner to infringe the patent claims.

NBL line collection

The NBL collection of human and animal cell lines was developed at the Naval Biosciences Laboratory (NBL) in Oakland, California, and transferred to ATCC in 1982.

One purpose of the NBL collection was to produce and distribute early passage cultures of cells from various species. Many of these cultures, unlike most others available from ATCC, are not well characterized and may be of mixed populations. NBL lines from tumors, for example, may consist of mixtures of stromal and cancer cells in which the former cell type predominates. As early passage cultures, they have a limited doubling potential and will be removed from the collection as they approach senescence. To ensure viability and post-freeze recovery these cultures are usually distributed in flasks as growing cultures.

Most of the NBL cell lines are neither fully characterized nor accessioned by ATCC; therefore, they are not warranted to the same extent as other accessioned cell lines. ATCC does not guarantee they will maintain a specific morphology, purity, or any other property upon passage. The information provided on these cell lines was not generated by ATCC. As noted in ATCC's Material Transfer Agreement, it is the purchaser's responsibility to assess and interpret this information in consideration of the use, selection, application, or suitability of these cell lines. NBL cell lines are noted with an asterisk (*) throughout the catalog. Whenever time and resources permit, ATCC will fully accession cultures from this collection. In these few cases the cells are distributed as frozen vials.

ATCC Special Collections

ATCC Special Collections represent collaborations with major research institutions around the world to provide valuable research tools to the scientific community. These items are noted as such in the product descriptions. Each collection has a distinct emphasis in the type of materials it offers, such as a focus on limited fields or applications, a wide spectrum of materials from one source, or unique or exclusive availability. Two ATCC Special Collections contain items of interest to cell biology:

Johns Hopkins Special Collection — materials developed by the Johns Hopkins University faculty.

Wistar Special Collection — a set of human vascular cell lines developed by researchers at the Wistar Institute in Philadelphia.

Third-party use agreements may be necessary for receiving these Special Collection cell lines and are described in the online catalog.

Institutions that participate in the formation of Special Collections benefit from ATCC capabilities in customizing storage and distribution services for their valuable materials.

ATCC Stem Cell Center

ATCC was awarded an NIH-NCRR grant (P40RR15452) in 2000 which included the following objectives:

- Characterization of animal stem cell lines
- Standardization and optimization of stem cell research methodologies and procedures
- Development of new reagents broadly applicable across a range of species and strains for stem cell research

ATCC subsequently launched the Stem Cell Center to ensure the availability of embryonic and tissue-specific stem cells as well as to provide a centralized source for information dissemination and exchange.

Today the Center houses one of the largest research teams focused on stem cells. The Center maintains nearly 70 human and mouse cells lines and has qualified media, sera, and other reagents for use in stem cell research.



Placing an Order

General Information

Distribution of ATCC materials in the United States and internationally is regulated by the US government. All orders are subject to applicable government regulations and ATCC policies. For these reasons, ATCC requires all customers to have an approved and current ATCC account to place an order.

ATCC has authorized distributors in many countries. Customers in locations without an authorized distributor should order directly from ATCC. With an ATCC account you can order by phone, fax, email or online.

Phone United States, Canada, and Puerto Rico:

800-638-6597

International: +1 703-365-2700

Fax 703-365-2750
Email sales@atcc.org

Web www.lgcpromochem.com/atcc

Postal mail ATCC

PO Box 1549

Manassas, VA 20108-1549

An order form can be found on the website under **Ordering Info.** To place an order by phone, have your account number, verification of the billing address, shipping information, end-user information and PO (purchase order) or credit card number ready.

An ATCC account number can be used to order directly through the website. When the desired item is located in the online catalog, click the "Order this item" button at the top of the description to add the product to the shopping cart.

Applying for an ATCC account

To apply for ATCC account, contact ATCC at sales@atcc.org for an application or download the application from the website. Go to **www.lgcpromochem.com/atcc** and select "Ordering Info" from the top of the page. Click on the link to New Account Application, fill out the form, and print it. Fax or mail the completed application to ATCC.

ATCC policy requires that all customers provide a description of their facility (including biosafety capabilities), as well as the full name and contact information for all the investigators who will be using the products.

New account approval takes approximately two weeks. To avoid delays, carefully complete all sections on the application and be sure to sign it.

Pricing

Current list prices are posted on the ATCC website and do not include shipping and handling fees. A discount off the current list price will be applied to most cultures for nonprofit institutions in the United States and Canada. Cultures that are ordered as test tubes or flasks will carry an additional laboratory fee. Prices are subject to change without notice. To receive a pro forma quote for an order, fill out an order form and indicate clearly that you are requesting a quote only.

Terms and conditions

Complete terms and conditions regarding the purchase of ATCC cultures can be found in the Material Transfer Agreement on page 287 of this catalogue and on the website. Terms and conditions are subject to change without notice; see the website for the most current information.



Distributors

Authentic ATCC products are only available from ATCC and its authorized distributors. Authorized ATCC distributors streamline the ordering process and provide local customer support. Customers in the following locations must order from a local distributor:

Australia/New Zealand

Cryosite 9 Sirius Road Lane Cove NSW 2066 Australia Tel: (61)2 9420 1400

Freecall (Australia only): 1800 220 410

Fax: (61)2 9420 1414 Email: atcc@cryosite.com Website: www.cryosite.com

China/Macau

Beijing Zhongyuan Limited Rm. 1001, South Building No. B3 Huayuan Road Beijing 100083, China Tel: 86-10-62355630 Fax: 86-10-82015198 Email: office@sinozhongyuan.com

Website: www.sinozhongyuan.com

Tin Hang Technology Limited Units 1904-06, 19/F. No. 340 Queen's Road Central Hong Kong Tel: 852-28172121 Fax: 852-25807763 Email: sales@tinhangtech.com Website: www.tinhangtech.com

Europe

LGC Promochem
Queens Road
Teddington
Middlesex TW11 0LY, UK
Email: atcc@lgcpromochem.com/atcc
Tel: 44 (0)20 8943 8489
Fax: 44 (0)20 8943 8405
Website: www.lgcpromochem/atcc
For technical inquiries: atcc-tech@lgcpromochem.com/atcc

Hong Kong

Tin Hang Technology Limited Units 1904-06, 19/F. No.340 Queen's Road Central Hong Kong Tel: 852-28172121 Fax: 852-25807763 Email: sales@tinhangtech.com Website: www.tinhangtech.com

India

LGC Promochem India Pvt. Ltd. 142, III Floor, 5th Cross RMV Extension Bangalore 560080 India

Tel: +91-80-23611256 / 23614774

Fax: +91-80-23613859

Email: in@lgcpromochem.com/atcc

Japan

Summit Pharmaceuticals Intl. Corp.
Harumi Island Triton Square Office Tower Z
1-8-12, Harumi, Chou-ku
Tokyo 104-6233, Japan
Tel: 81-3-3536-8640
Fax: 81-3-3536-8641
Email: atcc@summitpharma.co.jp
Website: www.summitpharma.co.jp (in English and Japanese)

Korea

KORAM Biotech Corp.
7F, Koram Venture Town
907-1, Daechi-Dong, Kangnam-ku
Seoul 135-280, South Korea
Tel: 82-2-556-0311
Fax: 82-2-556-0828
Email: koram@korambiotech.com
Website: www.korambiotech.com

Singapore

BioGen Pte Ltd 36 Toh Guan Road East #01-39 Enterprise Hub Singapore 608 580 Tel: (65) 6273 3022 Fax: (65) 6273 3020 Email: sales@biogensin.com Website: www.biogensin.com

Taiwan, R.O.C.

Union Biomed Inc. P.O. Box 7-0955 No. 202, 9/F, Sec. 1 Hoping East Road Taipei, Taiwan R.O.C. Tel: (02)2368-3600 Toll Free Tel: 0800-231-045 Fax: (02)2368-7887 Email: ubis@ms75.hinet.net



Depositing with ATCC

The ATCC Cell Biology Collection was established in 1962 through the cooperative efforts of ATCC, scientific advisory committees, and a group of collaborating laboratories. Today as a biological resource center, ATCC continues to offer a broad and comprehensive collection of animal cell lines and hybridomas through the efforts of many scientists.

Depositing a cell line into the general collection

ATCC welcomes deposits of valuable research material into the cell biology general collection. Unfortunately, all items that are offered cannot be accepted. Several factors are generally considered in selecting new cell lines:

- A characteristic or application not yet represented in the collection
- Literature citations
- Useful life expectancy in vitro
- Broad scientific utility for meeting the needs of many researchers

Use the "Make a Deposit" section of the website to offer materials for deposit. The first step will be to contact a staff scientist with a description of the material and applicable literature references. After an evaluation of the information, you will be contaced about transferring the cell line to ATCC. There is no charge for depositing materials into the general collection.

Cell Storage Services

ATCC has been providing patent and safe deposit services for corporations, government laboratories, and academic institutions for over 50 years. As a neutral nonprofit organization, ATCC stores valuable cells, microorganisms, and related materials safely and dependably without conflict-of-interest concerns.

Patent deposit

ATCC has been providing dependable, legally compliant storage of materials for patent purposes since 1949, long before depositing was a formal requirement of any patent office. The patent depository currently includes more than 20,000 strains of biological materials.

ATCC offers the following assurances with patent deposits:

- Compliance with legal requirements ATCC will process the documentation to ensure that legal requirements are met for each deposit.
- Dependable storage ATCC has been storing biological materials since 1925 and is the leader in maintaining viability and integrity of cultures.
- International patenting ATCC is an International Depository Authority (IDA) under the International Budapest Treaty for deposits to meet patent office requirements in many countries.
 All countries signatory to the Budapest Treaty must recognize the deposit of biological material with any IDA. Standard patent deposit, which meets the requirements of the United States

- Patent and Trademark Office (USPTO), is also available.
- Versatile storage ATCC accepts the following biological material for patent purposes: Algae, animal viruses, bacteria, bacteriophages, cell lines, cloned genes, nonhuman embryos, filamentous fungi, hybridomas, plant tissue cultures, plant viruses, purified DNA, protozoa, genomics materials (clones, vectors, libraries, etc.), seeds, and yeasts.
- Security and confidentiality The ATCC facility is specially designed for secure long-term storage of biological materials. All deposits are strictly confidential until the patent issues.
- Related services ATCC also provides custom freezing, interim storage and depositor notification of purchasers upon request.

The first step in depositing materials for patent purposes is to contact the **Patent Depository**.

PO Box 1549 Manassas, VA 20108-1549 Fax: 703-365-2745 Email: PatentDeposit@atcc.org

ATCC staff will provide the forms and information required to deposit patent materials.

Safe deposit

ATCC offers two types of safe deposit services for proprietary materials.

Standard safe deposit is consistent with ATCC practices for handling and storage of materials entrusted to ATCC since its founding in 1925.

cGMP safe deposit provides cell bank storage that is compliant with current good manufacturing practices (cGMP).

Both the cGMP safe deposit and the standard safe deposit services offer secure, confidential storage of valuable materials and include the following assurances:

Security

- The ATCC facility is specifically designed for large-capacity storage of cell lines, microorganisms, and other biological materials.
- ATCC has a long history of safe, trouble-free operation in the storing of biological materials.
- All cell lines are stored in liquid nitrogen freezers equipped with monitoring systems and 24-hour surveillance to safeguard stored material.

Confidentiality

- All rights to the cell cultures remain with the depositor.
- All information concerning deposited material is retained in confidence.
- Culture material is available only to the depositor or his or her designee. All requests must be made in writing.

Optional special services



Depositing with ATCC

- One vial of each culture can be returned to the depositor for analysis after a one-week storage period to ensure viability of material received.
- Cultures for standard safe deposit can be prepared for freezing by ATCC staff.
- Standard safe deposit material can be distributed to the depositor or designated individual(s).
- Multi-year discounts are available.

Additional features of cGMP safe deposit:

- Dedicated and validated liquid nitrogen freezer with access restricted to cGMP-trained staff with QA oversight.
- Tracking labels for all shipments to ensure segregation of cGMP materials immediately upon receipt at ATCC.
- Separate storage boxes for each cell bank or multiple banks in one box (depositor's option). Materials from only one customer are stored in a box.
- Direct QA supervision of all freezer entry and retrieval activities.
- Dedicated and trained staff.
- Annual third-party audit report for all depositors (included with fee).

If you currently have materials stored in the ATCC Standard Safe Deposit that should be handled under cGMP conditions, ATCC can arrange to transfer these materials.

For additional information or to initiate cGMP safe deposit, contact ATCC Professional Services at SafeDep@atcc.org or call 703-365-2700 ext 2519

Section II: Cell Culture Bioproducts



High-performance liquid media
High-performance sera
Media supplements and antibiotics
Reagents, buffers and stains
Extracellular matrix products
Hybridoma development and
cryopreservation
MTT Cell Proliferation Assay
ELF® Phosphatase Detection Kit

High-Performance Liquid Media

ATCC media contain specific component concentrations following the recommendations of ATCC cell culture scientists. These recommendations are based on extensive evaluation of growth and viability requirements of individual cell lines.

All ATCC products are manufactured to exact specifications and each lot is rigorously tested to meet the standards of performance and quality imposed by the ATCC Cell Culture Facility, where distribution stocks for numerous cell lines are produced routinely.

Media by the same name from different manufacturers may have subtle but important differences in their compositions. Such differences may alter or disturb normal cell growth.

Using ATCC high-performance media and sera is the best way to guarantee robust cell growth with minimum cell loss, especially when reviving cells from cryopreservation.



 $These\ products\ are\ for\ laboratory\ research\ use\ only. Not\ intended\ for\ use\ in\ humans, animals\ or\ for\ diagnostics.$



High-Performance Liquid Media

| Product Name | ATCC® No. | Key Components | Uses and Benefits |
|--|-----------------------|---|---|
| Dulbecco's Modified Eagle's Medium (DMEM) | 30-2002 (500 ml) | 4 mM L-glutamine 4500 mg/l glucose | Optimized energy sources for protein production and nucleic acid metabolism while limiting toxic ammonia build-up |
| | | 1500 mg/l sodium bicarbonate | To be used with 5% CO₂ to maintain pH |
| ES-DMEM | SCRR-2010 (500 ml) | 4500 mg/l glucose No L-glutamine | Optimized for embryonic stem cells To be used with ${\bf 5\%}$ ${\bf CO_2}$ to maintain pH |
| DMEM: F12 Medium | 30-2006 (500 ml) | 2.5 mM L-glutamine 0.5 mM sodium pyruvate | 1:1 mix of Dulbecco's medium and Ham's F12 |
| | | 15 mM HEPES | Optimized to maintain pH |
| | | 1200 mg/l sodium bicarbonate | To be used with 5% CO ₂ to maintain pH |
| Eagle's Minimum Essential Medium (EMEM) | 30-2003 (500 ml) | 1 mM sodium pyruvate 2 mM L-glutamine | Balanced energy sources to serve as carbon skeletons for anabolic processes as well as protein production and nucleic acid metabolism while limiting toxic ammonia build-up |
| | | 1500 mg/l sodium bicarbonate | To be used with 5% CO ₂ to maintain pH |
| F-12K Medium | 30-2004 (500 ml) | 2 mM L-glutamine | Designed to support the growth and differentiation of primary cells with or without serum |
| | | 1500 mg/l sodium bicarbonate | To be used with 5% CO ₂ to maintain pH |
| Hybri-Care Medium Powder | 46-X | | Formulated to support the growth of hybridomas and fastidious cell lines |
| lscove's Modified Dulbecco's Medium (IMDM) | 30-2005 (500 ml) | 4 mM L-glutamine 4500 mg/l glucose | Optimized energy sources for protein production and nucleic acid metabolism while limiting toxic ammonia build-up |
| | | 1500 mg/l sodium bicarbonate | To be used with 5% CO ₂ to maintain pH |
| Leibovitz's L-15 Medium | 30-2008 (500 ml) | 2 mM L-glutamine | Optimized energy source for protein production and nucleic acid metabolism while limiting toxic ammonia build-up No added sodium bicarbonate; to be used without CO ₂ |
| McCoy's 5A Medium Modified | 30-2007 (500 ml) | 1.5 mM L-glutamine | Optimized energy source for protein production and nucleic acid metabolism while limiting toxic ammonia build-up |
| | | 2200 mg/l sodium bicarbonate | To be used with 5% CO ₂ to maintain pH |
| RPMI-1640 Medium | 30-2001 (500 ml) | 1 mM sodium pyruvate 2 mM L-glutamine 4500 mg/l glucose | Balanced energy sources to serve as carbon skeletons for anabolic processes as well as for protein production and nucleic acid metabolism while limiting toxic ammonia build-up. |
| | | 10 mM HEPES | Optimized to maintain pH |
| | | | |

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.



High-Performance Sera

ATCC high-performance animal sera come from United States Department of Agriculture-approved origins. Experienced technicians thoroughly test the packaged sera to eliminate contamination concerns.

All ATCC sera are prequalified on multiple cell lines to ensure robust growth using both sequential subcultures and plating efficiencies.

- Each lot of ATCC high-performance sera is subjected to comprehensive tests for sterility and performance.
- Sterility tests are performed on each lot using USP XXIII methods for bacterial and fungal contamination.
- Comprehensive viral testing adheres to 9 CFR 113.53 guidelines.
- Mycoplasma testing is performed via direct culture and Hoechst DNA staining.
- Limulus amoebocyte lysate (LAL) procedure is used to measure endotoxin values.
- All tests are performed post-packaging to guarantee the highest-quality, best-performing sera.

| | Catalogue No. | Volume |
|-----------------------------------|---------------|--------|
| | | |
| Fetal Bovine Serum | 30-2020 | 500 ml |
| | 30-2021 | 100 ml |
| Fetal Bovine Serum, ES Qualified* | SCRR-30-2020 | 500 ml |
| Calf Bovine Serum | 30-2030 | 500 ml |
| | 30-2031 | 100 ml |
| Horse Serum | 30-2040 | 500 ml |
| | 30-2041 | 100 ml |
| | | |

^{*} Qualified for mouse and human embryonic stem cells by the ATCC Stem Cell Center



These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.



Media Supplements and Antibiotics

Media supplements from ATCC allow you to customize the growth conditions for your cells.

Catalogue No. Volume

L-Glutamine Solution, 200 mM 30-2214 100 ml

L-Glutamine is an essential amino acid required by virtually all mammalian and insect cells grown in culture. L-Glutamine is more labile in liquid cell culture media than other amino acids and thus is often added as a supplement prior to use.

L-Alanyl-L-Glutamine Solution 200mM 30-2115 100 ml

L-alanyl-L-glutamine can be used as a direct substitute for L-glutamine. Whereas L-glutamine is labile in cell culture medium and its degradation results in deleterious build-up of ammonia, this dipeptide supplement is very stable with minimal ammonia production.

MEM Nonessential Amino Acid Solution 30-2116 100 ml

This solution is added as a supplement to minimal basal media. The nonessential amino acids in this solution are 100 times the concentration found in MEM-alpha Medium.

Penicillin Streptomycin Solution 30-2300 100 ml

10,000 IU/ml penicillin 10,000 µg/ml streptomycin

Penicillin-Streptomycin Solution reduces the chances of microbial contamination in cell culture. Between 0.5 and 1 ml of Penicillin-Streptomycin Solution is added to 100 ml of cell culture media for a final concentration of 50 to 100 IU/ml penicillin and 50 to 100 µg/ml streptomycin. NOTE: Most cell culture technologists avoid using antibiotics for routine culture work. Antibiotics may eliminate susceptible bacteria while permitting mycoplasma to flourish unnoticed or may interfere with the metabolism of sensitive cells in culture. However, one may elect to introduce antibiotics for short periods to primary cultures or as a safeguard while propagating specific valuable stocks.

Penicillin-Streptomycin-Glutamine 30-2220 100 ml Solution

10,000 IU/ml penicillin 10,000 µg/ml streptomycin 200 mM L-glutamine

This convenient solution allows you to add these common cell culture supplements to your medium in one step, thereby reducing the risk of contamination.





Reagents, Buffers and Stains

Catalogue No. Volume

Trypsin EDTA Solution 30-2101 100 ml

0.25% trypsin, 0.53mM EDTA in Hank's Balanced Salt Solution (HBSS) without calcium chloride or magnesium chloride.

Trypsin-EDTA solution is suitable for the dissociation of most adherent cell lines.

Dulbecco's Phosphate Buffered 30-2200 500 ml Saline (DPBS)

Without calcium chloride or magnesium chloride

Phosphate Buffered Saline ES Qualified* SCRR-2201 500 ml

Without calcium or magnesium

Hanks' Balanced Salt Solution (HBSS) 30-2213 500 ml

Without calcium chloride, magnesium chloride, or phenol red

Vital Stains

Vital stains are used to determine cell viability. Viable cells will actively exclude these dyes, while nonviable cells (those whose plasma membrane is damaged) will take up the stain and appear red (erythrosin B) or blue (trypan blue) in color.

Erythrosin B Stain Solution 30-2404 40 ml

0.1% solution in PBS. Cell culture tested.

Erythrosin B Stain Solution gives more accurate results with fewer false negatives and false positives than trypan blue stain. Erythrosin B penetrates nonviable cells immediately; there is no need to wait before counting. Simply mix the stain solution 1:1 with your cell suspension, load into a hemocytometer, and record your data.

Trypan Blue Stain Solution 30-2402 40 ml

0.4% solution in PBS. Cell culture tested.

* Qualified for mouse and human embryonic stem cells by the ATCC Stem Cell Center



Water, Cell-Culture Grade 30-2205 500 ml

ATCC water for cell culture is stringently tested for sterility and meets WFI (water for injection) quality standards. Use it as a diluent or for reconstituting powdered media and salt solutions.

 $These \ products \ are for \ laboratory \ research \ use \ only. Not \ intended \ for \ use \ in \ humans, animals \ or \ for \ diagnostics.$



Extracellular Matrix Products

ATCC offers a selection of natural cellular support matrix products to facilitate the growth and differentiation of animal cells in culture. These products are thoroughly tested for optimal performance and greatly enhance cell growth and differentiation by more closely reproducing the in vivo environment of whole tissue.

| | Catalogue No. | Volume | |
|---|---------------|--------|--|
| Extracellular Matrix Solution | 30-2501 | 5 ml | |
| Extracellular Matrix Solution, Reduced Growth Factor | 30-2503 | 5 ml | |

Extracellular Matrix Solutions are reconstituted basement membrane preparations derived from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma (ATCC® CRL-2108™). Cells can be grown on it as a gelled support layer, embedded within it as a three-dimensional matrix, or embedded within it as a surrogate tissue 'plug' and injected into mice for in vivo studies.


Purified protein solutions from the EHS sarcoma have been used to study the differentiation of various cell types in vitro, to facilitate in vitro invasion assays, to study tumor formation by cell lines in athymic mice, and to study angiogenesis in vitro and in vivo.

The major structural elements of ATCC Extracellular Matrix Solution are laminin, collagen IV, heparan sulfate proteoglycans, and entactin. It also contains tissue plasminogen activator as well as a number of growth factors including TGF- β , EGF, IGF-1, bFGF, and PDGF. A preparation with reduced concentrations of growth factors is also available.

Cellular Attachment Factors

| Laminin | 30-2505 | 1 mg |
|-------------|---------|------|
| Collagen IV | 30-2511 | 1 mg |

ATCC Laminin and Collagen IV are also prepared from the EHS mouse sarcoma. Both can be applied as a thin coating on tissue culture dishes to promote the attachment and proliferation of epithelial, endothelial, muscle, and nerve cells.



These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.



Hybridoma Development and Cryopreservation

Catalogue No. Volume

Polyethylene Glycol (PEG)

PEG 1450 50-X 5 x 2 g

PEG 4000 52-X 5 x 2 g

Polyethylene glycol is used to assist the fusion of myeloma fusion partner cells and spleen cells to form hybridomas. ATCC PEG is supplied sterile and tested for cytotoxicity.

HAT (Hypoxanthine – Aminopterin – Thymidine)
500x concentrate 69-X 5 x 2 ml

HAT is a medium supplement used to select for hybridomas from among normal cell populations. Each vial of 2 ml is sufficient for 1 liter of cell culture medium. Sterile and cell culture tested.

HT (Hypoxanthine – Thymidine)
500x concentrate
71-X
5 x 2 ml

HT is a medium supplement used to maintain hybridoma selection in cell culture. Each vial of 2 ml is sufficient for 1 liter of cell culture medium. Sterile and cell culture tested.

Hybri-Care Medium 46-X 1 liter (powder)

This special medium is formulated to support the growth of hybridomas and fastidious cell lines.

Hybridoma Fusion Partner Cell Lines

ATCC offers over 30 hybridoma fusion partners (B and T cells) derived from human, mouse, and rat. See page 184.

Dimethylsulfoxide (DMSO) 4-X 5 x 5 ml

DMSO is used as a cryoprotectant in the freezing of cell cultures. The product is cell culture grade and has been tested to ensure cell viability. Each lot is also tested for the absence of bacteria, fungi, and endotoxin.



 $These \ products \ are for \ laboratory \ research \ use \ only. Not \ intended \ for \ use \ in \ humans, animals \ or for \ diagnostics.$



MTT Cell Proliferation Assay

Catalogue No. Quantity

MTT Cell Proliferation Assay Kit

30-1010K 2500 tests

The ATCC MTT Cell Proliferation Assay Kit provides a rapid and convenient method for determining viable cell number in proliferation, cytotoxicity, cell attachment, chemotaxis, and apoptosis assays. It is particularly suited for high-throughput screening assays using multiwell plates.

The method is a modification to and improvement of the MTT tetrazolium salt assay described by Mosmann. In the assay, the MTT reagent (3,[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) is added to cells in culture. During a 4-hour incubation, viable cells convert the MTT tetrazolium salt into an insoluble and brightly colored formazan. The Detergent Reagent is then added to the cells to stop the conversion and solubilize the formazan. The amount of formazan produced is recorded by absorbance at 570 nm using a multiwell plate reader.

The amount of formazan correlates directly with the number of viable cells. However, due to differences between cell types and culture conditions, a standard curve should be established for each cell line.

Features

- Safe No radioactivity or scintillation cocktails
- Accurate Formazan absorbance correlates directly with cell metabolism and cell number
- Sensitive Assays as few as 1,000 cells
- Rapid All reactions occur in the individual multiplate well without washing or harvesting cells
- Easy to use Straightforward, simple procedure with ready-to-use reagents

References

van de Loosdrecht AA et al. J. Immunol. Methods 174(1-2): 311-320, 1994. Ohno M and Abe T. J. Immunol. Methods 145(1-2): 199-203, 1991. Ferrari M et al. J. Immunol. Methods 131(2): 165-172, 1990. Alley MC et al. Cancer Res. 48(3): 589-601, 1988. Carmichael J et al. Cancer Res. 47(4): 936-42, 1987. Gerlier D and Thomasset N. J. Immunol. Methods 94(1-2): 57-63, 1986. Mosmann T. J. Immunol. Methods 65(1-2): 55-63, 1983.





ELF® Phosphatase Detection Kit

Catalogue No. Quantity

ELF® Phosphatase Detection Kit for Embryonic Stem Cells SCRR-3010 60 test

The ATCC ELF® Phosphatase Detection Kit for Embryonic Stem Cells offers a reliable, sensitive, and stable assay to determine if stem cells are undifferentiated or are starting to differentiate. Using fluorescent detection of endogenous phosphatase activity in embryonic stem cells, researchers can confidently proceed with experiments knowing that their stem cell populations have been maintained in the undifferentiated state.

- Robust Cleavage of the phosphatase substrate generates a precipitate that will fluoresce yellow-green, indicating phosphatase activity
 — a marker for the undifferentiated state. The absence of fluorescence indicates differentiation. The fluorescent precipitate is very photostable and will withstand relatively long periods of light exposure, allowing time to examine and image the sample.
- Easy to use The procedure is simple and requires no specialized skills. Staining is visualized through a standard Hoechst/DAPI longpass filter set.
- Rapid The protocol can be completed with visualization of fluorescent signal within 30 minutes.
- Convenient The kit is stable when stored under refrigeration in the dark
- Added value The precipitate fluorescent signal makes the phosphatase substrate ideal for use in dual and multicolor applications. More comprehensive analyses using multiple stem cell markers can be performed to assess overall in vitro stem cell pluripotency.



 $These \ products \ are for \ laboratory \ research \ use \ only. Not \ intended \ for \ use \ in \ humans, animals \ or \ for \ diagnostics.$



Notes

 $These \ products \ are for laboratory \ research \ use \ only. \ Not \ intended \ for \ use \ in \ humans, animals \ or \ for \ diagnostics.$



Notes

 $These\ products\ are\ for\ laboratory\ research\ use\ only. Not\ intended\ for\ use\ in\ humans, animals\ or\ for\ diagnostics.$

Section III: Cell Line Indexes



Alphanumeric

Tissue source

Species

Hybridomas

Tumor cell lines by disease

Tumor cell lines by metastatic sites

Tumor/normal matched cell line pairs

Stem cells

Cell lines used as tools and models

Neurobiology

Genetic variant fibroblasts

Immortalized cells

Genes and bioactive compounds



This index includes basic information on all ATCC cell lines and hybridomas which are listed in alphanumeric order by name. Complete information about each item including price, propagation instructions and references can be found on the ATCC website. Use the catalogue number to find the entry in the cell biology section of the online catalog.

| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-----------------------|------------------------|-------------|---|----------------|-------------|
| #490 | HB-12029 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| (BF1) 8A3.31 | HB-9283 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| +/+ (A) | CRL-6470* | mouse | embryo; pooled | , , | adherent |
| +/+ (B) | CRL-6471* | mouse | embryo; pooled | | adherent |
| +/+ Li | CRL-6467* | mouse | liver | | adherent |
| +/+ MGT | CRL-6468* | mouse | mammary gland; cancer | | adherent |
| +/+ SCT | CRL-6469* | mouse | mixed connective and soft tissue; cancer | | adherent |
| 022HU-NSO | CRL-11177 [†] | mouse | myeloma; transfected | epithelial | suspension |
| 10.014 pRSV-T | CRL-11515 [†] | human | eye (cornea) | epithelial | adherent |
| 10-1.D.2 | TIB-165 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 10-2.16 | TIB-93 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 10-3.6.2 | TIB-92 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 104C1 | CRL-1405 | guinea pig | fetus | fibroblast | adherent |
| 10B9 | HB-172 | mouse/mouse | hybridoma | lymphoblast | suspension |
| I0C4.1.3 | HB-11029 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 10C7 | CRL-2430 | mouse/mouse | hybridoma | lymphoblast | mixed |
| 10D2F6 | HB-11103 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 10E5 | HB-8513 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| IOF7MN | HB-8162 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| I0H2.12.1 | HB-11494 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| I0P12 | CRL-2036 | mouse | mast cell; AMLV-induced tumor | mast cell | suspension |
| 0P2 | CRL-2034 | mouse | mast cell; AMLV-induced tumor | mast cell | suspension |
| 110-5 | HB-8984 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1116-NS-19-9 | HB-8059 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| I116NS-3d | CRL-8019 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 11-26c | HB-250 | rat/mouse | hybridoma | lymphoblast | suspension |
| 1-4.1 | TIB-95 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 11-5.2.1.9 | TIB-94 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 16 | HB-9367 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 16-13.1 | HB-129 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 11B11 | HB-188 | rat/mouse | hybridoma | lymphoblast | suspension |
| 11E10 | CRL-1907 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1F11 | CRL-1908 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1P0-1 | CRL-2037 | mouse | mast cell; AMLV-induced tumor | mast cell | suspension |
| 1205Lu | CRL-2812 | human | skin, melanocyte; primary superficial spreading melanoma in vertical growth phase; from lung metastases in mice | spindle-shaped | adherent |
| 12.1 | HB-228 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 12.1 121-19B10 | CRL-2652 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2-2-2S clone 5F11) | HB-50 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 23-10 | CRL-1707 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 123-28 | CRL-1713 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 12/44 | HB-9070 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 12/49 | HB-9070 | mouse/mouse | hybridoma | lymphoblast | suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-----------------------|--|---|--|--|
| HB-11911 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| CRL-2817 | mouse | embryo, fibroblast; immortalized with SV40 large T antigen | fibroblast | adherent |
| HB-8087 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| CRL-6476* | mouse | embryo; SV40 transformed | epithelial | adherent |
| HB-8328 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| CRL-1576 | monkey, African green | lung (bronchus) | epithelial | adherent |
| HB-8326 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| HB-8088 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| | HB-11911 [†] CRL-2817 HB-8087 [†] CRL-6476* HB-8328 [†] CRL-1576 HB-8326 [†] | HB-11911 [†] mouse/mouse CRL-2817 mouse HB-8087 [†] mouse/mouse CRL-6476* mouse HB-8328 [†] mouse/mouse CRL-1576 monkey, African green HB-8326 [†] mouse/mouse | HB-11911 [†] mouse/mouse hybridoma CRL-2817 mouse embryo, fibroblast; immortalized with SV40 large T antigen HB-8087 [†] mouse/mouse hybridoma CRL-6476* mouse embryo; SV40 transformed HB-8328 [†] mouse/mouse hybridoma CRL-1576 monkey, African green HB-8326 [†] mouse/mouse hybridoma | HB-11911 [†] mouse/mouse hybridoma lymphoblast CRL-2817 mouse embryo, fibroblast; immortalized with SV40 large T fibroblast antigen HB-8087 [†] mouse/mouse hybridoma lymphoblast CRL-6476* mouse embryo; SV40 transformed epithelial HB-8328 [†] mouse/mouse hybridoma lymphoblast CRL-1576 monkey, African green HB-8326 [†] mouse/mouse hybridoma lymphoblast |

ATCC Cell Biology Trivia #1

When did ATCC publish its first catalog?

The first ATCC catalogue was published in 1927, two years after ATCC was founded to manage a bacterial collection at the Museum of Natural History in New York. The loss of microbial strains was common until Lore Rogers, chairman of the board of ATCC, pioneered freeze-drying of cultures in the 1940s.

| 131-94H4 | CRL-2739 | mouse/mouse | hybridoma | lymphoblast | suspension |
|-----------------|------------------------|---------------|---|-------------|------------|
| 132-1C8 | CRL-2737 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 132C4A/4 | HB-8086 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 133-10F6 | CRL-2738 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 13-5-9-6-2 | HB-8934 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 13762 MAT B III | CRL-1666 | rat | mammary gland; adenocarcinoma | epithelial | suspension |
| 13.90.2 | HB-8337 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 13C4 | CRL-1794 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1410 KG7 | HB-43 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 141PF11 | HB-45 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 142-24E5 | CRL-2649 [†] | mouse/mouse | hybridoma | lymphoblast | mixed |
| 143.98.2 | CRL-11226 [†] | human | bone; osteosarcoma | | adherent |
| 143-2-A6-11 | HB-8325 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 143-4-2 | CRL-1970 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 143B | CRL-8303 [†] | human | bone; osteosarcoma | fibroblast | adherent |
| 143B PML BK TK | CRL-8304 [†] | human | bone; osteosarcoma | fibroblast | adherent |
| 14-4-4S | HB-32 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 145-2C11 | CRL-1975 | hamster/mouse | hybridoma | lymphoblast | suspension |
| 146-03E04 | CRL-2650 [†] | mouse/mouse | hybridoma | lymphoblast | mixed |
| 147-67C6 | CRL-2654 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 14.8 | TIB-164 | rat/mouse | hybridoma | lymphoblast | suspension |
| 14E5 | HB-174 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 151-5-G2-12 | HB-8322 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 151-5-G3-5 | HB-8323 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 15-1-5P | HB-53 | mouse/mouse | hybridoma | lymphoblast | suspension |
| I51-6-A7-9 | HB-8324 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 151TAg | CRL-2823 | mouse | embryo, fibroblast; immortalized with SV40 large T antigen | | adherent |
| 15-3-1S | HB-13 | mouse/mouse | hybridoma | lymphoblast | suspension |
| | | | <u> </u> | <u> </u> | · |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. research use only. Not intended for use in humans, animals or for diagnostics.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------|------------------------|--------------------|--|-------------|-------------|
| 15-5-5S | HB-24 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 15-79-2 | HB-34 | mouse/mouse | liver/pre-B lymphoblast hybridoma | lymphoblast | suspension |
| 58.2 | HB-8466 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| 5B2 | HB-8510 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 5C6 | CRL-2431 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 5C6 | HB-326 | rat/mouse | hybridoma | lymphoblast | mixed |
| 5F3-1 | HB-47 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 5F7 | HB-322 | rat/mouse | hybridoma | lymphoblast | mixed |
| 5P-1 | CRL-2618 | mouse (transgenic) | testis, Sertoli cells; expresses polyoma virus large T protein | | adherent |
| 6-10A1 | HB-301 | hamster/mouse | hybridoma | lymphoblast | suspension |
| 6-1-11N | HB-16 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 6-1-2N | HB-14 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 62-21.2 | HB-241 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 62-46.2 | HB-187 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 6-3-1N | HB-25 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 6-3-22S | HB-5 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 66-ME SK | CRL-1533 | human | skin; hereditary adenomatosis (Gardner's variant) | fibroblast | adherent |
| 6H3 | CRL-2385 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 6M3F10 | HB-8363 [†] | human/mouse | hybridoma | lymphoblast | suspension |
| 71-11B9 | CRL-2661 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 71-4 | HB-296 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 7/14 | HB-8153 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 72-12A4 | CRL-2660 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 73-1C11 | CRL-2659 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 7-3-3S | HB-6 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 7aba | HB-248 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 7D | HB-262 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 82-PF SK | CRL-1532 | human | skin; hereditary adenomatosis | fibroblast | adherent |
| 84A1 | CRL-8798 [†] | human | mammary gland, epithelium; chemically transformed | epithelial | adherent |
| 84B5 | CRL-8799 [†] | human | mammary gland, epithelium; chemically transformed | epithelial | adherent |
| 87.1 | HB-58 | rat/mouse | hybridoma | lymphoblast | suspension |
| 8C2.8.3 | HB-9571 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 939-3G5 | HB-8133 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 939-8G2 | HB-8134 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 9F8 | HB-321 | rat/mouse | hybridoma | lymphoblast | mixed |
| A2 | CRL-8119 [†] | human | B lymphoblast; lymphoma | lymphoblast | suspension |
| A ₃ | HB-8563 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| A3.1 | CRL-1961 | mouse/mouse | hybridoma | lymphoblast | suspension |
| A3.3.13 | HB-11894 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| A6 | CRL-2742 [†] | human | bladder; carcinoma; produces p-CSF | epithelial | adherent |
| B2-1B7 | TIB-189 | mouse/mouse | hybridoma | lymphoblast | suspension |
| B2A3 | CRL-1965 | mouse/mouse | hybridoma | lymphoblast | suspension |
| B7.11 | TIB-191 | mouse/mouse | hybridoma | lymphoblast | suspension |
| B8-F11 | CRL-1852 | mouse/mouse | hybridoma | lymphoblast | suspension |
| C3 | CRL-2441 | mouse/mouse | hybridoma | lymphoblast | suspension |
| C6 | HB-12330 [†] | mouse/mouse | hybridoma | | suspension |
| D11.16.8 | HB-9849 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| D3 | HB-305 | rat/mouse | hybridoma | lymphoblast | suspension |
| D4 | HB-8068 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| F5 | HB-9645 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| G1 | HB-12624 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| G10 | CRL-2223 | rat/mouse | hybridoma | lymphoblast | suspension |
| G12 | CRL-2827 | mouse/mouse | hybridoma | lymphoblast | suspension |
| G2 | CRL-13005 [†] | human | kidney, peripheral blood; somatic cell hybrid; Burkitt's lymphoma | epithelial | adherent |
| | | | | | |
| G3 | CRL-2434 | mouse/mouse | hybridoma | lymphoblast | mixed |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|---|------------------------|------------------------|--|-------------|-------------|
| 1H10-6 | HB-48 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1H11 | HB-10611 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1H3 | HB-284 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2.03.7 | HB-8389 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2.040 pRSV-T | CRL-11516 [†] | human | eye (cornea); immortalized with SV40 early region | epithelial | adherent |
| 2.28 M1 | HB-166 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2.43 | TIB-210 | rat/mouse | hybridoma | lymphoblast | suspension |
| .4G2 | HB-197 | rat/mouse | hybridoma | lymphoblast | suspension |
| 00-3-G6-4 | HB-8737 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 0-10-5S | HB-23 | mouse/mouse | hybridoma | lymphoblast | suspension |
| :01-45E9 | CRL-2670 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 018 | CRL-10907 [†] | mouse | liver; stroma | fibroblast | adherent |
| :02-11A8 | CRL-2669 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 0.3 | CRL-2655 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 03-7D10 | CRL-2651 [†] | mouse/mouse | hybridoma | lymphoblast | mixed |
| 04-4 | HB-185 | mouse/mouse | hybridoma | lymphoblast | suspension |
| .0-8-4S | HB-11 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 0B8 | CRL-12582 [†] | human | kidney, B cell; Burkitt's lymphoma | | adherent |
| :0C2 | CRL-2382 | rat/mouse | hybridoma | lymphoblast | suspension |
| 0H11 | CRL-9300 [†] | human | spleen, B lymphocyte; EBV transformed | lymphoblast | suspension |
| :0H2 | HB-323 | rat/mouse | hybridoma | lymphoblast | mixed |
| :19 | HB-9371 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 25 | HB-8508 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 254-62.2 | CRL-8544 [†] | hamster, Syrian golden | kidney | fibroblast | adherent |
| 26H | HB-12592 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2Rv1 | CRL-2505 | human | prostate; carcinoma | epithelial | adherent |
| :32 | HB-9372 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 236L | HB-12593 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3A-5-21S | HB-36 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3B6 | HB-8521 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| 3 ScCr | CRL-2751 | mouse | bone marrow | macrophage | adherent |
| 240-13D10 | CRL-2672 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 24IA ₂ E ₂ E ₁₀ D ₅ | HB-8049 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| :5-5-16S | HB-37 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 5-9-17S II | HB-26 | mouse/mouse | hybridoma | lymphoblast | suspension |
| .5-9-3S | HB-38 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 260-33C4 | CRL-2667 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 166-6 | CRL-2151 | mouse | pancreas; acinar cell tumor | epithelial | adherent |
| .6-7-11S | HB-15 | mouse/mouse | hybridoma | lymphoblast | suspension |
| ?6-8-16S | HB-42 | mouse/mouse | hybridoma | lymphoblast | suspension |
| :6CB-1 | CRL-1495 | baboon, African | spleen, lymphoblast; HVS transformed | lymphoblast | suspension |
| 6ic | HB-246 | mouse/mouse | hybridoma | lymphoblast | suspension |
| .8-11-5S | HB-19 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 8-13-35 | HB-41 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 8-14-8S | HB-27 | mouse/mouse | hybridoma | lymphoblast | suspension |
| !8-16-8S | HB-35 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 83TAg | CRL-2822 | mouse | embryo, fibroblast; immortalized with SV40 large Tantigen | fibroblast | adherent |
| !8-8-6S | HB-51 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 8S.3 | CRL-2758 | channel catfish | peripheral blood, Tlymphoblast | lymphoblast | suspension |
| 90-4E10 | CRL-2662 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 93 | CRL-1573 | human | kidney, fetal | epithelial | adherent |
| 93 c18 | CRL-10852 [†] | human | kidney; high transfection frequencies | epithelial | adherent |
| 93/CHE-Fc | CRL-2368 | human | kidney; produces soluble CHE-Fc | epithelial | adherent |
| 93 EcR Shh | CRL-2782 | human | kidney; transformed with adenovirus 5 DNA | epithelial | adherent |
| 93T/17 | CRL-11268 [†] | human | kidney; highly transfective | epithelial | adherent |
| 2A | CRL-12013 [†] | human | kidney; amphotropic retroviral | epithelial | adherent |
| | | | nackading line | | |
| A11 | CRL-2442 | mouse/mouse | packaging line hybridoma | lymphoblast | suspension |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------|------------------------|-------------|---|-------------|-----------------|
| 2A3A1H | HB-8555 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2A5 | CRL-2444 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2AB1-IA10 | HB-8210 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| 2B5 | HB-8963 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2B5.3 | CRL-1960 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2B7 | CRL-2443 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2B8 | CRL-12569 [†] | human | ascites, B lymphocyte; Burkitt's lymphoma | lymphoblast | suspension |
| 2BD4E4 K99 | HB-8178 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2C1H7 | CRL-2746 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2C4 | CRL-1760 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2C5-6 | HB-8995 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with |
| | | | | | feeder cells |

ATCC Cell Biology Trivia #2

How many pea plants did Gregor Mendel cross-breed in an 8 year period?

Between 1856 and 1863 Mendel and his assistants cross-bred 30,000 pea plants and noted the appearance of the progeny, laying the groundwork for the field of genetics. His work was the model of meticulous record-keeping.

| 2D10 | CRL-2226 | rat/mouse | la de via de casa | المام والمام والمرود | |
|----------|------------------------|---------------|--|----------------------|------------|
| | | | hybridoma | lymphoblast | suspension |
| 2D12 | CRL-1689 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2D4 | TIB-185 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2D-7 | HB-9667 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2D7F10 | CRL-2025 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2E10-H2 | CRL-1812 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2E.6 | HB-128 | rat/mouse | hybridoma | lymphoblast | suspension |
| 2E6 | HB-226 | hamster/mouse | hybridoma | lymphoblast | suspension |
| 2E8 | TIB-239 | mouse | bone marrow | lymphoblast | suspension |
| 2F.11.15 | TIB-194 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2F-2B | CRL-2168 | mouse | axillary lymph node, vascular epithelium; | epithelial | adherent |
| | | | SV40 transformed | | |
| 2F7 | CRL-10237 [†] | human | lymph node; Burkitt's lymphoma | lymphoblast | suspension |
| 2FLB.Ln | CRL-6045* | bovine | lymph node; leukemia | | |
| 2G3 | CRL-2435 | mouse/mouse | hybridoma | lymphoblast | mixed |
| 2G8.D6 | HB-8190 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2H-11 | CRL-2163 | mouse | axillary lymph node, vascular epithelium; | epithelial | adherent |
| | | | SV40 transformed | | |
| 2H6-C2 | CRL-1853 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2Hx-2 | HB-8117 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2LBLN | CRL-6047* | bovine | lymph node | | |
| 2PK-3 | TIB-203 | mouse | B lymphocyte; lymphoma | lymphoblast | suspension |
| 2T8-3E10 | HB-8213 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2V6.11 | CRL-2784 | human | kidney; transformed with adenovirus 5 DNA | epithelial | adherent |
| 30/15 | HB-8152 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 30-5-7S | HB-31 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 308TAg | CRL-2819 | mouse | embryo, fibroblast; immortalized with SV40 | fibroblast | adherent |
| - | | | large T antigen | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647TM) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|---|-----------------------------------|----------------------------|--|----------------------------|-----------------------------|
| 30-C7 | TIB-106 | rat/mouse | hybridoma | lymphoblast | suspension |
| 30-H12 | TIB-107 | rat/mouse | hybridoma | lymphoblast | suspension |
| 310-29F7 | CRL-2656 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 311-3D4 | CRL-2657 | mouse/mouse | hybridoma | lymphoblast | mixed |
| 312-13E8 | CRL-2658 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 31-3-4S | HB-77 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 31-42-19 | HB-9726 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3.155 | TIB-211 | rat/mouse | hybridoma | lymphoblast | suspension |
| 317G5.C1D3 | HB-8691 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 31-90-25 | HB-9725 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3197-3 | CRL-1568 | mouse | embryo | fibroblast | adherent |
| 31E9 | HB-11052 [†] | human/human | hybridoma; produces GIF | lymphoblast | suspension |
| 32.2 | HB-9469 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 32B11 | CRL-2559 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 32D Clone 3 | CRL-11346 [†] | mouse | bone marrow | lymphoblast | mixed |
| 331.12 | TIB-129 | rat/mouse | hybridoma | lymphoblast | suspension |
| 339-1 | HB-186 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3D1 | TIB-227 | rat/mouse | hybridoma | lymphoblast | suspension |
| 34 | CRL-1889 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 34-1-2S | HB-79 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4-2-125 | HB-87 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4-4-205 | HB-75 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 34-4-215 | HB-76 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 34-5-3S | HB-85 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 34-5-8S | HB-102 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 34-7-23S | HB-101 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 35.1 | HB-222 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 35.6 | CRL-10052 [†] | hamster, Chinese | ovary; produces human CR1 | epithelial | adherent |
| 356-1 | HB-181 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 36 | CRL-8193 [†] | human/mouse | hybridoma fusion partner | lymphoblast | suspension |
| 36.5 (CD8+) | CRL-11116 [†] | mouse | embryonic stem cell; pluripotent; null for Lyt-2 (CD8) expression | epithelial | adherent on feeder cells |
| 36F-18C | HB-285 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 37.04.12 | HB-9312 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 37.04.12 372 | CRL-1893 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 88.1 | HB-231 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 38-1 | HB-182 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3-83P | HB-20 | | hybridoma | lymphoblast | |
| 39-S | HB-8180 [†] | mouse/mouse mouse/mouse | hybridoma | lymphoblast | suspension suspension |
| BA(tPA-30-1) | CRL-1583 | | • | lymphobiast | adherent |
| | | human | placenta | li ina ia la la at | |
| 3A5 3A8 | CRL-2440 HB-12024 [†] | mouse/mouse | hybridoma hybridoma | lymphoblast lymphoblast | suspension |
| BA-sub E [post | | mouse/mouse | • | туптрпортаві | suspension |
| | CRL-1584 | human | placenta | | adherent |
| crisis of 3A(tPA-30 3B-11 | CRL-2160 | mouse | axillary lymph node, vascular epithelium; | epithelial | adherent |
| DD11 | רטו אדרי | channal satfala | SV40 transformed | lymphoblest | cucponsis = |
| BB11 BB18 | CRL-2757 | channel catfish | peripheral blood, B lymphoblast | lymphoblast | suspension |
| | HB-8654 [†] | mouse/mouse | hybridoma | lymphoblast | mixed |
| C10 | TIB-228 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CE 1 | HB-8511 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| C5.1 | CRL-2284 | mouse/mouse | hybridoma | lymphoblast | suspension |
| C7.2 | CRL-1959 | mouse/mouse | hybridoma | lymphoblast | suspension |
| C9-D11-H11 | CRL-1745 | mouse/mouse | hybridoma | lymphoblast | suspension |
| E1 | HB-8067 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 8F6 | HB-8512 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| IG3 | HB-8516 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| | CRL-1814 | mouse/mouse | hybridoma | lymphoblast | suspension |
| | | | | | |
| G9F3 | CRL-1843 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3G9F3 3H5-1 | HB-46 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3G5 3G9F3 3H5-1 3LBLN 3Pt12B8 | | | • | | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------------|------------------------|--------------------------|--|----------------|-------------|
| 3T3-L1 | CL-173 | mouse | embryo | fibroblast | adherent |
| 3T3 MEFs KO | CRL-2753 | mouse | embryo;Cav-1 (–/–) | fibroblast | adherent |
| 3T3 MEFs WT | CRL-2752 | mouse | embryo;Cav-1 (+/+) | fibroblast | adherent |
| 3T3-Swiss albino | CCL-92 | mouse | embryo; feeder layer cell | fibroblast | adherent |
| 3T6-Swiss albino | CCL-96 | mouse | embryo | fibroblast | adherent |
| 4/4 R.M4 | CCL-216 | rat | visceral pleura | epithelial | adherent |
| 40.10.09 | HB-9311 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 411-14E10 | CRL-2663 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 41-2 | CRL-2695 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 41-3.48 | HB-130 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 413-15D12 | CRL-2653 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 12.08.07 | HB-9313 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 12TA | CRL-2759 | channel catfish | peripheral blood, macrophage | macrophage | mixed |
| 143-15D3-2F12 | HB-11342 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 148-D 100, 10, 1 | HB-10895 [†] | human/(human x mouse) | hybridoma | lymphoblast | suspension |
| 14aacb | HB-249 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 451Lu | CRL-2813 | human | skin, melanocyte; nodular melanoma in vertical | spindle-shaped | adherent |
| | | | growth phase; from lung metastases in mice | | |
| 45.6.TG1.7 | CRL-1608 | mouse | hybridoma fusion partner | lymphoblast | suspension |
| 154C11 | HB-8484 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 155 | HB-8507 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 16-2 | CRL-2186 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 16/4 | HB-67 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 16-4 | CRL-2178 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 16-5 | CRL-2184 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 18 | CRL-1913 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4A4B11 | HB-8327 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4A6 | CRL-1928 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4B2 | HB-196 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4B2-6C3-1C9 | HB-12466 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4C | HB-8311 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4C2.4A7.5H11 | CRL-2744 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1C4 | HB-327 | rat/mouse | hybridoma | lymphoblast | mixed |
| 4C5G | CRL-2538 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4C9 | CRL-2437 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4D1.5.7 | HB-11495 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1D11 | HB-240 | rat/mouse | hybridoma | lymphoblast | suspension |
| 4D12 | HB-178 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4D9D4 | CRL-1818 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4E11 | HB-9259 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4E8C12 | HB-10452 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4F2C13 | HB-22 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 4H1-A7 | CRL-1813 | mouse/mouse | hybridoma | lymphoblast | suspension |
| IMBr-5 | CCL-208 | monkey, Rhesus | lung (bronchus) | epithelial | adherent |
| IT1 | CRL-2539 | mouse | mammary gland tumor; metastatic tumor model | epithelial | adherent |
| 5/9 m α3-18 | CRL-10154 [†] | hamster, Chinese | ovary; produces human M-CSF | epithelial | adherent |
| 50-6 | CRL-2696 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 51.1 | HB-230 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 514 | CRL-1914 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 52 | HB-9361 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 520C9 | HB-8696 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 528 | HB-8509 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 52-S | HB-8181 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 53-6.72 | TIB-105 | rat/mouse | hybridoma | lymphoblast | suspension |
| 33-7.313 | TIB-104 | rat/mouse | hybridoma | lymphoblast | suspension |
| 53-S | HB-8182 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 548 | CRL-1890 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 55-2 | CRL-2155 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 55-36 | CRL-2153 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 55-6 | CRL-2156 | mouse/mouse | hybridoma | lymphoblast | suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

36

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name ATCC® No. | | Species | Source/Application | Morphology | Growth Mode | |
|---|------------------------|--------------------------|---|------------------|--------------------------|--|
| 55-83 | CRL-2185 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 558-D 100, 10, 1 | HB-10894 [†] | human/(human x mouse) | hybridoma | lymphoblast | suspension | |
| 559/64-D 100, 10, 1 | HB-10893 [†] | human/(human x mouse) | hybridoma | lymphoblast | suspension | |
| 5637 | HTB-9 | human | urinary bladder; carcinoma | epithelial | adherent | |
| 66B3 | CRL-2542 [†] | mouse | embryonic stem cell; disrupted <i>lck</i> gene | | adherent on feeder cells | |
| 579 | HB-8506 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 58-S | HB-8183 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 5A1 | CRL-2702 | rat/rat | hybridoma | lymphoblast | suspension | |
| C6 Clone 1 | CRL-1969 | rat/mouse | hybridoma | lymphoblast | suspension | |
| 5c8 | HB-10916 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| C9 | HB-8371 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| D4-11 | HB-49 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| D5.11.6 | HB-11895 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| E4 | CRL-2635 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| E9C11 | HB-21 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| F12 AD3 | HB-8209 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| G5 | CRL-2633 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| H8 | CRL-2646 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| LBLN | CRL-6049* | bovine | lymph node | | | |
| 0bca | HB-247 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 5.12 | CRL-13006 [†] | mouse | somatic cell hybrid | lymphoblast | suspension | |
| 1/7 | HB-8154 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| -23 (Clone 6) | CRL-1607 | rat | thyroid; medullary thyroid carcinoma | | adherent | |
| 3D3 | HB-44 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 50E2-2B12 | HB-10812 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 58-1-2 | CRL-1712 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 6A7M | HB-8159 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| A8.6F10.1A6 | CRL-2743 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| D8MB4 | CRL-1842 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| E6 | CRL-11398 [†] | hamster, Chinese | ovary; produces 23FG2; anti CD18 Mab | epithelial | adherent | |
| F4C5 | CRL-1869 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| G4.2.5 | HB-11722 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| SLBLN | CRL-6050* | bovine | lymph node | 1 1 1 . | | |
| 703D4 | HB-8301 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 70Z/3 | TIB-158 | mouse | pre-B lymphoblast; methylnitrosourea- induced lymphoma | lymphoblast | suspension | |
| 1A7 | TIB-147 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| ² 2A1 | HB-168 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| '3/1 | HB-66 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| ′-34-1 | CRL-1945 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 4-11-10 | HB-139 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 4-12-4 | HB-147 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 4-22-15 | HB-142 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 4-22-15A | HB-142.1 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 4-9-3 | HB-156 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 6-2-11 | HB-143 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 6-5-28 | HB-153 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 6-6-7 | HB-141 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 6-7-4 | HB-140 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 69-P | CRL-1933 | human | kidney; renal cell adenocarcinoma | epithelial | adherent | |
| 786-O | CRL-1932 | human | kidney; renal cell adenocarcinoma | epithelial | adherent | |
| AGE/EVED | HB-10135 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AC5/EYFP | SCRC-1033 | mouse | embryo; embryonic stem cell | h manual 1 - 1 4 | adherent | |
| C ₂ C ₅ C ₁₂ | HB-8678 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 7C6.5.4 | HB-9574 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| C8 D2-1.4.1.5 | HB-8465 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| UZ-1.4.1.D | HB-92 | rat/mouse | hybridoma | lymphoblast | suspension with | |

* Part of the NBL collection; see page 12. + Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | C® No. Species Source/Application | | Morphology | Growth Mode | |
|-------------------------------------|------------------------|-----------------------------------|--|----------------------------|-----------------------------|--|
| 7D3A.2 | CRL-1886 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 7D4 | CRL-1698 | rat/mouse | hybridoma | lymphoblast | suspension | |
| 7E11C5 | HB-10494 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 7E12H12 | HB-9397 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 7E3 | HB-8832 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 7F2 | CRL-12557 [†] | mouse | bone marrow; osteoblast; inducible adipocyte differentiation model | fibroblast | adherent | |
| 7F2-6D4-8E7 | HB-11945 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 7G7B6 | HB-8784 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 30 V 5B4 | TIB-132 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 303-15.6 | CRL-2395 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 307.15 | CRL-2287 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 307.31 | CRL-2282 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 307.33 | CRL-2290 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 30T | CRL-7901* | human | unknown | fibroblast | adherent | |
| 33-12-5 | CRL-1971 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 36D | HB-286 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 38B | CRL-1967 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 88TAg | CRL-2820 | mouse | embryo, fibroblast; immortalized with SV40 large T antigen | fibroblast | adherent | |
| 39MS30 | HB-11300 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BA2N | HB-8161 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 3A3B.6 | CRL-1875 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 3B1B.1 | CRL-1877 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BE5 | CRL-8993 [†] | human | peripheral blood, B lymphoblast; acute lymphoblastic leukemia | lymphoblast | suspension | |
| 3E7 | CRL-8795 [†] | human | spleen; B lymphoblast; EBV transformed | lymphoblast | suspension | |
| 90196B | CRL-9853 [†] | human | spleen; macrophage; monocyte | monocyte/ macrophage | suspension | |
| 90.74 | CRL-11654 [†] | human | kidney; transformed with adenovirus 5 DNA; packaging cell line | epithelial | adherent | |
| 91MS441 | HB-11301 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 92TAg | CRL-2816 | mouse | embryo, fibroblast; immortalized with SV40 large Tantigen | fibroblast | adherent | |
| 9.3F10 | HB-180 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 9.4 | HB-10508 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 9-4-3 | HB-8935 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 9-A5 | CRL-1844 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| PAE10 | CRL-1761 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 9-B1 | CRL-1845 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 9BG5 | HB-167 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 9D10 | CRL-8752 [†] | human | spleen, B lymphocyte; EBV transformed | lymphoblast | suspension | |
| 9D9 | CRL-1703 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 9F12 | HB-8177 [†] | human/mouse | hybridoma | lymphoblast | suspension | |
| PL/lacZ | CRL-2200 | rat | brain; gliosarcoma; expresses beta- galactosidase | fibroblast | adherent | |
| 9TR#1 | CRL-11379 [†] | mouse | embryonic stem cell; disrupted TNFR p55 gene | epithelial | adherent on feeder cells | |
| α Intermediate filament | TIB-131 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| A.P. | CRL-6295* | mongoose, African water | skin | fibroblast | adherent | |
| A-10 | CRL-1476 | rat | thoracic aorta, medial layer | myoblast | adherent | |
| A101D | CRL-7898* | human | skin; melanoma | epithelial | adherent | |
| A11.1 M | HB-164 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| | HB-8451 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| A123 | HB-8452 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| | | | • | .,р.1001030 | | |
| A124 | | human | brain: glioblastoma | | adherent | |
| A124 A172 | CRL-1620 | human mouse/mouse | brain; glioblastoma hybridoma | lymphoblast | adherent suspension | |
| A123 A124 A172 A1G3 A20 | | human mouse/mouse mouse | brain; glioblastoma hybridoma B lymphocyte; reticulum cell sarcoma | lymphoblast lymphoblast | suspension suspension | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

38

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ame ATCC® No. | | No. Species Source/Application | | Growth Mode | |
|----------------------------------|------------------------|----------------------------|---|----------------|--------------|--|
| A2058 | CRL-11147 [†] | human | lymph node (metastasis); malignant melanoma (skin primary) | epithelial | adherent | |
| A253 | CRL-7902* | human | epidermis; epidermoid carcinoma | epithelial | adherent | |
| A-253 | HTB-41 | human | submaxillary salivary gland; epidermoid | epithelial | adherent | |
| | 1110 11 | naman | carcinoma | сринени | udiferent | |
| A2B5 clone 105 | CRL-1520 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| A2E11 | CRL-1846 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| A3 | CRL-2570 | human | T lymphocyte; control for I 9.2 and I 2.1 | lymphoblast | suspension | |
| .5 | CITE 2370 | Trainian | Fas-mediated apoptosis models | iyiiipiioolast | 343961131011 | |
| \3.4H2 | HB-12319 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| \3.6B10 | HB-12318 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| N-375 | CRL-1619 | human | skin; malignant melanoma | • | adherent | |
| \375.S2 | CRL-1872 | human | skin; malignant melanoma | | adherent | |
| \388 | CRL-7905* | human | lymph nodes (metastasis); carcinoma, | epithelial | adherent | |
| | | | epidermoid (unknown primary) | | | |
| \4.74 | CRL-2041 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| \4.840 | CRL-2043 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 4.951 | CRL-2046 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| \-427 | HTB-53 | human | lung; carcinoma | epithelial | adherent | |
| \-431 | CRL-1555 | human | epidermis; epidermoid carcinoma | epithelial | adherent | |
| \431NS | CRL-2592 | human | epidermis; epidermoid carcinoma | epithelial | adherent | |
| \-498 | HTB-44 | human | kidney; carcinoma | epithelial | adherent | |
| \5.12.14 | HB-11553 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| \5.4 | CRL-2275 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| \549 | CCL-185 | human | lung; carcinoma | epithelial | adherent | |
| 16 | CRL-8192 [†] | human/mouse | hybridoma fusion partner | lymphoblast | suspension | |
| \6 | CCL-102 | toad, South African | kidney | epithelial | adherent | |
| | 002 .02 | clawed | aey | epitire.ia. | dancient | |
| A-673 | CRL-1598 | human | muscle; rhabdomyosarcoma | fibroblast | adherent | |
| A68177 | CRL-7714* | human | skin; xeroderma pigmentosum | fibroblast | adherent | |
| ١7 | CRL-2500 | human | skin; melanoma; transfected to express filamin-1 | melanocytic | adherent | |
| ١704 | CRL-7911* | human | kidney; adenocarcinoma | epithelial | adherent | |
| \-704 | HTB-45 | human | kidney; adenocarcinoma | epithelial | adherent | |
| \717 | HB-9596 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| \-72 | CRL-1542 | dog | unknown; tumor | fibroblast | adherent | |
| A7r5 | CRL-1444 | rat | thoracic aorta; smooth muscle | fibroblast | adherent | |
| 19 | CCL-1.4 | mouse | subcutaneous connective tissue (areolar | fibroblast | adherent | |
| | | | and alveolar) | | | |
| ١9 | CRL-1811 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| \-9 | CRL-6319* | mouse | connective tissue | fibroblast | adherent | |
| 49 L hD2 S.C. 18 | CRL-10225 [†] | mouse | subcutaneous connective tissue; expresses | fibroblast | adherent | |
| | | | human dopamine D2 receptor | | | |
| AA224 | HB-10183 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| \A5 | CRL-2637 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AA8 | CRL-1859 | hamster, Chinese | ovary | fibroblast | mixed | |
| \b 21.1 | HB-11601 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| Ab 23.1 | HB-11602 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AB.9 | CRL-2298 | zebrafish | caudal fin | fibroblast | adherent | |
| AB1-2 | HB-33 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| ABE-8.1/2 | TIB-205 | mouse | · · · · · · · · · · · · · · · · · · · | lymphoblast | suspension | |
| C133.1 | HB-12346 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| ACHN | CRL-1611 | human | kidney; renal cell adenocarcinoma | epithelial | adherent | |
| | HB-80 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| ACT I | HB-81 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| | | human | skin; Ehlers-Danlos syndrome, type II | fibroblast | adherent | |
| ACT IV | CRL-1227 | | , | | | |
| ACT IV Ad Hot | CRL-1227 HB-72 | | hybridoma | lymphoblast | suspension | |
| ACT I ACT IV Ad Hot AE-1 AF-2 | HB-72 | mouse/mouse | hybridoma hybridoma | lymphoblast | suspension | |
| ACT IV Ad Hot AE-1 AE-2 | HB-72 HB-73 | mouse/mouse mouse/mouse | hybridoma | lymphoblast | suspension | |
| ACT IV Ad Hot AE-1 | HB-72 | mouse/mouse | | | | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. bry research use only. Not intended for use in humans, animals or for diagnostics.



| Name ATCC® No. | | CC® No. Species Source/Application | | Morphology | Growth Mode | |
|--|------------------------|------------------------------------|---|------------------|------------------------|--|
| Aedes albopictus clone C6/36 | CRL-1660 | mosquito | whole larva | | adherent | |
| AF3-12.1.3 | HB-160 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AF4-73.3.1 | HB-201 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AF6-120.1.2 | HB-163 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AF6-122.2.5 | HB-199 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AF6-78.25.4 | HB-162 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AF6-88.5.3 | HB-158 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AFT024 | SCRC-1007 | mouse | embryonic liver; feeder layer | fibroblast | adherent | |
| AGS | CRL-1739 | human | stomach; gastric adenocarcinoma | epithelial | adherent | |
| A-HER2 | CRL-10463 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| AHH-1 | CRL-8146 [†] | human | peripheral blood, B lymphocyte; EBNA positive | lymphoblast | clusters in | |
| | | | | | suspension | |
| AHL-1 | CCL-195 | hamster, Armenian | lung | fibroblast | adherent | |
| Ainv15 | SCRC-1029 | mouse | embryonic stem cell | spherical colony | adherent | |
| AK-D | CCL-150 | cat | lung | epithelial | adherent | |
| AKR/JA.Sp | CRL-6320* | mouse | spleen | fibroblast | adherent | |
| AKR1.G.1.OVA ^R .1.26 | TIB-232 | mouse | hybridoma fusion partner, T cell | lymphoblast | suspension | |
| AL 1-27 | HB-8441 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| Al Ke | CRL-1325 | human | skin; Ehlers-Danlos syndrome, presumed heterozygote | fibroblast | adherent | |
| AL/N | CRL-6506* | mouse | unknown | | | |
| α-ACE 3.1.1 | HB-8191 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| αBL5C2.870005 | HB-9907 [†] | bovine/mouse | hybridoma | lymphoblast | suspension | |
| αBL5C2.870009 | HB-9908 [†] | bovine/mouse | hybridoma | lymphoblast | suspension | |
| αBL5C2.870016 | HB-9909 [†] | bovine/mouse | hybridoma | lymphoblast | suspension | |
| αIR-1 | HB-175 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| αM346C7C1 | HB-11124 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| αTC1 Clone 9 | CRL-2350 | mouse (transgenic) | pancreas, alpha cell; adenoma | epithelial | adherent | |
| Am Coo | CRL-1286 | human | skin; osteogenesis imperfecta (tarda) | fibroblast | adherent | |
| AML14.3D10 | CRL-12079 [†] | human | peripheral blood; acute myeloid leukemia | | suspension | |
| /CCCKR3 Clone 16 | | | | | | |
| Am Ric | CRL-1129 | human | skin; osteogenesis imperfecta | fibroblast | adherent | |
| Amdur II | CCL-124 | human | skin; methylmalonic acidemia | fibroblast | adherent | |
| AMJ2-C11 | CRL-2456 | mouse | lung; alveolar macrophage | macrophage | mixed | |
| AMJ2-C8 | CRL-2455 | mouse | lung; alveolar macrophage | macrophage | mixed | |
| AML12 | CRL-2254 | mouse (transgenic) | liver | epithelial | adherent | |
| AML-193 | CRL-9589 [†] | human | peripheral blood; monocyte; acute monocytic leukemia | lymphoblast | suspension | |
| AMS 9.1.1.1 | HB-161 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| An Zan | CRL-1266 | human | skin; Marfan syndrome | fibroblast | adherent | |
| AN3 CA | HTB-111 | human | lymph node (metastasis); adenocarcinoma (endometrium primary) | epithelial | adherent | |
| ANJOU 65 | CRL-11269 [†] | human | kidney; highly transfective | epithelial | adherent | |
| Antheraea cells, adapted | CCL-80 | moth | ovary | varied | suspension | |
| anti-130-kDa Mesothelial- Ciliated Cells | CRL-2401 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| Antibody 2.06 | HB-104 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| Anti-My-10 clone 28/8/8/ | HB-8483 [†] | mouse/mouse | hybridoma lympho hybridoma lympho | | suspension | |
| Anti-SC35 | CRL-2031 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| anti-SR | CRL-2031 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| anti-SRp20 | CRL-2384 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| апи- <u>зкр</u> 20 AP-3 | HB-242 | | hybridoma | lymphoblast | | |
| AP.6 | | mouse/mouse | · | lymphoblast | suspension | |
| Ar Ke-2 | CRL-2227 CRL-1324 | mouse/mouse human | hybridoma skin; Ehlers-Danlos syndrome, presumed | fibroblast | suspension adherent | |
| AD421 | CDI 1402 | rat | heterozygote | | adherent | |
| AR42J | CRL-1492 | rat | exocrine pancreas; tumor | | adherent | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | pecies Source/Application | | Growth Mode | |
|-------------------|------------------------|--------------------|--|----------------|------------------------------|--|
| ARH-77 | CRL-1621 | human | peripheral blood, B lymphoblast; plasma cell leukemia | lymphoblast | suspension | |
| ARIP | CRL-1674 | rat | exocrine pancreas; tumor | epithelial | adherent | |
| ARPE-19 | CRL-2302 | human | eye (retina), pigmented epithelium | epithelial | adherent | |
| ARPE-19/HPV-16 | CRL-2502 | human | eye (retina), pigmented epithelium; HPV-16 transfected | epithelial | adherent | |
| AS 33 | HB-8779 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells | |
| As4.1 | CRL-2193 | mouse (transgenic) | kidney; intraparenchymal | epithelial | adherent | |
| ASK | CRL-2747 | Atlantic salmon | kidney | epithelial | adherent | |
| AsPC-1 | CRL-1682 | human | ascites (metastasis); adenocarcinoma (pancreas primary) | | adherent | |
| ATRFLOX | CRL-2780 | human | colon; colorectal carcinoma | epithelial | adherent | |
| AtT-20 | CCL-89 | mouse | pituitary tumor | small, rounded | clusters in suspension | |
| AtT-20/D16v-F2 | CRL-1795 | mouse | pituitary tumor | small rounded | adherent | |
| AtT-20ins (CGT-6) | CRL-11285 [†] | mouse | pituitary tumor; glucose-stimulated insulin release | | adherent | |
| AT3B-1 | CRL-2375 | rat | prostate; malignant carcinoma | epithelial | adherent | |
| AU565 | CRL-2351 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | epithelial | adherent | |
| AV. | CCL-21 | human | HeLa contaminant | epithelial | adherent | |
| AVE-115 | CRL-6507* | rat | unknown | • | | |
| Aw3.18.14 | CRL-2826 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| B/C3T3.We | CRL-6327* | mouse | embryo | fibroblast | adherent | |
| B/CMBA.Ov | CRL-6331* | mouse | ovary | epithelial | adherent | |
| B/CWE | CRL-6334* | mouse | embryo | | adherent | |
| B104-1-1 | CRL-1887 | mouse | embryo; expresses her2/neu | fibroblast | adherent | |
| B11 | HB-8372 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| B13-24 | CRL-11397 [†] | hamster, Chinese | ovary; produces 23FG2; anti CD18 Mab | epithelial | adherent | |
| B14FAF28-G3 | CCL-14 | hamster, Chinese | peritoneum | fibroblast | adherent | |
| B16-F0 | CRL-6322* | mouse | skin; melanoma | | adherent | |
| B16-F1 | CRL-6323* | mouse | skin; melanoma | | adherent | |

ATCC Cell Biology Trivia #3

Who is credited with inventing the microscope?

The first microscope is generally attributed to Zacharias Janssen around 1590. Another Dutch lensmaker, Antoni van Leeuwenhoek, took a small microscope used for examining textiles and tinkered with it until its magnification was vastly improved. Although he was unschooled in the sciences, his drawings of protozoa delighted the Royal Society in London around 1668.

| B16-F10 | CRL-6475* | mouse | skin; melanoma | | adherent |
|-----------|-----------------------|-------------|---|-------------|------------|
| B1B3 | CRL-2249 | mouse/mouse | hybridoma | lymphoblast | suspension |
| B1B6 | CRL-2248 | mouse/mouse | hybridoma | lymphoblast | suspension |
| B2.Ln | CRL-6022* | bovine | lymph node | | |
| B2.Sp | CRL-6023* | bovine | spleen | | |
| B2.Sp/Thy | CRL-6024* | bovine | mixed spleen and thymus | | |
| B2-1 | CRL-8085 [†] | mouse | embryo; thymidine kinase negative (TK-) | fibroblast | adherent |

* Part of the NBL collection; see page 12. † Patent item; see page 12.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. Species Source/Application | | Source/Application | Morphology | Growth Mode | |
|---------------------------------|--------------------------------------|-----------------|--|------------------|-------------|--|
| B21-2 | TIB-229 | rat/mouse | hybridoma | lymphoblast | suspension | |
| B25.2 | HB-8107 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| B27M1 | HB-157 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| B27M2 | HB-165 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 329 | HB-9746 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| B-3 | CRL-11421 [†] | human | eye (lens); AdV12-SV40 transformed | epithelial | adherent | |
| B3/25 | CRL-8034 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 335 | CRL-2754 | rat | central nervous system; nitrosoethylurea-induced neuroblastoma | neuronal | adherent | |
| 338.1 | HB-8110 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 33D | CRL-2634 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 35 | HB-8453 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 3505 | HB-12000 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 35 NIH | HB-10569 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 36.2 | HB-8106 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 369 | HB-9437 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 36H12.2 | HB-9771 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 372.3 | HB-8108 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 37-24-E1G4 | HB-11341 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 38-24-3 | TIB-139 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| Ba Pot | CRL-1280 | human | skin; osteogenesis imperfecta (congenita) | fibroblast | adherent | |
| 3A7.3C.9 | HB-10716 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BA-D5 | HB-287 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 3A-G5 | HB-276 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BALB/3T12-3 | CCL-164 | | | fibroblast | adherent | |
| | | mouse | embryo | | | |
| BALB/3T3 clone A31 | CCL-163 | mouse | embryo | fibroblast | adherent | |
| 3ALB/B 0.75BAE 4.1R.1 HD A.8 | TIB-84 | mouse | embryo; chemically transformed | fibroblast | adherent | |
| BALB/c 10CrMCA A.2R.1 | TIB-86 | mouse | embryo; chemically transformed | fibroblast | adherent | |
| BALB/c 10ME HD A.5R.1 | TIB-85 | mouse | embryo; chemically transformed | fibroblast | adherent | |
| BALB/c AMuLV A.3R.1 | TIB-87 | mouse | embryo; AMLV transformed | fibroblast | adherent | |
| BALB/c AMuLV A.6R.1 | TIB-90 | mouse | embryo; AMLV transformed | fibroblast | adherent | |
| BALB/c CL.7 | TIB-80 | mouse | embryo | fibroblast | adherent | |
| BALB SFME Serum | CRL-9392 [†] | mouse | embryo | fibroblast | adherent | |
| Free Mouse Embryo | JIL 7372 | | ,0 | | adricient | |
| BB | CCL-59 | bullhead, brown | mixed connective tissue and muscle | fibroblast | adherent | |
| 3B7.1 | HB-56 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 3B7.2 | HB-82 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BB7.5 | HB-120 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BB7.6 | HB-115 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BB7.7 | HB-94 | | hybridoma | lymphoblast | <u> </u> | |
| | | mouse/mouse | spleen; erythroblast; leukemia | <u> </u> | suspension | |
| 3B88 | TIB-55 | mouse | | lymphoblast | suspension | |
| BBM | CRL-6016* | bovine | bone marrow | epithelial | adherent | |
| BBM | CRL-9482 [†] | human | lung (bronchus); virus transformed | epithelial | adherent | |
| BBM.1 | HB-28 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 3C-1 | CRL-2230 | human | B lymphoblast; lymphoma; EBV and KSHV positive | lymphoblast | suspension | |
| BC16A | TIB-59 | mouse | spleen; leukemia | lymphoblast | suspension | |
| 3C-2 | CRL-2231 | human | B lymphoblast; lymphoma; EBV and KSHV positive | lymphoblast | suspension | |
| 3C3 | HB-10166 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BC-3 | CRL-2277 [†] | human | B lymphoblast; lymphoma; KSHV positive | lymphoblast | suspension | |
| BC3A | TIB-60 | mouse | spleen; leukemia | lymphoblast | suspension | |
| BC ₃ H1 | CRL-1443 | mouse | brain; methylnitrosourea-induced smooth | 13 III Priodiast | adherent | |
| 200 55 | CDL 1670 | | muscle-like tumor | Lancardo et 1 | · · · · · · | |
| BC9-E5 | CRL-1670 | mouse/mouse | hybridoma | lymphoblast | suspension | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | ATCC® No. Species Source/Application | | Morphology | Growth Mode | |
|------------------------------|------------------------|--------------------------------------|--|-----------------|-------------|--|
| bcd mab23 | CRL-2107 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BCE C/D-1b | CRL-2048 | bovine | eye (cornea) | endothelial | adherent | |
| BCL, clone 5B,b | TIB-197 | mouse | B lymphocyte; leukemia; lymphoma | lymphoblast | adherent | |
| BCP-1 | CRL-2294 | human | peripheral blood, B lymphoblast; body cavity-based lymphoma | lymphoblast | suspension | |
| BD5-2d | HB-9689 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BDCM | CRL-2740 | human | peripheral blood, B lymphoblast; acute myelogenous leukemia | lymphoblast | suspension | |
| Be Ar | CRL-1167 | human | skin; xeroderma pigmentosum, presumed heterozygote | fibroblast | adherent | |
| Be Sal | CRL-1140 | human | skin; osteoporosis | fibroblast | adherent | |
| Be Tim | CRL-1254 | human | skin; xeroderma pigmentosum, presumed heterozygote | fibroblast | adherent | |
| 3E2 | TIB-182 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 3E29G1 | HB-233 | rat/mouse | hybridoma | lymphoblast | suspension | |
| BE(2)-C | CRL-2268 | human | bone marrow (metastasis); neuroblastoma (brain primary) | neuroblast | adherent | |
| BE(2)-M17 | CRL-2267 | human | bone marrow (metastasis); neuroblastoma (brain primary) | neuroblast | adherent | |
| 3E3F9 | HB-133 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BEAS-2B | CRL-9609 [†] | human | lung (bronchus); virus transformed | epithelial | adherent | |
| BEND | CRL-2398 | bovine | uterus (endometrium) | epithelial | adherent | |
| End.3 | CRL-2299 | mouse | brain (cerebral cortex); endothelioma; polyoma middle T antigen transformed | endothelial | adherent | |
| Ber Lin | CRL-1132 | human | skin; osteoporosis | fibroblast | adherent | |
| Bet-1 | HB-100 | rat/mouse | hybridoma | lymphoblast | suspension | |
| Bet-2 | HB-88 | rat/mouse | hybridoma | lymphoblast | suspension | |
| Beta-TC-6 | CRL-11506 [†] | mouse (transgenic) | pancreas, beta cell; insulinoma | , , , , , , , , | adherent | |
| BeWo | CCL-98 | human | placenta; choriocarcinoma | epithelial | adherent | |
| 3F-11 | CRL-8164 [†] | rat/mouse | hybridoma | lymphoblast | suspension | |
| 3F-2 | CCL-91 | bluegill | caudal trunk | fibroblast | adherent | |
| 3F-45 | HB-278 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BF-F3 | HB-283 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 3ge | CRL-1494 | snail | embryo | | adherent | |
| 3HK-21 (C-13) | CCL-10 | hamster, Syrian golden | | fibroblast | adherent | |
| BHK21-pcDNA3.1- IC | CRL-13001 [†] | hamster, Syrian golden | BHK-21 transformed; expresses human erythropoietin | fibroblast | adherent | |
| 3HK570 | CRL-10314 [†] | hamster | kidney | fibroblast | adherent | |
| Bi Fin | CRL-1219 | human | skin; Ehlers-Danlos syndrome | fibroblast | adherent | |
| Bing | CRL-11554 [†] | human | kidney; amphotropic retroviral packaging line | epithelial | adherent | |
| 3) | CRL-2522 | human | skin (foreskin) | fibroblast | adherent | |
| BJ-5ta | CRL-4001 | human | foreskin; immortalized with hTERT | fibroblast | adherent | |
| BL-3 | CRL-8037 [†] | bovine | lymphosarcoma; leukemia | lymphoblast | suspension | |
| 3L3.1 | CRL-2306 | bovine | B lymphocyte; lymphosarcoma | lymphoblast | suspension | |
| BLK CL.4 | TIB-81 | mouse | embryo | fibroblast | adherent | |
| BLK SV HD.2 A.5R.1 A.3R.1 | TIB-88 | mouse | embryo; SV40 transformed | fibroblast | adherent | |
| BLn | CRL-6017* | bovine | lymph node | | | |
| BLO-11 | CCL-198 | mouse | skeletal muscle; lysyl oxidase deficiency | fibroblast | adherent | |
| BM-N | CRL-8910 [†] | silkworm | mixed | | | |
| NL 1ME A.7R.1 | TIB-75 | mouse | liver; chemically transformed | | adherent | |
| BNL 1NG A.2 | TIB-76 | mouse | liver; chemically transformed | | adherent | |
| SNL CL.2 | TIB-73 | mouse | liver; embryonic | | adherent | |
| BNL SV A.8 | TIB-74 | mouse | liver; SV40 transformed | Claus la la st | adherent | |
| Bo Gin | CRL-1180 | human | skin; Ehlers-Danlos syndrome, type I fibroblast (autosomal dominant type) | | adherent | |
| 3P107.2.2 | TIB-154 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BpRcl | CRL-2217 | mouse | liver; hepatoma | epithelial | adherent | |
| BRL 3A | CRL-1442 | rat | liver | | adherent | |
| BS-C-1 | CCL-26 | monkey, African | kidney | epithelial | adherent | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. esearch use only. Not intended for use in humans, animals or for diagnostics.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name ATCC® N | | Species | Source/Application | Morphology | Growth Mode | |
|--------------------------------------|-----------------------------|--------------------|---|--------------------------|----------------------|--|
| BSC40 | CRL-2761 African green monk | | kidney | epithelial | | |
| BSp | CRL-6019* | bovine | spleen | amoeboid | | |
| BT. | CRL-1390 | bovine | turbinate | | adherent | |
| BT-20 | HTB-19 | human | mammary gland; carcinoma | epithelial | adherent | |
| BT-474 | HTB-20 | human | mammary gland; ductal carcinoma | epithelial | adherent, patchy | |
| 3T-483 | HTB-121 | human | mammary gland; ductal carcinoma | epithelial | adherent, patchy | |
| 3T-549 | HTB-122 | human | mammary gland; ductal carcinoma | epithelial | adherent | |
| BThy | CRL-6020* | bovine | mixed spleen and thymus | | | |
| 3TV10XSp2/0- Ag-14-10D4.90 | HB-8377 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| BUD-8 | CRL-1554 | human | skin | fibroblast | adherent | |
| 3VD2-21C11.3 | HB-9569 [†] | rat/mouse | hybridoma | lymphoblast | suspension | |
| 3VD2-23B6.4 | HB-9568 [†] | rat/mouse | hybridoma | lymphoblast | suspension | |
| 3W5147(T200 ⁻ a) 5.2 | TIB-233 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension | |
| 3W5147.3 | TIB-47 | mouse | thymus, Tlymphocyte; lymphoma | lymphoblast | suspension | |
| BW5147.3(Thy- 1⁻e).10 | TIB-234 | mouse | thymus, T lymphocyte; lymphoma | lymphoblast | suspension | |
| BW5147.G.1.4 | TIB-48 | mouse | hybridoma fusion partner; T cell | lymphoblast | suspension | |
| 3W5147.G.1.4. DUA ^R .1 | CRL-1588 | mouse | hybridoma fusion partner; T cell | lymphoblast | suspension | |
| 3xPC-3 | CRL-1687 | human | pancreas; adenocarcinoma | | adherent | |
| BZR | CRL-9483 [†] | human | lung (bronchus); virus transformed | epithelial | adherent | |
| 1 (B6NLxv1c2) | CRL-2716 | mouse | liver; hepatoma | epithelial | adherent | |
| 1.18.4 | TIB-11 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension | |
| 11C1 | HB-8964 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| :12 (B15ECiii2) | CRL-2710 | mouse | liver; hepatoma | epithelial | adherent | |
| 127:LT | CRL-1804 | mouse | mammary gland tumor | epithelial | adherent | |
| 1271 | CRL-1616 | mouse | mammary gland tumor | epithelial | adherent | |
| 129 | HB-9516 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 13589 | CRL-2704 | human | B lymphoblast; EBV transformed; fragile X | lymphoblast | suspension | |
| 1498 | TIB-49 | mouse | leukemia; acute myeloid | lymphoblast | suspension | |
| 166 | CRL-2581 | mouse (transgenic) | yolk sac; endothelial cell differentiation model; stem cell feeder layer | endothelial | adherent | |
| C166-GFP | CRL-2583 | mouse (transgenic) | yolk sac; GFP-expressing version of C166 | endothelial | adherent | |
| 171 | HB-9515 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 180 | HB-9517 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 1R-B7 | CRL-2371 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | mixed | |
| C1R-neo | CRL-2369 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension | |
| C1R-sB7 | CRL-2370 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | mixed | |
| 211 | CCL-123 | human | skin; Cri du Chat syndrome | fibroblast | adherent | |
| 273 | HB-9303 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 2BBe1 | CRL-2102 | human | colon; colorectal adenocarcinoma | epithelial | adherent | |
| C ₂ C ₁₂ | CRL-1772 | mouse | muscle | fibroblast | adherent | |
| 305 | CRL-2424 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 3-124 | HB-60 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| 32 | CRL-1585 | human | skin; amelanotic melanoma | | adherent | |
| 32TG | CRL-1579 | human | skin; amelanotic melanoma | | adherent | |
| C-33 A | HTB-31 | human | cervix; carcinoma | epithelial | adherent | |
| :35 (B16GBi1c3) | CRL-2715 | mouse | liver; hepatoma | epithelial | adherent | |
| :37 (B7IFi1) :38 | CRL-2711 CRL-2779 | mouse human | liver; hepatoma bronchus; cystic fibrosis; immortalized with | epithelial epithelial | adherent adherent | |
| | | | Ad12-SV40 hybrid | | | |
| C3A | CRL-10741 [†] | human | liver; hepatocellular carcinoma | epithelial | adherent | |
| C ₃ H/10T1/2, Clone 8 | CCL-226 | mouse | embryo | fibroblast | adherent | |
| C3H/MCA clone 15 | CRL-1411 | mouse | embryo | fibroblast | adherent | |
| C3H/MCA clone 16 | CRL-1412 | mouse | embryo | fibroblast | adherent | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | lame ATCC® No. | | ATCC® No. Species Source/Application | | Growth Mode | |
|--|----------------------------|----------------------------|---|----------------------------|--------------------------|--|
| | CRL-2717 | mouse | liver; hepatoma | epithelial | adherent | |
| C-4 I | CRL-1594 | human | cervix; carcinoma | epithelial | adherent | |
| C-4 II | CRL-1595 | human | cervix; carcinoma | epithelial | adherent | |
| C44 | CRL-1943 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| C5 | HB-8669 [†] | human/(human x mouse | hybridoma | lymphoblast | suspension | |
| C5/MJ | CRL-8293 [†] | human | cord blood, T lymphocyte; HTLV-1 infected | lymphoblast | suspension | |
| C57L/J.We | CRL-6336* | mouse | embryo | · · | adherent | |
| C58(NT)D.1.G. OVA ^R .1 | TIB-236 | rat | hybridoma fusion partner; T cell | lymphoblast | suspension | |
| C5B7 | CRL-8753 [†] | human | spleen; B lymphocyte; EBV transformed | lymphoblast | suspension | |
| <u> </u> | CCL-107 | rat | brain; glioma | fibroblast | adherent | |
| C6/LacZ | CRL-2199 | rat | brain; gliosarcoma; expresses beta- galactosidase | fibroblast | adherent | |
| C6/lacZ7 | CRL-2303 | rat | brain; gliosarcoma; expresses beta- galactosidase | fibroblast | adherent | |
| C7 | CRL-1691 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| C8-B4 | CRL-1091 | mouse | brain (cerebellum) | neuronal | adherent | |
| C8-D1A | CRL-2541 | mouse | brain (cerebellum) | neuronal | adherent | |
| C8-D1A | CRL-2534 | mouse | brain (cerebellum) | neuronal | adherent | |
| C8-S | CRL-2535 | mouse | brain (cerebellum) | neuronal | adherent | |
| Ca Ski | CRL-1550 | human | mesentery, small bowel (metastasis); epidermoid carcinoma (cervix primary) | epithelial | adherent | |
| CA3-F4 | CRL-1667 | mouse/mouse | hybridoma | lymphoblast | cucnoncion | |
| CA46 | CRL-1648 | human | | lymphoblast | suspension | |
| CAB 117-12D10 | HB-10558 [†] | | B lymphocyte; Burkitt's lymphoma hybridoma | lymphoblast | suspension | |
| Caco-2 | HTB-37 | mouse/mouse human | colon; colorectal adenocarcinoma | epithelial | suspension adherent | |
| CA-HPV-10 | CRL-2220 | human | prostate; adenocarcinoma; HPV-18 | epithelial | adherent | |
| Caki-1 | HTB-46 | human | transfected skin (metastasis); clear cell carcinoma epithelial (kidney primary) | | adherent | |
| Caki-2 | HTB-47 | human | kidney; clear cell carcinoma | epithelial | adherent | |
| CAL 27 | CRL-2095 | human | tongue; squamous cell carcinoma | epithelial | adherent | |
| Calu-1 | HTB-54 | human | pleura (metastasis); epidermoid carcinoma (lung primary) | epithelial | adherent | |
| Calu-3 | HTB-55 | human | pleural effusion (metastasis); adenocarcinoma (lung primary) | epithelial | adherent | |
| Calu-6 | HTB-56 | human | unknown, probably lung anaplastic carcinoma | epithelial | adherent | |
| CAMA-1 | HTB-21 | human | pleural effusion (metastasis); adeno- | epithelial | adherent, | |
| C/ 1141/ \ 1 | 1110 21 | Haman | carcinoma (mammary gland primary) | еріпіснаі | patchy | |
| Caov-3 | HTB-75 | human | ovary; adenocarcinoma | epithelial | adherent | |
| Caov-4 | HTB-76 | human | fallopian tube (metastasis); adenocarcinoma (ovary primary) | epithelial | adherent | |
| Capan-1 | HTB-79 | human | liver (metastasis); adenocarcinoma (pancreas primary) | epithelial | adherent | |
| Capan-2 | HTB-80 | human | pancreas; adenocarcinoma | polygonal | adherent | |
| CAR | CCL-71 | goldfish | fin | fibroblast | adherent | |
| Cates-1B | HTB-104 | human | testis; embryonal carcinoma | mixed | adherent | |
| CATH.a | CRL-11179 [†] | mouse (transgenic) | brain, neuron | mixed | | |
| CBL-1 | HB-8214 [†] | mouse/mouse | hybridoma | lymphoblast | suspension | |
| CC15 | HB-265 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| C17 | HB-281 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| C20 | HB-267 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| | HB-288 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| | HB-269 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| CC21 | | | | | | |
| CC21 CC29 | | mouse/mouse | hybridoma | lymphoblast | Suspension | |
| CC21 CC29 CC30 | HB-270 | mouse/mouse mouse/mouse | hybridoma hybridoma | lymphoblast lymphoblast | suspension suspension | |
| CC21 CC29 CC30 CC38 | HB-270 HB-266 | mouse/mouse | hybridoma | lymphoblast | suspension | |
| CC21 CC29 CC30 CC38 CC39 | HB-270 HB-266 HB-274 | mouse/mouse mouse/mouse | hybridoma hybridoma | lymphoblast lymphoblast | suspension suspension | |
| CC21 CC29 CC30 CC38 CC39 CC42 | HB-270 HB-266 | mouse/mouse | hybridoma | lymphoblast | suspension | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | ® No. Species Source/Application | | Morphology | Growth Mode |
|----------------|-----------|----------------------------------|--|-------------|-------------|
| CC55 | HB-282 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CC56 | HB-273 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CC57 | HB-268 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CC58 | HB-275 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CC63 | HB-264 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CC8 | HB-280 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CC9C10 | HB-123 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CCD 1102 KERTr | CRL-2310 | human | skin; keratinocyte; HPV-16 E6/E7 transformed | epithelial | adherent |
| CCD 1103 KIDTr | CRL-2304 | human | kidney; HPV-16 E6/E7 transformed | epithelial | adherent |
| CCD 1105 KIDTr | CRL-2305 | human | kidney; HPV-16 E6/E7 transformed | epithelial | adherent |
| CCD 1106 KERTr | CRL-2309 | human | skin; keratinocyte; HPV-16 E6/E7 transformed | epithelial | adherent |
| CCD 1108Sk | CRL-2352 | human | skin | fibroblast | adherent |
| CCD 18Lu | CCL-205 | human | lung | fibroblast | adherent |
| CCD 841 CoN | CRL-1790 | human | colon, fetal | epithelial | adherent |
| CCD 841 CoTr | CRL-1807 | human | colon, fetal; SV40 transformed | epithelial | adherent |
| CCD-1037Sk | CRL-2054 | human | skin | fibroblast | adherent |
| CCD-1058Sk | CRL-2071 | human | skin | fibroblast | adherent |
| CCD-1059Sk | CRL-2072 | human | skin | fibroblast | adherent |
| CCD-1064Sk | CRL-2076 | human | skin | fibroblast | adherent |
| | | | | | |

ATCC Cell Biology Trivia #4

How were early models of the centrifuge used?

It's uncertain who developed the first centrifuge, but the early models were used to separate milk from cream around 1880. The invention of the ultracentrifuge earned Theodor Svedberg the Nobel Prize in Chemistry in 1926.

| CCD-1065Sk | CRL-2077 | human | skin | fibroblast adherent |
|------------|----------|-------|------|---------------------|
| CCD-1068Sk | CRL-2086 | human | skin | fibroblast adherent |
| CCD-1069Sk | CRL-2089 | human | skin | fibroblast adherent |
| CCD-1070Sk | CRL-2091 | human | skin | fibroblast adherent |
| CCD-1072Sk | CRL-2088 | human | skin | fibroblast adherent |
| CCD-1074Sk | CRL-2090 | human | skin | fibroblast adherent |
| CCD-1076Sk | CRL-2096 | human | skin | fibroblast adherent |
| CCD-1077Sk | CRL-2094 | human | skin | fibroblast adherent |
| CCD-1079Sk | CRL-2097 | human | skin | fibroblast adherent |
| CCD-1086Sk | CRL-2103 | human | skin | fibroblast adherent |
| CCD-1087Sk | CRL-2104 | human | skin | fibroblast adherent |
| CCD-1090Sk | CRL-2106 | human | skin | fibroblast adherent |
| CCD-1092Sk | CRL-2114 | human | skin | fibroblast adherent |
| CCD-1093Sk | CRL-2115 | human | skin | fibroblast adherent |
| CCD-1094Sk | CRL-2120 | human | skin | fibroblast adherent |
| CCD-1095Sk | CRL-2122 | human | skin | fibroblast adherent |
| CCD-1096Sk | CRL-2129 | human | skin | fibroblast adherent |
| CCD-1097Sk | CRL-2124 | human | skin | fibroblast adherent |
| CCD-1098Sk | CRL-2127 | human | skin | fibroblast adherent |
| CCD-1099Sk | CRL-2201 | human | skin | fibroblast adherent |
| CCD-1100Sk | CRL-2211 | human | skin | fibroblast adherent |
| CCD-1101Sk | CRL-2281 | human | skin | fibroblast adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------------------|----------------------|-----------------|--|-------------|-------------|
| CCD-1109Sk | CRL-2361 | human | skin | fibroblast | adherent |
| CCD-1112Sk | CRL-2429 | human | skin (foreskin) | fibroblast | adherent |
| CCD-1113Sk | CRL-2439 | human | skin | fibroblast | adherent |
| CCD-1114Sk | CRL-2450 | human | skin (foreskin) | fibroblast | adherent |
| CCD-1117Sk | CRL-2465 | human | skin | fibroblast | adherent |
| CD-1118Sk | CRL-2466 | human | skin | fibroblast | adherent |
| CD-112 CoN | CRL-1541 | human | colon | fibroblast | adherent |
| CD-1120Sk | CRL-2510 | human | skin | fibroblast | adherent |
| CD-1121Sk | CRL-2511 | human | skin | fibroblast | adherent |
| CD-1122Sk | CRL-2513 | human | skin | fibroblast | adherent |
| CD-1123Sk | CRL-2524 | human | skin | fibroblast | adherent |
| CD-1124Sk | CRL-2529 | human | skin | fibroblast | adherent |
| CD-1126Sk | CRL-2564 | human | skin | fibroblast | adherent |
| CD-1127Sk | CRL-2565 | human | skin | fibroblast | adherent |
| CD-1128Sk | CRL-2566 | human | skin | fibroblast | adherent |
| CD-1129SK | CRL-2575 | human | skin | fibroblast | adherent |
| CD-1131Sk | CRL-2617 | human | skin | fibroblast | adherent |
| CD-1132Sk | CRL-2622 | human | skin | fibroblast | adherent |
| CD-1134Sk | CRL-2673 | human | skin | fibroblast | adherent |
| CD-1135Sk | CRL-2691 | human | skin | fibroblast | adherent |
| CD-1136Sk | CRL-2697 | human | skin | fibroblast | adherent |
| CD-1137Sk | CRL-2703 | human | skin (foreskin) | fibroblast | adherent |
| CD-1138Sk | CRL-2707 | human | skin | fibroblast | adherent |
| CD-1139Sk | CRL-2708 | human | skin | fibroblast | adherent |
| CD-1140Sk | CRL-2714 | human | skin | fibroblast | adherent |
| CD-1141Sk | CRL-2796 | human | skin | fibroblast | adherent |
| CD-11Lu | CCL-202 | human | lung | fibroblast | adherent |
| CD-13Lu | CCL-200 | human | lung | fibroblast | adherent |
| CD-16Lu | CCL-204 | human | lung | fibroblast | adherent |
| CD-186Sk | CRL-1563 | human | skin; cystic fibrosis | fibroblast | adherent |
| CD-18Co | CRL-1459 | human | colon | fibroblast | adherent |
| CD-19Lu | CCL-210 | human | lung | fibroblast | adherent |
| CD-25Lu | CCL-215 | human | lung | fibroblast | adherent |
| CD-25Sk | CRL-1474 | human | skin | fibroblast | adherent |
| CD-27Sk | CRL-1475 | human | skin | fibroblast | adherent |
| CD-29Lu | CRL-1478 | human | lung; emphysema | fibroblast | adherent |
| CD-32Lu | CRL-1485 | human | lung | fibroblast | adherent |
| CD-32Sk | CRL-1489 | human | skin | fibroblast | adherent |
| CD-33Co | CRL-1539 | human | colon | fibroblast | adherent |
| CD-33Lu | CRL-1490 | human | lung | fibroblast | adherent |
| CD-34Lu | CRL-1491 | human | lung | fibroblast | adherent |
| CCD-34Sk | CRL-1497 | human | skin | fibroblast | adherent |
| CD-39Lu | CRL-1498 | human | lung; hyaline membrane disease | fibroblast | adherent |
| CD-39Sk | CRL-1501 | human | skin | fibroblast | adherent |
| CD-42Sk | CRL-1513 | human | skin | fibroblast | adherent |
| CD-43Sk | CRL-1509 | human | skin | fibroblast | adherent |
| CD-8Lu | CCL-201 | human | lung | fibroblast | adherent |
| CD-944Sk | CRL-1836 | human | skin | fibroblast | adherent |
| CD-986Sk | CRL-1947 | human | skin | fibroblast | adherent |
| CF-STTG1 | CRL-1718 | human | brain; astrocytoma | astrocytic | adherent |
| CK061 | HB-8786 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| CO | CRL-2772 | channel catfish | ovary | fibroblast | adherent |
| CRF S-180 II | CCL-8 | mouse | sarcoma | fibroblast | adherent |
| CRF-CEM | CCL-119 | human | peripheral blood, Tlymphoblast; acute lymphoblastic leukemia | lymphoblast | suspension |
| CCRF-HSB-2 | CCL-120.1 | human | peripheral blood, T lymphoblast; acute lymphoblastic leukemia | lymphoblast | suspension |
| | CCL-120 | human | peripheral blood, B lymphoblast; acute | lymphoblast | suspension |
| CRF-SB | 002 .20 | | lymphoblastic leukemia | | |
| CCRF-SB CDC 1C42H11 | HB-216 | mouse/mouse | lymphoblastic leukemia hybridoma | lymphoblast | suspension |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.

Order online at www.lgcpromochem.com/atcc, or contact your local LGC Promochem office. See back cover for details.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------------------|-----------------------|--------------------|--|------------------|-------------|
| CDR2 | HB-214 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CE-1 | SCRC-1038 | mouse | cassette exchange for double lox targeting; hygromycin resistant | spherical colony | adherent |
| CE-3 | SCRC-1039 | mouse | cassette exchange for double lox targeting; puromycin resistant | spherical colony | adherent |
| Ce Ar | CRL-1165 | human | skin; xeroderma pigmentosum, presumed heterozygote | fibroblast | adherent |
| Ce Geg | CRL-1173 | human | skin; Marfan syndrome | fibroblast | adherent |
| Ce Wal | CRL-1351 | human | skin; poikiloderma | fibroblast | adherent |
| CE9H9 | HB-127 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CEM/C1 | CRL-2265 | human | peripheral blood, Tlymphoblast; acute lymphoblastic leukemia | lymphoblast | suspension |
| CEM/C2 | CRL-2264 | human | peripheral blood, Tlymphoblast; acute lymphoblastic leukemia | lymphoblast | suspension |
| CEM-CM3 | TIB-195 | human | hybridoma fusion partner; T cell | lymphoblast | suspension |
| CESS | TIB-190 | human | lymphoblast; myelomonocytic leukemia | lymphoblast | suspension |
| CF11.T | CRL-6217* | dog | bone; connective tissue; osteosarcoma | | · |
| CF17.T | CRL-6219* | dog | connective tissue; cancer | | |
| CF-1 MEF | SCRC-1040 | mouse | embryonic fibroblasts; feeder layer | fibroblast | adherent |
| CF21.T | CRL-6220* | dog | connective tissue; cancer | | adherent |
| F24.T | CRL-6221* | dog | connective tissue; cancer | | |
| F28 | CRL-6223* | dog | unknown | | |
| f2Th | CRL-1430 | dog | thymus | | adherent |
| F3.Th | CRL-6575* | dog | thymus | | |
| F30.Mg | CRL-6225* | dog | mammary gland | | |
| F33.MT | CRL-6227* | dog | mammary gland; cancer | epithelial | adherent |
| F34.Mg | CRL-6228* | dog | mammary gland; cancer | | |
| CF35.Mg | CRL-6229* | dog | mammary gland; cancer | | |
| CF37.Mg | CRL-6230* | dog | mammary gland | | |
| CF38.Mg | CRL-6231* | dog | mammary gland | | |
| CF41.Mg | CRL-6232* | dog | mammary gland; cancer | | adherent |
| CF43.Mg | CRL-6234* | dog | mammary gland | | |
| CF44.Mg | CRL-6235* | dog | mammary gland | | |
| F45B.Mg | CRL-6237* | dog | mammary gland; cancer | | a alla a |
| CF46.Tr | CRL-6238* | dog | trachea | | adherent |
| CF47.Mg | CRL-6239* | dog | mammary gland | | |
| CF48.Mg | CRL-6240* | dog | mammary gland | | |
| CF49.Mg CF4-C4 | CRL-6241* CRL-1716 | dog mouse/mouse | mammary gland hybridoma | lymphoblast | suspension |
| 2F52.Tr | CRL-1716 CRL-6244* | dog | trachea | fibroblast | adherent |
| CF8.Thy | CRL-6244** | dog | thymus | IIDIODIASE | aunerent |
| CFPAC-1 | CRL-1918 | human | pancreas; ductal adenocarcinoma; cystic fibrosis | epithelial | adherent |
| CFZT(A) | CRL-6338* | mouse | unknown; cancer | | |
| CFZT(B) | CRL-6339* | mouse | unknown; cancer | | |
| CG7C7 | HB-126 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CGBQ | CCL-169 | goose | sternum | fibroblast | adherent |
| Ch 1 Es (NBL-8) | CCL-73 | goat | esophagus | fibroblast | adherent |
| CH1 | TIB-221 | mouse | B lymphocyte; lymphoma | lymphoblast | suspension |
| Ch1.Es | CRL-6581* | goat | esophagus | fibroblast | adherent |
| Ch13 | HB-8573 [†] | human/mouse | hybridoma | lymphoblast | suspension |
| Ch2.D | CRL-6270* | goat | unknown, possibly skin | | |
| CH26-1352 | HB-8329 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| ChaGo-K-1 | HTB-168 | human | subcutaneous (metastasis); bronchogenic carcinoma (bronchus primary) | epithelial | adherent |
| Chang Liver | CCL-13 | human | HeLa contaminant | epithelial | adherent |
| CH-EB6 | HB-200 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CHH-1 | CRL-1680 | salmon, chum | heart | fibroblast | adherent |
| CHL/IU | CRL-1935 | hamster, Chinese | lung | fibroblast | adherent |
| CHL-1 | CRL-9446 [†] | human | skin; melanoma | epithelial | adherent |
| CHO 1-15 ₅₀₀ | CRL-9606 [†] | hamster, Chinese | ovary; produces human t-PA | epithelial | adherent |
| | | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------------------|------------------------|------------------|---|------------------------|-------------|
| CHO/dhFr | CRL-9096 [†] | hamster, Chinese | ovary; deficient in dihydrofolate reductase | epithelial | adherent |
| CHO-1C6 | CRL-1793 | hamster, Chinese | ovary; produces neuroleukin | epithelial | adherent |
| CHO-CD36 | CRL-2092 | hamster, Chinese | ovary; produces human CD36 | epithelial | adherent |
| CHO DP-12, clone# | CRL-12444 [†] | Chinese hamster | ovary; expresses IgG1 (kappa) against IL-8 | fibroblast | adherent |
| 1933 alL8.92 NB | | | | | |
| 28605/12 | | | | | |
| CHO DP-12, clone# | CRL-12445 [†] | Chinese hamster | ovary; expresses IgG1 (kappa) against IL-8 | fibroblast | adherent |
| 1934 alL8.92 NB | | | | | |
| 28605/14 | | | | | |
| CHO-ICAM-1 | CRL-2093 | hamster, Chinese | ovary; produces human ICAM-1 | epithelial | adherent |
| CHO-K1 | CCL-61 | hamster, Chinese | ovary | epithelial | adherent |
| CHO-K1 | CRL-9618 [†] | hamster, Chinese | ovary | epithelial | adherent |
| CHP-212 | CRL-2273 | human | brain, neuroblastoma | neuroblast | adherent |
| CHP 3 (M.W.) | CCL-132 | human | skin; galactosemia; galactose-1-phosphate uridyl transferase deficient | fibroblast | adherent |
| CHP 4 | CCL-133 | human | skin; galactosemia; galactose-1-phosphate uridyl transferase deficient | fibroblast | adherent |
| CHSE-214 | CRL-1681 | salmon, Chinook | embryo | | adherent |
| CIA-E-4.15 | HB-235 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CIA-E-7.12 | HB-236 | mouse/mouse | hybridoma | lymphoblast | suspension |
| citrullinemia | CCL-76 | human | skin; citrullinemia | fibroblast | adherent |
| CKMM 14.15 | HB-9419 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| CKMM 14.5 | HB-9420 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| CKMM 14.52 | HB-9421 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| CL18/6 | CRL-2518 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CL2 | CRL-2514 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CL3 | CRL-2515 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CL37 | CRL-2516 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Cl. Ly1+2-/9 | CRL-8179 [†] | mouse | spleen; helper/inducer T lymphocyte (Th-2) | lymphoblast | suspension |
| CLN | CRL-6245* | dog | lymph node | , | |
| CLN H11.4 | HB-8307 [†] | human/human | hybridoma | lymphoblast | suspension |
| CLNH5.5 | HB-8206 [†] | human/human | hybridoma | lymphoblast | suspension |
| Clone 1-5c-4 | CCL-20.2 | human | HeLa contaminant | epithelial | adherent |
| Clone 15 HL-60 | CRL-1964 | human | peripheral blood; promyeloblast; acute promyelocytic leukemia | lymphoblast | suspension |
| Clone 9 | CRL-1439 | rat | liver | epithelial | adherent |
| Clone C | CRL-2531 | rabbit | kidney (cortex) | epithelial | adherent |
| Clone M-3 | CCL-53.1 | mouse | skin, melanocyte; melanoma | epithelial | adherent |
| CL-S1 | CRL-1615 | mouse | mammary gland tumor; premalignant | epithelial | adherent |
| CLT 152 | HB-8244 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| CLT 85 | HB-8240 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| CMH1a | CRL-8399 [†] | mouse | mammary gland; carcinoma | fibroblast | adherent |
| CMMT | CRL-6299* | monkey, Rhesus | mammary gland; cancer | epithelial | adherent |
| CMT-93 | CCL-223 | mouse | rectum; polyploid carcinoma | epithelial | adherent |
| CO 88BV59-1 | CRL-10624 [†] | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| Co88BV59H21-2 | CRL-11538 [†] | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| Co88BV59H21- 2V67-66 | CRL-11539 [†] | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| COLO 201 | CCL-224 | human | ascites (metastasis); colorectal adenocarcinoma | bipolar, slightly | mixed |
| 2020 201 | JCL 22-1 | uiiiuii | (colon primary) | refractile, fibro- | mixed |
| | | | (colon primary) | blast-like | |
| COLO 205 | CCL-222 | human | ascites (metastasis); colorectal adenocarcinoma | epithelial | mixed |
| | | | (colon primary) | | |
| COLO 320DM | CCL-220 | human | colon; colorectal adenocarcinoma | rounded, refractile | mixed |
| COLO 320HSR | CCL-220.1 | human | colon; colorectal adenocarcinoma | rounded, refractile | mixed |
| | | | | | |
| COLO 829 | CRL-1974 | human | skin; malignant melanoma | fibroblast | adherent |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--------------------------------|------------------------------------|--------------------------|---|------------------|------------------------------|
| CON.1 | CRL-2229 | mouse/mouse | hybridoma | lymphoblast | suspension |
| ConA-B1-VICK | CRL-12357 [†] | chicken | spleen; T lymphocyte; transformed with REV-T; produces G-CSF | lymphoblast | clusters in suspension |
| ConA-C1-VICK | CRL-12135 [†] | chicken | spleen;T lymphocyte; transformed with REV-T; produces G-CSF | lymphoblast | clusters in suspension |
| COS-1 | CRL-1650 | monkey, African green | kidney | fibroblast | adherent |
| COS-7 | CRL-1651 | monkey, African green | kidney | fibroblast | adherent |
| CPA 47 | CRL-1733 | bovine | pulmonary artery; vascular endothelium | cobblestone | adherent |
| CPAE | CCL-209 | bovine | pulmonary artery, vascular endothelium | endothelial | adherent |
| CRE BAG 2 | CRL-1858 | mouse | embryo; produces a retrovirus containing the beta-galactosidase gene | fibroblast | adherent |
| CRFK | CCL-94 | cat | kidney (cortex) | epithelial | adherent |
| Cri du Chat | CCL-90 | human | skin; Cri du Chat syndrome | fibroblast | adherent |
| CSMαβ1H | CRL-8401 [†] | mouse | mammary gland; carcinoma | fibroblast | adherent |
| CSΜαβ111 | CRL-8400 [†] | mouse | mammary gland; carcinoma | fibroblast | adherent |
| CT26.CL25 | CRL-2639 | mouse | colon; carcinoma; model for testing | fibroblast | adherent |
| _ 1 | CIL ZUJA | HIOUSE | immunotherapy protocols in vivo | iibiObiast | aunerent |
| CT26.WT | CRL-2638 | mouse | colon; carcinoma; model for testing immunotherapy protocols in vivo | fibroblast | adherent |
| CT6-1D7 | CRL-2438 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CTLA4 lg-24 | CRL-2438 CRL-10762 [†] | hamster, Chinese | ovary; expresses CTLA4Ig fusion protein | epithelial | suspension adherent |
| CTLL-2 | TIB-214 | mouse | T lymphocyte; cytotoxic | lymphoblast | |
| | CRL-6496* | | skin; papilloma | iyiiipiiobidSt | suspension |
| CTPS CTX TNA2 | CRL-6496* CRL-2006 | rabbit, cottontail | brain (cortex); SV40 transfected | fibroblast | adherent |
| | | rat | | | |
| CV-1 | CCL-70 | monkey, African green | kidney | fibroblast | adherent |
| CV-1/EBNA-1 | CRL-10478 [†] | monkey, African green | kidney; EBNA-1 expression | fibroblast | adherent |
| CVC.1 | TIB-135 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CVC.4 | TIB-137 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CVC.7 | TIB-138 | mouse/mouse | hybridoma | lymphoblast | suspension |
| CW13.20-3B3 clone of BCL 1) | CRL-1669 | mouse | B lymphocyte; leukemia | lymphoblast | adherent |
| Cy34.1.2 | TIB-163 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Cyt c-/- | CRL-2613 | mouse | embryo; null for cytochrome c; apoptosis studies | , _I , | adherent |
| D 14 | HB-8439 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| D1.1 | CRL-10915 [†] | human | T lymphoblast; acute T cell leukemia; CD4 negative | lymphoblast | suspension |
| D10.G4.1 | TIB-224 | mouse | helper/inducer T lymphocyte | lymphoblast | suspension with feeder cells |
| D1-4G2-4-15 | HB-112 | mouse/mouse | hybridoma | lymphoblast | suspension |
| D17 | CRL-6248* | dog | bone; osteosarcoma | epithelial | adherent |
| D17 | CRL-8468 [†] | dog | bone; osteosarcoma | epithelial | adherent |
| D-17 | CCL-183 | dog | lung (metastasis); osteosarcoma (bone primary) | epithelial | adherent |
| D1B | TIB-56 | mouse | spleen, erythroblast; leukemia | lymphoblast | suspension |
| D1 ORL UVA | CRL-12424 [†] | mouse | bone marrow; multipotent stromal precursor | .,ролиос | adherent |
| 022 | CRL-6250* | dog | bone; osteosarcoma | | |
| 024 | CRL-2701 | rat/rat | hybridoma | lymphoblast | suspension |
| D283 Med | HTB-185 | human | ascites and peritoneum (metastasis); | epithelial | mixed |
| | | | medulloblastoma (cerebellum primary) | <u> </u> | |
| D2N | TIB-58 | mouse | spleen; leukemia | lymphoblast | suspension |
| D3-2H2-9-21 | HB-114 | mouse/mouse | hybridoma | lymphoblast | suspension |
| D341 Med | HTB-187 | human | brain (cerebellum); medulloblastoma | spheroid | suspension |
| D8/17 | HB-8783 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Da Bon | CRL-1251 | human | skin; osteogenesis imperfecta (tarda) | fibroblast | adherent |
| Da Cav | CRL-1388 | human | skin; stiff skin syndrome | fibroblast | adherent |
| Da Hol | CRL-1379 | human | skin; Ehlers-Danlos syndrome, variant type | fibroblast | adherent |
| Da Mo | CRL-1383 | human | skin; Ehlers-Danlos syndrome, type V | fibroblast | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-----------------------------------|------------------------|---------------------------|---|--------------------------|---------------------------------|
| DA4-4 | HB-57 | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| DAKIKI | TIB-206 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| DAL K20 | CRL-2288 | mouse/mouse | hybridoma | lymphoblast | suspension |
| DAL K29 | CRL-2291 | mouse/mouse | hybridoma | lymphoblast | suspension |
| DAL K45 | CRL-2292 | mouse/mouse | hybridoma | lymphoblast | suspension |
| DAN | CRL-2130 | dog | osteosarcoma; amphotropic retroviral | fibroblast | adherent |
| | | 3 | packaging line | | |
| Daoy | HTB-186 | human | brain (cerebellum); desmoplastic cerebellar medulloblastoma | polygonal | adherent |
| DATK32 | HB-294 | rat/mouse | hybridoma | lymphoblast | suspension |
| Daudi | CCL-213 | human | peripheral blood, B lymphoblast; Burkitt's lymphoma | lymphoblast | suspension |
| DB | CRL-2289 | human | B lymphoblast; large cell lymphoma | lymphoblast | suspension |
| DB9G8 | HB-124 | mouse/mouse | hybridoma | lymphoblast | suspension |
| DBA A.Sp | CRL-6340* | mouse | spleen | , _F oo.asc | adherent |
| DBA C.Sp | CRL-6342* | mouse | spleen | | uarierent |
| DBS-FCL-1 | CCL-161 | monkey, African | lung | fibroblast | adherent |
| - JJ . CL 1 | CC2 101 | green | 9 | | adirectit |
| DBS-FCL-2 | CCL-162 | monkey, African green | lung | fibroblast | adherent |
| DBS-FRhL-2 | CL-160 | monkey, Rhesus | lung | fibroblast | adherent |
| DBTRG-05MG | CRL-2020 | human | brain, glial cell; glioblastoma | fibroblast | adherent |
| DC101 | HB-11534 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| DD-4 | HB-9743 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| DDT, MF-2 | CRL-1701 | | ductus deferens, smooth muscle; leiomyosarcoma | туттртюыазс | adherent |
| | CRL-1701 | | | | adherent |
| DDT ₁ -MF-2 De Te | CRL-12031* | | skin; Marfan syndrome | fibroblast | |
| DEC-205 | HB-290 | human | <u> </u> | | adherent |
| | | rat/mouse | hybridoma | lymphoblast | suspension |
| Dede | CCL-39 | hamster, Chinese | lung | fibroblast | adherent |
| δTA4-1 | HB-70 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Dempsey | CCL-28 | human | skin; Klinefelter syndrome | fibroblast | adherent |
| Detroit 510 | CCL-72 | human | skin; galactosemia | fibroblast | adherent |
| Detroit 525 | CCL-65 | human | skin; Turner syndrome | fibroblast | adherent |
| Detroit 529 | CCL-66 | human | skin; Down syndrome | fibroblast | adherent |
| Detroit 532 | CCL-54 | human | skin (foreskin); Down syndrome | fibroblast | adherent |
| Detroit 539 | CCL-84 | human | skin; Down syndrome | fibroblast | adherent |
| Detroit 548 | CCL-116 | human | skin | fibroblast | adherent |
| Detroit 551 | CCL-110 | human | skin, fetal | fibroblast | adherent |
| Detroit 562 | CCL-138 | human | pleural effusion (metastasis); carcinoma (pharynx primary) | epithelial | adherent |
| Detroit 573 | CCL-117 | human | skin | fibroblast | adherent |
| DH82 | CRL-10389 [†] | dog | histiocytosis; malignant | macrophage | adherent |
| DH82ECOK | CRL-10390 [†] | dog | histiocytosis; malignant | macrophage | adherent |
| DHFR-G8 | CRL-1915 | mouse | embryo; expresses her2/neu | fibroblast | adherent |
| DITNC, | CRL-2005 | rat | brain (diencephalon); SV40 transfected | fibroblast | adherent |
| DII 33.1 | CRL-1827 | mouse/mouse | hybridoma | lymphoblast | suspension |
| DLD-1 | CCL-221 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| DMS 114 | CRL-2066 | human | lung; carcinoma; small cell lung cancer | p | adherent |
| DMS 153 | CRL-2064 | human | liver (metastasis); carcinoma; small cell | | adherent |
| | C 2007 | | lung cancer (lung primary) | | clusters |
| DMS 53 | CRL-2062 | human | lung; carcinoma; small cell lung cancer | | adherent |
| DMS 79 | CRL-2002 | human | lung; carcinoma; small cell lung cancer | | clusters in |
| | | | | | suspension |
| DNI.Tr | CRL-6009* | armadillo, nine-banded | trachea | fibroblast | adherent |
| | CCL-34.1 | dog | kidney | epithelial | adherent |
| DoCl1 (S+L-) | | | | | |
| | CCL-16 | hamster, Chinese | lung | fibroblast | adherent |
| DoCl1 (S+L-) Don DoTc2 4510 | | hamster, Chinese human | lung cervix; carcinoma lung, fetal | fibroblast epithelial | adherent adherent |

* Part of the NBL collection; see page 12. + Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------------------------------|------------------------|------------------|---|-------------------------|-----------------|
| DR4 MEF | SCRC-1045 | mouse | embryonic fibroblast; feeder layer | fibroblast | adherent |
| DREG200 | HB-302 | mouse/mouse | hybridoma | lymphoblast | suspension |
| DREG56 | HB-300 | mouse/mouse | hybridoma | lymphoblast | suspension |
| DRS | CRL-6497* | rabbit | skin | fibroblast | adherent |
| DS-1 | CRL-11102 [†] | human | pleural effusion (metastasis); | lymphoblast | suspension with |
| | | | lymphangiectasia (B lymphocyte primary); IL-6 dependent | ,, | feeder cells |
| DS-1 | HB-8906 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| DS-3 | HB-8651 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| DS-5 | HB-8653 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| DS-6 | HB-8652 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| DSDh | CRL-2131 | dog | osteosarcoma; retroviral packaging line | fibroblast | adherent |
| DSL-6A/C1 | CRL-2132 | rat | pancreas; carcinoma | epithelial | adherent |
| DSL-6B/C2 | CRL-2133 | rat | pancreas; carcinoma | epithelial | adherent |
| DSN DSN | CRL-9939 [†] | dog | osteosarcoma; produces SNV helper virus | epithelial | adherent |
| DT40 | CRL-9939* | chicken | bursa; lymphoma | lymphoblast | suspension |
| DT95 | CRL-2111 | chicken | bursa; lymphoma | lymphoblast | suspension |
| | | | • | | adherent |
| DU 145 | HTB-81 | human | brain (metastasis); carcinoma (prostate primary) | epithelial | |
| DU1-29 | HB-263 | mouse/mouse | hybridoma | lymphoblast | suspension |
| DU4475 | HTB-123 | human | mammary gland; ductal carcinoma | epithelial | suspension |
| Dubca | CRL-2276 | camel | skin | fibroblast | adherent |
| Duck embryo | CCL-141 | duck, Pekin | embryo | fibroblast | adherent |
| DUKX B1 | CRL-9010 [†] | hamster, Chinese | ovary; production of mouse c-myc protein | epithelial | adherent |
| DV68F | CRL-6345* | human/mouse | hybrid | | |
| E 20 | HB-8443 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| E. Derm (NBL-6) | CCL-57 | horse | skin (dermis) | fibroblast | adherent |
| E.G7-OVA | CRL-2113 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| E.H. IV | CCL-104 | human | peripheral blood; infectious mononucleosis | lymphoblast | suspension |
| E13 161-7 | HB-215 | rat/mouse | hybridoma | lymphoblast | suspension |
| E5BB3IIA2 | HB-121 | mouse/mouse | hybridoma | lymphoblast | suspension |
| E6(2)2 | HB-8172 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| E-8 | HB-10179 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with |
| | | | | | feeder cells |
| EB | CRL-1365 | human | skin; Ehlers-Danlos syndrome, variant type | fibroblast | adherent |
| EB1 | HTB-60 | human | upper maxilla; Burkitt's lymphoma | lymphoblast | suspension |
| EB2 | HTB-61 | human | ovary (metastasis); Burkitt's lymphoma | lymphoblast | suspension |
| | | | (B lymphocyte primary) | | |
| EB-3 | CCL-85 | human | B lymphocyte; Burkitt's lymphoma | lymphoblast | suspension |
| EBTr (NBL-4) | CCL-44 | bovine | trachea | fibroblast | adherent |
| Ect1/E6E7 | CRL-2614 | human | ectocervix; HPV-16 E6/E7 transformed | epithelial | adherent |
| ED1-19-1-6-5 | HB-90 | rat/mouse | hybridoma | lymphoblast | suspension with |
| | | | | | feeder cells |
| EGC/PK060399egfr | CRL-2690 | rat | jejunum (myenteric plexus); enteroglial | glial | adherent |
| EH17a | CRL-2209 | mouse/mouse | hybridoma | lymphoblast | suspension |
| EH7a | CRL-2194 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Ehrlich-Lettre ascites, strain E | CCL-77 | mouse | carcinoma | epithelial | adherent |
| EHS | CRL-2108 | mouse | connective tissue; sarcoma | fibroblast | adherent |
| EIAV 12E8.1 | HB-8917 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| EJ-6-2-Bam-6a | CRL-1888 | mouse | embryo | fibroblast | adherent |
| EJG | CRL-8659 [†] | bovine | adrenal gland; capillary endothelium | endothelial | adherent |
| EL 1 | CRL-9854 [†] | human | spleen; macrophage; monocyte | monocyte/ macrophage | suspension |
| El Don | CRL-1149 | human | skin; Ehlers-Danlos syndrome, type VII (arthrochalasia type) | fibroblast | adherent |
| EL4 | TIB-39 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| EL4.BU | TIB-39 | mouse | hybridoma fusion partner, T cell | lymphoblast | suspension |
| EL4.BU.1.OUA'.1.1 | TIB-40 | | T lymphocyte; lymphoma | lymphoblast | |
| ↔ DU LUUA' LI | 110 -4 1 | mouse | | | suspension |
| EL4.IL-2 | TIB-181 | mouse | thymus; lymphoma | lymphoblast | suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------|------------------------|------------------|---|-------------|-------------|
| Em Ar | CRL-1168 | human | skin; Ehlers-Danlos syndrome, possible heterozygote | fibroblast | adherent |
| EMT6 | CRL-2755 | mouse | breast; mammary carcinoma | epithelial | adherent |
| EM9 | CRL-1861 | hamster, Chinese | ovary; defective in single strand break repair | fibroblast | mixed |
| EML Cell Line, | CRL-11691 [†] | mouse | bone marrow; lymphohematopoietic progenitor | stem cell | mixed |
| Clone 1 | | | cell line | | |
| EN9F10 | CRL-2403 | mouse/mouse | hybridoma | lymphoblast | suspension |
| End1/E6E7 | CRL-2615 | human | endocervix; HPV-16 E6/E7 transformed | epithelial | adherent |
| EOC 13.31 | CRL-2468 | mouse | brain, microglia/macrophage | macrophage | adherent |
| EOC 2 | CRL-2467 | mouse | brain, microglia/macrophage | macrophage | adherent |
| EOC 20 | CRL-2469 | mouse | brain, microglia/macrophage | macrophage | adherent |
| EOMA | CRL-2586 | mouse | hemangio endo thelioma; microvascular endo thelial cell model | endothelial | adherent |

ATCC Cell Biology Trivia #5 When did concerns over the contamination of cell cultures first arise?

In the late 1950s scientists found that many laboratory cell cultures were mixed or contaminated. A committee was formed to oversee the collecting and characterizing of animal cell lines. ATCC was named as a storage and distribution center, which was the start of the ATCC Cell Biology Collection.

| EOMA-GFP | CRL-2587 | mouse | hemangioendothelioma; microvascular endothelial cell model; expresses GFP | endothelial | adherent |
|-------------|------------------------|-------------|---|-------------|--------------|
| Ep-16 | HB-155 | mouse/mouse | hybridoma | lymphoblast | suspension |
| ER4.7G.11 | HB-11642 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| ES-2 | CRL-1978 | human | ovary; clear cell carcinoma | fibroblast | adherent |
| ES-C57BL/6 | SCRC-1002 | mouse | embryonic stem cell | spherical | adherent on |
| | | | | | feeder cells |
| ES-D3 | CRL-11632 [†] | mouse | embryonic stem cell; pluripotent | epithelial | adherent on |
| | | | | | feeder cells |
| ES-D3 | CRL-1934 | mouse | embryonic stem cell; pluripotent | epithelial | adherent on |
| | | | | | feeder cells |
| ES-D3 GL | SCRC-1003 | mouse | embryonic stem cell; germline competent | spherical | adherent on |
| | | | | | feeder cells |
| ES-E14TG2a | CRL-1821 | mouse | embryonic stem cell; pluripotent; HGRPT | spherical | adherent on |
| | | | deficient | | feeder cells |
| ESK-4 | CL-184 | pig | kidney | | adherent |
| F1.652 | CRL-2039 | mouse/mouse | hybridoma | lymphoblast | suspension |
| F1-3G8-1 | HB-192 | mouse/mouse | hybridoma | lymphoblast | suspension |
| F18 AF1 | HB-8208 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| F19 | CRL-2733 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| F1A3-23 | HB-8207 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| F₁B | CRL-6168* | cat | submandibular lymph node; lymphoma | fibroblast | adherent |
| F21-1D3G7C8 | HB-9463 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| F24 | HB-9257 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| F25 | CRL-6566* | cat | bone marrow; erythroleukemia | fibroblast | adherent |
| F32 VIII C4 | CRL-1653 | mouse/mouse | hybridoma | lymphoblast | suspension |
| F3B6 | HB-8785 [†] | human/mouse | hybridoma fusion partner | lymphoblast | suspension |
| | | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------------|------------------------|-------------|--|--------------------------|----------------------|
| F4/80 | HB-198 | rat/mouse | hybridoma | lymphoblast | suspension |
| F45J | HB-9740 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| -5-A-1/22.8.13 | HB-8051 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| -8 | CRL-6074* | cat | unknown | .,ро | adherent |
| 9 | CRL-1720 | mouse | testis; embryonic carcinoma; testicular teratoma | epithelial | adherent |
| 98 | CRL-2397 | rat | brain; undifferentiated malignant glioma | glial | adherent |
| āDu | HTB-43 | human | pharynx; squamous cell carcinoma | epithelial | adherent |
| AK-/- | CRL-2644 | mouse | embryo; null for both FAK and p53, integrin signaling pathway | fibroblast | adherent |
| FAK+/+ | CRL-2645 | mouse | embryo; positive for FAK but null for p53, integrin signaling pathway | fibroblast | adherent |
| arage | CRL-2630 | human | lymph node (metastasis); non-Hodgkin's | lymphoblast | suspension |
| -AT 7 | CRL-2109 | rat | nasal; squamous cell carcinoma | epithelial | adherent |
| B2 | CRL-1891 | mouse/mouse | hybridoma | lymphoblast | suspension |
| B2.K | CRL-6033* | bovine | kidney, fetal | yp | |
| B2.Ln | CRL-6034* | bovine | lymph node, fetal | | |
| B2.Thy | CRL-6036* | bovine | mixed spleen and thymus | | |
| B3.Ln | CRL-6038* | bovine | lymph node, fetal | | |
| B3.Thy | CRL-6039* | bovine | thymus, fetal | | |
| B4.Ln | CRL-6041* | bovine | lymph node, fetal | | |
| B4.Sp/Thy | CRL-6041* | bovine | mixed spleen and thymus, fetal | | |
| B5.Bm | CRL-6042* | bovine | bone marrow, fetal | | |
| B5.Ln | CRL-6044* | bovine | lymph node, fetal | | |
| B8H3 [Mab8H3] | CRL-2402 | mouse/mouse | hybridoma | lymphoblast | suspension |
| ВНЕ | CRL-1395 | bovine | heart (vascular endothelium), fetal | endothelial | adherent |
| C100.Ln | CRL-6117* | cat | cervical lymph node | fibroblast | adherent |
| C100.En | CRL-6116* | cat | spleen; sarcoma | fibroblast | adherent |
| C100.3p | CRL-6115* | cat | connective tissue; sarcoma | fibroblast | adherent |
| C100.1 | CRL-6118* | cat | whole fetus | fibroblast | adherent |
| C101 | CRL-6119* | cat | whole fetus | fibroblast | adherent |
| C102 C104.We | CRL-6152* | cat | whole fetus | fibroblast | adherent |
| C104.We | CRL-6154* | cat | whole fetus | fibroblast | adherent |
| C100.We | CRL-6155* | | whole fetus | fibroblast | adherent |
| C107.We | CRL-6156* | cat | whole fetus | fibroblast | adherent |
| C108.We | CRL-6157* | | whole fetus | fibroblast | adherent |
| | CRL-6088* | cat | bone marrow; reticulum cell sarcoma | IIDIODIast | aunerent |
| C11.BM C110.We | CRL-6158* | cat | whole fetus | fibroblast | adherent |
| | | | | fibroblast | adherent |
| C112 | CRL-6120* | cat | whole fetus | | |
| C113 C114E.Tr | CRL-6121* CRL-6167* | cat | whole fetus | fibroblast fibroblast | adherent |
| -C114E.1r -C115.K | | cat | trachea, fetal | | adherent |
| | CRL-6122* | cat | kidney | fibroblast | adherent adherent |
| C118 C119 | CRL-6124* | cat | whole fetus | fibroblast | |
| | CRL-6125* | cat | whole fetus | fibroblast fibroblast | adherent |
| C16.Sp | CRL-6174* | cat | spleen; lymphoma | | adherent |
| C2.K | CRL-6126* | cat | kidney | fibroblast | adherent |
| C2.Lu | CRL-6569* | cat | lung | fibroblast | adherent |
| C28.Lu | CRL-6130* | cat | lung, fetal | fibroblast | adherent |
| c2Lu | CCL-217 | cat | lung | mixed | adherent |
| c3Tg | CCL-176 | cat | tongue | fibroblast | adherent |
| C47 | CRL-6094* | cat | placenta | fibroblast | adherent |
| C5.K | CRL-6078* | cat | kidney | fibroblast | adherent |
| C56.Thy | CRL-6134* | cat | thymus, fetal | | |
| C57.Thy | CRL-6136* | cat | thymus, fetal | | |
| C58.Thy | CRL-6137* | cat | thymus, fetal | | |
| C59.Thy | CRL-6139* | cat | thymus, fetal | | |
| -C6.Bm | CRL-6081* | cat | bone marrow | fibroblast | adherent |
| -C6.K | CRL-6082* | cat | kidney | fibroblast | adherent |
| FC60(A).We | CRL-6571* | cat | whole embryo | fibroblast | adherent |
| FC60(B).We | CRL-6098* | cat | whole fetus | fibroblast | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------------------------|------------------------|-----------------|---|---------------------|---------------------------------|
| FC60A.We | CRL-6140* | cat | whole fetus | fibroblast | adherent |
| FC60B.We | CRL-6141* | cat | whole fetus | fibroblast | adherent |
| FC61 | CRL-6099* | cat | fetus | fibroblast | adherent |
| FC63.Res | CRL-6143* | cat | fetus | fibroblast | adherent |
| -C70.We | CRL-6102* | cat | whole fetus | fibroblast | adherent |
| C71A.We | CRL-6145* | cat | whole fetus | fibroblast | adherent |
| FC77.T | CRL-6105* | cat | connective tissue; fibrosarcoma | fibroblast | adherent |
| FC79.We | CRL-6106* | cat | whole fetus | fibroblast | adherent |
| -C81.Sp | CRL-6107* | cat | spleen; fibrosarcoma | fibroblast | adherent |
| -C81.T | CRL-6108* | cat | connective tissue; fibrosarcoma | fibroblast | adherent |
| C81.Thy | CRL-6109* | cat | thymus; fibrosarcoma | fibroblast | adherent |
| C83.Res | CRL-6567* | cat | mixed spleen, thymus, and bone marrow | fibroblast | adherent |
| -C83.Sp | CRL-6110* | cat | spleen; fibrosarcoma | fibroblast | adherent |
| C87.Sk | CRL-6150* | cat | skin | fibroblast | adherent |
| C94.T | CRL-6113* | cat | connective tissue; fibrosarcoma | fibroblast | adherent |
| C95.Thy | CRL-6114* | cat | thymus; osteosarcoma | fibroblast | adherent |
| cwf-4 | CRL-2787 | cat | whole fetus; macrophage | spindle to stellate | adherent |
| D441.8 | TIB-213 | rat/mouse | hybridoma | lymphoblast | suspension |
| DC-P1 | CRL-12103 [†] | mouse | bone marrow | lymphoblast | suspension |
| e Bos | CRL-1177 | human | skin; Ehlers-Danlos syndrome, type II (hemorrhagic type) | fibroblast | adherent |
| eLV-3281 | CRL-9116 [†] | cat | lymphoma | lymphoblast | suspension |
| eT-1C | CRL-11968 [†] | cat | peripheral blood mononuclear cells, | .,рож.аж | suspension |
| | | | T lymphocytes | | 545pc5.6 |
| eT-J | CRL-11967 [†] | cat | peripheral blood mononuclear cells, | | suspension |
| | | | T lymphocytes | 241 12 1 | |
| HC | CRL-1831 | human | colon, fetal | epithelial | adherent |
| FHCR-1-2075/FH4 | HB-8775 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| FHCR-1-2075/FH5 | HB-8770 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| HCR-1-2516/FH7 | HB-8861 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| HCR-1-2624/FH6/ HOT-1-3019 | HB-8873 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| FHCR-1-2813/FDC-6 | HB-9018 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| HM | CCL-42 | minnow, fathead | mixed connective tissue and muscle | epithelial | adherent |
| Hs 173We | HTB-158 | human | whole fetus | fibroblast | adherent |
| Hs 738Lu | HTB-157 | human | lung | fibroblast | adherent |
| Hs 74 Int | CCL-241 | human | small intestine | epithelial | adherent |
| FIB21 | HB-295 | rat/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| -IB504.64 | HB-293 | rat/mouse | hybridoma | lymphoblast | suspension |
| FIGR | CRL-2173 | mouse/mouse | hybridoma | lymphoblast | suspension |
| EL | CCL-62 | human | HeLa contaminant | epithelial | adherent |
| L 62891 | CRL-11005 [†] | human | liver; immortalized with SV40 large T antigen | fibroblast | adherent |
| -L74-UCD-1 | CRL-8012 | cat | lymphoblast; lymphoma | lymphoblast | suspension |
| EL83B | CRL-3012 | mouse | liver | epithelial | adherent |
| :NS | CRL-2390 CRL-6170* | cat | unknown | ерісісіші | adifficial |
| :0 | CRL-0170 | mouse | hybridoma fusion partner | lymphoblast | suspension |
| O-4 | CRL-1040 CRL-6171* | cat | unknown | iyiiipiioblast | зазрензіон |
| oLu | CCL-168 | fox, grey | lung | fibroblast | adherent |
| OX-NY | CRL-1732 | | hybridoma fusion partner | lymphoblast | |
| | | mouse | · | fibroblast | suspension |
| R BANA | CRL-1213 | rat mausa/mausa | skin | | adherent |
| RAN4 | HB-10830 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| RhK-4 | CRL-1688 | monkey, Rhesus | kidney, fetal | epithelial | adherent |
| RTL | CRL-1468 | rat | thyroid | hansa ha Lilia | adherent |
| SHR-18 | CRL-2688 | mouse/mouse | hybridoma | lymphoblast | suspension |
| SHR-323 | CRL-2689 | mouse/mouse | hybridoma | lymphoblast | suspension |
| FT | CCL-41 | bullfrog | tongue | fibroblast | adherent |
| F.thy 62891 | CRL-10936 [†] | human | thymus; immortalized with SV40 large T antigen | fibroblast | adherent |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|---|---|------------------------------|---|---------------------------|---------------------------------|
| Fugu eye | CRL-2641 | Fugu rubripes (torafugu) | eye | epithelial | adherent |
| Fugu fry | CRL-2642 | Fugu niphobles (kusafugu) | whole fry | fibroblast | adherent |
| -W11-10-3 | HB-257 | mouse/mouse | hybridoma | lymphoblast | suspension |
| W11-24-17-36 | HB-258 | mouse/mouse | hybridoma | lymphoblast | suspension |
| W11-9-2 | HB-256 | mouse/mouse | hybridoma | lymphoblast | suspension |
| -W3-218-1 | HB-261 | mouse/mouse | hybridoma | lymphoblast | suspension |
| W4-101-1-1 | HB-289 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 314D | CRL-2760 | channel catfish | peripheral blood, T lymphocyte | lymphoblast | suspension, multicel aggregates |
| G1B | CRL-2536 | catfish; walking | gill | pleomorphic | adherent |
| G253 | HB-9706 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| G26.4.1C3/86 | HB-9893 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| G28-5 | HB-9110 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3-292, clone | CRL-1423 | human | bone; osteosarcoma | fibroblast | adherent |
| \141B1 | | | | | |
| 32a.5 | HB-110 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 52b.2 | HB-109 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3-3-5 | CRL-2252 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 3355-5 | CRL-2033 | cat | brain, astrocyte | glial, astrocyte | adherent |
| G-361 | CRL-1424 | human | skin; malignant melanoma | epithelial | adherent |
| G-401 | CRL-1441 | human | kidney; rhabdoid tumor | epithelial | adherent |
| G-402 | CRL-1440 | human | kidney; renal leiomyoblastoma | | adherent |
| G-7 | CRL-1447 | mouse | skeletal muscle, fetal | myoblast | adherent on coated surface |
| G-8 | CRL-1456 | mouse | skeletal muscle, fetal | myoblast | adherent |
| Ga Va | CRL-1394 | human | skin; Ehlers-Danlos syndrome | fibroblast | adherent |
| GA-10 | CRL-2392 | human | B lymphocyte; Burkitt's lymphoma | lymphoblast | suspension |
| GA-10 (Clone 20) | CRL-2394 | human | B lymphocyte; Burkitt's lymphoma | lymphoblast | suspension |
| GA-10 (Clone 4) | CRL-2393 | human | B lymphocyte; Burkitt's lymphoma | lymphoblast | suspension |
| GAD-1 | HB-184 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Gam Per | CRL-1326 | human | skin; Ehlers-Danlos syndrome, possible heterozygote | fibroblast | adherent |
| γ3-11.1 | HB-8700 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| GAP 8.3 | HB-12 | mouse/mouse | hybridoma | lymphoblast | suspension |
| GAP A3 | HB-122 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Gap Per | CRL-1335 | human | skin; Ehlers-Danlos syndrome, possible heterozygote | fibroblast | adherent |
| GC-1 spg | CRL-2053 | mouse (transgenic) | testis; spermatogonia | epithelial | adherent |
| GC-2spd(ts) | CRL-2196 | mouse | spermatocyte; SV40 large T antigen transfected | epithelial | adherent |
| GCT | TIB-223 | human | lung (metastasis); fibrous histiocytoma (primary unknown) | | adherent |
| Gd1T | CRL-6180* | chicken | unknown | | |
| Gd1WE | CRL-6181* | chicken | embryo | | |
| GDM-1 | CRL-2627 | human | peripheral blood; monoblast; myelomonoblastic leukemia | lymphoblast | suspension |
| Gekko lung-1 | CCL-111 | lizard, gekko | lung | epithelial | adherent |
| GeLu | CCL-100 | gerbil, Mongolian | lung | fibroblast | adherent |
| Genox 3.53 | HB-103 | mouse/mouse | hybridoma | lymphoblast | suspension |
| GFPu-1 | CRL-2794 | human | kidney; transformed with adenovirus 5 DNA | epithelial | adherent |
| | CCL-82 | rat | pituitary tumor | epithelial | adherent |
| лH | CCL-82.1 | rat | pituitary tumor | epithelial | adherent |
| | CCL 02.1 | human | HeLa transformed with adenovirus E1a and E1b | epithelial | suspension |
| GH ₃ | CBI -13002† | | ricea danisionnea with auchovilus e la allu e lu | cpitiiciiai | |
| GH ₃ GH329 | CRL-13002 [†] | | | enithelial | adhoront |
| GH ₃ GH329 GH354 | CRL-13003 [†] | human | cervix; generates E1-deleted adenovirus vectors | epithelial | adherent |
| GH ₃ GH329 GH354 GH ₄ C ₁ | CRL-13003 [†] CCL-82.2 | human rat | cervix; generates E1-deleted adenovirus vectors pituitary tumor | epithelial | adherent |
| GH ₃ GH329 GH354 GH ₄ C ₁ GK1.5 | CRL-13003 [†] CCL-82.2 TIB-207 | human rat rat/mouse | cervix; generates E1-deleted adenovirus vectors pituitary tumor hybridoma | epithelial lymphoblast | adherent suspension |
| GH, GH ₃ GH329 GH354 GH ₄ C, GK1.5 GK-5 | CRL-13003 [†] CCL-82.2 | human rat | cervix; generates E1-deleted adenovirus vectors pituitary tumor | epithelial | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-----------------------|-----------------------------------|------------------------------|--|------------------|------------------------|
| glomotel | CRL-2597 | human | kidney (glomus); glomangioma; immortalized with hTERT | fibroblast | adherent |
| GMMe [EPI] | CRL-2674 | mink | uterus (endometrium) | epithelial | adherent |
| GMMs [STR] | CRL-2675 | mink | uterus (endometrium) | fibroblast | adherent |
| Go Je | CRL-1381 | human | skin; Ehlers-Danlos syndrome, variant type | fibroblast | adherent |
| G-Olig2 | SCRC-1037 | mouse | lineage-specific GFP expression | spherical colony | adherent |
| GP+E-86 | CRL-9642 [†] | mouse | embryo; ecotropic retroviral packaging line | fibroblast | adherent |
| GP+envAM-12 | CRL-9641 [†] | mouse | embryo; amphotropic retroviral packaging line | fibroblast | adherent |
| GPC-16 | CCL-242 | | colon; colorectal adenocarcinoma | epithelial | adherent |
| | | guinea pig | · · · · · · · · · · · · · · · · · · · | | |
| GR-20 | CRL-2024 | rat/mouse | hybridoma | lymphoblast | suspension |
| Gr431 | HB-8575† | human/mouse | hybridoma | lymphoblast | suspension |
| GR-96 | CRL-2013 | rat/mouse | hybridoma | lymphoblast | suspension |
| GS-109-IV-8 | CRL-1672 | human | skin; Gardner's syndrome | fibroblast | adherent |
| GS-109-V-20 | CRL-1610 | human | skin; Gardner's syndrome | fibroblast | adherent |
| SS-109-V-21 | CRL-1643 | human | skin; Gardner's syndrome | fibroblast | adherent |
| S-109-V-34 | CRL-1613 | human | skin; Gardner's syndrome | fibroblast | adherent |
| GS-109-V-63 | CRL-1614 | human | skin; Gardner's syndrome | fibroblast | adherent |
| GSML | CRL-2699 | monkey, Guyanese squirrel | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| 11.6 | CRL-2567 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 116-L10-4R5 | HB-65 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 118/7 | HB-11684 [†] | mouse/mouse | hybridoma | lymphoblast | • |
| 118/7 119-7/IGF-IR | CRL-2526 | | • | fibroblast | suspension adherent |
| | | rat | hippocampus | | |
| 11HeLa | CRL-1958 | human | cervix; adenocarcinoma | epithelial | adherent |
| 12.35 | CRL-1995 | mouse | liver; hepatocyte; SV40 transformed | epithelial | adherent |
| 12.8 | CRL-2568 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 121F8-1 | CRL-8018 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| H25B10 | CRL-8017 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| H25B10 | CRL-8017A [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| l3.1 | CRL-2569 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 136.12a | CRL-2445 | mouse/mouse | macrophage; hybrid | macrophage | mixed |
| 136.12b | CRL-2446 | mouse/mouse | macrophage; hybrid | macrophage | mixed |
| H36.12d | CRL-2447 | mouse/mouse | macrophage; hybrid | macrophage | mixed |
| 136.12e | CRL-2448 | mouse/mouse | macrophage; hybrid | macrophage | mixed |
| 136.12j | CRL-2449 | mouse/mouse | macrophage; hybrid | macrophage | mixed |
| | | | | epithelial | |
| 14 | HTB-148 | human | brain; neuroglioma | | adherent |
| 1-4-II-E | CRL-1548 | rat | liver; hepatoma | epithelial | adherent |
| H4-II-E-C3 | CRL-1600 | rat | liver; hepatoma | epithelial | adherent |
| H4TG | CRL-1578 | rat | liver; hepatoma | epithelial | adherent |
| H57-597 | HB-218 | hamster/mouse | hybridoma | lymphoblast | suspension |
| H69AR | CRL-11351 [†] | human | lung; carcinoma; small cell lung cancer; multidrug resistant | epithelial | adherent |
| 1 9 | HTB-176 | human | peripheral blood, Tlymphocyte; cutaneous; lymphoma | lymphoblast | suspension |
| H9/HTLV-IIIB | CRL-8543 [†] | human | T lymphocyte; lymphoma | lymphoblast | suspension |
| H9c2(2-1) | CRL-1446 | rat | heart (myocardium) | myoblast | adherent |
| HAA1 | HB-8534 [†] | human/human | hybridoma | lymphoblast | suspension |
| HAAE-1 | CRL-2472 [†] | human | abdominal aorta | endothelial | adherent |
| IAAE-2 | CRL-2472 CRL-2473 [†] | human | abdominal aorta | endothelial | adherent |
| la Fe | CRL-2473 | | skin; cutis laxa | fibroblast | adherent |
| | | human | | | |
| laK | CCL-15 | hamster, Syrian golden | | epithelial | adherent |
| lB | CRL-7729* | human | skin; epidermolysis bullosa simplex | fibroblast | adherent |
| IBE135-E6E7 | CRL-2741 | human | lung, bronchus; HPV-16 E6/E7 transformed | epithelial | adherent |
| HBE4-E6/E7 | CRL-2078 | human | lung (bronchus) | epithelial | adherent |
| HBE4-E6/E7-C1 | CRL-2079 | human | lung (bronchus) | epithelial | adherent |
| HCC1007 BL | CRL-2319 | human | peripheral blood, B lymphoblast; EBV | lymphoblast | clusters in |
| | | | transformed | • | suspension |
| HCC1008 | CRL-2320 | human | lymph node (metastasis); ductal carcinoma (mammary gland primary) | epithelial | adherent |
| HCC1143 | CRL-2321 | human | mammary gland; primary ductal carcinoma | epithelial | adherent |
| 1001143 | CINE-232 I | Hullian | mammary gianu, primary ductai carcinoma | ерішенаі | aunerellt |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------|------------------------|-------------|--|-------------|---------------------------------|
| HCC1143 BL | CRL-2362 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | clusters in suspension |
| HCC1187 | CRL-2322 | human | mammary gland; primary ductal carcinoma | epithelial | mixed |
| HCC1187 BL | CRL-2323 | human | peripheral blood, B lymphoblast; EBV | lymphoblast | clusters in |
| | | | transformed | , , | suspension |
| HCC1395 | CRL-2324 | human | mammary gland; primary ductal carcinoma | epithelial | adherent |
| HCC1395 BL | CRL-2325 | human | peripheral blood, B lymphoblast; EBV | lymphoblast | clusters in |
| | | | transformed | | suspension |
| HCC1419 | CRL-2326 | human | mammary gland; primary ductal carcinoma | epithelial | adherent, patchy |
| ICC1428 | CRL-2327 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | epithelial | adherent |
| HCC1428 BL | CRL-2328 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | clusters in suspension |
| HCC1500 | CRL-2329 | human | mammary gland; primary ductal carcinoma | epithelial | adherent |
| HCC1569 | CRL-2330 | human | mammary gland; primary metaplastic carcinoma | epithelial | adherent |
| HCC1599 | CRL-2331 | human | mammary gland; primary ductal carcinoma | epithelial | clusters in |
| | | | | • | suspension |
| HCC1599 BL | CRL-2332 | human | peripheral blood, B lymphoblast; EBV | lymphoblast | clusters in |
| | | | transformed | | suspension |
| HCC1739 BL | CRL-2334 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | clusters in suspension |
| HCC1806 | CRL-2335 | human | mammary gland; primary acantholytic squamous cell carcinoma | epithelial | adherent |
| HCC1937 | CRL-2336 | human | mammary gland; primary ductal carcinoma | epithelial | adherent |
| HCC1937 BL | CRL-2337 | human | peripheral blood, B lymphoblast; EBV | lymphoblast | clusters in |
| | | | transformed | | suspension |
| HCC1954 | CRL-2338 | human | mammary gland; ductal carcinoma | epithelial | adherent |
| HCC1954 BL | CRL-2339 | human | peripheral blood, B lymphoblast; EBV | lymphoblast | clusters in |
| | | | transformed | | suspension |
| ICC202 | CRL-2316 | human | mammary gland; primary ductal carcinoma | epithelial | mixed |
| HCC2157 | CRL-2340 | human | mammary gland; primary ductal carcinoma | epithelial | suspension |
| HCC2157 BL | CRL-2341 | human | peripheral blood, B lymphoblast; EBV | lymphoblast | clusters in |
| | | | transformed | | suspension |
| HCC2218 | CRL-2343 | human | mammary gland; primary ductal carcinoma | epithelial | clusters in suspension |
| HCC2218 BL | CRL-2363 | human | peripheral blood, B lymphoblast; EBV | lymphoblast | clusters in |
| | | | transformed | | suspension |
| ICC2935 | CRL-2869 | human | lung, pleural effusion | epithelial | adherent |
| HCC38 | CRL-2314 | human | mammary gland; primary ductal carcinoma | epithelial | adherent |
| HCC38 BL | CRL-2346 | human | peripheral blood, B lymphoblast; EBV | lymphoblast | clusters in |
| | | | transformed | | suspension |
| HCC4006 | CRL-2871 | human | pleural effusion (metastasis); adenocarcinoma (lung primary) | epithelial | adherent |
| HCC70 | CRL-2315 | human | mammary gland; primary ductal carcinoma | epithelial | adherent |
| ICC827 | CRL-2868 | human | lung; adenocarcinoma | epithelial | adherent |
| nCD40L-M90 | HB-12055 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| CD40L-M91 | HB-12056 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| ICE-2 | CRL-11135† | human | eye (cornea); AdV12-SV40 transformed | epithelial | adherent |
| HCN-1A | CRL-10442 [†] | human | brain, cortical neuron | neuronal | adherent |
| HCN-2 | CRL-10742 [†] | human | brain, cortical neuron | neuronal | adherent |
| ICT 116 | CCL-247 | human | colon; colorectal carcinoma | epithelial | adherent on feeder cells |
| ICT-15 | CCL-225 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| ICT-8 (HRT-18) | CCL-244 | human | colon; ileocecal colorectal adenocarcinoma | epithelial | adherent |
| HD168 | HB-252 | rat/mouse | hybridoma | lymphoblast | suspension |
| HD2-4 | HB-86 | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| He We | CRL-1338 | human | skin; stiff skin syndrome | fibroblast | adherent |
| HEC-1-A | HTB-112 | human | uterus (endometrium); adenocarcinoma | epithelial | adherent |
| HEC-1-B | HTB-113 | human | uterus (endometrium); adenocarcinoma | epithelial | adherent |
| HECA-452 | HB-11485 [†] | rat/mouse | hybridoma | lymphoblast | suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

58

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|---------------|------------------------|---------------------------------------|--|------------------|--------------|
| HEK001 | CRL-2404 | human | skin, keratinocyte; HPV-16 E6/E7 transformed | epithelial | adherent |
| HEL 299 | CCL-137 | human | lung, fetal | fibroblast | adherent |
| HEL 92.1.7 | TIB-180 | human | bone marrow, erythroblast; erythroleukemia | lymphoblast | suspension |
| HeLa | CCL-2 | human | cervix; adenocarcinoma | epithelial | adherent |
| HeLa 229 | CCL-2.1 | human | cervix; adenocarcinoma | epithelial | adherent |
| HeLa NR1 | CRL-13011 [†] | human | cervix; HeLa cells transfected with plasmid pSV2neoNR101 | epithelial | adherent |
| leLa S3 | CCL-2.2 | human | cervix; adenocarcinoma | epithelial | adherent |
| HE-LU(Rifkin) | CRL-7717* | human | lung, fetal | fibroblast | adherent |
| Hep 3B2.1-7 | HB-8064 [†] | human | liver; hepatocellular carcinoma | epithelial | adherent |
| lep G2 | HB-8065 [†] | human | liver; hepatocellular carcinoma | epithelial | adherent |
| IEP G2/2.2.1 | CRL-11997 [†] | human | liver; hepatocellular carcinoma; transfected with a CYP7 minigene/luciferase construct | epithelial | adherent |
| lEp-2 | CCL-23 | human | HeLa contaminant | epithelial | adherent |
| Hepa 1-6 | CRL-1830 | mouse | liver; hepatoma | epithelial | adherent |
| lepa-1c1c7 | CRL-2026 | mouse | liver; hepatoma | epithelial | adherent |
| HEPM | CRL-1486 | human | palatal mesenchyme, fetal | fibroblast | adherent |
| lermes-3 | HB-9480 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| nES BG01V | SCRC-2002 | human | variant of human embryonic stem cell line BG01 | spherical colony | adherent |
| HE-SK | CRL-7718* | human | skin, fetal | fibroblast | adherent |
| let-1A | CRL-2692 | human | esophagus; SV40 large T antigen transfected | epithelial | adherent |
| IF 282.Sp | CRL-7701* | human | spleen, fetal | | |
| IF 322.Sk | CRL-7703* | human | skin, fetal | fibroblast | adherent |
| IF 333.We | CRL-7706* | human | whole fetus | fibroblast | adherent |
| IF 345.We | CRL-7708* | human | whole fetus | fibroblast | adherent |
| HF 358.We | CRL-7709* | human | whole fetus | mixed | adherent |
| IFAE-2 | CRL-2474 [†] | human | femoral artery | endothelial | adherent |
| HFF-1 | SCRC-1041 | human | foreskin fibroblasts, newborn; feeder layer | fibroblast | adherent |
| HFF-2 | SCRC-1042 | human | foreskin fibroblasts, newborn; feeder layer | fibroblast | adherent |
| HFL1 | CCL-153 | human | lung, fetal | fibroblast | adherent |
| HFN 36.3 | CRL-1605 | mouse/mouse | hybridoma | lymphoblast | suspension |
| IFN 7.1 | CRL-1606 | mouse/mouse | hybridoma | lymphoblast | suspension |
| FOB 1.19 | CRL-11372 [†] | human | bone, osteoblast; SV40 large T antigen transfected | ., | adherent |
| IG-261 | CCL-122 | human | skin; Fanconi anemia | fibroblast | adherent |
| HGF-1 | CRL-2014 | human | gingiva | fibroblast | adherent |
| HGH-B | HB-10596 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1H | CRL-2105 | human | peripheral blood, T lymphocyte; cutaneous T cell | lymphoblast | suspension |
| HAE-101 | CRL-2478 | human | iliac artery | endothelial | adherent |
| HIAE-38 | CRL-2599 | human | iliac artery | endothelial | adherent |
| HAE-55 | CRL-2608 | human | iliac artery | endothelial | adherent |
| HAE-65 | CRL-2606 | human | iliac artery | endothelial | adherent |
| HAE-78 | CRL-2475 | human | iliac artery | endothelial | adherent |
| HG-82 | CRL-1832 | rabbit | synovium | fibroblast | adherent |
| HIF-D | CRL-8200 [†] | hamster, Chinese | ovary; produces human gamma interferon | epithelial | adherent |
| HL12R1.2B10 | CRL-2359 | rat/mouse | hybridoma | lymphoblast | suspension |
| IL-15-M110 | HB-12061 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| nIL-15-M111 | HB-12062 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| HIT-T15 | CRL-1777 | hamster, Syrian golden | pancreas (islet of Langerhans); beta cell | epithelial | adherent |
| IIVE-26 | CRL-2603 | human | iliac vein | endothelial | adherent |
| IIVE-55 | CRL-2609 | human | iliac vein | endothelial | adherent |
| IIVE-65 | CRL-2605 | human | iliac vein | endothelial | adherent |
| IIVE-78 | CRL-2476 | human | iliac vein | endothelial | adherent |
| IIVS-125 | CRL-2482 | human | iliac vein, smooth muscle | | adherent |
| IJ1.Ov | CRL-6274* | tahr | ovary | epithelial | adherent |
| IJ2.Lu | CRL-6277* | tahr | lung, fetal | -1 | |
| KB-11 | CRL-12568 | human | kidney, B cell; Burkitt's lymphoma | epithelial | adherent |
| 1K-2 | CRL-2190 | human | kidney (cortex, proximal tubule); HPV-16 | epithelial | adherent |
| | J 2170 | | transformed | | |
| HK-PEG-1 | CL-189 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HL-60 | CCL-240 | human | peripheral blood; promyeloblast; acute | myeloblastic | suspension |
| 00 | CCL 2-10 | · · · · · · · · · · · · · · · · · · · | periprieral biood, profity crobiast, acute | , | 202601121011 |

* Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|---------------------------------|-------------------------------|-------------|--|--|-------------|
| HL-60/MX1 | CRL-2258 | human | peripheral blood; promyeloblast; acute promyelocytic leukemia | lymphoblast | suspension |
| HL-60/MX2 | CRL-2257 | human | peripheral blood; promyeloblast; acute promyelocytic leukemia | lymphoblast | suspension |
| HLF-a | CCL-199 | human | lung; epidermoid carcinoma | fibroblast | adherent |
| HM2 | HB-8587 [†] | human/human | hybridoma | lymphoblast | suspension |
| HMCB (Human Melanoma Cell Bo | CRL-9607 [†] wes) | human | skin; melanoma | epithelial | adherent |
| HMy2.CIR | CRL-1993 | human | B lymphoblast | lymphoblast | suspension |
| HNK-1 | TIB-200 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HO-13-4 | TIB-99 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HO-2.2 | TIB-150 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HO-22-1 | TIB-100 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HOPC 1F/12 | TIB-13 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| Horse | CRL-6583* | horse | unknown | | |
| HOS | CRL-1543 | human | bone; osteosarcoma | mixed, fibroblast and epithelial-like | adherent |
| HP | CRL-12012 [†] | human | fibrosarcoma; transfected; polytropic retroviral packaging cell line | | adherent |

ATCC Cell Biology Trivia #6

Who first crystallized tobacco mosaic virus?

Wendell Stanley crystallized tobacco mosaic virus in 1935. His work brought a new dimension to the study of viruses. Are they infectious organisms or large molecules?

| HP6000 | CRL-1754 | mouse/mouse | hybridoma | lymphoblast | suspension |
|-----------|-----------|-------------|--------------------------|-------------|------------|
| HP6001 | CRL-1755 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6002 | CRL-1788 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6003 | CRL-1756 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6014 | CRL-1752 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6016 | CRL-1787 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6017 | CRL-1753 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6020 | CRL-1789 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6023 | CRL-1776 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6025 | CRL-1775 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6045 | CRL-1757 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6047 | CRL-1774 | mouse/mouse | hybridoma | lymphoblast | mixed |
| HP6050 | CRL-1768 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6053 | CRL-1758 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6054 | CRL-1763 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HP6058 | CRL-1786 | mouse/mouse | hybridoma | lymphoblast | suspension |
| HPAC | CRL-2119 | human | pancreas; adenocarcinoma | epithelial | adherent |
| HPAE-26 | CRL-2598 | human | pulmonary artery | endothelial | adherent |
| HPAF-II | CRL-1997 | human | pancreas; adenocarcinoma | epithelial | adherent |
| HPME | CRL-6589* | mouse | whole embryo | fibroblast | adherent |
| HPVE-26 | CRL-2607 | human | pulmonary vein | endothelial | adherent |
| HR/+ A.Sp | CRL-6347* | mouse | spleen | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-----------------------|------------------------|----------------|---|--------------------------|----------------------|
| HR/+ C.Sp | CRL-6349* | mouse | spleen | | |
| HR/+ D.Sp | CRL-6350* | mouse | spleen . | | |
| HR/+ E.Sp | CRL-6351* | mouse | spleen | | |
| HR/+ F.Sp | CRL-6352* | mouse | spleen | | |
| IR/+ G.Sp | CRL-6353* | mouse | spleen | | |
| IR/+B.Sp | CRL-6348* | mouse | spleen | | |
| r/hr (WE) A | CRL-6357* | mouse | embryo | | |
| nr/hr (WE) B | CRL-6358* | mouse | embryo | | |
| IR/HR 1.Sp | CRL-6354* | mouse | spleen | | |
| IR/HR 2.Sp | CRL-6355* | mouse | spleen | | |
| HR/HR 3.Sp | CRL-6356* | mouse | spleen | | |
| IRT-18G | CRL-11663 [†] | human | rectum; ileocecal colorectal adenocarcinoma | epithelial | adherent |
| ls 1.lnt | CRL-7820* | human | intestine | fibroblast | adherent |
| ls 1.Lu | CRL-7000* | human | lung | fibroblast | adherent |
| ls 1.Sk/Mu | CRL-7001* | human | mixed skin and muscle | fibroblast | adherent |
| ls 1.Tes | CRL-7002* | human | testis | fibroblast | adherent |
| ls 103.Sp/Th | CRL-7068* | human | mixed spleen and thymus | fibroblast | adherent |
| ls 104.Sp/Th | CRL-7070* | human | mixed spleen and thymus | fibroblast | adherent |
| ls 112.Sk | CRL-7074* | human | skin | fibroblast | adherent |
| ls 115.Lu | CRL-7077* | human | lung or bronchus | fibroblast | adherent |
| ls 127.T | CRL-7081* | human | connective tissue; giant cell sarcoma | fibroblast | adherent |
| ls 13.Sk | CRL-7011* | human | skin | fibroblast | adherent |
| ls 132.T | CRL-7085* | human | connective tissue; spindle cell sarcoma | fibroblast | adherent |
| ls 137.Fs | CRL-7087* | human | skin (foreskin) | fibroblast | adherent |
| ls 14.T | CRL-7823* | human | bone; osteosarcoma | fibroblast | adherent |
| ls 142.Sp | CRL-7090* | human | spleen; Down syndrome | fibroblast | adherent |
| ls 142.Th | CRL-7091* | human | thymus; Down syndrome | fibroblast | adherent |
| ls 143.We | CRL-7092* CRL-7093* | human | whole fetus | fibroblast | adherent |
| ls 144.We ls 15.T | CRL-7093* | human human | whole fetus connective tissue; fibrosarcoma | fibroblast fibroblast | adherent adherent |
| 1s 15.1 1s 154.Fs | CRL-7098* | human | · · · · · · · · · · · · · · · · · · · | fibroblast | |
| ls 154.FS ls 156.T | CRL-7096** | human | skin (foreskin) | fibroblast | adherent adherent |
| ls 165.Fs | CRL-7102 CRL-7118* | human | skin; xanthogranuloma skin (foreskin) | fibroblast | adherent |
| ls 168.Fs | CRL-7118 | human | skin (foreskin) | fibroblast | adherent |
| ls 172.T | CRL-7122 CRL-7833* | human | urinary bladder; carcinoma | fibroblast | adherent |
| ls 172.1 | CRL-7123* | human | spleen | fibroblast | adherent |
| ls 173.We | CRL-7834* | human | whole fetus | fibroblast | adherent |
| ls 174.We | CRL-7124* | human | whole fetus | fibroblast | adherent |
| ls 18.Fs | CRL-7014* | human | skin (foreskin) | fibroblast | adherent |
| ls 181.Sk | CRL-7129* | human | skin | fibroblast | adherent |
| ls 181.Tes | CRL-7131* | human | testis | fibroblast | adherent |
| ls 184.Sk | CRL-7133* | human | skin | fibroblast | adherent |
| ls 184.T | CRL-7134* | human | bone; osteosarcoma | fibroblast | adherent |
| ls 186.Sk | CRL-7138* | human | skin | fibroblast | adherent |
| ls 188.T | CRL-7140* | human | bone; osteosarcoma | fibroblast | adherent |
| ls 190.T | CRL-7145* | human | mammary gland; cancer | fibroblast | adherent |
| ls 193.Sp | CRL-7148* | human | spleen | fibroblast | adherent |
| s 195.T | CRL-7150* | human | urinary bladder; carcinoma | epithelial | adherent |
| s 198.Ton | CRL-7156* | human | tonsil | fibroblast | adherent |
| s 2.We | CRL-7003* | human | whole fetus | fibroblast | adherent |
| s 200.T | CRL-7159* | human | rectum; colorectal adenocarcinoma | fibroblast | adherent |
| s 201.Sk | CRL-7161* | human | skin | fibroblast | adherent |
| s 202.Sp | CRL-7162* | human | spleen | fibroblast | adherent |
| ls 202.Th | CRL-7163* | human | thymus | fibroblast | adherent |
| ls 203.Sp | CRL-7164* | human | spleen | fibroblast | adherent |
| ls 203.Th | CRL-7165* | human | thymus | fibroblast | adherent |
| ls 204.Sp | CRL-7166* | human | spleen | fibroblast | adherent |
| s 208.Sp | CRL-7169* | human | spleen | fibroblast | adherent |
| ls 208.Th | CRL-7170* | human | thymus | fibroblast | adherent |
| ls 209.Sp | CRL-7171* | human | spleen | fibroblast | adherent |
| ls 21.Fs | CRL-7015* | human | skin (foreskin) | fibroblast | adherent |
| | | | | | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.



| 2315.In CRL-7155* human mesenteric lymph node; abnormal fibroblast adherent 2315.Th CRL-7176* human splen; abnormal fibroblast adherent 2315.Th CRL-7187* human thymus; abnormal fibroblast adherent 2318.Lu CRL-7180* human lung fibroblast adherent 2319.T CRL-7188* human spleen fibroblast adherent 232.Th CRL-7189* human spleen fibroblast adherent 232.Th CRL-7189* human spleen fibroblast adherent 232.Th CRL-7199* human spleen fibroblast adherent 232.Th CRL-7196* human urings proncheric adenocarcinoma fibroblast adherent 232.Th CRL-7196* human urings proncheric adenocarcinoma fibroblast adherent 232.Th CRL-7197* human spleen fibroblast adherent 232.Th CRL-7197* | Hs 215.Ln CRL-7175* human mesenteric lympl Hs 215.Sp CRL-7176* human spleen; abnormal Hs 215.Th CRL-7177* human thymus; abnormal Hs 216.We CRL-7178* human whole fetus Hs 218.Lu CRL-7180* human lung Hs 219.T CRL-7184* human rectum; colorecta Hs 221.Sp CRL-7187* human spleen Hs 221.Th CRL-7188* human thymus | h node; abnormal fibroblast adhe fibroblast adheration adheration adheration and fibroblast adheration adhe | erent |
|---|--|--|---|
| 23 15 LD CRL 7755* human mesenteric lymph node; abnormal fibroblast adherent 23 15 Th CRL 7776* human spleen abnormal fibroblast adherent 23 15 Th CRL 7178* human thympus; abnormal fibroblast adherent 23 18 LU CRL 7180* human lung fibroblast adherent 23 18 LU CRL 7181* human lung fibroblast adherent 23 19 T CRL 7181* human spleen fibroblast adherent 23 22 Th CRL 7189* human spleen fibroblast adherent 23 22 Th CRL 7193* human urbysen fibroblast adherent 23 22 Th CRL 7194* human urbysen fibroblast adherent 23 25 Th CRL 7196* human urbysen fibroblast adherent 23 25 Th CRL 7197* human spleen fibroblast adherent 23 25 Th CRL 7195* human s | Hs 215.Ln CRL-7175* human mesenteric lympl Hs 215.Sp CRL-7176* human spleen; abnormal Hs 215.Th CRL-7177* human thymus; abnormal Hs 216.We CRL-7178* human whole fetus Hs 218.Lu CRL-7180* human lung Hs 219.T CRL-7184* human rectum; colorecta Hs 221.Sp CRL-7187* human spleen Hs 221.Th CRL-7188* human thymus | fibroblast adhe fibroblast adheration adherat | erent |
| 215.5p CRL 7176* human spleen, abnormal fibroblast adherent 216.1b CRL 7178* human whole fetus fibroblast adherent 218.1b CRL 7188* human lung fibroblast adherent 219.1 CRL 7188* human lung fibroblast adherent 221.1b CRL 7188* human thyman fibroblast adherent 222.1b CRL 7188* human thymus fibroblast adherent 222.1b CRL 7198* human thymus fibroblast adherent 222.1b CRL 7199* human thymus fibroblast adherent 222.1b CRL 7194* human thymus fibroblast adherent 222.1b CRL 7195* human lungbronchogenic adenocarcinoma fibroblast adherent 23.05.0 CRL 7198* human thymus fibroblast adherent 23.21.1 CRL 718* human thymus fibrobla | Hs 215.Sp CRL-7176* human spleen; abnormal Hs 215.Th CRL-7177* human thymus; abnormal Hs 216.We CRL-7178* human whole fetus Hs 218.Lu CRL-7180* human lung Hs 219.T CRL-7184* human rectum; colorecta Hs 221.Sp CRL-7187* human spleen Hs 221.Th CRL-7188* human thymus | fibroblast adher fibrob | erent |
| 23.51.Th CRL 7177 human thymus abnormal fibroblist adherent 23.18.Lu CRL 7180 human lung fibroblist adherent 23.19.T CRL 7184 human lung fibroblist adherent 5.27.5 CRL 7187 human speen fibroblast adherent 5.27.5 CRL 71881 human speen fibroblast adherent 5.22.5 CRL 71891 human speen fibroblast adherent 5.22.5 CRL 71931 human urinary bladder; carcinoma fibroblast adherent 5.22.5 CRL 71931 human urinary bladder; carcinoma fibroblast adherent 5.23.5 CRL 71961 human urinary bladder; carcinoma fibroblast adherent 5.23.5 CRL 71974 human speen fibroblast adherent 5.23.5 CRL 71981 human speen fibroblast adherent 5.23.5 CRL 7187 human thyrus </td <td>ds 215.Th CRL-7177* human thymus; abnormal ds 216.We CRL-7178* human whole fetus ds 218.Lu CRL-7180* human lung ds 219.T CRL-7184* human rectum; colorectal ds 221.Sp CRL-7187* human spleen ds 221.Th CRL-7188* human thymus</td> <td>al fibroblast adhe fibroblast adhe</td> <td>erent erent erent erent erent erent erent erent erent</td> | ds 215.Th CRL-7177* human thymus; abnormal ds 216.We CRL-7178* human whole fetus ds 218.Lu CRL-7180* human lung ds 219.T CRL-7184* human rectum; colorectal ds 221.Sp CRL-7187* human spleen ds 221.Th CRL-7188* human thymus | al fibroblast adhe | erent erent erent erent erent erent erent erent erent |
| 216.146 CRI-7187 | Hs 216.We CRL-7178* human whole fetus Hs 218.Lu CRL-7180* human lung Hs 219.T CRL-7184* human rectum; colorecta Hs 221.Sp CRL-7187* human spleen Hs 221.Th CRL-7188* human thymus | fibroblast adhe fibroblast adhe fibroblast adhe adhe fibroblast adhere fibroblast ad | erent erent erent erent erent erent erent erent |
| 218.LIU CR.17180* human lung fibroblast adherent 219.T CR.17187* human spleen fibroblast adherent 212.Tsp CR.17188* human spleen fibroblast adherent 222.Fsp CR.17188* human thymus fibroblast adherent 222.Fs CR.17189* human thymus fibroblast adherent 222.Fs CR.17193* human urinary bladder; carcinoma fibroblast adherent 222.Fs CR.17198* human urinary bladder; carcinoma fibroblast adherent 222.Fs CR.17196* human ulung bronchogenic adenocarcinoma fibroblast adherent 222.Fs CR.17196* human spleen fibroblast adherent 222.Fs CR.17198* human spleen fibroblast adherent 222.Fs CR.17198* human thymus fibroblast adherent 223.Fs CR.1719.Fs human thymus fibroblast adherent 223.Fs CR.17218* human thymus fibroblas | Is 218.Lu CRL-7180* human lung Is 219.T CRL-7184* human rectum; colorecta Is 221.Sp CRL-7187* human spleen Is 221.Th CRL-7188* human thymus | fibroblast adher fibrob | erent erent erent erent erent |
| 221.5 | As 219.T CRL-7184* human rectum; colorecta As 221.Sp CRL-7187* human spleen As 221.Th CRL-7188* human thymus | al adenocarcinoma fibroblast adhe fibroblast adhe fibroblast adhe fibroblast adhe fibroblast adhe carcinoma fibroblast adhe | erent erent erent erent |
| 221.5p CR.J.7188" human spleen fibrobilast adherent 222.5p CR.J.7188" human thymus fibrobilast adherent 222.5p CR.J.7198" human thymus fibrobilast adherent 222.5c CR.J.7193" human urinary bladder; carcinoma fibrobilast adherent 22.8c CR.J.7198" human urinary bladder; carcinoma fibrobilast adherent 2.20.5c CR.J.7196" human lung bronchogenic adenocarcinoma fibrobilast adherent 2.20.5c CR.J.7198" human thymus fibrobilast adherent 2.22.5c CR.J.7198" human spleen fibrobilast adherent 2.22.5c CR.J.7198" human thymus fibrobilast adherent 2.23.5c CR.J.7198" human thymus fibrobilast adherent 2.23.5c CR.J.7202" human mixed skin and muscle fibrobilast adherent 2.24.1b CR.J.7218" human mixed skin and muscle fibrobilast adherent 2.25.5.1 CR.J.7218" human | ls 221.Sp CRL-7187* human spleen ls 221.Th CRL-7188* human thymus | fibroblast adhe fibroblast adhe fibroblast adhe fibroblast adhe carcinoma fibroblast adhe | erent erent erent |
| 3.21.Th CRI-1788* human thymus fibroblast adherent 3.22.Sp CRI-1791* human thymus fibroblast adherent 3.22.St CRI-1791* human thymus fibroblast adherent 3.22.St CRI-1794* human lung-bronchogenic adenocarcinoma fibroblast adherent 3.20.Th CRI-1795* human thymus fibroblast adherent 4.20.Th CRI-1795* human thymus fibroblast adherent 4.20.Th CRI-1795* human thymus fibroblast adherent 4.20.Th CRI-1798* human thymus fibroblast adherent 4.20.Th CRI-1798* human thymus fibroblast adherent 4.20.Th CRI-1798* human mixed skin and muscle fibroblast adherent 4.20.Th CRI-1720* human mixed skin and muscle fibroblast adherent 4.20.Th CRI-17218* human colony, adenocarcinoma fibroblast adherent 4.20.Th Human yelony, adenocarcinoma fi | Is 221.Th CRL-7188* human thymus | fibroblast adhe fibroblast adhe fibroblast adhe carcinoma fibroblast adhe | erent erent |
| 3 22 5.5 p CRI-1918* human spleen fibroblast adherent 2 22 5.7 m CRI-1919* human urinary bladder, carcinoma fibroblast adherent 2 28 T CRI-1918* human urinary bladder, carcinoma fibroblast adherent 4 230 Th CRI-1918* human spleen fibroblast adherent 2 30 Th CRI-1918* human spleen fibroblast adherent 2 32 Th CRI-1918* human spleen fibroblast adherent 2 32 Th CRI-1919* human thyman thyman fibroblast adherent 2 32 Th CRI-1919* human thyman thyman fibroblast adherent 2 32 Th CRI-1919* human mixed skin and muscle fibroblast adherent 2 32 Th CRI-2019* human mixed skin and muscle fibroblast adherent 2 32 Th CRI-2016* human skin foreskin) fibroblast adherent 2 32 Th CRI-2014* human colon; colorectal adenocarcinoma fibroblast adherent 2 32 | | fibroblast adhe fibroblast adhe carcinoma fibroblast adhe | erent |
| 2.25.Th CRI-19191* human thymus fibroblast adherent 2.29.T CRI-1934* human uninary bladder; carcinoma fibroblast adherent 2.20.T CRI-1994* human lung; bronchogenic adenocarcinoma fibroblast adherent 4.20.Th CRI-1995* human thymus fibroblast adherent 4.20.Th CRI-1998* human thymus fibroblast adherent 4.20.Th CRI-1998* human thymus fibroblast adherent 4.20.Th CRI-27000* human thymus fibroblast adherent 4.20.E. M. CRI-27008* human mixed skin and muscle fibroblast adherent 4.20.E. CRI-27018* human mixed skin and muscle fibroblast adherent 5.20.E. CRI-2718* human colon; adenocarcinoma fibroblast adherent 5.20.T. CRI-2718* human loon; adenocarcinoma fibroblast adherent 5.20.T. CRI-27218* human lymph node; pymphogranulomatosis fibroblast adherent 5.20.T. CRI-27228* human skin fibroblast adherent | | fibroblast adhe carcinoma fibroblast adhe | |
| 2.28.T CRI-1793* human u/inary bladder, carcinoma fibroblast adherent 2.29.T CRI-1796* human spleen fibroblast adherent 2.30.Sp CRI-1796* human spleen fibroblast adherent 2.30.Th CRI-1798* human thyman spleen fibroblast adherent 2.32.Th CRI-1798* human thyman spleen fibroblast adherent 2.32.Th CRI-1799* human thyman thyman fibroblast adherent 2.32.Th CRI-2709* human mixed skin and muscle fibroblast adherent 3.23.S.S. CRI-27016* human mixed skin and muscle fibroblast adherent 3.24.F. CRI-27016* human skin foreskin) fibroblast adherent 3.25.T. CRI-2714* human colon; colon; coladencarcinoma fibroblast adherent 3.27.T. CRI-27214* human colon; colorectal adenocarcinoma fibroblast adherent 3.27.T. CRI-27222* human mammary gland; adenocarcinoma fibroblast a | | carcinoma fibroblast adhe | |
| 3.29.1 CRL 7194* human lung; bronchogenic adenocarcinoma fibroblast adherent 3.20.15 CRL 7195* human thymus fibroblast adherent 3.20.17 CRL 7195* human thymus fibroblast adherent 3.23.17 CRL 7197* human thymus fibroblast adherent 3.23.17 CRL 7197* human thymus fibroblast adherent 3.23.17 CRL 7200* human mixed skin and muscle fibroblast adherent 3.23.58.K CRL 7203* human mixed skin and muscle fibroblast adherent 3.25.57.T CRL 7213* human colon; colorectal adenocarcinoma fibroblast adherent 3.25.57.T CRL 7213* human colon; colerectal adenocarcinoma fibroblast adherent 3.25.58.K CRL 7218* human hymph node; hymphogranulomatosis fibroblast adherent 3.27.57.K CRL 7222* human mammary gland; adenocarcinoma fibroblast adherent 3.27.77.K CRL 7222* human mammary gland; adenocarcinoma fibroblast adherent | · | | |
| 32305p CRL 7196* human spleen fibroblast adherent 2321Th CRL 7198* human thymus fibroblast adherent 2322Th CRL 7198* human spleen fibroblast adherent 2321Th CRL 7198* human thymus fibroblast adherent 2321Th CRL 7201* human thymus fibroblast adherent 2325SK CRL 7201* human mixed skin and muscle fibroblast adherent 234Th CRL 72016* human mixed skin and muscle fibroblast adherent 234Ts CRL 72118* human colon, adenocarcinoma fibroblast adherent 235Ts CRL 72118* human colon, colorectal adenocarcinoma fibroblast adherent 237AT CRL 72128* human lymph node; ymphoparaulomatosis fibroblast adherent 237AT CRL 72228* human lymph node; adenocarcinoma fibroblast adherent 2325Ts CRL 72228* human lymph node; adenocarcinoma fibroblast adherent 2326T CRL 72228* huma | | nic adenocarcinoma noroniast ado | |
| 230.Th CRL-7195* human thymus fibroblast adherent 232.Th CRL-7197* human thymus fibroblast adherent 232.Th CRL-7200* human thymus fibroblast adherent 232.Th CRL-7200* human mixed skin and muscle fibroblast adherent 232.Sh CRL-7203* human mixed skin and muscle fibroblast adherent 232.Sh CRL-7203* human mixed skin and muscle fibroblast adherent 232.Sh CRL-7213* human colon; adenocarcinoma fibroblast adherent 232.Sh CRL-7213* human colon; adenocarcinoma fibroblast adherent 232.Th CRL-7218* human lymph node; hymphogranulomatosis fibroblast adherent 232.Th CRL-7222* human mammary gland; adenocarcinoma fibroblast adherent 232.Th CRL-7222* human mammary gland; adenocarcinoma fibroblast adherent 232.Th CRL-7222* human mammary gland; adenocarcinoma fibroblast adherent 232.T | <u> </u> | | |
| 2323.Dp CRL 7198* human spleen fibroblast adherent 232.Th CRL 7200* human thymus fibroblast adherent 234.Th CRL 7200* human thymus fibroblast adherent 235.Sk CRL 7201* human mixed skin and muscle fibroblast adherent 234.Fs CRL 72016* human skin (foreskin) fibroblast adherent 237.T CRL 7214* human colon, colorectal adenocarcinoma fibroblast adherent 237.T CRL 7214* human colon, colorectal adenocarcinoma adherent adherent 237.T CRL 7212* human mammary gland, adenocarcinoma fibroblast adherent 237.T CRL 7222* human mammary gland, adenocarcinoma fibroblast adherent 237.T CRL 7222* human mammary gland, adenocarcinoma fibroblast adherent 237.T CRL 7222* human mammary gland, adenocarcinoma fibroblast adherent 230.T CRL 7222* human mammary gland, adenocarcinoma fibroblast adherent | · | | |
| 232.Th CRL-7197* human thymus fibroblast adherent 233.Th CRL-7201* human thymus fibroblast adherent 238.Sk CRL-7203* human mixed skin and muscle fibroblast adherent 235.SL CRL-7208* human skin (foreskin) fibroblast adherent 235.SL CRL-7218* human colon; adenocarcinoma fibroblast adherent 255.T. CRL-7218* human colon; colorectal adherocarcinoma adherent 258.R. CRL-7218* human lymph node; lymphogranulomatosis fibroblast adherent 275.Sk CRL-7222* human skin fibroblast adherent 277.T. CRL-7222* human skin fibroblast adherent 280.T. CRL-7222* human mammary gland; adenocarcinoma fibroblast adherent 281.T. CRL-7222* human mammary gland; adenocarcinoma fibroblast adherent 281.T. CRL-7222* <td></td> <td></td> <td></td> | | | |
| \$234.Th CRL-7200* human mixed skin and muscle fibroblast adherent \$238.5k CRL-7201* human mixed skin and muscle fibroblast adherent \$238.5k CRL-7201* human mixed skin and muscle fibroblast adherent \$24.Fs CRL-7016* human skin (foreskin) fibroblast adherent \$24.Fs CRL-7016* human skin (foreskin) fibroblast adherent \$255.T CRL-7213* human colon; adenocarcinoma fibroblast adherent \$257.T CRL-7214* human colon; adenocarcinoma fibroblast adherent \$257.T CRL-7214* human lymph node; hympogranulomatosis fibroblast adherent \$275.K CRL-7222* human mammary gland; adenocarcinoma fibroblast adherent \$275.K CRL-7222* human mammary gland; adenocarcinoma fibroblast adherent \$275.K CRL-7223* human lymph node; hympogranulomatosis fibroblast adherent \$280.T CRL-7225* human lymph node; adenocarcinoma fibroblast adherent \$280.T CRL-7226* human mammary gland; adenocarcinoma fibroblast adherent \$280.T CRL-7226* human mammary gland; adenocarcinoma fibroblast adherent \$284.Pe CRL-7228* human mammary gland; adenocarcinoma fibroblast adherent carcinoma (flung primary) \$294.T HTB-140 human lymph node (metastasic); epidermoid fibroblast adherent (acarcinoma (flung primary) \$295.K CRL-7223* human skin; fibroblast adherent (skin primary) \$295.T CRL-7233* human skin; dermatofibrosarcoma protuberans fibroblast adherent \$3.50.F CRL-7233* human skin; dermatofibrosarcoma protuberans fibroblast adherent \$3.50.F CRL-7235* human skin; dermatofibrosarcoma fibroblast adherent \$3.50.F CRL-7235* human lymph node; reticulum cell sarcoma fibroblast adherent \$3.50.F CRL-7235* human lymph node; reticulum cell sarcoma fibroblast adherent \$3.50.F CRL-7235* human mammary gland; cancer fibroblast adherent \$3.50.F CRL-7246* human mammary gland; cancer fibroblast adherent \$3.50.F CRL-7246* human mammary gland; cancer fibroblast adherent \$3.50.F CRL-7246* hu | | | |
| 2.325.Sk CRL-7201* human mixed skin and muscle fibroblast adherent 2.38.Sk CRL-7203* human mixed skin and muscle fibroblast adherent 3.25.F.T CRL-7213* human colon; adenocarcinoma fibroblast adherent 3.25.F.T CRL-7218* human colon; colorectal adherocarcinoma fibroblast adherent 3.268.T CRL-7218* human lymph node; lymphogranulomatosis fibroblast adherent 3.275.T CRL-7222* human skin fibroblast adherent 3.275.F.X CRL-7222* human skin fibroblast adherent 3.277.T CRL-7222* human lymph node; adenocarcinoma fibroblast adherent 3.281.T CRL-7222* human mammary gland; adenocarcinoma fibroblast adherent 3.281.T CRL-7228* human mammary gland; adenocarcinoma fibroblast adherent 3.28.QF.X CRL-7228* human mammary gland; adenocarcinoma fibroblast <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td> | · · · · · · · · · · · · · · · · · · · | | |
| s 238.5k CRL-7203* human skin (foreskin) fibroblast adherent s257.T CRL-7213* human colon; adenocarcinoma fibroblast adherent adherent colon; colon; adenocarcinoma fibroblast adherent adherent s257.T CRL-7214* human colon; adenocarcinoma fibroblast adherent s274.T CRL-7222* human skin fibroblast adherent fibroblast adherent adherent adherent adherent adherent s278.T CRL-7225* human skin fibroblast adherent fibroblast adherent mammary gland; adenocarcinoma fibroblast adherent mammary gland; adenocarcinoma fibroblast adherent adherent pleural effusion (metastasis); epidermoid fibroblast adherent carcinoma (lung primary) adherent fibroblast adherent adherent pleural effusion (metastasis); epidermoid fibroblast adherent s284.Pe CRL-7228* human pleural effusion (metastasis); epidermoid fibroblast adherent (skin primary) and polygonal skin primary) and polygonal skin primary) and polygonal skin primary) and polygonal skin primary) and polygonal fibroblast adherent s3.5.X CRL-7232* human skin skin fibroblast adherent s3.5.X CRL-7233* human skin; dematorarcinoma protuberans fibroblast adherent s3.5.X CRL-7235* human bone; osteosarcoma fibroblast adherent s3.5.X CRL-7205* human bone; osteosarcoma fibroblast adherent s3.5.X CRL-7236* human lymph node; hymphoma fibroblast adherent s3.5.X CRL-7236* human lymph node; hymphoma fibroblast adherent s3.5.X CRL-7237* human mammary gland; cancer fibroblast adherent mammary gland; cancer fibroblast adherent mammary gland; cancer fibroblast adherent s3.5.X CRL-7240* human mammary gland; cancer fibroblast adherent s3.5.X CRL-7240* human mammary gland; cancer fibroblast adherent adherent s3.5.X CRL-7240* human mammary gland; cancer fibroblast adherent s3.5.X CRL-7240* human mammary gland; cancer fibroblast adherent s3.5.X CRL-7240* human mammary gland; cancer fibroblast a | · · · · · · · · · · · · · · · · · · · | | |
| 5 2 4 Fs CRL-7016* human skin (foreskin) fibroblast adherent 2 255.T CRL-7213* human colon; adenocarcinoma fibroblast adherent 3 257.T CRL-7218* human lymph node; lymphogranulomatosis fibroblast adherent 3 268.T CRL-7218* human mammary gland; adenocarcinoma fibroblast adherent 3 275.Sk CRL-72228* human skin fibroblast adherent 3 277.T CRL-7225* human lymph node; abnormal fibroblast adherent 3 280.T CRL-7225* human mammary gland; adenocarcinoma fibroblast adherent 3 281.T CRL-7227* human pleural effusion (metastasis); epidemoid adherent 5 294.T HTB-140 human pleural effusion (metastasis); epidemoid fibroblast adherent 5 295.T CRL-7232* human skin fibroblast adherent 5 295.T CRL-7233* human skin fibroblast adherent <tr< td=""><td></td><td></td><td>erent</td></tr<> | | | erent |
| \$255.T CRL-7213* human colon; adenocarcinoma fibroblast adherent adherent (RL-7214* human colon; colorectal adenocarcinoma adherent adherent september (RL-7214* human lymph node; lymphogranulomatosis fibroblast adherent september (RL-7222* human skin fibroblast adherent description (RL-7222* human skin fibroblast adherent description (RL-7222* human skin fibroblast adherent description (RL-7225* human lymph node; abnormal fibroblast adherent description (RL-7225* human lymph node; abnormal fibroblast adherent description (RL-7226* human mammary gland; adenocarcinoma fibroblast adherent adherent set (RL-7228* human mammary gland; adenocarcinoma fibroblast adherent set (RL-7228* human mammary gland; adenocarcinoma fibroblast adherent carcinoma (lung primary) (RL-7228* human pleural effusion (metastasis); epidermoid fibroblast adherent (skin primary) (RL-7228* human skin (kin primary) (RL-7228* human skin fibroblast adherent (skin primary) (RL-7233* human skin (RL-7233* human skin; dematofibrosarcoma protuberans fibroblast adherent set (RL-7233* human skin; dematofibrosarcoma protuberans fibroblast adherent set (RL-7233* human skin; dematofibrosarcoma fibroblast adherent set (RL-7233* human bone; osteosarcoma fibroblast adherent set (RL-7235* human bone; osteosarcoma fibroblast adherent set (RL-7235* human lymph node; primphoma fibroblast adherent set (RL-7239* human lymph node; cancer fibroblast adherent set (RL-7240* human lymph node; cancer fibroblast adherent mammary gland; cancer fibroblast adherent mammary gland; cancer fibroblast adherent set (RL-7245* human mammary gland; cancer f | ls 238.Sk CRL-7203* human mixed skin and m | nuscle fibroblast adhe | erent |
| \$ 257.T CRL-7214* human colon; colorectal adenocarcinoma adherent daherent CRL-7218* human lymph node; hymphogranulomatosis fibroblast adherent siz75.Sk CRL-7222* human mammary gland; adenocarcinoma fibroblast adherent fibroblast adherent siz75.Sk CRL-7223* human lymph node; abnormal fibroblast adherent fibroblast adherent fibroblast adherent fibroblast adherent siz75.Sk CRL-7225* human lymph node; abnormal fibroblast adherent fibroblast adherent siz75.Sk CRL-7225* human mammary gland; adenocarcinoma fibroblast adherent adherent carcinoma (flung primary) siz75.Sk CRL-7228* human mammary gland; adenocarcinoma fibroblast adherent carcinoma (flung primary) siz75.Sk CRL-7228* human pleural effusion (metastasis); epidermoid fibroblast adherent carcinoma (flung primary) siz75.Sk CRL-7233* human skin fibroblast adherent (skin primary) siz75.Sk CRL-7233* human skin; dermatofibrosarcoma protuberans fibroblast adherent siz75.T CRL-7233* human skin; dermatofibrosarcoma protuberans fibroblast adherent siz75.T CRL-7235* human skin; dermatofibrosarcoma fibroblast adherent siz75.T CRL-7236* human bone; osteosarcoma fibroblast adherent siz75.T CRL-7236* human bone; osteosarcoma fibroblast adherent siz75.T CRL-7237* human lymph node; hymphoma fibroblast adherent siz75.T CRL-7239* human lymph node; retriculum cell sarcoma fibroblast adherent mammary gland; cancer fibroblast adherent mammary gland; cancer fibroblast adherent siz75.T CRL-7242* human mammary gland; cancer fibroblast adherent mammary gland; cancer fibroblast adherent siz75.T CRL-7248* human mammary gland; cancer fibroblast adherent siz75.T CRL-7248* human mammary gland; cancer fibroblast adherent siz75.T CRL-7248* human mammary gland; cancer fibroblast adherent siz75.Sk CRL-7248* human mammary gland; cancer fibroblast adherent siz75.Sk CRL-7255* human mammary gland; cancer fibroblast adherent siz75.Sk CRL-7256* human skin dermatoric fibroblast adherent siz75.Sk CRL-7256* human hone; osteosarcoma fibroblast adherent siz75.Sk CRL-7256* human bone; osteosarcoma fibrobl | s 24.Fs CRL-7016* human skin (foreskin) | fibroblast adhe | erent |
| \$ 288.T CRL-7218* human lymph node; lymphogranulomatosis fibroblast adherent adherent CRL-7222* human skin fibroblast adherent siz77.T CRL-7222* human lymph node; abnormal fibroblast adherent fibroblast adherent cRL-7226* human lymph node; abnormal fibroblast adherent pleural elffusion (metastasis); epidermoid fibroblast adherent carcinoma (ing primary) \$ 281.T CRL-7228* human pleural elffusion (metastasis); epidermoid fibroblast adherent (skin primary) \$ 294.T HTB-140 human lymph node (metastatic); amelonotic melanoma mixed, stellate adherent (skin primary) \$ 295.Sk CRL-7232* human skin fibroblast adherent fibroblast adherent skin cRL-7006* human skin fibroblast adherent plant skin fibroblast adherent sin sin skin fibroblast adherent sin | s 255.T CRL-7213* human colon; adenocarc | inoma fibroblast adhe | erent |
| \$ 288.T CRL-7218* human lymph node; lymphogranulomatosis fibroblast adherent mammary gland; adenocarcinoma fibroblast adherent siz75.5k CRL-7222* human skin fibroblast adherent fibroblast adherent siz77.T CRL-7225* human lymph node; abnormal fibroblast adherent graph adherent gland; adenocarcinoma fibroblast adherent siz87.T CRL-7226* human mammary gland; adenocarcinoma fibroblast adherent graph adherent gra | s 257.T CRL-7214* human colon; colorectal | adenocarcinoma adho | erent |
| 5 274.T CRL-7222* human human mammary gland; adenocarcinoma fibroblast adherent 5 275.Sk CRL-7225* human skin fibroblast adherent 5 280.T CRL-7225* human lymph node; abnormal fibroblast adherent 5 280.T CRL-7226* human mammary gland; adenocarcinoma fibroblast adherent 5 281.T CRL-7228* human pleural effusion (metastasis); epidermoid fibroblast adherent 5 284.Pe CRL-7228* human lymph node (metastasis); epidermoid fibroblast adherent 5 294.T HTB-140 human skin fibroblast adherent 5 295.S CRL-7232* human skin fibroblast adherent 3 25.S CRL-7233* human skin fibroblast adherent 3 3.T CRL-7233* human skin fibroblast adherent 3 3.T CRL-7235* human bone; osteosarcoma fibroblast adherent 3 3 3.T CRL-7235* human bymph node; metastasicy, epidermoid fibroblast adherent | · | | |
| \$275.5k CRL-7223* human lymph node; abnormal fibroblast adherent seems of the common s | · · · · · · · · · · · · · · · · · · · | · · · | |
| \$277.T CRL-7225* human lymph node; abnormal fibroblast adherent \$280.T CRL-7225* human mammary gland; adenocarcinoma fibroblast adherent \$281.T CRL-7227* human mammary gland; adenocarcinoma fibroblast adherent \$284.Pe CRL-7228* human pleural effusion (metastasis); epidermoid fibroblast adherent \$294.T HTB-140 human lymph node (metastatic); amelonotic melanoma mixed, stellate adherent \$295.Sk CRL-7232* human skin fibroblast adherent \$295.T CRL-7232* human skin; dermatofibrosarcoma protuberans fibroblast adherent \$3.3.K CRL-7006* human skin; dermatofibrosarcoma protuberans fibroblast adherent \$3.1.T CRL-7232* human lymph node; lymphoma fibroblast adherent \$3.1.T CRL-7235* human lymph node; lymphoma fibroblast adherent \$3.1.T CRL-7232* human mammary gland; cancer fibroblast adherent \$3.25.L CRL-7240* human lymph node; r | , 5 | | |
| S 280.T CRL-7226* human mammary gland; adenocarcinoma fibroblast adherent s 281.T CRL-7227* human mammary gland; adenocarcinoma fibroblast adherent s 281.T CRL-7228* human pleural effusion (metastatis); epidermoid fibroblast adherent carcinoma (lung primary) S 294T HTB-140 human lymph node (metastatic); amelonotic melanoma (skin primary) S 295.Sk CRL-7232* human skin; dermatofibrosarcoma protuberans fibroblast adherent s 295.T CRL-7233* human skin; dermatofibrosarcoma protuberans fibroblast adherent s 3.T CRL-7006* human skin fibroblast adherent fibroblast adherent s 3.T CRL-7006* human bone; osteosarcoma fibroblast adherent fibroblast adherent s 3.T CRL-7236* human lymph node; plymphoma fibroblast adherent s 3.T CRL-7236* human lymph node; plymphoma fibroblast adherent s 3.T CRL-7236* human lymph node; chronic lymphadentis fibroblast adherent s 3.T CRL-7236* human lymph node; chronic lymphadentis fibroblast adherent s 3.T CRL-7242* human lymph node; chronic lymphadentis fibroblast adherent s 3.T CRL-7242* human mammary gland; cancer fibroblast adherent s 3.T CRL-7242* human mammary gland; cancer fibroblast adherent s 3.T CRL-7242* human mammary gland; cancer fibroblast adherent s 3.T CRL-7242* human mammary gland; cancer fibroblast adherent s 3.T CRL-7245* human mammary gland; cancer fibroblast adherent s 3.T CRL-7245* human mammary gland; cancer fibroblast adherent s 3.T CRL-7245* human mammary gland; cancer fibroblast adherent s 3.T CRL-7245* human mammary gland; cancer fibroblast adherent s 3.T CRL-7245* human mammary gland; cancer fibroblast adherent s 3.T CRL-7245* human mammary gland; cancer fibroblast adherent s 3.T CRL-7245* human mammary gland; cancer fibroblast adherent s 3.T CRL-7255* human mammary gland; cancer fibroblast adherent s 3.T CRL-7255* human mammary gland; cancer fibroblast adherent s 3.T CRL-7255* human mammary gland; cancer fibroblast adherent s 3.T CRL-7255* human mammary gland; cancer fibroblast adherent s 3.T CRL-7255* human human skin fibroblast adherent s 3.T CRL-7256* human hum | | | |
| s 281.T CRL-7227* human mammary gland; adenocarcinoma fibroblast adherent s 284.Pe CR. 7228* human pleural effusion (metastasis); epidermoid fibroblast adherent carcinoma (lung primary) s 294T HTB-140 human lymph node (metastatic); amelonotic melanoma (skin primary) s 295.Sk CRL-7232* human skin; dermatofibrosarcoma protuberans fibroblast adherent s 3.5.K CRL-7333* human skin; dermatofibrosarcoma protuberans fibroblast adherent s 3.5.K CRL-7005* human skin; dermatofibrosarcoma fibroblast adherent s 3.5.K CRL-7005* human bone; osteosarcoma fibroblast adherent s 3.5.K CRL-7235* human lymph node; prophoma fibroblast adherent s 3.5.K CRL-7235* human lymph node; prophoma fibroblast adherent s 3.5.K CRL-7235* human lymph node; prophoma fibroblast adherent s 3.5.K CRL-7239* human lymph node; prophoma fibroblast adherent s 3.5.K CRL-7239* human lymph node; prophoma fibroblast adherent s 3.5.K CRL-7240* human lymph node; prophoma fibroblast adherent s 3.5.K CRL-7240* human lymph node; prophoma fibroblast adherent s 3.5.K CRL-7240* human lymph node; prophoma fibroblast adherent s 3.5.K CRL-7240* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7245* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7246* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7248* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7248* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7252* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7252* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7255* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7255* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7255* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7255* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7255* human mammary gland; cancer fibroblast adherent s 3.5.K CRL-7255* human bone; osteosarcoma fibroblast adherent s 3.5.K CRL-7255* human bone; osteosarcoma fibroblast adherent s 3.5.K CRL-7265* human lung fibroblast adh | | | |
| s 284.Pe CRL-7228* human pleural effusion (metastasis); epidermoid fibroblast adherent carcinoma (lung primary) s 295.Sk CRL-7232* human skin fibroblast adherent (skin primary) s 295.Sk CRL-7233* human skin; dermatofibrosarcoma protuberans fibroblast adherent s 3.Sk CRL-7006* human bone; osteosarcoma protuberans fibroblast adherent s 3.1.T CRL-7233* human bone; osteosarcoma fibroblast adherent s 319.T CRL-7236* human bone; osteosarcoma fibroblast adherent s 324.T CRL-7236* human lymph node; lymphoma fibroblast adherent s 324.T CRL-7236* human lymph node; reticulum cell sarcoma mixed s 325.Ln CRL-7240* human lymph node; chronic lymphadenitis fibroblast adherent s 329.T CRL-7242* human mammary gland; cancer fibroblast adherent s 344.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7253* human mammary gland; cancer fibroblast adherent s 362.T CRL-7254* human mammary gland; cancer fibroblast adherent s 362.T CRL-7255* human connective tissue; fascia fibroblast adherent s 362.T CRL-7256* human warny gland; cancer fibroblast adherent s 362.T CRL-7256* human connective tissue; fascia fibroblast adherent s 362.T CRL-7256* human bone; osteosarcoma fibroblast adherent s 362.T CRL-7266* human bone; osteosarcoma fibroblast adherent s 362.T CRL-7266* human bone; osteosarcoma fibroblast adherent s 362.F CRL-7266* human bone; osteosarcoma fibroblast adherent s 362.F CRL-7266* human bone; osteosarcoma fibroblast adherent | , , , | | |
| s 294T HTB-140 human lymph node (metastatic); amelonotic melanoma mixed, stellate and polygonal s 295.5k CRL-7232* human skin fibroblast adherent s 3295.T CRL-7233* human skin; dermatofibrosarcoma protuberans fibroblast adherent s 3.5k CRL-7006* human skin fibroblast adherent s 3.5k CRL-7006* human skin fibroblast adherent s 3.5k CRL-7005* human bone; osteosarcoma fibroblast adherent s 3.5k CRL-7235* human lymph node; lymphoma fibroblast adherent s 3.5k CRL-7235* human lymph node; lymphoma fibroblast adherent s 3.5k CRL-7236* human lymph node; lymphoma fibroblast adherent s 3.5k CRL-7239* human lymph node; chronic lymphadenitis fibroblast adherent s 3.5k CRL-7240* human lymph node; chronic lymphadenitis fibroblast adherent s 3.5k CRL-7240* human mammary gland; cancer fibroblast adherent s 3.5k CRL-7242* human mammary gland; cancer fibroblast adherent s 3.5k CRL-7244* human mammary gland; cancer fibroblast adherent s 3.5k CRL-7248* human mammary gland; cancer fibroblast adherent s 3.5k CRL-7248* human mammary gland; cancer fibroblast adherent s 3.5k CRL-7248* human mammary gland; cancer fibroblast adherent s 3.5k CRL-7248* human mammary gland; cancer fibroblast adherent s 3.5k CRL-7248* human mammary gland; cancer fibroblast adherent s 3.5k CRL-7258* human mammary gland; cancer fibroblast adherent s 3.5k CRL-7258* human connective tissue; fascia fibroblast adherent s 3.5k CRL-7255* human connective tissue; fascia fibroblast adherent s 3.5k CRL-7255* human connective tissue; fascia fibroblast adherent s 3.5k CRL-7255* human skin fibroblast adherent s 3.5k CRL-7256* human skin fibroblast adherent s 3.5k CRL-7256* human bone; osteosarcoma mixed adherent s 3.5k CRL-7268* human bone; osteosarcoma fibroblast adher | , , , | | |
| s 295.5k CRL-7232* human skin primary) and polygonal s 295.5k CRL-7233* human skin; dermatofibrosarcoma protuberans fibroblast adherent s 3.5k CRL-7006* human skin fibroblast adherent s 3.17 CRL-7005* human bone; osteosarcoma fibroblast adherent s 313.7 CRL-7235* human lymph node; lymphoma fibroblast adherent s 319.7 CRL-7236* human lymph node; lymphoma fibroblast adherent s 329.7 CRL-7239* human lymph node; etroiculum cell sarcoma mixed s 324.7 CRL-7240* human lymph node; retriculum cell sarcoma mixed s 325.Ln CRL-7240* human lymph node; ctronic lymphadenitis fibroblast adherent s 329.7 CRL-7242* human mammary gland; cancer fibroblast adherent s 344.7 CRL-7248* human mammary gland; cancer fibroblast adherent s 357.7 <td< td=""><td>carcinoma (lung _l</td><td>primary)</td><td>erent</td></td<> | carcinoma (lung _l | primary) | erent |
| s 295.T CRL-7203* human skin; dermatofibrosarcoma protuberans fibroblast adherent s 3.5.K CRL-7006* human skin fibroblast adherent s 31.T CRL-7005* human bone; osteosarcoma fibroblast adherent s 313.T CRL-7235* human lymph node; lymphoma fibroblast adherent s 319.T CRL-7236* human lymph node; lymphoma fibroblast adherent s 324.T CRL-7239* human lymph node; cancer fibroblast adherent s 324.T CRL-7239* human lymph node; chronic lymphadenitis fibroblast adherent s 325.Ln CRL-7240* human lymph node; chronic lymphadenitis fibroblast adherent s 329.T CRL-7242* human mammary gland; cancer fibroblast adherent s 343.T CRL-7245* human mammary gland; cancer fibroblast adherent s 344.T CRL-7246* human mammary gland; cancer fibroblast adherent s 350.T CRL-7248* human mammary gland; cancer fibroblast adherent s 350.T CRL-7252* human mammary gland; cancer fibroblast adherent s 360.T CRL-7252* human mammary gland; cancer fibroblast adherent s 360.T CRL-7255* human mammary gland; cancer fibroblast adherent s 360.T CRL-7255* human mammary gland; cancer fibroblast adherent s 360.T CRL-7255* human mammary gland; cancer fibroblast adherent s 360.T CRL-7255* human mammary gland; cancer fibroblast adherent s 360.T CRL-7255* human mammary gland; cancer fibroblast adherent s 360.T CRL-7255* human mammary gland; cancer fibroblast adherent s 360.Ct CRL-7255* human mammary gland; cancer fibroblast adherent s 371.T CRL-7267* human mammary gland; cancer fibroblast adherent s 371.T CRL-7267* human skin fibroblast adherent s 381.T CRL-7265* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7266* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7266* human | | | erent |
| s 3.5k CRL-7006* human skin fibroblast adherent s 3.1T CRL-7055* human bone; osteosarcoma fibroblast adherent s 3.13.T CRL-7235* human lymph node; lymphoma fibroblast adherent s 3.19.T CRL-7236* human mammary gland; cancer fibroblast adherent s 3.24.T CRL-7239* human lymph node; reticulum cell sarcoma mixed s 3.24.T CRL-7240* human lymph node; chronic lymphadenitis fibroblast adherent s 3.29.T CRL-7242* human mammary gland; cancer fibroblast adherent s 3.29.T CRL-7245* human mammary gland; cancer fibroblast adherent s 3.24.T CRL-7246* human mammary gland; cancer fibroblast adherent s 3.25.T CRL-7246* human mammary gland; cancer fibroblast adherent s 3.25.T CRL-7246* human mammary gland; cancer fibroblast adherent s 3.25.T CRL-7248* human mammary gland; cancer fibroblast adherent s 3.25.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 3.25.T CRL-7253* human mammary gland; cancer fibroblast adherent s 3.25.T CRL-7253* human mammary gland; cancer fibroblast adherent s 3.25.C CRL-7254* human mammary gland; cancer fibroblast adherent s 3.25.C CRL-7255* human connective tissue; fascia fibroblast adherent s 3.25.C CRL-7256* human connective tissue; fascia fibroblast adherent s 3.25.C CRL-7257* human skin fibroblast adherent s 3.25.C CRL-7257* human skin fibroblast adherent s 3.25.C CRL-7257* human skin fibroblast adherent s 3.25.C CRL-7256* human skin fibroblast adherent s 3.25.C CRL-7266* human bone; osteosarcoma fibroblast adherent s 3.25.C CRL-7265* human lung fibroblast adherent s 3.25.C CRL-7266* human bone; osteosarcoma fibroblast adherent s 3.25.C CRL-7268* human bone; osteosarcoma fibroblast adherent s 3.25.C CRL-7268* human bone; osteosarcoma fibroblast adherent s 3.25.C CRL-726 | ls 295.Sk CRL-7232* human skin | fibroblast adhe | erent |
| s 3.T | ls 295.T CRL-7233* human skin; dermatofibro | osarcoma protuberans fibroblast adhe | erent |
| s 313.T CRL-7235* human lymph node; lymphoma fibroblast adherent s 319.T CRL-7236* human mammary gland; cancer fibroblast adherent s 324.T CRL-7239* human lymph node; reticulum cell sarcoma mixed s 325.Ln CRL-7240* human lymph node; chronic lymphadenitis fibroblast adherent s 329.T CRL-7242* human mammary gland; cancer fibroblast adherent s 343.T CRL-7245* human mammary gland; adenocarcinoma fibroblast adherent s 344.T CRL-7246* human mammary gland; cancer fibroblast adherent s 350.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7253* human mammary gland; adenocarcinoma adherent s 364.Ct CRL-7253* human mammary gland; adenocarcinoma adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7255* human mammary gland; cancer fibroblast adherent s 371.T CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7255* human mammary gland; cancer fibroblast adherent s 371.T CRL-7255* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7255* human mammary gland; cancer fibroblast adherent s 383.Sk CRL-7256* human mammary gland; cancer fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 389(A).Lu CRL-7266* human lung fibroblast adherent s 389(A).Lu CRL-7266* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 391.We CRL-7266* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human skin fibroblast adherent s 391.We CRL-7269* human skin fibroblast adherent s 391.We CRL-7269* human skin fibroblast adherent s 391.We CRL-7269* human skin skin fibroblast adherent s 391.We CRL-72 | s 3.Sk CRL-7006* human skin | fibroblast adhe | erent |
| s 313.T CRL-7235* human lymph node; lymphoma fibroblast adherent s 319.T CRL-7236* human mammary gland; cancer fibroblast adherent s 324.T CRL-7239* human lymph node; reticulum cell sarcoma mixed s 325.Ln CRL-7240* human lymph node; chronic lymphadenitis fibroblast adherent s 329.T CRL-7242* human mammary gland; cancer fibroblast adherent s 343.T CRL-7245* human mammary gland; adenocarcinoma fibroblast adherent s 344.T CRL-7246* human mammary gland; cancer fibroblast adherent s 350.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7253* human mammary gland; adenocarcinoma adherent s 364.Ct CRL-7253* human mammary gland; adenocarcinoma adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7255* human mammary gland; cancer fibroblast adherent s 371.T CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7255* human mammary gland; cancer fibroblast adherent s 371.T CRL-7255* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7255* human mammary gland; cancer fibroblast adherent s 383.Sk CRL-7256* human mammary gland; cancer fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 389(A).Lu CRL-7266* human lung fibroblast adherent s 389(A).Lu CRL-7266* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 391.We CRL-7266* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human skin fibroblast adherent s 391.We CRL-7269* human skin fibroblast adherent s 391.We CRL-7269* human skin fibroblast adherent s 391.We CRL-7269* human skin skin fibroblast adherent s 391.We CRL-72 | s 3.T CRL-7005* human bone; osteosarco | ma fibroblast adhe | erent |
| s 319.T CRL-7236* human mammary gland; cancer fibroblast adherent s 324.T CRL-7239* human lymph node; reticulum cell sarcoma mixed s 325.Ln CRL-7240* human lymph node; reticulum cell sarcoma fibroblast adherent s 329.T CRL-7242* human mammary gland; cancer fibroblast adherent s 343.T CRL-7245* human mammary gland; cancer fibroblast adherent s 344.T CRL-7246* human mammary gland; cancer fibroblast adherent s 350.T CRL-7248* human mammary gland; cancer fibroblast adherent s 350.T CRL-7252* human mammary gland; cancer fibroblast adherent s 362.T CRL-7253* human skin; dermatofibrosarcoma fibroblast adherent s 364.Ct CRL-7255* human mammary gland; adenocarcinoma adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7256* human skin fibroblast adherent s 388.T CRL-7826* human skin fibroblast adherent s 388.T CRL-7826* human skin fibroblast adherent s 389.A.Lu CRL-7266* human lung fibroblast adherent s 389(A).Lu CRL-7266* human bone; osteosarcoma mixed adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 391.We CRL-7266* human whole fetus fibroblast adherent s 391.We CRL-7267* human skin fibroblast adherent s 392.Sk CRL-7267* human skin fibroblast adherent s 391.We CRL-7266* human skin fibroblast adherent s 392.Sk CRL-7267* human skin fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 392.Sk CRL-7269* human skin | · | | |
| s 324.T CRL-7239* human lymph node; reticulum cell sarcoma mixed s 325.Ln CRL-7240* human lymph node; chronic lymphadenitis fibroblast adherent s 329.T CRL-7242* human mammary gland; cancer fibroblast adherent s 343.T CRL-7245* human mammary gland; cancer fibroblast adherent s 344.T CRL-7246* human mammary gland; cancer fibroblast adherent s 344.T CRL-7248* human mammary gland; cancer fibroblast adherent s 350.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7253* human mammary gland; adenocarcinoma fibroblast adherent s 364.Ct CRL-7254* human connective tissue; fascia fibroblast adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 383.Sk CRL-7267* human skin fibroblast adherent s 383.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.T CRL-7826* human skin fibroblast adherent s 383.T CRL-7266* human bone; osteosarcoma mixed adherent s 387.T CRL-7268* human bone; osteosarcoma fibroblast adherent s 389(A).Lu CRL-7268* human lung fibroblast adherent s 391.We CRL-7266* human whole fetus fibroblast adherent s 391.We CRL-7268* human skin fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 391.We CRL-7268* human skin fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent | , , , , , | | |
| s 325.Ln CRL-7240* human lymph node; chronic lymphadenitis fibroblast adherent fibroblast adherent s 329.T CRL-7242* human mammary gland; cancer fibroblast adherent fibroblast adherent s 343.T CRL-7246* human mammary gland; adenocarcinoma fibroblast adherent s 354.T CRL-7246* human mammary gland; cancer fibroblast adherent s 350.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7253* human mammary gland; adenocarcinoma adherent s 364.Ct CRL-7253* human connective tissue; fascia fibroblast adherent s 365.Ct CRL-7256* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 383.T CRL-7257* human skin fibroblast adherent s 383.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 383.T CRL-7266* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7266* human lung fibroblast adherent s 389(A).Lu CRL-7266* human lung fibroblast adherent s 389(B).Lu CRL-7266* human bone; osteosarcoma fibroblast adherent s 399.Sk CRL-7266* human bone; osteosarcoma fibroblast adherent s 399.Sk CRL-7266* human bone; osteosarcoma fibroblast adherent s 399.Sk CRL-7266* human skin fibroblast adherent s 399.Sk CRL-7266* human skin fibroblast adherent s 391.We CRL-7266* human skin fibroblast adherent s 391.We CRL-7266* human skin fibroblast adherent s 391.We CRL-7268* human skin fibroblast adherent s 392.Sk CRL-7268* human skin skin fibroblast adherent s 392.Sk CRL-7268* human skin skin fibro | | | |
| s 329.T CRL-7242* human mammary gland; cancer fibroblast adherent s 343.T CRL-7245* human mammary gland; adenocarcinoma fibroblast adherent s 344.T CRL-7246* human mammary gland; cancer fibroblast adherent s 350.T CRL-7248* human mammary gland; cancer fibroblast adherent s 350.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7252* human mammary gland; adenocarcinoma fibroblast adherent s 364.Ct CRL-7253* human connective tissue; fascia fibroblast adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 383.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 383.Sk CRL-7864* human skin fibroblast adherent s 383.T CRL-7266* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7266* human lung fibroblast adherent s 389(A).Lu CRL-7266* human bone; osteosarcoma fibroblast adherent s 399.Sk CRL-7268* human bone; osteosarcoma fibroblast adherent s 399.We CRL-7267* human bone; osteosarcoma fibroblast adherent s 399.We CRL-7268* human skin fibroblast adherent s 399.Sk CRL-7269* human skin skin fibroblast adherent s 399.Sk CRL-7268* human skin fibroblast adherent s 399.Sk CRL-7269* human skin fibroblast adherent s 399.Sk CRL-7269* human skin fibroblast adherent s 399.Sk CRL-7269* human skin skin | | | |
| s 343.T CRL-7245* human mammary gland; adenocarcinoma fibroblast adherent mammary gland; cancer fibroblast adherent s 350.T CRL-7248* human skin; dermatofibrosarcoma fibroblast adherent s 357.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7253* human mammary gland; adenocarcinoma adherent s 364.Ct CRL-7254* human connective tissue; fascia fibroblast adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 383.Sk CRL-7257* human skin fibroblast adherent s 383.Sk CRL-7842* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7866* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(A).Lu CRL-7266* human bone; osteosarcoma fibroblast adherent s 389(B).Lu CRL-7266* human bone; osteosarcoma fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 399.Sk CRL-7267* human skin fibroblast adherent s 399.Sk CRL-7267* human skin fibroblast adherent s 399.Sk CRL-7268* human skin fibroblast adherent s 399.Sk CRL-7269* human skin fibroblast adherent s 399.Lu CRL-7269* human skin fibroblast adherent s 399.Sk CRL-7269* human skin fibroblast adherent s 399.Lu CRL-7269* human skin | | | |
| s 344.T CRL-7248* human mammary gland; cancer fibroblast adherent s 350.T CRL-7248* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7252* human mammary gland; adenocarcinoma adherent s 364.Ct CRL-7254* human connective tissue; fascia fibroblast adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 383.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.T CRL-7826* human skin fibroblast adherent s 387.T CRL-7263* human skin fibroblast adherent s 389(A).Lu CRL-7266* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 389(B).Lu CRL-7267* human bone; osteosarcoma fibroblast adherent s 399.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 399.T CRL-7267* human skin fibroblast adherent s 399.T CRL-7268* human bone; osteosarcoma fibroblast adherent s 399.T CRL-7268* human skin fibroblast adherent s 399.Sk CRL-7268* human skin fibroblast adherent s 399.Sk CRL-7268* human skin fibroblast adherent s 399.Lu CRL-7268* human skin fibroblast adherent s 390.Sk CRL-7268* human skin fibroblast adherent s 390.Sk CRL-7268* human skin fibroblast adherent s 390.Lu CRL-7268* human skin fibroblast adherent s 390.Lu CRL-7268* human skin fibroblast adherent s 390.Sk CRL-7268* human skin fibroblast adherent s 390.Lu CRL-7268* human skin fibroblast adherent s 390.Lu CRL-7268* human skin fibroblast adherent s 390.Lu CRL-7269* human skin fibroblast adherent s 390.Lu CRL-7269* human skin skin skin skin skin s | , , , | | |
| s 350.T CRL-7248* human mammary gland; cancer fibroblast adherent s 357.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent s 362.T CRL-7253* human mammary gland; adenocarcinoma adherent s 364.Ct CRL-7254* human connective tissue; fascia fibroblast adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 388.T CRL-7256* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 383.T CRL-7826* human ovary; carcinoma fibroblast adherent s 387.T CRL-7263* human skin fibroblast adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 389(B).Lu CRL-7266* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7023* human whole fetus fibroblast adherent s 391.We CRL-7268* human skin fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 393.Lu CRL-7269* human skin fibroblast adherent s 394.Lu CRL-7269* human skin fibroblast adherent s 394.Lu CRL-7269* human skin adherent s 394.Lu CRL-7269* | , , | | |
| s 357.T CRL-7252* human skin; dermatofibrosarcoma fibroblast adherent adherent s 362.T CRL-7253* human mammary gland; adenocarcinoma adherent s 364.Ct CRL-7254* human connective tissue; fascia fibroblast adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 383.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 387.T CRL-7863* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 391.We CRL-7033* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7268* human skin fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent s 394.L | , , , | | |
| s 362.T CRL-7253* human mammary gland; adenocarcinoma adherent s 364.Ct CRL-7254* human connective tissue; fascia fibroblast adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 383.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 387.T CRL-7863* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 391.We CRL-7268* human skin fibroblast adherent s 392.Sk CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | , , , | | |
| s 364.Ct CRL-7254* human connective tissue; fascia fibroblast adherent s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 38.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 387.T CRL-7842* human skin fibroblast adherent s 387.T CRL-7263* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | · | | |
| s 365.Ct CRL-7255* human connective tissue; fascia fibroblast adherent s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 38.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 387.T CRL-7842* human skin fibroblast adherent s 387.T CRL-7263* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | , , , | | |
| s 371.T CRL-7256* human mammary gland; cancer fibroblast adherent s 372.Sk CRL-7257* human skin fibroblast adherent s 38.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 387.T CRL-7263* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent | | • | |
| s 372.Sk CRL-7257* human skin fibroblast adherent s 38.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 387.T CRL-7263* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7268* human lung fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | | • | |
| s 38.T CRL-7826* human ovary; carcinoma fibroblast adherent s 383.Sk CRL-7842* human skin fibroblast adherent s 387.T CRL-7263* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | | | |
| s 383.5k CRL-7842* human skin fibroblast adherent s 387.T CRL-7263* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | s 372.Sk CRL-7257* human skin | fibroblast adhe | erent |
| s 387.T CRL-7263* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | s 38.T CRL-7826* human ovary; carcinoma | fibroblast adhe | erent |
| s 387.T CRL-7263* human bone; osteosarcoma mixed adherent s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | s 383.Sk CRL-7842* human skin | fibroblast adhe | erent |
| s 389(A).Lu CRL-7265* human lung fibroblast adherent s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | | | |
| s 389(B).Lu CRL-7266* human lung fibroblast adherent s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | · | | |
| s 39.T CRL-7023* human bone; osteosarcoma fibroblast adherent s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | | | |
| s 391.We CRL-7267* human whole fetus fibroblast adherent s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | | | |
| s 392.Sk CRL-7268* human skin fibroblast adherent s 394.Lu CRL-7269* human lung fibroblast adherent | · | | |
| s 394.Lu CRL-7269* human lung fibroblast adherent | | | |
| <u> </u> | | | |
| s 394.Sk CRL-7270* human mixed skin and muscle fibroblast adherent | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--------------|-----------|---------|--|-------------|-------------|
| Hs 395.We | CRL-7271* | human | whole fetus | fibroblast | adherent |
| Hs 397.Lu | CRL-7272* | human | lung | | adherent |
| ds 399.Li | CRL-7274* | human | liver; abnormal | | |
| Hs 401.Lu | CRL-7275* | human | lung | fibroblast | adherent |
| ls 402.Sk | CRL-7276* | human | skin | | |
| Hs 404.Sk | CRL-7278* | human | skin | | |
| ls 405.Sk | CRL-7279* | human | skin | | |
| ls 409.We | CRL-7281* | human | whole fetus | | |
| ls 410.We | CRL-7282* | human | whole fetus | fibroblast | adherent |
| ls 412.Lu | CRL-7285* | human | lung or bronchus | | |
| ls 413.We | CRL-7286* | human | whole fetus | fibroblast | |
| ls 414.T | CRL-7287* | human | lymph node (metastasis); fibrosarcoma mixed (connective tissue primary) | | adherent |
| ls 415.Sk | CRL-7288* | human | skin | fibroblast | adherent |
| ls 416.T | CRL-7289* | human | skin; squamous papilloma | | adherent |
| ls 417.Lu | CRL-7291* | human | lung (bronchus) | | |
| Hs432.T | CRL-7299 | human | skin; melanoma | | |
| ls 443.T | CRL-7300* | human | lymph node; reactive hyperplasia | | |
| ls 445 | HTB-146 | human | lymph node; lymphoma; Hodgkin's disease | lymphoblast | suspension |
| ls 446.Sk | CRL-7801* | human | skin | fibroblast | adherent |
| ls 45.Fs | CRL-7025* | human | skin (foreskin) | fibroblast | adherent |
| ls 454.T | CRL-7802* | human | bone; eosinophilic granuloma | fibroblast | adherent |
| ls 456.Bt | CRL-7805* | human | skin; benign lesion | | |
| ls 456.Sk | CRL-7804* | human | skin | | adherent |
| ls 46.Fs | CRL-7026* | human | skin (foreskin) | fibroblast | adherent |
| ls 466.Sk | CRL-7807* | human | skin (scalp) | fibroblast | adherent |
| ls 467.Sk | CRL-7808* | human | skin | fibroblast | adherent |
| ls 468.Lu | CRL-7810* | human | lung | fibroblast | adherent |
| ls 469.Sk | CRL-7811* | human | skin | fibroblast | adherent |
| ls 479.T | CRL-7813* | human | mammary gland; cancer | fibroblast | adherent |
| ls 48.Fs | CRL-7027* | human | skin (foreskin) | fibroblast | adherent |
| ls 483.Sk | CRL-7815* | human | skin | fibroblast | adherent |
| ls 483.T | CRL-7814* | human | skin; chronic dermatitis | fibroblast | adherent |
| ls 49.Fs | CRL-7028* | human | skin (foreskin) | fibroblast | adherent |
| ls 491.T | CRL-7818* | human | lymph node; lymphocytic lymphoma | fibroblast | adherent |
| ls 5.T | CRL-7822* | human | connective tissue; leiomyosarcoma | fibroblast | adherent |
| ls 505.T | CRL-7306* | human | lymph node; lymphocytic lymphoma | fibroblast | adherent |
| ls 507.Sk | CRL-7307* | human | skin | fibroblast | adherent |
| ls 517.Sk | CRL-7311* | human | skin | fibroblast | adherent |
| ls 518.T | CRL-7313* | human | spleen; lymphocytic lymphoma | fibroblast | adherent |
| ls 52.Sk | CRL-7031* | human | skin; Down syndrome | fibroblast | adherent |
| ls 52.Th | CRL-7032* | human | thymus; Down syndrome | fibroblast | adherent |
| ls 523.Sk | CRL-7314* | human | skin | fibroblast | adherent |
| ls 53.T | CRL-7033* | human | mouth; non-neoplastic tumor | fibroblast | adherent |
| ls 531.Sk | CRL-7315* | human | skin | fibroblast | adherent |
| ls 540.T | CRL-7316* | human | mammary gland; carcinoma | fibroblast | adherent |
| ls 544Sk | CRL-7317* | human | skin | fibroblast | adherent |
| ls 545.Sk | CRL-7318* | human | skin | fibroblast | adherent |
| ls 548.Sk | CRL-7320* | human | skin | fibroblast | adherent |
| ls 55.Fs | CRL-7035* | human | skin (foreskin) | fibroblast | adherent |
| ls 556.Sk | CRL-7321* | human | skin | fibroblast | adherent |
| ls 559.Sk | CRL-7323* | human | skin | fibroblast | adherent |
| ls 56.Fs | CRL-7036* | human | skin (foreskin) | fibroblast | adherent |
| ls 564(E).Mg | CRL-7329* | human | mammary gland | | |
| ls 565(A).Mg | CRL-7330* | human | mammary gland; cyst | | |
| ls 565(D).Mg | CRL-7333* | human | mammary gland; cyst | | |
| ls 566(B).T | CRL-7336* | human | mammary gland; carcinoma | | |
| ls 568.We | CRL-7340* | human | whole fetus | fibroblast | adherent |
| ls 57.T | CRL-7037* | human | lung; sarcoma or lymphoma | fibroblast | adherent |
| ls 571.T | CRL-7846* | human | ovary; carcinoma | fibroblast | adherent |
| | | | . , | | |

* Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-----------------------|------------|---------|--|---------------------------------------|----------------|
| Hs 573.T | CRL-7343* | human | lung; cancer | fibroblast | adherent |
| ls 574.Sk | CRL-7346* | human | skin | fibroblast | adherent |
| ls 574.T | CRL-7345* | human | mammary gland; ductal carcinoma | fibroblast | adherent |
| ls 578Bst | HTB-125 | human | mammary gland | fibroblast | adherent |
| ds 578T | HTB-126 | human | mammary gland; ductal carcinoma | epithelial | adherent |
| ls 579.Mg | CRL-7347* | human | mammary gland | еринения | dancient |
| Is 58.Fs | CRL-7038* | human | skin (foreskin) | fibroblast | adherent |
| ls 587.Int | CRL-7352* | human | colon; colorectal adenocarcinoma | Поторіазс | adricient |
| ls 587.IIIC | CRL-7850* | human | cervix: adenocarcinoma | | adherent |
| | CRL-7353* | human | whole fetus | fibroblast | adherent |
| ls 590.We ls 60.Fs | CRL-7040* | human | skin (foreskin) | fibroblast | adherent |
| 1s 600.FS 1s 600.T | | | | IIDIODIast | |
| | CRL-7360* | human | skin; melanoma | | adherent |
| ls 602 | HTB-142 | human | cervical lymph node; lymphoma | single spherical or small clusters | suspension |
| ls 604.T | CRL-7362* | human | lymph node; lymphoma; Hodgkin's disease | fibroblast | adherent |
| ls 605.Sk | CRL-7364* | human | skin | fibroblast | adherent |
| ls 605.T | CRL-7365* | human | mammary gland; carcinoma | fibroblast | adherent |
| ls 606 | CRL-7368* | human | mammary gland; carcinoma | fibroblast | adherent |
| ls 606.Sk | CRL-7367* | human | skin | fibroblast | adherent |
| ls 61.Fs | CRL-7041* | human | skin (foreskin) | fibroblast | adherent |
| ls 610.Sk | CRL-7372* | human | skin; DiGeorge syndrome | fibroblast | adherent |
| ls 611.T | CRL-7373* | human | lymph node, spleen; lymphoma; Hodgkin's disease | lymphoblast | mixed |
| ls 613.Sk | CRL-7375* | human | skin | | |
| ls 616.T | CRL-7378* | human | lymph node,thymus; lymphoma; Hodgkin's | | adherent |
| ls 617 Ma | CRL-7379* | human | disease | | |
| Hs 617.Mg Hs 618.T | CRL-7380* | | mammary gland | | |
| | CRL-7360** | human | lung; adenocarcinoma | £la ua la la at | a alla a ua ua |
| ls 62.Fs | | human | skin (foreskin) | fibroblast | adherent |
| ls 621.Sk | CRL-7383* | human | skin | fibroblast | adherent |
| ls 622.Sk | CRL-7385* | human | skin (scalp) | fibroblast | adherent |
| ls 63.T | CRL-7043* | human | skin; dermatofibrosarcoma protuberans | fibroblast | adherent |
| ls 67 | HTB-163 | human | thymus | fibroblast | adherent |
| ls 67.Th | CRL-7828* | human | thymus | fibroblast | adherent |
| ls 674.Sk | CRL-7397* | human | skin | fibroblast | adherent |
| ls 675.T | CRL-7400* | human | colon; colorectal cancer | fibroblast | adherent |
| ls 677.Sk | CRL-7406* | human | skin | fibroblast | adherent |
| ls 677.Tg | CRL-7408* | human | tongue | fibroblast | adherent |
| ls 680.Rec | CRL-7418* | human | rectum, fetal | | adherent |
| ls 680.Sk | CRL-7419* | human | skin | fibroblast | adherent |
| ls 680.Tg | CRL-7421* | human | tongue | fibroblast | adherent |
| ls 680.Tr | CRL-7422* | human | trachea | fibroblast | adherent |
| ls 683 | HTB-138 | human | brain; glioma | fibroblast | adherent |
| ls 687.Sk | CRL-7424* | human | skin | fibroblast | adherent |
| ls 688(A).T | CRL-7425* | human | skin; melanoma | fibroblast | adherent |
| ls 688(B).T | CRL-7426* | human | inguinal lymph node (metastasis); melanoma (skin primary) | fibroblast | adherent |
| ls 69.Fs | CRL-7047* | human | skin (foreskin) | fibroblast | adherent |
| Hs 692(A).T | CRL-7428* | human | lymph node (metastasis); intestinal carcinoma | .ioropiust | adherent |
| | | | (unknown primary) | fibroblast | |
| ls 695.Sk | CRL-7855* | human | skin | fibroblast | adherent |
| ls 695T | HTB-137 | human | lymph node (metastasis); amelanotic melanoma (skin primary) | epithelial | adherent |
| ls 696 | HTB-151 | human | bone (metastasis); adenocarcinoma (unknown primary) | epithelial | adherent |
| ls 696.Sk | CRL-7431* | human | skin | fibroblast | adherent |
| ls 697.Ln | CRL-7434* | human | lymph node; noncaseating granuloma | fibroblast | adherent |
| ls 697.Sp | CRL-7433* | human | spleen | fibroblast | adherent |
| ls 698.T | CRL-7435* | human | connective tissue (metastasis); adenocar- | .ioiooiust | adherent |
| | | | cinoma (colon primary) | | |
| Hs 70.Fs | CRL-7048* | human | skin (foreskin) | fibroblast | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------------------|-----------|---------|---|------------|-------------|
| Hs 700.Sk | CRL-7439* | human | skin | fibroblast | adherent |
| Hs 700T | HTB-147 | human | bone, pelvis (metastasis); adenocarcinoma (intestines or pancreas primary) | epithelial | adherent |
| Hs 701.T | CRL-7440* | human | connective tissue; synovial sarcoma | fibroblast | adherent |
| ls 704.Sk | CRL-7443* | human | skin | fibroblast | adherent |
| ls 704.T | CRL-7444* | human | bone; osteosarcoma | fibroblast | adherent |
| ls 706.Sk | CRL-7446* | human | skin | fibroblast | adherent |
| ls 706.T | CRL-7447* | human | bone; giant cell sarcoma | fibroblast | adherent |
| ls 707(A).T | CRL-7448* | human | bone; osteosarcoma | fibroblast | adherent |
| ls 707(B).Ep | CRL-7449* | human | skin (epidermis) | fibroblast | adherent |
| ls 709.Sk | CRL-7452* | human | skin | fibroblast | adherent |
| ls 709.T | CRL-7453* | human | bone; periostitis; granuloma | | darrerent |
| ls 72.Fs | CRL-7049* | human | skin (foreskin) | fibroblast | adherent |
| ls 722.T | CRL-7456* | human | rectum; colorectal carcinoma | fibroblast | adherent |
| ls 726.Pl | CRL-7460* | human | placenta | fibroblast | adherent |
| ls 728.Sk/Mu | CRL-7460* | human | mixed skin and muscle | fibroblast | adherent |
| | | | | | |
| ls 728.Sp | CRL-7463* | human | spleen | fibroblast | adherent |
| ls 729 | HTB-153 | human | muscle; rhabdomyosarcoma | fibroblast | adherent |
| ls 729.T | CRL-7862* | human | connective tissue; rhabdomyosarcoma | fibroblast | adherent |
| ls 730.Pl | CRL-7464* | human | placenta | fibroblast | adherent |
| ls 731.Sk | CRL-7465* | human | skin | fibroblast | adherent |
| ls 733.Sk | CRL-7469* | human | skin | fibroblast | adherent |
| ls 734.Sk | CRL-7470* | human | skin | fibroblast | adherent |
| ls 735.T | CRL-7471* | human | bone; osteosarcoma | fibroblast | adherent |
| ls 737.T | CRL-7473* | human | bone; giant cell sarcoma | fibroblast | adherent |
| ls 738.Lu | CRL-7868* | human | lung | fibroblast | adherent |
| ls 738.St/Int | CRL-7869* | human | mixed stomach and intestine | fibroblast | adherent |
| ls 739.Sk | CRL-7476* | human | skin | fibroblast | adherent |
| ls 739.T | CRL-7477* | human | mammary gland; adenocarcinoma | mixed | adherent |
| ls 740.Sk | CRL-7478* | human | skin | fibroblast | adherent |
| ls 740.T | CRL-7870* | human | stomach; carcinoma | mixed | adherent |
| ls 741.Sk | CRL-7479* | human | skin | fibroblast | adherent |
| ls 741.T | CRL-7480* | human | mammary gland; adenocarcinoma | mixed | adherent |
| ls 742.Sk | CRL-7481* | human | skin | fibroblast | adherent |
| ls 742.T | CRL-7482* | human | mammary gland; scirrhous adenocarcinoma | fibroblast | adherent |
| ls 746T | HTB-135 | human | muscle (metastasis); gastric carcinoma (stomach primary | epithelial | adherent |
| ls 748.T | CRL-7486* | human | mammary gland; cancer | mixed | adherent |
| ls 749.Sk | CRL-7487* | human | skin | fibroblast | adherent |
| ls 751.T | CRL-7488* | human | lymph node; lymphoma; Hodgkin's disease | fibroblast | adherent |
| ls 755(B).T | CRL-7489* | human | bone; osteosarcoma | mixed | adherent |
| ls 757.T | CRL-7490* | human | lymph node; benign hyperplasia | mixed | adherent |
| ls 762.Sk | CRL-7490* | human | connective tissue | mixed | adherent |
| ls 762.3k ls 764.Mu | CRL-7494* | human | connective tissue | fibroblast | adherent |
| ls 766T | HTB-134 | human | lymph node (metastasis); carcinoma (pancreas primary) | epithelial | adherent |
| ls 769.T | CRL-7882* | human | urethra; transitional cell carcinoma | mixed | adherent |
| ls 77.Fs | CRL-7055* | human | skin (foreskin) | fibroblast | adherent |
| ls 774.Pl | CRL-7502* | human | placenta | mixed | adherent |
| ls 777.T | CRL-7507* | human | lymph node; lymphoma | mixed | mixed |
| s 778(A).T | CRL-7508* | human | connective tissue; fibrosarcoma | fibroblast | adherent |
| ls 778(B).T | CRL-7509* | human | connective tissue; fibrosarcoma | epithelial | adherent |
| | | | | | |
| s 781.Sk | CRL-7510* | human | skin | fibroblast | adherent |
| s 781.T | CRL-7511* | human | bone; osteosarcoma | mixed | adherent |
| ls 782.Sk | CRL-7513* | human | skin | fibroblast | adherent |
| ls 782.T | CRL-7512* | human | connective tissue; benign histiocytic lesion | mixed | adherent |
| ls 788.Sk | CRL-7516* | human | skin | fibroblast | adherent |
| ls 789.Sk | CRL-7518* | human | skin | fibroblast | adherent |
| ls 789.T | CRL-7886* | human | ureter; transitional cell carcinoma | epithelial | adherent |
| Hs 791.Sk | CRL-7519* | | | fibroblast | adherent |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--------------|-----------|--------------|--|------------|-------------|
| Hs 792(A).T | CRL-7520* | human | cervical lymph node (metastasis); osteosarcoma (bone primary) | mixed | adherent |
| Hs 792(B).T | CRL-7521* | human | bone; osteosarcoma | fibroblast | adherent |
| Hs 792(C).M | CRL-7522* | human | muscle; connective and soft tissue | fibroblast | adherent |
| ls 793.Sk | CRL-7523* | human | skin | fibroblast | adherent |
| ls 793.T | CRL-7524* | human | mesenteric lymph node; hyperplasia | mixed | adherent |
| ls 795.PI | CRL-7526* | human | placenta | fibroblast | adherent |
| ls 798.PI | CRL-7529* | human | placenta | fibroblast | adherent |
| ls 799.Pl | CRL-7530* | human | placenta | fibroblast | adherent |
| ls 80.Fs | CRL-7058* | human | skin (foreskin) | fibroblast | adherent |
| ls 801.Pl | CRL-7888* | human | placenta | fibroblast | adherent |
| ls 803.Sk | CRL-7533* | human | skin | fibroblast | adherent |
| ls 803.T | CRL-7534* | human | skin | fibroblast | adherent |
| ls 805.T | CRL-7537* | human | bone; osteosarcoma | fibroblast | adherent |
| ls 811.T | CRL-7543* | human | bone; osteosarcoma | epithelial | adherent |
| ls 813.Sk | CRL-7545* | human | skin | fibroblast | adherent |
| ls 814.Sk | CRL-7546* | human | skin | fibroblast | adherent |
| ls 814.T | CRL-7547* | human | vertebral column; giant cell sarcoma | mixed | adherent |
| ls 815.Pl | CRL-7548* | human | placenta | fibroblast | adherent |
| ls 819.T | CRL-7891* | human | bone; chondrosarcoma | fibroblast | adherent |
| ls 820.Sk | CRL-7551* | human | skin | fibroblast | adherent |
| ls 820.T | CRL-7551* | human | bone; heterophilic osteofication | fibroblast | adherent |
| ls 821.Sk | CRL-7553* | human | skin | fibroblast | adherent |
| | | | | fibroblast | |
| ls 821.T | CRL-7554* | human | bone; giant cell sarcoma | | adherent |
| ls 822.T | CRL-7556* | human | bone; Ewing's sarcoma | epithelial | adherent |
| ls 824.Sk | CRL-7558* | human | skin | fibroblast | adherent |
| ls 828.Sk | CRL-7564* | human | skin | mixed | adherent |
| ls 832(C).T | CRL-7566* | human | ovary; endometriosis; abnormal | mixed | adherent |
| ls 833(C).Sk | CRL-7567* | human | skin | mixed | adherent |
| ls 834.T | CRL-7568* | human | lymph node, neck (metastasis); melanoma (skin primary) | fibroblast | adherent |
| ls 835.T | CRL-7569* | human; mouse | kidney; cancer | mixed | adherent |
| ls 836.Sk | CRL-7570* | human | skin | fibroblast | adherent |
| ls 839.T | CRL-7572* | human | skin; melanoma | fibroblast | adherent |
| ls 840.T | CRL-7573* | human | pharynx; papilloma | fibroblast | adherent |
| ls 841.T | CRL-7574* | human | mammary gland; cancer | mixed | adherent |
| ls 844.Sk | CRL-7576* | human | skin | fibroblast | adherent |
| ls 845.T | CRL-7577* | human | bone (metastasis); osteosarcoma (femur primary) | fibroblast | adherent |
| ls 846.Sk | CRL-7578* | human | skin | fibroblast | adherent |
| ls 846.T | CRL-7579* | human | bone; giant cell sarcoma | | adherent |
| ls 849.T | CRL-7583* | human | mammary gland; cancer | fibroblast | adherent |
| ls 851.T | CRL-7584* | human | mammary gland; cancer | | adherent |
| ls 852.T | CRL-7585* | human | skin; melanoma | epithelial | adherent |
| ls 854.Sk | CRL-7589* | human | skin | fibroblast | adherent |
| ls 855.Sk | CRL-7591* | human | skin | fibroblast | adherent |
| ls 855.T | CRL-7592* | human | bone; mesenchyme; fibrous dysplasia | | adherent |
| ls 856.T | CRL-7593* | human | connective tissue; histiocytoma | mixed | adherent |
| ls 859.T | CRL-7594* | human | skin; acanthocytosis | TIIACG | adherent |
| ls 86.Fs | CRL-7059* | human | skin (foreskin) | fibroblast | adherent |
| ls 860.T | CRL-7595* | human | lung (metastasis); osteosarcoma (bone primary) | fibroblast | adherent |
| ls 861.T | CRL-7595* | human | mammary gland; cancer | fibroblast | adherent |
| | CRL-7598* | | bone; Ewing's sarcoma | fibroblast | |
| ls 863.T | | human | | | adherent |
| ls 864.Sk | CRL-7599* | human | skin (scalp) | fibroblast | adherent |
| ls 864.T | CRL-7600* | human | bone, connective tissue; osteosarcoma | fibroblast | adherent |
| ls 865.Sk | CRL-7601* | human | skin | fibroblast | adherent |
| ls 866.T | CRL-7602* | human | bone; osteosarcoma | fibroblast | adherent |
| ls 867.Sk | CRL-7603* | human | skin | fibroblast | adherent |
| ls 868.T | CRL-7604* | human | unknown; fibrosarcoma | fibroblast | adherent |
| ls 870.T | CRL-7606* | human | bone; osteosarcoma | fibroblast | adherent |
| ds 871.Sk | CRL-7608* | human | skin | fibroblast | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--------------|-----------|---------|---|------------|-------------|
| Hs 871.T | CRL-7609* | human | bone; osteosarcoma | fibroblast | adherent |
| Hs 873.T | CRL-7610* | human | mammary gland, abnormal | fibroblast | adherent |
| Hs 874.T | CRL-7611* | human | mammary gland, abnormal | fibroblast | adherent |
| Hs 875.T | CRL-7612* | human | mammary gland, abnormal | fibroblast | adherent |
| Hs 877.T | CRL-7613* | human | mammary gland, abnormal | fibroblast | adherent |
| Hs 879(B).T | CRL-7615* | human | mammary gland | | |
| Hs 88.T | CRL-7060* | human | bone, connective tissue; osteosarcoma | fibroblast | adherent |
| Hs 880.T | CRL-7616* | human | mammary gland, abnormal | fibroblast | adherent |
| Hs 883.T | CRL-7617* | human | bone; giant cell sarcoma | fibroblast | adherent |
| Hs 885.T | CRL-7618* | human | mammary gland, abnormal | fibroblast | adherent |
| Hs 888.Lu | CRL-7624* | human | lung | fibroblast | adherent |
| Hs 888.Sk | CRL-7623* | human | skin | fibroblast | adherent |
| Hs 888.T | CRL-7622* | human | lung (metastasis); osteosarcoma (bone primary) | mixed | adherent |
| Hs 889.Sk | CRL-7625* | human | skin | fibroblast | adherent |
| Hs 889.T | CRL-7626* | human | bone; osteosarcoma | mixed | adherent |
| Hs 890.Sk | CRL-7627* | human | skin | fibroblast | adherent |
| Hs 890.T | CRL-7628* | human | bone; osteosarcoma | mixed | adherent |
| Hs 891.T | CRL-7629* | human | lymph node (metastasis); carcinoma (kidney primary) | fibroblast | adherent |
| Hs 892.T | CRL-7630* | human | skin; keratoacanthoma | mixed | adherent |
| Hs 894(A).T | CRL-7631* | human | lung (metastasis); osteosarcoma (bone primary) | fibroblast | adherent |
| Hs 894(B).T | CRL-7632* | human | lung (metastasis); osteosarcoma (bone primary) | mixed | adherent |
| Hs 894(C).T | CRL-7633* | human | lung (metastasis); osteosarcoma (bone primary) | fibroblast | adherent |
| Hs 894(D).T | CRL-7634* | human | lung (metastasis); osteosarcoma (bone primary) | fibroblast | adherent |
| Hs 894(E).Lu | CRL-7635* | human | lung | mixed | adherent |
| Hs 895.Sk | CRL-7636* | human | skin | fibroblast | adherent |
| Hs 895.T | CRL-7637* | human | lung (metastasis); melanoma (skin primary) | fibroblast | adherent |
| Hs 898.Sk | CRL-7640* | human | skin | fibroblast | adherent |
| Hs 898.T | CRL-7641* | human | skin; malignant acanthocytosis; keratoacanthoma | fibroblast | adherent |
| Hs 899(A).T | CRL-7642* | human | lung (metastasis); osteosarcoma (bone primary) | fibroblast | adherent |
| Hs 899(B).T | CRL-7643* | human | lung (metastasis); osteosarcoma (bone primary) | fibroblast | adherent |

ATCC Cell Biology Trivia #7 When were animal cells first maintained in culture?

Wilhelm Roux first maintained animal cells in culture in 1885. In the early 20th century, the work of Ross Granville Harrison helped cell culture become an essential laboratory technique.

| Hs 904.Sk Hs 904.T | CRL-7650* CRL-7651* | human human | skin omentum (metastasis); carcinoma (unknown | fibroblast fibroblast | adherent adherent |
|-----------------------|------------------------|----------------|--|--------------------------|----------------------|
| | | | · 3 | | |
| Hs 903.Sk Hs 903.T | CRL-7648* CRL-7649* | human human | skin bone; benign osteoid osteoma | fibroblast epithelial | adherent adherent |
| Hs 900.T | CRL-7646* | human | bone; benign osteoid osteoma | mixed | adherent |
| Hs 899(D).Lu | CRL-7645* | human | lung (metastasis); osteosarcoma (bone primary) | fibroblast | adherent |
| Hs 899(C).T | CRL-7644* | human | lung (metastasis); osteosarcoma (bone primary) | fibroblast | adherent |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. esearch use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--|-------------------------------------|-------------------------|--|--------------|------------------|
| Hs 906(A).T | CRL-7653* | human | skin; melanoma | mixed | adherent |
| Hs 906(B).T | CRL-7654* | human | skin; melanoma | mixed | adherent |
| Hs 907.Lu | CRL-7657* | human | lung | fibroblast | adherent |
| Hs 908.Sk | CRL-7658* | human | skin; melanoma | fibroblast | adherent |
| Hs 910.Sk | CRL-7894* | human | skin | fibroblast | adherent |
| Hs 910.Thm | CRL-7660* | human | thymus | mixed | adherent |
| Hs 912.T | CRL-7661* | human | mammary gland, abnormal | mixed | adherent |
| Hs 913(B).T | CRL-7664* | human | lung or bronchus (metastasis); fibrosarcoma | fibroblast | adherent |
| Hs 913(C).T | CRL-7665* | human | (connective tissue primary) lung or bronchus (metastasis); fibrosarcoma | | |
| | | | (connective tissue primary) | | a alla a u a u a |
| Hs 913(D).T | CRL-7666* | human | lung or bronchus (metastasis); fibrosarcoma (unknown primary) | | adherent |
| Hs 913(F).T | CRL-7668* | human | lung or bronchus (metastasis); fibrosarcoma (unknown primary) | epithelial | adherent |
| Hs 913T | HTB-152 | human | lung (metastasis); fibrosarcoma (unknown (unknown primary) | fibroblast | adherent |
| Hs 914 | CRL-7895* | human | unknown | | |
| Hs 915 | CRL-7896* | human | unknown | | |
| Hs 916 | CRL-7897* | human | unknown | | |
| Hs 917.T | CRL-7669* | human | parotid salivary gland; benign sebaceous cyst | fibroblast | adherent |
| Hs 919.Sk | CRL-7671* | human | skin | | adherent |
| Hs 919.T | CRL-7672* | human | bone; benign osteoid osteoma | | adherent |
| Hs 924.Sk | CRL-7674* | human | skin | fibroblast | adherent |
| ls 925.Sk | CRL-7676* | human | skin | fibroblast | adherent |
| Is 925.3k Is 925.T | CRL-7677* | human | skin; pagetoid sarcoma | fibroblast | adherent |
| 1s 925.1 1s 926.T | CRL-7678* | human | kidney; renal rhabdomyosarcoma | epithelial | adherent |
| Hs 929.Sk | CRL-7678 | human | skin | mixed | |
| ns 929.3k Hs 93.T | CRL-7062* | | mixed connective and soft tissue; fibrosarcoma | fibroblast | adherent |
| ns 93.1 Hs 933.T | CRL-7683* | human | · · · · · · · · · · · · · · · · · · · | fibroblast | adherent |
| | | human | lymph node; Wiskott-Aldrich syndrome | IIDIODIast | adherent |
| Hs 934.T | CRL-7684* | human | connective tissue; malignant melanoma | CL LL . | |
| Hs 935.T | CRL-7685* | human | connective tissue; malignant melanoma | fibroblast | adherent |
| Hs 936.T | CRL-7686* | human | skin; melanoma | epithelial | adherent |
| Hs 936.T(C1) | CRL-7687* | human | skin; melanoma | epithelial | adherent |
| Hs 938.T | CRL-7688* | human | mammary gland, abnormal | fibroblast | adherent |
| Hs 939.T | CRL-7690* | human | skin; melanoma | epithelial | adherent |
| Hs 94.T | CRL-7064* | human | skeletal muscle; rhabdomyosarcoma | fibroblast | adherent |
| Hs 940.T | CRL-7691* | human | skin; malignant melanoma | fibroblast | adherent |
| Hs 941.T | CRL-7692* | human | skin; dermatofibrosarcoma | fibroblast | adherent |
| Hs 944.T | CRL-7693* | human | lymph node (metastasis); melanoma (skin primary) | fibroblast | adherent |
| Hs 97.Fs | CRL-7065* | human | skin (foreskin) | fibroblast | adherent |
| HS-21 | HB-255 | mouse/mouse | hybridoma | lymphoblast | suspension |
| (subclone 1H3) | CDL 462.1 | I | altin (fama altin) | Claura I. I. | - 41 |
| Hs27 | CRL-1634 | human | skin (foreskin) | fibroblast | adherent |
| HS-27A | CRL-2496 [†] | human | bone marrow; stroma | epithelial | adherent |
| HS-5 | CRL-11882 [†] | human | bone marrow; stroma; HPV-16 E6/E7 transformed | fibroblast | adherent |
| Hs68 | CRL-1635 | human | skin (foreskin); aspartoacylase deficiency; possible Canavan disease | fibroblast | adherent |
| Hs888Lu | CCL-211 | human | lung | fibroblast | adherent |
| HSDM ₁ C ₁ | CCL-148 | mouse | connective tissue; fibrosarcoma | fibroblast | adherent |
| HS-Sultan | CRL-1484 | human | B lymphocyte; Burkitt's lymphoma | lymphoblast | suspension |
| HT | CRL-2260 | human | ascites; diffuse mixed lymphoma; B lymphoblast | lymphoblast | suspension |
| HT 1417 | CRL-7797* | human | unknown; lymphoma | lymphoblast | suspension |
| HT 29/26 | HB-8247 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| HT 29/36 | HB-8248 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| | CRL-7782* | human | skin; actinic keratosis | epithelial | adherent |
| | | | | | |
| HT 297.T | CRL-7783* | human | bone: osteosarcoma | fibroblast | adherent |
| HT 297.T HT 728.T | CRL-7783* | human | bone; osteosarcoma | fibroblast | adherent |
| HT 297.T HT 728.T HT 762.T HT 768.M | CRL-7783* CRL-7789* CRL-7790* | human human human | bone; osteosarcoma breast (nipple); cancer connective tissue; abnormal | fibroblast | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--|------------------------|---|--|---|--|
| HT-1197 | CRL-1473 | human | urinary bladder; carcinoma | | adherent |
| HT-1376 | CRL-1472 | human | urinary bladder; carcinoma | epithelial | adherent |
| HT-144 | HTB-63 | human | skin; malignant melanoma | fibroblast | adherent |
| HT-2 clone A5E | CRL-1841 | mouse | spleen; T lymphocyte | lymphoblast | suspension |
| HT-29 | HTB-38 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| HT-3 | HTB-32 | human | lymph node (metastasis); carcinoma (cervix primary) | epithelial epithelial | adherent |
| nTERT-HME1 | CRL-4010 | human | mammary gland; TERT immortalized | epithelial | adherent |
| TERT RPE-1 | CRL-4000 | human | eye, retina; pigmented epithelium; immortalized with hTERT | epithelial | adherent |
| HTZ17BE | CRL-1361 | human | skin; xeroderma pigmentosum, presumed heterozygote | fibroblast | adherent |
| nuFasM3 | HB-11726 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| ıuFasM38 | HB-11465 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| luNS1 | CRL-8644 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| luT 102 | TIB-162 | human | T lymphocyte, cutaneous; lymphoma; mycosis fungoides | lymphoblast | suspension |
| luT 78 | TIB-161 | human | T lymphocyte, cutaneous; lymphoma | lymphoblast | suspension |
| łuTu 80 | HTB-40 | human | duodenum; adenocarcinoma | epithelial | adherent |
| IUVE-12 | CRL-2480 | human | umbilical vein | endothelial | adherent |
| IUV-EC-C | CRL-1730 | human | umbilical vein, vascular endothelium | endothelial | adherent |
| IUVS-112D | CRL-2481 | human | umbilical vein, smooth muscle | fibroblast | adherent |
| IX | CRL-12011 [†] | human | fibrosarcoma; transfected; xenotropic retroviral packaging cell line | epithelial | adherent |
| HY3-11.27 | HB-8116 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| lybridoma 231 | HB-9401 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| lybridoma 234 s.2a | | mouse/mouse | hybridoma | lymphoblast | suspension |
| lybridoma 234 s.2a | | mouse/mouse | hybridoma | lymphoblast | suspension |
| 2.1 | CRL-2572 | human | T lymphocyte; FADD mutant; Fas-mediated apoptosis model | lymphoblast | suspension |
| 9.2 | CRL-2571 | human | T lymphocyte; caspase-8 mutant; Fas-mediated apoptosis model | lymphoblast | suspension |
| (TL.m9) | HB-131 | mouse/mouse | hybridoma | lymphoblast | suspension |
| ′24.D6 | HB-251 | rat/mouse | hybridoma | lymphoblast | suspension |
| 10 | CCL-83 | mouse | testis; Leydig cell tumor | epithelial | adherent |
| ·11.15 | CRL-2470 | mouse | spleen, macrophage | macrophage | adherent |
| 13.35 | CRL-2471 | mouse | spleen, macrophage | macrophage | adherent |
| I-Hybridoma | CRL-2700 | mouse/mouse | hybridoma | lymphoblast | suspension |
| A-XsSBR | CRL-1677 | rat | small intestine; adenocarcinoma | epithelial | adherent |
| B3-1 | CRL-2777 | human | bronchus; cystic fibrosis; immortalized with Ad12-SV40 hybrid | epithelial | adherent |
| B4 | HB-10164 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| C-21 | TIB-186 | mouse | peritoneal macrophage | ,p= | adherent |
| CR 134 | CCL-128 | frog, grass | embryo; gynogenetic haploid | epithelial | adherent |
| CR-2A | CCL-145 | frog, grass | embryo; androgenetic haploid | fibroblast | adherent |
| CR MEF | SCRC-1046 | mouse | embryonic fibroblast; feeder layer | fibroblast | adherent |
| E-10 | CRL-2462 | rat/mouse | hybridoma | lymphoblast | suspension |
| E-3 | CRL-2463 | rat/mouse | hybridoma | lymphoblast | suspension |
| C-18 | CRL-1589 | rat | ileum | epithelial | adherent |
| EC-6 | CRL-1509 | rat | small intestine; epithelium | epithelial | adherent |
| GCP-F1BA10 | HB-8291 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| (1a)8.3 | TIB-148 | mouse/mouse | hybridoma | lymphoblast | suspension |
| g(4a)10.9 | HB-146 | mouse/mouse | hybridoma | lymphoblast | suspension |
| g(5a)7.2 | TIB-149 | mouse/mouse | hybridoma | lymphoblast | suspension |
| | TIB-149 TIB-96 | | hybridoma | lymphoblast | |
| g(5b)6.3 | | mouse/mouse | | <u> </u> | suspension |
| | TIB-142 | mouse/mouse | hybridoma | lymphoblast | suspension |
| GEL a2 | TIB-141 | mouse/mouse | hybridoma | lymphoblast | suspension |
| GEL b4 | | | les de ut el eure e | عدادا ما مرموريا | a a.a. a.a ! |
| GEL b4 gG-11H4 | CRL-1936 | mouse/mouse | hybridoma | lymphoblast | suspension |
| GEL a2 GEL b4 gG-11H4 gG-11H9 gG-1B3 | | mouse/mouse mouse/mouse mouse/mouse | hybridoma hybridoma hybridoma | lymphoblast lymphoblast lymphoblast | suspension suspension suspension |

* Part of the NBL collection; see page 12. + Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------------|--|-------------------|---|----------------------------|---------------------------------------|
| lgG-1D2 | CRL-2545 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gG-2A4 | CRL-2121 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gG-2F1 | CRL-2419 | mouse/mouse | hybridoma | lymphoblast | suspension |
| lgG-3B2 | CRL-2693 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gG-4A4 | CRL-1898 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gG-5D7 | CRL-1938 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gG-6A6 | CRL-2197 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gG-7D4 | CRL-2198 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gG-9D5 | CRL-2347 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gG-B16 | CRL-1899 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gG-IB7 | CRL-2418 | mouse/mouse | hybridoma | lymphoblast | suspension |
| gH-2 | CCL-108 | iguana | heart | epithelial | adherent |
| L-A11 | CRL-1879 | mouse/mouse | hybridoma | lymphoblast | suspension |
| L-A29 | CRL-1874 | mouse/mouse | hybridoma | lymphoblast | suspension |
| L-A30 | CRL-1894 | mouse/mouse | hybridoma | lymphoblast | suspension |
| L-A42 | CRL-1870 | mouse/mouse | hybridoma | lymphoblast | suspension |
| L-A42 L-A51 | CRL-1871 | mouse/mouse | hybridoma | lymphoblast | · · · · · · · · · · · · · · · · · · · |
| L-A31 LB1-H21 | HB-10220 [†] | mouse/mouse | hybridoma | | suspension |
| | | | , | lymphoblast lymphoblast | suspension |
| LB1-H34 LB1-H6 | HB-10221 [†] HB-10219 [†] | mouse/mouse | hybridoma | | suspension |
| | | mouse/mouse | hybridoma | lymphoblast | suspension |
| LB1-H67 | HB-10222 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| M7.8.1 | TIB-235 | rat/mouse | hybridoma | lymphoblast | suspension |
| M-9 | CCL-159 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| MM002.69.47.4 | CRL-13007 [†] | mouse/mouse | B lymphoblast; antibody reactive with cell surface membranes of cancer cells | lymphoblast | suspension |
| MR-32 | CCL-127 | human | brain, neuroblast; neuroblastoma | fibroblast | adherent |
| MR-33 | CCL-146 | gerbil, Mongolian | connective tissue; fibroma | fibroblast | adherent |
| MR-90 | CCL-186 | human | lung | fibroblast | adherent |
| ndian Muntjac | CCL-157 | muntjac | skin | fibroblast | adherent |
| ntestine 407 | CCL-6 | human | HeLa contaminant | epithelial | adherent |
| P-1B | CRL-2162 | mouse | axillary lymph node, vascular epithelium; SV40 transformed | epithelial | adherent |
| P2-E4 | CRL-2171 | mouse | axillary lymph node, vascular epithelium; SV40 transformed | epithelial | adherent |
| V.3 | HB-217 | mouse/mouse | hybridoma | lymphoblast | suspension |
| VA12 | HB-145 | mouse/mouse | hybridoma | lymphoblast | suspension |
| VD12 | HB-144 | mouse/mouse | hybridoma | lymphoblast | suspension |
| ZD-MB-0503 | CRL-8003 [†] | moth, cabbage | larva | , , | loosely adherent |
| .CaM1.6 | CRL-2063 | human | T lymphocyte; acute T cell leukemia | lymphoblast | suspension |
| .γ1 | CRL-2678 | human | T lymphocyte; PLC-gamma1 negative; model for T-cell receptor signaling | lymphoblast | clusters in suspension |
| l.γ1.WT | CRL-2679 | human | T lymphocyte; transfected with PLC-gamma1 expression vector; control for J.γ1 cells | lymphoblast | clusters in suspension |
| I.RT3-T3.5 | TIB-153 | human | T lymphocyte; acute T cell leukemia | lymphoblast | suspension |
| 1 | SCRC-1010 | mouse | embryonic stem cell; derived from 129 substrain | spherical colony | adherent |
| 11d.2 | TIB-183 | rat/mouse | hybridoma | lymphoblast | suspension |
| 1-31 | CRL-2253 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1j.10 | TIB-184 | rat/mouse | hybridoma | lymphoblast | suspension |
| 1J.10 26 | | | · · · · · · · · · · · · · · · · · · · | fibroblast | |
| | CRL-1802 | mouse | subcutaneous connective tissue (areolar and adipose) | | adherent |
| 27-B7 | CRL-2374 | mouse | subcutaneous connective tissue (areolar and adipose) | fibroblast | adherent |
| 27-neo | CRL-2372 | mouse | subcutaneous connective tissue (areolar and adipose) | fibroblast | adherent |
| 45.01 | CRL-1990 | human | T lymphocyte; acute T cell leukemia; CD45 deficient | lymphoblast | suspension |
| 5-1 | HB-8297 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 5-2 | HB-8298 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 558 | TIB-6 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| | | | | | |
| 1774A.1 | TIB-67 | mouse | macrophage; monocyte; reticulum cell sarcoma | macrophage | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|---|---|---|---|-----------------------|---|
| la Bos | CRL-1176 | human | skin; Ehlers-Danlos syndrome, type II (hemorrhagic type) | fibroblast | adherent |
| Ja Coo | CRL-1294 | human | skin; osteogenesis imperfecta (tarda) | fibroblast | adherent |
| JAA-F11 | CRL-2381 | mouse/mouse | hybridoma | lymphoblast | suspension |
| IAR | HTB-144 | human | placenta; choriocarcinoma | epithelial | adherent |
| IAWSII | CRL-11904 [†] | mouse | bone marrow; immature dendritic cell | monocyte | mixed |
| ay Sen | CRL-1215 | human | skin; Ehlers-Danlos syndrome, type I (autosomal dominant type) | fibroblast | adherent |
| IB6 CI 30-7b | CRL-2007 | mouse | skin (epidermis); chemically transformed | epithelial | adherent |
| B6 Cl 41-5a | CRL-2010 | mouse | skin (epidermis); chemically transformed | epithelial | adherent |
| C | CRL-2116 | mouse | mammary gland; adenocarcinoma | epithelial | adherent |
| EG-3 | HTB-36 | human | placenta; choriocarcinoma | epithelial | adherent |
| ensen Sarcoma | CCL-45 | rat | sarcoma | fibroblast | adherent |
| ES3-19F1.1.1 | HB-10487 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| H4 clone 1 | CCL-158 | guinea pig | lung | fibroblast | adherent |
| iyoye | CCL-87 | human | B lymphocyte; Burkitt's lymphoma | lymphoblast | suspension |
| ILS-V5 | CRL-6359* | mouse | mixed spleen and thymus | fibroblast | adherent |
| LS-V9 | CRL-6360* | mouse | mixed spleen and thymus | innioniast | adherent |
| L3-V9 M1 | CRL-0300" CRL-10423 [†] | human | pre-B lymphoblast; leukemia; lymphoma | lymphoblast | |
| lo Per | CRL-10423 | human | skin; Ehlers-Danlos syndrome, possible | fibroblast | suspension adherent |
| | | | heterozygote | | |
| 01-1 | HB-8638 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| SC-1 | CRL-2769 | human | peritoneal effusion; B cell lymphoma (metastatic site: peritoneal cavity) | lymphoblast | suspension |
| urkat, Clone E6-1 | TIB-152 | human | T lymphocyte; acute T cell leukemia | lymphoblast | suspension |
| (114 | HB-8444 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| (:Molv NIH/3T3 | CRL-6361* | mouse | embryo | | adherent |
| (117 | HB-8553 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| (204 | HB-221 | rat/rat | hybridoma | lymphoblast | suspension |
| (-562 | CCL-243 | human | pleural effusion (metastatic); chronic myelo- genous leukemia (bone marrow primary) | lymphoblast | suspension |
| < 66 | HB-8767 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| K6H6/B5 | CRL-1823 | human/mouse | hybridoma fusion partner | lymphoblast | suspension |
| /acumai 1 | CDL 2724 | human | peripheral blood; acute myeloblastic leukemia | muoloblast | suspension |
| (asumi-1 | CRL-2724 | | peripheral blood; acute myeloblastic leukemia | myeloblast | suspension |
| (asumi-3 | CRL-2725 | human | , , | myeloblast | suspension |
| (asumi-4 | CRL-2726 | human | peripheral blood; chronic myeloblastic leukemia | myeloblast | suspension |
| Kasumi-6 | CRL-2775 | human | peripheral blood; acute myeloid leukemia, subtype M2 | myeloblast | suspension |
| (ATO III | HTB-103 | human | pleural effusion (metastasis); gastric carcinoma (stomach primary) | spherical | suspension |
| (B | CCL-17 | human | HeLa contaminant | epithelial | adherent |
| (-BALB (K-234) | CCL-163.3 | mouse | embryo | fibroblast | adherent |
| C-4G3 | HB-8709 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| (C-4M1 | HB-8710 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| (EL FIB | CRL-1762 | human | skin; connective tissue; keloid | fibroblast | adherent |
| (G-1 | CCL-246 | human | bone marrow; myeloblast; acute lymphoblastic leukemia | myeloblast | suspension |
| | | | bone marrow; myeloblast; acute lymphoblastic | lymphoblast | suspension |
| | CRL-8031 [†] | human | | утриовазс | |
| G-1 | CRL-8031 [†] CCL-246.1 | human | leukemia bone marrow;promyeloblast; acute lympho- | myeloblast | suspension |
| (G-1a | CCL-246.1 | human | leukemia bone marrow;promyeloblast; acute lympho- blastic leukemia | | suspension |
| (G-1a (HOS/NP (R-970-5) | CCL-246.1 CRL-1544 | human | leukemia bone marrow;promyeloblast; acute lympho- blastic leukemia bone; osteosarcoma | myeloblast | suspension |
| (G-1 (G-1a (HOS/NP (R-970-5) (HOS-240S | CCL-246.1 CRL-1544 CRL-1545 | human human human | leukemia bone marrow;promyeloblast; acute lympho- blastic leukemia bone; osteosarcoma bone; osteosarcoma | | suspension adherent adherent |
| (G-1 (G-1a (HOS/NP (R-970-5) (HOS-240S (HOS-321H | CCL-246.1 CRL-1544 CRL-1545 CRL-1546 | human human human human | leukemia bone marrow;promyeloblast; acute lymphoblastic leukemia bone; osteosarcoma bone; osteosarcoma bone; osteosarcoma | myeloblast | suspension adherent adherent adherent |
| KG-1a KHOS/NP (R-970-5) KHOS-240S KHOS-321H KL277 | CRL-1544 CRL-1545 CRL-1546 CRL-2030 | human human human human hamster/mouse | leukemia bone marrow;promyeloblast; acute lymphoblastic leukemia bone; osteosarcoma bone; osteosarcoma bone; osteosarcoma hybridoma | myeloblast fibroblast | suspension adherent adherent adherent suspension |
| (G-1 (G-1a (HOS/NP (R-970-5) (HOS-2405 (HOS-321H (L277 (L295 (L304 | CCL-246.1 CRL-1544 CRL-1545 CRL-1546 | human human human human | leukemia bone marrow;promyeloblast; acute lymphoblastic leukemia bone; osteosarcoma bone; osteosarcoma bone; osteosarcoma | myeloblast | suspension adherent adherent adherent |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-----------|------------------------|-------------|---|-------------|--------------------|
| KLN 205 | CRL-1453 | mouse | lung; squamous cell carcinoma | | adherent |
| KM114 | TIB-242 | rat/mouse | hybridoma | lymphoblast | suspension |
| KM201 | TIB-240 | rat/mouse | hybridoma | lymphoblast | suspension |
| KM703 | CRL-1896 | rat/mouse | hybridoma | lymphoblast | suspension |
| KM81 | TIB-241 | rat/mouse | hybridoma | lymphoblast | suspension |
| KMA | CRL-9856 [†] | human | spleen; macrophage; monocyte | monocyte/ | clusters in |
| | | | | macrophage | suspension |
| KMC8.8 | CRL-2212 | rat/mouse | hybridoma | lymphoblast | suspension |
| KMI6 | CRL-2179 | rat/mouse | hybridoma | lymphoblast | suspension |
| KNRK | CRL-1569 | rat | kidney | | mixed |
| KR-12 | CRL-8658 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| KU812 | CRL-2099 | human | peripheral blood, basophil; chronic myelogenous leukemia | myeloblast | suspension |
| KU812E | CRL-2100 | human | peripheral blood, basophil; chronic myelogenous leukemia | myeloblast | suspension |
| KU812F | CRL-2101 | human | peripheral blood, basophil; chronic myelogenous leukemia | myeloblast | suspension |
| L Cells | CRL-2648 | mouse | subcutaneous connective tissue, areolar and adipose; control for L Wnt-3A cells | fibroblast | adherent |
| L Wnt-3A | CRL-2647 | mouse | subcutaneous connective tissue, areolar and adipose; souce of Wnt-3A conditioned medium | fibroblast | adherent |
| L.N. 4159 | CRL-10998 [†] | mouse | liver | epithelial | adherent |
| L101 | HB-8447 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| L11/135 | TIB-188 | mouse/mouse | hybridoma | lymphoblast | suspension |
| L1210 | CCL-219 | mouse | lymphocytic leukemia | lymphoblast | suspension |
| L-132 | CCL-5 | human | HeLa contaminant | epithelial | adherent |
| L-14 | HB-8554 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |

ATCC Cell Biology Trivia #8

Who coined the word "cell"?

Robert Hooke was a theoretician in physics, an architect, and an inventor. But he is best known for coining the word "cell" in 1665 from microscopic observations of cork bark, which reminded him of monks' cells.

| L18 | HB-8628 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
|--------------------|------------------------|-------------|--|-------------|------------|
| L2 | CCL-149 | rat | lung | epithelial | adherent |
| L-2/M Δ 2-3 | CRL-10191 [†] | Drosophila | embryo; overproduces P element transposase | epithelial | mixed |
| L203 | HB-171 | mouse/mouse | hybridoma | lymphoblast | suspension |
| L227 | HB-96 | mouse/mouse | hybridoma | lymphoblast | suspension |
| L230 | HB-8448 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| L235 | HB-8446 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| L243 | HB-55 | mouse/mouse | hybridoma | lymphoblast | suspension |
| L2I-6 | HB-8705 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| L2-RYC | CRL-2180 | rat | embryo; yolk sac; carcinoma | epithelial | adherent |
| L368 | HB-149 | mouse/mouse | hybridoma | lymphoblast | suspension |
| L368 | HB-8450 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| L5 | HB-8627 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| L5.1 | HB-84 | mouse/mouse | hybridoma | lymphoblast | suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------------|------------------------|------------------|--|-------------|-------------|
| L5178-R (LY-R) | CRL-1722 | mouse | thymus; lymphoma | lymphoblast | suspension |
| L5178-S (LY-S) | CRL-1723 | mouse | thymus; lymphoma | lymphoblast | suspension |
| L5178YTK+/- | CRL-9518 [†] | mouse | lymphoma | lymphoblast | suspension |
| (clone 3.7.2C) | | | | | |
| L6 | CRL-1458 | rat | skeletal muscle | myoblast | adherent |
| L612 | CRL-10724 [†] | human | lymph node; B lymphoblast; EBV transformed | lymphoblast | suspension |
| L8 | CRL-1769 | rat | skeletal muscle | fibroblast | adherent |
| LA 3-5 | CRL-10101 [†] | hamster, Chinese | ovary; methotrexate resistant | epithelial | adherent |
| ∟a Bel | CRL-1179 | human | skin; Ehlers-Danlos syndrome, type VI (hemorrhagic type) | fibroblast | adherent |
| La Bel II | CRL-1195 | human | skin; Ehlers-Danlos syndrome, type VI (hemorrhagic type) | fibroblast | adherent |
| _a1 | HB-8609 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| _A-4 | CCL-196 | mouse | lung; adenoma | epithelial | adherent |
| .A7 | CRL-2283 | rat | mammary gland tumor; feeder layer cell | epithelial | adherent |
| _ADMAC | CRL-2420 | mouse | bone marrow | lymphoblast | mixed |
| alpha-1a L-cells | CRL-11138 [†] | mouse | subcutaneous connective tissue; areolar and adipose | fibroblast | adherent |
| L-α-1b | CRL-11139 [†] | mouse | subcutaneous connective tissue; expresses human adrenergic alpha 1B receptor | fibroblast | adherent |
| L-alpha-2A L-cells | CRL-11180 [†] | mouse | subcutaneous connective tissue; areolar and adipose | fibroblast | adherent |
| alpha-2C L-cells | CRL-11181 [†] | mouse | subcutaneous connective tissue; areolar and adipose | fibroblast | adherent |
| NGC-alpha2B cells | CRL-10275 [†] | mouse | subcutaneous connective tissue; areolar and adipose | fibroblast | adherent |
| LB 27.4 | HB-99 | mouse/mouse | hybridoma | lymphoblast | suspension |
| .B10.Bm | CRL-6060* | bovine | bone marrow; lymphosarcoma | , , | |
| .B10.K | CRL-6061* | bovine | kidney | | |
| .B10.Ln | CRL-6062* | bovine | lymph node | | |
| B10.Sp | CRL-6063* | bovine | spleen; lymphosarcoma | | |
| B10.Thy | CRL-6064* | bovine | thymus; lymphosarcoma | | |
| B11.Ln | CRL-6066* | bovine | lymph node | | |
| _B11.Sp | CRL-6067* | bovine | spleen; lymphosarcoma | | |
| B11.Thy | CRL-6068* | bovine | thymus; lymphosarcoma | | |
| _B3.1 | HB-298 | mouse/mouse | hybridoma | lymphoblast | suspension |
| B9.Bm | CRL-6053* | bovine | bone marrow; lymphosarcoma | | adherent |
| _B9.D | CRL-6054* | bovine | skin (dermis) | | |
| B9.Ln | CRL-6057* | bovine | lymph node | | |
| LB9.Sp | CRL-6058* | bovine | spleen; lymphosarcoma | | |
| LB9.Sp/Thy/Bm | CRL-6052* | bovine | mixed: spleen, thymus, and bone marrow; lymphosarcoma | | |
| _B9.Thy | CRL-6059* | bovine | thymus; lymphosarcoma | | |
| BLN | CRL-6046* | bovine | lymph node | | |
| BRM TG6 | CRL-1778 | mouse | T lymphocyte; radiation-induced lymphoma | lymphoblast | suspension |
| BRM-33 clone 4A2 | TIB-155 | mouse | T lymphocyte; radiation-induced lymphoma | lymphoblast | mixed |
| BRM-33-1A5 | CRL-8079 [†] | mouse | spleen; lymphoma | lymphoblast | suspension |
| .C-540 | CCL-43 | rat | testis; Leydig cell tumor | epithelial | adherent |
| .CL 8664 | CRL-1805 | monkey, Rhesus | B lymphocyte; lymphoma | lymphoblast | suspension |
| e Ana | CRL-1192 | human | skin; Marfan syndrome | fibroblast | adherent |
| ec1 | CRL-1735 | hamster, Chinese | ovary; lacks GlcNAc glycosyl transferase function | epithelial | adherent |
| .ec2 | CRL-1736 | hamster, Chinese | ovary; reduced transport of CMP-sialic acid into Golgi compartment | epithelial | adherent |
| .ec8 | CRL-1737 | hamster, Chinese | ovary; reduced transport of UDP-galactose into Golgi compartment | epithelial | adherent |
| .ei Cap | CRL-1098 | human | skin; Darier-White disease | fibroblast | adherent |
| FC16.Ln | CRL-6173* | cat | lymph node | fibroblast | adherent |
| _HR-1055 | CRL-2687 | mouse/mouse | hybridoma | lymphoblast | suspension |
| LHR-29 | CRL-2685 | mouse/mouse | hybridoma | lymphoblast | suspension |
| _HR-74 | CRL-2686 | mouse/mouse | hybridoma | lymphoblast | suspension |
| LI 27 | HB-8437 [†] | mouse/mouse | hybridoma | lymphoblast | mixed |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. research use only. Not intended for use in humans, animals or for diagnostics.

Order online at **www.lgcpromochem.com/atcc**, or contact your local LGC Promochem office. See back cover for details.



| 1.0 | LK 35.2 HB-98 mouse/mouse hybridoma lymphoblast susp LK-4 (CRL-2345 mouse/mouse hybridoma lymphoblast susp RL 24 (CL-1511 human lung fibroblast adhe LL 29 (AnHa) CCL-135 human lung fibroblast adhe LL 37 (MaDo) CCL-135 human lung fibroblast adhe LL 37 (MaMy) CCL-190 human lung fibroblast adhe LL 97 A (AlMy) CCL-191 human lung lung fibroblast adhe LL 97 A (AlMy) CCL-191 human lung lung lewis lung carcinoma mixe LLC-101 (CRL-1642 mouse lung; Lewis lung carcinoma epithelial adhe LLC-24 (LC-17 monkey, Rhesus kidney epithelial adhe LLC-25 (LC-17 monkey, Rhesus kidney epithelial adhe LLC-26 (CL-101 pig kidney epithelial adhe LLC-27 (LC-101 pig kidney epithelial adhe LLC-37 (CL-106 rabbit kidney epithelial adhe LLC-38 (CL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LLC-38 (CL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LLC-38 (CL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LLC-38 (CL-118 chicken liver; hepatocellular carcinoma epithelial adhe LLC-18 (CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe LN-18 (CRL-218 chicken liver; hepatocellular carcinoma epithelial adhe LN-19 (CRL-2610 human brain; glioblastoma; p53 expression under epithelia | ension ension rent rent rent rent |
|---|---|--|
| May | LK-3E. HB-98 mouse/mouse hybridoma lymphoblast susp LK-4 CRL-2345 mouse/mouse hybridoma lymphoblast susp LK-4 CRL-2345 mouse/mouse hybridoma lymphoblast susp LK-4 CRL-2345 mouse/mouse hybridoma lymphoblast susp LL 24 (CCL-151 human lung fibroblast adhe LL 29 (AnHa) CCL-134 human lung; idiopathic pulmonary fibrosis fibroblast adhe LL 68 (LESa) CCL-190 human lung LL 97 (AlMy) CCL-191 human lung; idiopathic pulmonary fibrosis fibroblast adhe LL 97 (AlMy) CCL-191 human lung; idiopathic pulmonary fibrosis fibroblast adhe LL 97 (AlMy) CCL-191 human lung; idiopathic pulmonary fibrosis fibroblast adhe LL 97 (AlMy) CCL-191 mouse lung; Lewis lung carcinoma epithelial adhe LLC-MK, CCL-7 monkey, Rhesus kidney epithelial adhe LLC-MK, CCL-7 monkey, Rhesus kidney epithelial adhe LLC-PK, CL-101 pig kidney epithelial adhe LLC-PK, CL-101 pig kidney epithelial adhe LLC-PK, CL-101 pig kidney epithelial adhe LLC-RK, CCL-106 rabbit kidney epithelial adhe LLC-MK CZ56 CCL-38 rat carcinoma epithelial adhe LLC-MK CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL-MITK) CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) LMM/16.11 HB-204 mouse/mouse hybridoma lymphoblast susp LMM-16.11 HB-204 mouse/mouse hybridoma LMH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe LN-18 CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe LN-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe LN-18 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe LN-18 CRL-2611 human brain; glioblastoma; p35 expression under tetracycline-induced promoter LNZTA3WT1 CRL-11541 human brain; glioblastoma; p35 expression under tetracycline-induced promoter LNZTA3WT4 CRL-11543 human brain; glioblastoma; p38 expression under tetracycline-induced promoter LNZTA3WT4 CRL-11543 human brain; glioblastoma; p58 expression under tetracycline-induced promoter LNZTA3WT4 CRL-11549 human skir; Ehlers-Danlos syndrome, type I (autosomal dominant type) | ension ension rent rent rent rent |
| L4 | LK-4 CRL-2345 mouse/mouse hybridoma Jymphoblast susp LL 24 CCCL-151 human lung fibroblast adhe LL 29 (AnHa) CCL-134 human lung idiopathic pulmonary fibrosis fibroblast adhe LL 47 (MaDo) CCL-135 human lung fibroblast adhe LL 86 (LeSa) CCL-190 human lung fibroblast adhe LL 87 (AiMy) CCL-191 human lung lung fibroblast adhe LL 97 (AiMy) CCL-191 human lung idiopathic pulmonary fibrosis fibroblast adhe LL 97 (AiMy) CCL-191 human lung: diopathic pulmonary fibrosis fibroblast adhe LL 97 (AiMy) CCL-7 monkey, Rhesus kidney epithelial adhe LL 97 (AiMy) CCL-7 monkey, Rhesus kidney epithelial adhe LL 0-MK, CCL-7, monkey, Rhesus kidney epithelial adhe LL 0-MK, CCL-7, monkey, Rhesus kidney epithelial adhe LL 0-MK, CCL-101 pig kidney epithelial adhe LL 0-MK, CCL-101 pig kidney epithelial adhe LL 0-MK, CCL-101 pig kidney epithelial adhe LL 0-MK, CCL-102 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-12 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse subcutaneous connective tissue (areolar and fibroblast adhe LL 0-MK CZCL-13 mouse mouse/mouse pridaR-14 mouse pribhelial adhe LL 0-MK CZCL-13 mouse mouse/mouse pridaR-14 mouse pridaR-14 mouse pribhelial ad | rent rent rent rent |
| LL 29 (AnHa) CCL-134 human lung: dilopathic pulmonary fibrosis fibroblast adherent LL 47 (MADp.) CCL-193 human lung fibroblast adherent LL 47 (MADp.) CCL-194 human lung: dilopathic pulmonary fibrosis fibroblast adherent LL 27 (ALMy) CCL-191 human lung: dilopathic pulmonary fibrosis fibroblast adherent LL 27 (ALMy) CCL-191 monkey, fibrosis lung: dilopathic pulmonary fibrosis fibroblast adherent LL 27 (ALMy) CCL-17 monkey, fibrosis didney epithelial adherent LLC-MK, CCL-71 monkey, fibrosis didney epithelial adherent LLC-PK, CL-101 pig didney epithelial adherent didney epithelial adherent LLC-PK, CL-101 epithelial adherent epithelial adherent lung dispose) lung dispose) lung dispose lung | LL 29 (AnHa) CCL-134 human lung: idiopathic pulmonary fibrosis fibroblast adhe LL 47 (MaDo) CCL-135 human lung fibroblast adhe L8 (L6 (L6 3) CCL-190 human lung fibroblast adhe L8 (L6 (L6 3) CCL-190 human lung fibroblast adhe LL 97 A (AlMy) CCL-191 human lung: idiopathic pulmonary fibrosis fibroblast adhe LL 97 A (AlMy) CCL-191 human lung: idiopathic pulmonary fibrosis fibroblast adhe LL7 (LLC1) CRL-1642 mouse lung: Lewis lung carcinoma mixe LLC-MK, CCL-7 monkey, Rhesus kidney epithelial adhe LLC-PK, CL-101 pig kidney epithelial adhe LLC-PK, CL-106 rabbit kidney epithelial adhe LLC-WK-C256 CCL-38 rat carcinoma epithelial adhe LLC-WK-C256 CCL-38 rat carcinoma epithelial adhe adipose) lung-L-M(TK') CCL-1.2 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) lung-L-M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) lung-L-M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) lung-L-M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) lung-L-M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) lung-L-M(TK') CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe LN-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- lung-p14ARF- lung-p14A | rent rent rent |
| LL47(MBDD) | LL 47 (MaDo) CCL-135 human lung fibroblast adhe LL 86 (LeSa) CCL-190 human lung fibroblast adhe LL 97A (AIMW) CCL-191 human lung; idiopathic pulmonary fibrosis fibroblast adhe LL 97A (AIMW) CCL-191 human lung; idiopathic pulmonary fibrosis fibroblast adhe LL 97A (AIMW) CCL-191 human lung; idiopathic pulmonary fibrosis fibroblast adhe LL 97A (AIMW) CCL-71 monkey, Rhesus kidney epithelial adhe LL C-MK, CCL-71 monkey, Rhesus kidney epithelial adhe LL C-MK, CCL-71 monkey, Rhesus kidney epithelial adhe LL C-MK, CCL-101 pig kidney epithelial adhe LL C-PK, CL-101 pig kidney epithelial adhe LL C-PK, CL-101 pig kidney epithelial adhe LL C-PK, CL-101 pig kidney epithelial adhe LL C-MK, CCL-1, mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) LL C-MK CL-1, mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) L-M(TK') CCL-1, mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) LM2/1.6.11 HB-204 mouse/mouse hybridoma lymphoblast susp LMH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe LN-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe LN-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe LN-19 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe LN-19 CRL-1740 human lymph node (metastasis); carcinoma (prostate primary) LN-29 CRL-2611 human lymph node (metastasis); carcinoma (prostate primary) LN-29 CRL-1544 human brain; glioblastoma; p53 expression under tetracycline-induced promoter LNZTA3WT11 CRL-11544 human brain; glioblastoma; p53 expression under tetracycline-induced promoter LNZTA3WT11 CRL-11543 human skin; Ehlers-Danlos syndrome; type I (autosomal fibroblast adhe tetracycline-induced promoter LNZTA3WT11 CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote LO-22 HB-8619 mouse/mouse hybridoma lymphologt; scute lympho- | rent |
| L86 (L86s) CCL-190 | L 86 (LeSa) CCL-190 human lung fibroblast adhe L 97A (AlMy) CCL-91 human lung; idiopathic pulmonary fibrosis fibroblast adhe L 97A (AlMy) CCL-91 human lung; lewis lung acrinoma mixe LC-MK, CCL-7 monkey, Rhesus kidney epithelial adhe LC-MK, CCL-7 monkey, Rhesus kidney epithelial adhe LC-MK, CCL-101 pig kidney epithelial adhe LC-PK, CL-101 pig kidney epithelial adhe LC-PK, CL-101 pig kidney epithelial adhe LC-PK, CL-103 rabbit kidney epithelial adhe LC-PK, CL-106 rabbit kidney epithelial adhe LC-MR CCL-108 rat carcinoma epithelial adhe LC-MR CCL-12 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) LMZ/1.6.11 HB-204 mouse/mouse hybridoma liver; hepatocellular carcinoma epithelial adhe adipose) MMZ/2.6.11 HB-204 mouse/mouse hybridoma epithelial adhe MH/2.A CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe MH/2.A CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-210 CRL-1740 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-210 CRL-1740 human brain; glioblastoma; p53 expression under primary) LNZTA3WT11 CRL-11543' human brain; glioblastoma; p53 expression under tetracycline-induced promoter NZTA3WT11 CRL-11543' human brain; glioblastoma; p53 expression under tetracycline-induced promoter NZTA3WT11 CRL-11543' human brain; glioblastoma; p53 expression under tetracycline-induced promoter NZTA3WT11 CRL-11541' human skin; xeroderma pigmentosum, presumed fibroblast adhe tetracycline-induced promoter NZTA3WT11 CRL-11549' human skin; xeroderma pigmentosum, presumed fibroblast subpoucous of the tetracycline-induced promoter NZTA3WT11 CRL-11549' human skin; xeroderma pigmentosum, presumed fibroblast subpoucous of the tetracycline-induced promoter NZTA3WT11 | rent |
| L.O.P.A. (AIMy) C.C.L-191 human lung-idiopathic pulmonary fibrosis fibroblast adherent mixed mouse with the control of the con | L97A (AlMy) CCL-191 human lung; idiopathic pulmonary fibrosis fibroblast adhe L1/2 (LLC1) CRL-1642 mouse lung; Lewis lung carcinoma mixe LLC-MK, CCL-7 monkey, Rhesus kidney epithelial adhe LC-MK, CCL-7.1 monkey, Rhesus kidney epithelial adhe LC-PK, CL-101 pig kidney epithelial adhe LC-PK, CL-101.1 pig kidney epithelial adhe LC-PK, CL-101.1 pig kidney epithelial adhe LC-PK, CL-105 rabbit kidney epithelial adhe LC-WR CZG-106 rabbit kidney epithelial adhe LC-WR CZG-106 rabbit kidney epithelial adhe LC-WR CZG-108 rat carcinoma epithelial adhe LC-WR CZG-1.2 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) -M(TK') CZL-1.3 mouse subcutaneous connective tissue (areolar and adipose) -M(TK') CZL-1.3 mouse subcutaneous connective tissue (areolar and adipose) -M2/1.6.11 HB-204 mouse/mouse hybridoma lymphoblast susp MH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe N-18 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe N-19 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe N-16-, p14ARF- N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe n-16-, p14ARF- N-219 CRL-1544* human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-1740 human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-11544* human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-11544* human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-11544* human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-11545* human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe tetracycline-induced promoter NCAP clone FGC CRL-11549* human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) NCAP clone FGC CRL-1159 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast susp nCAP cl | |
| L.O.P.A. (AIMy) C.C.L-191 human lung-idiopathic pulmonary fibrosis fibroblast adherent mixed mouse with the control of the con | L97A (AlMy) CCL-191 human lung; idiopathic pulmonary fibrosis fibroblast adhe L1/2 (LLC1) CRL-1642 mouse lung; Lewis lung carcinoma mixe LLC-MK, CCL-7 monkey, Rhesus kidney epithelial adhe LC-MK, CCL-7.1 monkey, Rhesus kidney epithelial adhe LC-PK, CL-101 pig kidney epithelial adhe LC-PK, CL-101.1 pig kidney epithelial adhe LC-PK, CL-101.1 pig kidney epithelial adhe LC-PK, CL-105 rabbit kidney epithelial adhe LC-WR CZG-106 rabbit kidney epithelial adhe LC-WR CZG-106 rabbit kidney epithelial adhe LC-WR CZG-108 rat carcinoma epithelial adhe LC-WR CZG-1.2 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) -M(TK') CZL-1.3 mouse subcutaneous connective tissue (areolar and adipose) -M(TK') CZL-1.3 mouse subcutaneous connective tissue (areolar and adipose) -M2/1.6.11 HB-204 mouse/mouse hybridoma lymphoblast susp MH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe N-18 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe N-19 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe N-16-, p14ARF- N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe n-16-, p14ARF- N-219 CRL-1544* human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-1740 human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-11544* human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-11544* human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-11544* human brain; glioblastoma; p53 expression under NCAP clone FGC CRL-11545* human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe tetracycline-induced promoter NCAP clone FGC CRL-11549* human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) NCAP clone FGC CRL-1159 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast susp nCAP cl | |
| Lug_LEwis lung_Lewis lung_Lewis lung_carcinoma | LLZ (LLC1) CRL-1642 mouse lung; Lewis lung carcinoma mixe LC-MK, CCL-7 monkey, Rhesus kidney epithelial adhe LC-MK, CCL-7.1 monkey, Rhesus kidney epithelial adhe LC-PK, CL-101 pig kidney epithelial adhe LC-PK, CL-101 pig kidney epithelial adhe LC-PK, CL-101 pig kidney epithelial adhe LC-PK, CL-106 rabbit kidney epithelial adhe LC-WRC 256 CCL-38 rat carcinoma epithelial adhe LC-WRC 256 CCL-1.2 mouse subcutaneous connective tissue (areolar and fibroblast adhe LC-WRC 256 CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK-1) CRL-117 chicken liver; hepatocellular carcinoma epithelial adhe | rent |
| LLCMK, CCL-7 monkey, Rhesus kidney epithelial adherent LCMK, CCL-71 monkey, Rhesus kidney epithelial adherent LCPK, CL-101 pig kidney epithelial adherent adherent LCPK, CL-101 pig kidney epithelial adherent LCPK, CL-101 pig kidney epithelial adherent adherent LCPK, CL-106 rabbit kidney epithelial adherent adherent LCPK, CL-106 rabbit kidney epithelial adherent adherent adherent epithelial adherent epithelial adherent epithelial adherent adipose) subcutaneous connective tissue (areolar and fibroblast adherent adipose) adherent epithelial e | LC-MK, CCL-7 monkey, Rhesus kidney epithelial adhe LC-MK, CCL-7.1 monkey, Rhesus kidney epithelial adhe LC-MK, CCL-101 pig kidney epithelial adhe LC-PK, CL-101.1 pig kidney epithelial adhe LC-PK, CL-101.1 pig kidney epithelial adhe LC-PK, CL-106 rabbit kidney epithelial adhe LC-RK, CCL-106 rabbit kidney epithelial adhe LC-WRC 256 CCL-38 rat carcinoma epithelial adhe LC-WRC 256 CCL-38 mouse subcutaneous connective tissue (areolar and fibroblast adipose) M(TK') CCL-1.2 mouse subcutaneous connective tissue (areolar and adipose) M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and adipose) M(TK') CCL-1.3 mouse hybridoma lymphoblast susp MH/2A.16.11 HB-204 mouse/mouse hybridoma liver; hepatocellular carcinoma epithelial adhe MH/2A.16.11 hybridoma liver; hepatocellular carcinoma epithelial adhe NH/2A.16.11 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-2611 human lymph node (metastasis); carcinoma (prostate primary) NCAP clone FGC CRL-1740 human lymph node (metastasis); carcinoma (prostate primary) NCAP clone FGC CRL-11544 human brain; glioblastoma; p53 expression under clusNGC-5HT2 CRL-11544 human brain; glioblastoma; p53 expression under brain; glioblastoma; p53 expression under steracycline-induced promoter NZTA3WT11 CRL-11543 human brain; glioblastoma; p53 expression under skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe tetracycline-induced promoter NZTA3WT4 CRL-1150 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe heterozygote human peripheral blood; T lymphocyte; acute lympho- lymphoblast susp. | d |
| LLCMK, CL-17, monkey,Rhesus kidney epithelal adherent LCPK, CL-101, pig kidney epithelal adherent LCPK, CL-101, pig kidney epithelal adherent LCPK, CL-101, pig kidney epithelal adherent LCPK, CL-101, pig kidney epithelal adherent LCPK, CL-101, rabbit kidney epithelal adherent LCPK, CL-102, rabbit kidney epithelal adherent LCPK, CL-103, rata carcinoma epithelal adherent LCPK, CL-12, mouse subcutaneous connective tissue (areolar and fibroblast adherent adherent adipose) mouse subcutaneous connective tissue (areolar and fibroblast adherent adherent adipose) mouse subcutaneous connective tissue (areolar and fibroblast adherent pithelal adh | LC-MK, CCL-7.1 monkey, Rhesus kidney epithelial adhe LC-PK, CL-101 pig kidney epithelial adhe LC-PK, CL-101.1 pig kidney epithelial adhe LC-PK, CL-101.1 pig kidney epithelial adhe LC-PK, CL-106 rabbit kidney epithelial adhe LC-RK, CCL-106 rabbit kidney epithelial adhe LC-WRC 256 CCL-38 rat carcinoma epithelial adhe -M CCL-1.2 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) subcutaneous connective tissue (areolar and fibroblast adhe material adhe paterial | rent |
| LC-PK, CL-101 pig kidney egithelial adherent | LC-PK, CL-101 pig kidney epithelial adhe LC-PK, CL-101.1 pig kidney epithelial adhe LC-PK, CL-106 rabbit kidney epithelial adhe LC-RK, CCL-106 rabbit kidney epithelial adhe LC-WRC 256 CCL-38 rat carcinoma epithelial adhe M CCL-1.2 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) | |
| LC-PK, CL-10.11 pig kidney | LC-PK _{IA} CL-101.1 pig kidney adhe LC-RK CCL-106 rabbit kidney epithelial adhe LC-RK CCL-138 rat carcinoma epithelial adhe cL-RK CCL-12 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) subcutaneous connective tissue (areolar and fibroblast adhe adipose) adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose adipose | rent |
| LLC-RKQ CCL-106 rabbit kidney epithelial adherent carcinoma epithelial adherent adipose) AM CCL-1.2 mouse subcutaneous connective tissue (areolar and fibroblast adherent adipose) -M(TK) CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adherent adipose) -M(TK) CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adherent adipose) -M(TK) RB-204 mouse/mouse hybridoma lymphodosat lymphodosat pithelial adherent adipose) -M(TK) CRL-2117 chicken liver; hepatocellular carcinoma epithelial adherent p16-p14ARF- p16-p14ARF | LC-RK, CCL-106 rabbit kidney epithelial adhe LC-WRC 256 CCL-38 rat carcinoma epithelial adhe .M CCL-1.2 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast susp in the subcutaneous connective tissue (areolar and fibroblast adhe adipose)M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast susp in the subcutaneous connective tissue (areolar and fibroblast susp in the subcutaneous connective tissue (areolar and fibroblast adhe pitch, pit | rent |
| LC-WRC 256 Ct. 1-8 | LC-WRC 256 CCL-38 rat carcinoma epithelial adhe -M CCL-1.2 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) -M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and fibroblast adhe adipose) -M2/1.6.11 HB-204 mouse/mouse hybridoma lymphoblast susp -MH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe -MH/ZA CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe -N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe -N-29 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe -N-29 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe -N-29 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe -N-29 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe -N-29 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe -N-29 CRL-10287† mouse subcutaneous connective tissue; expresses fibroblast adhe -N-30-1-30-1-30-1-30-1-30-1-30-1-30-1-30 | |
| ### CCL-1.2 mouse subcutaneous connective tissue (areolar and adipose) ### Adipose subcutaneous connective tissue (areolar and fibroblast adherent adipose) ### Adipose subcutaneous connective tissue (areolar and adipose) ### Adipose subcutaneous connective tiss | subcutaneous connective tissue (areolar and fibroblast adhe adipose) -M(TK') CCL-1.3 mouse subcutaneous connective tissue (areolar and adipose) -M2/1.6.11 HB-204 mouse/mouse hybridoma lymphoblast susp -MH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe -MH/2A CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe -N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe -N-18 P16-, p14ARFN-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe -N-18 P16-, p14ARFN-229 CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial loose -N-16C-5HT2 CRL-10287† mouse subcutaneous connective tissue; expresses fibroblast adhe -N-18 N-18 human brain; glioblastoma; p53 expression under tetracycline-induced promoter -N-18 N-18 N-18 CRL-11544† human brain; glioblastoma; p53 expression under tetracycline-induced promoter -N-18 N-18 N-18 Numan skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe | |
| SMCTA SMCTA SMCTA SMCTATA MUSE SUBCUTATEOUS CONNECTIVE VISSUE (areolar and adjopse) M2/1.6.11 HB-204 mouse/mouse hybridoma lymphoblast suspension ML CRL-2117 chicken liver; hepatocellular carcinoma epithelial adherent ML/2A CRL-2118 chicken liver; hepatocellular carcinoma epithelial adherent p16-p14ARF- repathelial repathelial adherent p16-p14ARF- repathelial | subcutaneous connective tissue (areolar and adipose) M2/1.6.11 HB-204 mouse/mouse hybridoma lymphoblast susp MH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe MH/ZA CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-1740 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-209 CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial loose primary) clus -NGC-5HT2 CRL-10287† mouse subcutaneous connective tissue; expresses fibroblast adhe human 5HT2 receptor NZTA3WT11 CRL-11544† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter NZTA3WT4 CRL-11543† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter O Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) O Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast susp O-22 HB-8619† mouse/mouse hybridoma lymphoblast susp | |
| MAZ16.11 HB-204 mouse/mouse hybridoma hymphoblast suspension MH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adherent adherent human brain; glioblastoma; apoptosis studies; p53+, epithelial adherent p16-, p14ARF- loosely adherent human human hymph node (metastasis); carcinoma (prostate epithelial loosely adherent p16-, p14ARF- loosely adherent human human hymph node (metastasis); carcinoma (prostate epithelial loosely adherent human | M2/1.6.11 HB-204 mouse/mouse hybridoma lymphoblast susp MH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe MH/2A CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe MH/2A CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial loose primary) clus -NGC-5HT2 CRL-10287† mouse subcutaneous connective tissue; expresses fibroblast adhe human 5HT2 receptor -NZTA3WT11 CRL-11544† human brain; glioblastoma; p53 expression under tetracycline-induced promoter -NZTA3WT4 CRL-11543† human brain; glioblastoma; p53 expression under tetracycline-induced promoter -NZTA3WT4 CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) -O Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast susp -O-22 HB-8619† mouse/mouse hybridoma lymphoblast susp | rent |
| MH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adherent MH/2A CRL-2610 chicken liver; hepatocellular carcinoma epithelial adherent N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, p16-, p14ARF- epithelial adherent N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, p16-, p14ARF- epithelial loosely adherent NCAP clone FGC CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial loosely adherent -NGC-5HT2 CRL-10287* mouse subcutaneous connective tissue; expresses fibroblast adherent -NTA3WT11 CRL-11544* human brain; glioblastoma; p53 expression under glial adherent -NZTA3WT4 CRL-11543* human brain; glioblastoma; p53 expression under glial adherent -NECTA3WT4 CRL-11543* human brain; glioblastoma; p53 expression under glial adherent -NECTA3WT4 CRL-11543* human skin; Erhers-Danlos syndrome, type I (autosomal fibroblast | MH CRL-2117 chicken liver; hepatocellular carcinoma epithelial adhe MH/2A CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial loose primary) clus -NGCP clone FGC CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial loose primary) -NGC-5HT2 CRL-10287† mouse subcutaneous connective tissue; expresses fibroblast adhe human 5HT2 receptor -NZTA3WT11 CRL-11544† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter -NZTA3WT4 CRL-11543† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter -O-Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) -O-Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote -O-22 HB-8619† mouse/mouse hybridoma lymphoblast susp | ension |
| MH/2A CRL-2118 chicken liver; hepatocellular carcinoma epithelial adherent brain; glioblastoma; apoptosis studies; p53+, epithelial adherent primary) NC2P CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adherent primary) NC2P CRL-2611 human lymph node (metastasis); carcinoma (prostate epithelial clossely adherent primary) NC3P CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial clossely adherent primary) NC4C-5HT2 CRL-10287' mouse subcutaneous connective tissue; expresses fibroblast adherent human SHT2 receptor NZTA3WT11 CRL-11544' human brain; glioblastoma; p53 expression under glial adherent tetracycline-induced promoter NZTA3WT4 CRL-11543' human brain; glioblastoma; p53 expression under glial adherent ettracycline-induced promoter NZTA3WT4 CRL-11543' human skin; xeroderma pigmentosum, presumed fibroblast adherent hetrozygote human skin; xeroderma pigmentosum, presumed fibroblast adherent hetrozygote human peripheral blood; T lymphocyte; acute lymphoblast suspension ovo CCL-229 human lymph node, left supraclavicular region (metastasis); colorectal adenocarcinoma (colon primary) p1 MAB 1 CRL-1765 mouse/mouse hybridoma lymphoblast suspension p1 MAB 2 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p1 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p1 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p1 MBB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p1 MBB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p1 MBB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension suspension p1 MBB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension suspension p1 MBB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p1 MBB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspe | MH/2A CRL-2118 chicken liver; hepatocellular carcinoma epithelial adhe N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- NCaP clone FGC CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial loose primary) -NGC-5HT2 CRL-10287† mouse subcutaneous connective tissue; expresses fibroblast adhe human 5HT2 receptor NZTA3WT11 CRL-11544† human brain; glioblastoma; p53 expression under tetracycline-induced promoter NZTA3WT4 CRL-11543† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter o. Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) o. Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote O-22 HB-8619† mouse/mouse hybridoma lymphoblast susp | |
| Description | N-18 CRL-2610 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-229 CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- N-260 CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial loose primary) clus N-NGC-5HT2 CRL-10287† mouse subcutaneous connective tissue; expresses fibroblast adhe human 5HT2 receptor NZTA3WT11 CRL-11544† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter NZTA3WT4 CRL-11543† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter N-NCTA3WT4 CRL-1150 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) N-NCWEN CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote N-NCC-22 HB-8619† mouse/mouse hybridoma lymphoblast susp | |
| N-229 CRI-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adherent p16-, p14ARF- p16-, p14ARF- clusters c | CRL-2611 human brain; glioblastoma; apoptosis studies; p53+, epithelial adhe p16-, p14ARF- NCaP clone FGC CRL-1740 human lymph node (metastasis); carcinoma (prostate epithelial loose primary) clust. -NGC-5HT2 CRL-10287† mouse subcutaneous connective tissue; expresses fibroblast adhe human 5HT2 receptor NZTA3WT11 CRL-11544† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter NZTA3WT4 CRL-11543† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter -O Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) -O Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote -O-22 HB-8619† mouse/mouse hybridoma lymphoblast susp | |
| NCAP clone FGC CRL-1740 Numan lymph node (metastasis); carcinoma (prostate primary) loosely adheren clusters | LNCaP clone FGC CRL-1740 human lymph node (metastasis); carcinoma (prostate prithelial loose primary) clus LNGC-5HT2 CRL-10287† mouse subcutaneous connective tissue; expresses fibroblast adhe human 5HT2 receptor LNZTA3WT11 CRL-11544† human brain; glioblastoma; p53 expression under tetracycline-induced promoter LNZTA3WT4 CRL-11543† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter LO Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) LO Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote LO-22 HB-8619† mouse/mouse hybridoma lymphoblast susp | rent |
| _NZTA3WT11 CRL-11543¹ human brain; glioblastoma; p53 expression under tetracycline-induced promoter _NZTA3WT4 CRL-11543¹ human brain; glioblastoma; p53 expression under tetracycline-induced promoter _NZTA3WT4 CRL-11543¹ human brain; glioblastoma; p53 expression under tetracycline-induced promoter _OREN CRL-11300 human skin; Ehlers-Danlos syndrome, type I (autosomal dominant type) _OWEN CRL-11590 human skin; xeroderma pigmentosum, presumed fibroblast adherent heterozygote _O-22 HB-8619¹ mouse/mouse hybridoma lymphoblast suspension _Oucy CRL-26290 human peripheral blood; Tlymphocyte; acute lymphoblast suspension _DI MAB 1 CRL-1765 mouse/mouse hybridoma lymphoblast suspension _DI MAB 2 CRL-1765 mouse/mouse hybridoma lymphoblast suspension _DI MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension _P3IIG2 HB-8472¹ mouse/mouse hybridoma lymphoblast suspension _P3IIG2 HB-8472¹ mouse/mouse hybridoma lymphoblast suspension _D1 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension _P4.4 HB-232 mouse/mouse hybridoma lymphoblast suspension _P3IIG2 HB-8472¹ mouse/mouse hybridoma lymphoblast suspension _P4.4 HB-232 mouse/mouse hybridoma lymphoblast suspension _P5.102.9 HB-97 mouse/mouse hybridoma lymphoblast suspension _S102.9 HB-12549¹ mouse/mouse hybridoma lymphoblast suspension _S | subcutaneous connective tissue; expresses fibroblast adhe human 5HT2 receptor NZTA3WT11 CRL-11544† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter NZTA3WT4 CRL-11543† human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter OREN CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) OWEN CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote O-22 HB-8619† mouse/mouse hybridoma lymphoblast susp | • |
| LNZTA3WT11 CRL-11544 ¹ human brain; glioblastoma; p53 expression under tetracycline-induced promoter LNZTA3WT4 CRL-11543 ¹ human brain; glioblastoma; p53 expression under glial adherent tetracycline-induced promoter Lo Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Wen CRL-1159 human skin; xeroderma pigmentosum, presumed heterozygote LO-22 HB-8619 ¹ mouse/mouse hybridoma lymphoblast suspension blastic leukemia; t1(16;20) translocation Loucy CRL-2629 human peripheral blood; T lymphocyte; acute lymphoblast suspension blastic leukemia; t1(16;20) translocation LOVO CCL-229 human lymph node, left supraclavicular region (metastasis); colorectal adenocarcinoma (colon primary) Lp1 MAB 1 CRL-1765 mouse/mouse hybridoma lymphoblast suspension ly1 MAB 2 CRL-1770 mouse/mouse hybridoma lymphoblast suspension ly1 MBA 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension ly1 MBA 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension ly1 MBA 4 HB-232 mouse/mouse hybridoma lymphoblast suspension ly1 MBA 4 HB-232 mouse/mouse hybridoma lymphoblast suspension ly1 MBA 4 HB-232 mouse/mouse hybridoma lymphoblast suspension ly1 MBA 5 CRL-1767 mouse/mouse hybridoma lymphoblast suspension ly1 MBA 6 HB-97 mouse/mouse hybridoma lymphoblast suspension ly1 MBA 6 HB-97 mouse/mouse hybridoma lymphoblast suspension ly1 MBA 6 HB-97 mouse/mouse hybridoma lymphoblast suspension ly129-3C3-8-3-1 HB-12643 ¹ mouse/mouse hybridoma lymphoblast suspension ly129-3C3-8-3-1 HB-12643 ¹ mouse/mouse hybridoma lymphoblast suspension ly129-3C3-8-3-1 HB-12643 ¹ mouse/mouse hybridoma lymphoblast suspension ly132-3C3 HB-12653 ² mouse/mouse hybridoma lymphoblast suspension ly132-3C3 HB-12643 ² mouse/mouse hybridoma lymphoblast suspension ly132-3C3 | LNZTA3WT11 CRL-11544 [†] human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter LNZTA3WT4 CRL-11543 [†] human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter Lo Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) Lo Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote LO-22 HB-8619 [†] mouse/mouse hybridoma lymphoblast susp Loucy CRL-2629 human preipheral blood; T lymphocyte; acute lympho- | |
| LNZTA3WT4 CRL-11543¹ human brain; glioblastoma; p53 expression under tetracycline-induced promoter skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adherent dominant type) Lo Wen CRL-1159 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adherent heterozygote Lo Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adherent heterozygote Lo Wen CRL-1659 human peripheral blood; T lymphocyte; acute lymphoblast suspension Lo Wen CCL-229 human peripheral blood; T lymphocyte; acute lymphoblast suspension Lo Wen CCL-229 human lymph node, left supraclavicular region (metastasis); colorectal adenocarcinoma (colon primary) Lo MAB 1 CRL-1765 mouse/mouse hybridoma lymphoblast suspension Lo MAB 2 CRL-1770 mouse/mouse hybridoma lymphoblast suspension Lo MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension Lo MAB 4 CRL-1767 mouse/mouse hybridoma lymphoblast suspension Lo MAB 5 CRL-1767 mouse/mouse hybridoma lymphoblast suspension Lo MAB 6 CRL-1767 mouse/mouse hybridoma lymphoblast suspension Lo MAB 7 CRL-1767 mouse/mouse hybridoma lymphoblast suspension Lo MAB 8 CRL-1767 mouse/mouse hybridoma lymphoblast suspension Lo MAB 9 CRL-1767 mouse/mouse hybridoma lymphoblast suspension Lo MAB 9 CRL-1767 mouse/mouse hybridoma lymphoblast suspension Lo MAB 9 CRL-188 human colon; colorectal adenocarcinoma epithelial adherent Lo MAB 9 CRL-187 human colon; colorectal adenocarcinoma epithelial adherent Lo MAB 9 CRL-187 human colon; colorectal adenocarcinoma epithelial adherent Lo MAB 9 CRL-187 human colon; colorectal adenocarcinoma epithelial adherent Lo MAB 9 CRL-187 human colon; colorectal adenocarcinoma epithelial adherent Lo MAB 9 CRL-187 human colon; colorectal adenocarcinoma epithelial adherent Lo MAB 9 CRL-187 human colon; colorectal adenocarcinoma epithelial adherent Lo MAB 9 CRL-187 human colon; colorectal adenocarcinoma epithelial adherent Lo MAB 9 CRL-1720* human colon; colorectal adenocarcinoma lymphoblast suspension Lo MAB 9 CRL-187 human colon; colorectal a | LNZTA3WT4 CRL-11543 [†] human brain; glioblastoma; p53 expression under glial adhe tetracycline-induced promoter Lo Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) Lo Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote LO-22 HB-8619 [†] mouse/mouse hybridoma lymphoblast susp | rent |
| Lo Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adherent dominant type) Lo Wen CRL-1159 human skin; xeroderma pigmentosum, presumed heterozygote LO-22 HB-8619¹ mouse/mouse hybridoma lymphoblast suspension blastic leukemia; t(16;20) translocation Lovo CRL-2629 human lymph node, left supraclavicular region (metastasis); colorectal adenocarcinoma (colon primary) Lp1 MAB 1 CRL-1765 mouse/mouse hybridoma lymphoblast suspension lymphoblast suspens | Lo Ren CRL-1130 human skin; Ehlers-Danlos syndrome, type I (autosomal fibroblast adhe dominant type) Lo Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote LO-22 HB-8619† mouse/mouse hybridoma lymphoblast susp Loucy CRL-2629 human peripheral blood; T lymphocyte; acute lympho- | rent |
| LO-22 HB-8619¹ mouse/mouse hybridoma lymphoblast suspension bybridoma lymphoblast suspension lymphoblast suspensio | Lo Wen CRL-1159 human skin; xeroderma pigmentosum, presumed fibroblast adhe heterozygote LO-22 HB-8619 [†] mouse/mouse hybridoma lymphoblast susp Loucy CRL-2629 human peripheral blood; Tlymphocyte; acute lympho-lymphoblast susp | rent |
| DO-22 HB-8619 [†] mouse/mouse hybridoma lymphoblast suspension peripheral blood; T lymphocyte; acute lymphosom lymphoblast suspension peripheral blood; T lymphocyte; acute lymphosom lymphoblast suspension lymphoblast lymphoblas | _O-22 HB-8619 [†] mouse/mouse hybridoma lymphoblast susp _oucy CRL-2629 human peripheral blood;T lymphocyte; acute lympho- lymphoblast susp | rent |
| Doucy CRL-2629 human peripheral blood; T lymphocyte; acute lymphoblast suspension blastic leukemia; t(16;20) translocation DoVO CCL-229 human lymph node, left supraclavicular region (metastasis); colorectal adenocarcinoma (colon primary) Deptiment of the properties of the propert | oucy CRL-2629 human peripheral blood; Tlymphocyte; acute lympho- lymphoblast susp | ansion |
| LOVO CCL-229 human lymph node, left supraclavicular region (metastasis); colorectal adenocarcinoma (colon primary) p. 1 MAB 1 CRL-1765 mouse/mouse hybridoma lymphoblast suspension p. 1 MAB 2 CRL-1770 mouse/mouse hybridoma lymphoblast suspension p. 1 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p. 1 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p. 1 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p. 1 MB-8472† mouse/mouse hybridoma lymphoblast suspension p. 1 MB-8472† mouse/mouse hybridoma lymphoblast suspension p. 2 MB-97 mouse/mouse hybridoma lymphoblast suspension p. 3 MB-125-2D4-11-10-1 HB-12644† mouse/mouse hybridoma lymphoblast suspension p. 3 MB-12549† mouse/mouse hybridoma lymphoblast suspension p. 3 MB-12549† mouse/mouse hybridoma lymphoblast suspension p. 3 MB-12550† mouse/mouse hybridoma lymphoblast suspension p. 3 MB-1250† mouse/mouse/mouse/mouse/mouse/ | Diastic leukemia; t(10;20) translocation | |
| p1 MAB 1 CRL-1765 mouse/mouse hybridoma lymphoblast suspension p1 MAB 2 CRL-1770 mouse/mouse hybridoma lymphoblast suspension p1 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p1 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p2 MB-8472† mouse/mouse hybridoma lymphoblast suspension p2 MB-8472† mouse/mouse hybridoma lymphoblast suspension p3 MB-97 mouse/mouse hybridoma lymphoblast suspension p3 MB-97 mouse/mouse hybridoma lymphoblast suspension p4 MB-97 mouse/mouse hybridoma lymphoblast suspension p4 MB-12644† mouse/mouse hybridoma lymphoblast suspension p4 MB-12652* mouse/mouse hybridoma lymphoblast suspension p4 MB-12653† mouse/mouse hybridoma lymphoblast suspension p4 MB-12549† mouse/mouse hybridoma lymphoblast suspension p4 MB-12549† mouse/mouse hybridoma lymphoblast suspension p4 MB-12549† mouse/mouse hybridoma lymphoblast suspension p4 MB-12549* mouse/mouse hybridoma lymphoblast suspension p4 MB-12549* mouse/mouse hybridoma lymphoblast suspension p4 MB-12549* human colon; colorectal adenocarcinoma epithelial adherent p5 MB-12550* human colon; colorectal carcinoma epithelial adherent p5 MB-12550* human colon; colorectal carcinoma epithelial adherent p5 MB-157 mouse/mouse hybridoma lymphoblast suspension p4 MB-1570* human colon; colorectal carcinoma epithelial adherent p5 MB-1570* human bone marrow; aplastic anemia | oVo CCL-229 human lymph node, left supraclavicular region (metas-epithelial adhe | rent |
| p1 MAB 2 CRL-1770 mouse/mouse hybridoma lymphoblast suspension p1 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p3 MAB 3 CRL-1767 mouse/mouse hybridoma lymphoblast suspension p4 MB-8472† mouse/mouse hybridoma lymphoblast suspension p4.4 HB-232 mouse/mouse hybridoma lymphoblast suspension p5 102.9 HB-97 mouse/mouse hybridoma lymphoblast suspension p5 174T CL-188 human colon; colorectal adenocarcinoma epithelial adherent p5 125-2D4-11-10-1 HB-12644† mouse/mouse hybridoma lymphoblast suspension p5 132.1D9 HB-12549† mouse/mouse hybridoma lymphoblast suspension p5 132.8G2 HB-12550† mouse/mouse hybridoma lymphoblast suspension p5 180 CL-187 human colon; colorectal adenocarcinoma epithelial adherent p5 133 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent p5 133-10 CRL-7720* human bone marrow; aplastic anemia | | oncion |
| hybridoma lymphoblast suspension PAL4 HB-232 mouse/mouse hybridoma lymphoblast suspension PAL4 HB-97 mouse/mouse hybridoma lymphoblast suspension PAL5 HB-97 mouse/mouse hybridoma lymphoblast suspension PAL6 HB-97 mouse/mouse hybridoma lymphoblast suspension PAL7 CL-188 human colon; colorectal adenocarcinoma epithelial adherent PAL7 HB-12644† mouse/mouse hybridoma lymphoblast suspension PAL7 HB-12653† mouse/mouse hybridoma lymphoblast suspension PAL7 HB-12559† mouse/mouse hybridoma lymphoblast suspension PAL7 HB-12559† mouse/mouse hybridoma lymphoblast suspension PAL7 HB-12550† mouse/mouse hybridoma lymphoblast suspension PAL7 HB-12550† mouse/mouse hybridoma lymphoblast suspension PAL7 HB-12550† human colon; colorectal adenocarcinoma epithelial adherent PAL7 HB-12550† mouse/mouse hybridoma lymphoblast suspension PAL7 HB-12550† human colon; colorectal adenocarcinoma epithelial adherent PAL7 HB-12550† mouse/mouse hybridoma lymphoblast suspension PAL7 HB-1250† mouse/mouse hybridoma lymphoblast suspension | , | |
| P3IIG2 HB-8472 [†] mouse/mouse hybridoma lymphoblast suspension P4.4 HB-232 mouse/mouse hybridoma lymphoblast suspension P5.102.9 HB-97 mouse/mouse hybridoma lymphoblast suspension P5.174T CL-188 human colon; colorectal adenocarcinoma epithelial adherent P5.125-2D4-11-10-1 HB-12644 [†] mouse/mouse hybridoma lymphoblast suspension P5.132.1D9 HB-12549 [†] mouse/mouse hybridoma lymphoblast suspension P5.132.8G2 HB-12550 [†] mouse/mouse hybridoma lymphoblast suspension P5.133.4 CRL-2158 human colon; colorectal adenocarcinoma epithelial adherent P5.136 TIB-157 mouse/mouse hybridoma lymphoblast suspension P6.136 TIB-157 mouse/mouse hybridoma lymphoblast suspension P6.136 TIB-157 mouse/mouse hybridoma lymphoblast suspension P6.136 TIB-157 mouse/mouse hybridoma lymphoblast suspension | , | |
| P4.4 HB-232 mouse/mouse hybridoma lymphoblast suspension S 102.9 HB-97 mouse/mouse hybridoma lymphoblast suspension S 174T CL-188 human colon; colorectal adenocarcinoma epithelial adherent S-125-2D4-11-10-1 HB-12644† mouse/mouse hybridoma lymphoblast suspension S 129-3C3-E3-1 HB-12653† mouse/mouse hybridoma lymphoblast suspension S 132.1D9 HB-12549† mouse/mouse hybridoma lymphoblast suspension S 132.8G2 HB-12550† mouse/mouse hybridoma lymphoblast suspension S 180 CL-187 human colon; colorectal adenocarcinoma epithelial adherent S 1034 CRL-2158 human cecum; colorectal carcinoma epithelial adherent S 123 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent S 186 TIB-157 mouse/mouse hybridoma lymphoblast suspension S 187-7720* human bone marrow; aplastic anemia | | |
| S 102.9 HB-97 mouse/mouse hybridoma lymphoblast suspension S 174T CL-188 human colon; colorectal adenocarcinoma epithelial adherent S-125-2D4-11-10-1 HB-12644† mouse/mouse hybridoma lymphoblast suspension S 129-3C3-E3-1 HB-12653† mouse/mouse hybridoma lymphoblast suspension S 132.1D9 HB-12549† mouse/mouse hybridoma lymphoblast suspension S 132.8G2 HB-12550† mouse/mouse hybridoma lymphoblast suspension S 180 CL-187 human colon; colorectal adenocarcinoma epithelial adherent S 1034 CRL-2158 human cecum; colorectal carcinoma epithelial adherent S 123 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent S 136 TIB-157 mouse/mouse hybridoma lymphoblast suspension S 3-10 CRL-7720* human bone marrow; aplastic anemia | , | |
| CL-188 human colon; colorectal adenocarcinoma epithelial adherent S-125-2D4-11-10-1 HB-12644† mouse/mouse hybridoma lymphoblast suspension S129-3C3-E3-1 HB-12653† mouse/mouse hybridoma lymphoblast suspenson S132.1D9 HB-12549† mouse/mouse hybridoma lymphoblast suspension S132.8G2 HB-12550† mouse/mouse hybridoma lymphoblast suspension S132.8G0 CL-187 human colon; colorectal adenocarcinoma epithelial adherent S1034 CRL-2158 human cecum; colorectal carcinoma epithelial adherent S123 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent S-136 TIB-157 mouse/mouse hybridoma lymphoblast suspension S3-10 CRL-7720* human bone marrow; aplastic anemia | , | |
| S-125-2D4-11-10-1 HB-12644 [†] mouse/mouse hybridoma lymphoblast suspension S129-3C3-E3-1 HB-12653 [†] mouse/mouse hybridoma lymphoblast suspenson S132.1D9 HB-12549 [†] mouse/mouse hybridoma lymphoblast suspension S132.8G2 HB-12550 [†] mouse/mouse hybridoma lymphoblast suspension S180 CL-187 human colon; colorectal adenocarcinoma epithelial adherent S1034 CRL-2158 human cecum; colorectal carcinoma epithelial adherent S123 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent S-136 TIB-157 mouse/mouse hybridoma lymphoblast suspension S3-10 CRL-7720* human bone marrow; aplastic anemia | , | |
| S129-3C3-E3-1 HB-12653† mouse/mouse hybridoma lymphoblast suspenson S132.1D9 HB-12549† mouse/mouse hybridoma suspension S132.8G2 HB-12550† mouse/mouse hybridoma lymphoblast suspension S180 CL-187 human colon; colorectal adenocarcinoma epithelial adherent S1034 CRL-2158 human cecum; colorectal carcinoma epithelial adherent S123 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent S-136 TIB-157 mouse/mouse hybridoma lymphoblast suspension S3-10 CRL-7720* human bone marrow; aplastic anemia | · | |
| S132.1D9 HB-12549 [†] mouse/mouse hybridoma suspension S132.8G2 HB-12550 [†] mouse/mouse hybridoma lymphoblast suspension S180 CL-187 human colon; colorectal adenocarcinoma epithelial adherent S1034 CRL-2158 human cecum; colorectal carcinoma epithelial adherent S123 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent S-136 TIB-157 mouse/mouse hybridoma lymphoblast suspension S3-10 CRL-7720* human bone marrow; aplastic anemia | | |
| S132.8G2 HB-12550 [†] mouse/mouse hybridoma lymphoblast suspension S180 CL-187 human colon; colorectal adenocarcinoma epithelial adherent S1034 CRL-2158 human cecum; colorectal carcinoma epithelial adherent S123 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent S-136 TIB-157 mouse/mouse hybridoma lymphoblast suspension S3-10 CRL-7720* human bone marrow; aplastic anemia | , | |
| S. 180 CL-187 human colon; colorectal adenocarcinoma epithelial adherent S. 1034 CRL-2158 human cecum; colorectal carcinoma epithelial adherent S. 123 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent S. 136 TIB-157 mouse/mouse hybridoma lymphoblast suspension S. 137 CRL-7720* human bone marrow; aplastic anemia | , | |
| S1034CRL-2158humancecum; colorectal carcinomaepithelialadherentS123CCL-255humancolon; colorectal adenocarcinomaepithelialadherentS-136TIB-157mouse/mousehybridomalymphoblastsuspensionS3-10CRL-7720*humanbone marrow; aplastic anemia | | |
| .S123 CCL-255 human colon; colorectal adenocarcinoma epithelial adherent .S-136 TIB-157 mouse/mouse hybridoma lymphoblast suspension .S3-10 CRL-7720* human bone marrow; aplastic anemia | | |
| S-136 TIB-157 mouse/mouse hybridoma lymphoblast suspension S3-10 CRL-7720* human bone marrow; aplastic anemia | | |
| LS3-10 CRL-7720* human bone marrow; aplastic anemia | • | |
| | | oncion |
| | | 1101011 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------------|------------------------|--------------------|--|-------------|-------------|
| LS513 | CRL-2134 | human | cecum; colorectal carcinoma | epithelial | adherent |
| Ltk-11 | CRL-10422 [†] | mouse | subcutaneous connective tissue; expresses human 5HT1D beta receptor | fibroblast | adherent |
| LTPA | CRL-2389 | mouse | pancreas; adenocarcinoma | epithelial | adherent |
| TR228 | HB-8502 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| Lu Rob | CRL-1397 | human | skin; Ehlers-Danlos syndrome, type IV | fibroblast | adherent |
| ₋u Vin | CRL-1144 | human | skin; Ehlers-Danlos syndrome, type I (autosomal dominant type) | fibroblast | adherent |
| L Wnt-5A | CRL-2814 | mouse | subcutaneous connective tissue; areolar and adipose | fibroblast | adherent |
| _YK-1 | HB-306 | rat/mouse | hybridoma | lymphoblast | suspension |
| YK-12 | HB-316 | rat/mouse | hybridoma | lymphoblast | suspension |
| YK-16 | HB-319 | rat/mouse | hybridoma | lymphoblast | suspension |
| YK-5 | HB-310 | rat/mouse | hybridoma | lymphoblast | suspension |
| YK-7 | HB-311 | rat/mouse | hybridoma | lymphoblast | suspension |
| YK-8 | HB-312 | rat/mouse | hybridoma | lymphoblast | suspension |
| YK-9 | HB-313 | rat/mouse | hybridoma | lymphoblast | suspension |
| _ym-1 | HB-8612 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| .ym-2 | HB-8613 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| M 111 | HB-8438 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| M 144 | HB-8440 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| M. dunni | CRL-2017 | mouse mouse | skin | fibroblast | adherent |
| Clone III8C) | | | | | |
| Λ/K-1.9 | CRL-1910 | rat/mouse | hybridoma | lymphoblast | suspension |
| Л/K-2.7 | CRL-1909 | rat/mouse | hybridoma | lymphoblast | suspension |
| Л059J | CRL-2366 | human | brain, glial cell; malignant glioblastoma; glioma | fibroblast | adherent |
| Л059K | CRL-2365 | human | brain, glial cell; malignant glioblastoma; glioma | fibroblast | adherent |
| Л1 | TIB-192 | mouse | myeloblast; myeloid leukemia | | suspension |
| M-1 | CRL-2038 | mouse (transgenic) | kidney (cortex), collecting duct | epithelial | adherent |
| Л1.4 | CRL-2464 | rat/mouse | hybridoma | lymphoblast | suspension |
| Л1/22.25.8.HL | TIB-121 | rat/mouse | hybridoma | lymphoblast | suspension |
| M1/42.3.9.8.HLK | TIB-126 | rat/mouse | hybridoma | lymphoblast | suspension |
| M1/69.16.11.HL | TIB-125 | rat/mouse | hybridoma | lymphoblast | suspension |
| И1/70.15.11.5.HL | TIB-128 | rat/mouse | hybridoma | lymphoblast | suspension |
| Л1/75.16.4.HLK | TIB-127 | rat/mouse | hybridoma | lymphoblast | suspension |
| M1/87.27.7.HLK | TIB-123 | rat/mouse | hybridoma | lymphoblast | suspension |
| И1/89.18.7.НК | TIB-124 | rat/mouse | hybridoma | lymphoblast | suspension |
| Л1/9.3.4.HL.2 | TIB-122 | rat/mouse | hybridoma | lymphoblast | suspension |
| Л17/4.4.11.9 | TIB-217 | rat/mouse | hybridoma | lymphoblast | suspension |
| Л17/5.2 | TIB-237 | rat/mouse | hybridoma | lymphoblast | suspension |
| M18/2.a.12.7 | TIB-218 | rat/mouse | hybridoma | lymphoblast | suspension |
| И195 | HB-10306 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| M1WT2 | CRL-1984 | hamster, Chinese | ovary; expresses rat m1 muscarinic acetylcholine receptor | epithelial | adherent |
| M1WT3 | CRL-1985 | hamster, Chinese | ovary; expresses rat m1 muscarinic acetylcholine receptor | epithelial | adherent |
| M1WT5 | CRL-1986 | hamster, Chinese | ovary; expresses rat m1 muscarinic acetylcholine receptor | epithelial | adherent |
| M2-10B4 | CRL-1972 | mouse | bone marrow, stroma | fibroblast | adherent |
| Л2-1C6-4R3 | HB-64 | mouse/mouse | hybridoma | lymphoblast | suspension |
| л-24 (M138) | HB-8449 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Л-2E6 | HB-138 | mouse/mouse | hybridoma | lymphoblast | suspension |
| //3/38.1.2.8 HL.2 | TIB-166 | rat/mouse | hybridoma | lymphoblast | suspension |
| //3/84.6.34 | TIB-168 | rat/mouse | hybridoma | lymphoblast | suspension |
| M3WT4 | CRL-1981 | hamster, Chinese | ovary; expresses rat m3 muscarinic acetylcholine receptor | epithelial | adherent |
| M3WT5 | CRL-1982 | hamster, Chinese | ovary; expresses rat m3 muscarinic acetylcholine receptor | epithelial | adherent |
| M3WT8 | CRL-1983 | hamster, Chinese | ovary; expresses rat m3 muscarinic acetylcholine receptor | epithelial | adherent |
| M5/114.15.2 | TIB-120 | rat/mouse | hybridoma | lymphoblast | suspension |
| | | | , | , | |

* Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

75



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--------------------------|-----------------------|--------------------------|--|---------------------------|---------------------------------|
| M5/49.4.1 | TIB-238 | rat/mouse | hybridoma | lymphoblast | suspension |
| M-7 | CRL-2804 | mouse | fibrosarcoma | fibroblast | adherent |
| Ma San | CRL-1148 | human | skin; Ehlers-Danlos syndrome, type VII (arthrochalasia type) | fibroblast | adherent |
| MA-104 Clone 1 | CRL-2378.1 | monkey, African green | kidney | epithelial | adherent |
| MA1-6 | CRL-1783 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MA2.1 | HB-54 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Mab 108 | HB-9764 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Mab 126 | HB-8568 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| mAb 13-1 | HB-10565 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MAb 151-45-4 | HB-12682 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MAb 1812-4-8 | HB-12683 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Mab 1E8 | HB-11490 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| mAB 24-1 | HB-11947 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| mAB 24-2 | HB-11946 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MAb 26-7-5 | HB-12681 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| mAb 270 | HB-189 | rat/mouse | hybridoma | lymphoblast | suspension |
| Mab 2B5 | HB-11491 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| mAb 35 | HB-8857 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| MAb 5.2 | HB-9148 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Mab 543 | HB-8592 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MAb 951-5-1 | HB-12684 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Mab 96 | HB-9763 [†] | mouse/mouse | hybridoma | lymphocyte | suspension |
| mAb BB7 | CRL-2501 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MAb104 | CRL-2067 | mouse/mouse | hybridoma | lymphoblast | suspension |
| mAb35 | TIB-175 | rat/mouse | hybridoma | lymphoblast | suspension |
| mAb64 | HB-8987 [†] | rat/rat | hybridoma | lymphoblast | suspension |
| MAC 2-48 | HB-10714 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Malme-3 | HTB-102 | human | skin | fibroblast | adherent |
| Malme-3M MAR 18.5 | HTB-64 TIB-216 | human | skin; malignant melanoma | mixed | adherent |
| Mar Nol | CRL-1257 | mouse/mouse | hybridoma skin; Marfan syndrome | lymphoblast fibroblast | suspension adherent |
| Mar Ton | CRL-1257 CRL-1252 | human human | skin; Marian syndrome skin; Ehlers-Danlos syndrome | fibroblast | adherent |
| Mar Vin | CRL-1232 | human | skin; Enlers-Danios syndrome, type I (autosomal | fibroblast | adherent |
| | | | dominant type) | | |
| MARC 29F8 | CRL-2508 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MARC 2B7 | CRL-2509 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MARC S5 | CRL-2507 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MAT-Lu | JHU-4 | rat | prostate; cancer | | adherent |
| MAT-Ly-Lu-B-2 | CRL-2376 | rat | prostate; malignant carcinoma | epithelial | adherent |
| May Roy | CRL-1250 | human | skin; Marfan syndrome | fibroblast | adherent |
| MB 157 | CRL-7721* | human | pleural effusion (metastasis); carcinoma (mammary gland primary) | epithelial | adherent |
| MB 40.3 | HB-105 | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| MB III (de Bruyn-Gey) | CCL-32 | mouse | lymphosarcoma | lymphoblast | mixed |
| MB16tsA, clone 1B5 | CRL-2307 | mouse | embryo; SV40 large T antigen transfected; control for MmB19tsA. clone 2B2 | fibroblast | adherent |
| MB19tsA, clone 2B2 | CRL-2308 | mouse | embryo; SV40 large T antigen transfected; Cre-lox recombination model | fibroblast | adherent |
| MB23G2 | HB-220 | rat/mouse | hybridoma | lymphoblast | suspension |
| MB352 | CRL-2821 | mouse | embryo, fibroblast; spontaneously immortalized | fibroblast | adherent |
| MB355 | CRL-2818 | mouse | embryo, fibroblast; immortalized SV40 large T antigen | fibroblast | adherent |
| MB40.2 | HB-59 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MB40.5 | HB-116 | mouse/mouse | hybridoma | lymphoblast | suspension with |
| | | | | | feeder cells |
| MB4B4 | HB-223 | rat/mouse | hybridoma | lymphoblast | suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

76

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------|------------------------|------------------------|---|-------------|-------------|
| MBA C57.We | CRL-6370* | mouse | whole fetus | | |
| MBC(5) | CRL-6069* | bovine | unknown | | |
| MBL-Sm-1A6 | HB-194 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MBL-Sm-4B1 | HB-193 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MC/9 | CRL-8306 [†] | mouse | liver, mast cell | lymphoblast | suspension |
| MC/CAR | CRL-8083 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| MC/CAR-Z2 | CRL-8147 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| MC116 | CRL-1649 | human | ascites, B lymphoblast; undifferentiated lymphoma | lymphoblast | suspension |
| MC17-51 | CRL-2799 | mouse | fibrosarcoma | fibroblast | adherent |
| MC2/3 | CRL-2143 | hamster, Chinese | somatic cell hybrid; mouse chromosome 8 | fibroblast | adherent |
| MC3T3-E1 | CRL-2594 | mouse | bone (calvaria); osteoblast differentiation model | fibroblast | adherent |
| Subclone 14 | | | | | |
| MC3T3-E1 | CRL-2595 | mouse | bone (calvaria); osteoblast differentiation model | fibroblast | adherent |
| Subclone 24 | | | | | |
| MC3T3-E1 | CRL-2596 | mouse | bone (calvaria); osteoblast differentiation model | fibroblast | adherent |
| Subclone 30 | | | | | |
| MC3T3-E1 | CRL-2593 | mouse | bone (calvaria); osteoblast differentiation model | fibroblast | adherent |
| Subclone 4 | | | | | |
| MC57G | CRL-2295 | mouse | methylcholanthrene-induced fibrosarcoma | | adherent |
| McA-RH7777 | CRL-1601 | rat | liver; hepatoma; Morris hepatoma 7777 | epithelial | adherent |
| McA-RH8994 | CRL-1602 | rat | liver; hepatoma; Morris hepatoma 8994 | epithelial | adherent |
| MCB3901 | CRL-9595 [†] | hamster, Syrian golden | tumor, adenovirus-12 induced; transfection host; | fibroblast | adherent |
| | | | exogenous gene expression | | |
| МсСоу | CRL-1696 | mouse | unknown | fibroblast | adherent |
| MCF 10A | CRL-10317 [†] | human | mammary gland; fibrocystic disease | epithelial | adherent |
| MCF 10F | CRL-10318 [†] | human | mammary gland; fibrocystic disease | epithelial | adherent |
| MCF-10-2A | CRL-10781 [†] | human | mammary gland; fibrocystic disease | epithelial | adherent |

ATCC Cell Biology Trivia #9 What is the origin of the HeLa cell line?

Cervical cancer cells from a woman named Henrietta Lacks became the first immortalized cell line and a critical tool in cell research. The cells proved to grow almost too well as HeLa cells are a frequent intraspecies contaminant in human cell cultures.

| MCF-12A | CRL-10782 [†] | human | mammary gland | epithelial | adherent |
|---------------|------------------------|-----------|--|-------------------------|------------|
| MCF-12F | CRL-10783 [†] | human | mammary gland | epithelial | adherent |
| MCF7 | HTB-22 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | epithelial | adherent |
| MC-IXC | CRL-2270 | human | supraorbital area (metastasis); neuroepithelioma (brain primary) | fibroblast | adherent |
| MCL-5 | CRL-10575 [†] | human | peripheral blood, B lymphocyte; EBNA positive | lymphoblast | suspension |
| MC-SV-HUC T-2 | CRL-9519 [†] | human | ureter (uroepithelium) | epithelial | adherent |
| MD | CRL-9850 [†] | human | spleen; macrophage; monocyte | monocyte/ macrophage | suspension |
| MD2 | HB-229 | rat/mouse | hybridoma | lymphoblast | suspension |
| MDA PCa 2b | CRL-2422 | human | bone (metastasis); adenocarcinoma (prostate primary) | epithelial | adherent |

* Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------|-----------------------|-------------|--|---|---------------------------------|
| MDA-kb2 | CRL-2713 | human | mammary gland; luciferase resposive; androgen agonist/antagonist | epithelial | adherent |
| MDA-MB-134-VI | HTB-23 | human | pleural effusion (metastasis); ductal carcinoma (mammary gland primary) | epithelial | loosely adherent |
| MDA-MB-157 | HTB-24 | human | pleural effusion (metastasis); carcinoma (mammary gland primary) | epithelial | adherent |
| MDA-MB-175-VII | HTB-25 | human | pleural effusion (metastasis); ductal carcinoma (mammary gland primary) | epithelial | loosely adherent |
| MDA-MB-231 | HTB-26 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | epithelial | adherent |
| MDA-MB-330 | HTB-127 | human | pleural effusion (metastasis); carcinoma (mammary gland primary) | epithelial | adherent |
| MDA-MB-361 | HTB-27 | human | brain (metastasis); adenocarcinoma (mammary gland primary) | epithelial | loosely adherent |
| MDA-MB-415 | HTB-128 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | epithelial | adherent |
| MDA-MB-435S | HTB-129 | human | pleural effusion; ductal carcinoma (mammary gland primary) | spindle shaped | adherent |
| MDA-MB-436 | HTB-130 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | pleomorphic with multinucleated component cells | adherent |
| MDA-MB-453 | HTB-131 | human | pleural effusion (metastasis); carcinoma (mammary gland primary) | epithelial | adherent |
| MDA-MB-468 | HTB-132 | human | pleural effusion (metastasis); adenocarcinoma (mammary gland primary) | epithelial | adherent |
| MDBK (NBL-1) | CCL-22 | bovine | kidney | epithelial | adherent |
| MDCK (NBL-2) | CCL-34 | dog | kidney | epithelial | adherent |
| MDOK | CRL-1633 | sheep | kidney | epithelial | adherent |
| MDTC-RP19 | CRL-8135 [†] | turkey | lymph node; Marek's disease | lymphoblast | suspension |
| ME | CRL-6371* | mouse | embryo | | |
| ME 1 | HB-119 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Me Jon | CRL-1288 | human | skin; osteogenesis imperfecta (congenita) | fibroblast | adherent |
| Me Mon | CRL-1342 | human | skin; Ehlers-Danlos syndrome, variant type | fibroblast | adherent |
| ME-180 | HTB-33 | human | omentum (metastasis); epidermoid carcinoma (cervix primary) | epithelial | adherent |
| ME195 | HB-8431 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| ME361S2a | HB-9326 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MECA-367 | HB-9478 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| MECA-79 | HB-9479 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| MECA-89 | HB-292 | rat/mouse | hybridoma | lymphoblast | suspension |
| MEF (C57BL/6) | SCRC-1008 | mouse | embryonic fibroblast; feeder layer | fibroblast | adherent |
| MEF (CF-1) | SCRC-1040 | mouse | embryonic fibroblast; feeder layer | fibroblast | adherent |
| MEF-1 | CRL-2214 | mouse | embryo; SV40 transformed | fibroblast | adherent |
| MEG-01 | CRL-2021 | human | bone marrow; megakaryoblast; chronic myelogenous leukemia | lymphoblast | mixed |
| Mel Neg | CRL-1193 | human | skin; Ehlers-Danlos syndrome, type VII (arthrochalasia type) | fibroblast | adherent |
| MEL-14 | HB-132 | rat/mouse | hybridoma | lymphoblast | suspension |
| MES-SA | CRL-1976 | human | uterus; uterine sarcoma | fibroblast | adherent |
| MES-SA/Dx5 | CRL-1977 | human | uterus; uterine sarcoma | fibroblast | adherent |
| MES-SA/MX2 | CRL-2274 | human | uterus; uterine sarcoma | fibroblast | adherent |
| MeT-5A | CRL-9444 [†] | human | mesothelium; virus transformed | epithelial | adherent |
| MeWo | HTB-65 | human | lymph node (metastasis); malignant melanoma (skin primary) | fibroblast | adherent |
| MF 116 | HB-8411 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| MG38 | CRL-2640 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MG-63 | CRL-1427 | human | bone; osteosarcoma | fibroblast | adherent |
| mh | CRL-2709 | mouse | muscle; Hermansky-Pudlak syndrome | fibroblast | adherent |
| MH1 | HB-9739 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

78

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------------|-----------------------------------|-----------------------------|--|---------------------------|---------------------------------|
| MH,C, | CCL-144 | rat | liver; hepatoma | epithelial | adherent |
| MH55 | HB-8412 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| MH-S | CRL-2019 | mouse | lung | macrophage | mixed |
| MH-SVM23 | HB-8870 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MH-SVM25 | HB-8871 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MH-SVM26 | HB-8872 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MH-SVM33C9 | HB-8975 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MIA PaCa-2 | CRL-1420 | human | pancreas; carcinoma | epithelial | adherent |
| MiCl1 (S+L-) | CCL-64.1 | mink | | fibroblast | adherent |
| ліст (3 L) ЛіF-6 | CRL-2802 | mouse | lung fibrosarcoma | fibroblast | adherent |
| | | | | | |
| nIMCD-3 NJ | CRL-2123 CRL-8294 [†] | mouse (transgenic) human | kidney (medulla, collecting duct) peripheral blood, T lymphocyte; cutaneous T cell lymphoma; mycosis fungoides | epithelial lymphoblast | adherent suspension |
| ΛK-D6 | HB-3 | mouse/mouse | hybridoma | lymphoblast | suspension |
| ΛK-S4 | HB-4 | mouse/mouse | hybridoma | lymphoblast | suspension |
| ΛLE 12 | CRL-2110 | mouse (transgenic) | lung | épithelial | adherent |
| ИLg | CCL-206 | mouse | lung | fibroblast | adherent |
| NLH1 | CRL-1766 | mouse/mouse | hybridoma | lymphoblast | suspension |
| /ILH2 | CRL-1779 | mouse/mouse | hybridoma | lymphoblast | suspension |
| 1LTC-1 | CRL-2065 | mouse | testis; Leydig cell tumor | epithelial | adherent |
| 1M14.Lu | CRL-6382* | mouse | lung or bronchus | - | adherent |
| 1M14.OT | CRL-6384* | mouse | unknown; cancer | epithelial | adherent |
| 1M14.Ov | CRL-6383* | mouse | ovary | epithelial | adherent |
| | CRL-6388* | | | еріпіснаі | |
| MM15.Sp/Thy | | mouse | mixed spleen and thymus | | adherent |
| MM15OT | CRL-6438* | mouse | unknown; cancer | 24 12 1 | |
| MM16.Ov | CRL-6390* | mouse | ovary | epithelial | adherent |
| /M19.Lu | CRL-6396* | mouse | lung | | |
| MM22.We | CRL-6400* | mouse | embryo | | |
| ИM23.We | CRL-6401* | mouse | embryo | | |
| /M27.We | CRL-6402* | mouse | embryo | | |
| /M29.We | CRL-6403* | mouse | embryo | | |
| лм2MT | CRL-6373* | mouse | mammary gland; cancer | epithelial | adherent |
| MM2MTC | CRL-6374* | mouse | mammary gland; cancer | epithelial | adherent |
| лм2SCT | CRL-6375* | mouse | mammary gland; cancer | epithelial | adherent |
| ЛМ31.We | CRL-6405* | mouse | embryo | | |
| ЛМ34.We | CRL-6408* | mouse | embryo | | |
| ЛМ36T(C) | CRL-6411* | mouse | connective tissue; cancer | | |
| лм36We | CRL-6413* | mouse | embryo | | |
| MM37T | CRL-6414* | mouse | connective tissue; cancer | | |
| имзмG | CRL-6376* | mouse | mammary gland | epithelial | adherent |
| лм4.We | CRL-6377* | mouse | embryo, pooled | - protection | adiretett |
| MM41We | CRL-6416* | mouse | embryo | | |
| MM43T | CRL-6418* | mouse | unknown; cancer | | |
| личэт ЛМ44.Sp | CRL-6419* | | spleen | | |
| лм44.5р ЛМ45T.BI | CRL-6420* | mouse | fibrosarcoma; bladder (adjacent) | miyad | adherent |
| | | mouse | | mixed | adherent |
| MM45T.Li | CRL-6421* | mouse | fibrosarcoma; liver (adjacent) | mixed | adherent |
| 1M45T.Sp | CRL-6422* | mouse | spleen; fibrosarcoma | mixed | adherent |
| 1M46T | CRL-6423* | mouse | fibrosarcoma | | |
| 1M47T | CRL-6424* | mouse | connective tissue; fibrosarcoma | | |
| IM48T | CRL-6425* | mouse | fibrosarcoma | | |
| IM49T | CRL-6426* | mouse | fibrosarcoma | | |
| 1M5.1 | CRL-6380* | mouse | mammary gland; cancer | epithelial | adherent |
| 1M5/C1 | CRL-6444* | mouse | mammary gland; cancer | epithelial | adherent |
| 1M51.Sp | CRL-6427* | mouse | spleen | epithelial | adherent |
| 1М52.Sp | CRL-6428* | mouse | spleen; fibrosarcoma | epithelial | adherent |
| ИМ52.T | CRL-6429* | mouse | fibrosarcoma | epithelial | adherent |
| 1M53.Sp | CRL-6430* | mouse | spleen; fibrosarcoma | epithelial | adherent |
| 1M54.K | CRL-6433* | mouse | kidney | ·P · · ····· | |
| 1M54.Sp/Thy | CRL-6434* | mouse | mixed spleen and thymus | | |
| 1M55.K | CRL-6436* | | kidney | epithelial | adherent |
| ירכואווי. | CNL-0430" | mouse | riulicy | еринена | adherent |

* Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|---|-----------------------------------|------------------|--|----------------|--------------|
| MM55.Sp/Thy | CRL-6437* | mouse | mixed spleen and thymus | mixed | adherent |
| Mm5MT | CRL-1637 | mouse | mammary gland | epithelial | adherent |
| MM5MT | CRL-6590* | mouse | mammary gland; cancer | epithelial | adherent |
| MM5MTC | CRL-6378* | mouse | mammary gland; cancer | epithelial | adherent |
| MM5MTM | CRL-6379* | mouse | mammary gland; cancer | epithelial | adherent |
| MM7-11.Sp | CRL-6381* | mouse | spleen; tumor | | |
| MMA | HB-78 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MMQ | CRL-10609 [†] | rat | pituitary tumor | epithelial | suspension |
| M-MSV-BALB/3T3 | CCL-163.2 | mouse | embryo | fibroblast | adherent |
| MMT 060562 | CCL-51 | mouse | mammary gland tumor | epithelial | adherent |
| MN-11 | CRL-2800 | mouse | fibrosarcoma | fibroblast | adherent |
| И-NFS-60 | CRL-1838 | mouse | peripheral blood; virus-induced myeloid leukemia | lymphoblast | suspension |
| MNNG/HOS (CI #5) | CRL-1547 | human | bone; osteosarcoma | | adherent |
| Mo | CRL-1347 CRL-8066 [†] | human | T lymphocyte; hairy cell leukemia | lymphoblast | suspension |
| Mo-B | CCL-245 | human | peripheral blood, B lymphoblast; hairy cell | lymphoblast | suspension |
| | | | leukemia | | |
| MOLT-3 | CRL-1552 | human | peripheral blood, Tlymphoblast; acute lympho- blastic leukemia | lymphoblast | suspension |
| MOLT-4 | CRL-1582 | human | T lymphoblast; acute lymphoblastic leukemia | lymphoblast | suspension |
| MOP-8 | CRL-1709 | mouse | embryo | fibroblast | adherent |
| MOPC 315 | TIB-23 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| MOPC-31C | CCL-130 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| Mouse | CRL-6440* | mouse | unknown | | |
| MPC 11 OUA ^r | TIB-15 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| ИРС-11 | CCL-167 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| Ирf | CRL-1656 | ferret | brain | | adherent |
| MPK | CCL-166 | minipig | kidney | fibroblast | adherent |
| MPRO Cell Line, Clone 2.1 | CRL-11422 [†] | mouse | bone marrow; neutrophil progenitor cell line | | suspension |
| MR1 | CRL-2580 | hamster/mouse | hybridoma | lymphoblast | suspension |
| MRC-5 | CCL-171 | human | lung | fibroblast | adherent |
| MRC-9 | CCL-212 | human | lung | fibroblast | adherent |
| MRSS-1 (D ₂ D ₄) | HB-69 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MS1 | CRL-2279 | mouse | pancreas (islet of Langerhans), endothelium | туптрповіць | adherent |
| MS1 VEGF | CRL-2460 | mouse | pancreas (islet of Langerhans), endothelium | endothelial | adherent |
| MS751 | HTB-34 | human | lymph node (metastasis); epidermoid carcinoma | epithelial | adherent |
| MSTO-211H | CRL-2081 | human | (cervix primary) pleural effusion (metastasis); mesothelioma, | fibroblast | adherent |
| CVI 101 | CDI 1053 | | biphasic (lung primary) | 1 111 | |
| mSXL 104 | CRL-1953 | mouse/mouse | hybridoma | lymphoblast | suspension |
| nSXL 114 | CRL-1954 | mouse/mouse | hybridoma | lymphoblast | suspension |
| nSXL 18 | CRL-1952 | mouse/mouse | hybridoma | lymphoblast | suspension |
| nSXL 5 | CRL-1951 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MT1.K | CRL-6309* | talapoin | unknown, possibly kidney | Charalta d | - alla . |
| MT-6 | CRL-2805 | mouse | fibrosarcoma | fibroblast | adherent |
| MTC-M | CRL-1806 | mouse | thyroid; medulla; C cell; carcinoma | epithelial | suspension |
| MTKP 97-12 | CRL-8985 [†] | mouse | subcutaneous connective tissue; produces p97 melanoma-associated antigen | fibroblast | adherent |
| ИU14.K | CRL-6485* | parakeet, shell | kidney | | |
| Murphy | CRL-7722* | human | bone; osteosarcoma | | |
| Mv 1 Lu (NBL-7) | CCL-64 | mink | lung | epithelial | adherent |
| MV-4-11 | CRL-9591 [†] | human | peripheral blood; biphenotypic B myelo- monocytic leukemia | lymphoblast | suspension |
| //vi/lt | CRL-6012* | bat, mouse-eared | interscapular tumor, possibly basal cell | | adherent |
| MX | HB-9158 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| My 43.51 | HB-12128 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MY904 | HB-9510 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| MYA-1 | CRL-2417 | cat | peripheral blood, T lymphoblast | lymphoblast | suspension |
| 71.1/ \ 1 | CILL ZTI/ | cut | periprieral biood, i lyllipilobidat | ryrripriobidat | JUJPCIIJIUII |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------|-----------------------|---------------|--|----------------|--------------|
| MYB 2-37.63 | CRL-1726 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MYB 2-7.77 | CRL-1724 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MYC 1-9E10.2 | CRL-1729 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MYC CT 14-G4.3 | CRL-1727 | mouse/mouse | hybridoma | lymphoblast | suspension |
| MYC CT 9-B7.3 | CRL-1725 | mouse/mouse | hybridoma | lymphoblast | suspension |
| N1.551 | CRL-2040 | mouse/mouse | hybridoma | lymphoblast | suspension |
| N1E-115 | CRL-2263 | mouse | brain, neuroblast; neuroblastoma | fibroblast | adherent |
| V1-S1 | CRL-1604 | rat | liver; hepatoma; Novikoff hepatoma | 110101010 | suspension |
| N1-S1 Fudr | CRL-1603 | rat | liver; hepatoma; Novikoff hepatoma | | suspension |
| N2.261 | CRL-2047 | mouse/mouse | hybridoma | lymphoblast | suspension |
| N22 | HB-225 | hamster/mouse | hybridoma | lymphoblast | suspension |
| N3.36 | CRL-2042 | mouse/mouse | hybridoma | lymphoblast | suspension |
| N418 | HB-224 | hamster/mouse | hybridoma | lymphoblast | suspension |
| NAMALWA | CRL-1432 | human | B lymphocyte; Burkitt's lymphoma | lymphoblast | |
| NB3 | | | | | suspension |
| | HB-10205 | mouse/mouse | hybridoma | lymphoblast | suspension |
| VB41A3 | CCL-147 | mouse | brain, neuroblast; neuroblastoma | neuroblast | adherent |
| NBT-II | CRL-1655 | rat | urinary bladder; tumor | epithelial | adherent |
| NC-37 | CCL-214 | human | peripheral blood, B lymphoblast; Burkitt's lymphoma | lymphoblast | suspension |
| NCCIT | CRL-2073 | human | embryonal carcinoma; teratocarcinoma; nullipotent | epithelial | adherent |
| NCE-F161 | CRL-8727 [†] | cat | embryo | lymphoblast | adherent |
| NCI-BL1184 | CRL-5949 | human | peripheral blood, B lymphoblast; | lymphoblast | suspension |
| | | Human | EBV transformed | | 303001131011 |
| NCI-BL128 | CRL-5947 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL1339 | CRL-5950 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL1395 | CRL-5957 | human | peripheral blood, B lymphoblast; | lymphoblast | suspension |
| NCI-BL1437 | CRL-5958 | human | EBV transformed peripheral blood, B lymphoblast; | lymphoblast | suspension |
| NCI-BL1450 | CRL-5951 | human | EBV transformed peripheral blood, B lymphoblast; | lymphoblast | suspension |
| | | | EBV transformed | | 303001131011 |
| NCI-BL1514 | CRL-5952 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL1607 | CRL-5953 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL1672 | CRL-5959 | human | peripheral blood, B lymphoblast; | lymphoblast | suspension |
| | | | EBV transformed | | |
| NCI-BL1770 | CRL-5960 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL2009 | CRL-5961 | human | peripheral blood, B lymphoblast; | lymphoblast | suspension |
| NCI-BL2028 | CRL-5962 | human | EBV transformed peripheral blood, B lymphoblast; | lymphoblast | suspension |
| | | | EBV transformed | | |
| NCI-BL2052 | CRL-5963 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL2087 | CRL-5965 | human | peripheral blood, B lymphoblast; | lymphoblast | suspension |
| NCI-BL209 | CRL-5948 | human | EBV transformed peripheral blood, B lymphoblast; | lymphoblast | suspension |
| NCI-BL2107 | CRL-5966 | human | EBV transformed peripheral blood, B lymphoblast; | lymphoblast | suspension |
| | | | EBV transformed | | • |
| NCI-BL2122 | CRL-5967 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL2126 | CCL-256.1 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL2141 | CRL-5955 | human | peripheral blood, B lymphoblast; | lymphoblast | suspension |
| INCITULZ I 4 I | CIVE-2323 | numan | EBV transformed | iyiripiloblast | suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------|-----------|---------|---|------------------------|------------------------|
| NCI-BL2171 | CRL-5969 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL2195 | CRL-5956 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-BL2347 | CRL-5970 | human | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | suspension |
| NCI-H1048 | CRL-5853 | human | pleural effusion (metastasis); carcinoma; small cell lung cancer (lung primary) | | adherent |
| NCI-H1092 | CRL-5855 | human | bone marrow (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | suspension |
| NCI-H1105 | CRL-5856 | human | lymph node (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | suspension |
| NCI-H1155 | CRL-5818 | human | lymph node (metastasis); large cell neuro- endocrine carcinoma (lung primary) | epithelial | clusters in suspension |
| NCI-H1184 | CRL-5858 | human | lymph node (metastasis); carcinoma; small cell lung cancer (lung primary) | | clusters in suspension |
| NCI-H1238 | CRL-5859 | human | bone marrow (metastasis); carcinoma; small cell lung cancer (lung primary) | | mixed |
| NCI-H128 | HTB-120 | human | pleural effusion (metastasis); carcinoma; small cell lung cancer (lung primary) | floating aggregates | clusters in suspension |
| NCI-H1299 | CRL-5803 | human | lymph node (metastasis); large cell neuro- endocrine carcinoma (lung primary) | epithelial | adherent |
| NCI-H1304 | CRL-5862 | human | pleural effusion (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | clusters in suspension |
| NCI-H1341 | CRL-5864 | human | cervix (metastasis); carcinoma; small cell lung cancer (lung primary) | | suspension |
| NCI-H1355 | CRL-5865 | human | pleural effusion (metastasis); adenocarcinoma (lung primary) | | suspension |
| NCI-H1373 | CRL-5866 | human | lung; adenocarcinoma | | adherent |
| NCI-H1385 | CRL-5867 | human | lymph node (metastasis); squamous cell neuro- endocrine carcinoma (lung primary) | | suspension |
| NCI-H1395 | CRL-5868 | human | lung; adenocarcinoma | | adherent |
| NCI-H1404 | CRL-5819 | human | lymph node (metastasis); papillary adenocar- cinoma (lung primary) | epithelial | clusters in suspension |
| NCI-H1417 | CRL-5869 | human | lung; carcinoma; classic small cell lung cancer | | suspension |
| NCI-H1435 | CRL-5870 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H1436 | CRL-5871 | human | lymph node (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | suspension |
| NCI-H1437 | CRL-5872 | human | pleural effusion (metastasis); adenocarcinoma; non-small cell lung cancer (lung primary) | | adherent |
| NCI-H146 | HTB-173 | human | bone marrow (metastasis); carcinoma; small cell lung cancer (lung primary) | epithelial | clusters in suspension |
| NCI-H1522 | CRL-5874 | human | pleural effusion (metastasis); carcinoma; small cell lung cancer (lung primary) | | suspension |
| NCI-H1563 | CRL-5875 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H1568 | CRL-5876 | human | lymph node (metastasis); adenocarcinoma; non-small cell lung cancer (lung primary) | | adherent |
| NCI-H1573 | CRL-5877 | human | soft tissue (metastasis); adenocarcinoma (lung primary) | | adherent |
| NCI-H1581 | CRL-5878 | human | lung; large cell adenocarcinoma; non-small cell lung cancer | | mixed |
| NCI-H1618 | CRL-5879 | human | bone marrow (metastasis); carcinoma; small cell lung cancer (lung primary) | | suspension |
| NCI-H1623 | CRL-5881 | human | lymph node (metastasis); adenocarcinoma; non-small cell lung cancer (lung primary) | | adherent |
| NCI-H1648 | CRL-5882 | human | lymph node (metastasis); adenocarcinoma (lung primary) | | adherent |
| NCI-H1650 | CRL-5883 | human | pleural effusion (metastasis); adenocarcinoma; bronchoalveolar carcinoma (lung primary) | | adherent |
| NCI-H1651 | CRL-5884 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------|-----------|---------|--|------------|-------------|
| NCI-H1666 | CRL-5885 | human | pleural effusion (metastasis); adenocarcinoma; bronchoalveolar carcinoma (lung primary) | | adherent |
| NCI-H1672 | CRL-5886 | human | lung; carcinoma; classic small cell lung cancer | | suspension |
| NCI-H1688 | CCL-257 | human | lung; carcinoma; classic small cell lung cancer | epithelial | adherent |
| NCI-H1693 | CRL-5887 | human | lymph node (metastasis); adenocarcinoma; | • | adherent |
| | | | non-small cell lung cancer (lung primary) | | |
| NCI-H1694 | CRL-5888 | human | ascites (metastasis); carcinoma; classic small | | suspension |
| | | | cell lung cancer (lung primary) | | |
| NCI-H1703 | CRL-5889 | human | lung; squamous cell adenocarcinoma; non-small cell lung cancer | | suspension |
| NCI-H1734 | CRL-5891 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H1755 | CRL-5892 | human | liver (metastasis); adenocarcinoma; non-small | | adherent |
| | | | cell lung cancer (lung primary) | | |
| NCI-H1770 | CRL-5893 | human | lymph node (metastasis); neuroendocrine carc- | | adherent |
| | | | cinoma; non-small cell lung cancer (lung primary) | | |
| NCI-H1781 | CRL-5894 | human | pleural effusion (metastasis); adenocarcinoma; | | adherent |
| | | | bronchoalveolar carcinoma (lung primary) | | |
| NCI-H1792 | CRL-5895 | human | pleural effusion (metastasis); adenocarcinoma | | adherent |
| | | | (lung primary) | | |
| NCI-H1793 | CRL-5896 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H1819 | CRL-5897 | human | lymph node (metastasis); adenocarcinoma (lung primary) | | suspension |
| NCI-H1836 | CRL-5898 | human | lung; carcinoma; classic small cell lung cancer | | clusters in |
| | | | | | suspension |
| NCI-H1838 | CRL-5899 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H1869 | CRL-5900 | human | pleural effusion (metastasis); squamous cell | | adherent |
| | | | carcinoma (lung primary) | | |
| NCI-H187 | CRL-5804 | human | pleural effusion (metastasis); carcinoma; classic | epithelial | clusters in |
| | | | small cell lung cancer (lung primary) | | suspension |
| NCI-H1870 | CRL-5901 | human | cervix (metastasis); carcinoma; small cell lung cancer (lung primary) | | adherent |
| NCI-H1876 | CRL-5902 | human | lymph node (metastasis); carcinoma; classic | | adherent |
| | | | small cell lung cancer (lung primary) | | |
| NCI-H1882 | CRL-5903 | human | bone marrow (metastasis); carcinoma; small | | suspension |
| | | | cell lung cancer (lung primary) | | • |
| NCI-H1915 | CRL-5904 | human | brain (metastasis); large cell carcinoma; poorly | | adherent |
| | | | differentiated (lung primary) | | |
| NCI-H1926 | CRL-5905 | human | lymph node (metastasis); carcinoma; small cell | | clusters in |
| | | | lung cancer (lung primary) | | suspension |
| NCI-H1930 | CRL-5906 | human | lymph node (metastasis); carcinoma; classic | | adherent |
| | | | small cell lung cancer (lung primary) | | |
| NCI-H1944 | CRL-5907 | human | soft tissue (metastasis); adenocarcinoma; | | adherent |
| | | | non-small cell lung cancer (lung primary) | | |
| NCI-H196 | CRL-5823 | human | pleural effusion (metastasis); carcinoma; variant | | adherent |
| | | | small cell lung cancer (lung primary) | | |
| NCI-H1963 | CRL-5982 | human | lung; carcinoma; small cell lung cancer | | suspension |
| NCI-H1975 | CRL-5908 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H1993 | CRL-5909 | human | lymph node (metastasis); adenocarcinoma; | | adherent |
| NCLUAGO: | CDI FOIO | In | non-small cell lung cancer (lung primary) | | · · · |
| NCI-H1994 | CRL-5910 | human | lymph node (metastasis); carcinoma; classic | | suspension |
| NCI LIDOCC | CD1 =211 | | small cell lung cancer (lung primary) | | |
| NCI-H2009 | CRL-5911 | human | lymph node (metastasis); adenocarcinoma (lung | | adherent |
| NCI Hagas | CD1 =212 | | primary) | | |
| NCI-H2023 | CRL-5912 | human | lymph node (metastasis); adenocarcinoma; | | adherent |
| NCL LIBORS | CDI FOIS | In | non-small cell lung cancer (lung primary) | | 11- |
| NCI-H2029 | CRL-5913 | human | lymph node (metastasis); carcinoma; small cell | | adherent |
| NCL H2020 | CDL 5014 | la | lung cancer (lung primary) | | ٠ ماله - |
| NCI-H2030 | CRL-5914 | human | lymph node (metastasis); adenocarcinoma; | | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. r research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-----------|-----------|---------|---|------------|------------------------|
| NCI-H2052 | CRL-5915 | human | pleural effusion (metastasis); mesothelioma (pleura primary) | | adherent |
| NCI-H2059 | CRL-5916 | human | lymph node (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | suspension |
| NCI-H2066 | CRL-5917 | human | lung, mixed; small cell lung cancer; adenocar- cinoma; squamous cell carcinoma | | adherent |
| NCI-H2073 | CRL-5918 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H2081 | CRL-5920 | human | pleural effusion (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | suspension |
| NCI-H2085 | CRL-5921 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H2087 | CRL-5922 | human | lymph node (metastasis); adenocarcinoma; non-small cell lung cancer (lung primary) | | loosely adherent |
| NCI-H209 | HTB-172 | human | bone marrow (metastasis); carcinoma; small cell lung cancer (lung primary) | epithelial | clusters in suspension |
| NCI-H2106 | CRL-5923 | human | lymph node (metastasis); large cell neuro- endocrine carcinoma (lung primary) | | adherent |
| NCI-H2107 | CRL-5983 | human | bone marrow (metastasis); carcinoma; small cell lung cancer (lung primary) | | adherent |
| NCI-H2108 | CRL-5984 | human | bone marrow (metastasis); carcinoma; small cell lung cancer (lung primary) | | clusters in suspension |
| NCI-H211 | CRL-5824 | human | bone marrow (metastasis); carcinoma; small cell lung cancer (lung primary) | | suspension |
| NCI-H2110 | CRL-5924 | human | pleural effusion (metastasis); non-small cell lung cancer (lung primary) | | adherent |
| NCI-H2122 | CRL-5985 | human | pleural effusion (metastasis); adenocarcinoma; non-small cell lung cancer (lung primary) | | adherent |
| NCI-H2126 | CCL-256 | human | lung; carcinoma; non-small cell lung cancer | epithelial | adherent |
| NCI-H2135 | CRL-5926 | human | lung; non-small cell lung cancer | · | adherent |
| NCI-H2141 | CRL-5927 | human | lymph node (metastasis); carcinoma; small cell lung cancer (lung primary) | | suspension |
| NCI-H2170 | CRL-5928 | human | lung; squamous cell carcinoma | | adherent |
| NCI-H2171 | CRL-5929 | human | pleural effusion (metastasis); carcinoma; small cell lung cancer (lung primary) | | adherent |
| NCI-H2172 | CRL-5930 | human | lung; non-small cell lung cancer | | adherent |
| NCI-H2195 | CRL-5931 | human | bone marrow (metastasis); carcinoma; small cell lung cancer (lung primary) | | adherent |
| NCI-H2196 | CRL-5932 | human | bone marrow (metastasis); carcinoma; small cell lung cancer (lung primary) | | adherent |
| NCI-H2198 | CRL-5933 | human | lymph node (metastasis); carcinoma; small cell lung cancer (lung primary) | | adherent |
| NCI-H220 | CRL-5825 | human | pleural effusion (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | mixed |
| NCI-H2227 | CRL-5934 | human | lung; carcinoma; small cell lung cancer | | adherent |
| NCI-H2228 | CRL-5935 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |

ATCC Cell Biology Trivia #10 Who discovered DNA and when?

Friedrich Miescher, a Swiss scientist, discovered DNA in 1869 and proposed that it might play a role in heredity. Seventy years later, Oswald Avery's landmark studies with bacteria confirmed Miescher's hunch.

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------------|------------------------|------------|---|---|---------------|
| NCI-H226 | CRL-5826 | human | pleural effusion (metastasis); squamous cell | | adherent |
| | | | carcinoma; mesothelioma (lung primary) | | |
| NCI-H2286 | CRL-5938 | human | lung, mixed; small cell lung cancer; adeno- | | adherent |
| | | | carcinoma; squamous cell carcinoma | | |
| NCI-H2291 | CRL-5939 | human | lymph node (metastasis); adenocarcinoma; | epithelial | adherent |
| | | | non-small cell lung cancer (lung primary) | • | |
| NCI-H23 | CRL-5800 | human | lung; adenocarcinoma; non-small cell lung cancer | epithelial | adherent |
| NCI-H2330 | CRL-5940 | human | lymph node (metastasis); carcinoma; small cell | | adherent |
| | | | lung cancer (lung primary) | | |
| NCI-H2342 | CRL-5941 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H2347 | CRL-5942 | human | lung; adenocarcinoma; non-small cell lung cancer | | adherent |
| NCI-H2405 | CRL-5944 | human | ascites (metastasis); adenocarcinoma; non-small | | adherent |
| NCI-112403 | CIL-3944 | Hullian | cell lung cancer (lung primary) | | adilelelit |
| NCI H2444 | CDL FOAF | human | 3 3, 7 | anithalial | adharant |
| NCI-H2444 | CRL-5945 | human | lung; non-small cell lung cancer | epithelial | adherent |
| NCI-H2452 | CRL-5946 | human | pleural effusion; mesothelioma | | adherent |
| NCI-H250 | CRL-5828 | human | brain (metastasis); carcinoma; classic small cell | | suspension |
| 1511122 | CD1 | | lung cancer (lung primary) | | |
| NCI-H28 | CRL-5820 | human | pleural effusion (metastasis); mesothelioma | | adherent |
| | | | (pleura primary) | | |
| NCI-H292 | CRL-1848 | human | lung; mucoepidermoid pulmonary carcinoma | epithelial | adherent |
| NCI-H295 | CRL-10296 [†] | human | adrenal gland; cortex adrenocortical carcinoma | epithelial | mixed |
| NCI-H295R | CRL-2128 | human | adrenal gland (cortex); carcinoma | epithelial | adherent |
| NCI-H345 | HTB-180 | human | bone marrow (metastasis); carcinoma; small cell | epithelial | mixed suspen- |
| | | | lung cancer (lung primary) | | sion |
| NCI-H358 | CRL-5807 | human | lung (bronchiole; alveolus); bronchioalveolar | epithelial | adherent |
| | | | carcinoma; non-small cell lung cancer | • | |
| NCI-H378 | CRL-5808 | human | pleural effusion (metastasis); carcinoma; classic | epithelial | clusters in |
| | | | small cell lung cancer (lung primary) | • | suspension |
| NCI-H441 | HTB-174 | human | pericardial fluid (metastasis); papillary adeno- | epithelial | adherent |
| | 1110 17 1 | naman | carcinoma (lung primary) | Сритена | udiferent |
| NCI-H446 | HTB-171 | human | pleural effusion (metastasis); carcinoma; small | epithelial | mixed |
| 1101-11440 | 1110-171 | Hullian | cell lung cancer (lung primary) | еріпіснаі | IIIIXEU |
| NCI-H460 | HTB-177 | human | pleural effusion (metastasis); large cell carci- | epithelial | adherent |
| NCI-H400 | ПІБ-1// | numan | | ерішенаі | aunerent |
| NCI-H498 | CCL 254 | la como mo | noma (lung primary) | a : : : : : : : : : : : : : : : : : : : | nativa d |
| | CCL-254 | human | cecum; colorectal adenocarcinoma | epithelial | mixed |
| NCI-H508 | CCL-253 | human | cecum; colorectal adenocarcinoma | epithelial | mixed |
| NCI-H510A | HTB-184 | human | adrenal gland (metastasis); carcinoma; small cell | epithelial | mixed |
| | | | lung cancer (unknown primary) | | |
| NCI-H520 | HTB-182 | human | lung; squamous cell carcinoma | epithelial | adherent |
| NCI-H522 | CRL-5810 | human | lung; adenocarcinoma; non-small cell lung | epithelial | adherent |
| | | | cancer | | |
| NCI-H524 | CRL-5831 | human | lymph node (metastasis); carcinoma; variant | | suspension |
| | | | small cell lung cancer (lung primary) | | |
| NCI-H526 | CRL-5811 | human | bone marrow (metastasis); carcinoma; classic | epithelial | clusters in |
| | | | small cell lung cancer (lung primary) | • | suspension |
| NCI-H548 | CCL-249 | human | colon; adenocarcinoma | epithelial | mixed |
| NCI-H596 | HTB-178 | human | lung; adenosquamous carcinoma | epithelial | adherent |
| NCI-H630 | CRL-5833 | human | liver (metastasis); carcinoma (rectum primary) | | adherent |
| VCI-H647 | CRL-5834 | human | pleural effusion (metastasis); mixed adeno- | | adherent |
| ·CI 110T/ | CIVE JUJ4 | maman | squamous and carcinoma (lung primary) | | udiferent |
| NCI-H650 | CDI - E02E | human | lymph node (metastasis); bronchioalveolar carci- | | suspension |
| vCI-П0ЭU | CRL-5835 | Hullidii | | | suspension |
| NCL LICCO | CDL 5043 | I | noma; non-small cell lung cancer (lung primary) | tel It - I | -location 1 |
| NCI-H660 | CRL-5813 | human | lymph node (metastasis); extrapulmonary small | epithelial | clusters in |
| | | | cell carcinoma (prostate primary) | | suspension |
| NCI-H661 | HTB-183 | human | lymph node (metastasis); carcinoma; large cell | epithelial | adherent |
| | | | lung cancer (lung primary) | | |
| | | la | pleural effusion (metastasis); adenocarcinoma | epithelial | mixed suspen- |
| NCI-H676B | HTB-179 | human | piculai cirasion (metastasis), adenocaremonia | epitriciiai | mixed suspen |
| NCI-H676B | HTB-179 | numan | (lung primary) | | sion |
| NCI-H676B NCI-H69 | HTB-179 HTB-119 | human | | floating | • |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

Order online at www.lgcpromochem.com/atcc, or contact your local LGC Promochem office. See back cover for details.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-----------------|-----------------------|------------------|--|--|-------------|
| NCI-H711 | CRL-5836 | human | bone marrow (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | suspension |
| NCI-H716 | CCL-251 | human | cecum; colorectal adenocarcinoma | epithelial | mixed |
| NCI-H719 | CRL-5837 | human | bone marrow (metastasis); carcinoma; classic | | suspension |
| 1.51.1.700 | CD1 =000 | | small cell lung cancer (lung primary) | | |
| NCI-H720 | CRL-5838 | human | lung; atypical carcinoid | 241 - 12 - 1 | suspension |
| NCI-H727 | CRL-5815 | human | lung (bronchus); carcinoid | epithelial | adherent |
| NCI-H735 | CRL-5978 | human | liver (metastasis); carcinoma; small cell lung cancer (lung primary) | | suspension |
| NCI-H740 | CRL-5840 | human | lymph node (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | suspension |
| NCI-H747 | CCL-252 | human | cecum; colorectal adenocarcinoma | epithelial | mixed |
| NCI-H748 | CRL-5841 | human | lymph node (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | suspension |
| NCI-H774 | CRL-5842 | human | soft tissue (metastasis); carcinoma; classic small | | suspension |
| | | | cell lung cancer (lung primary) | | |
| NCI-H810 | CRL-5816 | human | lung; large cell; neuroendocrine; carcinoma; non-small cell lung cancer | epithelial | adherent |
| NCI-H82 | HTB-175 | human | pleural effusion (metastasis); carcinoma; small | epithelial | clusters in |
| | | | cell lung cancer (lung primary) | * | suspension |
| NCI-H820 | HTB-181 | human | lymph node (metastasis); papillary adenocarci- | epithelial | mixed |
| | | | noma (lung primary) | * | |
| NCI-H835 | CRL-5843 | human | lung; carcinoid | | suspension |
| NCI-H838 | CRL-5844 | human | lymph node (metastasis); adenocarcinoma; non- small cell lung cancer (lung primary) | | adherent |
| NCI-H841 | CRL-5845 | human | lymph node (metastasis); carcinoma; variant | | mixed |
| NCL LIGAT | CDL F04C | h | small cell lung cancer (lung primary) | | |
| NCI-H847 | CRL-5846 | human | pleural effusion (metastasis); carcinoma; classic small cell lung cancer (lung primary) | | suspension |
| NCI-H865 | CRL-5849 | human | pleural effusion (metastasis); carcinoma; classic | | clusters in |
| | | | small cell lung cancer (lung primary) | | suspension |
| NCI-H889 | CRL-5817 | human | lymph node (metastasis); carcinoma; classic | epithelial | clusters in |
| | | | small cell lung cancer (lung primary) | | suspension |
| NCI-H920 | CRL-5850 | human | lymph node (metastasis); adenocarcinoma; non-small cell lung cancer (lung primary) | | suspension |
| NCI-H929 | CRL-9068 [†] | human | bone marrow, B lymphocyte; plasmacytoma; | lymphoblast | suspension |
| NCI-H969 | CRL-5852 | human | myeloma pleural effusion (metastasis); adenocarcinoma; | | mixed |
| | | | non-small cell lung cancer (lung primary) | | |
| NCI-N87 | CRL-5822 | human | liver (metastasis); gastric carcinoma (stomach primary) | epithelial | adherent |
| NCTC 3749 | CCL-46.1 | mouse | monocyte; macrophage; lymphoma | fibroblast | adherent |
| NCTC 4093 | CCL-40.1 | mouse | embryo | fibroblast | adherent |
| NCTC 4206 | CCL-14.2 | hamster, Chinese | peritoneum | fibroblast | adherent |
| NCTC clone 1469 | CCL-14.2 | mouse | liver | epithelial | adherent |
| NCTC clone 2472 | CCL-9.1 | mouse | subcutaneous connective tissue (areolar and | fibroblast | adherent |
| NCTC clone 2555 | CCL-12 | mouse | adipose) subcutaneous connective tissue (areolar and adipose) | fibroblast | adherent |
| NCTC clone 3526 | CCL-7.2 | monkey, Rhesus | kidney | epithelial | adherent |
| NCTC clone 929 | CCL-1.2 | mouse | subcutaneous connective tissue (areolar and | fibroblast | adherent |
| | | mouse | adipose) | | |
| NE | CRL-2070 | mouse | embryonic carcinoma; teratocarcinoma; nullipotent | epithelial | adherent |
| Ne Loc | CRL-1205 | human | skin; stiff skin syndrome | fibroblast | adherent |
| NEF26.Ov | CRL-6175* | cat | ovary | | |
| NEF36.Sg | CRL-6176* | cat | sublingual salivary gland | | |
| Neuro-2a | CCL-131 | mouse | brain, neuroblast; neuroblastoma | neuronal and amoeboid stem cells | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|---------------|-----------------------|-------------------------------|---|---------------------------------------|------------------------|
| NF-1 | CRL-2075 | mouse | embryonic carcinoma; teratocarcinoma; nullipotent | epithelial | adherent |
| NFPE | CRL-2069 | mouse | embryo; embryonic carcinoma | epithelial | adherent |
| NFS-25 C-3 | CRL-1695 | mouse | pre-B lymphoblast; lymphoma | lymphoblast | suspension |
| NFS-5 C-1 | CRL-1693 | mouse | pre-B lymphoblast; lymphoma | lymphoblast | suspension |
| NFS-70 C-10 | CRL-1694 | mouse | pro-B lymphoblast; lymphoma | lymphoblast | suspension |
| NG108-15 | HB-12317 [†] | mouse/rat | brain; glial cell; neuron; glioblastoma; neuro- blastoma (hybrid) | flat; round | adherent |
| NIH/3T3 | CRL-1658 | mouse | embryo | fibroblast | adherent |
| NIH:OVCAR-3 | HTB-161 | human | ascites (metastasis); adenocarcinoma (ovary primary) | epithelial | adherent |
| VIT-1 | CRL-2055 | mouse (transgenic) | pancreas (islet of Langerhans); insulinoma | epithelial | adherent |
| NIT-2 | CRL-2364 | mouse (transgenic) | pancreas, beta cell; adenoma; carboxypeptidase E defective | epithelial epithelial | adherent |
| NK-92 | CRL-2407 | human | natural killer cell; IL-2 dependent, cytotoxic to a wide range of malignant cells | lymphoblast | clusters in suspension |
| NK-92MI | CRL-2408 | human | natural killer cell; IL-2 independent, cytotoxic to | lymphoblast | clusters in |
| | | ********* | a wide range of malignant cells | ,p | suspension |
| NL20 | CRL-2503 | human | lung (bronchus); immortalized with SV40 large T plasmid, p129 | epithelial | adherent |
| NL20-TA | CRL-2504 | human | lung (bronchus); immortalized with SV40 large T plasmid, p129 | epithelial | adherent |
| NMU | CRL-1743 | rat | mammary gland; adenocarcinoma | epithelial | adherent |
| Mu3Li | CRL-6447* | mouse | liver | adherent | |
| MuLi | CRL-1638 | mouse | liver | epithelial | adherent |
| MuMG | CRL-1636 | mouse | mammary gland | epithelial | adherent |
| N-3 | HB-8474 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| NN-4 | HB-8473 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| NN-5 | HB-8476 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| No Per | CRL-1327 | human | skin; Ehlers-Danlos syndrome, possible | fibroblast | adherent |
| 10 1 61 | CILE 1527 | Trainian | heterozygote | Horobiase | dancient |
| NOR-10 | CCL-197 | mouse | skeletal muscle | fibroblast | adherent |
| NR8383 | CRL-2192 | rat | lung | macrophage | mixed |
| NRbM | CRL-1839 | mouse/mouse | hybridoma | lymphoblast | suspension |
| NRK | CRL-6509* | rat | kidney | epithelial | adherent |
| NRK-49F | CRL-1570 | rat | kidney | fibroblast | adherent |
| NRK-52E | CRL-1571 | rat | kidney | epithelial | adherent |
| N-S.2.1 | TIB-108 | mouse/mouse | hybridoma | lymphoblast | suspension |
| N-S.4.1 | TIB-110 | mouse/mouse | hybridoma | lymphoblast | suspension |
| N-S.7 | TIB-114 | mouse/mouse | hybridoma | lymphoblast | suspension |
| N-S.8.1 | TIB-109 | mouse/mouse | hybridoma | lymphoblast | suspension |
| NTERA-2 cl.D1 | CRL-1973 | human | lung (metastasis); malignant; pluripotent embryonal carcinoma (testis primary) | fibroblast | adherent |
| NULLI-SCC1 | CRL-1566 | mouse | testis; teratocarcinoma; nullipotent | flattened colonies on coated surfaces | adherent |
| NZP-12 | CRL-1921 | cusimanse | lung | fibroblast | adherent |
| NZP-29 | CRL-1925 | oryx, short-horned | lung | epithelial | adherent |
| NZP-36 | CRL-1922 | zebra, Burchell's | kidney | fibroblast | adherent |
| NZP-46 | CRL-1926 | squirrel, plantain | embryo | fibroblast | adherent |
| NZP-60 | CRL-1924 | marmoset, black tailed | kidney | epithelial | adherent |
| DA1 | CRL-6538* | sheep | brain | fibroblast | adherent |
| DA3.Ts | CRL-6546* | sheep | testis, fetal | epithelial | adherent |
| DA4.Bm | CRL-6547* | sheep | bone marrow, fetal | epithelial | adherent |
| DA4.K/S1 | CRL-6549* | sheep | kidney, fetal | epithelial | adherent |
| OD-3 | HB-10204 | mouse/mouse | hybridoma | lymphoblast | suspension |
| OHH1.K | CRL-6193* | deer, Columbian black tail | kidney | fibroblast | adherent |
| OHH1.Li | CRL-6194* | deer, Columbian black tail | liver | epithelial | adherent |
| OHH1.Lu | CRL-6195* | deer, Columbian black tail | lung | mixed | adherent |

* Part of the NBL collection; see page 12. + Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--|------------------------|-------------|---|-------------------------|---------------------------|
| OK | CRL-1840 | opossum | kidney (cortex), proximal tubule | epithelial | adherent |
| OKM 1 | CRL-8026 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 1 | CRL-8000 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 10 | CRL-8022 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 11 | CRL-8027 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 3 | CRL-8001 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 4 | CRL-8002 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 5 | CRL-8013 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 5 | CRL-8016 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 6 | CRL-8020 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 8 | CRL-8014 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OKT 9 | CRL-8021 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| OLGA-PH-J/92 | CRL-2576 | crayfish | brain, cerebral ganglion | dendritic | adherent |
| OM 3-1.1 | HB-134 | mouse/mouse | hybridoma | lymphoblast | suspension |
| OMK(637-69) | CRL-1556 | monkey, owl | kidney | epithelial | adherent |
| OML, clone 13C | CRL-2312 | monkey, owl | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | clusters in suspension |
| OP9 | CRL-2749 | mouse | bone marrow, stroma | fibroblast | adherent |
| Or De | CRL-2749 CRL-1366 | human | skin; Ehlers-Danlos syndrome, type III | fibroblast | adherent |
| Os Te | CRL-1366 | human | skin, fetal; osteogenesis imperfecta | fibroblast | adherent |
| OSU1 | CRL-1202 CRL-6178* | cat | whole fetus | fibroblast | adherent |
| OV-90 | CRL-11732 [†] | human | ascites (metastasis); malignant papillary serous | epithelial | adherent |
| OV/D 2 | LID 01 47 ⁺ | | adenocarcinoma (ovary primary) | la constante de la cata | |
| OVB-3 | HB-9147 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| P-1 | CRL-2588 | mouse/mouse | hybridoma | lymphoblast | suspension |
| P1 1Ut (NBL-9) | CCL-74 | raccoon | uterus | fibroblast | adherent |
| P1.17 | TIB-10 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| P116 | CRL-2676 | human | T lymphocyte; ZAP-70 negative; model for T cell receptor signaling | lymphoblast | clusters in suspension |
| P116.cl39 | CRL-2677 | human | T lymphocyte; transfected with ZAP-70 expression vector; control for P116 cells | lymphoblast | clusters in suspension |
| P19 | CRL-1825 | mouse | embryo; teratocarcinoma; embryonic carcinoma | epithelial | adherent |
| P25.48 | HB-9119 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| P3 6D4 (SCRF 43.1) | HB-9168 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| P3 8D2 (SCRF 43.1) | HB-9169 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| P3.6.2.8.1 | TIB-8 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| P3/NSI/1-Ag4-1 (NS-1) | TIB-18 | mouse | hybridoma fusion partner | lymphoblast | suspension |
| P388D, | CCL-46 | mouse | macrophage; monocyte; lymphoma | lymphoblast | suspension |
| P388D, | TIB-63 | mouse | macrophage; monocyte; lymphoma | 13.111011001031 | adherent |
| P3D | HB-11129 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| P3HR-1 | HTB-62 | human | ascites; Burkitt's lymphoma; B lymphoblast | lymphoblast | suspension |
| P ₃ NP/PFn | HB-91 | mouse/mouse | hybridoma | lymphoblast | suspension |
| P3X63Ag8 | TIB-91 | mouse | hybridoma fusion partner | lymphoblast | suspension |
| P3X63Ag8.653 | CRL-1580 | mouse | hybridoma fusion partner | lymphoblast | suspension |
| P3X63Ag8U.1 | CRL-1500 | mouse | hybridoma fusion partner | lymphoblast | suspension |
| o53NiS1 | CRL-1597 | mouse | fibrous histiocytoma; malignant; p53+/- | fibroblast | adherent |
| P-6 | CRL-2589 | mouse/mouse | hybridoma | lymphoblast | suspension |
| P815 | TIB-64 | mouse | mast cell; mastocytoma | .,р.1001030 | mixed |
| P-9 | CRL-2590 | mouse/mouse | hybridoma | lymphoblast | suspension |
| PA 2.6 | HB-118 | mouse/mouse | hybridoma | lymphoblast | suspension |
| PA-1 | CRL-1572 | human | ascites (metastasis); teratocarcinoma (ovary | epithelial | adherent |
| | | | primary) | • | |
| PA2.1 | HB-117 | mouse/mouse | hybridoma | lymphoblast | suspension |
| PA317 | CRL-9078 [†] | mouse | embryo; amphotropic retroviral packaging line | fibroblast | adherent |
| PA317 cell line containing JR- <i>gal</i> | CRL-9995 [†] | mouse | embryo | fibroblast | adherent |
| PA317 cyclin E-L | CRL-2187 | mouse | embryo; produces a retrovirus containing the human cyclin E-L gene | fibroblast | adherent |
| PA317 cyclin E-S | CRL-2188 | mouse | embryo; produces a retrovirus containing the human cyclin E-S gene | fibroblast | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------------|------------------------|------------------|--|------------------|------------------------|
| PA317 LXSN | CRL-2202 | mouse | embryo; produces amphotropic control retrovirus; G418 resistant | fibroblast | adherent |
| PA317 LXSN 16E6 | CRL-2204 | mouse | embryo; amphotropic retroviral packaging line | fibroblast | adherent |
| PA317 LXSN 16E6E7 | CRL-2203 | mouse | embryo; amphotropic retroviral packaging line | fibroblast | adherent |
| PA317 LXSN 16E7 | CRL-2205 | mouse | embryo; amphotropic retroviral packaging line | fibroblast | adherent |
| PA317 LXSN 6E6 | CRL-2206 | mouse | embryo; amphotropic retroviral packaging line | fibroblast | adherent |
| PA317 LXSN 6E7 | CRL-2207 | mouse | embryo; amphotropic retroviral packaging line | fibroblast | adherent |
| PAb 100 | TIB-115 | mouse/mouse | hybridoma | lymphoblast | suspension |
| PAb 101 | TIB-117 | mouse/mouse | hybridoma | lymphoblast | suspension |
| PAb 108 | TIB-230 | mouse/mouse | hybridoma | lymphoblast | suspension |
| PAb 122 | TIB-116 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Pa Kel-1 | CRL-1341 | human | skin; Ehlers-Danlos syndrome, type I (autosomal | fibroblast | adherent |
| Pa Kel-2 | CRL-1344 | human | dominant type) skin; Ehlers-Danlos syndrome, type I (autosomal | fibroblast | adherent |
| | | | dominant type) | | |
| Panc 02.03 | CRL-2553 | human | pancreas; adenocarcinoma | epithelial | adherent |
| Panc 02.13 | CRL-2554 | human | pancreas; adenocarcinoma | epithelial | adherent |
| Panc 03.27 | CRL-2549 | human | pancreas; adenocarcinoma | epithelial | adherent |
| Panc 04.03 | CRL-2555 | human | pancreas; adenocarcinoma | epithelial | adherent |
| Panc 05.04 | CRL-2557 | human | pancreas; adenocarcinoma | epithelial | adherent |
| Panc 08.13 | CRL-2551 | human | pancreas; adenocarcinoma | epithelial | adherent |
| Panc 10.05 | CRL-2547 | human | pancreas; adenocarcinoma; same patient as PL45 | epithelial | adherent |
| PANC-1 | CRL-1469 | human | pancreas (duct); epithelioid carcinoma | epithelial | adherent |
| PC 61 5.3 | TIB-222 | rat/mouse | hybridoma | lymphoblast | suspension |
| PC-12 | CRL-1721 | rat | adrenal gland; pheochromocytoma | polygonal | loosely adherent |
| PC-3 | CRL-1435 | human | bone (metastasis); adenocarcinoma (prostate primary) | epithelial | adherent |
| PCA 31.1 | HB-12314 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| PCA 33.28 | HB-12315 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| PDL-1 | CRL-1882 | | hybridoma | lymphoblast | |
| PEA 10 | CRL-1002 | mouse/mouse | embryo; LRP deficient | fibroblast | suspension adherent |
| PEA 13 | CRL-2215 | mouse | embryo; LRP deficient | fibroblast | adherent |
| PEAKrapid | CRL-2210 | mouse | | | |
| | | human | kidney; transformed with adenovirus 5 DNA | loosely adherent | epithelial |
| Peccary.K | CRL-6488* | peccary | kidney | CL LL . | adherent |
| Per Sel | CRL-1107 | human | skin; osteogenesis imperfecta | fibroblast | adherent |
| Pfeiffer | CRL-2632 | human | pleural effusion (metastasis); diffuse large cell non-Hodgkin's lymphoma (B lymphocyte primary) | lymphoblast | suspension |
| PFHR 9 | CRL-2423 | mouse | embryo; embryonic carcinoma; HAT resistant | epithelial | adherent |
| PFSK-1 | CRL-2060 | human | brain (cerebellum); malignant primitive neuroectodermal tumor | fibroblast | adherent |
| PG13 | CRL-10686 [†] | mouse | embryo; retroviral packaging line | fibroblast | adherent |
| PG13/LN c8 | CRL-10685 [†] | mouse | embryo; produces an infectious retrovirus with a neomycin resistance gene | fibroblast | adherent |
| PG-4 (S+L-) | CRL-2032 | cat | brain, astrocyte; Mo-MSV transformed | glial, astrocyte | adherent |
| ogsA-745 | CRL-2242 | hamster, Chinese | ovary; xylosyltransferase I deficient | epithelial | adherent |
| ogsB-618 | CRL-2241 | hamster, Chinese | ovary; galactosyltransferase I deficient | epithelial | adherent |
| ogsB-650 | CRL-2243 | hamster, Chinese | ovary; galactosyltransferase I deficient | epithelial | adherent |
| ogsC-605 | CRL-2245 | hamster, Chinese | ovary; sulfate transporter deficient | epithelial | adherent |
| ogsD-677 | CRL-2244 | hamster, Chinese | ovary; heparin sulfate deficient | epithelial | adherent |
| ogsE-606 | CRL-2246 | hamster, Chinese | ovary; heparin sulfate N-sulfotransferase deficient | epithelial | adherent |
| PHL | CRL-2750 | Pacific herring | larvae | epithelial | adherent |
| PI-11 | CRL-2591 | mouse/mouse | hybridoma | lymphoblast | suspension |
| PI 153/3 | TIB-198 | mouse/mouse | hybridoma | lymphoblast | suspension |
| PK(15) | CCL-33 | pig | kidney | epithelial | adherent |
| PK(D1) | CRL-6490* | pig | unknown | | adherent |
| PK13 | CRL-6489* | pig | kidney | epithelial | adherent |
| PK136 | HB-191 | mouse/mouse | hybridoma | lymphoblast | suspension |
| | | | | | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------------------|------------------------|-----------------------|---|--|------------------|
| PL45 | CRL-2558 | human | pancreas; ductal adenocarcinoma; same patient as Panc 10.05 cells | epithelial | adherent |
| PLC/PRF/5 | CRL-8024 | human | liver, Alexander cells; hepatoma | epithelial | adherent |
| PLHC-1 | CRL-2406 | topminnow | liver; hepatocellular carcinoma | epithelial | adherent |
| PMC2 | CRL-9852 [†] | human | spleen | lymphoblast | clusters in sus- |
| | | | • | , , | pension, some |
| | | | | h J2 virus macrophage h J2 virus macrophage epithelial eging line epithelial lymphoblast lymphoblast lymphoblast lymphoblast lymphoblast lymphoblast lymphoblast ining the fibroblast ining the fibroblast ining fibroblast epithelial | adherent cells |
| PMJ2-PC | CRL-2457 | mouse | peritoneal macrophage; infected with J2 virus | macrophage | mixed |
| PMJ2-R | CRL-2458 | mouse | peritoneal macrophage; infected with J2 virus | | mixed |
| Pro⁻5 | CRL-1781 | hamster, Chinese | ovary; proline auxotroph | | adherent |
| ProPak-A.52 | CRL-12479 [†] | human | kidney; amphotropic retroviral packaging line | | adherent |
| Clone #52 | | | ,, | | |
| ProPakA.6 | CRL-12006 [†] | human | kidney; amphotropic retroviral packaging line | epithelial | adherent |
| ProPak-X.36 | CRL-12007 [†] | human | kidney; xenotropic retroviral packaging line | | adherent |
| Prost 410 | HB-11426 [†] | mouse/mouse | hybridoma | <u> </u> | suspension |
| PS 38 | CRL-1950 | mouse/mouse | hybridoma | | suspension |
| PS 41 | CRL-1799 | mouse/mouse | hybridoma | | suspension |
| PS 45 | CRL-1798 | mouse/mouse | hybridoma | | suspension |
| PS 60 | CRL-1800 | mouse/mouse | hybridoma | | suspension |
| PS 67 | CRL-1797 | mouse/mouse | hybridoma | | suspension |
| PS/2 | CRL-1797 | rat/mouse | hybridoma | | suspension |
| Y 2 BAG alpha | CRL-9560 [†] | mouse | embryo; produces a retrovirus containing the | | adherent |
| • | | | beta-galactosidase gene | | |
| y2 12S6 | CRL-1808 | mouse | embryo; produces a retrovirus containing the adenovirus 12S E1A gene | | adherent |
| ψ2 13s1 | CRL-1809 | mouse | embryo; produces a retrovirus containing the adenovirus 13S E1A gene | fibroblast | adherent |
| ψ2 DAP | CRL-1949 | mouse | embryo; produces a retrovirus containing human alkaline phosphatase gene | fibroblast | adherent |
| PSP-36 | CRL-11171 [†] | monkey, African green | kidney | fibroblast | adherent |
| Pt K1 (NBL-3) | CCL-35 | potoroo | kidney | | adherent |
| PT67 | CRL-12284 [†] | mouse | embryo; amphotropic retroviral packaging line | | adherent |
| PtK1 | CRL-6493* | potoroo | kidney | | adherent |
| PtK2 (NBL-5) | CCL-56 | potoroo | kidney | <u> </u> | adherent |
| PT-K75 | CRL-2528 | pig | nasal turbinate, mucosa | | adherent |
| P-tyr-1 | CRL-1955 | mouse/mouse | hybridoma | | suspension |
| PU5-1.8 (PU5-1R) | TIB-61 | mouse | macrophage; monocyte; lymphoma | утгриовизе | mixed |
| PV1 | HB-12352 [†] | hamster/mouse | hybridoma | lymphoblast | suspension |
| PWR-1E | CRL-11611 [†] | human | prostate; immortalized with Ad12-SV40 hybrid | epithelial | adherent |
| PYS-2 | CRL-2745 | mouse | virus yolk sac, parietal endoderm; carcinoma | enithelial | adherent |
| PZ-HPV-7 | CRL-2743 CRL-2221 | mouse | prostate, epithelium; transformed with HPV-18 | epithelial epithelial | adherent |
| | HB-11765 [†] | human mouse/mouse | | lymphoblast | |
| QCRL-1 | | | hybridoma | | suspension |
| QCRL-3 | HB-11766 [†] | mouse/mouse | hybridoma muscle; chemically induced fibrosarcoma | lymphoblast | suspension |
| QM7 | CRL-1962 | quail, Japanese | | fibroblast | adherent |
| QNR/D | CRL-2532 | quail, Japanese | neuroretina | | adherent |
| QNR/K2 | CRL-2533 | quail, Japanese | neuroretina | lumande e le le -+ | adherent |
| QPN1 12C9 SCRF 43.2) | HB-9500 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| QPN1 22F5 SCRF 43.2) | HB-9509 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| QT6 | CRL-1708 | quail, Japanese | fibrosarcoma | fibroblast | adherent |
| R1 | SCRC-1011 | mouse | embryonic stem cell; derived from 129 substrain | spherical colony | adherent |
| R 1610 | CRL-1657 | hamster, Chinese | lung | fibroblast | adherent |
| R1.1 | TIB-42 | mouse | thymus, T lymphocyte; lymphoma | lymphoblast | suspension |
| R1/E | SCRC-1036 | mouse | embryo; embryonic stem cell | spherical colony | adherent |
| R1.G1 | TIB-44 | mouse | thymus, T lymphocyte; lymphoma | lymphoblast | suspension |
| R1-2 | HB-227 | rat/mouse | hybridoma | lymphoblast | suspension |
| | CRL-2360 | rat/mouse | hybridoma | lymphoblast | suspension |
| R1-5D9 | | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--------------------------|----------------------|-------------|-------------------------------|-------------|-------------|
| R17 217.1.3 | TIB-219 | rat/mouse | hybridoma | lymphoblast | suspension |
| R187 | CRL-1912 | rat/mouse | hybridoma | lymphoblast | suspension |
| R1E/TL8x.1 | TIB-43 | mouse | thymus,T lymphocyte; lymphoma | lymphoblast | suspension |
| R1E/TL8x.1.G1. OUA'.1 | TIB-45 | mouse | thymus, Tlymphocyte; lymphoma | lymphoblast | suspension |
| R2-10F6 | CRL-2358 | rat/mouse | hybridoma | lymphoblast | suspension |
| R ₃₄ | HB-8445 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| R2-9A5 | CRL-2357 | rat/mouse | hybridoma | lymphoblast | suspension |
| R2C | CCL-97 | rat | testis; Leydig cell tumor | epithelial | adherent |
| R2LBLN | CRL-6070* | bovine | lymph node | | |

ATCC Cell Biology Trivia #11

When did ATCC move to Rockville, Maryland?

ATCC moved into its first custom-designed facility in Rockville, Maryland, in 1964. It was a vast improvement over the two previous locations, which were small apartment buildings retrofitted with laboratories.

| R-3327-AT-1 | JHU-29 | rat | prostate; cancer | | adherent |
|-----------------|----------------------|-------------|--|-------------|------------|
| R-3327-AT-2.1 | JHU-30 | rat | prostate; cancer | | adherent |
| R-3327-AT-3.1 | JHU-31 | rat | prostate; cancer | | adherent |
| R3327-G | JHU-3 | rat | prostate; cancer | | adherent |
| R3 [33-10ras3] | CRL-2764 | rat | Schwann cell; immortalized with SV40 large | neuronal | adherent |
| | | | T antigen | | |
| R4-6A2 | HB-170 | rat/mouse | hybridoma | lymphoblast | suspension |
| R6.5.D6.E9.B2 | HB-9580 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| R63 | HB-9490 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| R-970-5 | CRL-7723* | human | bone; osteosarcoma | transformed | adherent |
| R9ab | CCL-193 | rabbit | lung, fetal | fibroblast | adherent |
| Ra Bot | CRL-1265 | human | skin; Marfan syndrome | fibroblast | adherent |
| Ra Lot | CRL-1289 | human | skin; Marfan syndrome | fibroblast | adherent |
| RA3-2C2/1 | TIB-145 | rat/mouse | hybridoma | lymphoblast | suspension |
| RA3-3A1/6.1 | TIB-146 | rat/mouse | hybridoma | lymphoblast | suspension |
| RAB-9 | CRL-1414 | rabbit | skin | fibroblast | adherent |
| RAG | CCL-142 | mouse | kidney; renal adenocarcinoma | amoeboid | adherent |
| Raji | CCL-86 | human | B lymphocyte; Burkitt's lymphoma | lymphoblast | suspension |
| Ramos (RA 1) | CRL-1596 | human | B lymphocyte; Burkitt's lymphoma (American) | lymphoblast | suspension |
| Ramos.2G6.4C10 | CRL-1923 | human | B lymphocyte; Burkitt's lymphoma (American) | lymphoblast | suspension |
| Ran De | CRL-1287 | human | skin; osteogenesis imperfecta (congenita) | fibroblast | adherent |
| Ran-2 | TIB-119 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Raszip 6 | CRL-1917 | mouse | embryo; produces a retrovirus containing the | fibroblast | adherent |
| | | | vHa-ras oncogene | | |
| Rat1-R12 | CRL-2210 | rat | connective tissue | epithelial | adherent |
| Rat2 | CRL-1764 | rat | fetus | fibroblast | adherent |
| RATV-NRK | CRL-6510* | rat | unknown, possibly kidney | | |
| RAW 264.7 | TIB-71 | mouse | monocyte; macrophage; AMLV-induced tumor | | adherent |
| RAW 264.7γNO(-) | CRL-2278 | mouse | macrophage; monocyte | | adherent |
| RAW 309 Cr.1 | TIB-69 | mouse | monocyte; macrophage; AMLV-induced tumor | | adherent |
| RAW 309F.1.1 | TIB-51 | mouse | spleen; lymphoma | lymphoblast | suspension |
| | | | · · · · · | · · | <u> </u> |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------------|------------------------|----------------|--|-------------------|-------------|
| RAW 8.1 | TIB-50 | mouse | spleen; B lymphocyte; lymphoma | lymphoblast | suspension |
| Ray Hot | CRL-1226 | human | skin; Ehlers-Danlos syndrome, type III | fibroblast | adherent |
| RBA | CRL-1747 | rat | mammary gland; adenocarcinoma | epithelial | adherent |
| RBL-1 | CRL-1378 | rat | peripheral blood; basophil; leukemia | lymphoblast | suspension |
| RBL-2H3 | CRL-2256 | rat | peripheral blood; basophil; leukemia | fibroblast | adherent |
| RC-4B/C | CRL-1903 | rat | anterior pituitary; adenoma | epithelial | adherent |
| RD | CCL-136 | human | muscle; rhabdomyosarcoma | spindle and large | adherent |
| RD-ES | HTB-166 | human | bone; Ewing's sarcoma | epithelial | mixed |
| | | | | | |
| RDP 45/20 | TIB-98 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Reh | CRL-8286 [†] | human | unknown; acute lymphocytic leukemia (non-T, non-B) | lymphoblast | suspension |
| RF/6A | CRL-1780 | monkey, Rhesus | eye (choroid), fetal | epithelial | adherent |
| RFGd10WE | CRL-6190* | chicken | unknown, possibly whole embryo | | |
| RFGd11WE | CRL-6191* | chicken | unknown, possibly whole embryo | | |
| RFGd12WE | CRL-6192* | chicken | unknown, possibly whole embryo | | |
| RFGd2WE | CRL-6182* | chicken | embryo | | |
| RFGd3WE | CRL-6183* | chicken | embryo | | |
| RFGd4WE | CRL-6184* | chicken | embryo | | |
| RFGd5WE | CRL-6185* | chicken | embryo | | |
| | | | · | fibroblast | adharant |
| RFL-6 | CCL-192 | rat | lung | fibroblast | adherent |
| RG11/39.4 | TIB-170 | mouse/mouse | hybridoma | lymphoblast | suspension |
| RG2 | CRL-2433 | rat | brain, undifferentiated malignant glioma | glial | adherent |
| RG7/1.30 | TIB-173 | mouse/mouse | hybridoma | lymphoblast | suspension |
| RG7/11.1 | TIB-174 | mouse/mouse | hybridoma | lymphoblast | suspension |
| RG7/7.6 HL | TIB-172 | mouse/mouse | hybridoma | lymphoblast | suspension |
| RG7/9.1 HLK | TIB-169 | mouse/mouse | hybridoma | lymphoblast | suspension |
| RG9/6.13 HLK | TIB-167 | mouse/mouse | hybridoma | lymphoblast | suspension |
| RIIIMT | CRL-6449* | mouse | mammary gland; cancer | epithelial | adherent |
| RIN-14B | CRL-2059 | rat | pancreas (islet of Langerhans); insulinoma; produces somatostatin and L-dopa-decarboxylase but not insulin | epithelial | adherent |
| RIN-5F | CRL-2058 | rat | pancreas (islet of Langerhans); insulinoma; produces insulin and L-dopa-decarboxylase but not somatostatin | epithelial | adherent |
| RIN-m | CRL-2057 | rat | pancreas (islet of Langerhans); insulinoma; produces insulin and somatostatin | epithelial | adherent |
| RIN-m5F | CRL-11605 [†] | rat | pancreas (islet of Langerhans); insulinoma; produces insulin and L-dopa-decarboxylase but not somatostatin | epithelial | adherent |
| RK ₁₃ | CCL-37 | rabbit | kidney | epithelial | adherent |
| RK3E | CRL-1895 | rat | kidney | epithelial | adherent |
| RKO | CRL-2577 | human | colon; carcinoma; control for RKO-E6 and RKO-AS45-1 cells | epithelial | adherent |
| RKO-AS45-1 | CRL-2579 | human | colon; carcinoma; apoptosis model; overexpression of GADD45 | epithelial | adherent |
| RKO-E6 | CRL-2578 | human | colon; carcinoma; apoptosis model; negligible p53 expression | epithelial | adherent |
| RL | CRL-2261 | human | ascites; non-Hodgkin's lymphoma; B lymphoblast | lymphoblast | suspension |
| RL-65 | CRL-10354 [†] | rat | lung | epithelial | adherent |
| L95-2 | CRL-1671 | human | uterus (endometrium); carcinoma | epithelial | adherent |
| RLE-6TN | CRL-2300 | rat | lung | epithelial | adherent |
| LSD06 | HB-8527 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| | | | • | <u> </u> | suspension |
| RLSD09 | HB-8525 [†] | mouse/mouse | hybridoma | lymphoblast | |
| RLTM01 | HB-8526 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| RLTM02 | HB-8523 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| RMC | CRL-2573 | rat | kidney | | adherent |
| RmcB | CRL-2379 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Rn 3T | CRL-6511* | rat | unknown; chemically induced tumor | | |
| Rn 4T | CRL-6512* | rat | unknown; chemically induced tumor | | |
| Rn 5TES | CRL-6513* | rat | testis | | |
| III J I L J | | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------------------------|------------------------|------------------------|---|---------------------------|------------------------|
| Rn2T | CRL-6599* | rat | mammary gland; cancer | | suspension |
| Rn6T | CRL-6601* | rat | unknown; 7, 12-dimethylbenz(a)anthracene- induced tumor | | |
| Ro Bon | CRL-1248 | human | skin; osteogenesis imperfecta (tarda) | fibroblast | adherent |
| Ro Dow | CRL-1337 | human | skin; Ehlers-Danlos syndrome, type II | fibroblast | adherent |
| Ro Shi | CRL-1310 | human | skin; porokeratosis | fibroblast | adherent |
| Ro Vid | CRL-1308 | human | skin; xeroderma pigmentosum; presumed heterozygote | fibroblast | adherent |
| Ron Har | CRL-1131 | human | skin; Ehlers-Danlos syndrome | fibroblast | adherent |
| RPC5.4 | TIB-12 | mouse | hybridoma fusion partner | lymphoblast | suspension |
| RPE-J | CRL-2240 | rat | eye (retina), pigmented epithelium; SV40 transformed | epithelial | adherent |
| RPMI 1788 | CCL-156 | human | peripheral blood, B lymphocyte; EBNA positive | lymphoblast | suspension |
| RPMI 1846 | CCL-49 | hamster, Syrian golden | | epithelial | adherent |
| RPMI 2650 | CCL-30 | human | pleural effusion (metastasis); squamous cell carcinoma (nasal septum primary) | epithelial | adherent |
| RPMI 6666 | CCL-113 | human | peripheral blood, lymphoblast; Hodgkin's disease | lymphoblast | suspension |
| RPMI 7666 | CCL-114 | human | peripheral blood, B lymphoblast; EBV producing | lymphoblast | suspension |
| RPMI 8226 | CCL-155 | human | peripheral blood, B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| RPMI-7951 | HTB-66 | human | skin; malignant melanoma | epithelial | adherent |
| RR1022 | CCL-47 | rat | sarcoma | epithelial | adherent |
| RS4;11 | CRL-1873 | human | bone marrow; acute lymphoblastic leukemia; t(4;11) translocation | lymphoblast | suspension |
| RSC96 | CRL-2765 | rat | Schwann cell; immortalized spontaneously | neuronal | adherent |
| RSOI | CRL-1419 | human | skin; osteogenesis imperfecta | fibroblast | adherent |
| RT101 | CRL-2002 | mouse | skin (epidermis); chemically transformed | epithelial | adherent |
| RT4 | HTB-2 | human | urinary bladder; transitional cell papilloma | epithelial | adherent |
| RT4-D6P2T | CRL-2768 | rat | Schwann cell; schwannoma | neuronal | adherent |
| RTG-2 | CCL-55 | trout, rainbow | mixed testis and ovary | fibroblast | adherent |
| RTgill-W1 | CRL-2523 | trout, rainbow | gill | epithelial | adherent |
| RTG-P1 | CRL-2829 | rainbow trout | gonadal tissue | fibroblast | adherent |
| RTH-149 | CRL-1710 | trout, rainbow | liver; hepatoma | epithelial | adherent |
| Ru Ra | CRL-1315 | human | skin; osteogenesis imperfecta (congenita) | fibroblast | adherent |
| RW.4 | SCRC-1018 | mouse | embryo; embryonic stem cell | spherical colony | adherent |
| RWPE-1 | CRL-11609 [†] | human | prostate; transfected with Ki-MSV | epithelial | adherent |
| RWPE-2 | CRL-11610 [†] | human | prostate; transfected with HPV-18 and Ki-MSV | epithelial | adherent |
| RWPE2-W99 5194/5.XXO.BU.1 | CRL-2853 TIB-20 | human | prostate hybridoma fusion partner | epithelial lymphoblast | adherent suspension |
| 5194/5.XXO.BO.1 | TIB-20 | mouse mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| 51A(Thy-1 ⁻ b) | TIB-231 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| 51A.TB.4.8.2 | TIB-231 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| 51E4 | HB-8332 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 53D3 | HB-8331 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 649 (Thy-1-a) | TIB-36 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| 549.1 | TIB-28 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| 549.1G.3 | TIB-34 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| 649.1G.3 PHA.100/0 | TIB-35 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| 549.1H.1AG.6/2 | TIB-29 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| 549.1TB.2 | TIB-30 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| 349.1TB.4 DEX R.63 | TIB-33 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| 54B6-1 | HB-10968 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| 55 | HB-9255 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 56F1 | HB-9579 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 59 | CRL-2778 | human | bronchus; cystic fibrosis; immortalized with Ad12-SV40 hybrid | epithelial | adherent |
| 59.6 | HB-8730 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| SA13 | HB-8501 [†] | human/human | hybridoma | lymphoblast | suspension |
| SA22 | CRL-2052 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Sal | CRL-2543 | mouse | ascites; dibenzanthracene-induced malignant fibrosarcoma | lymphoblast | suspension |

* Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|----------------------------------|-----------------------|--------------------|--|--|-----------------------------|
| Sal Mat | CRL-1110 | human | skin; Lesch-Nyhan syndrome | fibroblast | adherent |
| Sal/N | CRL-2544 | mouse | dibenzanthracene-induced fibrosarcoma | fibroblast | adherent |
| Saos-2 | HTB-85 | human | bone; osteosarcoma | epithelial | adherent |
| Sarcoma 180 | TIB-66 | mouse | sarcoma | • | suspension |
| Sar Nis | CRL-1231 | human | skin; pseudoachondroplasia (autosomal dominant) | fibroblast | adherent |
| SBAC | CRL-1796 | bovine | adrenal gland (cortex); zona fasciculata; zona reticularis | fibroblast | adherent |
| SC | CRL-9855† | human | peripheral blood; macrophage; monocyte | monocyte/ macrophage | suspension |
| SC-1 | CRL-8756 [†] | human | peripheral blood, B lymphocyte; EBV transformed | lymphoblast | suspension |
| SC-1 | CRL-1404 | mouse | embryo | fibroblast | adherent |
| SC-1 | CRL-6450* | mouse | embryo | epithelial | adherent |
| SC-71 | HB-277 | mouse/mouse | hybridoma | | suspension |
| SCA-9 clone 15 | CRL-1734 | mouse | submandibular salivary gland; carcinoma | | adherent |
| SCaBER | HTB-3 | human | urinary bladder; transitional cell carcinoma | | adherent |
| SCC-15 | CRL-1623 | human | tongue; squamous cell carcinoma | epititeilai | adherent |
| SCC-15 | CRL-1628 | human | tongue; squamous cell carcinoma | | adherent |
| SCC-25 SCC-4 | CRL-1628 CRL-1624 | | tongue; squamous cell carcinoma tongue; squamous cell carcinoma | | |
|)CC-4 | CRL-1024 | human | tongue; squamous cen carcinoma | fibroblast fibroblast epithelial fibroblast fibroblast monocyte/ macrophage lymphoblast fibroblast | adherent on |
| 266.0 | CDL 1522 | 1 | | | feeder cells |
| SCC-9 | CRL-1629 | human | tongue; squamous cell carcinoma | | adherent on feeder cells |
| SCC-PSA1 | CRL-1535 | mouse | embryonic carcinoma; teratocarcinoma; | | adherent on |
| | | | pluripotent | | feeder cells |
| Schneider's Drosophila Line 2 | CRL-1963 | Drosophila | embryo | epithelial | mixed |
| SCP | CRL-1700 | sheep | brain (choroid plexus) | | adherent |
| SE-1.3 | HB-137 | mouse/mouse | hybridoma | lymphoblast | suspension |
| f 1 Ep (NBL-11) | CCL-68 | rabbit, cottontail | skin; epidermis | epithelial | adherent |
| F1-1.1.10 | HB-159 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Sf1Ep | CRL-6502* | rabbit, cottontail | skin (ear) | mixed | adherent |
| Sf9 | CRL-1711 | armyworm, fall | ovary | epithelial | adherent |
| SFR3-DR5 | HB-151 | rat/mouse | hybridoma | | suspension |
| SFR8-B6 | HB-152 | rat/mouse | hybridoma | | suspension |
| 5H2 | HB-10743 [†] | mouse/mouse | hybridoma | , , | suspension |
| 5H3 | HB-10744 [†] | mouse/mouse | hybridoma | | suspension |
| 5H-34 | CRL-2405 | mouse/mouse | hybridoma | | suspension |
| 5H4 | HB-10745 [†] | mouse/mouse | hybridoma | | |
| 5H-4 | CRL-7724* | human | pleural effusion (metastasis); melanoma (skin | | suspension adherent |
| 7 7 | CNL-//24 | naman | primary) | Gansionneu | aunerent |
| Shh Light II | CRL-2795 | mouse | embryo | fibroblast | adherent |
| SHM-D33 | CRL-1668 | human/mouse | hybridoma fusion partner | | suspension |
| SHP-77 | CRL-2195 | human | lung; carcinoma; small cell lung cancer; large cell variant | | mixed |
| SH-SY5Y | CRL-2266 | human | bone marrow (metastasis); neuroblastoma (brain primary) | epithelial | adherent |
| SiHa | HTB-35 | human | cervix; squamous cell carcinoma | epithelial | adherent |
| SIRC (Statens Se- | CCL-60 | rabbit | eye (cornea) | <u> </u> | adherent |
| ruminstitut Rabbit Cornea) | 222 33 | .30010 | c) = (correct) | | adirectit |
| SJD.1 | CRL-2296 | zebrafish | caudal fin | fibroblast | adherent |
| SJK-132-20 | CRL-2296 CRL-1640 | | hybridoma | | |
| | CRL-1640 CRL-1645 | mouse/mouse | | , , | suspension |
| SJK-237-71 | | mouse/mouse | hybridoma | | suspension |
| SJK-287-38 | CRL-1644 | mouse/mouse | hybridoma | iymphoblast | suspension |
| SJL/JB | CRL-6452* | mouse | spleen | | |
| SJL/JC | CRL-6453* | mouse | spleen | | |
| SJRH30 | CRL-2061 | human | bone marrow (metastasis); rhabdomyosarcoma | fibroblast | adherent |
| | | | (muscle primary) | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------------|-------------------------|------------------------------|---|-------------|------------------------|
| SK-BR-3 | HTB-30 | human | pleural effusion (metastasis); adenocarcinoma (colon primary) | epithelial | adherent |
| SK-CO-1 | HTB-39 | human | ascites (metastasis); colorectal adenocarcinoma (colon primary) | epithelial | adherent |
| SK-ES-1 | HTB-86 | human | bone; sarcoma (anaplastic osteosarcoma or Ewing's sarcoma) | epithelial | adherent |
| SK-HEP-1 | HTB-52 | human | ascites (metastasis); adenocarcinoma (liver primary) | epithelial | adherent |
| SK-LMS-1 | HTB-88 | human | vulva; leiomyosarcoma | fibroblast | adherent |
| SK-LU-1 | HTB-57 | human | lung; adenocarcinoma | epithelial | adherent |
| SK-MEL-1 | HTB-67 | human | thoracic duct (metastasis); malignant melanoma (skin primary) | spherical | suspension |
| SK-MEL-2 | HTB-68 | human | skin (metastasis); malignant melanoma (skin primary) | polygonal | adherent |
| SK-MEL-24 | HTB-71 | human | skin; malignant melanoma | stellate | adherent |
| SK-MEL-28 | HTB-72 | human | skin; malignant melanoma | polygonal | adherent |
| SK-MEL-3 | HTB-69 | human | lymph node (metastasis); malignant melanoma (skin primary) | fibroblast | adherent |
| SK-MEL-31 | HTB-73 | human | skin; malignant melanoma | epithelial | adherent |
| SK-MEL-5 | HTB-70 | human | skin; malignant melanoma | stellate | adherent |
| SK-MES-1 | HTB-58 | human | pleural effusion (metastasis); squamous cell carcinoma (lung primary) | epithelial | adherent |
| SK-N-AS | CRL-2137 | human | bone marrow (metastasis); embryonal neuro- blastoma (brain/neuroblast primary) | epithelial | adherent |
| SK-N-BE(2) | CRL-2271 | human | bone marrow (metastasis); neuroblastoma brain primary) | neuroblast | adherent |
| SK-N-DZ | CRL-2149 | human | bone marrow (metastasis); embryonal neuro- blastoma (brain/neuroblast primary) | epithelial | adherent |
| SK-NEP-1 | HTB-48 | human | pleural effusion (metastasis); Wilms' tumor (kidney primary) | epithelial | suspension |
| SK-N-FI | CRL-2142 | human | bone marrow (metastasis); embryonal neuro- blastoma (brain/neuroblast primary) | epithelial | adherent |
| SK-N-MC | HTB-10 | human | supraorbital area (metastasis); neuroepithelioma (brain primary) | epithelial | adherent |
| SK-N-SH | HTB-11 | human | bone marrow (metastasis); neuroblastoma (brain primary) | epithelial | adherent |
| SKO-007 | CRL-8033-1 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| KO-007 [clone J3] | CRL-8033-2 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| SK-OV-3 | HTB-77 | human | ascites (metastasis); adenocarcinoma (ovary primary) | epithelial | adherent |
| SK-PN-DW | CRL-2139 | human | embryonal tumor; retroperitoneal; malignant; primitive neuroectodermal tumor | epithelial | adherent |
| SK-UT-1 | HTB-114 | human | uterus; mesodermal tumor (mixed); consistent with leiomyosarcoma | epithelial | adherent |
| SK-UT-1B | HTB-115 | human | uterus (endometrium); mesodermal tumor (mixed); consistent with leiomyosarcoma | epithelial | adherent |
| SKW 6.4 | TIB-215 | human | peripheral blood, B lymphocyte; EBV transformed | lymphoblast | suspension |
| 51/S14 | CRL-2452 | mouse | liver, stroma, fetal; Steel factor deficient; SV40 large T immortalized | fibroblast | adherent |
| SI/SI4 hSCF220 | CRL-2453 | mouse | liver, stroma, fetal; SV40 large T immortalized | fibroblast | adherent |
| SI/SI4 hSCF248 | CRL-2454 | mouse | liver, stroma, fetal | fibroblast | adherent |
| SL-29 | CRL-1590 | chicken | embryo | fibroblast | adherent |
| SM27-1045 | HB-11917 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| SML, clone 4D8 | CRL-2311 | monkey, Bolivian squirrel | peripheral blood, B lymphoblast; EBV transformed | lymphoblast | clusters in suspension |
| SMT/2A LNM | CRL-6602* | rat | mammary gland; adenocarcinoma | | adherent |
| SNU-1 | CRL-5971 | human | stomach; gastric carcinoma | epithelial | clusters in suspension |
| SNU-16 | CRL-5974 | human | ascites (metastasis); gastric carcinoma (stomach primary) | epithelial | clusters in suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------------|------------------------|----------------|--|------------|--------------------|
| SNU-182 | CRL-2235 | human | liver; hepatocellular carcinoma | epithelial | adherent |
| SNU-387 | CRL-2237 | human | liver; pleomorphic hepatocellular carcinoma | epithelial | adherent |
| SNU-398 | CRL-2233 | human | liver; hepatocellular carcinoma | epithelial | mixed |
| SNU-423 | CRL-2238 | human | liver; pleomorphic hepatocellular carcinoma | epithelial | adherent |
| SNU-449 | CRL-2234 | human | liver; hepatocellular carcinoma | epithelial | adherent |
| SNU-475 | CRL-2236 | human | liver; hepatocellular carcinoma | epithelial | adherent |
| SNU-5 | CRL-5973 | human | ascites (metastasis); gastric carcinoma (stomach | epithelial | clusters in |
| | | | primary) | | suspension |
| SNU-C1 | CRL-5972 | human | peritoneum (metastasis); adenocarcinoma | epithelial | mixed |
| | | | colon primary) | | |
| SNU-C2A | CCL-250.1 | human | cecum; colorectal carcinoma | epithelial | mixed |
| SNU-C2B | CCL-250 | human | cecum; colorectal carcinoma | epithelial | mixed |
| SOB-15 | CRL-2301 | trout, rainbow | liver | epithelial | adherent |
| SODK1 [SODK1293] | CRL-12386 [†] | human | kidney; transformed with adenovirus 5 DNA; | epithelial | adherent |
| | | | packaging cell line | | |
| Sol8 | CRL-2174 | mouse | skeletal muscle | fibroblast | adherent |

ATCC Cell Biology Trivia #12

Who made the discovery that a virus could cause cancer?

The discovery that a virus could cause cancer was made by Peyton Rous in 1910, who induced tumor growth in chickens by injecting them with a cellfree tumor extract. The Rous sarcoma virus was later found to be an RNA retrovirus.

| Sp2/01-Ag | CRL-8006 [†] | mouse | hybridoma fusion partner | lymphoblast | suspension |
|------------------|-----------------------|-----------------------------|---|--------------------|------------|
| Sp2/0-Ag14 | CRL-1581 | mouse/mouse | hybridoma fusion partner | lymphoblast | suspension |
| Sp2/0-Ag14 | CRL-8287 [†] | mouse/mouse | hybridoma fusion partner | lymphoblast | suspension |
| Sp2/mIL-6 | CRL-2016 | mouse/mouse | hybridoma fusion partner | lymphoblast | suspension |
| SQMK-FP | CRL-2762 | Bolivian squirrel monkey | kidney, tubule | epithelial | adherent |
| SR | CRL-2262 | human | pleural effusion (metastasis); large cell immuno- blastic lymphoma (unknown primary) | lymphoblast | suspension |
| SR-4987 | CRL-2028 | mouse | bone marrow, stroma | fibroblast | adherent |
| Src++ | CRL-2497 | mouse | embryo; immortalized with SV40 large T antigen; deficient for Yes and Fyn | fibroblast | adherent |
| S-S.1 | TIB-111 | mouse/mouse | hybridoma | lymphoblast | suspension |
| S-S.3 | TIB-112 | mouse/mouse | hybridoma | lymphoblast | suspension |
| ST | CRL-1746 | pig | testis | fibroblast | adherent |
| ST486 | CRL-1647 | human | ascites, B lymphoblast; Burkitt's lymphoma | lymphoblast | suspension |
| STK 1 | CRL-1652 | mouse/mouse | hybridoma | lymphoblast | suspension |
| STO | CRL-1503 | mouse | embryo | fibroblast | adherent |
| SU.86.86 | CRL-1837 | human | liver (metastasis); ductal carcinoma (pancreas primary) | epithelial | adherent |
| SUP-B15 | CRL-1929 | human | B lymphoblast; acute lymphoblastic leukemia | lymphoblast | suspension |
| Super Dome | CRL-2286 | dog | kidney | epithelial | adherent |
| Super Tube | CRL-2285 | dog | kidney | epithelial | adherent |
| SUP-T1 | CRL-1942 | human | T lymphoblast; lymphoblastic leukemia | lymphoblast | suspension |
| SV40 MES 13 | CRL-1927 | mouse (transgenic) | kidney (glomerulus) | myofibroblast-like | adherent |
| SV40LT-SMC Clone | CRL-2018 | rat | aorta; smooth muscle | fibroblast | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--------------|------------------------|----------------|--|-----------------------------|------------------------------|
| HEP-SA | | | | | |
| SV63 | HB-8766 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| SV7tert | CRL-2461 | human | kidney; angiomyolipoma; immortalized with SV40 large T antigen and human telomerase | epithelial | adherent |
| SVEC4-10 | CRL-2181 | mouse | axillary lymph node, vascular epithelium; endothelial; SV40 transformed | epithelial | adherent |
| SVEC4-10EE2 | CRL-2167 | mouse | axillary lymph node, vascular epithelium; endothelial; SV40 transformed | cobblestone; endothelial | adherent |
| SVEC4-10EHR1 | CRL-2161 | mouse | axillary lymph node, vascular epithelium; SV40 transformed | spindle cell; epithelial | adherent |
| SVG p12 | CRL-8621 [†] | human | brain, astroglia; SV40 transformed | fibroblast | adherent |
| SV-HUC-1 | CRL-9520 [†] | human | ureter (uroepithelium) | epithelial | adherent |
| SVR | CRL-2280 | mouse | pancreas (islet of Langerhans), endothelium | · | adherent |
| SVR A221a | CRL-2386 | mouse | pancreas (islet of Langerhans), endothelium | | adherent |
| SVR bag4 | CRL-2387 | mouse | pancreas (islet of Langerhans), endothelium | | adherent |
| SV-T2 | CCL-163.1 | mouse | embryo | fibroblast | adherent |
| SW 1088 | HTB-12 | human | brain; astrocytoma | fibroblast | adherent |
| SW 1271 | CRL-2177 | human | lung; carcinoma; small cell lung cancer | epithelial | adherent |
| SW 1353 | HTB-94 | human | bone; chondrosarcoma | fibroblast | adherent |
| SW 156 | CRL-2175 | human | kidney; hypernephroma | epithelial | adherent |
| SW 1573 | CRL-2170 | human | lung; alveolar cell carcinoma | epithelial | adherent |
| SW 1783 | HTB-13 | human | brain; astrocytoma | fibroblast | adherent |
| SW 1990 | CRL-2172 | human | spleen (metastasis); adenocarcinoma (pancreas primary) | epithelial | adherent |
| SW 626 | HTB-78 | human | ovary (metastasis); adenocarcinoma (colon primary) | epithelial | adherent |
| SW 684 | HTB-91 | human | connective tissue; fibrosarcoma | fibroblast | adherent |
| SW 780 | CRL-2169 | human | urinary bladder; transitional cell carcinoma | epithelial | adherent |
| SW 872 | HTB-92 | human | connective tissue; liposarcoma | fibroblast | adherent |
| SW 900 | HTB-59 | human | lung; squamous cell carcinoma | epithelial | adherent |
| SW 954 | HTB-117 | human | vulva; squamous cell carcinoma | epithelial | adherent |
| SW 962 | HTB-118 | human | lymph node (metastasis); carcinoma (vulva primary) | mixed | adherent |
| SW 982 | HTB-93 | human | synovium; synovial sarcoma | mixed | adherent |
| SW10 | CRL-2766 | mouse | Schwann cell; immortalized with SV40 large T antigen | neuronal | adherent |
| SW1116 | CCL-233 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| 5W-13 | CCL-105 | human | adrenal gland (cortex); primary small cell carcinoma | epithelial | adherent |
| SW1417 | CCL-238 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| SW1463 | CCL-234 | human | rectum; colorectal adenocarcinoma | epithelial | adherent |
| SW403 | CCL-230 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| 5W48 | CCL-231 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| 5W480 | CCL-228 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| SW527 | CRL-7940* | human | mammary gland; Paget's disease | epithelial | adherent |
| SW579 | HTB-107 | human | thyroid; squamous cell carcinoma | epithelial | adherent |
| W620 | CCL-227 | human | lymph node (metastasis); colorectal adenocarcinoma (colon primary) | epithelial | adherent |
| SW756 | CRL-10302 [†] | human | cervix; squamous cell carcinoma | epithelial | adherent |
| SW837 | CCL-235 | human | rectum; adenocarcinoma | epithelial | adherent |
| SW948 | CCL-237 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| Swiss SFME | CRL-9391 [†] | mouse | embryo | fibroblast | clusters in suspensi |
| SWLA1 | HB-12559† | mouse/mouse | hybridoma | lymphoblast | suspension |
| SWLA1 | HB-12560 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| SWLA2 | HB-12558 [†] | mouse/mouse | hybridoma | lymphoblast | mixed suspension |
| SWR/J.We | | | • | туппрповіазі | mixed suspension |
| SYF | CRL-6458* CRL-2459 | mouse mouse | embryo embryo; immortalized with SV40 large T antigen; | fibroblast | adherent |
| SYF + c-Src | CRL-2498 | mouse | deficient for Src, Yes, and Fyn embryo; immortalized with SV40 large T antigen; | fibroblast | adherent |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--------------------------|------------------------|------------------|--|------------------------------|--------------------------|
| | | | deficient for Src, Yes, and Fyn | | |
| T/G HA-VSMC | CRL-1999 | human | aorta, smooth muscle | fibroblast | adherent |
| T1 (174 x CEM.T1) | CRL-1991 | human/human | lymphoblast cell hybrid | lymphoblast | suspension |
| T11D7e2 | TIB-103 | mouse/mouse | hybridoma | lymphoblast | suspension |
| T1-73 | CRL-7943* | human | bone; osteosarcoma | fibroblast | adherent |
| T2 (174 x CEM.T2) | CRL-1992 | human/human | lymphoblast cell hybrid | lymphoblast | suspension |
| T24 | HTB-4 | human | urinary bladder; transitional cell carcinoma | epithelial | adherent |
| Г27А | TIB-57 | mouse | spleen; leukemia | lymphoblast | suspension |
| Г3-3А1 | HB-2 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Γ³6274 | CRL-2012 | mouse | skin (epidermis); chemically transformed | epithelial | adherent |
| T4 Clone 5 | HB-8500 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| 10-0101,0062-83) | | | | | |
| Γ-47D | HTB-133 | human | pleural effusion (metastasis); ductal carcinoma (mammary gland primary) | epithelial | adherent |
| Γ529-15D3-18- 1A3-1B7 | HB-10500 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Γ529-15D3-2E5- 4G12-1 | HB-10501 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| T84 | CCL-248 | human | lung (metastasis); colorectal carcinoma (colon primary) | epithelial | adherent |
| Γ84.66A3.1A.1F2 | HB-8747 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| T98G | CRL-1690 | human | brain; glioblastoma multiforme | fibroblast | adherent |
| TA 99 | HB-8704 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| TAC-1 | CRL-10632 [†] | marmoset | colon; adenocarcinoma | fibroblast and epithelial | mixed |
| Tal Jo | CRL-1267 | human | skin; osteogenesis imperfecta (congenita) | fibroblast | adherent |
| TA-1 | HB-10206 | mouse/mouse | hybridoma | lymphoblast | suspension |
| T-AL/N | CRL-6514* | mouse | unknown | туптрпоотазс | заэрсплоп |
| TALL-104 | CRL-11386 [†] | human | T lymphoblast; acute lymphoblastic leukemia | lymphoblast | suspension |
| TAM.T | CRL-6001* | anteater | skin | polygonal | adherent |
| tao BpRcl | CRL-2218 | mouse | liver; hepatoma | epithelial | adherent |
| Tb 1 Lu | CCL-88 | bat, free-tailed | lung | epithelial | adherent |
| TB 28-2 | HB-61 | mouse/mouse | hybridoma | lymphoblast | suspension with |
| Tb1.Lu | CRL-6564* | bat, free-tailed | lung | epithelial | feeder cells adherent |
| | | <u> </u> | lung | | |
| TBM-54 | CRL-2051 | toad, tropical | urinary bladder | epithelial | adherent |
| TC-1 TCCSUP | CRL-2785 | mouse | lung; HPV-16 E6/E7 and c-Ha-ras cotransformed | epithelial | adherent |
| | HTB-5 | human | urinary bladder; transitional cell carcinoma | epithelial | adherent |
| TCMK-1 | CCL-139 | mouse | kidney | epithelial | adherent |
| TD.1 | CRL-2232 | mouse/mouse | hybridoma | lymphoblast | suspension |
| TE 115.T | CRL-7744* | human | mixed connective and soft tissue; fibromatosis | fibroblast | adherent |
| TE 125.T | CRL-7945* | human | rhabdomyosarcoma | fibroblast | adherent |
| TE 130.T | CRL-7746* | human | bone; sacrococcygeal teratoma | | adherent |
| ΓΕ 149.T | CRL-7751* | human | muscle; leiomyosarcoma | | |
| ΓΕ 159.T | CRL-7752* | human | unknown; rhabdomyosarcoma | fibroblast | adherent |
| TE 161.T | CRL-7753* | human | lymph node; possible Burkitt's lymphoma | fibroblast | adherent |
| TE 170.M | CRL-7754* | human | connective tissue; fascia | CI | |
| ΓΕ 175.T | CRL-7755* | human | lymph node; lymphosarcoma | fibroblast | adherent |
| TE 199.T | CRL-7757* | human | thymus; thymic alymphoplasia | | |
| ΓΕ 206.T | CRL-7758* | human | unknown; adenocarcinoma | | |
| ΓΕ 353.Sk | CRL-7761* | human | skin | fibroblast | adherent |
| ΓΕ 354.T | CRL-7762* | human | skin; basal cell carcinoma | | |
| ΓΕ 381.T | CRL-7763* | human | mixed connective and soft tissue; rhabdomyosa | fibroblast | adherent |
| ΓΕ 417.T | CRL-7765* | human | bone; osteosarcoma | fibroblast | adherent |
| ΓΕ 418.T | CRL-7766* | human | bone; osteosarcoma | fibroblast | adherent |
| TE 441.T | CRL-7767* | human | connective tissue; rhabdomyosarcoma | mixed | adherent |
| TE 617.T | CRL-7774* | human | connective tissue; rhabdomyosarcoma | epithelial | adherent |
| TE 76.T | CRL-7732* | human | bone; sacrococcygeal teratoma | - | |
| TE 84.T | CRL-7944* | human | ovary; teratoma | | adherent |
| TE 90.Sk | CRL-7739* | human | skin | fibroblast | adherent |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------|----------------------|-------------|---|-------------|-------------|
| TE 91.Sk | CRL-7740* | human | skin | fibroblast | adherent |
| TE 98.T | CRL-7741* | human | unknown; histiocytosis | | |
| TE15 | HB-206 | mouse/mouse | hybridoma | lymphoblast | suspension |
| TE16 | HB-210 | mouse/mouse | hybridoma | lymphoblast | suspension |
| TE19 | HB-211 | mouse/mouse | hybridoma | lymphoblast | suspension |
| TE3 | HB-209 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Te39 | HB-8577 [†] | human/mouse | hybridoma | lymphoblast | suspension |
| TE4 | HB-207 | mouse/mouse | hybridoma | lymphoblast | suspension |
| TE7 | HB-208 | mouse/mouse | hybridoma | lymphoblast | suspension |
| TE8 | HB-212 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Тер Ве | CRL-1336 | human | skin; Cockayne syndrome | fibroblast | adherent |
| Tera-1 | HTB-105 | human | embryonal malignant carcinoma | epithelial | adherent |
| Tera-2 | HTB-106 | human | embryonal malignant carcinoma | epithelial | adherent |
| TF-1 | CRL-2003 | human | bone marrow, erythroblast; model for cytokine | lymphoblast | suspension |
| | | | (IL-3) signaling pathways and myeloid progenitor cell differentiation | | |
| TF-1.CN5a.1 | CRL-2512 | human | bone marrow; erythroblast; erythroleukemia; CTNF responsive | lymphoblast | suspension |

ATCC Cell Biology Trivia #13 When did ATCC move to Manassas, Virginia?

ATCC moved from Rockville, Maryland, to its current facility in 1998. Transporting the liquid nitrogen units filled with vials was planned down to the smallest detail, except that the keys to open the trailers could not be located. Upon arriving in Manassas, the locks had to be removed with bolt cutters.

| TF-1a | CRL-2451 | human | bone marrow, erythroblast; control cell line for TF-1 | lymphoblast | suspension |
|------------------|------------------------|------------------------|---|-------------|--------------|
| TFTA1 | CRL-1771 | mouse/mouse | hybridoma | lymphoblast | suspension |
| TFTB1 | CRL-1759 | mouse/mouse | hybridoma | lymphoblast | suspension |
| TGP47 | CRL-2141 | mouse (transgenic) | pancreas; acinar cell carcinoma | epithelial | adherent |
| TGP49 | CRL-2136 | mouse (transgenic) | pancreas; acinar cell carcinoma | epithelial | adherent |
| TGP52 | CRL-2140 | mouse (transgenic) | pancreas; islet cell tumor; insulinoma | epithelial | adherent |
| TGP55 | CRL-2150 | mouse (transgenic) | pancreas; small cell tumor | epithelial | adherent |
| TGP61 | CRL-2135 | mouse (transgenic) | pancreas; islet cell tumor; insulinoma | epithelial | adherent |
| TH-1, Subline B1 | CCL-50 | turtle, box | heart | epithelial | adherent |
| THB-5 | HB-135 | mouse/mouse | hybridoma | lymphoblast | suspension |
| THB-7 | HB-136 | mouse/mouse | hybridoma | lymphoblast | suspension |
| THLE-2 | CRL-2706 [†] | human | liver, left lobe; SV40 transformed | epithelial | adherent |
| THLE-3 | CRL-11233 [†] | human | liver, left lobe; immortalized with SV40 T antigen | epithelial | adherent |
| THP-1 | TIB-202 | human | monocyte; acute monocytic leukemia | monocyte | suspension |
| TIMI.4 | TIB-37 | mouse | thymus; lymphoma | lymphoblast | suspension |
| TIMI.4G.1.3 | TIB-38 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| tk- ts13 | CRL-1632 | hamster, Syrian golden | kidney | | adherent |
| TK#1 | CRL-11383 [†] | mouse | embryonic stem cell; disrupted IRF-2 gene | epithelial | adherent on |
| | | | | | feeder cells |
| TK-1 | CRL-2396 | mouse | T lymphocyte; lymphoma | lymphoblast | suspension |
| TK6 | CRL-8015 | human | spleen; hereditary spherocytosis | lymphoblast | suspension |
| TM1 | HB-169 | mouse/mouse | hybridoma | lymphoblast | suspension |
| | | | | | |

* Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

Vesearch use only Not intended for use in humans animals or for diagnostics.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|---|------------------------|----------------------------|--|----------------|--|
| TM-28 | CRL-2803 | mouse | fibrosarcoma | fibroblast | adherent |
| ГМ3 | CRL-1714 | mouse | testis | epithelial | adherent |
| ΓM-34 | CRL-2801 | mouse | fibrosarcoma | fibroblast | adherent |
| M4 | CRL-1715 | mouse | testis | epithelial | adherent |
| M-7 | CRL-2798 | mouse | fibrosarcoma | fibroblast | adherent |
| O 166.M | CRL-7776* | human | connective tissue | fibroblast | adherent |
| O 175.T | CRL-7779* | human | skin (metastasis); lymphoma; Hodgkin's disease (lymph node primary) | | adherent |
| O 203.T | CRL-7780* | human | bone; osteosarcoma | | adherent |
| oledo | CRL-2631 | human | peripheral blood, B lymphocyte; diffuse large cell lymphoma, non-Hodgkin's | lymphoblast | suspension |
| OV-112D | CRL-11731 [†] | human | ovary; primary malignant adenocarcinoma; endometrioid carcinoma | epithelial | adherent |
| TOV-21G | CRL-11730 [†] | human | ovary; primary malignant adenocarcinoma; clear cell carcinoma | epithelial | adherent |
| R 310 | HB-219 | rat/mouse | hybridoma | lymphoblast | suspension |
| RA-171 | CRL-1591 | mosquito | whole larva | fibroblast | adherent |
| RAMP-C1 | CRL-1391 CRL-2730 | mouse (transgenic) | prostate; adenocarcinoma | epithelial | adherent |
| RAMP-C2 | CRL-2731 | mouse (transgenic) | prostate; adenocarcinoma | epithelial | adherent |
| RAMP-C3 | CRL-2731 | mouse (transgenic) | prostate; adenocarciona prostate (metastasis); adenocarcinoma (prostate primary) | epithelial | adherent |
| ΓS 106 | HB-12497 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| S1/18.1.2.11 | HB-203 | mouse/mouse | hybridoma | lymphoblast | suspension |
| S1/22.1.1.13 | HB-202 | mouse/mouse | hybridoma | lymphoblast | suspension |
| S2/16.2.1 | HB-243 | mouse/mouse | hybridoma | lymphoblast | suspension |
| S2/18.1.1 | HB-195 | | hybridoma | lymphoblast | suspension |
| S2/4.1.1 | HB-244 | mouse/mouse mouse/mouse | hybridoma | lymphoblast | • |
| S2/7.1.1 | HB-245 | | hybridoma | lymphoblast | suspension suspension |
| S2/7.1.1 S2/9.1.4.3 | HB-205 | mouse/mouse | hybridoma | lymphoblast | |
| | | mouse/mouse | | lymphobiast | suspension |
| sc2 ang1 | CRL-2620 | mouse | sarcoma; cutaneous; heterozygous for tuberin; tuberous sclerosis model | | adherent |
| SHR-R5T-34 | CRL-2683 | mouse/mouse | hybridoma | lymphoblast | suspension |
| SHR-R5T-44 | CRL-2681 | mouse/mouse | hybridoma | lymphoblast | mixed |
| SHR-T3-365 | CRL-2684 | mouse/mouse | hybridoma | lymphoblast | suspension |
| SHR-T5-51 | CRL-2680 | mouse/mouse | hybridoma | lymphoblast | suspension |
| SHR-T5U-317 | CRL-2682 | mouse/mouse | hybridoma | lymphoblast | suspension |
| T | CRL-1803 | human | thyroid; medulla carcinoma | epithelial | adherent |
| u To | CRL-1298 | human | skin; osteogenesis imperfecta (severe congenita) | fibroblast | adherent |
| UR | CRL-2367 | human | macrophage; histiocytic lymphoma; neomycin resistant | monocyte | suspension |
| J-118 MG | HTB-15 | human | brain; glioblastoma; astrocytoma | mixed | adherent |
| J-138 MG | HTB-16 | human | brain; glioblastoma | polygonal | adherent |
| J-2 OS | HTB-96 | human | bone; osteosarcoma | epithelial | adherent |
| J266B1 | TIB-196 | human | B lymphoblast; plasmacytoma; myeloma | lymphoblast | suspension |
| I-87 MG | HTB-14 | human | brain; glioblastoma; astrocytoma | epithelial | adherent |
| J-937 | CRL-1593.2 | human | macrophage; histiocytic lymphoma | monocyte | suspension |
| JACC-812 | CRL-1897 | human | mammary gland; ductal carcinoma | epithelial | adherent |
| JACC-893 | CRL-1902 | human | mammary gland; primary ductal carcinoma | epithelial | adherent |
| JC10-4F10-11 | HB-304 | hamster/mouse | hybridoma | lymphoblast | suspension |
| JC1B | CRL-6465* | mouse | embryo | | adherent |
| JC1BC1 | CRL-6460* | mouse | embryo | epithelial | adherent |
| IC1BC2 | CRL-6461* | mouse | embryo | epithelial | adherent |
| JC1BC3 | CRL-6462* | mouse | embryo | epithelial | adherent |
| JC1BC4 | CRL-6463* | mouse | embryo | epithelial | adherent |
| JC1BC5 | CRL-6464* | mouse | embryo | epithelial | adherent |
| | CRL-1988 | hamster/mouse | hybridoma | lymphoblast | suspension |
| JC3-10A6 | | mouse/mouse | hybridoma | lymphoblast | suspension |
| JC3-10A6 JC7 | HR-9753 [†] | | HIVEHIOUHU | 17111011001031 | Juspension |
| JC7 | HB-9753 [†] | | • | | suspension |
| JC7 JC7-13D5 | CRL-1989 | hamster/mouse | hybridoma | lymphoblast | suspension |
| JC3-10A6 JC7 JC7-13D5 JC8-1B9 JCD/AB 6.01 | | | • | | suspension suspension suspension |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|------------------------|------------------------|--------------------------|---|---------------------|------------------------------|
| UCD/PR 10.11 | HB-8694 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| UMC-11 | CRL-5975 | human | lung; carcinoid | epithelial | adherent |
| JMNSAH/DF-1 | CRL-12203 [†] | chicken | embryo | fibroblast | adherent |
| JMR-106 | CRL-1661 | rat | bone; osteosarcoma | epithelial | adherent |
| JMR-108 | CRL-1663 | rat | bone; osteosarcoma | fibroblast | adherent |
| JM-UC-3 | CRL-1749 | human | urinary bladder; transitional cell carcinoma | epithelial | adherent |
| JSASK/DSIL- .HRH-A1 | HB-9094 [†] | mouse/mouse | hybridoma | lymphoblast | suspension with feeder cells |
| JV135 | CRL-1867 | hamster, Chinese | ovary; defective in nucleotide excision repair | fibroblast | mixed |
| JV20 | CRL-1862 | hamster, Chinese | ovary; defective in nucleotide excision repair | fibroblast | mixed |
| JV24 | CRL-1866 | hamster, Chinese | ovary; defective in nucleotide excision repair | fibroblast | mixed |
| JV41 | CRL-1860 | hamster, Chinese | ovary; defective in nucleotide excision repair | fibroblast | mixed |
| JV5 | CRL-1865 | hamster, Chinese | ovary; defective in nucleotide excision repair | fibroblast | mixed |
| JVE-10 | CRL-6515* | rat | unknown | Погоріазс | Пілси |
| /79-4 | CCL-93 | hamster, Chinese | lung | fibroblast | adherent |
| /A-ES-BJ | CRL-2138 | human | bone marrow (metastasis); carcinoma, | epithelial | adherent |
| | | | epithelioid (bone primary) | <u> </u> | |
| /D-10 | HB-68 | mouse/mouse | hybridoma | lymphoblast | suspension |
| /EPT | CRL-2087 | rabbit | kidney (proximal tubule) | epithelial | adherent |
| /ero | CCL-81 | monkey, African green | kidney | epithelial | adherent |
| /ERO 76 | CRL-1587 | monkey, African green | kidney | epithelial | adherent |
| /ERO C1008 | CRL-1586 | monkey, African green | kidney | epithelial | adherent |
| /H 2 | CCL-140 | viper, Russell's | heart | fibroblast | adherent |
| /III-6G10 | HB-10519 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| /K2/E6E7 | CRL-2616 | human | vagina, mucosa; HPV-16 E6/E7 transformed | epithelial | adherent |
| /LN3G2 | HB-8636 [†] | human/human | hybridoma | lymphoblast | suspension |
| /LN6H2 | HB-8633 [†] | human/human | hybridoma | lymphoblast | suspension |
| /M-2 | HB-8530 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| /SW | CCL-129 | viper, Russell's | spleen (metastatic); tumor (unknown primary) | epithelial | adherent |
| /T{2} | CRL-2712 | mouse | liver; hepatoma | epithelial | adherent |
| /X7 | CRL-6504* | rabbit | unknown; papilloma virus-induced carcinoma | fibroblast | adherent |
| V162 | CRL-2783 | African green monkey | kidney | epithelial | adherent |
| N-20-17 | CRL-2623 | mouse | bone marrow; stroma; assay system for hBMP-2 | fibroblast | adherent |
| V4F.5B | HB-9282 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| V6/32 | HB-95 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Va Fen | CRL-1271 | human | skin; Marfan syndrome | fibroblast | adherent |
| WAPS 12.2 | HB-299 | mouse/mouse | hybridoma | lymphoblast | suspension |
| NBC264-9C | HB-8902 [†] | human /mouse | macrophage; mouse/human hybrid | macrophage | adherent |
| WBE | CRL-2773 | white bass | embryo | epithelial | adherent |
| WCH-17 | CRL-2082 | woodchuck, Eastern | liver; hepatoma | epithelial | adherent |
| VEHI 164 | CRL-1751 | mouse | methylcholanthrene-induced fibrosarcoma | fibroblast | adherent |
| WEHI 22.1 | TIB-54 | mouse | thymus, T and B cell characteristics; lymphoma | lymphoblast | suspension |
| VEHI 7.1 | TIB-53 | mouse | thymus, T lymphocyte; lymphoma | lymphoblast | suspension |
| WEHI-13VAR | CRL-2148 | mouse | fibrosarcoma | fibroblast | adherent |
| WEHI-231 | CRL-1702 | mouse | B lymphocyte; lymphoma | lymphoblast | suspension |
| VEHI-265.1 | TIB-204 | mouse | monocyte; AMLV-induced tumor | | suspension |
| VEHI-274.1 | CRL-1679 | mouse | monocyte; AMLV-induced tumor | monocyte | suspension |
| VEHI-279 | CRL-1704 | mouse | B lymphocyte; lymphoma | lymphoblast | suspension |
| VEHI-3 | TIB-68 | mouse | myelomonocyte; macrophage like; leukemia | | mixed |
| VERI-Rb-1 | HTB-169 | human | eye (retina); retinoblastoma | grape-like clusters | suspension |
| VFL3C6.1 | HB-8157 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| VFL4F12.3 | HB-8156 [†] | rat/mouse | hybridoma | lymphoblast | suspension |
| Vgd5 | CRL-1817 | mouse | connective tissue; MoMuLV retroviral packaging line | fibroblast | adherent |
| WI 38 | CCL-75 | human | lung | fibroblast | adherent |
| WI-26 VA4 | CCL-95.1 | human | lung | epithelial | adherent |
| WI-38 VA-13 | CCL-75.1 | human | lung | epithelial | adherent |
| · · · | | | • | 6 2 2 2 | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|--------------|-----------------------|-------------|---|----------------|--------------------|
| WiDr | CCL-218 | human | colon; colorectal adenocarcinoma | epithelial | adherent |
| WI-L2-729HF2 | CRL-8062 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| WIL2-NS | CRL-8155 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| WIL2-S | CRL-8885 [†] | human | hybridoma fusion partner | lymphoblast | suspension |
| WI-MN-1 | HB-8672 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Win Mec | CRL-1172 | human | skin; xeroderma pigmentosum, presumed heterozygote | fibroblast | adherent |
| WISH | CCL-25 | human | HeLa contaminant | epithelial | adherent |
| WM 1043 | CRL-6466* | mouse | embryo | • | |
| WM-115 | CRL-1675 | human | skin; melanoma | epithelial | adherent |
| WM1552C | CRL-2808 | human | skin; primary superficial spreading melanoma in radial growth phase/vertical growth phase | spindle-shaped | adherent |
| WM-266-4 | CRL-1676 | human | skin (metastasis); melanoma (skin primary) | epithelial | adherent |
| WM278 | CRL-2809 | human | skin, melanocyte; nodular melanoma in vertical growth phase | epithelial | adherent |
| WM35 | CRL-2807 | human | skin, melanocyte; primary superficial spreading melanoma in radial growth phase/vertical growth phase | spindle-shaped | adherent |
| WM39 | CRL-2811 | human | skin, melanocyte; primary melanoma in vertical growth phase | spindle-shaped | adherent |
| WM793B | CRL-2806 | human | skin, melanocyte; primary superficial spreading melanoma in vertical growth phase | spindle-shaped | adherent |
| Wo Fel | CRL-1273 | human | skin; Ehlers-Danlos syndrome | fibroblast | adherent |
| Wo Jo | CRL-1247 | human | skin; osteogenesis imperfecta (tarda) | fibroblast | adherent |

ATCC Cell Biology Trivia #14

Who invented the process of making monoclonal antibodies?

Antibodies made to order became a reality after 1975, when César Milstein and Georges Köhler produced a monoclonal antibody from a hybridoma. At the time they were advised not to patent the process because its commercial potential was unclear. There are currently almost 1,000 hybridomas deposited at ATCC.

| WPE1-NA22 | CRL-2849 | human | prostate | epithelial | adherent |
|-----------|----------|--------------------|---|----------------|--------------|
| WPE1-NB11 | CRL-2851 | human | prostate | epithelial | adherent |
| WPE1-NB14 | CRL-2850 | human | prostate | epithelial | adherent |
| WPE1-NB26 | CRL-2852 | human | prostate | epithelial | adherent |
| WPMY-1 | CRL-2854 | human | prostate; adenovirus 12-SV40 hybrid transformed | spindle-shaped | adherent |
| WR19L | TIB-52 | mouse | lymphoma | lymphoblast | suspension |
| WR19M.1 | TIB-70 | mouse | monocyte; macrophage; AMLV-induced tumor | | adherent |
| WR21 | CRL-2189 | mouse (transgenic) | submandibular salivary gland; adenocarcinoma | fibroblast | adherent |
| WRL 68 | CL-48 | human | HeLa contaminant | epithelial | adherent |
| WS1 | CRL-1502 | human | skin | fibroblast | adherent |
| WSS-1 | CRL-2029 | human | kidney; expresses rat GABAA receptor | epithelial | adherent |
| WU E-14 | CRL-2255 | mouse/mouse | hybridoma | lymphoblast | suspension |
| WU E-4 | CRL-2247 | mouse/mouse | hybridoma | lymphoblast | suspension |
| X16C8.5 | TIB-209 | mouse | B lymphocyte; reticulum cell sarcoma | lymphoblast | suspension |
| X22 | CRL-2228 | mouse/mouse | hybridoma | lymphoblast | suspension |
| XB-2 | CL-177 | mouse | keratinocyte; teratoma | | adherent on |
| | | | | | feeder cells |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name | ATCC® No. | Species | Source/Application | Morphology | Growth Mode |
|-------------|------------------------|-------------------------------|--|---------------------------|-------------|
| XC | CCL-165 | rat | Rous sarcoma virus-induced tumor | epithelial | adherent |
| XC1.5/51 | TIB-16 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| XLK-WG | CRL-2527 | toad, South African clawed | kidney | epithelial | adherent |
| XMMCO-791 | HB-9173 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| XMMEN-OE5 | HB-9081 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| XMMME-001 | HB-8759 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| XMMME-002 | HB-8760 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| XP17BE | CRL-1360 | human | skin; xeroderma pigmentosum | fibroblast | adherent |
| xrs5 | CRL-2348 | hamster, Chinese | ovary; Ku autoantigen mutant | epithelial | adherent |
| XR-V15B | CRL-2349 | hamster, Chinese | lung | fibroblast | adherent |
| XS63 | TIB-17 | mouse | B lymphocyte; plasmacytoma; myeloma | lymphoblast | suspension |
| XVI E6E6G10 | HB-9496 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| Y-1 | CCL-79 | mouse | adrenal gland (cortex) | epithelial | adherent |
| Y13-238 | CRL-1741 | rat/rat | hybridoma | lymphoblast | suspension |
| Y13-259 | CRL-1742 | rat/rat | hybridoma | lymphoblast | suspension |
| Y-17 | HB-179 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Y-3 | HB-176 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Y3-Ag 1.2.3 | CRL-1631 | rat | hybridoma fusion partner | lymphoblast | suspension |
| Y-3P | HB-183 | mouse/mouse | hybridoma | lymphoblast | suspension |
| Y79 | HTB-18 | human | eye (retina); retinoblastoma | multicellular clusters | suspension |
| YAC-1 | TIB-160 | mouse | Mo-MuLV induced lymphoma | lymphoblast | suspension |
| YB2/0 | CRL-1662 | rat/rat | hybridoma fusion partner | lymphoblast | suspension |
| YI 328-18 | HB-9306 [†] | mouse/mouse | hybridoma | lymphoblast | suspension |
| YN1/1.7.4 | CRL-1878 | rat/rat | hybridoma | lymphoblast | suspension |
| YPEN-1 | CRL-2222 | rat | prostate, endothelium; immortalized with adenovirus 12-SV40 virus hybrid | epithelial | adherent |
| YS001 | CRL-11776 [†] | mouse | embryonic stem cell | epithelial | adherent |
| ZEM2S | CRL-2147 | zebrafish | embryo | fibroblast | adherent |
| ZF4 | CRL-2050 | zebrafish | embryo | fibroblast | adherent |
| ZFL | CRL-2643 | zebrafish | liver, parenchymal cells | epithelial | adherent |
| ZR-75-1 | CRL-1500 | human | ascites (metastasis); ductal carcinoma (mammary gland epithelium primary) | epithelial | adherent |
| ZR-75-30 | CRL-1504 | human | ascites (metastasis); ductal carcinoma (mammary gland epithelium primary) | epithelial | adherent |



This index consists of cell lines from noncancerous tissues listed by anatomical source. For more information on a cell line, see the main list starting on page 30 or use the catalogue number to find the entry in the cell biology section of the ATCC online catalog.

| Species | Cell Line Name | ATCC® No. | Description |
|---------------------------------|---------------------------|------------------------|--|
| Adrenal Gland | | | |
| bovine | SBAC | CRL-1796 | cortex; zona fasciculata, zona reticularis |
| bovine | EJG | CRL-8659 [†] | capillary endothelium |
| mouse | Y-1 | CCL-79 | cortex |
| Amniotic Fluid | | | |
| human | Hs 598.Af | CRL-7358 | |
| Aorta | | | |
| human | T/G HA-VSMC | CRL-1999 | smooth muscle |
| human | HAAE-1 | CRL-2472 | abdominal |
| human | HAAE-2 | CRL-2473 | abdominal |
| rat | A7r5 | CRL-1444 | thoracic; smooth muscle |
| rat | A-10 | CRL-1476 | thoracic; medial layer |
| rat | SV40LT-SMC Clone HEP-SA | CRL-2018 | smooth muscle |
| Artery See also Aorta | | | |
| bovine | CPAE | CCL-209 | pulmonary; vascular endothelium |
| bovine | CPA 47 | CRL-1733 | pulmonary; vascular endothelium |
| human | HFAE-2 | CRL-2474 | femoral |
| human | HIAE-78 | CRL-2475 | iliac |
| human | HIAE-101 | CRL-2478 | iliac |
| human | HPAE-26 | CRL-2598 | pulmonary |
| human | HIAE-38 | CRL-2599 | iliac |
| human | HIAE-65 | CRL-2606 | iliac |
| human | HIAE-55 | CRL-2608 | iliac |
| Bladder | | | |
| toad, tropical | TBM-54 | CRL-2051 | urinary bladder |
| Bone See also Bone Marro | | | , |
| human | hFOB 1.19 | CRL-11372 [†] | osteoblast; SV40 large T antigen transfected |
| human | Hs 820.T | CRL-7552 | heterophilic osteofication |
| human | Hs 855.T | CRL-7592* | mesenchyme; fibrous dysplasia |
| mouse | MC3T3-E1 Subclone 4 | CRL-2593 | calvaria |
| mouse | MC3T3-E1 Subclone 14 | CRL-2594 | calvaria |
| mouse | MC3T3-E1 Subclone 24 | CRL-2595 | calvaria |
| mouse | MC3T3-E1 Subclone 30 | CRL-2596 | calvaria |
| Bone Marrow | | | |
| bovine | BBm | CRL-6016* | |
| bovine | FB5.Bm | CRL-6043* | fetal |
| cat | FC6.Bm | CRL-6081* | |
| human | HS-5 | CRL-11882 [†] | stroma; HPV-16 E6/E7 transformed |
| human | TF-1 | CRL-2003 | erythroblast |
| human | TF-1a | CRL-2451 | erythroblast |
| human | HS-27A | CRL-2496 | stroma |
| mouse | 32D Clone 3 | CRL-11346 [†] | |
| mouse | MPRO Cell Line, Clone 2.1 | CRL-11422 [†] | neutrophil progenitor |
| mouse | EML Cell Line, Clone 1 | CRL-11691 [†] | lymphohematopoietic progenitor |
| mouse | JAWSII | CRL-11904 [†] | immature dendritic cell |
| mouse | FDC-P1 | CRL-12103 [†] | |
| mouse | D1 ORL UVA | CRL-12424 [†] | multipotent stromal precursor |
| mouse | 7F2 | CRL-12557 [†] | osteoblast |
| | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|------------------------------|---------------------------------------|------------------------|--|
| mouse | M2-10B4 | CRL-1972 | stroma |
| mouse | SR-4987 | CRL-2028 | stroma |
| mouse | LADMAC | CRL-2420 | Stroma |
| nouse | 23 ScCr | CRL-2751 | macrophage; deficient in toll-like receptor 4 (TLR4) |
| nouse | OP9 | CRL-2749 | stroma |
| nouse | 2E8 | TIB-239 | Stroma |
| sheep | OA4.Bm | CRL-6547* | fetal |
| • | OA4.DIII | CNE-0547 | ictai |
| Brain | | | |
| cat | PG-4 (S ⁺ L ⁻) | CRL-2032 | astrocyte; virus transformed |
| cat | G355-5 | CRL-2033 | astrocyte |
| crayfish | OLGA-PH-J/92 | CRL-2576 | cerebral ganglion |
| erret | Mpf | CRL-1656 | |
| numan | HCN-1A | CRL-10442 [†] | cortical neuron |
| numan | HCN-2 | CRL-10742 [†] | cortical neuron |
| numan | SVG p12 | CRL-8621 [†] | astroglia; SV40 transformed |
| nouse | EOC 2 | CRL-2467 | microglia/macrophage |
| nouse | EOC 13.31 | CRL-2468 | microglia/macrophage |
| nouse | EOC 20 | CRL-2469 | microglia/macrophage |
| nouse | C8-D30 | CRL-2534 | cerebellum |
| nouse | C8-S | CRL-2535 | cerebellum |
| nouse | C8-B4 | CRL-2540 | cerebellum |
| nouse | C8-D1A | CRL-2541 | cerebellum |
| nouse, transgenic | CATH.a | CRL-11179 [†] | neuron |
| at | DITNC, | CRL-2005 | diencephalon; transfected |
| at | CTX TNA2 | CRL-2006 | cortex: transfected |
| at | H19-7/IGF-IR | CRL-2526 | hippocampus |
| heep | SCP | CRL-1700 | choroid plexus |
| <u> </u> | OA1 | CRL-6538* | Citorola piexas |
| sheep | UAT | CRL-0536" | |
| Brain/Neural Tissue | | | |
| quail, Japanese | QNR/D | CRL-2532 | neuroretina |
| quail, Japanese | QNR/K2 | CRL-2533 | neuroretina |
| Breast See Mammary Gl | and | | |
| Cervix | | | |
| numan | Ect1/E6E7 | CRL-2614 | ectocervix; HPV-16 E6/E7 transformed |
| numan | End1/E6E7 | CRL-2615 | endocervix; HPV-16 E6/E7 transformed |
| Colon | | | |
| numan | CCD-18Co | CRL-1459 | |
| numan | CCD-33Co | CRL-1539 | |
| numan | CCD-112 CoN | CRL-1541 | |
| numan | CCD 841 CoN | CRL-1790 | fetal |
| numan | CCD 841 CoTr | CRL-1807 | fetal; SV40 transformed |
| numan | FHC | CRL-1831 | fetal |
| | 1110 | CIL 1031 | retui |
| Connective Tissue | | CDL =1=0 V | |
| numan | Hs 212.M | CRL-7173* | fascia |
| numan | Hs 364.Ct | CRL-7254* | fascia |
| numan | Hs 365.Ct | CRL-7255* | fascia |
| numan | Hs 762.Sk | CRL-7492* | |
| numan | Hs 764.Mu | CRL-7494* | |
| numan | Hs 782.T | CRL-7512* | benign histiocytic lesion |
| uman | TE 170.M | CRL-7754* | fascia |
| numan | TO 166.M | CRL-7776* | |
| numan | HT 768.M | CRL-7790* | abnormal |
| nouse | NCTC clone 929 | CCL-1 | subcutaneous; areolar and adipose |
| nouse | L-M | CCL-1.2 | subcutaneous; areolar and adipose |
| nouse | L-M(TK ⁻) | CCL-1.3 | subcutaneous; areolar and adipose |
| nouse | A9 | CCL-1.4 | subcutaneous; areolar and adipose |
| nouse | NCTC clone 2472 | CCL-11 | subcutaneous; areolar and adipose |
| nouse | NCTC clone 2555 | CCL-12 | subcutaneous; areolar and adipose |
| nouse | J26 | CRL-1802 | subcutaneous; areolar and adipose |
| House | 320 | CIL 1002 | Subcutaneous, areolai and adipose |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|-----------------------------|----------------------------------|------------------------|--|
| Connective Tissue | ontinued | | |
| mouse | J27-neo | CRL-2372 | subcutaneous; areolar and adipose |
| mouse | J27-B7 | CRL-2374 | subcutaneous; areolar and adipose |
| mouse | L Wnt-5A | CRL-2814 | subcutaneous; areolar and adipose |
| mouse | L-alpha-1a L-cells | CRL-11138 [†] | subcutaneous; areolar and adipose |
| mouse | L-alpha-2A L-cells | CRL-11180 [†] | subcutaneous; areolar and adipose |
| mouse | L-alpha-2C L-cells | CRL-11181 [†] | subcutaneous; areolar and adipose |
| mouse | L-NGC-alpha2B L-cells | CRL-10275 [†] | subcutaneous; areolar and adipose |
| mouse | A-9 | CRL-6319* | , , |
| rat | Rat1-R12 | CRL-2210 | |
| Dermis See Skin | | | |
| Embryo See also Fetu | ıc | | |
| bass, white | WBE | CRL-2773 | |
| cat | OSU1 | CRL-6178* | whole |
| cat | FC60(A).We | CRL-6571* | whole |
| | NCE-F161 | CRL-8727† | WHOLE |
| cat | | | |
| chicken chicken | UMNSAH/DF-1 SL-29 | CRL-12203 [†] | |
| | | CRL-1590 | |
| chicken | Gd1WE | CRL-6181* | |
| chicken | RFGd2WE | CRL-6182* | |
| chicken | RFGd3WE | CRL-6183* | |
| chicken | RFGd4WE | CRL-6184* | |
| chicken | RFGd5WE | CRL-6185* | |
| Drosophila | Schneider's Drosophila Line 2 | CRL-1963 | |
| duck, Pekin | Duck embryo | CCL-141 | |
| frog, grass | ICR 134 | CCL-128 | gynogenetic haploid |
| frog, grass | ICR-2A | CCL-145 | androgenetic haploid |
| mouse | BALB/3T3 clone A31 | CCL-163 | |
| mouse | SV-T2 | CCL-163.1 | |
| mouse | M-MSV-BALB/3T3 | CCL-163.2 | |
| mouse | K-BALB (K-234) | CCL-163.3 | |
| mouse | BALB/3T12-3 | CCL-164 | |
| mouse | C ₃ H/10T1/2, Clone 8 | CCL-226 | |
| mouse | NCTC 4093 | CCL-63 | |
| mouse | 3T3-Swiss albino | CCL-92 | |
| mouse | 3T6-Swiss albino | CCL-96 | |
| mouse | 3T3-L1 | CL-173 | |
| mouse | 36.5 (CD8+) | CRL-11116 [†] | stem cell; pluripotent |
| mouse | 9TR#1 | CRL-11379 [†] | stem cell |
| mouse | TK#1 | CRL-11383 [†] | stem cell |
| mouse | ES-D3 | CRL-11632 [†] | stem cell; pluripotent |
| mouse | SC-1 | CRL-1404 | |
| mouse | C3H/MCA clone 15 | CRL-1411 | |
| mouse | C3H/MCA clone 16 | CRL-1412 | |
| mouse | STO | CRL-1503 | |
| mouse | 3197-3 | CRL-1568 | |
| mouse | NIH/3T3 | CRL-1658 | |
| mouse | MOP-8 | CRL-1709 | |
| mouse | EJ-6-2-Bam-6a | CRL-1888 | |
| mouse | ES-D3 | CRL-1934 | stem cell; pluripotent |
| mouse | 56B3 | CRL-2542 | stem cell |
| mouse | 127TAg | CRL-2817 | immortalized with SV40 large T antigen |
| mouse | 151TAg | CRL-2823 | immortalized with SV40 large T antigen |
| mouse | 283TAg | CRL-2822 | immortalized with SV40 large T antigen |
| mouse | 3T3 MEFs KO | CRL-2753 | fibroblasts; Cav-1 (–/–) |
| mouse | 3T3 MEFs WT | CRL-2752 | fibroblasts; Cav-1 (+/+) |
| mouse | 308TAg | CRL-2819 | immortalized with SV40 large T antigen |
| mouse | 88TAg | CRL-2819 CRL-2820 | immortalized with SV40 large T antigen |
| | 92TAg | | immortalized with SV40 large T antigen |
| mouse | BALB SFME Serum Free | CRL-2816 | serum free |
| mouse | Mouse Embryo | CRL-9392 | serum nee |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|---------------------------|--|------------------------|--|
| mouse | MB352 | CRL-2821 | spontaneously immortalized |
| mouse | MB355 | CRL-2818 | immortalized with SV40 large T antigen |
| mouse | Shh Light II | CRL-2795 | GLI-responsive firefly luciferase reporter element |
| mouse | B/C3T3.We | CRL-6327* | der responsive meny identities reporter element |
| mouse | B/CWE | CRL-6334* | |
| mouse | C57L/J.We | CRL-6336* | |
| mouse | hr/hr (WE) A | CRL-6357* | |
| mouse | hr/hr (WE) B | CRL-6358* | |
| mouse | K:Molv NIH/3T3 | CRL-6361* | |
| mouse | ME | CRL-6371* | |
| mouse | MM4.We | CRL-6377* | pooled |
| mouse | MM22.We | CRL-6400* | p. C. C. C. |
| mouse | MM23.We | CRL-6401* | |
| mouse | MM27.We | CRL-6402* | |
| mouse | MM29.We | CRL-6403* | |
| mouse | MM31.We | CRL-6405* | |
| mouse | MM34.We | CRL-6408* | |
| mouse | MM36We | CRL-6413* | |
| mouse | MM41We | CRL-6416* | |
| mouse | SC-1 | CRL-6450* | |
| mouse | SWR/J.We | CRL-6458* | |
| mouse | UC1BC1 | CRL-6460* | |
| mouse | UC1BC2 | CRL-6461* | |
| mouse | UC1BC3 | CRL-6462* | |
| mouse | UC1BC4 | CRL-6463* | |
| mouse | UC1BC5 | CRL-6464* | |
| mouse | UC1B | CRL-6465* | |
| mouse | WM 1043 | CRL-6466* | |
| mouse | +/+ (A) | CRL-6470* | pooled |
| mouse | +/+ (B) | CRL-6471* | pooled |
| mouse | 12-A-3 | CRL-6476* | SV40 transformed |
| mouse | HPME | CRL-6589* | |
| mouse | B2-1 | CRL-8085 [†] | thymidine kinase negative (TK-) |
| mouse | Swiss SFME | CRL-9391 [†] | |
| mouse | PA317 cell line containing JR- <i>gal</i> | CRL-9995 [†] | |
| mouse | ES-C57BL/6 | SCRC-1002 | stem cell |
| mouse | BALB/c CL.7 | TIB-80 | |
| mouse | BLK CL.4 | TIB-81 | |
| mouse | BALB/B 0.75BAE A.1R.1 HD A.8 | TIB-84 | chemically transformed |
| mouse | BALB/c 10ME HD A.5R.1 | TIB-85 | chemically transformed |
| mouse | BALB/c 10CrMCA A.2R.1 | TIB-86 | chemically transformed |
| mouse | BALB/c AMuLV A.3R.1 | TIB-87 | AMLV transformed |
| mouse | BLK SV HD.2 A.5R.1 A.3 | TIB-88 | SV40 transformed |
| mouse | BALB/c AMuLV A.6R.1 | TIB-90 | AMLV transformed |
| salmon; Chinook | CHSE-214 | CRL-1681 | |
| snail | Bge | CRL-1494 | |
| squirrel; plantain | NZP-46 | CRL-1926 | |
| zebrafish | ZF4 | CRL-2050 | |
| zebrafish | ZEM2S | CRL-2147 | |
| Epidermis See Skin | | | |
| Esophagus | | | |
| goat | Ch 1 Es (NBL-8) | CCL-73 | |
| goat | Ch1.Es | CRL-6581* | Strole Test of the |
| human | Het-1A | CRL-2692 | SV40 large T antigen transfected |
| Eye | | | |
| bovine | BCE C/D-1b | CRL-2048 | cornea |
| Fugu rubripes (torafugu) | Fugu eye | CRL-2641 | telomerase positive; sequenced |
| human | HCE-2 | CRL-11135 [†] | cornea; AdV12-SV40 transformed |
| human | B-3 | CRL-11421 [†] | lens; AdV12-SV40 transformed |
| human | 10.014 pRSV-T | CRL-11515 [†] | cornea |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|-------------------------------|-------------------------------|------------------------------------|---|
| | | | |
| Eye continued | 2.040 DCV T | CDL 11516 [†] | company in the control of the CVAO and the control of |
| human | 2.040 pRSV-T ARPE-19 | CRL-11516 [†] CRL-2302 | cornea; immortalized with SV40 early region |
| human | | | retina, pigmented epithelium |
| human | ARPE-19/HPV-16 hTERT RPE-1 | CRL-2502 | retina, pigmented epithelium; HPV-16 transfected |
| human | | CRL-4000 | pigmented retinal epithelium; hTERT immortalized |
| monkey, Rhesus | RF/6A | CRL-1780 | retina, choroid; fetal |
| rabbit | SIRC RPE-J | CCL-60 CRL-2240 | cornea |
| rat | KPE-J | CRL-2240 | retina, pigmented epithelium; SV40 transformed |
| Fetus See also Embryo | | | |
| cat | Fcwf-4 | CRL-2787 | whole |
| cat | FC60(B).We | CRL-6098* | |
| cat | FC61 | CRL-6099* | |
| cat | FC70.We | CRL-6102* | |
| cat | FC79.We | CRL-6106* | whole |
| cat | FC101 | CRL-6118* | whole |
| cat | FC102 | CRL-6119* | whole |
| cat | FC112 | CRL-6120* | whole |
| cat | FC113 | CRL-6121* | whole |
| cat | FC118 | CRL-6124* | |
| cat | FC119 | CRL-6125* | whole |
| cat | FC60A.We | CRL-6140* | |
| cat | FC60B.We | CRL-6141* | |
| cat | FC63.Res | CRL-6143* | |
| cat | FC71A.We | CRL-6145* | |
| cat | FC104.We | CRL-6152* | |
| cat | FC106.We | CRL-6154* | |
| cat | FC107.We | CRL-6155* | |
| Fetus continued | 55100111 | CDL 44.54V | |
| cat | FC108.We | CRL-6156* | |
| cat | FC109.We | CRL-6157* | |
| cat | FC110.We | CRL-6158* | |
| guinea pig | 104C1 | CRL-1405* | |
| human | Hs 2.We | CRL-7003* | |
| human | Hs 143.We | CRL-7092* | |
| human | Hs 144.We | CRL-7093* | |
| human | Hs 174.We | CRL-7124* | |
| human | Hs 216.We | CRL-7178* | |
| human | Hs 391.We | CRL-7267* | |
| human | Hs 395.We | CRL-7271* | |
| human | Hs 409.We | CRL-7281* | |
| human | Hs 410.We | CRL-7282* | |
| human | Hs 413.We | CRL-7286* | |
| human | Hs 568.We | CRL-7340* | |
| human | Hs 590.We | CRL-7353* | |
| human | HF 333.We | CRL-7706* | |
| human | HF 345.We | CRL-7708* | |
| human | HF 358.We | CRL-7709* | |
| human | Hs 173.We FHs 173We | CRL-7834* | |
| human | | HTB-158 | |
| mouse | MBA C57.We | CRL-6370* | |
| rat | Rat2 | CRL-1764 | |
| Fin | | | |
| goldfish | CAR | CCL-71 | |
| grunt, blue-striped | Grunt Fin | CCL-58 | |
| zebrafish | SJD.1 | CRL-2296 | caudal |
| zebrafish | AB.9 | CRL-2298 | caudal |
| Foreskin See also Skin | | | |
| human | Hs27 | CRL-1634 | |
| human | CCD-1112Sk | CRL-2429 | |
| human | CCD-1114Sk | CRL-2450 | |
| | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|----------------------------|----------------------|------------------------|---|
| | | | 2 3337, 1333 |
| human | BJ | CRL-2522 | I TENT I I I I |
| human | BJ-5ta | CRL-4001 | hTERT immortalized |
| human | CCD-1137Sk | CRL-2703 | |
| human | Hs 18.Fs | CRL-7014* | |
| human | Hs 21.Fs | CRL-7015* | |
| human | Hs 24.Fs | CRL-7016* | |
| human human | Hs 45.Fs Hs 46.Fs | CRL-7025* CRL-7026* | |
| human | Hs 48.Fs | CRL-7026** | |
| human | Hs 49.Fs | CRL-7028* | |
| human | Hs 55.Fs | CRL-7028 | |
| human | Hs 56.Fs | CRL-7036* | |
| human | Hs 58.Fs | CRL-7038* | |
| human | Hs 60.Fs | CRL-7030* | |
| human | Hs 61.Fs | CRL-7041* | |
| human | Hs 62.Fs | CRL-7042* | |
| human | Hs 69.Fs | CRL-7047* | |
| human | Hs 70.Fs | CRL-7048* | |
| human | Hs 72.Fs | CRL-7049* | |
| human | Hs 77.Fs | CRL-7055* | |
| human | Hs 80.Fs | CRL-7058* | |
| human | Hs 86.Fs | CRL-7059* | |
| human | Hs 97.Fs | CRL-7065* | |
| human | Hs 137.Fs | CRL-7087* | |
| human | Hs 154.Fs | CRL-7098* | |
| human | Hs 165.Fs | CRL-7118* | |
| human | Hs 168.Fs | CRL-7122* | |
| Gill | | | |
| catfish, walking | G1B | CRL-2536 | |
| trout, rainbow | RTgill-W1 | CRL-2523 | |
| Gingiva | g | C.1.2 2323 | |
| human | HGF-1 | CRL-2014 | |
| Gonadal Tissue | TIGI T | CILL 2014 | |
| rainbow trout (Oncorhynchu | ıs RTG-P1 | CRL-2829 | mixed testis and ovary; expresses firefly luciferase gene under |
| mykiss) | .5 | CHE ZOZO | control of Mx1 |
| Heart | | | CONTROL OF MIXT |
| bovine | FBHE | CRL-1395 | vascular endothelium; fetal |
| iguana | IgH-2 | CCL-108 | raseata. Ettastiteitatti, teta |
| rat | H9c2(2-1) | CRL-1446 | myocardium |
| salmon, chum | CHH-1 | CRL-1680 | , |
| turtle, box | TH-1, Subline B1 | CCL-50 | |
| viper, Russell's | VH 2 | CCL-140 | |
| Intestine, Large See Colon | | | |
| Intestine, Small | | | |
| human | FHs 74 Int | CCL-241 | |
| human | Hs 1.Int | CRL-7820* | |
| rat | IEC-18 | CRL-1589 | ileum |
| rat | IEC-6 | CRL-1592 | epithelium |
| rat | EGC/PK060399egfr | CRL-2690 | jejunum, myenteric plexus; enteroglial |
| Kidney | | | , , , , , , , , , , , , , , , , , , , |
| bovine | MDBK (NBL-1) | CCL-22 | |
| bovine | FB2.K | CRL-6033* | fetal |
| bovine | LB10.K | CRL-6061* | |
| cat | CRFK | CCL-94 | cortex |
| cat | FC5.K | CRL-6078* | |
| cat | FC6.K | CRL-6082* | |
| cat | FC115.K | CRL-6122* | |
| cat | FC2.K | CRL-6126* | |
| deer, Columbian black tail | OHH1.K | CRL-6193* | |
| dog | MDCK (NBL-2) | CCL-34 | |
| | | | |



| Species | Cell Line Name | ATCC® No. | Description |
|---------------------------|--------------------------------|------------------------|--|
| Kidney continued | | | |
| dog | DoCl, (S+L-) | CCL-34.1 | |
| dog | Super Tube | CRL-2285 | |
| dog | Super Dome | CRL-2286 | |
| dog | DK | CRL-6247* | |
| hamster, Syrian golden | BHK-21 (C-13) | CCL-10 | |
| hamster, Syrian golden | HaK | CCL-15 | |
| hamster, Syrian golden | tk- ts13 | CRL-1632 | |
| hamster, Syrian golden | 2254-62.2 | CRL-8544 [†] | |
| hamster, Syrian, golden | BHK21-pcDNA3.1-HC | CRL-13001 [†] | produces recombinant human erythropoeitin |
| hamster, Syrian golden | BHK570 | CRL-10314 [†] | thymidine kinase deficient |
| human | 90.74 | CRL-11654 [†] | transformed with adenovirus 5 DNA; packaging cell line |
| human | 293 c18 | CRL-10852 [†] | high transfection frequencies |
| human | SODK1 [SODK1293] | CRL-12386 [†] | transformed with adenovirus 5 DNA; packaging cell line |
| human | ANJOU 65 | CRL-11269 [†] | highly transfective |
| human | 293 | CRL-1573 | fetal |
| human | HK-2 | CRL-2190 | cortex, proximal tubule; HPV-16 transformed |
| human | CCD 1103 KIDTr | CRL-2304 | HPV-16 E6/E7 transformed |
| human | 2V6.11 | CRL-2784 | transformed with adenovirus 5 DNA |
| human | GFPu-1 | CRL-2794 | transformed with adenovirus 5 DNA |
| human | PEAKrapid | CRL-2828 | transformed with adenovirus 5 DNA |
| human | 293 EcR Shh | CRL-2782 | transformed with adenovirus 5 DNA |
| human | CCD 1105 KIDTr | CRL-2305 | HPV-16 E6/E7 transformed |
| marmoset; black tailed | NZP-60 | CRL-1924 | |
| minipig | MPK | CCL-166 | |
| monkey, African green | BS-C-1 | CCL-26 | |
| monkey, African green | CV-1 | CCL-70 | |
| monkey, African green | Vero | CCL-81 | |
| monkey, African green | CV-1/EBNA-1 | CRL-10478 [†] | EBNA-1 expression |
| monkey, African green | PSP-36 | CRL-11171 [†] | |
| monkey, African green | VERO C1008 | CRL-1586 | |
| monkey, African green | VERO 76 | CRL-1587 | |
| monkey, African green | COS-1 | CRL-1650 | |
| monkey, African green | COS-7 | CRL-1651 | |
| monkey, African green | MA-104 Clone 1 | CRL-2378.1 | |
| monkey, African green | BSC40 | CRL-2761 | high-temperature tolerant |
| monkey, African green | W162 | CRL-2783 | supports growth of defective adenoviral deletion mutant (H2dl808) |
| monkey, Bolivian squirrel | SQMK-FP | CRL-2762 | tubule; elevated expression of the FK506-binding immunophilin FKBP51 |
| monkey, owl | OMK(637-69) | CRL-1556 | |
| monkey, Rhesus | LLC-MK ₂ | CCL-7 | |
| monkey, Rhesus | LLC-MK ₂ derivative | CCL-7.1 | |
| monkey, Rhesus | NCTC clone 3526 | CCL-7.2 | |
| monkey, Rhesus | FRhK-4 | CRL-1688 | fetal |
| mouse | TCMK-1 | CCL-139 | |
| mouse | SV40 MES 13 | CRL-1927 | glomerulus |
| mouse | As4.1 | CRL-2193 | intraparenchymal |
| mouse | MM54.K | CRL-6433* | |
| mouse | MM55.K | CRL-6436* | and the college of the second |
| mouse, transgenic | mIMCD-3 | CRL-2123 | medulla, collecting duct |
| mouse, transgenic | M-1 | CRL-2038 | cortex, collecting duct |
| opossum | OK NALI14 K | CRL-1840 | cortex, proximal tubule |
| parakeet, shell | MU14.K | CRL-6485* | |
| peccary | Peccary.K | CRL-6488* | |
| pig | PK(15) | CCL-33 | |
| pig | LLC-PK | CL-101 | |
| pig | LLC-PK _{1A} | CL-101.1 | |
| pig | ESK-4 | CL-184 | |
| pig | PK13 | CRL-6489* | |
| pig | PK-2a/CL 13 | CRL-6492* | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|---|---|---|--|
| potoroo | Pt K1 (NBL-3) | CCL-35 | |
| potoroo | PtK2 (NBL-5) | CCL-56 | |
| potoroo | PtK1 | CRL-6493* | |
| rabbit | LLC-RK, | CCL-106 | |
| rabbit | RK ₁₃ | CCL-37 | |
| rabbit | vEPT | CRL-2087 | proximal tubule |
| rabbit | Clone C | CRL-2531 | • |
| | KNRK | CRL-2551 CRL-1569 | cortex |
| rat | | | |
| rat | NRK-49F | CRL-1570 | |
| rat | NRK-52E | CRL-1571 | |
| rat | RK3E | CRL-1895 | |
| rat | RMC | CRL-2573 | |
| rat | NRK | CRL-6509* | |
| salmon, Atlantic | ASK | CRL-2747 | may be used to propagate infectious salmon anemia virus (ISAV) |
| sheep | MDOK | CRL-1633 | |
| sheep | OA4.K/S1 | CRL-6549* | fetal |
| toad, South African | A6 | CCL-102 | |
| clawed | | | |
| toad, South African clawed | XLK-WG | CRL-2527 | |
| | NZD 26 | CDL 1022 | |
| zebra, Burchell's | NZP-36 | CRL-1922 | |
| Larva | D. II | CD1 2750 | |
| herring, Pacific | PHL | CRL-2750 | sensitive to the cytotoxic effects of naphthalene |
| mosquito | Aedes aegypti | CCL-125 | |
| mosquito | Aedes albopictus | CCL-126 | |
| mosquito | TRA-171 | CRL-1591 | whole |
| mosquito | Aedes albopictus clone C6/36 | CRL-1660 | whole |
| moth, cabbage | IZD-MB-0503 | CRL-8003 [†] | |
| Liver | | | |
| deer, Columbian black tail | OHH1.Li | CRL-6194* | |
| human | FL 62891 | CRL-11005 [†] | immortalized with SV40 large T antigen |
| human | THLE-3 | CRL-11233 [†] | left lobe; immortalized with SV40 T antigen |
| | THLE-3 | CRL-17253 CRL-2706 | left lobe; SV40 transformed |
| human | Hs 399.Li | | abnormal |
| human | | CRL-7274* | abnormai |
| mouse | NCTC clone 1469 | CCL-9.1 | |
| mouse | 2018 | CRL-10907 [†] | stroma; immortalized with SV40 large Tantigen |
| mouse | L.N. 4159 | CRL-10998 [†] | |
| mouse | NMuLi | CRL-1638 | |
| mouse | H2.35 | CRL-1995 | hepatocyte; SV40 transformed |
| mouse | AML12 | CRL-2254 | |
| mouse | FL83B | CRL-2390 | |
| mouse | SI/SI4 | CRL-2452 | stroma; fetal; SV40 large T immortalized |
| mouse | SI/SI4 hSCF220 | CRL-2453 | stroma; fetal; SV40 large T immortalized |
| mouse | SI/SI4 hSCF248 | CRL-2454 | stroma; fetal |
| mouse | NMu3Li | CRL-6447* | , |
| mouse | +/+ Li | CRL-6467* | |
| mouse | BNL CL.2 | TIB-73 | embryonic |
| mouse | BNL SV A.8 | TIB-74 | SV40 transformed |
| mouse | BNL 1ME A.7R.1 | TIB-75 | chemically transformed |
| | BNL 1NG A.2 | TIB-76 | chemically transformed |
| mouse | DINI LINCEM.Z | | Chemically transformed |
| rat | | ("DI _1/I") | |
| rat | Clone 9 | CRL-1439 | |
| rat | Clone 9 BRL 3A | CRL-1442 | |
| rat trout, rainbow | Clone 9 BRL 3A SOB-15 | CRL-1442 CRL-2301 | |
| rat trout, rainbow zebrafish | Clone 9 BRL 3A | CRL-1442 | parenchymal cells |
| rat trout, rainbow zebrafish Lung | Clone 9 BRL 3A SOB-15 ZFL | CRL-1442 CRL-2301 CRL-2643 | parenchymal cells |
| rat trout, rainbow zebrafish Lung bat, free-tailed | Clone 9 BRL 3A SOB-15 ZFL Tb 1 Lu | CRL-1442 CRL-2301 CRL-2643 CCL-88 | parenchymal cells |
| rat trout, rainbow zebrafish Lung | Clone 9 BRL 3A SOB-15 ZFL Tb 1 Lu Tb1.Lu | CRL-1442 CRL-2301 CRL-2643 CCL-88 CRL-6564* | parenchymal cells |
| rat trout, rainbow zebrafish Lung bat, free-tailed | Clone 9 BRL 3A SOB-15 ZFL Tb 1 Lu Tb1.Lu AK-D | CRL-1442 CRL-2301 CRL-2643 CCL-88 | parenchymal cells |
| rat trout, rainbow zebrafish Lung bat, free-tailed bat, free-tailed | Clone 9 BRL 3A SOB-15 ZFL Tb 1 Lu Tb1.Lu | CRL-1442 CRL-2301 CRL-2643 CCL-88 CRL-6564* | parenchymal cells |



| Species | Cell Line Name | ATCC® No. | Description |
|----------------------------|-------------------------|-----------------------|--|
| Lung continued | | | · |
| cat | FC2.Lu | CRL-6569* | |
| cusimanse | NZP-12 | CRL-1921 | |
| deer, Columbian black tail | OHH1.Lu | CRL-6195* | |
| fox, grey | FoLu | CCL-168 | |
| gerbil, Mongolian | GeLu | CCL-100 | |
| guinea pig | JH4 clone 1 | CCL-158 | |
| hamster, Armenian | AHL-1 | CCL-195 | |
| hamster, Chinese | Don | CCL-16 | |
| hamster, Chinese | Dede | CCL-39 | |
| hamster, Chinese | V79-4 | CCL-93 | |
| hamster, Chinese | R 1610 | CRL-1657 | |
| hamster, Chinese | CHL/IU | CRL-1935 | |
| hamster, Chinese | XR-V15B | CRL-2349 | |
| human | LL 29 (AnHa) | CCL-134 | idiopathic pulmonary fibrosis |
| human | LL 47 (MaDo) | CCL-135 | |
| human | HEL 299 | CCL-137 | fetal |
| human | LL 24 | CCL-151 | |
| human | HFL1 | CCL-153 | fetal |
| human | MRC-5 | CCL-171 | |
| human | IMR-90 | CCL-186 | |
| human | LL 86 (LeSa) | CCL-190 | |
| human | LL 97A (AlMy) | CCL-191 | idiopathic pulmonary fibrosis |
| human | CCD-13Lu | CCL-200 | |
| human | CCD-8Lu | CCL-201 | |
| human | CCD-11Lu | CCL-202 | |
| human | CCD-16Lu | CCL-204 | |
| human | CCD 18Lu | CCL-205 | |
| human | CCD-19Lu | CCL-210 | |
| human | MRC-9 | CCL-212 | |
| human | CCD-25Lu | CCL-215 | |
| human | WI 38 | CCL-75 | |
| human | WI-38 VA-13 subline 2RA | CCL-75.1 | |
| human | WI-26 VA4 | CCL-95.1 | |
| human | CCD-29Lu | CRL-1478 | emphysema |
| human | CCD-32Lu | CRL-1485 | |
| human | CCD-33Lu | CRL-1490 | |
| human | CCD-34Lu | CRL-1491 | |
| human | CCD-39Lu | CRL-1498 | hyaline membrane disease |
| human | HBE4-E6/E7 | CRL-2078 | bronchus |
| human | HBE4-E6/E7-C1 | CRL-2079 | bronchus T. I. 120 |
| numan | NL20 | CRL-2503 | bronchus; immortalized with SV40 large T plasmid, p129 |
| human | NL20-TA | CRL-2504 | bronchus; immortalized with SV40 large T plasmid, p129 |
| human | C38 HBE135-E6E7 | CRL-2779 | cystic fibrosis; immortalized with Ad12-SV40 hybrid bronchus; HPV-16 E6/E7 transformed |
| human | | CRL-2741 | , |
| human | IB3-1 S9 | CRL-2777 CRL-2778 | bronchus; cystic fibrosis; immortalized with Ad12-SV40 hybrid |
| human | TC-1 | | bronchus; cystic fibrosis; immortalized with Ad12-SV40 hybrid HPV-16 E6/E7 and C-Ha-ras cotransformed |
| human | Hs 1.Lu | CRL-2785 CRL-7000* | TIF V-10 EO/E/ ATIU C-FId-TdS COUTATISTOFFIED |
| human | Hs 1.Lu Hs 115.Lu | CRL-7000^ | hronchus |
| human human | Hs 218.Lu | CRL-7077* | bronchus |
| human | Hs 389(A).Lu | CRL-7180** | |
| human | Hs 389(B).Lu | CRL-7265* | |
| human | Hs 394.Lu | CRL-7269* | |
| human | Hs 394.Lu | CRL-7269" | |
| | Hs 401.Lu | CRL-7275* | |
| human human | Hs 412.Lu | CRL-7275** | bronchus |
| human | Hs 417.Lu | CRL-7285* | bronchus |
| | Hs 573.Lu | CRL-7344* | DIOTICIUS |
| human human | Hs 888.Lu | CRL-7344* | |
| | Hs 894(E).Lu | CRL-7624" | |
| human | 1 15 074(E/.LU | CUT-\022. | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|---------------------------|---------------------------------|----------------------------------|---|
| - Species | | | 2 complion |
| human | Hs 907.Lu | CRL-7657* | |
| human | HE-LU(Rifkin) | CRL-7717* | fetal |
| human | Hs 468.Lu | CRL-7810* | |
| human | Hs 738.Lu | CRL-7868* | huan ahuan imua tuan afa una a d |
| human | BBM | CRL-9482 [†] | bronchus; virus transformed |
| human | BZR BEAS-2B | CRL-9483 [†] | bronchus; virus transformed |
| human human | FHs 738Lu | CRL-9609 [†] HTB-157 | bronchus; virus transformed |
| | | CCL-111 | |
| lizard, gekko mink | Gekko lung-1 Mv 1 Lu (NBL-7) | CCL-64 | |
| mink | MiCl1 (S+L-) | CCL-64.1 | |
| monkey, African green | DBS-FCL-1 | CCL-161 | |
| monkey, African green | DBS-FCL-2 | CCL-162 | |
| monkey, African green | 12MBr6 | CRL-1576 | bronchus |
| monkey, Bolivian squirrel | DPSO 114/74 | CCL-194 | fetal |
| monkey, Rhesus | 4MBr-5 | CCL-208 | bronchus |
| monkey, Rhesus | DBS-FRhL-2 | CL-160 | Diolicius |
| mouse | MLg | CCL-206 | |
| mouse | MH-S | CRL-2019 | |
| mouse | MM14.Lu | CRL-6382* | bronchus |
| mouse | MM19.Lu | CRL-6396* | N. O. T. C. |
| mouse, transgenic | MLE 12 | CRL-2110 | |
| oryx, short-horned | NZP-29 | CRL-1925 | |
| rabbit | R9ab | CCL-193 | fetal |
| rat | L2 | CCL-149 | |
| rat | RFL-6 | CCL-192 | |
| rat | RL-65 | CRL-10354 [†] | |
| rat | NR8383 | CRL-2192 | |
| rat | RLE-6TN | CRL-2300 | |
| tahr | HJ2.Lu | CRL-6277* | fetal |
| Lymph Node | | | |
| bovine | BLn | CRL-6017* | |
| bovine | B2.Ln | CRL-6022* | |
| bovine | FB2.Ln | CRL-6034* | fetal |
| bovine | FB3.Ln | CRL-6038* | fetal |
| bovine | FB4.Ln | CRL-6041* | fetal |
| bovine | FB5.Ln | CRL-6044* | fetal |
| bovine | LBLN | CRL-6046* | |
| bovine | 2LBLN | CRL-6047* | |
| bovine | 3LBLN | CRL-6048* | |
| bovine | 5LBLN | CRL-6049* | |
| bovine | 6LBLN | CRL-6050* | |
| bovine | LB9.Ln | CRL-6057* | |
| bovine | LB10.Ln | CRL-6062* | |
| bovine | LB11.Ln | CRL-6066* | |
| bovine | R2LBLN | CRL-6070* | |
| cat | FC100.Ln | CRL-6117* | cervical |
| cat | LFC16.Ln | CRL-6173* | |
| dog | CLN | CRL-6245* | |
| human | Hs 215.Ln | CRL-7175* | mesenteric; abnormal |
| human | Hs 277.T | CRL-7225* | abnormal |
| human | Hs 325.Ln | CRL-7240* | chronic lymphadenitis |
| human | Hs 443.T | CRL-7300* | reactive hyperplasia |
| human | Hs 757.T | CRL-7490* | benign hyperplasia |
| human | Hs 793.T | CRL-7524* | mesenteric; hyperplasia |
| human | Hs 933.T | CRL-7683* | Wiskott-Aldrich syndrome |
| mouse | 3B-11 | CRL-2160 | axillary; vascular epithelium; SV40 transformed |
| mouse | SVEC4-10EHR1 | CRL-2161 | axillary; vascular epithelium; SV40 transformed |
| mouse | IP-1B | CRL-2162 | axillary; vascular epithelium; SV40 transformed |
| mouse | 2H-11 | CRL-2163 | axillary; vascular epithelium; SV40 transformed |
| mouse | SVEC4-10EE2 | CRL-2167 | axillary; vascular epithelium; SV40 transformed |



| Species | Cell Line Name | ATCC® No. | Description |
|--|-------------------|--|--|
| Lymph Node continued | | | |
| mouse | 2F-2B | CRL-2168 | axillary; vascular epithelium; SV40 transformed |
| mouse | IP2-E4 | CRL-2171 | axillary; vascular epithelium; SV40 transformed |
| mouse | SVEC4-10 | CRL-2181 | axillary; vascular epithelium; SV40 transformed |
| turkey | MDTC-RP19 | CRL-8135 [†] | Marek's disease |
| Lymphoblast | MB1C11115 | CHE 0133 | Hureks disease |
| baboon, African | 26CB-1 | CRL-1495 | spleen; HVS transformed |
| human | TK6 | CRL-8015 [†] | spleen; hereditary spherocytosis |
| human/human | T1 (174 x CEM.T1) | CRL-1991 | cell hybrid |
| human/human | T2 (174 x CEM.T2) | CRL-1992 | cell hybrid |
| Lymphoblast, B | 12 (17 17 222) | 0.12 1772 | cennyana |
| catfish, channel | 1G8 | CRL-2756 | peripheral blood; expresses moderately increased level of p53 mRNA |
| catfish, channel | 3B11 | CRL-2757 | peripheral blood; constitutively expresses telomerase |
| human | E.H. IV | CCL-104 | peripheral blood; infectious mononucleosis |
| human | RPMI 7666 | CCL-114 | peripheral blood; EBV producing |
| human | RPMI 1788 | CCL-156 | peripheral blood; EBNA positive |
| human | IM-9 | CCL-159 | peripheral blood; EBV producing |
| human | MCL-5 | CRL-10575 [†] | peripheral blood; EBNA positive |
| human | HMy2.CIR | CRL-1993 | |
| human | HCC1428 BL | CRL-2328 | peripheral blood; EBV transformed |
| human | HCC1739 BL | CRL-2334 | peripheral blood; EBV transformed |
| human | C1R-neo | CRL-2369 | peripheral blood; EBV transformed |
| human | C1R-sB7 | CRL-2370 | peripheral blood; EBV transformed |
| human | C1R-B7 | CRL-2371 | peripheral blood; EBV transformed |
| human | NCI-BL1339 | CRL-5950 | peripheral blood; EBV transformed |
| human | NCI-BL1450 | CRL-5951 | peripheral blood; EBV transformed |
| human | NCI-BL1514 | CRL-5952 | peripheral blood; EBV transformed |
| human | NCI-BL1607 | CRL-5953 | peripheral blood; EBV transformed |
| human | NCI-BL2141 | CRL-5955 | peripheral blood; EBV transformed |
| human | NCI-BL2009 | CRL-5961 | peripheral blood; EBV transformed |
| human | NCI-BL2347 | CRL-5970 | peripheral blood; EBV transformed |
| human | AHH-1 | CRL-8146 [†] | peripheral blood; EBNA positive |
| human | SC-1 | CRL-8756 [†] | peripheral blood; EBV transformed |
| human | DAKIKI | TIB-206 | peripheral blood; EBV transformed |
| human | SKW 6.4 | TIB-215 | peripheral blood; EBV transformed |
| monkey, Bolivian squirrel | SML, clone 4D8 | CRL-2311 | peripheral blood; EBV transformed |
| monkey, Guyanese | GSML | CRL-2699 | peripheral blood; EBV transformed |
| squirrel | | | |
| monkey, owl | OML, clone 13C | CRL-2312 | peripheral blood; EBV producing |
| Lymphocyte, T | | | |
| cat | FeT-J | CRL-11967 [†] | peripheral blood; mononuclear cells |
| cat | FeT-1C | CRL-11968 [†] | peripheral blood; mononuclear cells |
| cat | MYA-1 | CRL-2417 | peripheral blood |
| catfish, channel | 28S.3 | CRL-2758 | peripheral blood |
| catfish, channel | G14D | CRL-2760 | peripheral blood; constitutively produces interleukin-like factors |
| human | C5/MJ | CRL-8293 [†] | cord blood; HTLV-1 infected |
| mouse | HT-2 clone A5E | CRL-1841 | spleen |
| mouse | Cl. Ly1+2-/9 | CRL-8179 [†] | spleen; helper/inducer (Th-2) |
| mouse | CTLL-2 | TIB-214 | cytotoxic |
| mouse | D10.G4.1 | TIB-224 | helper/inducer |
| Macrophage | | -r: | |
| catfish, channel | 42TA | CRL-2759 | peripheral blood |
| dog | DH82 | CRL-10389 [†] | histiocytosis; malignant |
| dog | DH82ECOK | CRL-10390 [†] | histiocytosis; chronically infected with Ehrlicia canis |
| human (leukocyte)/ mouse (macrophage) | WBC264-9C | HB-8902 [†] | hybrid |
| human | MD | CRL-9850 [†] | spleen; monocyte |
| human | PMC2 90196B | CRL-9852 [†] CRL-9853 [†] | spleen; monocyte |
| human | | | spleen; monocyte |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|-----------------------|------------------|------------------------|------------------------------------|
| human | EL 1 | CRL-9854 [†] | spleen; monocyte |
| human | SC | CRL-9855† | peripheral blood; monocyte |
| human | KMA | CRL-9856 [†] | spleen; monocyte |
| mouse | AMJ2-C8 | CRL-2455 | alveolar |
| mouse | AMJ2-C11 | CRL-2456 | alveolar |
| mouse | RAW 264.7 γNO(-) | CRL-2278 | monocyte |
| mouse | PMJ2-PC | CRL-2457 | peritoneal; infected with J2 virus |
| mouse | PMJ2-R | CRL-2458 | peritoneal; infected with J2 virus |
| mouse | I-11.15 | CRL-2470 | spleen |
| mouse | I-13.35 | CRL-2471 | spleen |
| mouse | IC-21 | TIB-186 | peritoneal |
| mouse (macrophage | H36.12a | CRL-2445 | hybrid |
| | | CRL-2445 | пурпа |
| tumor)/mouse (peritor | | CDL 2446 | 1.1.1 |
| mouse (macrophage | H36.12b | CRL-2446 | hybrid |
| tumor)/mouse (peritor | . 3: | CDL 0.4.= | |
| mouse (macrophage | H36.12d | CRL-2447 | hybrid |
| tumor)/mouse (peritor | . 3 | | |
| mouse (macrophage | H36.12e | CRL-2448 | hybrid |
| tumor)/mouse (peritor | neal macrophage) | | |
| mouse (macrophage | H36.12j | CRL-2449 | hybrid |
| tumor)/mouse (peritor | neal macrophage) | | |
| Mammary Gland | | | |
| dog | CF30.Mg | CRL-6225* | |
| dog | CF37.Mg | CRL-6230* | |
| dog | CF38.Mg | CRL-6231* | |
| dog | CF43.Mg | CRL-6234* | |
| dog | CF44.Mg | CRL-6235* | |
| dog | CF47.Mg | CRL-6239* | |
| dog | CF48.Mg | CRL-6240* | |
| dog | CF49.Mg | CRL-6241* | |
| human | MCF 10A | CRL-10317 [†] | fibrocystic disease |
| human | MCF 10F | CRL-10317 | fibrocystic disease |
| | MCF-10-2A | CRL-10318 | fibrocystic disease |
| human | | | iibiocystic disease |
| human | MCF-12A | CRL-10782 [†] | TERT in an antalian d |
| human | hTERT-HME1 | CRL-4010 | TERT immortalized |
| human | MCF-12F | CRL-10783 [†] | |
| human | Hs 564(E).Mg | CRL-7329* | |
| human | Hs 565(A).Mg | CRL-7330* | cyst |
| human | Hs 565(D).Mg | CRL-7333* | cyst |
| human | Hs 579.Mg | CRL-7347* | |
| human | Hs 617.Mg | CRL-7379* | |
| human | Hs 873.T | CRL-7610* | abnormal |
| human | Hs 874.T | CRL-7611* | abnormal |
| human | Hs 875.T | CRL-7612* | abnormal |
| human | Hs 877.T | CRL-7613* | abnormal |
| human | Hs 879(B).T | CRL-7615* | |
| human | Hs 880.T | CRL-7616* | abnormal |
| human | Hs 885.T | CRL-7618* | abnormal |
| human | Hs 912.T | CRL-7661* | abnormal |
| human | Hs 938.T | CRL-7688* | abnormal |
| human | SW527 | CRL-7940* | Paget's disease |
| human | 184A1 | CRL-8798 [†] | epithelium; chemically transformed |
| human | 184B5 | CRL-8799 [†] | epithelium; chemically transformed |
| | NMuMG | CRL-1636 | epithelium, chemicany transformed |
| mouse | | | |
| mouse | Mm5MT | CRL-1637 | |
| mouse | MM3MG | CRL-6376* | |
| Mast Cell | | | |
| mouse | MC/9 | CRL-8306 [†] | liver |
| Mesothelium | | | |
| human | MeT-5A | CRL-9444 [†] | virus transformed |
| | | | **** ** |



| Species | Cell Line Name | ATCC® No. | Description |
|------------------------|--------------------------|------------------------|--|
| Mixed Tissue | | | |
| bovine | BThy | CRL-6020* | spleen and thymus |
| bovine | B2.Sp/Thy | CRL-6024* | spleen and thymus |
| povine | FB2.Thy | CRL-6036* | spleen and thymus |
| povine | FB4.Sp/Thy | CRL-6042* | spleen and thymus and fetal |
| | BB | | · |
| oullhead, brown | | CCL-59 | connective tissue and muscle |
| cat | FC83.Res | CRL-6567* | spleen, thymus and bone marrow |
| numan | Hs 1.Sk/Mu | CRL-7001* | skin and muscle |
| numan | Hs 103.Sp/Th | CRL-7068* | spleen and thymus |
| numan | Hs 104.Sp/Th | CRL-7070* | spleen and thymus |
| numan | Hs 235.Sk | CRL-7201* | skin and muscle |
| numan | Hs 238.Sk | CRL-7203* | skin and muscle |
| numan | Hs 394.Sk | CRL-7270* | skin and muscle |
| numan | Hs 728.Sk/Mu | CRL-7462* | skin and muscle |
| numan | Hs 738.St/Int | CRL-7869* | stomach and intestine |
| ninnow; fathead | FHM | CCL-42 | connective tissue and muscle |
| nouse | JLS-V5 | CRL-6359* | spleen and thymus |
| nouse | JLS-V9 | CRL-6360* | spleen and thymus |
| nouse | MM15.Sp/Thy | CRL-6388* | spleen and thymus |
| nouse | MM54.Sp/Thy | CRL-6434* | spleen and thymus |
| | MM55.Sp/Thy | CRL-6437* | spleen and thymus |
| nouse | | | |
| rout, rainbow | RTG-2 | CCL-55 | testis and ovary |
| Muscle | ===(=) | | |
| numan | Hs 792(C).M | CRL-7522* | connective and soft tissue |
| nouse | NOR-10 | CCL-197 | skeletal |
| nouse | BLO-11 | CCL-198 | skeletal; lysyl oxidase deficiency |
| nouse | G-7 | CRL-1447 | skeletal; fetal |
| nouse | G-8 | CRL-1456 | skeletal; fetal |
| nouse | C,C,, | CRL-1772 | |
| nouse | Sol8 | CRL-2174 | skeletal |
| nouse | mh | CRL-2709 | Hermansky-Pudlak syndrome (HPS) |
| at | L6 | CRL-1458 | skeletal |
| at | L8 | CRL-1769 | skeletal |
| Natural Killer Cell | | C.1.2 1709 | J.C.C.C. |
| | NIV 02 | CDL 2407 | II 2 decreades to the trade of the could be seen a fine line and selle |
| numan | NK-92 | CRL-2407 | IL-2 dependent, cytotoxic to a wide range of malignant cells |
| numan | NK-92MI | CRL-2408 | IL-2 independent, cytotoxic to a wide range of malignant cells |
| Ovary | | | |
| rmyworm, fall | Sf9 | CRL-1711 | |
| at | NEF26.Ov | CRL-6175* | |
| atfish, channel | CCO | CRL-2772 | |
| namster, Chinese | CHO-K1 | CCL-61 | |
| namster, Chinese | AA8 | CRL-1859 | |
| namster, Chinese | CHO DP-12, clone#1933 | CRL-12444 [†] | expresses IgG1 (kappa) against IL-8 |
| | alL8.92 NB 28605/12 | | |
| namster, Chinese | CHO DP-12, clone#1934 | CRL-12445 [†] | expresses IgG1 (kappa) against IL-8 |
| | alL8.92 NB 28605/14 | | |
| namster, Chinese | CHO-K1 | CRL-9618 [†] | |
| numan | Hs 832(C).T | CRL-7566* | abnormal |
| noth | Antheraea cells, adapted | CCL-80 | |
| nouse | B/CMBA.Ov | CRL-6331* | |
| nouse | MM14.Ov | CRL-6383* | |
| | | | |
| nouse | MM16.0v | CRL-6390* | |
| ahr | HJ1.Ov | CRL-6274* | |
| Palate | | | |
| numan | HEPM | CRL-1486 | mesenchyme; fetal |
| Pancreas | | | |
| namster, Syrian golden | HIT-T15 | CRL-1777 | islet of Langerhans; beta cell |
| nouse | MS1 | CRL-2279 | islet of Langerhans; beta cell |
| | SVR | CRL-2279 CRL-2280 | islet of Langerhans; endothelium |
| nouse | | | |
| mouse | SVR A221a | CRL-2386 | islet of Langerhans; endothelium |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|--------------------------------------|--|------------------------|--|
| | CVD board | CDL 2207 | idat af Lauranhaura an dath alium |
| mouse mouse | SVR bag4 MS1 VEGF | CRL-2387 CRL-2460 | islet of Langerhans; endothelium islet of Langerhans; endothelium |
| | M31 VEGI | CNL-2400 | isiet of Langernans, endothendin |
| Peritoneum | D1 4F4F20 C2 | CCL 14 | |
| hamster, Chinese | B14FAF28-G3 | CCL-14 CCL-14.2 | |
| hamster, Chinese | NCTC 4206 | CCL-14.2 | |
| Placenta | 56.5 | CD1 | |
| cat | FC47 | CRL-6094* | |
| human | 3A(tPA-30-1) | CRL-1583 | |
| human | 3A-sub E [post crisis of 3A(tPA-30-1)] | CRL-1584 | |
| human | Hs 726.Pl | CRL-7460* | |
| human | Hs 730.Pl | CRL-7464* | |
| human | Hs 774.Pl | CRL-7502* | |
| human | Hs 795.Pl | CRL-7526* | |
| human | Hs 798.Pl | CRL-7529* | |
| human | Hs 799.PI | CRL-7530* | |
| human | Hs 815.Pl | CRL-7548* | |
| human | Hs 801.Pl | CRL-7888* | |
| Pleura | | | |
| rat | 4/4 R.M4 | CCL-216 | visceral |
| Prostate | | | |
| human | RWPE-1 | CRL-11609 [†] | transfected with Ki-MSV |
| human | RWPE-2 | CRL-11610 [†] | transfected with HPV-18 and Ki-MSV |
| human | PWR-1E | CRL-11611 [†] | immortalized with Ad12-SV40 hybrid virus |
| human | PZ-HPV-7 | CRL-2221 | epithelium; HPV-18 transformed |
| human | WPE1-NA22 | CRL-2849 | expresses androgen receptor and kallikrein 3 upon exposure to |
| | | | androgen |
| human | WPE1-NB14 | CRL-2850 | expresses androgen receptor and kallikrein 3 upon exposure to |
| | | | androgen |
| human | WPE1-NB11 | CRL-2851 | expresses androgen receptor and kallikrein 3 upon exposure to |
| | | | androgen |
| human | WPE1-NB26 | CRL-2852 | expresses androgen receptor and kallikrein 3 upon exposure to androgen |
| human | RWPE2-W99 | CRL-2853 | expresses androgen receptor and kallikrein 3 upon exposure to androgen |
| human | WPMY-1 | CRL-2854 | expresses androgen receptor upon exposure to androgen |
| rat | YPEN-1 | CRL-2222 | endothelium; immortalized with adenovirus 12 - SV40 |
| | 11 LIV 1 | CILL 2222 | virus hybrid |
| Rectum | | | |
| human | Hs 680.Rec | CRL-7418* | fetal |
| Salivary Gland | | | |
| cat | NEF36.Sg | CRL-6176* | sublingual |
| human | Hs 917.T | CRL-7669* | parotid; benign sebaceous cyst |
| Schwann Cell | | | |
| mouse | SW10 | CRL-2766 | immortalized with SV40 large Tantigen |
| rat | R3 [33-10ras3] | CRL-2764 | immortalized with SV40 large Tantigen |
| rat | RSC96 | CRL-2765 | immortalized spontaneously |
| Skin <i>See also</i> Foreskin | | | |
| anteater | TAM.T | CRL-6001* | |
| bovine | LB9.D | CRL-6054* | dermis |
| camel | Dubca | CRL-2276 | |
| cat | FC87.Sk | CRL-6150* | |
| horse | E. Derm (NBL-6) | CCL-57 | dermis |
| human | Detroit 551 | CCL-110 | fetal |
| human | Detroit 548 | CCL-116 | |
| human | Detroit 573 | CCL-117 | |
| human | CCD-25Sk | CRL-1474 | |
| Hullian | | | |
| human | CCD-27Sk | CRL-1475 | |
| | CCD-27Sk CCD-32Sk | CRL-1475 CRL-1489 | |



| Species | Cell Line Name | ATCC® No. | Description |
|-------------------------|--------------------------|----------------------|--|
| | | | · |
| Skin continued human | CCD-39Sk | CRL-1501 | |
| human | WS1 | CRL-1502 | |
| human | CCD-43Sk | CRL-1509 | |
| human | CCD-42Sk | CRL-1513 | |
| human | BUD-8 | CRL-1554 | |
| human | CCD-944Sk | CRL-1836 | |
| human | CCD-986Sk | CRL-1947 | |
| human | CCD-1037Sk | CRL-2054 | |
| human | CCD-1058Sk | CRL-2071 | |
| human | CCD-1059Sk | CRL-2072 | |
| human | CCD-1064Sk | CRL-2076 | |
| human | CCD-1065Sk | CRL-2077 | |
| human | CCD-1068Sk | CRL-2086 | |
| human | CCD-1072Sk | CRL-2088 | |
| human | CCD-1069Sk | CRL-2089 | |
| human | CCD-1074Sk | CRL-2090 | |
| human | CCD-1070Sk | CRL-2091 | |
| human | CCD-1077Sk | CRL-2094 | |
| human | CCD-1076Sk | CRL-2096 | |
| human | CCD-1079Sk | CRL-2097 | |
| human | CCD-1086Sk | CRL-2103 | |
| human | CCD-1087Sk | CRL-2104 | |
| human | CCD-1090Sk | CRL-2106 | |
| human | CCD-1092Sk | CRL-2114 | |
| human | CCD-1093Sk | CRL-2115 | |
| human | CCD-1094Sk | CRL-2120 | |
| human | CCD-1095Sk | CRL-2122 | |
| human | CCD-1097Sk | CRL-2124 | |
| human | CCD-1098Sk | CRL-2127 | |
| human | CCD-1096Sk | CRL-2129 | |
| human | CCD-1099Sk | CRL-2201 | |
| human | CCD-1100Sk | CRL-2211 | |
| human | CCD-1101Sk | CRL-2281 | |
| human | CCD 1106 KERTr | CRL-2309 | keratinocyte; HPV-16 E6/E7 transformed |
| human | CCD 1102 KERTr | CRL-2310 | keratinocyte; HPV-16 E6/E7 transformed |
| human | CCD 1108Sk | CRL-2352 | |
| human | CCD-1109Sk | CRL-2361 | |
| human | HEK001 | CRL-2404 | keratinocyte; HPV-16 E6/E7 transformed |
| human | CCD-1113Sk | CRL-2439 | |
| human | CCD-1117Sk | CRL-2465 | |
| human | CCD-1118Sk | CRL-2466 | |
| human | CCD-1120Sk | CRL-2510 | |
| human | CCD-1121Sk | CRL-2511 | |
| human | CCD-1122Sk | CRL-2513 | |
| human | CCD-1123Sk | CRL-2524 | |
| human | CCD-1124Sk | CRL-2529 | |
| human | CCD-1126Sk | CRL-2564 | |
| human | CCD-1127Sk | CRL-2565 | |
| human | CCD-1128Sk CCD-1129SK | CRL-2566 | |
| human | | CRL-2575 | |
| human | CCD-1131Sk CCD-1132Sk | CRL-2617 | |
| human | CCD-1132Sk CCD-1134Sk | CRL-2622 CRL-2673 | |
| human | CCD-11345K CCD-1135Sk | CRL-2673 CRL-2691 | |
| human | CCD-1135Sk CCD-1136Sk | CRL-2697 | |
| human human | CCD-11365k | CRL-2697 CRL-2707 | |
| human | CCD-11365k | CRL-2707 CRL-2708 | |
| human | CCD-11393k | CRL-2706 CRL-2714 | |
| human | CCD-11403k | CRL-2714 | |
| human | Hs 3.Sk | CRL-7006* | |
| TIGHTIGHT | 113 3.31 | CITE / 000 | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| | e 11.1. N | A-66 N | |
|----------------|---------------------------|------------------------|-------------|
| Species | Cell Line Name | ATCC® No. | Description |
| human | Hs 13.Sk | CRL-7011* | |
| human | Hs 112.Sk | CRL-7074* | |
| human | Hs 181.Sk | CRL-7129* | |
| human | Hs 184.Sk | CRL-7133* | |
| human | Hs 186.Sk | CRL-7138* | |
| human | Hs 201.Sk | CRL-7161* | |
| human | Hs 275.Sk | CRL-7223* | |
| human | Hs 295.Sk | CRL-7232* | |
| human human | Hs 372.Sk Hs 392.Sk | CRL-7257* CRL-7268* | |
| human | Hs 402.Sk | CRL-7276* | |
| human | Hs 404.Sk | CRL-7278* | |
| human | Hs 405.Sk | CRL-7279* | |
| human | Hs 415.Sk | CRL-7288* | |
| human | Hs 507.Sk | CRL-7307* | |
| human | Hs 517.Sk | CRL-7311* | |
| human | Hs 523.Sk | CRL-7314* | |
| human | Hs 531.Sk | CRL-7315* | |
| human | Hs 544Sk | CRL-7317* | |
| human | Hs 545.Sk | CRL-7318* | |
| human | Hs 548.Sk | CRL-7320* | |
| human | Hs 556.Sk | CRL-7321* | |
| human | Hs 559.Sk | CRL-7323* | |
| human | Hs 613.Sk | CRL-7375* | |
| human | Hs 621.Sk | CRL-7383* | |
| human | Hs 622.Sk | CRL-7385* | scalp |
| human | Hs 674.Sk | CRL-7397* | |
| human | Hs 677.Sk | CRL-7406* | |
| human | Hs 680.Sk | CRL-7419* | |
| human | Hs 687.Sk Hs 696.Sk | CRL-7424* CRL-7431* | |
| human human | Hs 700.Sk | CRL-7431** | |
| human | Hs 706.5k | CRL-7439 | |
| human | Hs 707(B).Ep | CRL-7449* | epidermis |
| human | Hs 731.Sk | CRL-7465* | еріастії |
| human | Hs 733.Sk | CRL-7469* | |
| human | Hs 734.Sk | CRL-7470* | |
| human | Hs 739.Sk | CRL-7476* | |
| human | Hs 740.Sk | CRL-7478* | |
| human | Hs 741.Sk | CRL-7479* | |
| human | Hs 749.Sk | CRL-7487* | |
| human | Hs 781.Sk | CRL-7510* | |
| human | Hs 782.Sk | CRL-7513* | |
| human | Hs 788.Sk | CRL-7516* | |
| human | Hs 793.Sk | CRL-7523* | |
| human | Hs 803.Sk | CRL-7533* | |
| human | Hs 803.T | CRL-7534* | |
| human | Hs 813.Sk | CRL-7545* | |
| human | Hs 824.Sk | CRL-7558* | |
| human | Hs 828.Sk Hs 833(C).Sk | CRL-7564* CRL-7567* | |
| human human | Hs 836.Sk | CRL-7570* | |
| human | Hs 844.Sk | CRL-7576* | |
| human | Hs 846.Sk | CRL-7578* | |
| human | Hs 854.Sk | CRL-7589* | |
| human | Hs 855.Sk | CRL-7591* | |
| human | Hs 864.Sk | CRL-7599* | scalp |
| human | Hs 865.Sk | CRL-7601* | ' |
| human | Hs 867.Sk | CRL-7603* | |
| human | Hs 871.Sk | CRL-7608* | |
| human | Hs 888.Sk | CRL-7623* | |
| | | | |



| Species | Cell Line Name | ATCC® No. | Description |
|-------------------------|------------------------|-----------|-----------------------------------|
| Skin continued | | | |
| human | Hs 898.Sk | CRL-7640* | |
| human | Hs 903.Sk | CRL-7648* | |
| human | Hs 904.Sk | CRL-7650* | |
| human | Hs 919.Sk | CRL-7671* | |
| human | Hs 924.Sk | CRL-7674* | |
| human | Hs 929.Sk | CRL-7681* | |
| human | HF 322.Sk | CRL-7703* | fetal |
| human | HE-SK | CRL-7718* | fetal |
| human | TE 90.Sk | CRL-7739* | retui |
| human | TE 91.Sk | CRL-7740* | |
| human | HT 297.T | CRL-7782* | actinic keratosis |
| human | Hs 446.Sk | CRL-7801* | deline relations |
| human | Hs 456.Sk | CRL-7804* | |
| human | Hs 456.Bt | CRL-7805* | benign lesion |
| human | Hs 466.Sk | CRL-7807* | scalp |
| human | Hs 467.Sk | CRL-7808* | errorp. |
| human | Hs 469.Sk | CRL-7811* | |
| human | Hs 483.Sk | CRL-7815* | |
| human | Hs 383.Sk | CRL-7842* | |
| human | Hs 695.Sk | CRL-7855* | |
| human | Hs 910.Sk | CRL-7894* | |
| human | Malme-3 | HTB-102 | |
| mongoose, African water | A.P. | CRL-6295* | |
| mouse | RT101 | CRL-2002 | epidermis; chemically transformed |
| mouse | JB6 Cl 30-7b | CRL-2007 | epidermis |
| mouse | JB6 CI 41-5a | CRL-2010 | epidermis |
| mouse | T ³ 6274 | CRL-2012 | epidermis; chemically transformed |
| mouse | M. dunni (Clone III8C) | CRL-2017 | |
| muntjac | Indian Muntjac | CCL-157 | |
| rabbit | RAB-9 | CRL-1414 | |
| rabbit | DRS | CRL-6497* | |
| rabbit, cottontail | Sf1Ep | CRL-6502* | ear |
| rabbit, cottontail | Sf 1 Ep (NBL-11) | CCL-68 | epidermis |
| rat | FR | CRL-1213 | |
| Spermatocyte | | | |
| mouse | GC-2spd(ts) | CRL-2196 | SV40 large Tantigen transfected |
| Spleen | 1 , | | |
| bovine | BSp | CRL-6019* | |
| bovine | B2.Sp | CRL-6023* | |
| human | Hs 142.Sp | CRL-7090* | Down syndrome |
| human | Hs 173.Sp | CRL-7123* | 201113,1101110 |
| human | Hs 193.Sp | CRL-7148* | |
| human | Hs 202.Sp | CRL-7162* | |
| human | Hs 203.Sp | CRL-7164* | |
| human | Hs 204.Sp | CRL-7166* | |
| human | Hs 208.Sp | CRL-7169* | |
| human | Hs 209.Sp | CRL-7171* | |
| human | Hs 215.Sp | CRL-7176* | abnormal |
| human | Hs 221.Sp | CRL-7187* | |
| human | Hs 222.Sp | CRL-7189* | |
| human | Hs 230.Sp | CRL-7196* | |
| human | Hs 232.Sp | CRL-7198* | |
| human | Hs 697.Sp | CRL-7433* | |
| human | Hs 728.Sp | CRL-7463* | |
| human | HF 282.Sp | CRL-7701* | fetal |
| mouse | AKR/JA.Sp | CRL-6320* | |
| mouse | DBA A.Sp | CRL-6340* | |
| mouse | DBA C.Sp | CRL-6342* | |
| mouse | HR/+ A.Sp | CRL-6347* | |
| | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Cell Line Name | ATCC® No. | Description |
|-------------------|--|------------------------|--|
| • | | | · |
| mouse | HR/+B.Sp | CRL-6348* | |
| mouse | HR/+ C.Sp | CRL-6349* | |
| mouse | HR/+ D.Sp | CRL-6350* | |
| mouse | HR/+ E.Sp | CRL-6351* | |
| mouse | HR/+ F.Sp | CRL-6352* | |
| mouse | HR/+ G.Sp | CRL-6353* | |
| mouse | HR/HR 1.Sp | CRL-6354* | |
| mouse | HR/HR 2.Sp | CRL-6355* | |
| mouse | HR/HR 3.Sp | CRL-6356* | |
| mouse | MM44.Sp | CRL-6419* | |
| mouse | MM51.Sp | CRL-6427* | |
| mouse | SJL/JB | CRL-6452* | |
| mouse | SJL/JC | CRL-6453* | |
| Sternum | | | |
| goose | CGBQ | CCL-169 | |
| Synovium | | | |
| rabbit | HIG-82 | CRL-1832 | |
| Testis | | | |
| human | Hs 1.Tes | CRL-7002* | |
| human | Hs 181.Tes | CRL-7002 CRL-7131* | |
| mouse | TM3 | CRL-1714 | |
| mouse | TM4 | CRL-1715 | |
| mouse, transgenic | 15P-1 | CRL-2618 | Sertoli cells |
| mouse, transgenic | GC-1 spg | CRL-2053 | spermatogonia |
| pig | ST ST | CRL-1746 | spermatogonia |
| rat | Rn 5TES | CRL-6513* | |
| sheep | OA3.Ts | CRL-6546* | fetal |
| Thymus | OA3.13 | CIL 0540 | ictai |
| bovine | FB3.Thy | CRL-6039* | fetal |
| cat | FC56.Thy | CRL-6134* | fetal |
| cat | FC57.Thy | CRL-6136* | fetal |
| cat | FC58.Thy | CRL-6137* | fetal |
| cat | FC59.Thy | CRL-6139* | fetal |
| dog | Cf2Th | CRL-1430 | retui |
| dog | CF8.Thy | CRL-6211* | |
| dog | CF3.Th | CRL-6575* | |
| human | F.thy 62891 | CRL-10936 | immortalized with SV40 large T antigen |
| human | Hs 52.Th | CRL-7032* | Down syndrome |
| human | Hs 142.Th | CRL-7091* | Down syndrome |
| human | Hs 202.Th | CRL-7163* | Down syndrome |
| human | Hs 203.Th | CRL-7165* | |
| human | Hs 208.Th | CRL-7170* | |
| human | Hs 215.Th | CRL-7177* | abnormal |
| human | Hs 220.Th | CRL-7186* | ubilofffidi |
| human | Hs 221.Th | CRL-7188* | |
| human | Hs 225.Th | CRL-7191* | |
| human | Hs 230.Th | CRL-7195* | |
| human | Hs 232.Th | CRL-7197* | |
| human | Hs 234.Th | CRL-7200* | |
| human | Hs 910.Thm | CRL-7660* | |
| human | TE 199.T | CRL-7757* | thymic alymphoplasia |
| human | Hs 67.Th | CRL-7828* | |
| human | Hs 67 | HTB-163 | |
| | 113 07 | 1110 100 | |
| Thyroid | CDTI CONTRACTOR OF THE CONTRAC | CDL 1460 | |
| rat | FRTL | CRL-1468 | |
| Tongue | | | |
| bullfrog | FT | CCL-41 | |
| | | CCL 176 | |
| cat | Fc3Tg | CCL-176 | |
| | Fc3Tg Hs 677.Tg Hs 680.Tg | CRL-7408* CRL-7421* | |



| Species | Cell Line Name | ATCC® No. | Description |
|------------------------|----------------|-----------------------|----------------------------------|
| Tonsil | | | |
| human | Hs 198.Ton | CRL-7156* | |
| Trachea | | | |
| armadillo, nine-banded | DNI.Tr | CRL-6009* | |
| bovine | EBTr (NBL-4) | CCL-44 | |
| cat | FC114E.Tr | CRL-6167* | fetal |
| dog | CF46.Tr | CRL-6238* | |
| dog | CF52.Tr | CRL-6244* | |
| human | Hs 680.Tr | CRL-7422* | |
| Trunk | | | |
| bluegill | BF-2 | CCL-91 | caudal |
| Turbinate | | | |
| bovine | ВТ | CRL-1390 | |
| pig | PT-K75 | CRL-2528 | nasal; mucosa |
| Unknown | | | |
| bovine | MBC(5) | CRL-6069* | |
| cat | F8 | CRL-6074* | |
| cat | FNS | CRL-6170* | |
| cat | FO-4 | CRL-6171* | |
| chicken | Gd1T | CRL-6180* | |
| chicken | RFGd10WE | CRL-6190* | possibly whole embryo |
| chicken | RFGd11WE | CRL-6191* | possibly whole embryo |
| chicken | RFGd12WE | CRL-6192* | possibly whole embryo |
| dog | CF28 | CRL-6223* | |
| goat | Ch2.D | CRL-6270* | possibly skin |
| horse | Horse | CRL-6583* | |
| human | TE 98.T | CRL-7741* | histiocytosis |
| human | Hs 914 | CRL-7895* | |
| human | Hs 915 | CRL-7896* | |
| human | Hs 916 | CRL-7897* | |
| human | 80T | CRL-7901* | |
| mouse | McCoy | CRL-1696 | |
| mouse | Mouse | CRL-6440* | |
| mouse | AL/N | CRL-6506* | |
| mouse | T-AL/N | CRL-6514* | |
| pig | PK(D1) | CRL-6490* | |
| rat | AVE-115 | CRL-6507* | |
| rat | RATV-NRK | CRL-6510* | possibly kidney |
| rat | UVE-10 | CRL-6515* | |
| talapoin | MT1.K | CRL-6309* | possibly kidney |
| Ureter | | | |
| human | MC-SV-HUC T-2 | CRL-9519 [†] | uroepithelium |
| human | SV-HUC-1 | CRL-9520 [†] | uroepithelium |
| Uterus | | | |
| bovine | BEND | CRL-2398 | endometrium |
| mink | GMMe [EPI] | CRL-2674 | endometrium |
| mink | GMMs [STR] | CRL-2675 | endometrium |
| raccoon | P1 1Ut (NBL-9) | CCL-74 | |
| Vagina | | | |
| human | VK2/E6E7 | CRL-2616 | mucosa; HPV-16 E6/E7 transformed |
| Vein | | | |
| human | HUV-EC-C | CRL-1730 | umbilical; vascular endothelium |
| human | HIVE-78 | CRL-2476 | iliac |
| human | HUVE-12 | CRL-2480 | umbilical |
| human | HUVS-112D | CRL-2481 | umbilical; smooth muscle |
| human | HIVS-125 | CRL-2482 | iliac; smooth muscle |
| human | HIVE-26 | CRL-2603 | iliac |
| human | HIVE-65 | CRL-2605 | iliac |
| human | HPVE-26 | CRL-2607 | pulmonary |
| human | HIVE-55 | CRL-2609 | iliac |
| | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



The ATCC Cell Biology Collection includes a broad range of species. This index lists cells from species other than human, mouse, and rat. Most of these cell lines are from the NBL collection, which is described on page 12. For more information on a cell line, see the main list starting on page 30 or use the catalogue number to find the entry in the cell biology section of the ATCC online catalog.

| anteater skin TAM.T CRL-6001* armadillo, nine-banded trachea DNI.Tr CRL-6009* armyworm, fall ovary Sf9 CRL-1711 baboon, African spleen, lymphoblast; HVS transformed 26CB-1 CRL-1495 bass, white (Morone chrysops) embryo WBE CRL-2773 bat, free-tailed lung Tb 1 Lu CCL-88 bat, free-tailed lung Tb 1 Lu CRL-6564* bat, mouse-eared interscapular tumor, possibly basal cell Mvi/It CRL-66012* bluegill caudal trunk BF-2 CCL-91 bovine adrenal gland; capillary endothelium EJG CRL-8659! bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA CRL-61010* bovine Blymphocyte; lymphosarcoma BL3.1 CRL-3306 bovine bone marrow BBM CRL-6016* bovine bone marrow, fetal FBS.Bm CRL-6016* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine eye (cornea) BCC //D-1b CRL-2048 bovine kidney LB10.K CRL-6061* bovine kidney LB10.K CRL-6061* bovine lymph node BL10.K CRL-6022* bovine lymph node BL10.K CRL-6046* bovine lymph node LB10.K CRL-6046* | Species | Description | Name | ATCC® No. |
|--|------------------|---|--------------|-----------------------|
| armadillo, nine-banded trachea DNI.Tr CRL-6009* armyworm, fall ovary SF9 CRL-1711 baboon, African spleen, lymphoblast; HVS transformed 26CB-1 CRL-1495 bass, white (Morone chrysops) embryo WBE CRL-2773 bat, free-tailed lung Tb 1 Lu CCL-88 bat, free-tailed lung Tb 1 Lu CRL-6564* bat, mouse-eared interscapular tumor, possibly basal cell Mvi/It CRL-6564* bluegill caudal trunk BF-2 CCL-91 bovine adrenal gland; capillary endothelium EJG CRL-8659* bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBB CRL-6016* bovine bone marrow, fetal FBS.Bm CRL-6043* bovine bone marrow, fetal FBS.Bm CRL-6043* bovine bone marrow, lymphosarcoma LB10.Bm CRL-6063* bovine bone marrow, lymphosarcoma LB10.Bm CRL-6060* bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney LB10.K CRL-6038* bovine kidney LB10.K CRL-6038* bovine kidney LB10.K CRL-6038* bovine kidney LB10.K CRL-6038* bovine lymph node BLL CRL-6022* bovine lymph node | anteater | skin | TAM.T | CRL-6001* |
| baboon, African spleen, lymphoblast; HVS transformed 26CB-1 CRL-1495 bass, white (Morone chrysops) embryo WBE CRL-2773 bat, free-tailed lung Tb 1 Lu CCL-88 bat, free-tailed lung Tb 1 Lu CRL-6564* bat, mouse-eared interscapular tumor, possibly basal cell Mvi/lt CRL-6612* bluegill caudal trunk BF-2 CCL-91 bovine adrenal gland; capillary endothelium EJG CRL-8659¹ bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA 47 CRL-1733 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBM CRL-6016* bovine bone marrow, fetal FBS.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine kidney MDBK (NBL-1) CCL-22 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-601* bovine lymph node BLn CRL-602* bovine lymph node BLn CRL-602* bovine lymph node BLn CRL-602* | | | DNI.Tr | |
| baboon, African spleen, lymphoblast; HVS transformed 26CB-1 CRL-1495 bass, white (Morone chrysops) embryo WBE CRL-2773 bat, free-tailed lung Tb 1 Lu CCL-88 bat, free-tailed lung Tb 1 Lu CRL-6564* bat, mouse-eared interscapular tumor, possibly basal cell Mvi/lt CRL-6612* bluegill caudal trunk BF-2 CCL-91 bovine adrenal gland; capillary endothelium EJG CRL-8659¹ bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA 47 CRL-1733 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBM CRL-6016* bovine bone marrow, fetal FBS.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine kidney MDBK (NBL-1) CCL-22 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-601* bovine lymph node BLn CRL-602* bovine lymph node BLn CRL-602* bovine lymph node BLn CRL-602* | armyworm, fall | ovarv | Sf9 | CRL-1711 |
| bass, white (Morone chrysops) embryo WBE CRL-2773 bat, free-tailed lung Tb 1 Lu CCL-88 bat, free-tailed lung Tb 1 Lu CRL-6564* bat, mouse-eared interscapular tumor, possibly basal cell Mvi/It CRL-6012* bluegill caudal trunk BF-2 CCL-91 bovine adrenal gland; capillary endothelium EJG CRL-8659¹ bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA47 CRL-1733 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBm CRL-6016* bovine bone marrow, fetal FB5.Bm CRL-6016* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine eye (cornea) BCE C/D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6033* bovine kidney LB10.K CRL-6033* bovine kidney LB10.K CRL-6033* bovine lymph node BLN CRL-6017* bovine lymph node BLN CRL-6017* bovine lymph node BLN CRL-6017* bovine lymph node BLN CRL-6022* | | • | | |
| bat, free-tailed lung Tb 1 Lu CCL-88 bat, free-tailed lung Tb1.Lu CRL-6564* bat, mouse-eared interscapular tumor, possibly basal cell Mvi/It CRL-6012* bluegill caudal trunk BF-2 CCL-91 bovine adrenal gland; capillary endothelium EJG CRL-8659† bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA 47 CRL-1733 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBm CRL-6016* bovine bone marrow, fetal FB5.Bm CRL-6016* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bovine kidney BCC C/D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney LB10.K CRL-6061* bovine kidney LB10.K CRL-6061* bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node | | | WBE | CRL-2773 |
| bat, free-tailed lung Tb1.Lu CRL-6564* bat, mouse-eared interscapular tumor, possibly basal cell Mwi/lt CRL-6012* bluegill caudal trunk BF-2 CCL-91 bovine adrenal gland; capillary endothelium EJG CRL-8659† bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA 47 CRL-1733 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow bone marrow, fetal FB5.Bm CRL-6016* bovine bone marrow, fetal FB5.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bovine bone heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney LB10.K CRL-6061* bovine lymph node BLN CRL-6012* bovine lymph node BLN CRL-6017* bovine lymph node B2.Ln CRL-6046* | bat, free-tailed | luna | Tb 1 Lu | CCL-88 |
| bat, mouse-eared interscapular tumor, possibly basal cell Mvi/lt CRL-6012* bluegill caudal trunk BF-2 CCL-91 bovine adrenal gland; capillary endothelium EJG CRL-8659† bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA 47 CRL-1733 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBm CRL-6016* bovine bone marrow, fetal FB5.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma BCC //D-1b CRL-2048 bovine bone marrow; lymphosarcoma BCC //D-1b CRL-2048 bovine bovine bone marrow; lymphosarcoma BCC //D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney BLN CRL-6061* bovine lymph node BLN CRL-6017* bovine lymph node BLN CRL-6022* bovine lymph node BLN CRL-6026* | | | | |
| bluegill caudal trunk BF-2 CCL-91 bovine adrenal gland; capillary endothelium EJG CRL-8659† bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA 47 CRL-1733 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBM CRL-6016* bovine bone marrow, fetal FB5.Bm CRL-6016* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-2048 bovine bone marrow; lymphosarcoma LB10.Bm CRL-2048 bovine bone heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node BLn CRL-6022* bovine lymph node | bat, mouse-eared | | Mvi/It | CRL-6012* |
| bovine adrenal gland; capillary endothelium EJG CRL-8659† bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA 47 CRL-1733 bovine Blymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBm CRL-6016* bovine bone marrow, fetal FBS.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-2048 bovine bone heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* | | | | |
| bovine adrenal gland (cortex); zona fasciculata, zona reticularis SBAC CRL-1796 bovine artery, pulmonary; vascular endothelium CPAE CCL-209 bovine artery, pulmonary; vascular endothelium CPA 47 CRL-1733 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBm CRL-6016* bovine bone marrow, fetal FB5.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-2048 bovine eye (cornea) BCE C/D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-603* bovine lymph node BLn CRL-6017* bovine lymph node BLn CRL-6022* bovine lymph node | | adrenal gland; capillary endothelium | EJG | CRL-8659 [†] |
| bovine artery, pulmonary; vascular endothelium CPA 47 CRL-1733 bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBm CRL-6016* bovine bone marrow, fetal FB5.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-2048 bovine eye (cornea) BCE C/D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node BLn CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | <u> </u> | SBAC | CRL-1796 |
| bovine B lymphocyte; lymphosarcoma BL3.1 CRL-2306 bovine bone marrow BBm CRL-6016* bovine bone marrow, fetal FB5.Bm CRL-6043* bovine bone marrow; lymphosarcoma LB9.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine bone marrow; lymphosarcoma LB10.Bm CRL-2048 bovine eye (cornea) BCE C/D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | artery, pulmonary; vascular endothelium | CPAE | CCL-209 |
| bovineB lymphocyte; lymphosarcomaBL3.1CRL-2306bovinebone marrowBBmCRL-6016*bovinebone marrow, fetalFB5.BmCRL-6043*bovinebone marrow; lymphosarcomaLB9.BmCRL-6053*bovinebone marrow; lymphosarcomaLB10.BmCRL-6060*bovineeye (cornea)BCE C/D-1bCRL-2048bovineheart, vascular endothelium; fetalFBHECRL-1395bovinekidneyMDBK (NBL-1)CCL-22bovinekidneyLB10.KCRL-6061*bovinekidney, fetalFB2.KCRL-6033*bovinelymph nodeBLnCRL-6017*bovinelymph nodeB2.LnCRL-6022*bovinelymph nodeLBLNCRL-6046* | bovine | 2:1 | CPA 47 | CRL-1733 |
| bovinebone marrow, fetalFB5.BmCRL-6043*bovinebone marrow; lymphosarcomaLB9.BmCRL-6053*bovinebone marrow; lymphosarcomaLB10.BmCRL-6060*bovineeye (cornea)BCE C/D-1bCRL-2048bovineheart, vascular endothelium; fetalFBHECRL-1395bovinekidneyMDBK (NBL-1)CCL-22bovinekidneyLB10.KCRL-6061*bovinekidney, fetalFB2.KCRL-6033*bovinelymph nodeBLnCRL-6017*bovinelymph nodeB2.LnCRL-6022*bovinelymph nodeLBLNCRL-6046* | bovine | | BL3.1 | CRL-2306 |
| bovine bone marrow; lymphosarcoma LB9.Bm CRL-6053* bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine eye (cornea) BCE C/D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | bone marrow | BBm | CRL-6016* |
| bovine bone marrow; lymphosarcoma LB10.Bm CRL-6060* bovine eye (cornea) BCE C/D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | bone marrow, fetal | FB5.Bm | CRL-6043* |
| bovine eye (cornea) BCE C/D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | bone marrow; lymphosarcoma | LB9.Bm | CRL-6053* |
| bovine eye (cornea) BCE C/D-1b CRL-2048 bovine heart, vascular endothelium; fetal FBHE CRL-1395 bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | | LB10.Bm | CRL-6060* |
| bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | | BCE C/D-1b | CRL-2048 |
| bovine kidney MDBK (NBL-1) CCL-22 bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | heart, vascular endothelium; fetal | FBHE | CRL-1395 |
| bovine kidney LB10.K CRL-6061* bovine kidney, fetal FB2.K CRL-6033* bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | | MDBK (NBL-1) | CCL-22 |
| bovine lymph node BLn CRL-6017* bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | kidney | LB10.K | |
| bovine lymph node B2.Ln CRL-6022* bovine lymph node LBLN CRL-6046* | bovine | kidney, fetal | FB2.K | CRL-6033* |
| bovine lymph node LBLN CRL-6046* | bovine | lymph node | BLn | CRL-6017* |
| , 1 | bovine | lymph node | B2.Ln | CRL-6022* |
| houing lymph node 3LPLN CPL 6047* | bovine | lymph node | LBLN | CRL-6046* |
| DOVINE SYMPHOUSE ZEDEN CKE-004/" | bovine | lymph node | 2LBLN | CRL-6047* |
| bovine lymph node 3LBLN CRL-6048* | bovine | lymph node | 3LBLN | CRL-6048* |
| bovine lymph node 5LBLN CRL-6049* | bovine | lymph node | 5LBLN | CRL-6049* |
| bovine lymph node 6LBLN CRL-6050* | bovine | lymph node | 6LBLN | CRL-6050* |
| bovine lymph node LB9.Ln CRL-6057* | bovine | lymph node | LB9.Ln | CRL-6057* |
| bovine lymph node LB10.Ln CRL-6062* | bovine | lymph node | LB10.Ln | |
| bovine lymph node LB11.Ln CRL-6066* | bovine | lymph node | LB11.Ln | CRL-6066* |
| bovine lymph node R2LBLN CRL-6070* | bovine | | R2LBLN | CRL-6070* |
| bovine lymph node, fetal FB2.Ln CRL-6034* | bovine | lymph node, fetal | FB2.Ln | CRL-6034* |
| bovine lymph node, fetal FB3.Ln CRL-6038* | bovine | lymph node, fetal | FB3.Ln | CRL-6038* |
| bovine lymph node, fetal FB4.Ln CRL-6041* | bovine | lymph node, fetal | FB4.Ln | CRL-6041* |
| bovine lymph node, fetal FB5.Ln CRL-6044* | | , , , | FB5.Ln | |
| bovine lymph node; leukemia 2FLB.Ln CRL-6045* | | , | 2FLB.Ln | |
| bovine lymphosarcoma; leukemia BL-3 CRL-8037* | bovine | lymphosarcoma; leukemia | BL-3 | CRL-8037* |
| bovine mixed spleen and thymus BThy CRL-6020* | | | BThy | |
| bovine mixed spleen and thymus B2.Sp/Thy CRL-6024* | bovine | mixed spleen and thymus | B2.Sp/Thy | CRL-6024* |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ory research use only. Not intended for use in humans, animals or for diagnostics.



| Species | Description | Name | ATCC® No. |
|-----------------|---|---------------------------------------|-----------------------|
| bovine | mixed spleen and thymus | FB2.Thy | CRL-6036* |
| bovine | mixed spleen, thymus, and bone marrow; lymphosarcoma | LB9.Sp/Thy/Bm | CRL-6052* |
| bovine | mixed spleen and thymus, fetal | FB4.Sp/Thy | CRL-6042* |
| bovine | skin, dermis | LB9.D | CRL-6054* |
| bovine | spleen | BSp | CRL-6019* |
| bovine | spleen | B2.Sp | CRL-6023* |
| bovine | spleen; lymphosarcoma | LB9.Sp | CRL-6058* |
| bovine | spleen; lymphosarcoma | LB10.Sp | CRL-6063* |
| bovine | spleen; lymphosarcoma | LB11.Sp | CRL-6067* |
| bovine | thymus, fetal | FB3.Thy | CRL-6039* |
| bovine | thymus; lymphosarcoma | LB9.Thy | CRL-6059* |
| bovine | thymus; lymphosarcoma | LB10.Thy | CRL-6064* |
| bovine | thymus; lymphosarcoma | LB11.Thy | CRL-6068* |
| bovine | trachea | EBTr (NBL-4) | CCL-44 |
| bovine | turbinate | BT | CRL-1390 |
| bovine | unknown | MBC(5) | CRL-6069* |
| bovine | uterus, endometrium | BEND | CRL-2398 |
| bullfrog | tongue | FT | CCL-41 |
| bullhead, brown | mixed connective tissue and muscle | BB | CCL-59 |
| camel | skin | Dubca | CRL-2276 |
| cat | bone marrow | FC6.Bm | CRL-6081* |
| cat | bone marrow; erythroleukemia | F25 | CRL-6566* |
| cat | bone marrow; reticulum cell sarcoma | FC11.BM | CRL-6088* |
| cat | brain, astrocyte | G355-5 | CRL-2033 |
| cat | brain, astrocyte; Mo-MSV transformed | PG-4 (S ⁺ L ⁻) | CRL-2032 |
| cat | connective tissue; fibrosarcoma | FC77.T | CRL-6105* |
| cat | connective tissue; fibrosarcoma | FC81.T | CRL-6108* |
| cat | connective tissue; fibrosarcoma | FC94.T | CRL-6113* |
| cat | connective tissue; sarcoma | FC100.T | CRL-6115* |
| cat | embryo | NCE-F161 | CRL-8727 [†] |
| cat | embryo, whole | OSU1 | CRL-6178* |
| cat | embryo, whole | FC60(A).We | CRL-6571* |
| cat | fetus | FC60(B).We | CRL-6098* |
| cat | fetus | FC61 | CRL-6099* |
| cat | fetus | FC70.We | CRL-6102* |
| cat | fetus | FC118 | CRL-6124* |
| cat | fetus | FC60A.We | CRL-6140* |
| cat | fetus | FC60B.We | CRL-6141* |
| cat | fetus | FC63.Res | CRL-6143* |
| cat | fetus | FC71A.We | CRL-6145* |
| cat | fetus | FC104.We | CRL-6152* |
| cat | fetus | FC106.We | CRL-6154* |
| cat | fetus | FC107.We | CRL-6155* |
| cat | fetus | FC108.We | CRL-6156* |
| cat | fetus | FC109.We | CRL-6157* |
| cat | fetus | FC110.We | CRL-6158* |
| cat | fetus, whole | FC79.We | CRL-6106* |
| cat | fetus, whole | FC101 | CRL-6118* |
| cat | fetus, whole | FC102 | CRL-6119* |
| cat | fetus, whole | FC112 | CRL-6120* |
| cat | fetus, whole | FC113 | CRL-6121* |
| cat | fetus, whole | FC119 | CRL-6125* |
| cat | whole fetus; macrophage | Fcwf-4 | CRL-2787 |
| cat | kidney | FC5.K | CRL-6078* |
| cat | kidney | FC6.K | CRL-6082* |
| cat | kidney | FC115.K | CRL-6122* |
| cat | kidney | FC2.K | CRL-6126* |
| cat | kidney (cortex) | CRFK | CCL-94 |
| cat | lung | AK-D | CCL-150 |
| cat | lung | Fc2Lu | CCL-217 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Description | Name | ATCC® No. |
|--|---|---|
| lung | FC2 Lu | CRL-6569* |
| | | CRL-6130* |
| | | CRL-6173* |
| , , | | CRL-6117* |
| | | CRL-6168* |
| | | CRL-8012 [†] |
| , | | CRL-9116 [†] |
| | | CRL-9116* |
| · · · · · | | CRL-6367** |
| | | |
| | | CRL-11967 [†] CRL-11968 [†] |
| | | |
| | | CRL-2417 |
| · · · · · · | | CRL-6094* |
| , , , , , | | CRL-6176* |
| - | | CRL-6150* |
| | | CRL-6107* |
| · · · · · · · · · · · · · · · · · · · | | CRL-6110* |
| spleen; lymphoma | FC16.Sp | CRL-6174* |
| spleen; sarcoma | FC100.Sp | CRL-6116* |
| thymus, fetal | FC56.Thy | CRL-6134* |
| thymus, fetal | FC57.Thy | CRL-6136* |
| thymus, fetal | FC58.Thy | CRL-6137* |
| thymus, fetal | FC59.Thy | CRL-6139* |
| thymus; fibrosarcoma | FC81.Thy | CRL-6109* |
| thymus; osteosarcoma | FC95.Thy | CRL-6114* |
| | | CCL-176 |
| <u> </u> | | CRL-6167* |
| <u>, </u> | | CRL-6074* |
| | | CRL-6170* |
| | | CRL-6171* |
| | | CRL-2772 |
| Ovary | cco | CIL 2772 |
| peripheral blood Tlymphocyte | G14D | CRL-2760 |
| periprieral biood, i lymphocyte | 4140 | CIL 2700 |
| navinhaval blood P lymphablast | 100 | CRL-2756 |
| periprieral biood, b lymphobiast | 100 | CRL-2/30 |
| a salah saal bla sal Dharrach abla st | 2011 | CDL 2757 |
| peripheral blood, B lymphoblast | 3811 | CRL-2757 |
| | | CD1 0==0 |
| peripheral blood, macrophage | 421A | CRL-2759 |
| | | |
| peripheral blood, Tlymphoblast | 285.3 | CRL-2758 |
| | | |
| | | CRL-2536 |
| | | CRL-2111 |
| bursa; lymphoma | DT95 | CRL-2112 |
| embryo | UMNSAH/DF-1 | CRL-12203† |
| embryo | SL-29 | CRL-1590 |
| embryo | Gd1WE | CRL-6181* |
| embryo | RFGd2WE | CRL-6182* |
| embryo | RFGd3WE | CRL-6183* |
| embryo | RFGd4WE | CRL-6184* |
| embryo | RFGd5WE | CRL-6185* |
| liver; hepatocellular carcinoma | LMH | CRL-2117 |
| | LMH/2A | CRL-2118 |
| liver; hepatocellular carcinoma | | |
| liver; hepatocellular carcinoma spleen, T lymphocyte; transformed with REV-T; | ConA-C1-VICK | CRL-12135 [†] |
| spleen, T lymphocyte; transformed with REV-T; produces G-CSF spleen, T lymphocyte; transformed with REV-T; | <u> </u> | |
| spleen, T lymphocyte; transformed with REV-T; produces G-CSF spleen, T lymphocyte; transformed with REV-T; produces G-CSF | ConA-C1-VICK ConA-B1-VICK | CRL-12135† CRL-12357† |
| spleen, T lymphocyte; transformed with REV-T; produces G-CSF spleen, T lymphocyte; transformed with REV-T; | ConA-C1-VICK | CRL-12135 [†] |
| | lung lung, fetal lymph node, cervical lymph node, submandibular; lymphoma lymphoblast; lymphoma lymphoma mixed spleen, thymus, and bone marrow ovary peripheral blood mononuclear cells, T lymphocytes peripheral blood, T lymphoblast placenta salivary gland, sublingual skin spleen; fibrosarcoma spleen; lymphoma spleen; sarcoma thymus, fetal thymus, fetal thymus, fetal thymus, fetal thymus, fetal thymus; osteosarcoma tongue trachea, fetal unknown unknown ovary peripheral blood, B lymphoblast peripheral blood, T lymphocyte peripheral blood, B lymphoblast peripheral blood, T lymphoblast | lung. fetal FC2.Lu lung.fetal FC28.Lu lymph node. LFC16.Ln lymph node, cervical FC100.Ln lymph node, submandibular; lymphoma F, B lymphoblast; lymphoma FL74-UCD-1 lymphoma FL74-UCD-1 lymphoma FELV-3281 mixed spleen, thymus, and bone marrow FC83.Res ovary NEF26.Ov peripheral blood mononuclear cells, T lymphocytes FeT-J peripheral blood mononuclear cells, T lymphocytes FeT-J peripheral blood, T lymphoblast MXA-1 placenta FC47 salivary gland, sublingual NEF36.Sg skin FC87.Sk spleen; fibrosarcoma FC81.Sp spleen; fibrosarcoma FC83.Sp spleen; fibrosarcoma FC83.Sp spleen; sarcoma FC16.Sp spleen; spleen; spleen; fibrosarcoma FC83.Sp spleen; spleen; spleen; fibrosarcoma FC83.Sp spleen; |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ese products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

Order online at **www.lgcpromochem.com/atcc**, or contact your local LGC Promochem office. See back cover for details.



| Species | Description | Name | ATCC® No. |
|----------------------------|---|----------------------------------|------------------------|
| chicken | unknown, possibly whole embryo | RFGd12WE | CRL-6192* |
| crayfish | brain, cerebral ganglion | OLGA-PH-J/92 | CRL-2576 |
| cusimanse | lung | NZP-12 | CRL-1921 |
| deer, Columbian black tail | kidney | OHH1.K | CRL-6193* |
| deer, Columbian black tail | liver | OHH1.Li | CRL-6194* |
| deer, Columbian black tail | lung | OHH1.Lu | CRL-6195* |
| dog | bone, connective tissue; osteosarcoma | CF11.T | CRL-6217* |
| dog | bone; osteosarcoma | D17 | CRL-6248* |
| dog | bone; osteosarcoma | D22 | CRL-6250* |
| dog | bone; osteosarcoma | D17 | CRL-8468 [†] |
| dog | connective tissue; cancer | CF17.T | CRL-6219* |
| dog | connective tissue; cancer | CF21.T | CRL-6220* |
| dog | connective tissue; cancer | CF24.T | CRL-6221* |
| dog | kidney | MDCK (NBL-2) | CCL-34 |
| dog | kidney | DoCl1 (S+L-) | CCL-34.1 |
| dog | kidney | Super Tube | CRL-2285 |
| dog | kidney | Super Dome | CRL-2286 |
| dog | lung; osteosarcoma | D-17 | CCL-183 |
| dog | lymph node | CLN | CRL-6245* |
| dog | macrophage; histiocytosis; malignant | DH82 | CRL-10389 [†] |
| dog | macrophage; histiocytosis; malignant | DH82ECOK | CRL-10390 [†] |
| dog | mammary gland | CF30.Mg | CRL-6225* |
| dog | mammary gland | CF37.Mg | CRL-6230* |
| dog | mammary gland | CF38.Mg | CRL-6231* |
| dog | mammary gland | CF43.Mg | CRL-6234* |
| dog | mammary gland | CF44.Mg | CRL-6235* |
| dog | mammary gland | CF47.Mg | CRL-6239* |
| dog | mammary gland | CF48.Mg | CRL-6240* |
| dog | mammary gland | CF49.Mg | CRL-6241* |
| dog | mammary gland, cancer | CF33.MT | CRL-6227* |
| dog | mammary gland, cancer | CF34.Mg | CRL-6228* |
| dog | mammary gland, cancer | CF35.Mg | CRL-6229* |
| dog | mammary gland, cancer | CF41.Mg | CRL-6232* |
| dog | mammary gland, cancer | CF45B.Mg | CRL-6237* |
| dog | osteosarcoma; amphotropic retroviral packaging line | DAN | CRL-2130 |
| dog | osteosarcoma; produces SNV helper virus | DSN | CRL-9939 [†] |
| dog | osteosarcoma; retroviral packaging line | DSDh | CRL-2131 |
| dog | thymus | Cf2Th | CRL-1430 |
| dog | thymus | CF8.Thy | CRL-6211* |
| dog | thymus | CF3.Th | CRL-6575* |
| dog | trachea | CF46.Tr | CRL-6238* |
| dog | trachea | CF52.Tr | CRL-6244* |
| dog | unknown | CF28 | CRL-6223* |
| dog | unknown; tumor | A-72 | CRL-1542 |
| Drosophila | embryo | Schneider's Drosophila Line 2 | CRL-1963 |
| Drosophila | embryo; overproduces P element transposase | L-2/M Δ2-3 | CRL-10191 [†] |
| duck, Pekin | embryo | Duck embryo | CCL-141 |
| ferret | brain | Mpf | CRL-1656 |
| fox, grey | lung | FoLu | CCL-168 |
| frog, grass | embryo; androgenetic haploid | ICR-2A | CCL-145 |
| frog, grass | embryo; gynogenetic haploid | ICR 134 | CCL-128 |
| gerbil, Mongolian | connective tissue; fibroma | IMR-33 | CCL-146 |
| gerbil, Mongolian | lung | GeLu | CCL-100 |
| goat | esophagus | Ch 1 Es (NBL-8) | CCL-73 |
| goat | esophagus | Ch1.Es | CRL-6581* |
| goat | unknown, possibly skin | Ch2.D | CRL-6270* |
| goldfish | fin | CAR | CCL-71 |
| goose | sternum | CGBQ | CCL-169 |
| guinea pig | colon; colorectal adenocarcinoma | GPC-16 | CCL-242 |
| guinea pig | fetus | 104C1 | CRL-1405 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Description | Name | ATCC® No. |
|--|---|--|------------------------|
| | | U14 1 4 | CCI 150 |
| guinea pig | lung | JH4 clone 1 | CCL-158 CCL-195 |
| hamster, Armenian | lung | AHL-1 | CCL-195 CCL-16 |
| hamster, Chinese | lung | Don | CCL-16 CCL-39 |
| hamster, Chinese | lung | Dede V79-4 | |
| hamster, Chinese hamster, Chinese | lung | R 1610 | CCL-93 CRL-1657 |
| | lung | CHL/IU | CRL-1037 CRL-1935 |
| hamster, Chinese hamster, Chinese | lung lung | XR-V15B | CRL-1935 CRL-2349 |
| hamster, Chinese | | CHO-K1 | CCL-61 |
| hamster, Chinese | ovary | AA8 | CRL-1859 |
| hamster, Chinese | ovary ovary; dihydrofolate reductase deficient | CHO/dhFr | CRL-9096 [†] |
| hamster, Chinese | ovary; expresses IgG1 (kappa) against IL-8 | CHO DP-12, clone#1933 | CRL-12444† |
| | | alL8.92 NB 28605/12 | |
| hamster, Chinese | ovary; expresses IgG1 (kappa) against IL-8 | CHO DP-12, clone#1934 aIL8.92 NB 28605/14 | CRL-12445 [†] |
| hamster, Chinese | peritoneum | B14FAF28-G3 | CCL-14 |
| hamster, Chinese | peritoneum | NCTC 4206 | CCL-14.2 |
| hamster, Chinese | somatic cell hybrid; mouse chromosome 8 | MC2/3 | CRL-2143 |
| hamster, Syrian golden | BHK-21 transformed and expressing human erythropoietin | BHK21-pcDNA3.1-HC | CRL-13001 [†] |
| hamster, Syrian golden | ductus deferens, smooth muscle; leiomyosarcoma | DDT ₁ MF-2 | CRL-1701 |
| hamster, Syrian golden | kidney | BHK-21 (C-13) | CCL-10 |
| hamster, Syrian golden | kidney | HaK | CCL-15 |
| hamster, Syrian golden | kidney | tk-ts13 | CRL-1632 |
| hamster, Syrian golden | kidney | 2254-62.2 | CRL-8544 [†] |
| hamster, Syrian golden | kidney | BHK570 | CRL-10314 [†] |
| hamster, Syrian golden | kidney; produces recombinant human erythropoeitin | BHK21-pcDNA3.1-HC | CRL-13001 [†] |
| hamster, Syrian golden | pancreas (islet of Langerhans); beta cell | HIT-T15 | CRL-1777 |
| hamster, Syrian golden | skin; melanotic melanoma | RPMI 1846 | CCL-49 |
| hamster, Syrian golden | tumor, adenovirus 12 induced; transfection host; exogenous gene expression | MCB3901 | CRL-9595 [†] |
| herring, Pacific (Clupea pallasi) | larvae | PHL | CRL-2750 |
| horse | skin, dermis | E. Derm (NBL-6) | CCL-57 |
| horse | unknown | Horse | CRL-6583* |
| iguana | heart | IgH-2 | CCL-108 |
| kusafugu (Fugu niphobles) | whole fry | Fugu fry | CRL-2642 |
| lizard, gekko | lung | Gekko lung-1 | CCL-111 |
| marmoset | colon; adenocarcinoma | TAC-1 | CRL-10632 [†] |
| marmoset, black tailed | kidney | NZP-60 | CRL-1924 |
| minipig | kidney | MPK | CCL-166 |
| mink | lung | Mv 1 Lu (NBL-7) | CCL-64 |
| mink | lung | MiCI1 (S+L-) | CCL-64.1 |
| mink | uterus, endometrium | GMMe [EPI] | CRL-2674 |
| mink | uterus, endometrium | GMMs [STR] | CRL-2675 |
| minnow, fathead | mixed connective tissue and muscle | FHM | CCL-42 |
| mongoose, African water | skin | A.P. | CRL-6295* |
| monkey, African green | kidney | BS-C-1 | CCL-26 |
| monkey, African green | kidney | CV-1 | CCL-70 |
| monkey, African green | kidney | Vero | CCL-81 |
| monkey, African green | kidney | PSP-36 | CRL-11171 [†] |
| monkey, African green | kidney | VERO C1008 | CRL-1586 |
| monkey, African green | kidney | VERO 76 | CRL-1587 |
| monkey, African green | kidney | COS-1 | CRL-1650 |
| monkey, African green | kidney | COS-7 | CRL-1651 |
| monkey, African green | kidney | MA-104 Clone 1 | CRL-2378.1 |
| monkey, African green | kidney | BSC40 | CRL-2761 |
| monkey, African green | kidney | W162 | CRL-2783 |
| monkey, African green | kidney; EBNA-1 expression | CV-1/EBNA-1 | CRL-10478 [†] |
| | | | |
| monkey, African green | lung | DBS-FCL-1 | CCL-161 |
| monkey, African green monkey, African green | lung lung | DBS-FCL-2 | CCL-161 CCL-162 |



| Species | Description | Name | ATCC® No. |
|--------------------------------|--|--------------------------------|-----------------------|
| monkey, Bolivian squirrel | kidney, tubule | SQMK-FP | CRL-2762 |
| monkey, Bolivian squirrel | lung, fetal | DPSO 114/74 | CCL-194 |
| monkey, Bolivian squirrel | peripheral blood; B lymphoblast; EBV transformed | SML, clone 4D8 | CRL-2311 |
| monkey, Guyanese squirrel | peripheral blood; B lymphoblast; EBV transformed | GSML | CRL-2699 |
| monkey, owl | kidney | OMK(637-69) | CRL-1556 |
| monkey, owl | peripheral blood; B lymphoblast; EBV transformed | OML, clone 13C | CRL-2312 |
| monkey, Rhesus | B lymphocyte; lymphoma | LCL 8664 | CRL-1805 |
| monkey, Rhesus | eye (retina, choroid), fetal | RF/6A | CRL-1780 |
| monkey, Rhesus | kidney | LLC-MK, | CCL-7 |
| monkey, Rhesus | kidney | LLC-MK, | CCL-7.1 |
| monkey, Rhesus | kidney | NCTC clone 3526 | CCL-7.2 |
| monkey, Rhesus | kidney, fetal | FRhK-4 | CRL-1688 |
| monkey, Rhesus | lung | DBS-FRhL-2 | CL-160 |
| monkey, Rhesus | lung (bronchus) | 4MBr-5 | CCL-208 |
| monkey, Rhesus | mammary gland; cancer | CMMT | CRL-6299* |
| mosquito | larva | Aedes aegypti | CCL-125 |
| mosquito | larva | Aedes albopictus | CCL-126 |
| mosquito | larva, whole | TRA-171 | CRL-1591 |
| mosquito | larva, whole | Aedes albopictus cloneC6/36 | CRL-1660 |
| moth | ovary | Antheraea cells, adapted | CCL-80 |
| moth, cabbage | larva | IZD-MB-0503 | CRL-8003 [†] |
| muntjac | skin | Indian Muntjac | CCL-157 |
| opossum | kidney (cortex, proximal tubule) | OK | CRL-1840 |
| oryx, short-horned | lung | NZP-29 | CRL-1925 |
| parakeet, shell | kidney | MU14.K | CRL-6485* |
| peccary | kidney | Peccary.K | CRL-6488* |
| pig | kidney | PK(15) | CCL-33 |
| pig | kidney | LLC-PK. | CL-101 |
| pig | kidney | LLC-PK _{1,0} | CL-101.1 |
| pig | kidney | ESK-4 | CL-184 |
| pig | kidney | PK13 | CRL-6489* |
| pig | kidney | PK-2a/CL 13 | CRL-6492* |
| pig | testis | ST | CRL-1746 |
| pig | turbinate, nasal; mucosa | PT-K75 | CRL-2528 |
| pig | unknown | PK(D1) | CRL-6490* |
| potoroo | kidney | Pt K1 (NBL-3) | CCL-35 |
| potoroo | kidney | PtK2 (NBL-5) | CCL-56 |
| potoroo | kidney | PtK1 | CRL-6493* |
| quail, Japanese | fibrosarcoma | QT6 | CRL-1708 |
| quail, Japanese | muscle; chemically induced fibrosarcoma | QM7 | CRL-1962 |
| quail, Japanese | neuroretina | QNR/D | CRL-2532 |
| quail, Japanese | neuroretina | QNR/K2 | CRL-2533 |
| rabbit | eye, cornea | SIRC | CCL-60 |
| rabbit | kidney | LLC-RK, | CCL-106 |
| rabbit | kidney | RK ₁₃ | CCL-37 |
| rabbit | kidney (cortex, proximal tubule) | Clone C | CRL-2531 |
| rabbit | kidney (proximal tubule) | vEPT | CRL-2087 |
| rabbit | lung, fetal | R9ab | CCL-193 |
| rabbit | skin | RAB-9 | CRL-1414 |
| rabbit | skin | DRS | CRL-6497* |
| rabbit | skin (ear) | Sf1Ep | CRL-6502* |
| rabbit | synovium | HIG-82 | CRL-1832 |
| rabbit | unknown; papilloma virus-induced carcinoma | VX7 | CRL-6504* |
| rabbit, cottontail | skin, epidermis | Sf 1 Ep (NBL-11) | CCL-68 |
| rabbit, cottontail | skin; papilloma | CTPS | CRL-6496* |
| raccoon | uterus | P1 1Ut (NBL-9) | CCL-74 |
| salmon, Atlantic (Salmo salar) | kidney | ASK | CRL-2747 |
| salmon, chum | heart | CHH-1 | CRL-1680 |
| salmon, Chinook | embryo | CHSE-214 | CRL-1681 |
| | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Species | Description | Name | ATCC® No. |
|----------------------------|---------------------------------|------------------|-----------------------|
| sheep | brain | OA1 | CRL-6538* |
| sheep | brain, choroid plexus | SCP | CRL-0538 |
| sheep | kidney | MDOK | CRL-1633 |
| sheep | kidney, fetal | OA4.K/S1 | CRL-6549* |
| sheep | testis, fetal | OA3.Ts | CRL-6546* |
| silkworm | unknown | BM-N | CRL-8910 [†] |
| snail | embryo | Bge | CRL-1494 |
| squirrel, plantain | embryo | NZP-46 | CRL-1926 |
| tahr | lung, fetal | HJ2.Lu | CRL-6277* |
| tahr | ovary | HJ1.Ov | CRL-6274* |
| talapoin | unknown; possibly kidney | MT1.K | CRL-6309* |
| toad, South African clawed | kidney | A6 | CCL-102 |
| toad, South African clawed | kidney | XLK-WG | CRL-2527 |
| toad, tropical | urinary bladder | TBM-54 | CRL-2051 |
| topminnow | liver; hepatocellular carcinoma | PLHC-1 | CRL-2406 |
| torafugu (Fugu rubripes) | eye | Fugu eye | CRL-2641 |
| trout, rainbow | gill | RTgill-W1 | CRL-2523 |
| trout, rainbow | gonadal tissue | RTG-P1 | CRL-2829 |
| trout, rainbow | liver | SOB-15 | CRL-2301 |
| trout, rainbow | liver; hepatoma | RTH-149 | CRL-1710 |
| trout, rainbow | mixed testis and ovary | RTG-2 | CCL-55 |
| turkey | lymph node; Marek's disease | MDTC-RP19 | CRL-8135 [†] |
| turtle, box | heart | TH-1, Subline B1 | CCL-50 |
| viper, Russell's | heart | VH 2 | CCL-140 |
| viper, Russell's | spleen; tumor, unknown primary | VSW | CCL-129 |
| woodchuck, Eastern | liver; hepatoma | WCH-17 | CRL-2082 |
| zebra, Burchell's | kidney | NZP-36 | CRL-1922 |
| zebrafish | embryo | ZF4 | CRL-2050 |
| zebrafish | embryo | ZEM2S | CRL-2147 |
| zebrafish | fin, caudal | SJD.1 | CRL-2296 |
| zebrafish | fin, caudal | AB.9 | CRL-2298 |
| zebrafish | liver, parenchymal cells | ZFL | CRL-2643 |
| | · | | |



There are approximately 1,000 hybridomas in the ATCC Cell Biology

Collection. They are listed by the antigenic determinant recognized

by their expressed monoclonal antibodies. For more information on a

hybridoma, see the main list on page 30 or use the catalogue number to

find the entry in the cell biology section of the ATCC online catalog.

| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|----------------|-------------|-----------------------|
| Abelson murine leukemia virus, 16-kDa antigen | rat/mouse | lgG2a | CDR1 | HB-213 |
| abl oncogene peptide, synthetic | mouse | IgG1 and IgG2b | 310-29F7 | CRL-2656 |
| abl oncogene peptide, synthetic | mouse | lgG1 and lgG2b | 311-3D4 | CRL-2657 |
| abl oncogene peptide, synthetic | mouse | lgG1 | 312-13E8 | CRL-2658 |
| Acetylcholine receptor (AChR) alpha subunit | rat | lgG2a | mAb64 | HB-8987 [†] |
| Acetylcholine receptor (AChR) alpha subunit | rat/mouse | lgG1 | mAb 35 | HB-8857 [†] |
| Acetylcholine receptor (AChR) alpha subunit | rat/mouse | lgG1 | mAb35 | TIB-175 |
| Acetylcholine receptor, neuronal, chicken | rat/mouse | lgG2a | mAb 270 | HB-189 |
| Acetylcholine receptor, neuronal, rat | rat/mouse | lgG2a | mAb 270 | HB-189 |
| Acetylcholinesterase, human | mouse | lgG1 | AE-1 | HB-72 |
| Acetylcholinesterase, human | mouse | lgG1 | AE-2 | HB-73 |
| Acid phosphatase, prostatic (PAP), human | mouse | lgG1 | RLTM01 | HB-8526 [†] |
| Acid phosphatase, prostatic (PAP), human | mouse | lgG1 | RLTM02 | HB-8523 [†] |
| Actin | mouse | lgG1 | ACT I | HB-80 |
| Actin | mouse | IgG1 | ACT IV | HB-81 |
| Actinin, alpha | mouse | IgM | G-3-5 | CRL-2252 |
| Addressin, mucosal vascular, mouse | rat/mouse | IgG2a | MECA-89 | HB-292 |
| Addressin, peripheral node, mouse | rat/mouse | IgM | MECA-79 | HB-9479 [†] |
| Adenocarcinoma, colon, human | mouse | lgG1 | CLT 85 | HB-8240 [†] |
| Adenocarcinoma, colon, human | mouse | IgG3 | HT 29/36 | HB-8248 [†] |
| Adenovirus group-specific antigen | mouse | lgG2a | 2Hx-2 | HB-8117 [†] |
| Agrobacterium tumefaciens biovar 3 | mouse | lgG1 | F21-1D3G7C8 | HB-9463 [†] |
| Aldosterone | mouse | lgG1 | A2E11 | CRL-1846 |
| Alpha fetoprotein (AFP), human | mouse | lgG1; kappa | OM 3-1.1 | HB-134 |
| Alpha-1,3-dextran | mouse | IgA; lambda | J558 | TIB-6 |
| Alveolar surfactant protein (ASP) | mouse | IgG | DS-1 | HB-8906 [†] |
| Alveolar surfactant protein (ASP) | mouse | IgG1 | DS-3 | HB-8651 [†] |
| Alveolar surfactant protein (ASP) | mouse | IgG1 | DS-5 | HB-8653 [†] |
| Alveolar surfactant protein (ASP) | mouse | lgG1 | DS-6 | HB-8652 [†] |
| Amylase, salivary, human | mouse | IgG2a | 110-5 | HB-8984 [†] |
| Angiotensin-converting enzyme (ACE) | mouse | lgM | α-ACE 3.1.1 | HB-8191 [†] |
| Annexin I, human | mouse | IgG1 | EH17a | CRL-2209 |
| Annexin I, human | mouse | IgG1 | EH7a | CRL-2194 |
| Annexin II, human | mouse | IgG1 | EH7a | CRL-2194 |
| Antigen-dependent killer (K) cells, human | mouse | IgM; kappa | HNK-1 | TIB-200 |
| AP-2 adaptor protein of clathrin coated vesicles | mouse | IgG1 | AP.6 | CRL-2227 |
| Apolipoprotein A-I (Apo-A-I), human | mouse | IgG1 | A5.4 | CRL-2275 |
| Apolipoprotein E (ApoE), human | mouse | IgG1 | WU E-14 | CRL-2255 |
| Apolipoprotein E (ApoE), human | mouse | lgG1 | WU E-4 | CRL-2247 |
| Asialo GM1 | mouse | IgM | SH-34 | CRL-2405 |
| Asialo GM2 | mouse | IgM | 2D4 | TIB-185 |
| Astrocyte protein, human | mouse | IgM | J1-31 | CRL-2253 |
| Astrocyte, rat | mouse | lgG2a | RAN-2 | TIB-119 |
| Astrocytoma cell line, human | mouse | lgG2a | G253 | HB-9706 [†] |
| Astrocytoma cell line, human | mouse | lgG1 | K117 | HB-8553 [†] |
| Astrocytoma cell line, human | mouse | lgG1 | S5 | HB-9255 [†] |
| Astrovirus group antigen | mouse | lgG1 | 7F2-6D4-8E7 | HB-11945 [†] |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|---|-------------------------|-----------------------|--------------------|-----------------------|
| ATPase, rat (Na, K dependent) | mouse | lgG1 | 9-A5 | CRL-1844 |
| ATPase, rat (Na, K dependent) | mouse | lgG1 | 9-B1 | CRL-1845 |
| Autocrine growth factor, 15 kDa, human | mouse | IgM | CBL-1 | HB-8214 [†] |
| s cell antigen (p50), mouse | rat/mouse | IgM | RA3-2C2/1 | TIB-145 |
| B cell derived malignancies, human | mouse | IgG2a | Lym-1 | HB-8612 [†] |
| S cell growth factor 1, mouse | rat/mouse | IgG1 | 11B11 | HB-188 |
| s cell precursors, mouse | rat/mouse | lgG2b | 14.8 | TIB-164 |
| s cell stimulatory factor 1, mouse | rat/mouse | IgG1 | 11B11 | HB-188 |
| cells, bovine | mouse | IgG2a | CC56 | HB-273 |
| s cells, human | mouse | IgG2a | Lym-1 | HB-8612 [†] |
| lymphocytes, mouse | rat/mouse | IgM | J11d.2 | TIB-183 |
| 220, mouse | rat/mouse | IgM | RA3-3A1/6.1 | TIB-146 |
| 7.1, mouse | hamster/mouse | IgG | 16-10A1 | HB-301 |
| 7.1, mouse | rat/mouse | lgG2a | 1G10 | CRL-2223 |
| 7.2, mouse | | IgG2b | 2D10 | CRL-2223 |
| · · · · · · · · · · · · · · · · · · · | rat/mouse | | | |
| 7.2, mouse | rat/mouse | lgG2a | GL1 | HB-253 |
| asal cells (skin), human | mouse | lgG1 | VM-2 | HB-8530 [†] |
| CGF-1, mouse | rat/mouse | lgG1 | 11B11 | HB-188 |
| licoid (bcd) protein, <i>Drosophila melanogaster</i> | mouse | lgG1 | bcd mab23 | CRL-2107 |
| lood group A antigen | human | IgM | HAA1 | HB-8534 [†] |
| luetongue virus VP7 | mouse | lgG2b | 7D3A.2 | CRL-1886 |
| luetongue virus VP7 | mouse | lgG2a | 8A3B.6 | CRL-1875 |
| Bluetongue virus VP7 | mouse | lgG2b | 8B1B.1 | CRL-1877 |
| Sovine herpesvirus 1 (BHV-1) | bovine/mouse | lgG1 | αBL5C2.870005 | HB-9907 [†] |
| Sovine herpesvirus 1 (BHV-1) | bovine/mouse | lgG1 | αBL5C2.870009 | HB-9908 [†] |
| ovine herpesvirus 1 (BHV-1) | bovine/mouse | lgG1 | αBL5C2.870016 | HB-9909 [†] |
| Bovine herpesvirus 1 (BHV-1) | mouse | lgG1 | 1B8-F11 | CRL-1852 |
| sovine herpesvirus 1 (BHV-1) | mouse | lgG2b | 2H6-C2 | CRL-1853 |
| 3p35 (B cell antigen), human | mouse | lgG2a | 1F5 | HB-9645 [†] |
| p50 (B cell antigen), human | mouse | lgG1 | G28-5 | HB-9110 [†] |
| reast cancer cells, human | mouse | lgG1 | 317G5.C1D3 | HB-8691 [†] |
| reast cancer cells, human | mouse | lgG2a | 454C11 | HB-8484 [†] |
| reast cancer cells, human | mouse | lgG1 | 520C9 | HB-8696 [†] |
| reast cancer cells, human | mouse | | 650E2-2B12 | HB-10812 [†] |
| SF-1, mouse | rat/mouse | lgG1 | 11B11 | HB-188 |
| Subonic plague bacillus | mouse | IgA | F1-3G8-1 | HB-192 |
| 3d receptor (CR2), human | mouse | lgG2a; kappa | THB-5 | HB-135 |
| Calpain 2 (CAPN2), bovine | mouse | lgG1 (kappa) | P-1 | CRL-2588 |
| Calpain, human | mouse | lgG1 (kappa) | P-6 | CRL-2589 |
| Calpain, human | mouse | IgG1 (kappa) | P-9 | CRL-2590 |
| Canine adenovirus type 1 (CAV-1) | mouse | IgG1 | 2E10-H2 | CRL-1812 |
| Canine adenovirus type 2 (CAV-2) | mouse | IgG2a | 4H1-A7 | CRL-1813 |
| Canine distemper virus (CDV) | mouse | IgG1 | CDC 1C42H11 | HB-216 |
| arcinoembryonic antigen (CEA) | mouse | IgM | 1116NS-3d | CRL-8019 [†] |
| arcinoembryonic antigen (CEA) | mouse | IgG1; kappa | T84.66A3.1A.1F2 | HB-8747 [†] |
| arcinoembryonic antigen (CEA) | mouse | IgG3 | KC-4G3 | HB-8709 [†] |
| arcinoma cells, human | mouse | IgM | KC-4M1 | HB-8710 [†] |
| arcinoma cens, numan arcinoma-associated antigen, heat stable, human | | IgG2a | AS 33 | HB-8779 [†] |
| alpastatin (CAST), human | mouse | IgG2a IgG1 (kappa) | PI-11 | CRL-2591 |
| -cadherin | mouse | іуот (карра) | AA5 | CRL-2591 CRL-2637 |
| | mouse | laC2h | | |
| C chemokine receptor CCR9 | mouse | lgG2b | LS129-3C3-E3-1 | HB-12653 [†] |
| C-chemokine receptor 1 (CCR1), human | mouse | IgG1 (kappa) | LS-125-2D4-11-10-1 | HB-12644 [†] |
| C-chemokine receptor 2 (CCR2), human | mouse | IgG2a (kappa) | LS132.1D9 | HB-12549 [†] |
| C-chemokine receptor 2 (CCR2), human | mouse | IgM | LS132.8G2 | HB-12550 [†] |
| hemokine receptor 4 (CCR4), human | mouse | IgG1 (kappa) | 1G1 | HB-12624 [†] |
| D1, bovine | mouse | lgG2a | CC20 | HB-267 |
| D1, human | mouse | lgG1 | OKT 6 | CRL-8020 [†] |
| D1, pig | mouse | lgG2a; kappa | 76-7-4 | HB-140 |
| D1.1, mouse | rat/mouse | IgG2b; kappa | 15C6 | HB-326 |
| D1.1, mouse | rat/mouse | lgG2b; kappa | 15F7 | HB-322 |
| . , | | | | |



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|---|-------------------------|--------------|---------------------------------------|-----------------------|
| CD1.1, mouse | rat/mouse | lgG1; kappa | 20H2 | HB-323 |
| CD1.1, mouse | rat/mouse | IgG2b | 4C4 | HB-327 |
| CD1w2, bovine | mouse | IgG2a | CC20 | HB-267 |
| CD2, bovine | mouse | IgG1 | CC42 | HB-272 |
| CD2, bovine | mouse | IgG2a | IL-A42 | CRL-1870 |
| ED2, human | mouse | IgG2a | 35.1 | HB-222 |
| ED2, human | | IgG1 | OKT 11 | CRL-8027 [†] |
| ED2, human | mouse | lgG1 | TS2/18.1.1 | HB-195 |
| CD2, sheep | mouse | IgG2a | 36F-18C | HB-285 |
| <u> </u> | mouse | | | |
| CD3 epsilon chain, human | mouse | lgG2b | BC3 | HB-10166 [†] |
| CD3, human | mouse | IgM | 38.1 | HB-231 |
| ED3, human | mouse | IgG2a | OKT 3 | CRL-8001 [†] |
| D3, mouse | hamster/mouse | IgG | 145-2C11 | CRL-1975 |
| D4, bovine | mouse | lgG1 | CC30 | HB-270 |
| D4, bovine | mouse | IgG2a | CC8 | HB-280 |
| D4, bovine | mouse | IgG2a | IL-A11 | CRL-1879 |
| D4, human | mouse | IgG2b | OKT 4 | CRL-8002 [†] |
| CD4, mouse | rat/mouse | lgG2b | GK1.5 | TIB-207 |
| CD4, sheep | mouse | lgG1 | 17D | HB-262 |
| D4a, pig | mouse | IgG2b; kappa | 74-12-4 | HB-147 |
| D4-binding domain of the gp120 protein of HIV-1 | human/mouse | lgG1 | 448-D | HB-10895 [†] |
| D4-binding domain of the gp120 protein of HIV-1 | human/mouse | lgG1 | 558-D | HB-10894 [†] |
| D4-binding domain of the gp120 protein of HIV-1 | human/mouse | lgG1 | 559/64-D | HB-10893 [†] |
| CD5, bovine | mouse | lgG1 | CC17 | HB-281 |
| CD5, bovine | mouse | lgG1 | CC29 | HB-269 |
| D5, human | mouse | lgG1 | OKT 1 | CRL-8000 [†] |
| D6, bovine | mouse | lgG2b | CC38 | HB-266 |
| CD6, human | mouse | lgG2a | 12.1 | HB-228 |
| ID6, human | mouse | IgM | 3Pt12B8 | HB-8136 [†] |
| ID7, human | mouse | lgG1; kappa | T3-3A1 | HB-2 |
| ID8, bovine | mouse | IgG1 | CC58 | HB-275 |
| CD8, bovine | mouse | lgG2a | CC63 | HB-264 |
| CD8, bovine | mouse | IgG1 | IL-A51 | CRL-1871 |
| CD8, human | mouse | IgG2a | 51.1 | HB-230 |
| CD8, human | mouse | IgG2a | OKT 8 | CRL-8014 [†] |
| CD8, human | mouse | IgG1 | S6F1 | HB-9579 [†] |
| D8 alpha 2.2, mouse | mouse | IgM | 83-12-5 | CRL-1971 |
| ED9, mouse | rat/mouse | | KMC8.8 | CRL-1971 |
| ED11a, human | | lgG2a | | |
| · | mouse | lgG1 | TS2/4.1.1 | HB-244 |
| ED11a, mouse | rat/mouse | lgG2b | FD441.8 | TIB-213 |
| CD11a, mouse | rat/mouse | lgG2a; kappa | M17/4.4.11.9 (new clone of M17/4.2) | TIB-217 |
| ED11a, mouse | rat/mouse | IgG2b; kappa | M17/5.2 | TIB-237 |
| D11b, human | mouse | IgM; kappa | 17aba | HB-248 |
| CD11b, human | mouse | lgG2a; kappa | 44aacb | HB-249 |
| D11b, human | mouse | lgG1 | LM2/1.6.11 | HB-204 |
| ID11b, human | mouse | lgG2b | OKM 1 | CRL-8026 [†] |
| ID11b, mouse | rat/mouse | lgG2b | 5C6 Clone 1 | CRL-1969 |
| CD11c, mouse | hamster/mouse | lgG | N418 | HB-224 |
| ED14, human | mouse | lgG2b; kappa | 26ic | HB-246 |
| ED14, human | mouse | lgG2b | 3C10 | TIB-228 |
| D14, human | mouse | lgG1; kappa | 60bca | HB-247 |
| D18, human | mouse | lgG2a; kappa | IB4 | HB-10164 [†] |
| ID18, human | mouse | lgG1 | TS1/18.1.2.11 | HB-203 |
| CD18, mouse | hamster/mouse | IgG | 2E6 | HB-226 |
| ED18, mouse | rat/mouse | IgG2a; kappa | M18/2.a.12.7 (new clone of M18/2.a.8) | TIB-218 |
| CD10 mouro | rat/mauss | IaC221k2n== | · | LD 30E |
| CD19, mouse | rat/mouse | IgG2a; kappa | 1D3 | HB-305 |
| ED20, human | mouse | lgG2a | 1F5 | HB-9645 [†] |
| D20, human | mouse | lgG1 | C273 | HB-9303 [†] |
| CD21, bovine | mouse | lgG2b | CC51 | HB-271 |
| | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|----------------------|---------------|-----------------------|
| CD21, human | mouse | IgG2a; kappa | THB-5 | HB-135 |
| ID25, human | mouse | IgG2a, Kappa | 7G7B6 | HB-8784 [†] |
| D25, mouse | rat/mouse | IgM; kappa | 7D4 | CRL-1698 |
| D25, mouse | rat/mouse | IgG1 | PC 61 5.3 | TIB-222 |
| D28 receptor, mouse | hamster/mouse | IgG | PV1 | HB-12352 [†] |
| D29, human | | lgG1 | TS2/16.2.1 | HB-243 |
| · | mouse | | KMI6 | CRL-2179 |
| D29, mouse | rat/mouse | lgG2a | FW4-101-1-1 | |
| D29, sheep | mouse | lgG1 | | HB-289 |
| D32, human | mouse | lgG2b | IV.3 | HB-217 |
| D32, mouse | rat/mouse | lgG2b | 2.4G2 | HB-197 |
| D33, human | mouse | IgG2a | M195 | HB-10306 [†] |
| D34, human | mouse | lgG1; kappa | AC133.1 | HB-12346 [†] |
| D35, human | mouse | lgG1; kappa | Mab 543 | HB-8592 [†] |
| D38, human | mouse | lgG1 | OKT 10 | CRL-8022 |
| D38, human | mouse | lgG1 | THB-7 | HB-136 |
| D40 ligand (CD154, CD40L), human | mouse | lgG1 | hCD40L-M90 | HB-12055 [†] |
| D40 ligand (CD154, CD40L), human | mouse | lgG1 | hCD40L-M91 | HB-12056 [†] |
| D40 ligand, human | mouse | lgG2a | 5c8 | HB-10916 [†] |
| D40 ligand, mouse | hamster/mouse | lgG | MR1 | CRL-2580 |
| D40, human | mouse | lgG2b | 3A8 | HB-12024 [†] |
| D40, human | mouse | lgG1 | G28-5 | HB-9110 [†] |
| D44, human | mouse | lgG2a | Hermes-3 | HB-9480 [†] |
| D44, mouse | rat/mouse | lgG1 | KM114 | TIB-242 |
| D44, mouse | rat/mouse | IgG1 | KM201 | TIB-240 |
| D44, mouse | rat/mouse | IgG2a | KM703 | CRL-1896 |
| D44, mouse | rat/mouse | IgG2a | KM81 | TIB-241 |
| D44, mouse | rat/mouse | IgG2a | LYK-12 | HB-316 |
| ID44, mouse | rat/mouse | IgG2a | LYK-16 | HB-319 |
| D44, mouse | rat/mouse | IgG1 | LYK-5 | HB-310 |
| D44, mouse, isoforms expressing variable exon V10 | rat/mouse | lgG1 | LYK-1 | HB-306 |
| CD44, mouse, isoforms expressing variable | rat/mouse | lgG1 | LYK-7 | HB-311 |
| CD44, mouse, isoforms expressing variable exon V10 | rat/mouse | lgG2a | LYK-8 | HB-312 |
| CD44, mouse, isoforms expressing variable exon V10 | rat/mouse | lgG2a | LYK-9 | HB-313 |
| D44, v4 variant, human | mouse | lgG2a | FW11-10-3 | HB-257 |
| ED44, v6 variant, human | mouse | lgG2a | FW11-9-2 | HB-256 |
| D44, v9 variant, human | mouse | IgG1 | FW11-24-17-36 | HB-258 |
| D45, human | mouse | IgG2a | 4B2 | HB-196 |
| D45, human | mouse | lgG2a | 9.4 | HB-10508 [†] |
| D45, human | mouse | IgG2a; kappa | GAP 8.3 | HB-12 |
| D45, mouse | rat/mouse | IgG2b | M1/89.18.7.HK | TIB-124 |
| D45, mouse | rat/mouse | IgG2a | M1/9.3.4.HL.2 | TIB-124 |
| D45, mouse | rat/mouse | IgG2a | MB23G2 | HB-220 |
| D45, mouse | rat/mouse | IgG2a | MB4B4 | HB-223 |
| • | | IgM; kappa | 74-9-3 | HB-156 |
| D45, pig | mouse | | | |
| D45R, mouse | rat/mouse | IgM | RA3-3A1/6.1 | TIB-146 |
| D45RA, mouse | rat/mouse | lgG2b | 14.8 | TIB-164 |
| D45RC, mouse | rat/mouse | IgM | I/24.D6 | HB-251 |
| D47, human | mouse | lgG1 | B6H12.2 | HB-9771 |
| D49a, human | mouse | lgG1 | TS2/7.1.1 | HB-245 |
| D49d, sheep | mouse | lgG2b | FW3-218-1 | HB-261 |
| D54, mouse | rat/mouse | lgG2a | BE29G1 | HB-233 |
| | mouse | lgM; kappa | HNK-1 | TIB-200 |
| D57, human | mouse | | TC2/0.1.4.2 | HB-205 |
| | mouse | lgG1 | TS2/9.1.4.3 | ПD-203 |
| D57, human D58, human | | lgG1 IgG2a; kappa | CL2 | CRL-2514 |
| D57, human | mouse mouse | IgG2a; kappa | CL2 | CRL-2514 |
| D57, human D58, human D62E, human | mouse | | | |



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|------------------------|---------------|------------------------|
| CD62L, human | mouso | lgG2a | 1H3 | HB-284 |
| CD62L, human | mouse | | DREG200 | HB-302 |
| • | mouse | lgG1 | | |
| CD62L, human | mouse | lgG1 | DREG56 | HB-300 |
| CD62L, mouse | rat/mouse | lgG2a | MEL-14 | HB-132 |
| CD62L, sheep and bovine | mouse | lgG1 | DU1-29 | HB-263 |
| CD62P, human | mouse | lgG1 | WAPS 12.2 | HB-299 |
| CD80, mouse | hamster/mouse | IgG | 16-10A1 | HB-301 |
| CD117, human | mouse | lgG2a | BA7.3C.9 | HB-10716 [†] |
| CDw128, human | mouse | lgG2a | 10H2.12.1 | HB-11494 [†] |
| CDw128, human | mouse | lgG2a | 4D1.5.7 | HB-11495 [†] |
| CD151, human | mouse | lgG1 | 41-2 | CRL-2695 |
| CD151, human | mouse | lgG1 | 50-6 | CRL-2696 |
| CD152, mouse | hamster/mouse | IgG | UC10-4F10-11 | HB-304 |
| CD154, human | | | 5c8 | HB-10916 [†] |
| <u> </u> | mouse | lgG2a | | |
| D154, mouse | hamster/mouse | IgG | MR1 | CRL-2580 |
| Cell surface antigen on bovine periodontal ligament cells | mouse | IgM | PDL-1 | CRL-1882 |
| Cell surface antigen on human myeloma cells (M-8 antigen system) | mouse | lgG1 | D 14 | HB-8439 [†] |
| Centromere protein B (CENP-B), human | mouse | lgG1 | 2D-7 | HB-9667 [†] |
| Cervical carcinoma, human | human | lgG1; kappa | CLN H11.4 | HB-8307 [†] |
| Cervical carcinoma, human | human | IgM | CLNH5.5 | HB-8206 [†] |
| Channel catfish immunoglobulin | mouse | lgG1; kappa | E-8 | HB-10179 [†] |
| Chlamydia genus-specific antigen | mouse | IgG2b; kappa | 89MS30 | HB-11300 [†] |
| Cholesterol | | <u> </u> | | |
| | mouse | IgM | 2C5-6 | HB-8995 [†] |
| Choriocarcinoma tumor cell antigen, human | mouse | lgG2a | K66 | HB-8767 [†] |
| Choriocarcinoma tumor cell antigen, human | mouse | lgG1 | SV63 | HB-8766 [†] |
| Choriocarcinomas, human | mouse | lgG1 (lgh-4a allotype) | 162-46.2 | HB-187 |
| Chronic lymphocytic leukemia (CLL) | mouse | lgG1 | Lym-2 | HB-8613 [†] |
| Class II antigen, beta chain, mouse | hamster/mouse | IgG | KL277 | CRL-2030 |
| Class II antigen, beta chain, mouse | mouse | lgG1 | KL295 | CRL-1996 |
| Class II antigen, beta chain, mouse | mouse | lgG2b | KL304 | CRL-2027 |
| Clathrin, bovine (brain) | mouse | IgM | CVC.4 | TIB-137 |
| Clathrin, heavy chain, human | mouse | lgG1 | TD.1 | CRL-2232 |
| Clathrin, heavy chain, human | mouse | lgG1 | X22 | CRL-2228 |
| Clathrin, fleavy Chain, floring (brain) | | | CVC.1 | TIB-135 |
| | mouse | lgG1 | | |
| Clathrin, light chain, bovine (brain) | mouse | lgG2a | CVC.7 | TIB-138 |
| Clathrin, light chain, human | mouse | lgG2b | CON.1 | CRL-2229 |
| Colchicine | mouse | lgG2a | C44 | CRL-1943 |
| Collagen, bone type 1 | mouse | lgG1 | 1H11 | HB-10611 [†] |
| Colon carcinoma-associated antigens (CCAA), human | mouse | lgG1; kappa | PCA 31.1 | HB-12314 [†] |
| Colon carcinoma-associated antigens (CCAA), human | mouse | IgG2a; kappa | PCA 33.28 | HB-12315 [†] |
| Colon cells, 29-kDa glycoprotein, human | mouse | lgG2a | HT 29/26 | HB-8247 [†] |
| Colon tumor-associated antigen (CTAA) 16.88 | human | lgG3; kappa | CO 88BV59-1 | CRL-10624 [†] |
| Colon, adenocarcinoma, human | mouse | IgG1 | CLT 85 | HB-8240 [†] |
| Colon, adenocarcinoma, numan | | IgG3 | HT 29/36 | HB-8248 [†] |
| | mouse | | | |
| Colonic mucin glycoprotein, human | mouse | lgG2a | UC7 | HB-9753 [†] |
| Colonic protein, human | mouse | IgM | 7E12H12 | HB-9397 [†] |
| Colony stimulating factor, subclass I (CSF-I), human | mouse | lgG1 | F18 AF1 | HB-8208 [†] |
| Colony stimulating factor, subclass I (CSF-I), human | mouse | lgG1 | F1A3-23 | HB-8207 [†] |
| Colorectal carcinoma monosialoganglioside | mouse | lgG1 | 1116-NS-19-9 | HB-8059 [†] |
| Colorectal carcinoma-associated tumor antigen | mouse | lgG2b | XMMCO-791 | HB-9173 [†] |
| Common leukocyte antigen, human | mouse | lgG2a | 4B2 | HB-196 |
| Common leukocyte antigen, mouse | rat/mouse | lgG2b | M1/89.18.7.HK | TIB-124 |
| Common leukocyte antigen, mouse | rat/mouse | lgG2a | M1/9.3.4.HL.2 | TIB-122 |
| | | IgG2a | MB23G2 | HB-220 |
| | | | IVII) / 3\1/ | DD=//U |
| Common leukocyte antigen, mouse | rat/mouse | | | |
| Common leukocyte antigen, mouse Common leukocyte antigen, mouse | rat/mouse | lgG2a | MB4B4 | HB-223 |
| Common leukocyte antigen, mouse Common leukocyte antigen, mouse Complement C1q, human Complement C1q, human | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|---------------------|---|-----------------------|
| Complement C3b receptor, human | mouse | lgG1; kappa | Mab 543 | HB-8592 [†] |
| Concanavalin A (Con A) | mouse | lgG1 | 71A7 | TIB-147 |
| Cortical thymic epithelium, mouse | rat/mouse | lgG2a | CDR1 | HB-213 |
| Cortical thymocytes, mouse | rat/mouse | IgM | J11d.2 | TIB-183 |
| Coxsackievirus B4 | mouse | IgG2a; kappa | 204-4 | HB-185 |
| Coxsackievirus B4 | mouse | IgG2a; kappa | 339-1 | HB-186 |
| Coxsackievirus B4 | mouse | IgG2a; kappa | 356-1 | HB-181 |
| Coxsackievirus B4 | mouse | IgG2a; kappa | 38-1 | HB-182 |
| Coxsackievirus-adenovirus receptor (CAR), human | mouse | IgG1 | RmcB | CRL-2379 |
| CR1, human | mouse | IgG1; kappa | Mab 543 | HB-8592 [†] |
| C-reactive protein, human | mouse | IgG2a; kappa | HD2-4 | HB-86 |
| Creatine kinase - MM and MB, human | rat/mouse | IgG2a; kappa | CKMM 14.15 | HB-9419 [†] |
| | | | CKMM 14.5 | |
| Creatine kinase - MM, human | rat/mouse | lgA; kappa | | HB-9420 [†] |
| Creatine kinase - MM, human | rat/mouse | lgG1; kappa | CKMM 14.52 | HB-9421 [†] |
| CTLA-4, mouse | hamster/mouse | IgG | UC10-4F10-11 | HB-304 |
| Cutaneous lymphocyte antigen (CLA), human | rat/mouse | IgM | HECA-452 | HB-11485 [†] |
| Cutaneous melanocytes (M-10 antigen system), human | mouse | lgG1 | M 144 | HB-8440 [†] |
| Cutaneous melanocytes (M-24 antigen system), human | mouse | lgG1 | M-24 (M138) | HB-8449 [†] |
| Cutaneous melanocytes (M-25 antigen system) , human | mouse | lgG2b | L368 | HB-8450 [†] |
| Cutaneous melanocytes (M-4 antigen system), human | mouse | IgG1 | M 111 | HB-8438 [†] |
| CXCR3 | mouse | IgG1 (kappa) | 1C6 | HB-12330 [†] |
| Cystic fibrosis transmembrane conductance regulator (CFTR) | mouse | IgG1 | mAb 13-1 | HB-10565 [†] |
| Cystic fibrosis transmembrane conductance | mouse | IgG2a; kappa | mAB 24-1 | HB-11947 [†] |
| regulator (CFTR) Cystic fibrosis transmembrane conductance regulator (CFTR) | mouse | lgG1; kappa | mAB 24-2 | HB-11946 [†] |
| Cytokeratin 18 (CK18) | mouse | IgG | UCD/PR 10.11 | HB-8694 [†] |
| Cytokeratin 18 (CK8) | | IgG | UCD/PR 10.11 | HB-8694 [†] |
| Cytomegalovirus (HCMV) UL18 heavy chain, human | mouse mouse | lgG1 | 10C7 | CRL-2430 |
| | | | | |
| Cytomegalovirus (HCMV), immediate - early | mouse | lgG1 | L-14 | HB-8554 [†] |
| antigen, human Cytomegalovirus (MCMV) m144 heavy chain, | mouse | lgG1 | 15C6 | CRL-2431 |
| mouse | | 1.621 | 14630 | CDL 2640 |
| DEC-205, human | mouse | lgG2b | MG38 | CRL-2640 |
| DEC-205, mouse | rat/mouse | IgG2a | DEC-205 | HB-290 |
| Delta heavy chain, human | mouse | lgG3; kappa | δΤΑ4-1 | HB-70 |
| Dendritic cell antigen, human | mouse | lgG2b | MG38 | CRL-2640 |
| Dendritic cell antigen, mouse | rat/mouse | lgG2a | DEC-205 | HB-290 |
| Dendritic cells, mouse | rat/mouse | lgG2b | 33D1 | TIB-227 |
| Dengue virus complex | mouse | lgG2a | D3-2H2-9-21 | HB-114 |
| Dengue virus type 1 | mouse | lgG1 | 15F3-1 | HB-47 |
| Dengue virus type 3 | mouse | lgG1 | 5D4-11 | HB-49 |
| Dengue virus type 4 | mouse | lgG1 | 1H10-6 | HB-48 |
| Dengue virus-2, type specific determinant | mouse | IgG1 | 3H5-1 | HB-46 |
| Dinitrophenyl (DNP) | hamster/mouse | IgG | UC8-1B9 | CRL-1968 |
| Dioxins | mouse | IgG2a; kappa | DD-4 | HB-9743 [†] |
| Diphtheria toxin | human/mouse | IgGza; kappa IgG | 16M3F10 | HB-8363 [†] |
| • | | | | |
| Disialosyl Lea (tumor associated fucoganglioside) | mouse | IgG3 | FHCR-1-2516/FH7 | HB-8861 [†] |
| DNA (single stranded) | mouse | IgG3 | MRSS-1 (D ₂ D ₄) | HB-69 |
| DNA polymerase alpha, human | mouse | lgG1 | SJK-132-20 | CRL-1640 |
| DNA polymerase alpha, human | mouse | lgG1 | SJK-237-71 | CRL-1645 |
| DNA polymerase alpha, human | mouse | lgG1 | SJK-287-38 | CRL-1644 |
| | mouse | lgG1 | STK 1 | CRL-1652 |
| DNA polymerase alpha, human | iiiouse | 1901 | | |
| | mouse | IgG2a | 3C5.1 | CRL-2284 |
| DNA polymerase alpha, human DNA polymerase epsilon (pol epsilon), human DNA polymerase III holoenzyme, <i>Escherichia coli</i> | | | 3C5.1 123-10 | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. aboratory research use only. Not intended for use in humans, animals or for diagnostics.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|---|-------------------------|----------------------|----------------------|--------------------------------|
| DNA polymerase III holoenzyme, Escherichia coli | mouse | IgM | 68-1-2 | CRL-1712 |
| DNA, double stranded | mouse | IgM | CH26-1352 | HB-8329 [†] |
| DNP and TNP substituted proteins | mouse | IgA; lambda 2 | MOPC 315 | TIB-23 |
| | | <u> </u> | 225 | HB-8508 [†] |
| GF receptor | mouse | lgG1 | 455 | HB-8507 [†] |
| GF receptor | mouse | lgG1 | | |
| GF receptor | mouse | lgG2a | 528 | HB-8509 [†] |
| GF receptor | mouse | IgG | 579 | HB-8506 [†] |
| GF receptor, human | mouse | lgM | Mab 96 | HB-9763 [†] |
| imeria tenella sporozoites | mouse | lgG1 | S1E4 | HB-8332 [†] |
| imeria tenella sporozoites | mouse | lgG2a | S3D3 | HB-8331 [†] |
| imeria tenella sporozoites and merozoites | mouse | lgG1 | 13.90.2 | HB-8337 [†] |
| imeria tenella sporozoites and merozoites | mouse | IgG2a | 2.03.7 | HB-8389 [†] |
| LAM-1, human | mouse | IgG2a; kappa | CL2 | CRL-2514 |
| LAM-1, human | mouse | lgG1; kappa | CL3 | CRL-2515 |
| LAM-1, human | mouse | IgG1; kappa | CL37 | CRL-2516 |
| LAM-1, human | mouse | lgG2a | H18/7 | HB-11684 [†] |
| M10 | mouse | lgM; kappa | SM27-1045 | HB-11917 [†] |
| ndothelial cells, IL-1 activated, human | mouse | lgG1 | 7A9 | HB-10135 [†] |
| Indothelial cells, peripheral lymph node, mouse | rat/mouse | IgM | MECA-79 | HB-9479 [†] |
| ndothelial leukocyte adhesion molecule 1 | mouse | lgG2a; kappa | CL2 | CRL-2514 |
| (ELAM-1), human | | | | |
| ndothelial leukocyte adhesion molecule 1 (ELAM-1), human | mouse | lgG1; kappa | CL3 | CRL-2515 |
| Endothelial leukocyte adhesion molecule 1 (ELAM-1), human | mouse | lgG1; kappa | CL37 | CRL-2516 |
| indothelial leukocyte adhesion molecule 1 (ELAM-1), human | mouse | lgG2a | H18/7 | HB-11684 [†] |
| Endothelium, human | mouse | IgG1; kappa | 10B9 | HB-172 |
| Indothelium, human | mouse | IgG1; kappa | 14E5 | HB-174 |
| pendymal cell, rat | mouse | lgG2a | RAN-2 | TIB-119 |
| pidermal growth factor (EGF) receptor | mouse | lgG1 | 225 | HB-8508 [†] |
| pidermal growth factor (EGF) receptor | mouse | IgG1 | 455 | HB-8507 [†] |
| pidermal growth factor (EGF) receptor | mouse | lgG2a | 528 | HB-8509 [†] |
| pidermal growth factor (EGF) receptor | mouse | IgG | 579 | HB-8506 [†] |
| pidermal growth factor (EGF) receptor, human | mouse | IgM | Mab 96 | HB-9763 [†] |
| pidermis, basal layer, fetal and neonatal, human | | IgG1 | DAL K20 | CRL-2288 |
| | mouse | | DAL K20 DAL K29 | CRL-2291 |
| pidermis, basal layer, fetal and neonatal, human | mouse | lgG1 | | |
| pithelial cells, gastrointestinal tract mucosa, 52-kDa protein, human | mouse | lgG1 | CLT 152 | HB-8244 [†] |
| pithelium, human | mouse | IgM; kappa | Ep-16 | HB-155 |
| pstein-Barr virus (EBV) | mouse | lgG1 | 72A1 | HB-168 |
| pstein-Barr virus (EBV) receptor quine infectious anemia virus (EIAV) core | mouse mouse | IgG2a; kappa IgG1 | THB-5 EIAV 12E8.1 | HB-135 HB-8917 [†] |
| antigen (p26) | mouse | igu í | LIAV IZLO.I | י / ולט-טוו |
| rb B (v-erb B) oncogene peptide, synthetic | mouse | lgG1 | 171-11B9 | CRL-2661 |
| rb B (v-erb B) oncogene peptide, synthetic | mouse | IgG1 | 172-12A4 | CRL-2660 |
| rb B (v-erb B) oncogene peptide, synthetic | mouse | lgG1; kappa | 173-1C11 | CRL-2659 |
| rb B2 (c-erb B2) protein, human | mouse | IgG1; kappa | 20.3 | CRL-2655 |
| rb B-2 protein, human | mouse | IgG1, kappa | Ab 21.1 | HB-11601 [†] |
| rb B-2 protein, human | | lgG1 | Ab 23.1 | HB-11602 [†] |
| rgonovine | mouse | | EN9F10 | CRL-2403 |
| | mouse | IgG2b (kappa) | | |
| rythrocytes, mouse | rat/mouse | IgM | J11d.2 | TIB-183 |
| rythropoietin | mouse | lgG1 | 5F12 AD3 | HB-8209 [†] |
| rythropoietin, human | rat/mouse | lgG2a | BF-11 | CRL-8164 [†] |
| scherichia coli 0157:H7 strain 932 | mouse | lgG2a | 4E8C12 | HB-10452 [†] |
| arnesyltransferase, alpha subunit | mouse | lgG1 | IgG-IB7 | CRL-2418 |
| as antigen, human | mouse | lgG1 | huFasM3 | HB-11726 [†] |
| as antigen, human | mouse | lgG1 | huFasM38 | HB-11465 [†] |
| c alpha receptor, human | mouse | IgM | My 43.51 | HB-12128 [†] |
| c gamma receptor, high affinity, human | mouse | IgG1; kappa | CT6-1D7 | CRL-2438 |
| | | | 2.4G2 | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|---|-------------------------|----------------|---------------------------------|------------------------|
| FcRI, human | mouse | lgG1; kappa | CT6-1D7 | CRL-2438 |
| FcRI, human | mouse | IgM | My 43.51 | HB-12128 [†] |
| FcRII, mouse | rat/mouse | lgG2b | 2.4G2 | HB-197 |
| FcRn heavy chain heterodimers | mouse | lgG1 | 1G3 | CRL-2434 |
| -cRn heavy chain heterodimers | mouse | lgG1 | 2G3 | CRL-2435 |
| Feline leukemia virus (FeLV), p27 protein | mouse | IgG | 24IA,E,E,D, | HB-8049 [†] |
| Fibrin, human | mouse | .90 | F45J | HB-9740 [†] |
| Fibrin, human | mouse | lgG1; kappa | MH1 | HB-9739 [†] |
| ibrinogen, human | mouse | ідот, карра | F45J | HB-9740 [†] |
| Fibronectin, human | mouse | lgG1 | HFN 36.3 | CRL-1605 |
| ibronectin, human | mouse | lgG1 | HFN 7.1 | CRL-1606 |
| ibronectin, human | | lgG1 | P,NP/PFn | HB-91 |
| ibronectin, human, onco-fetal determinant | mouse | | 3 | |
| | mouse | lgG1 | FHCR-1-2813/FDC-6 | HB-9018 [†] |
| imbriae (2134P) of enterotoxigenic <i>E. coli</i> | mouse | lgG1 | αM346C7C1 | HB-11124 [†] |
| Flavivirus group antigen | mouse | lgG2a | D1-4G2-4-15 | HB-112 |
| ilk-1/KDR | rat/mouse | lgG1; kappa | DC101 | HB-11534 [†] |
| ollicle stimulating hormone (FSH) receptor, human | mouse | lgG1 | FSHR-18 | CRL-2688 |
| orssman antigen | rat/mouse | IgM | M1/22.25.8.HL | TIB-121 |
| orssman antigen | rat/mouse | IgM | M1/87.27.7.HLK | TIB-123 |
| os oncogene peptide, synthetic | mouse | IgG2b; kappa | 411-14E10 | CRL-2663 |
| os oncogene peptide, synthetic | mouse | lgG1 and lgG2b | 413-15D12 | CRL-2653 |
| umonisin B1 | mouse | lgG1 (kappa) | FB8H3 [Mab8H3] | CRL-2402 |
| Gamma heavy chain, human | mouse | lgG1; kappa | 1410 KG7 | HB-43 |
| Gamma heavy chain, human | mouse | IgG2b; lambda | C3-124 | HB-60 |
| B Ganglioside (tumor-associated fucoganglioside) | mouse | lgM | FHCR-1-2624/FH6/ FHOT-1-3019 | HB-8873 [†] |
| Ganglioside associated with endocrine cells, human T lymphocytes, and neuronal cells | mouse | IgM; kappa | 3G5 | CRL-1814 |
| Ganglioside GD2 | mouse | IgM | Mab 126 | HB-8568 [†] |
| Gangliosides GD2 and GD3 | mouse | IgG2a | ME361S2a | HB-9326 [†] |
| Gangliosides GM3 and GM4, human | human | IgM; kappa | L612 | CRL-10724 [†] |
| Giardia muris trophozoites | mouse | lgG3; kappa | 1A3.1 | CRL-1961 |
| Giardia muris trophozoites | mouse | IgG2b; kappa | 2B5.3 | CRL-1960 |
| Giardia muris trophozoites | mouse | lgG1; kappa | 3C7.2 | CRL-1959 |
| Glioblastoma, human | | IgM | PI 153/3 | TIB-198 |
| · · · · · · · · · · · · · · · · · · · | mouse | IgM; kappa | 32B11 | CRL-2559 |
| Glomalin (soil glycoprotein) | mouse | | | |
| Glucocorticoid receptor, mouse and rat | mouse | lgG2b | FIGR | CRL-2173 |
| Glutamic acid decarboxylase (GAD) | mouse | lgG1 | GAD-1 | HB-184 |
| Glycated serum albumin (glycoalbumin) | mouse | IgG | A717 | HB-9596 [†] |
| Glycolipid antigen | mouse | IgM | A2B5 clone 105 | CRL-1520 |
| Glycolipids, di- and trifucosylated type 2 chain | mouse | lgG3 | FHCR-1-2075/FH4 | HB-8775 [†] |
| Glycophorin A, type M | mouse | lgG1; kappa | 6A7M | HB-8159 [†] |
| Glycophorin A, type M and type N | mouse | lgG1; kappa | 10F7MN | HB-8162 [†] |
| Glycophorin A, type N | mouse | lgG1; kappa | 8A2N | HB-8161 [†] |
| Glycophorin A, type N | mouse | IgG2a; kappa | NN-4 | HB-8473 [†] |
| Glycophorin A, type N, human | mouse | IgM; kappa | NN-3 | HB-8474 [†] |
| Glycophorin A, type N, human | mouse | lgG1; kappa | NN-5 | HB-8476 [†] |
| Glycophorin, human | mouse | lgG1 | G26.4.1C3/86 | HB-9893 [†] |
| Glycoprotein antigen, tumor vascular endothelium | mouse | lgG1 | H572 | HB-11608 [†] |
| Glycosphingolipid | mouse | lgM | 1B2-1B7 | TIB-189 |
| Slycosphingolipid | mouse | IgG3 | YI 328-18 | HB-9306 [†] |
| Glycosphingolipid, type II chain H structure | mouse | IgM | BE2 | TIB-182 |
| Golgi complex (GCI), rat | mouse | IgG1 | 6F4C5 | CRL-1869 |
| Golgi vesicular transport protein | mouse | IgM | 4A6 | CRL-1928 |
| ionadotropin releasing hormone, carboxy terminal | mouse | IgG1 | USASK/DSIL-LHRH-A1 | HB-9094 [†] |
| | | | | |
| gp120 glycoprotein | mouse | lgG1 | S5 | HB-9255† |
| gp39, mouse | hamster/mouse | lgG | MR1 | CRL-2580 |
| pp70 envelope antigen (ENV) protein of murine leukemia viruses (MuLV) | mouse | lgG2a | 48 | CRL-1913 |
| pp70 envelope antigen (ENV) protein of murine | mouse | IgM | 514 | CRL-1914 |



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|------------------------------|------------------------|------------------------|
| gp90 glycoprotein, human | mouse | lgG2a | G253 | HB-9706 [†] |
| GPIIIa, platelet, human | mouse | lgG1 | AP-3 | HB-242 |
| Granulocyte macrophage colony stimulating factor (GM-CSF), human | rat/mouse | IgG2a | BVD2-21C11.3 | HB-9569 [†] |
| Granulocyte macrophage colony stimulating factor (GM-CSF), human | rat/mouse | IgG2a | BVD2-23B6.4 | HB-9568 [†] |
| Granulocyte, human | mouse | lgG2b | OKM 1 | CRL-8026 [†] |
| Granulocyte, pig | mouse | lgG1; kappa | 74-22-15 | HB-142 |
| Granulocyte, pig | mouse | IgG2b; kappa | 74-22-15A | HB-142.1 |
| Growth hormone (hGH), human | mouse | lgG1; kappa | HGH-B | HB-10596 [†] |
| H-2 (all haplotypes) | rat/mouse | lgG2a | M1/42.3.9.8.HLK | TIB-126 |
| I-2 b | mouse | lgG1; kappa | B8-24-3 | TIB-139 |
| I-2 D b | mouse | IgM; kappa | 23A-5-21S | HB-36 |
| 1-2 D b | mouse | IgM; kappa | 28-11-5\$ | HB-19 |
| 1-2 D d | mouse | IgG2a; kappa | 34-2-12S | HB-87 |
| 1-2 D d | mouse | IgG2a; kappa | 34-4-20S | HB-75 |
| 1-2 D d | mouse | IgM | 34-4-215 | HB-76 |
| 1-2 D d | mouse | lgG2a; kappa | 34-5-8S | HB-102 |
| 1-2 D k | mouse | IgG2a; kappa | 15-5-5S | HB-24 |
| 1-2 from non-k haplotype mice | rat | lgG2a | K204 | HB-221 |
| 1-2 K b | mouse | IgM; kappa | 28-13-35 | HB-41 |
| 1-2 K b | mouse | lgG2a | AF6-88.5.3 | HB-158 |
| 1-2 K b | mouse | lgG2b; kappa | Y-3 | HB-176 |
| H-2 K b, D b | mouse | lgG2a; kappa | 28-8-6\$ | HB-51 |
| 1-2 K d | mouse | IgM | 31-3-4\$ | HB-77 |
| 1-2 K d | mouse | lgG2a | SF1-1.1.10 | HB-159 |
| 1-2 K d, D d | mouse | lgG2a; kappa | 34-1-2S | HB-79 |
| 1-2 K d, D d | mouse | IgM | 34-7-23S | HB-101 |
| 1-2 K k | mouse | lgG2a; kappa | 16-1-11N | HB-16 |
| 1-2 K k | mouse | lgG2a; kappa | 16-3-1N | HB-25 HB-5 |
| | mouse | lgG2a; kappa lgG1 | 16-3-22S AF3-12.1.3 | HB-160 |
| 1-2 K k, D k | mouse | | 12-2-2S (clone 5F11) | HB-50 |
| | mouse | IgM; kappa | 15-1-5P | HB-53 |
| H-2 K k, D k H-2 K k, D k | mouse | IgG2b; kappa IgG2a; kappa | 15-3-15 | HB-13 |
| 1-2 K k, D k | mouse mouse | IgG2a; kappa | 16-1-2N | HB-14 |
| 1-2 K k, D k | | IgG2a; kappa | 3-83P | HB-20 |
| H-2 K of the k, q, p and r haplotypes | mouse mouse | IgG2a, kappa | 11-4.1 | TIB-95 |
| 17 flagella, <i>E. coli</i> | mouse | lgG1 | MARC 2B7 | CRL-2509 |
| Hassall's bodies, human | mouse | IgM | TE15 | HB-206 |
| Hassall's bodies, human | mouse | lgG1 | TE16 | HB-210 |
| Hassall's bodies, human | mouse | IgM | TE19 | HB-211 |
| Hassall's bodies, human | mouse | lgG2a | TE8 | HB-212 |
| Heat-stable antigen, mouse | rat/mouse | lgG2b | M1/69.16.11.HL | TIB-125 |
| Heat-stable antigen, mouse | rat/mouse | IgG2c | M1/75.16.4.HLK | TIB-127 |
| HeLa cells | mouse | .5 | 1A ₃ | HB-8563 [†] |
| Hematopoietic cells, human | mouse | lgG1 | B3/25 | CRL-8034 [†] |
| Hen egg lysozyme (HEL) | mouse | lgG1 | Aw3.18.14 | CRL-2826 |
| Hepatitis B virus surface antigen (HBsAg) | mouse | IgM | H21F8-1 | CRL-8018 [†] |
| Hepatitis B virus surface antigen (HBsAg) | mouse | lgG1 | H25B10 | CRL-8017 [†] |
| lepatitis B virus surface antigen (HBsAg) | mouse | lgG1 | H25B10 | CRL-8017A [†] |
| lepatocyte growth factor receptor | mouse | lgG1 (kappa) | 1A3.3.13 | HB-11894 [†] |
| lepatocyte growth factor receptor | mouse | IgG1 (kappa) | 5D5.11.6 | HB-11895 [†] |
| HER-2/neu | mouse | lgG1 (kappa) | BD5-2d | HB-9689 [†] |
| HER-2/neu | mouse | IgG1 (kappa) | NB3 | HB-10205 [†] |
| HER-2/neu | mouse | lgG1 (kappa) | TA-1 | HB-10206 [†] |
| HER-2/neu | mouse | IgM (kappa) | OD-3 | HB-10204 [†] |
| HER2 receptor | mouse | IgG1 | A-HER2 | CRL-10463 [†] |
| Herpes simplex virus type 1 (HSV-1) glycoprotein | mouse | lgG2a | 52-S | HB-8181 [†] |
| Herpes simplex virus type 1 (HSV-1) glycoprotein | mouse | lgG2a | 53-S | HB-8182 [†] |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|---------------------|-----------------|----------------------|
| Herpes simplex virus type 1 (HSV-1), immediate early protein (ICP 4) | mouse | lgG2a | 58-S | HB-8183 [†] |
| Herpes simplex virus type 1 (HSV-1), internal capsid protein 8 (ICP 8) | mouse | lgG2a | 39-S | HB-8180 [†] |
| Herpes simplex virus type 1 (HSV-1), nucleocapsid protein (p40) | mouse | lgG1 | 1D4 | HB-8068 [†] |
| Herpes simplex virus type 2 (HSV-2), nucleocapsid protein (p40) | mouse | lgG1 | 3E1 | HB-8067 [†] |
| IFE | mouse | lgG1 | 1C3 | CRL-2441 |
| IFE | mouse | lgG1 | 2A11 | CRL-2442 |
| IFE | mouse | IgM; kappa | 2A5 | CRL-2444 |
| lFE | mouse | lgG1 | 2B7 | CRL-2443 |
| IFE | mouse | IgM; kappa | 3A5 | CRL-2440 |
| IIV gp41 | mouse | lgG1; kappa | MH-SVM25 | HB-8871 [†] |
| IIV p17 | mouse | lgG1; kappa | MH-SVM33C9 | HB-8975 [†] |
| IIV p24 | mouse | lgG2; kappa | MH-SVM23 | HB-8870 [†] |
| IIV p24 | mouse | lgG1; kappa | MH-SVM26 | HB-8872 [†] |
| IIV-1 gp120 | mouse | lgG1 | 46-2 | CRL-2186 |
| IIV-1 gp120 | mouse | lgG1 | 46-4 | CRL-2178 |
| IIV-1 gp120 | mouse | lgG1 | 46-5 | CRL-2184 |
| IV-1 gp120 | mouse | lgG1 | 55-2 | CRL-2155 |
| IIV-1 gp120 | mouse | lgG1 | 55-36 | CRL-2153 |
| IIV-1 gp120 | mouse | lgG2a | 55-6 | CRL-2156 |
| IIV-1 gp120 | mouse | lgG2a | 55-83 | CRL-2185 |
| IIV-1 gp120 | mouse | lgG1 | 803-15.6 | CRL-2395 |
| IV-1 p17 | mouse | lgG1; kappa | MH-SVM33C9 | HB-8975 [†] |
| IIV-1 p24 | mouse | lgG1 | 31-42-19 | HB-9726 [†] |
| IIV-1 p24 | mouse | lgG1 | 31-90-25 | HB-9725 [†] |
| ILA A2, B17 ILA A3 | mouse | lgG1 | MA2.1 GAP A3 | HB-54 HB-122 |
| ILA A3 | mouse | lgG2a; kappa lgM | WFL3C6.1 | HB-8157 [†] |
| ILA B27, B7 | rat/mouse mouse | IgG2a | B27M1 | HB-157 |
| ILA B27, Bw47 | mouse | IgM | B27M2 | HB-165 |
| ILA B5 | mouse | IgG1 | 4D12 | HB-178 |
| ILA B7 | mouse | lgG1 | BB7.1 | HB-56 |
| ILA B7, B40 | mouse | lgG1 | MB 40.3 | HB-105 |
| ILA B7, B40 | mouse | lgG1 | MB40.2 | HB-59 |
| ILA B7, Bw22, B27 | mouse | lgG1 | ME 1 | HB-119 |
| LA B7,B40 | mouse | lgG1 | BB7.6 | HB-115 |
| LA Bw6 | rat/mouse | lgG2b | SFR8-B6 | HB-152 |
| ILA DC1 | mouse | lgG2a | G2a.5 | HB-110 |
| LA DC1 | mouse | lgG2b | G2b.2 | HB-109 |
| ILA DQ | mouse | lgG1; kappa | IVD12 | HB-144 |
| ILA DQw1 | mouse | lgG1 | Genox 3.53 | HB-103 |
| ILA DR | mouse | lgG1 | Antibody 2.06 | HB-104 |
| ILA DR, DP, DQ | mouse | lgG1; kappa | IVA12 | HB-145 |
| LA DR, DQ | mouse | lgG2a | 9.3F10 | HB-180 |
| LA DR5 | rat/mouse | lgG2b | SFR3-DR5 | HB-151 |
| ILA heavy chain | mouse | lgG2a; kappa | 171-4 | HB-296 |
| ILA-DR alpha chain | mouse | lgG2a | LB3.1 | HB-298 |
| MG-CoA reductase (3-hydroxy-3-methyl-glutaryl Coenzyme A reductase) | mouse | lgG1 | A9 | CRL-1811 |
| og renin | mouse | lgG1 | F32 VIII C4 | CRL-1653 |
| TLV-III gp41 | mouse | lgG1; kappa | MH-SVM25 | HB-8871 [†] |
| ITLV-III p17 | mouse | lgG1; kappa | MH-SVM33C9 | HB-8975 [†] |
| TLV-III p24 | mouse | lgG2; kappa | MH-SVM23 | HB-8870 [†] |
| ITLV-III p24 | mouse | lgG1; kappa | MH-SVM26 | HB-8872 [†] |
| luman epidermal growth factor (EGF) receptor | mouse | lgG2a; kappa | Mab 108 | HB-9764 [†] |
| -Y antigen | mouse | IgM; kappa | 12/44 | HB-9070 [†] |
| l-Y antigen | mouse | IgM; kappa | 12/49 | HB-9071 [†] |
| | | | Y-3P | HB-183 |



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|---|---|--|--|---|
| -A b | mouse | lgM | 25-5-16S | HB-37 |
| -A b | mouse | IgM | 25-9-3S | HB-38 |
| -A b | mouse | IgG2a | AF6-120.1.2 | HB-163 |
| -A b and I-A d | mouse | lgG2a; kappa | 25-9-17S II | HB-26 |
| -A b and I-A d | | IgG3 | BP107.2.2 | TIB-154 |
| -A b and 1-A d | mouse | IgM; kappa | 28-16-8S | HB-35 |
| | mouse | | M5/114.15.2 | TIB-120 |
| -A b, I-A d, I-A q, I-E d and I-E k | rat/mouse | lgG2b; kappa | | |
| -A b,d | rat/mouse | lgG2b | B21-2 | TIB-229 |
| -A d | mouse | IgG2a; kappa | 34-5-3S | HB-85 |
| -A d | mouse | IgG2a; kappa | MK-D6 | HB-3 |
| -A k | mouse | lgG2b | 11-5.2.1.9 | TIB-94 |
| -A k | mouse | IgM; kappa | 26-7-11\$ | HB-15 |
| -A k | mouse | IgM | 26-8-16S | HB-42 |
| -A of k, r, f and s haplotypes | mouse | lgG2a | 10-3.6.2 | TIB-92 |
| -A of the k, r, f and s haplotypes | mouse | lgG2b | 10-2.16 | TIB-93 |
| -A s | mouse | lgG2b | MK-S4 | HB-4 |
| a, human | mouse | lgG1; kappa | L203 | HB-171 |
| a, human | mouse | lgG1; kappa | L227 | HB-96 |
| a, human | mouse | lgG2a | L243 | HB-55 |
| -A, I-E, monomorphic, mouse | hamster/mouse | IgG | N22 | HB-225 |
| a, rabbit | mouse | IgG2a | 2C4 | CRL-1760 |
| CAM-1, canine | mouse | lgG1 | CL18/6 | CRL-2518 |
| CAM-1, human | mouse | IgG2a | R6.5.D6.E9.B2 | HB-9580 [†] |
| CAM-1, mouse | rat | lgG2b | YN1/1.7.4 | CRL-1878 |
| CAM-1, mouse | rat/mouse | IgG2a | BE29G1 | HB-233 |
| CAM-4, rat | mouse | IgG1 | 127H | HB-11911 [†] |
| diotypic determinant on on anti-chlamydia genus | mouse | lgG1; kappa | 91MS441 | HB-11301 [†] |
| antibody diotypic determinant on the P3X63Ag8 | mouse protein | IgG2b; kappa | 80 V 5B4 | TIB-132 |
| myeloma | | | | |
| -E | mouse | lgG2b | Y-17 | HB-179 |
| | | IgG2a; kappa | 14-4-4S | HB-32 |
| -E k | mouse | iguza, kappa | כד ד דו | 110 32 |
| -E k -E k | mouse mouse | IgG2a; kappa | 17-3-3S | HB-6 |
| -E k | | | | |
| | mouse | IgG2a; kappa IgG2a | 17-3-3S | HB-6 |
| -E k g-4a allotype on mouse IgG1 | mouse mouse | IgG2a; kappa | 17-3-3S Ig(4a)10.9 | HB-6 HB-146 |
| -E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse | mouse mouse mouse | IgG2a; kappa IgG2a IgG1; kappa | 17-3-3S lg(4a)10.9 CH-EB6 lg(5a)7.2 (formerly 10- | HB-6 HB-146 HB-200 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse | mouse mouse mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a | 17-3-3S lg(4a)10.9 CH-EB6 lg(5a)7.2 (formerly 10- 4-22) | HB-6 HB-146 HB-200 TIB-149 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human | mouse mouse mouse mouse rat/mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10- 4-22) 11-26c | HB-6 HB-146 HB-200 TIB-149 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human | mouse mouse mouse mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human | mouse mouse mouse mouse rat/mouse mouse mouse mouse mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa IgG2a; kappa | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human | mouse mouse mouse mouse rat/mouse mouse mouse mouse mouse mouse mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa IgG2a; kappa IgG2b | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human gG (Fc), human | mouse mouse mouse mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa IgG1; kappa IgG2a; kappa IgG2b IgG2a | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human gG (Fc), human gG (Fc), human | mouse mouse mouse mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa IgG1; kappa IgG2a; kappa IgG2b IgG2a IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1786 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gG (Fc), human | mouse mouse mouse mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa IgG1; kappa IgG2a; kappa IgG2b IgG2a IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1753 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gG (Fc), human | mouse mouse mouse mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa IgG1; kappa IgG2a; kappa IgG2b IgG2a IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gG (Fc), human | mouse mouse mouse mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa IgG1; kappa IgG2a; kappa IgG2b IgG2a IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gG (Fc), human | mouse mouse mouse mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa IgG1; kappa IgG2a; kappa IgG2b IgG2a IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gG (Fc), human | mouse mouse mouse mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG1; kappa IgG1; kappa IgG2a; kappa IgG2b IgG2a IgG1 IgG2a IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gG (Fc), human gG (Fc), human gG (Fc), human gG (Fd, F(ab')2, Fab), human gG Fc receptor, human gG I (Fc), human gG I (Fc), human gG I (Fc), human gG I (Fc), human | mouse mouse mouse mouse mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2; kappa IgG2b IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2a IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 CRL-1752 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human | mouse mouse mouse mouse mouse rat/mouse mouse rat/mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2; kappa IgG2b IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG1 | 17-3-3S | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 CRL-1752 HB-92 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human | mouse mouse mouse mouse mouse rat/mouse mouse rat/mouse rat/mouse rat/mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2; kappa IgG2b IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2b IgG2c IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 7D2-1.4.1.5 ED1-19-1-6-5 | HB-6 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 CRL-1752 HB-92 HB-90 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human gG1 (Fc), human gG1 (Fc), human gG1 (Fc), rat gG2 (Fc), human gG2 (Fd), human gG3 (Fd), human gG3 (Fd), human | mouse mouse mouse mouse mouse rat/mouse mouse rat/mouse rat/mouse rat/mouse mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2; kappa IgG2b IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2b IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 7D2-1.4.1.5 ED1-19-1-6-5 RG9/6.13 HLK | HB-6 HB-146 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 CRL-1752 HB-92 HB-90 TIB-167 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gG (Fc), human gG1 (Fc), human gG1 (Fc), rat gG2 (Fc), human gG2 (Fd), human gG3 (Fc), rat gG2 (Fd), human gG4 (Fc), rat gG4 (Fc), rat gG5 (Fd), human gG6 (Fd), human | mouse mouse mouse mouse mouse rat/mouse mouse rat/mouse rat/mouse rat/mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2; kappa IgG2b IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG2a IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 7D2-1.4.1.5 ED1-19-1-6-5 RG9/6.13 HLK RG7/1.30 | HB-6 HB-146 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 CRL-1752 HB-92 HB-90 TIB-167 TIB-173 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human gG1 (Fc), human gG1 (Fc), rat gG2 (Fc), human gG2 (Fd), human gG3 (Fc), rat gG2 (Fd), human gG3 (Fd), human gG4 (Fc), rat gG4 (Fc), rat gG5 (Fd), human | mouse mouse mouse mouse mouse rat/mouse mouse rat/mouse rat/mouse rat/mouse mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2; kappa IgG2b IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2b IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 7D2-1.4.1.5 ED1-19-1-6-5 RG9/6.13 HLK RG7/1.30 Ig(1a)8.3 (formerly 20-8.3) | HB-6 HB-146 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 CRL-1752 HB-92 HB-90 TIB-167 TIB-173 TIB-148 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human gG1 (Fc), human gG1 (Fc), rat gG2 (Fc), human gG2 (Fd), human gG3 (Fc), rat gG4 (Fc), rat gG5, mouse gG6, mouse gG6, mouse gG6, mouse gG6, rat gG62 (Fc), rat | mouse mouse mouse mouse mouse rat/mouse mouse rat/mouse mouse rat/mouse mouse mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2; kappa IgG2b IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG2a IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 7D2-1.4.1.5 ED1-19-1-6-5 RG9/6.13 HLK RG7/1.30 | HB-6 HB-146 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 CRL-1752 HB-92 HB-90 TIB-167 TIB-173 |
| FE k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human gG1 (Fc), human gG1 (Fc), rat gG2 (Fc), human gG2 (Fd), human gG3 (Fc), rat gG4 (Fc), rat gG5, mouse gG5, mouse gG6, mouse gG6, mouse gG6, rat gG62 (Fc), rat gG62 (Fc), rat | mouse mouse mouse mouse mouse rat/mouse mouse rat/mouse mouse rat/mouse mouse mouse mouse mouse mouse mouse mouse mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2; kappa IgG2b IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2a IgG1 IgG2b IgG2b IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG2b; kappa IgG2a IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 7D2-1.4.1.5 ED1-19-1-6-5 RG9/6.13 HLK RG7/1.30 Ig(1a)8.3 (formerly 20-8.3) | HB-6 HB-146 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 CRL-1752 HB-92 HB-90 TIB-167 TIB-173 TIB-148 |
| E k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gE, human gG (Fc), human gG1 (Fc), rat gG2 (Fc), human gG2 (Fd), human gG3 (Fc), rat gG2 (Fd), human gG4, mouse gG2, mouse | mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2a IgG1; kappa IgG1; kappa IgG2b IgG2b IgG2b IgG2b IgG1 IgG1 IgG2b IgG2b IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG2b IgG2b IgG1 IgG1 IgG1 IgG2b IgG1 IgG1 IgG1 IgG2b IgG2b IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 7D2-1.4.1.5 ED1-19-1-6-5 RG9/6.13 HLK RG7/1.30 Ig(1a)8.3 (formerly 20-8.3) RDP 45/20 | HB-6 HB-146 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1758 CRL-1752 HB-92 HB-90 TIB-167 TIB-173 TIB-148 TIB-98 |
| FE k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human gG1 (Fc), human gG1 (Fc), rat gG2 (Fc), human gG2 (Fd), human gG3 (Fc), human gG4 (Fc), rat gG2 (Fd), human gG5, mouse gG6, mouse | mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2a IgG1; kappa IgG1; kappa IgG2b IgG2b IgG2b IgG2b IgG1 IgG1 IgG2b IgG2b IgG2b IgG1 IgG1 IgG2b IgG1 IgG2b IgG1 IgG2b IgG1 IgG1 IgG2b IgG1 IgG2b IgG1 IgG2b IgG1 IgG1 IgG2b IgG1 IgG2b IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 7D2-1.4.1.5 ED1-19-1-6-5 RG9/6.13 HLK RG7/1.30 Ig(1a)8.3 (formerly 20-8.3) RDP 45/20 RG7/11.1 | HB-6 HB-146 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1752 HB-92 HB-90 TIB-167 TIB-173 TIB-148 TIB-98 TIB-174 |
| FE k g-4a allotype on mouse IgG1 gA, human gD, Ig-5a allotype, mouse gD, mouse gE, human gE, human gE, human gG (Fc), human gG1 (Fc), human gG1 (Fc), rat gG2 (Fc), human gG2 (Fd), human gG3 (Fc), rat gG4 (Fc), rat gG5, mouse gG6, mouse gG6, mouse gG6, mouse gG6, mouse gG6, mouse gG6, rat gG6, Ig-1a allotype, mouse gG6, Ig-1a allotype, mouse gG6, Ig-1b, rat | mouse rat/mouse mouse | IgG2a; kappa IgG2a IgG1; kappa IgG2a IgG1; kappa IgG2a IgG1; kappa IgG1; kappa IgG2b IgG2b IgG2b IgG2b IgG1 IgG1 IgG2b IgG2b IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG2b IgG2b IgG1 IgG1 IgG1 IgG2b IgG1 IgG1 IgG1 IgG2b IgG2b IgG1 | 17-3-3S Ig(4a)10.9 CH-EB6 Ig(5a)7.2 (formerly 10-4-22) 11-26c CIA-E-4.15 CIA-E-7.12 E5BB3IIA2 HP6000 HP6017 HP6058 HP6045 IV.3 HP6001 RG11/39.4 HP6002 HP6014 7D2-1.4.1.5 ED1-19-1-6-5 RG9/6.13 HLK RG7/1.30 Ig(1a)8.3 (formerly 20-8.3) RDP 45/20 RG7/11.1 HP6003 | HB-6 HB-146 HB-146 HB-200 TIB-149 HB-250 HB-235 HB-236 HB-121 CRL-1754 CRL-1753 CRL-1757 HB-217 CRL-1755 TIB-170 CRL-1788 CRL-1752 HB-92 HB-90 TIB-167 TIB-173 TIB-148 TIB-98 TIB-174 CRL-1756 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|---|-------------------------|---------------|---------------------|-----------------------------------|
| gG4 (Fab), human | mouse | lgG2a | HP6020 | CRL-1789 |
| gG4 (Fc), human | mouse | lgG3 | HP6023 | CRL-1776 |
| gG4 (Fc), human | mouse | lgG1 | HP6025 | CRL-1775 |
| gh-5.3 (IgD b,e) | mouse | lgG1 | AF6-122.2.5 | HB-199 |
| gh-5.4 (IgD a) | mouse | lgG2b | AMS 9.1.1.1 | HB-161 |
| gh-5.5 (IgD e) | mouse | lgG2b | AF4-73.3.1 | HB-201 |
| gh-5b (IgD b allotype) | mouse | lgG1 | lg(5b)6.3 | TIB-96 |
| gh-6.6 (IgM b) | mouse | lgG1 | AF6-78.25.4 | HB-162 |
| gM (Igh-6.5 allotype), mouse | rat/mouse | lgG1; kappa | Bet-1 | HB-100 |
| gM (lambda), human | mouse | lgG2b; kappa | LP4.4 | HB-232 |
| gM (mu heavy chain), mouse | rat/mouse | lgG2b | 331.12 | TIB-129 |
| gM, bovine | mouse | IgG1 | IL-A30 | CRL-1894 |
| gM, human | mouse | IgG1 | M-2E6 | HB-138 |
| gM, mouse | rat/mouse | lgG1; kappa | Bet-2 | HB-88 |
| gM, pig | mouse | IgG1; kappa | 5C9 | HB-8371 [†] |
| gM, rabbit | mouse | IgG1 | NRbM | CRL-1839 |
| L-1 beta, human | mouse | lgG1; kappa | ILB1-H21 | HB-10220 [†] |
| 1 beta, human | | lgG1; kappa | ILB1-H34 | HB-10221 [†] |
| 1 beta, human 1 beta, human | mouse mouse | IgG1; kappa | ILB1-H34 ILB1-H6 | HB-10221 [†] |
| L-1 beta, human L-1 beta, human | | lgG2b; kappa | ILB1-H67 | HB-10219 [†] |
| • | mouse | <u> </u> | | |
| 1 beta, recombinant, bovine 2, mouse | mouse | lgG1 lgG2a | SA22 S4B6-1 | CRL-2052 HB-10968 [†] |
| • | rat/mouse | | | |
| L-4, mouse | rat/mouse | lgG1 | 11B11 | HB-188 |
| L-8, human | mouse | lgG1 | EL-NC-1S | HB-9647 [†] |
| L-12 p40, mouse | rat/mouse | IgG2a | R1-5D9 | CRL-2360 |
| L-12 p40, mouse | rat/mouse | lgG2b | R2-10F6 | CRL-2358 |
| L-12 p75, mouse | rat/mouse | lgG2b | R2-9A5 | CRL-2357 |
| L-12, human | rat/mouse | lgG1 | 20C2 | CRL-2382 |
| L-15, human | mouse | lgG1 | hIL-15-M110 | HB-12061 [†] |
| L-15, human | mouse | lgG1 | hIL-15-M111 | HB-12062 [†] |
| nfectious bovine rhinotracheitis virus (IBRV) | mouse | lgG1 | 1B8-F11 | CRL-1852 |
| nfectious bursal disease (IBD) virus | mouse | IgG2a; kappa | B69 | HB-9437 [†] |
| nfectious bursal disease (IBD) virus | mouse | IgG2a; kappa | R63 | HB-9490 [†] |
| nfectious bursal disease (IBD) virus, serotypes | mouse | lgG1; kappa | B29 | HB-9746 [†] |
| 1 and 2 | | | | |
| nflammatory cells, human | mouse | lgG1 | MY904 | HB-9510 [†] |
| nfluenzavirus A matrix protein (M) | mouse | lgG1 | M2-1C6-4R3 | HB-64 |
| nfluenzavirus A nucleoprotein | mouse | lgG1 | 46/4 | HB-67 |
| nfluenzavirus A nucleoprotein | mouse | lgG2a | H16-L10-4R5 | HB-65 |
| nfluenzavirus hemagglutinin | mouse | lgG2a | 73/1 | HB-66 |
| nsulin | mouse | lgG2a; kappa | BE3F9 | HB-133 |
| nsulin | mouse | lgG1; kappa | CC9C10 | HB-123 |
| nsulin | mouse | lgG1; kappa | CE9H9 | HB-127 |
| nsulin | mouse | lgG1; kappa | CG7C7 | HB-126 |
| nsulin | mouse | IgG2a; kappa | DB9G8 | HB-124 |
| nsulin (residues A8-10), human | mouse | IgG1; kappa | AE9D6 | HB-125 |
| nsulin receptor, human | mouse | IgG1; kappa | αIR-1 | HB-175 |
| nsulin receptor, placental, human | mouse | IgG1 | DII 33.1 | CRL-1827 |
| ntegrin, alpha 1, human | mouse | IgG1 | TS2/7.1.1 | HB-245 |
| ntegrin, alpha 4, sheep | mouse | IgG2b | FW3-218-1 | HB-261 |
| ntegrin, alpha 4, sheep ntegrin, alpha 4/beta 7, mouse | rat/mouse | IgG2a | DATK32 | HB-294 |
| ntegrin alpha V, integrin beta 3 | mouse | IgG1 (kappa) | 10C4.1.3 | HB-11029 |
| (vitronectin receptor), human | mouse | igu i (kappa) | 1004.1.3 | רשוו דיטוו |
| ntegrin, beta 1 subunit, mouse | rat/mouse | laG2a | KMI6 | CRL-2179 |
| <u> </u> | rat/mouse | lgG2a | | |
| ntegrin, beta 1, human | mouse | lgG1 | TS2/16.2.1 | HB-243 |
| ntegrin, beta 1, sheep | mouse | lgG1 | FW4-101-1-1 | HB-289 |
| ntegrin, beta 2, mouse | hamster/mouse | lgG | 2E6 | HB-226 |
| ntegrin, beta 3, human | mouse | lgG1 | AP-3 | HB-242 |
| ntegrin, beta 7 Integrin, mouse | rat/mouse | lgG2a | FIB21 | HB-295 |
| ntegrin, beta 7 Integrin, mouse | rat/mouse | lgG2a | FIB504.64 | HB-293 |
| ntegrin, leukocyte, mouse | hamster/mouse | IgG | N418 | HB-224 |



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|--------------|----------------------------|-----------------------|
| ntegrin-associated protein, human | mouse | lgG1 | B6H12.2 | HB-9771 [†] |
| Integrin-like cellular adhesion molecule | rat/mouse | lgG2b | PS/2 | CRL-1911 |
| ntercellular adhesion molecule 1, mouse | rat | lgG2b | YN1/1.7.4 | CRL-1878 |
| ntercellular adhesion molecule 1, mouse | rat/mouse | lgG2a | BE29G1 | HB-233 |
| nterferon gamma receptor, mouse | rat/mouse | lgA; kappa | GR-96 | CRL-2013 |
| nterferon gamma receptor, mouse | rat/mouse | lgG2a; kappa | GR-20 | CRL-2024 |
| nterferon, gamma, human | mouse | IgG1 | γ3-11.1 | HB-8700 [†] |
| nterferon, gamma, human | mouse | lgG1 | IFGCP-F1BA10 | HB-8291 [†] |
| nterferon, gamma, mouse | rat/mouse | lgG1 | R4-6A2 | HB-170 |
| nterleukin 1 beta, human | mouse | IgG1; kappa | ILB1-H21 | HB-10220 [†] |
| nterleukin 1 beta, human | mouse | IgG1; kappa | ILB1-H34 | HB-10221 [†] |
| nterleukin 1 beta, human | mouse | IgG1; kappa | ILB1-H6 | HB-10219 [†] |
| nterleukin 1 beta, human | mouse | IgG2b; kappa | ILB1-H67 | HB-10222 [†] |
| nterleukin 1 beta, ruman nterleukin 1 beta, recombinant, bovine | | IgG1 | SA22 | CRL-2052 |
| · · · · · · · · · · · · · · · · · · · | mouse | | | HB-12061 [†] |
| nterleukin 15, human | mouse | lgG1 | hIL-15-M110 | |
| nterleukin 15, human | mouse | lgG1 | hIL-15-M111 | HB-12062 [†] |
| nterleukin 2 receptor, human | mouse | lgG1 | 2A3A1H | HB-8555 [†] |
| nterleukin 2 receptor, human | mouse | lgG2a | 7G7B6 | HB-8784 [†] |
| nterleukin 2 receptor, mouse | rat/mouse | IgM; kappa | 7D4 | CRL-1698 |
| nterleukin 2 receptor, mouse | rat/mouse | lgG1 | PC 61 5.3 | TIB-222 |
| nterleukin 2, mouse | rat/mouse | lgG2a | S4B6-1 | HB-10968 [†] |
| nterleukin 8 receptor type B (IL-8R-B), human | mouse | lgG2a | 10H2.12.1 | HB-11494 [†] |
| nterleukin 8 receptor type B (IL-8R-B), human | mouse | IgG2a | 4D1.5.7 | HB-11495 [†] |
| nterleukin 8, human | mouse | lgG1 | EL-NC-1S | HB-9647 [†] |
| nterleukin 8 (IL-8), human | mouse | lgG2a | A5.12.14 | HB-11553 [†] |
| nterleukin 8 (IL-8), rabbit | mouse | lgG2a | 6G4.2.5 | HB-11722 [†] |
| ntermediate filaments | mouse | lgG1 | lpha Intermediate Filament | TIB-131 |
| ntracellular adhesion molecule 1 (ICAM-1), canine | mouse | lgG1 | CL18/6 | CRL-2518 |
| ntracellular adhesion molecule 1 (ICAM-1), human | mouse | lgG2a | R6.5.D6.E9.B2 | HB-9580 [†] |
| ntracellular adhesion molecule 1 (ICAM-1), mouse | rat | lgG2b | YN1/1.7.4 | CRL-1878 |
| ntracellular adhesion molecule 1 (ICAM-1), mouse | rat/mouse | lgG2a | BE29G1 | HB-233 |
| ntracellular adhesion molecule 1 (ICAM-1), rat | mouse | lgG1 | 127H | HB-11911 [†] |
| nvected protein, Drosophila melanogaster | mouse | lgG1 | 4D9D4 | CRL-1818 |
| 5 endotoxin core, Escherichia coli | mouse | lgG1 | J5-1 | HB-8297 [†] |
| 5 endotoxin core, <i>Escherichia coli</i> | mouse | lgG1 | J5-2 | HB-8298 [†] |
| (99 pilus, Escherichia coli | mouse | lgG1; kappa | 2BD4E4 K99 | HB-8178 [†] |
| Kappa light chain (monotypic determinant), rat | mouse | lgG2b | RG7/9.1 HLK | TIB-169 |
| (appa light chain (RI-1a and RI-1b allotypes), rat | mouse | lgG2a; kappa | MAR 18.5 | TIB-216 |
| Kappa light chain [kappa 1b (LEW)], rat | mouse | IgG2a, Kappa | RG7/7.6 HL | TIB-172 |
| Kappa light chain, human | mouse | IgG1; kappa | 141PF11 | HB-45 |
| Kappa light chain, human | mouse | IgG1, kappa | HP6053 | CRL-1758 |
| Kappa light chain, human | mouse | IgG1; kappa | TB 28-2 | HB-61 |
| Kappa light chain, mouse | rat/mouse | IgG1, kappa | 187.1 | HB-58 |
| (idney tubules, human | mouse | IgG1 | DAL K20 | CRL-2288 |
| (idney tubules, human | mouse | IgG1 | DAL K29 | CRL-2291 |
| Kidney tubules, numan Kininogen heavy chain, human | mouse | IgG1 | 2B5 | HB-8963 [†] |
| Kininogen light chain, human | mouse | IgG1 | C11C1 | HB-8964 [†] |
| Kunitz soybean trypsin inhibitor | | | | |
| Cunitz soybean trypsin inhibitor (unitz soybean trypsin inhibitor | mouse | lgG1; kappa | C129 | HB-9516 [†] |
| , ,, | mouse | lgG1; kappa | C171 | HB-9515 [†] |
| Kunitz soybean trypsin inhibitor | mouse | lgG1; kappa | C180 | HB-9517 [†] |
| d, D b and D q | mouse | IgG2a; kappa | 28-14-85 | HB-27 |
| d, D q, L q and L b | mouse | IgG2a; kappa | 30-5-75 | HB-31 |
| 3T4 antigen (T cell), mouse | rat/mouse | lgG2b | GK1.5 | TIB-207 |
| a Crosse Virus, G1 envelope glycoprotein | mouse | lgG2b | 807.15 | CRL-2287 |
| .a Crosse Virus, G1 envelope glycoprotein | mouse | lgG1 | 807.31 | CRL-2282 |
| a Crosse Virus, G1 envelope glycoprotein | mouse | lgG2a | 807.33 | CRL-2290 |
| .a/SSB, bovine | mouse | IgG | La1 | HB-8609 [†] |
| AM-1, human | mouse | lgG1 | DREG200 | HB-302 |
| AM-1, human | mouse | lgG1 | DREG56 | HB-300 |
| ambda 1 light chain, mouse | mouse | lgG1; kappa | LS-136 | TIB-157 |
| | | | HP6054 | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|---|-------------------------|----------------------|---------------------------------------|---|
| Laminin | rat/mouse | lgG2b | 2AB1-IA10 | HB-8210 [†] |
| LECAM, human | mouse | IgG1 | DREG200 | HB-302 |
| ECAM, human | mouse | lgG1 | DREG56 | HB-300 |
| egionella pneumophila | mouse | lgG2a | LP3IIG2 | HB-8472 [†] |
| egionella pneumophila serogroup 1 | mouse | lgG3 | Lp1 MAB 1 | CRL-1765 |
| egionella pneumophila serogroup 1 | mouse | lgG2b | Lp1 MAB 2 | CRL-1770 |
| egionella pneumophila serogroup 1 | | lgG2b | Lp1 MAB 3 | CRL-1770 |
| eptomeningeal cell, rat neural antigen-2, RAN-2) | mouse | | Ran-2 | TIB-119 |
| | mouse | lgG2a | 2D7F10 | |
| eptospira pomona type kennewicki | mouse | lgA | 4C | CRL-2025 |
| eu 200 glycoproteins, human | mouse | lgG2a; kappa | | HB-8311 [†] |
| eu-5 | mouse | IgM | TM1 | HB-169 |
| eu8, human | mouse | lgG1 | DREG200 | HB-302 |
| eu8, human | mouse | lgG1 | DREG56 | HB-300 |
| eu8, mouse | rat/mouse | lgG2a | MEL-14 | HB-132 |
| eukocyte common antigen, human | mouse | IgG2a; kappa | GAP 8.3 | HB-12 |
| eukocyte function antigen 1, alpha subunit, mouse | rat/mouse | IgG2a; kappa | M17/4.4.11.9 (new clone of M17/4.2) | TIB-217 |
| eukocyte function antigen 1, mouse | rat/mouse | lgG2b | FD441.8 | TIB-213 |
| EW RT1.A | rat/mouse | lgM | WFL3C6.1 | HB-8157 [†] |
| EW RT1.A | rat/mouse | lgM | WFL4F12.3 | HB-8156 [†] |
| ewis a and b blood group antigens, human | mouse | lgG3 | 151-5-G2-12 | HB-8322 [†] |
| ewis a and b blood group antigens, human | mouse | IgG3 | 151-5-G3-5 | HB-8323 [†] |
| ewis a antigen | mouse | lgG1 | BC9-E5 | CRL-1670 |
| ewis a antigen | mouse | lgG2a; kappa | CA3-F4 | CRL-1667 |
| ewis a antigen | mouse | lgG1; kappa | CF4-C4 | CRL-1716 |
| ewis a blood group antigen, human | mouse | IgG3 | 151-6-A7-9 | HB-8324 [†] |
| ewis b blood group antigen, human | mouse | lgG1 | 130-3-F7-5 | HB-8326 [†] |
| | | | 143-2-A6-11 | HB-8325 [†] |
| ewis b blood group antigen, human | mouse | IgM | | |
| ex (tumor-associated fucoganglioside) | mouse | IgM | FHCR-1-2624/FH6/ FHOT-1-3019 | HB-8873 [†] |
| FA-1, beta subunit, mouse | rat/mouse | IgG2a; kappa | M18/2.a.12.7 (new clone of M18/2.a.8) | TIB-218 |
| .FA-1, mouse | rat/mouse | lgG2b | FD441.8 | TIB-213 |
| FA-1, mouse | rat/mouse | IgG2a; kappa | M17/4.4.11.9 (new clone of M17/4.2) | TIB-217 |
| .FA-1, mouse | rat/mouse | lgG2b; kappa | M17/5.2 | TIB-237 |
| GL-1 | rat/mouse | IgG2a | 4D11 | HB-240 |
| gp100a | rat/mouse | lgG2a | 30-C7 | TIB-106 |
| ipopolysaccharide, chlamydia | mouse | lgG3 | L2I-6 | HB-8705 [†] |
| ipoprotein H2, Pseudomonas aeruginosa | | | MA1-6 | CRL-1783 |
| ipoprotein Hz, Pseudornonas deruginosa. ipoprotein receptor related protein (LRP), | mouse | lgG1 lgG1 | IgG-5D7 | CRL-1763 CRL-1938 |
| 515-kDa subunit, rabbit | mouse | | | |
| ipoprotein receptor related protein (LRP), 85-kDa subunit, rabbit | mouse | lgG1 | lgG-1B3 | CRL-1937 |
| ipoprotein receptor related protein (LRP), carboxy terminal | mouse | lgG1 | lgG-11H4 | CRL-1936 |
| ow density lipoprotein (LDL) receptor, bovine | mouse | lgG1 | 9D9 | CRL-1703 |
| ow density lipoprotein (LDL) receptor, bovine | mouse | lgG2b | C7 | CRL-1691 |
| ow density lipoprotein (LDL) receptor, human | mouse | lgG1 | IgG-4A4 | CRL-1898 |
| ow density lipoprotein (LDL), human | mouse | IgG1 | B1B3 | CRL-2249 |
| ow density lipoprotein (LDL), human | mouse | lgG1 | B1B6 | CRL-2248 |
| PAM-1, mouse | rat/mouse | lgG2b | R1-2 | HB-227 |
| ung cancer | mouse | lgG1 | L18 | HB-8628 [†] |
| ung cancer | mouse | IgM | L5 | HB-8627 [†] |
| ung cancer ung cancer, human | | IgG2a; kappa | 703D4 | HB-8301 [†] |
| | mouse | | | |
| uteinizing hormone (hLH) beta core fragment, human uteinizing hormone releasing hormone (LHRH), | mouse | IgG1 (kappa) IgG1 | B505 USASK/DSIL-LHRH-A1 | HB-12000 [†] HB-9094 [†] |
| carboxy terminal .uteinizing hormone/chorionic gonadotropin | mouse | lgG2a | FSHR-323 | CRL-2689 |



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|--------------------|---------------------------------------|---------------------------------|
| Luteinizing hormone/chorionic gonadotropin (LH/hCG) receptor, human | mouse | lgG1 | LHR-1055 | CRL-2687 |
| Luteinizing hormone/chorionic gonadotropin (LH/hCG) receptor, human | mouse | lgG1 | LHR-29 | CRL-2685 |
| Luteinizing hormone/chorionic gonadotropin (LH/hCG) receptor, human | mouse | lgG1 | LHR-74 | CRL-2686 |
| Ly 6.2C, mouse | mouse | lgG1 | 143-4.2 | CRL-1970 |
| Lyb 2.1, mouse | mouse | lgG2b | 10-1.D.2 | TIB-165 |
| Lyb 8.2, mouse | mouse | lgG1 | Cy34.1.2 | TIB-163 |
| Lymphocyte function antigen 1 (LFA-1) alpha subunit, human | mouse | lgG1 | TS1/22.1.1.13 | HB-202 |
| Lymphocyte function antigen 1 (LFA-1) beta subunit, human | mouse | lgG1 | TS1/18.1.2.11 | HB-203 |
| Lymphocyte function antigen 1 (LFA-1), human | mouse | lgG1 | TS2/4.1.1 | HB-244 |
| Lymphocyte function antigen 1, mouse | rat/mouse | IgG2b; kappa | M17/5.2 | TIB-237 |
| Lymphocyte function antigen 2 (LFA-2), human | mouse | lgG1 | TS2/18.1.1 | HB-195 |
| Lymphocyte function antigen 3 (LFA-3), human | mouse | lgG1 | TS2/9.1.4.3 | HB-205 |
| Lymphocyte Peyer's patch HEV adhesion molecule, mouse | rat/mouse | lgG2b | R1-2 | HB-227 |
| Lymphocyte surface receptor for endothelium, mouse | rat/mouse | lgG2a | MEL-14 | HB-132 |
| Lymphocyte, mouse | rat/mouse | IgM | GL7 | HB-254 |
| Lymphoma cells, canine | mouse | lgG2a | Hybridoma 231 | HB-9401 [†] |
| Lymphoma cells, canine | mouse | lgG1 | Hybridoma 234 | HB-9402 [†] |
| Lymphoma cells, canine | mouse | lgG2a | Hybridoma 234 s.2a | HB-9403 [†] |
| Lyt 2.2, mouse | mouse | IgM | 83-12-5 | CRL-1971 |
| Lyt-1 (all alleles), mouse | rat/mouse | lgG2a | 53-7.313 | TIB-104 |
| Lyt-2 (all alleles), mouse | rat/mouse | IgM | 3.155 | TIB-211 |
| Lyt-2 (all alleles), mouse | rat/mouse | lgG2a | 53-6.72 | TIB-105 |
| Lyt-2.1, mouse | mouse | lgG2a | 116-13.1 | HB-129 |
| Lyt-2.2, mouse | mouse | IgM | 41-3.48 | HB-130 |
| Lyt-2.2, mouse | mouse | IgM | HO-2.2 | TIB-150 |
| Lyt-2.2, mouse | rat/mouse | lgG2b | 2.43 | TIB-210 |
| Mac-1, alpha chain, mouse | rat/mouse | lgG2b | M1/70.15.11.5.HL | TIB-128 |
| Mac-1, beta subunit, mouse | rat/mouse | IgG2a; kappa | M18/2.a.12.7 (new clone of M18/2.a.8) | TIB-218 |
| Mac-1, human | mouse | lgG1 | LM2/1.6.11 | HB-204 |
| Mac-2, mouse | rat/mouse | IgG2a; kappa | M3/38.1.2.8 HL.2 | TIB-166 |
| Mac-3 (mouse macrophage antigen, 110-kDa glycoprotein) | rat/mouse | lgG1; kappa | M3/84.6.34 | TIB-168 |
| Macrophage, activated, mouse | rat/mouse | lgG2a | 158.2 | HB-8466 [†] |
| Macrophage, human | mouse | lgG1; kappa | 14E5 | HB-174 |
| Macrophage, mouse | rat/mouse | lgG2b | F4/80 | HB-198 |
| Macrophage, mouse | rat/mouse | lgG2b | M1/70.15.11.5.HL | TIB-128 |
| Macrophage, mouse | rat/mouse | lgG2a; kappa | M3/38.1.2.8 HL.2 | TIB-166 |
| Macrophage, pig | mouse | lgG1; kappa | 74-22-15 | HB-142 |
| Macrophage, pig | mouse | lgG2b; kappa | 74-22-15A | HB-142.1 |
| Macrophage, pig | mouse | IgM; kappa | 76-5-28 | HB-153 |
| Macrophage, pig | mouse | IgM; kappa | 76-6-7 | HB-141 HB-9478 [†] |
| MAdCAM 1 mouse | rat/mouse | lgG2a | MECA 90 | |
| MAdCAM-1, mouse Malignant cultured cells, human | rat/mouse | IgG2a | MECA-89 B5 NIH | HB-292 HB-10569 [†] |
| Mangnant cultured cells, numan Mammalian H-Y antigen | mouse | IgM IgM: kappa | HY3-11.27 | HB-8116 |
| Mammalian H-Y antigen Mammalian sperm acrosomal vesicle | mouse | lgM; kappa lgG1 | HS-21 (subclone 1H3) | HB-255 |
| Mammalian splicing factor (SC35) | mouse mouse | IgG1 | anti-SC35 | CRL-2031 |
| Mammary carcinoma cell line, human | mouse | igui | UCD/AB 6.01 | HB-8693 [†] |
| Mammary carcinoma cell line, human | mouse | | UCD/AB 6.01 | HB-8458 [†] |
| Mammary tumor cell cytoplasmic antigen, human | mouse | lgG1 | 3B18 | HB-8654 [†] |
| Mammary tumor cells, human | mouse | IgM | B25.2 | HB-8107 [†] |
| mannary tarrior cens, number | mouse | 19111 | ULJ.L | /ווט טוו |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|---|---|---|---|
| Nammary tumor cells, human | mouse | lgG1 | B6.2 | HB-8106 [†] |
| Nammary tumor cells, human | mouse | lgG1 | B72.3 | HB-8108 [†] |
| Medullary thymic epithelium, mouse | rat/mouse | IgM | MD2 | HB-229 |
| 1elanoma associated antigens, human | mouse | IgG | WI-MN-1 | HB-8672 [†] |
| Melanoma cell line, human (M-1 antigen system) | mouse | IgG1 | LI 27 | HB-8437 [†] |
| lelanoma cell line, human (M-11 antigen system) | mouse | IgG2a | AL 1-27 | HB-8441 [†] |
| Melanoma cell line, human (M-12 antigen system) | mouse | IgG1 | LI 66 | HB-8442 [†] |
| felanoma cell line, human (M-13 antigen system) | mouse | lgG1 | E 20 | HB-8443 [†] |
| 1elanoma cell line, human (M-16 antigen system) | mouse | IgM | K 114 | HB-8444 [†] |
| Melanoma cell line, human (M-18 antigen system) | mouse | IgG3 | R ₂₄ | HB-8445 [†] |
| Melanoma cell line, human (M-19 antigen system) | mouse | lgG1 | L235 | HB-8446 [†] |
| Melanoma cell line, human (M-20 antigen system) | mouse | IgG2a | L101 | HB-8447 [†] |
| Melanoma cell line, human (M-23 antigen system) | mouse | lgG1; kappa | L230 | HB-8448 [†] |
| 1elanoma cell line, human (M-26 antigen system) | mouse | IgG1 | A123 | HB-8451 [†] |
| 1elanoma cell line, human (M-27 antigen system) | mouse | IgM | A124 | HB-8452 [†] |
| Melanoma cell line, human (M-28 antigen system) | mouse | IgG2a | B5 | HB-8453 [†] |
| Melanoma tumor-specific antigen, human | mouse | lgG2a | XMMME-001 | HB-8759 [†] |
| Melanoma tumor-specific antigen, human | mouse | IgG2a | XMMME-002 | HB-8760 [†] |
| Mesothelial and ciliated cell protein, 130 kDa, | mouse | IgM; kappa | anti-130-kDa | CRL-2401 |
| human and rat | | | Mesothelial-Ciliated Cells | |
| licroglobulin, beta-2, human | mouse | lgG2b | BBM.1 | HB-28 |
| 1icroglobulin, beta-2, human | mouse | lgG1; kappa | L368 | HB-149 |
| 1 Aicroglobulin, beta-2, rat | mouse | lgG1 | 4C9 | CRL-2437 |
| Monocyte Fc receptor (high affinity, FcRI), human | mouse | lgG1 | 32.2 | HB-9469 [†] |
| Monocyte, human | mouse | lgG2b | 3C10 | TIB-228 |
| lonocyte, human | mouse | IgG2a; kappa | 4F2C13 | HB-22 |
| lonocyte, human | mouse | lgG1 | 63D3 | HB-44 |
| Monocyte, human Monocyte-derived neutrophil chemotactic factor, | mouse mouse | IgM; kappa IgG1 | MMA EL-NC-1S | HB-78 HB-9647 [†] |
| human Mononuclear cells, human | mouse | lgG2b | OKM 1 | CRL-8026 |
| MOPC167 idiotype (V kappa 24) | rat/mouse | lgG1 and lgG2a | 28-6-20 | CRL-2489 |
| Mu heavy chain, human | mouse | IgG1; kappa | DA4-4 | HB-57 |
| 1u heavy chain, mouse | rat/mouse | IgG2b | 331.12 | TIB-129 |
| Multidrug resistance protein (MRP) | mouse | IgG1 | QCRL-1 | HB-11765 [†] |
| | mouse | IgG2a | QCRL-3 | HB-11766 [†] |
| MUITIARUA PACISTANCA NYATAIN (MDD) | iiiouse | IgG2a; kappa | 356-1 | HB-181 |
| Multidrug resistance protein (MRP) | mouso | | 330-1 | |
| Nuscle, heart | mouse | | | |
| Muscle, heart nyb (c-myb), chicken | mouse | lgG2b | MYB 2-3.76 | CRL-1728 |
| Muscle, heart nyb (c-myb), chicken nyb (c-myb), chicken | mouse mouse | lgG2b lgG2b | MYB 2-3.76 MYB 2-37.63 | CRL-1728 CRL-1726 |
| Muscle, heart nyb (c-myb), chicken nyb (c-myb), chicken nyb (c-myb), chicken | mouse mouse mouse | IgG2b IgG2b IgG1 | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 | CRL-1728 CRL-1726 CRL-1724 |
| Muscle, heart nyb (c-myb), chicken nyb (c-myb), chicken nyb (c-myb), chicken nyb (v-myb) | mouse mouse mouse mouse | lgG2b lgG2b lgG1 lgG2b | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 |
| Muscle, heart nyb (c-myb), chicken nyb (c-myb), chicken nyb (c-myb), chicken nyb (c-myb), chicken nyb (v-myb) nyb (v-myb) | mouse mouse mouse mouse mouse | IgG2b IgG2b IgG1 IgG2b IgG2b | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 |
| Muscle, heart nyb (c-myb), chicken nyb (c-myb), chicken nyb (c-myb), chicken nyb (v-myb) nyb (v-myb) nyb (v-myb) | mouse mouse mouse mouse mouse mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1724 |
| Muscle, heart nyb (c-myb), chicken nyb (c-myb), chicken nyb (c-myb), chicken nyb (v-myb) nyb (v-myb) nyb (v-myb) nyb (v-myb) nyb (v-myb) nyb (v-myb) | mouse mouse mouse mouse mouse mouse mouse mouse mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1724 CRL-1729 |
| Muscle, heart nyb (c-myb), chicken nyb (c-myb), chicken nyb (c-myb), chicken nyb (v-myb) nyb (v-myb) nyb (v-myb) nyb (v-myb) nyc (c-myc) protein, human nyc (c-myc) protein, human | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1724 CRL-1729 CRL-1727 |
| Muscle, heart hyb (c-myb), chicken hyb (c-myb), chicken hyb (c-myb), chicken hyb (v-myb) hyb (v-myb) hyb (v-myb) hyb (v-myb) hyb (v-myb) hyb (c-myc) protein, human | mouse mouse mouse mouse mouse mouse mouse mouse mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1724 CRL-1729 |
| Muscle, heart nyb (c-myb), chicken nyb (c-myb), chicken nyb (c-myb), chicken nyb (v-myb) nyb (v-myb) nyb (v-myb) nyb (v-myb) nyc (c-myc) protein, human nyc (c-myc) protein, human | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1724 CRL-1729 CRL-1727 CRL-1725 |
| Muscle, heart hyb (c-myb), chicken hyb (c-myb), chicken hyb (c-myb), chicken hyb (v-myb) hyb (v-myb) hyb (v-myb) hyb (v-myb) hyc (c-myc) protein, human hyc (c-myc) protein, human hyc (c-myc) protein, human hyeloid cell antigen, human Myeloid leukemia (CD33), human | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG61 IgG61 | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1724 CRL-1729 CRL-1727 CRL-1727 CRL-1725 HB-8483 [†] |
| Juscle, heart Ju | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG61 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1724 CRL-1729 CRL-1727 CRL-1725 HB-8483† |
| Juscle, heart Juscle, heart Juscle, heart Juscle, cheart J | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG2a IgG2a; kappa | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 356-1 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1726 CRL-1729 CRL-1727 CRL-1727 CRL-1725 HB-8483† HB-10306† HB-181 |
| Juscle, heart Juscle | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG4 IgG2a;kappa IgG2a IgG2a IgG2a | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 356-1 A4.1025 A4.840 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1726 CRL-1727 CRL-1727 CRL-1727 CRL-1725 HB-8483† HB-10306† HB-181 CRL-2044 CRL-2043 |
| Juscle, heart Ju | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG2a IgG2a IgG2a; kappa IgG2a IgG2a IgG2a IgG2b | MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 356-1 A4.1025 A4.840 BA-G5 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1726 CRL-1727 CRL-1727 CRL-1727 CRL-1725 HB-8483† HB-10306† HB-181 CRL-2044 CRL-2043 HB-276 |
| duscle, heart by b (c-myb), chicken by b (c-myb), chicken by b (c-myb), chicken by b (v-myb) by (v-myb) by (v-myb) by (v-myb) by (v-myb) by (v-myc) by (c-myc) protein, human by c (c-myc) protein, human by c (c-myc) protein, human by eloid cell antigen, human by eloid leukemia (CD33), human by coardium by cosin heavy chain, adult, human by cosin heavy chain, adult, slow, human and rodent by cosin heavy chain, cardiac alpha, rat by cosin heavy chain, embryonic, human and rodent | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG2a IgG2a; kappa IgG2a IgG2a IgM IgG2b IgG1 | MYB 2-3.76 MYB 2-3.763 MYB 2-7.77 MYB 2-3.76 MYB 2-3.76 MYB 2-3.763 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 356-1 A4.1025 A4.840 BA-G5 F1.652 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1726 CRL-1727 CRL-1727 CRL-1727 CRL-1725 HB-8483† HB-10306† HB-181 CRL-2044 CRL-2043 HB-276 CRL-2039 |
| duscle, heart by b (c-myb), chicken by b (c-myb), chicken by b (c-myb), chicken by b (v-myb), by b (v-myb) by (v-myb) by (v-myb) by (v-myb) by (v-myb) by (c-myc) protein, human by c (c-myc) protein, human by c (c-myc) protein, human by eloid cell antigen, human by eloid leukemia (CD33), human by coardium by cosin heavy chain, adult, human by cosin heavy chain, adult, slow, human and rodent by osin heavy chain, cardiac alpha, rat by osin heavy chain, embryonic, human and rodent | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG2a IgG2a; kappa IgG2a IgG2a IgG2b IgG4 IgG1 IgG1 IgG1 | MYB 2-3.76 MYB 2-3.763 MYB 2-7.77 MYB 2-3.76 MYB 2-3.76 MYB 2-3.763 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 356-1 A4.1025 A4.840 BA-G5 F1.652 BF-45 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1726 CRL-1726 CRL-1729 CRL-1727 CRL-1727 CRL-1725 HB-8483† HB-10306† HB-181 CRL-2044 CRL-2043 HB-276 CRL-2039 HB-278 |
| Muscle, heart Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myc) Anyc (c-myc) Anyc (c-myc) Anyc (c-myc) Anyeloid cell antigen, human Anyeloid cell antigen, human Anyeloid leukemia (CD33), human Anyocardium Anyosin heavy chain, adult, human Anyosin heavy chain, adult, slow, human and rodent Anyosin heavy chain, cardiac alpha, rat Anyosin heavy chain, embryonic, human and rodent Anyosin heavy chain, embryonic, human and rodent Anyosin heavy chain, embryonic, rat Anyosin heavy chain, embryonic, rat | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG2a IgG2a IgG2a; kappa IgG2a IgG2b IgG1 IgG1 IgG1 IgG1 | MYB 2-3.76 MYB 2-3.76 MYB 2-3.763 MYB 2-7.77 MYB 2-3.76 MYB 2-3.763 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 356-1 A4.1025 A4.840 BA-G5 F1.652 BF-45 BF-B6 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1726 CRL-1726 CRL-1729 CRL-1727 CRL-1727 CRL-1725 HB-8483† HB-10306† HB-181 CRL-2044 CRL-2043 HB-276 CRL-2039 HB-278 HB-279 |
| Auscle, heart Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myc) Anyb (v | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG2a IgG2a IgG2a; kappa IgG2a IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 | MYB 2-3.76 MYB 2-3.763 MYB 2-3.763 MYB 2-7.77 MYB 2-3.76 MYB 2-3.763 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 356-1 A4.1025 A4.840 BA-G5 F1.652 BF-45 BF-B6 N2.261 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1726 CRL-1726 CRL-1729 CRL-1727 CRL-1727 CRL-1725 HB-8483† HB-10306† HB-181 CRL-2044 CRL-2043 HB-276 CRL-2039 HB-278 HB-279 CRL-2047 |
| Muscle, heart Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myc) Anyc (c-myc) Anyc (c-myc) Anyc (c-myc) Anyc (c-myc) Anyc (c-myc) Anyc (c-myc) Anycloid cell antigen, human Anycloid cell antigen, human Anycloid leukemia (CD33), human Anycoardium Anyosin heavy chain, adult, human Anyosin heavy chain, adult, slow, human and rodent Anyosin heavy chain, embryonic, human Anyosin heavy chain, embryonic, rat Anyosin heavy chain, embryonic, rat Anyosin heavy chain, embryonic, rat Anyosin heavy chain, fast lla, human and rodent | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG2a IgG2a IgG2a; kappa IgG2a IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 | MYB 2-3.76 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYB 2-3.76 MYB 2-37.63 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 356-1 A4.1025 A4.840 BA-G5 F1.652 BF-45 BF-86 N2.261 A4.74 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1726 CRL-1726 CRL-1729 CRL-1727 CRL-1725 HB-8483† HB-10306† HB-181 CRL-2044 CRL-2043 HB-276 CRL-2039 HB-278 HB-279 CRL-2047 CRL-2041 |
| Auscle, heart Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (c-myb), chicken Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myb) Anyb (v-myc) Anyb (v | mouse | IgG2b IgG2b IgG1 IgG2b IgG2b IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG2a IgG2a IgG2a; kappa IgG2a IgG2b IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 IgG1 | MYB 2-3.76 MYB 2-3.763 MYB 2-3.763 MYB 2-7.77 MYB 2-3.76 MYB 2-3.763 MYB 2-7.77 MYC 1-9E10.2 MYC CT 14-G4.3 MYC CT 9-B7.3 Anti-My-10 clone 28/8/8/14/4 M195 356-1 A4.1025 A4.840 BA-G5 F1.652 BF-45 BF-B6 N2.261 | CRL-1728 CRL-1726 CRL-1724 CRL-1728 CRL-1726 CRL-1726 CRL-1726 CRL-1729 CRL-1727 CRL-1727 CRL-1725 HB-8483† HB-10306† HB-181 CRL-2044 CRL-2043 HB-276 CRL-2039 HB-278 HB-279 CRL-2047 |



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|---|-------------------------|--------------|-------------------|----------------------|
| Myosin heavy chain, slow, human and rodent | mouse | lgG1 | A4.951 | CRL-2046 |
| Myosin heavy chain, slow, human and rodent | mouse | lgG1 | N2.261 | CRL-2047 |
| Myosin heavy chain, type 1, rat | mouse | lgG1 | BA-D5 | HB-287 |
| Myosin heavy chain, type 2A, rat | mouse | lgG1 | SC-71 | HB-277 |
| Myosin heavy chain, type 2B, rat | mouse | IgM | BF-F3 | HB-283 |
| NAP-1 (neutrophil attractant/activation protein 1) | mouse | IgG1 | EL-NC-1S | HB-9647 [†] |
| Nerve growth factor (NGF) receptor, primate | mouse | | 200-3-G6-4 (20.4) | HB-8737 [†] |
| Neuroblastoma, human | | lgG1 | PI 153/3 | TIB-198 |
| · | mouse | IgM | EL-NC-1S | |
| Neutrophil attractant/activation protein 1, human | mouse | lgG1 | | HB-9647 [†] |
| Neutrophils, mouse | rat/mouse | IgM | J11d.2 | TIB-183 |
| nG4m(b) isoallotope, human | mouse | lgG1 | HP6016 | CRL-1787 |
| Nicotinic acetylcholine receptor, Torpedo californica | mouse | lgG1 | 88B | CRL-1967 |
| NK cell antigen, mouse (LGL-1) | rat/mouse | lgG2a | 4D11 | HB-240 |
| NK cell target ligand on NC-37 cells | mouse | IgM | 18C2.8.3 | HB-9571 [†] |
| NK cell target ligand on NC-37 cells | mouse | IgM | 7C6.5.4 | HB-9574 [†] |
| NK cells, human | mouse | IgM; kappa | HNK-1 | TIB-200 |
| NK cells, mouse | mouse | lgG2a | PK136 | HB-191 |
| Non-small cell lung carcinoma (NSCLC), human | mouse | lgG1 | L18 | HB-8628 [†] |
| Non-small cell lung carcinoma (NSCLC), human | mouse | IgM | L5 | HB-8627 [†] |
| O-antigen, <i>Escherichia coli</i> O157 | mouse | IgM | MARC 29F8 | CRL-2508 |
| O-antigen, <i>Escherichia coli</i> O157 | mouse | lgM | MARC S5 | CRL-2507 |
| OKT-10 like molecule, human | mouse | lgG1 | THB-7 | HB-136 |
| p-Phosphotyrosine | mouse | lgG1; kappa | 2G8.D6 | HB-8190 [†] |
| Ornithine decarboxylase (ODC), mouse | mouse | IgM | B11 | HB-8372 [†] |
| Ovarian carcinoma cell line (2774), human | mouse | lgG1 | ME195 | HB-8431 [†] |
| Ovarian carcinoma cell line (2774), human | | | MF 116 | HB-8411 [†] |
| | mouse | lgG2a | | |
| Ovarian carcinoma cell lines, human | mouse | IgM | MH55 | HB-8412 [†] |
| Ovarian carcinoma, human | mouse | lgG2a; lgG2b | OVB-3 | HB-9147 [†] |
| Oxysterol binding protein | mouse | lgG2a | IgG-B16 | CRL-1899 |
| Oxysterol binding protein (OSBP), rabbit | mouse | lgG1 | IgG-11H9 | CRL-2213 |
| Oxytocin-neurophysin (NP-OT), rat | mouse | lgG2b; kappa | PS 38 | CRL-1950 |
| Oxytocin-neurophysin (NP-OT), rat | mouse | IgG2b; kappa | PS 60 | CRL-1800 |
| Oxytocin-neurophysin (NP-OT), rat | mouse | IgG2a; kappa | PS 67 | CRL-1797 |
| p12 gag protein of murine leukemia viruses (MuLV) | mouse | lgG2b | 548 | CRL-1890 |
| p15 gag protein of murine leukemia viruses (MuLV) | mouse | lgG2b | 34 | CRL-1889 |
| o15E <i>env</i> protein of murine leukemia viruses (MuLV) | mouse | lgG3 | 372 | CRL-1893 |
| o30 gag protein of murine leukemia virus (MuLV) | rat/mouse | lgG1 | R187 | CRL-1912 |
| Parainfluenzavirus type 3, fusion glycoprotein (F), | mouse | lgG1 | 9-4-3 | HB-8935 [†] |
| human Parainfluenzavirus type 3, hemagglutinin (HN), | mouse | lgG2a | 13-5-9-6-2 | HB-8934 [†] |
| human | | | | |
| Paramyosin, Schistosoma mansoni | mouse | lgG2a | MBL-Sm-1A6 | HB-194 |
| Paramyosin, Schistosoma mansoni | mouse | lgG2a | MBL-Sm-4B1 | HB-193 |
| Pasturella multocida type D dermonecrotic toxin | mouse | lgG1 | 1B2A3 | CRL-1965 |
| PDGF B, v-sis form | mouse | lgG2a | 116 | HB-9367 [†] |
| PDGF B, v-sis form | mouse | lgG2b | 232 | HB-9372 [†] |
| PDGF B, v-sis form | mouse | lgG1 | 52 | HB-9361 [†] |
| Peptidoglycan, bacterial | mouse | lgG3; kappa | 15B2 | HB-8510 [†] |
| Peptidoglycan, bacterial | mouse | lgG1; kappa | 3C11 | HB-8511 [†] |
| Peptidoglycan, bacterial | mouse | lgM; kappa | 3F6 | HB-8512 [†] |
| Peptidoglycan, bacterial | mouse | IgM; lambda | 3G3 | HB-8516 [†] |
| Periostin | mouse | lgG1; kappa | 5H8 | CRL-2646 |
| PETA-3 (CD151) | mouse | lgG1 | 41-2 | CRL-2695 |
| PETA-3 (CD151) | mouse | lgG1 | 50-6 | CRL-2696 |
| Peyer's patch endothelial cells, human | | lgG2a | Hermes-3 | HB-9480 [†] |
| · · · · | mouse | | MECA-367 | |
| Peyer's patch endothelial cells, mouse | rat/mouse | lgG2a | | HB-9478 [†] |
| P-glycoprotein, human | mouse | lgG2b | 443-17F9-1C6 | CRL-2694 |
| Pgp-1 glycoprotein, mouse | rat/mouse | lgG2b | IM7.8.1 | TIB-235 |
| Pgp-1, mouse | rat/mouse | lgG1 | KM114 | TIB-242 |
| lan 1 mauca | rat/mouse | lgG1 | KM201 | TIB-240 |
| Pgp-1, mouse Pgp-1, mouse | rat/mouse | lgG2a | KM703 | CRL-1896 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | lsotype | Name | ATCC® No. |
|--|-------------------------|----------------|-----------------------|-----------------------|
| Pgp-1, mouse | rat/mouse | lgG2a | KM81 | TIB-241 |
| Phenylarsonate | mouse | IgE | SE-1.3 | HB-137 |
| Phosphatidylinositol 4-kinase, type II, bovine | | IgG1; kappa | 4C5G | CRL-2538 |
| | mouse | | | |
| Phosphotyrosine | mouse | lgG1; kappa | 2G8.D6 | HB-8190 [†] |
| Phosphotyrosine | mouse | IgG3; kappa | FB2 | CRL-1891 |
| Phosphotyrosine | mouse | lgG1 | P-tyr-1 | CRL-1955 |
| Plasmodium falciparum merozoite antigen | mouse | lgG2b | MAb 5.2 | HB-9148 |
| Platelet glycoprotein GPIIIa, human | mouse | lgG1; kappa | LK-4 | CRL-2345 |
| Platelet-derived growth factor B chain (PDGF B, v-sis form) | mouse | IgG2a | 116 | HB-9367 [†] |
| Platelet-derived growth factor B chain (PDGF B, v-sis form) | mouse | lgG2b | 232 | HB-9372 [†] |
| Platelet-derived growth factor B chain (PDGF B, v-sis form) | mouse | IgG1 | 52 | HB-9361 [†] |
| Platelets, human | mouse | lgG1 | 7E3 | HB-8832 [†] |
| o-nitroanaline amide derivatives | mouse | lgG1 | P3 6D4 (SCRF 43.1) | HB-9168 [†] |
| p-nitroanaline amide derivatives | mouse | lgG1 | P3 8D2 (SCRF 43.1) | HB-9169 [†] |
| o-nitroanaline amide derivatives | mouse | lgG1 | QPN1 12C9 (SCRF 43.2) | HB-9500 [†] |
| o-nitroanaline amide derivatives | mouse | lgG1 | QPN1 22F5 (SCRF 43.2) | HB-9509 [†] |
| Polypeptide, synthetic | mouse | IgM | 7C8 | HB-8465 [†] |
| Polypeptide, synthetic, Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Asp-Lys | mouse | lgG2b | 4E11 | HB-9259 [†] |
| Polypyrimidine tract binding protein (PTB) | mouse | lgG2b; kappa | mAb BB7 | CRL-2501 |
| Pig parvovirus (PPV) | mouse | IgG1 | 3C9-D11-H11 | CRL-1745 |
| Primate tissue, normal | mouse | IgM | B5 NIH | HB-10569 [†] |
| Prostate antigen (PA), human | mouse | IgM; kappa | F5-A-1/22.8.13 | HB-8051 [†] |
| Prostate antigen (PA), human | mouse | IgG1 | RLSD06 | HB-8527 [†] |
| | | | RLSD09 | HB-8525 [†] |
| Prostate antigen (PA), human | mouse | lgG1 | | |
| rostate cancer antigen, human | mouse | lgG1 | 7E11C5 | HB-10494 [†] |
| Prostate cancer, human | mouse | lgG3 | P25.48 | HB-9119 [†] |
| Prostate epithelial cells | mouse/mouse | lgG1 | Prost 410 | HB-11426 [†] |
| Prothrombin, abnormal, human | mouse | lgG1 | JO1-1 | HB-8638 [†] |
| P-selectin, human | mouse | lgG1 | WAPS 12.2 | HB-299 |
| Pseudomonas aeruginosa (flagella type b) | human | | 20H11 | CRL-9300 [†] |
| Pseudomonas aeruginosa lipopolysaccharide (LPS) Fisher immunotype 1 (IATS type 6) | human | lgM | C5B7 | CRL-8753 [†] |
| Pseudomonas aeruginosa lipopolysaccharide (LPS) Fisher immunotype 4 (IATS type 1) | human | lgM | 9D10 | CRL-8752 [†] |
| Pseudomonas aeruginosa lipopolysaccharide (LPS) Fisher immunotype 7 | human | lgM | 8E7 | CRL-8795 [†] |
| Pseudorabies virus (PRV) | mouse | lgG2b | 3G9F3 | CRL-1843 |
| Pseudorabies virus (PRV) | mouse | lgG2b | 6D8MB4 | CRL-1842 |
| Qa-1b, mouse | mouse | IgG1 (kappa) | 4C2.4A7.5H11 | CRL-2744 |
| Qa-1b, mouse | mouse | IgG1 (kappa) | 6A8.6F10.1A6 | CRL-2743 |
| RAN-2 (rat neural antigen-2) | mouse | IgG2a | Ran-2 | TIB-119 |
| as (c-ras) protein, p21 | rat | IgG2a | Y13-238 | CRL-1741 |
| as (c-ras) protein, p21 | | IgG2a | Y13-259 | CRL-1741 |
| | rat | | | |
| as (v-ras K) oncogene peptide, synthetic | mouse | lgG1 and lgG2b | 147-67C6 | CRL-2654 |
| as (v-ras) protein, p21 | rat | IgG2a | Y13-238 | CRL-1741 |
| as (v-ras) protein, p21 | rat | lgG1 | Y13-259 | CRL-1742 |
| as oncogene peptide, synthetic | mouse | lgG1; kappa | 146-03E04 | CRL-2650 |
| as, H/N, peptide, synthetic | mouse | lgG1; kappa | 142-24E5 | CRL-2649 |
| as, Ha, p21 | mouse | lgG1 | MX | HB-9158 [†] |
| Rat neural antigen-2 (RAN-2) | mouse | lgG2a | RAN-2 | TIB-119 |
| Receptor, 1,25-dihydroxy vitamin D3, pig | mouse | IgG1 | XVI E6E6G10 | HB-9496 [†] |
| Receptor, 1,25 diriyaroxy vitamin 25, pig | rat/mouse | IgG2a | mAb 270 | HB-189 |
| Receptor, acetylcholine, neuronal, rat | rat/mouse | IgG2a | mAb 270 | HB-189 |
| | | | | |
| Receptor, CD28, mouse | hamster/mouse | lgG | PV1 | HB-12352 [†] |
| Receptor, complement, type 3 (CR3), mouse | rat/mouse | IgG2b | 5C6 Clone 1 | CRL-1969 |
| Receptor, Coxsackievirus-adenovirus, human | mouse | lgG1 | RmcB | CRL-2379 |
| Receptor, epidermal growth factor (EGF) | | lgG1 | 225 | HB-8508 [†] |



| Species of Hybridoma | Isotype | Name | ATCC® No. |
|-------------------------|--|---|---|
| mouse | laG1 | 455 | HB-8507 [†] |
| | | | HB-8509 [†] |
| | | | HB-8506 [†] |
| | | | HB-9764 [†] |
| | | | HB-9763 [†] |
| | J | | HB-135 |
| | | | HB-12128 [†] |
| | | | CRL-2688 |
| | | | HB-175 |
| | | | CRL-1827 |
| | | | CRL-1027 |
| | | | |
| | | | CRL-2013 |
| | | | CRL-2359 |
| mouse | | | HB-8555 [†] |
| mouse | | | HB-8784 [†] |
| rat/mouse | | 7D4 | CRL-1698 |
| rat/mouse | lgG1 | | TIB-222 |
| mouse | lgG2a | 10H2.12.1 | HB-11494 [†] |
| mouse | lgG2a | 4D1.5.7 | HB-11495 [†] |
| mouse | lgG2a | FSHR-323 | CRL-2689 |
| mouse | lgG1 | LHR-1055 | CRL-2687 |
| mouse | lgG1 | LHR-29 | CRL-2685 |
| mouse | lgG1 | LHR-74 | CRL-2686 |
| mouso | InC1 | 200 2 C6 4 (20 4) | HB-8737 [†] |
| | | | HB-10716 [†] |
| | | | HB-84 |
| | | | CRL-8021 |
| | | | TIB-220 |
| | | | |
| | | | TIB-219 |
| rat/mouse | | | HB-11534 [†] |
| mouse | | | CRL-2197 |
| mouse | | | HB-9771 [†] |
| mouse | | | TIB-108 |
| mouse | IgM; kappa | N-S.4.1 | TIB-110 |
| mouse | | N-S.7 | TIB-114 |
| mouse | lgG2b | N-S.8.1 | TIB-109 |
| mouse | IgG2a; kappa | S-S.1 | TIB-111 |
| mouse | IgM; kappa | S-S.3 | TIB-112 |
| mouse | lgG1 | ME195 | HB-8431 [†] |
| mouse | lgG2a | MF 116 | HB-8411 [†] |
| mouse | lgG1 | DAL K20 | CRL-2288 |
| mouse | lgG1 | DAL K29 | CRL-2291 |
| mouse | lgG1 | DAL K45 | CRL-2292 |
| mouse | lgG1 | F32 VIII C4 | CRL-1653 |
| mouse | lgG2a | 9BG5 | HB-167 |
| mouse | | | CRL-2419 |
| mouse | | RAN-2 | TIB-119 |
| | | PI 153/3 | TIB-198 |
| | | | CRL-1771 |
| | | | CRL-1759 |
| | | | HB-8730 [†] |
| | | | CRL-2381 |
| mouse | lgG1 | VD-10 | HB-68 |
| uat /ma a · · · - | I=C2= | F12 161 7 | LID 245 |
| rat/mouse | iggza | E13 101-/ | HB-215 |
| | mouse rat/mouse rat/mouse rat/mouse rat/mouse mouse mo | mouse IgG1 mouse IgG2a mouse IgG2a; kappa mouse IgG2a; kappa mouse IgG2a; kappa mouse IgG1 mouse IgG3 mouse IgG3 mouse IgG3 mouse IgG3 mouse IgG3 mouse IgG2a rat/mouse IgG2a rat/mouse IgG2a rat/mouse IgG2a rat/mouse IgG2a mouse IgG2a mouse IgG2a mouse IgG2a mouse IgG2a mouse IgG3 mouse IgG3 mouse IgG3 mouse IgG1 mouse IgG3 mouse IgG3 mouse IgG3 mouse IgG2a mouse IgG2a mouse IgG2a mouse IgG1 mouse IgG3; kappa mouse IgG3 mouse IgG3 mouse IgG1 mouse IgG1 mouse IgG1 mouse IgG1 mouse IgG1 mouse IgG3 mouse IgG4 mouse | Hybridoma mouse IgG1 455 mouse IgG2a 528 mouse IgG 579 mouse IgM Mab 108 mouse IgM Mab 96 mouse IgM My 43.51 mouse IgG1 FSHR-18 mouse IgG1 DII 33.1 rat/mouse IgG1 DII 33.1 rat/mouse IgG2a; kappa GR-20 rat/mouse IgG2a HIL12R1.2B10 mouse IgG2a TG7B6 rat/mouse IgG2a TG7B6 rat/mouse IgG2a TC7B6 rat/mouse IgG2a TD4.12.1 mouse IgG2a 4D1.5.7 mouse IgG2a 4D1.5.7 mouse IgG2a BA |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| ntigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|----------------|-------------------|------------------------|
| CAP | mouse | lgG2b | IgG-9D5 | CRL-2347 |
| chistosoma mansoni surface (cercariae) glycoprotein | mouse | IgA | 129A3/1 | HB-8087 [†] |
| chistosoma mansoni surface (cercariae) glycoprotein | mouse | lgG1 | 130C3/2B/8 | HB-8088 [†] |
| chistosoma mansoni surface (cercariae) | mouse | lgG1 | 132C4A/4 | HB-8086 [†] |
| glycoprotein Selectin, human | mouse | lgG1 | DREG200 | HB-302 |
| Selectin, human | mouse | lgG1 | DREG56 | HB-300 |
| Selectin, mouse | rat/mouse | IgG2a | MEL-14 | HB-132 |
| Selectin, mouse -Selectin, sheep and bovine | mouse | lgG1 | DU1-29 | HB-263 |
| ex lethal gene product (Sxl), female specific, | | IgG1 | mSXL 104 | CRL-1953 |
| | mouse | igai | 1113AL 104 | CRL-1955 |
| Drosophila melanogaster | mouso | InC1 | mCVI 114 | CDL 1054 |
| ex lethal gene product (SxI), female specific, | mouse | lgG1 | mSXL 114 | CRL-1954 |
| Drosophila melanogaster | | IC1 | CVI 10 | CDL 1052 |
| ex lethal gene product (SxI), female specific, | mouse | lgG1 | mSXL 18 | CRL-1952 |
| Drosophila melanogaster | | 1C1 | CVI 5 | CD1 40=1 |
| ex lethal gene product (Sxl), female specific, | mouse | lgG1 | mSXL 5 | CRL-1951 |
| Drosophila melanogaster | | 1.64.1 | 1261 | CDI 1771 |
| higa toxin | mouse | lgG1; kappa | 13C4 | CRL-1794 |
| higa-like toxin I (SLTI) | mouse | lgG1; kappa | 13C4 | CRL-1794 |
| higa-like toxin II (SLT-II) | mouse | lgG1; kappa | 11E10 | CRL-1907 |
| higa-like toxin II (SLT-II) | mouse | IgG2a; kappa | 11F11 | CRL-1908 |
| LA a, c, d | mouse | lgG2a | 7-34-1 | CRL-1945 |
| LA ABd (pig histocompatibility antigen) | mouse | IgG2b; kappa | 74-11-10 | HB-139 |
| R proteins (pre-mRNA splicing factors) | mouse | lgG1 | anti-SR (1H4) | CRL-2383 |
| R proteins (pre-mRNA splicing factors) | mouse | IgM | MAb104 | CRL-2067 |
| R proteins, conserved epitope | mouse | lgG1 | 16H3 | CRL-2385 |
| c (v-src) oncogene peptide, synthetic | mouse | lgG1 | 201-45E9 | CRL-2670 |
| c (v-src) oncogene peptide, synthetic | mouse | lgG2a; lgG2b | 203-7D10 | CRL-2651 |
| c (v-s/c) oncogene peptide, synthetic | | IgG1 | 202-11A8 | CRL-2669 |
| | mouse | | | CRL-2347 |
| REBP cleavage activating protein | mouse | lgG2b | IgG-9D5 | |
| REBP-2, hamster | mouse | lgG2b | IgG-7D4 | CRL-2198 |
| Rp20 proteins (pre-mRNA splicing factors) | mouse | lgG1 | anti-SRp20 (7B4) | CRL-2384 |
| tem cell antigen 1, mouse (Sca-1) | rat/mouse | lgG2a | E13 161-7 | HB-215 |
| tem cell factor (SCF) receptor, human | mouse | lgG2a | BA7.3C.9 | HB-10716 [†] |
| tem cells, mesenchymal, human | mouse | lgG1 | SH2 | HB-10743 [†] |
| tem cells, mesenchymal, human | mouse | lgG2b | SH3 | HB-10744 [†] |
| tem cells, mesenchymal, human | mouse | lgG1 | SH4 | HB-10745 [†] |
| terol regulatory element binding protein (dSREBP), | mouse | lgG1; kappa | lgG-3B2 | CRL-2693 |
| Drosophila melanogaster | | 5 / 11/ | <u>-</u> | |
| terol regulatory element binding protein (SREBP), | mouse | lgG1 | IgG-2A4 | CRL-2121 |
| human | | • | <u>-</u> | |
| terol regulatory element binding protein 2 | mouse | lgG2b | IgG-7D4 | CRL-2198 |
| (SREBP-2), hamster | mouse | .9020 | 190 / DT | CILL 2170 |
| terol regulatory element binding protein 2 | mouse | lgG1 | IgG-1C6 | CRL-2224 |
| (SREBP-2), human | mouse | 1901 | 190 100 | CILL ZZZT |
| terol regulatory element binding protein 2 | mouse | lgG1;kappa | lgG-1D2 | CRL-2545 |
| | mouse | іуч і, карра | 19G-1D2 | CNL-2343 |
| (SREBP-2), human | | ImCa- I | CVA/L A 1 | LID 43550† |
| treptococcus mutans | mouse | lgG2a; kappa | SWLA1 | HB-12559 [†] |
| treptococcus mutans | mouse | IgG2a; kappa | SWLA2 | HB-12560 [†] |
| treptococcus mutans | mouse | | SWLA3 | HB-12558 [†] |
| urface membranes of cancer cells | mouse | lgG1 (kappa) | IMM002.69.47.4 | CRL-13007 [†] |
| V40 T antigen | mouse | IgG2a | PAb 101 | TIB-117 |
| | mouse | lgG1 | PAb 100 | TIB-115 |
| V40 T antigen | mouse | lgG2a | PAb 108 | TIB-230 |
| | IIIOUSC | | | |
| V40 T antigen, N terminal | | lgG2a | PAb 108 | TIB-230 |
| V40 T antigen, N terminal V40 T antigen, N terminal | mouse | lgG2a lgG2a | PAb 108 7-34-1 | TIB-230 CRL-1945 |
| V40 T antigen, N terminal V40 T antigen, N terminal wine leucocyte antigen (SLA) | mouse mouse | lgG2a | 7-34-1 | CRL-1945 |
| V40 T antigen, N terminal V40 T antigen, N terminal | mouse | | | |



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|-------------------------|--------------|--------------|-----------------------|
| Γantigen, SV40 | mouse | lgG1 | PAb 100 | TIB-115 |
| Γ cell (activated), human | mouse | IgG1 | 10D2F6 | HB-11103 [†] |
| Cell (activated), human | mouse | lgG1 | OKT 9 | CRL-8021 |
| Γ cell antigen receptor (Jurkat cells), human | mouse | IgM; kappa | C305 | CRL-2424 |
| Γ cell antigen receptor, gamma/delta negative, sheep | mouse | IgG1; kappa | 86D | HB-286 |
| F cell antigen receptor, human, major framework | mouse | IgG1 | (BF1) 8A3.31 | HB-9283 [†] |
| determinant | mouse | | | |
| Fcell antigen receptor, human, major framework determinant | mouse | lgG2a | W4F.5B | HB-9282 [†] |
| Cell antigen receptor, mouse | hamster/mouse | lgG | H57-597 | HB-218 |
| ۲ cell antigen receptor, mouse | rat/mouse | lgG2b | TR 310 | HB-219 |
| ۲ cell precursor, human | mouse | lgG1 | OKT 10 | CRL-8022 [†] |
| Cell receptor | mouse | lgG1 | 1G12 | CRL-2827 |
| cell receptor, gamma/delta, mouse | hamster/mouse | IgG | UC3-10A6 | CRL-1988 |
| cell receptor, gamma/delta, mouse | hamster/mouse | IgG | UC7-13D5 | CRL-1989 |
| Cells, cytotoxic, pig | mouse | lgG2a; kappa | 76-2-11 | HB-143 |
| cells, cytotoxic/suppressor, human | mouse | lgG1 | OKT 5 | CRL-8013 [†] |
| cells, cytotoxic/suppressor, human | mouse | lgG1 | OKT 5 | CRL-8016 [†] |
| Cells, cytotoxic/suppressor, human | mouse | lgG2a | OKT 8 | CRL-8014 |
| cells, gamma/delta positive, bovine | mouse | lgG1 | IL-A29 | CRL-1874 |
| cells, helper/inducer, human | mouse | lgG2b | OKT 4 | CRL-8002 [†] |
| cells, helper/inducer, mouse | rat/mouse | lgG2b | GK1.5 | TIB-207 |
| cells, human | mouse | IgM | 2T8-3E10 | HB-8213 [†] |
| cells, human | mouse | IgM | 3Pt12B8 | HB-8136 [†] |
| cells, human | mouse | lgG1; kappa | 5E9C11 | HB-21 |
| Cells, human | mouse | IgG1 | OKT 1 | CRL-8000 [†] |
| cells, human | mouse | IgG1 | OKT 11 | CRL-8027 [†] |
| Cells, human | mouse | IgG2a | OKT 3 | CRL-8001 [†] |
| cells, human | mouse | lgG1; kappa | T3-3A1 | HB-2 |
| cells, mouse | mouse | IgM; kappa | 20-10-5S | HB-23 |
| Cells, pig | mouse | IgM; kappa | 76-5-28 | HB-153 |
| cells, pig | mouse | IgM; kappa | 76-6-7 | HB-141 |
| Cells, rabbit | mouse | IgM | 9AE10 | CRL-1761 |
| Cells, rabbit | mouse | IgG1 | L11/135 | TIB-188 |
| T12 (120 kDa) antigen, human T cells | | | 3Pt12B8 | HB-8136 [†] |
| F15 idiotype | mouse | IgM | AB1-2 | HB-33 |
| | mouse | lgG1; kappa | CC 49 | HB-9459 [†] |
| FAG-72 (tumor-associated glycoprotein), human | mouse | lgG1; kappa | | |
| T-B activating molecule (T-BAM), human | mouse | IgG2a | 5c8 | HB-10916 [†] |
| Fetanus toxin | human/mouse | lgG1 | 9F12 | HB-8177 [†] |
| Fetanus toxoid | human | IgG; kappa | SA13 | HB-8501 [†] |
| FGF-beta-2, mouse | mouse | lgG1 | 1D11.16.8 | HB-9849† |
| Theophylline | mouse | lgG1; kappa | 17/14 | HB-8153 [†] |
| Theophylline | mouse | lgG1; kappa | 30/15 | HB-8152 [†] |
| heophylline | mouse | lgG1; kappa | 61/7 | HB-8154 [†] |
| hy-1 antigen, human | mouse | lgG1 | K117 | HB-8553 [†] |
| Thy-1 antigen, mouse | mouse | IgM | HO-22-1 | TIB-100 |
| hy-1 antigen, mouse | rat/mouse | lgG2a | M5/49.4.1 | TIB-238 |
| Thy-1.1 antigen, mouse | mouse | IgM | T11D7e2 | TIB-103 |
| hy-1.2 antigen, mouse | mouse | IgM | HO-13-4 | TIB-99 |
| hy-1.2 antigen, mouse | rat/mouse | lgG2b | 30-H12 | TIB-107 |
| hy-1.2 antigen, mouse | rat/mouse | lgM | J1j.10 | TIB-184 |
| hymic lymphocyte, human | mouse | lgG1 | OKT 6 | CRL-8020 [†] |
| hymocyte (E rosette positive), human | mouse | lgG1 | OKT 11 | CRL-8027 [†] |
| hymocyte, human | mouse | lgG2a | A1G3 | HB-177 |
| hymocyte, human | mouse | lgG1 | OKT 6 | CRL-8020 [†] |
| Thymocytes, rabbit | mouse | IgM | 9AE10 | CRL-1761 |
| Thymus, cortical epithelium, human | mouse | lgG2b | CDR2 | HB-214 |
| Thymus, cortical epithelium, human | mouse | IgG2 | TE3 | HB-209 |
| Thymus, cortical epithelium, human | mouse | IgM | TE4 | HB-207 |
| Thymus, epithelium, human | mouse | IgM | TE15 | HB-206 |
| | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|--|---|--|------------------------------------|---|
| Thymus, epithelium, human | mouse | IgM | TE19 | HB-211 |
| Thymus, epithelium, human | mouse | IgG2a | TE8 | HB-212 |
| Thymus, human | mouse | IgG1 | TE7 | HB-208 |
| Thyroid stimulating hormone (TSH) receptor alpha | mouse | lgG1 | TSHR-R5T-44 | CRL-2681 |
| subunit, human | mouse | 1901 | 131111131 44 | CHE 2001 |
| Fhyroid stimulating hormone (TSH) receptor alpha subunit, human | mouse | lgG1 | TSHR-T5-51 | CRL-2680 |
| Thyroid stimulating hormone (TSH) receptor alpha subunit, human | mouse | lgG1 | TSHR-T5U-317 | CRL-2682 |
| hyroid stimulating hormone (TSH) receptor beta subunit, human | mouse | lgG1 | TSHR-R5T-34 | CRL-2683 |
| hyroid stimulating hormone (TSH) receptor beta subunit, human | mouse | lgG2a | TSHR-T3-365 | CRL-2684 |
| -Thyroxine (T4, 3,5,3',5'-tetraiodo-L-thyronine) | mouse | lgG1 | T4 Clone 5 (10-0101, 0062-83) | HB-8500 [†] |
| ilb antigen, human | mouse | IgM | 2T8-3E10 | HB-8213 [†] |
| L antigen, mouse | mouse | lgG2a | I(TL.m9) | HB-131 |
| TL antigen, mouse | rat/mouse | lgG2a | HD168 | HB-252 |
| Fransferrin receptor, human | mouse | IgG2a | L5.1 | HB-84 |
| ransferrin receptor, human | mouse | IgG1 | OKT 9 | CRL-8021 |
| ransferrin receptor, mouse | rat/mouse | IgM | R17 208.2 | TIB-220 |
| ransferrin receptor, mouse | rat/mouse | IgG2a | R17 217.1.3 | TIB-219 |
| ransforming growth factor-beta2, mouse | mouse | IgG1 | 1D11.16.8 | HB-9849 [†] |
| reponema pallidum | mouse | IgM | 1939-3G5 | HB-8133 [†] |
| reponema pallidum | mouse | IgG1 | 1939-8G2 | HB-8134 [†] |
| Trichinella spiralis | | IgM | 7C,C,C, | HB-8678 [†] |
| rifucosylated type 2 chain glycolipids | mouse | IgM | FHCR-1-2075/FH5 | HB-8770 [†] |
| 2,4,6-Trinitrophenyl (TNP) | mouse | | 1B7.11 | TIB-191 |
| | mouse | lgG1 | 2F.11.15 | |
| 2,4,6-Trinitrophenyl (TNP) | mouse | IgA | | TIB-194 |
| 2,4,6-Trinitrophenyl (TNP) | mouse | IgE (Iga haplotype) | IGEL a2 | TIB-142 |
| 2,4,6-Trinitrophenyl (TNP) | mouse | IgE (Igb haplotype) | IGEL b4 | TIB-141 |
| rop-1, human rop-2, human | mouse mouse | lgG2a lgG1 (lgh-4a | 162-21.2 162-46.2 | HB-241 HB-187 |
| | | allotype) | | |
| Trophoblasts, human | mouse | lgG1 (lgh-4a allotype) | 162-46.2 | HB-187 |
| Tubulin, beta, nematode | mouse | lgG | P3D | HB-11129 [†] |
| Tumor, intracellular antigen, human | human/mouse | IgM | Ch13 | HB-8573 [†] |
| Tumor, intracellular antigen, human | human/mouse | IgM | Gr431 | HB-8575 [†] |
| Tumor, intracellular antigen, human | human/mouse | IgM | Te39 | HB-8577 [†] |
| Tumor-associated glycoprotein (TAG-72), human | mouse | IgG1 kappa | CC 49 | HB-9459 [†] |
| Tumors, human | mouse | IgM | B5 NIH | HB-10569 [†] |
| umors, neuroectoderm, human | mouse | IgM | PI 153/3 | TIB-198 |
| Jracil DNA glycosylase (UDG), human | mouse | IgM | 37.04.12 | HB-9312 [†] |
| Jracil DNA glycosylase (UDG), human | mouse | IgG | 40.10.09 | HB-9311 [†] |
| Jracil DNA glycosylase (UDG), human | mouse | IgM | 42.08.07 | HB-9313 [†] |
| Jterine carcinoma cell lines, human | mouse | IgM | MH55 | HB-8412 [†] |
| /acA (vacuolating cytotoxin) | mouse | lgG1; kappa | 5E4 | CRL-2635 |
| /acA (vacuolating cytotoxin) | mouse | lgG1; kappa | 5G5 | CRL-2633 |
| | mouse | lgG1; kappa | B3D | CRL-2634 |
| | mouse | lgG1; kappa | VIII-6G10 | HB-10519 [†] |
| ascular cell adhesion molecule 1, human and | | | | |
| /ascular cell adhesion molecule 1, human and macaque | | laG1·kanna | M/K-1 9 | CRI -1010 |
| /ascular cell adhesion molecule 1, human and macaque /ascular cell adhesion molecule 1, mouse | rat/mouse | lgG1; kappa | M/K-1.9 M/K-2.7 | CRL-1910 |
| /acA (vacuolating cytotoxin) /ascular cell adhesion molecule 1, human and macaque /ascular cell adhesion molecule 1, mouse /ascular cell adhesion molecule 1, mouse /ascular endothelial growth factor (VEGF) | | lgG1; kappa lgG1; kappa lgG1; kappa | M/K-1.9 M/K-2.7 DC101 | CRL-1910 CRL-1909 HB-11534 [†] |
| Vascular cell adhesion molecule 1, human and macaque Vascular cell adhesion molecule 1, mouse Vascular cell adhesion molecule 1, mouse Vascular endothelial growth factor (VEGF) | rat/mouse rat/mouse | lgG1; kappa | M/K-2.7 | CRL-1909 |
| /ascular cell adhesion molecule 1, human and macaque /ascular cell adhesion molecule 1, mouse /ascular cell adhesion molecule 1, mouse /ascular endothelial growth factor (VEGF) receptor-2, mouse | rat/mouse rat/mouse rat/mouse | lgG1; kappa lgG1; kappa | M/K-2.7 DC101 | CRL-1909 HB-11534 [†] |
| Vascular cell adhesion molecule 1, human and macaque Vascular cell adhesion molecule 1, mouse Vascular cell adhesion molecule 1, mouse Vascular endothelial growth factor (VEGF) receptor-2, mouse Vasopressin-neurophysin (NP-AVP), rat | rat/mouse rat/mouse rat/mouse | IgG1; kappa IgG1; kappa IgG2b; kappa | M/K-2.7 DC101 PS 41 | CRL-1909 HB-11534 [†] CRL-1799 |
| /ascular cell adhesion molecule 1, human and macaque /ascular cell adhesion molecule 1, mouse /ascular cell adhesion molecule 1, mouse /ascular endothelial growth factor (VEGF) receptor-2, mouse /asopressin-neurophysin (NP-AVP), rat /asopressin-neurophysin (NP-AVP), rat | rat/mouse rat/mouse rat/mouse mouse mouse | lgG1; kappa lgG1; kappa lgG2b; kappa lgG2b; kappa | M/K-2.7 DC101 PS 41 PS 45 | CRL-1909 HB-11534 [†] CRL-1799 CRL-1798 |
| /ascular cell adhesion molecule 1, human and macaque /ascular cell adhesion molecule 1, mouse /ascular cell adhesion molecule 1, mouse /ascular endothelial growth factor (VEGF) receptor-2, mouse /asopressin-neurophysin (NP-AVP), rat | rat/mouse rat/mouse rat/mouse | IgG1; kappa IgG1; kappa IgG2b; kappa | M/K-2.7 DC101 PS 41 | CRL-1909 HB-11534 [†] CRL-1799 |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

Order online at **www.lgcpromochem.com/atcc**, or contact your local LGC Promochem office. See back cover for details.



| Very late antigen 1 (VLA-1) alpha, human mouse IgG1 TS2/7.1.1 HB-245 Very late antigen 1 (VLA-1) beta, human mouse IgG1 TS2/16.2.1 HB-243 Very late antigen 4 (VLA-1) mouse rat/mouse IgG2b R1-2 HB-227 Very late antigen 4 (VLA-4), sheep mouse IgG2b FW3-218-1 HB-261 Very low density lipoprotein (VLDL) receptor mouse IgG1 IJG-6A6 CRL-2197 Vesicular stomatitis virus surface glycoprotein mouse IgG1 II-Hybridoma CRL-2700 Verisconcogene peptide (synthetic) mouse IgG1 E6(2)2 HB-81721 Vitamin B6 mouse IgG1 XVI E6E6G10 HB-81721 Vitamin D3 receptor, pig mouse IgG1 XVI E6E6G10 HB-94961 Vitonectin receptor (VnR), human mouse IgG4 XVI NGC2 HB-86361 Vulva, cancer human IgG4 VLN3G2 HB-86361 WC1, bovine mouse IgG3 CC15 HB-265 WC1, bovine mouse IgG1< | Antigenic Determinant | Species of Hybridoma | Isotype | Name | ATCC® No. |
|---|---|-------------------------|---------------------|--------------|------------------------|
| Very late antigen 1 (VLA-1) beta, human mouse IgG1 TS2/16.2.1 HB-243 Very late antigen 4 (VLA-4), mouse rat/mouse IgG2b R1-2 HB-227 Very late antigen 4 (VLA-4), sheep mouse IgG2b FW3-218-1 HB-261 Very low density lipoprotein (VLDU) receptor mouse IgG1 IgG-66A6 CRL-2197 Vesicular stomatitis virus surface glycoprotein mouse IgG1 I1-Hybridoma CRL-2700 v-fms oncogene peptide (synthetic) mouse IgG1 and 2b (kappa) 290-4E10 CRL-2662 Vitamin B6 mouse IgG1 KIE66G10 HB-8172° Vitamin B7 mouse IgG1 XVI E66G610 HB-9496° Vitamin B8 mouse IgG1 XVI E66G610 HB-9496° Vitamin B7 mouse IgG1 B6H12.2 HB-9771° Vulva, cancer human IgG4 VLN3C2 HB-8636° Vulva, cancer human IgG4 VLN6H2 HB-8633° WC1, bovine mouse IgG1 CC39 HB | VEGF receptor 1 | mouse | lgG1 (kappa) | 6.12 | CRL-13006 [†] |
| Very late antigen 4 (VLA-4), mouse rat/mouse IgG2b R1-2 HB-227 Very late antigen 4 (VLA-4), sheep mouse IgG2b FW3-218-1 HB-261 Very low density lipoprotein (VLDL) receptor mouse IgG1 IgG-6A6 CRL-2197 Versicular stomatitis virus surface glycoprotein mouse IgG1 I1-Hybridoma CRL-2700 V-fms oncogene peptide (synthetic) mouse IgG1 and 2b (kappa) 290-4E10 CRL-2662 Vitamin B6 mouse IgG1 E6(2)2 HB-8172¹ Vitamin D3 receptor, pig mouse IgG1 B6(1)2.2 HB-8172¹ Vitamin D3 receptor (VnR), human mouse IgG1 B6H12.2 HB-9771¹ Vitamin D3 receptor (VnR), human mouse IgG1 B6H12.2 HB-9771¹ Vitamin D3 receptor (VnR), human mouse IgG4 VLN3G2 HB-8633¹ Vulva, cancer human IgG4 VLN6H2 HB-8633¹ WC1, bovine mouse IgG2a CC15 HB-265 WC1, bovine mouse IgG1 | Very late antigen 1 (VLA-1) alpha, human | mouse | | TS2/7.1.1 | HB-245 |
| Very late antigen 4 (VLA-4), sheep mouse IgG2b FW3-218-1 HB-261 Very low density lipoprotein (VLDL) receptor mouse IgG1 IgG-6A6 CRL-2197 Vesicular stomatitis virus surface glycoprotein mouse IgG1 I1-Hybridoma CRL-2700 V-fms oncogene peptide (synthetic) mouse IgG1 and 2b (kappa) 290-4E10 CRL-2662 Vitamin B6 mouse IgG1 E6(2)2 HB-8172¹ Vitamin D3 receptor, pig mouse IgG1 XVI E6E6G10 HB-9496¹ Vitonectin receptor (VnR), human mouse IgG1 B6H12.2 HB-9496¹ Vitonectin receptor (VnR), human mouse IgG4 VLN3G2 HB-8636¹ Vulva, cancer human IgG4 VLN3G2 HB-8636¹ Vulva, cancer human IgG2a CC15 HB-8636¹ WC1, bovine mouse IgG2a CC15 HB-265 WC1, bovine mouse IgG1 CC39 HB-274 WC3 bovine B cell antigen (BoWC3) mouse IgG1 CC21 | Very late antigen 1 (VLA-1) beta, human | mouse | lgG1 | TS2/16.2.1 | HB-243 |
| Very low density lipoprotein (VLDL) receptor mouse IgG1 IgG-6A6 CRL-2197 Vesicular stomatitis virus surface glycoprotein mouse IgG1 11-Hybridoma CRL-2700 v-fms oncogene peptide (synthetic) mouse IgG1 and 2b (kappa) 290-4E10 CRL-2662 Vitamin B6 mouse IgG1 E6(2)2 HB-8172¹ Vitamin D3 receptor, pig mouse IgG1 XVI E6E6G10 HB-9496¹ Vitonectin receptor (VnR), human mouse IgG1 B6H12.2 HB-9771¹ Vulva, cancer human IgG4 VLN3G2 HB-8636¹ WC1, bovine mouse IgG2a CC15 HB-8636¹ WC1, bovine mouse IgG1 CC39 HB-274 WC3, bovine mouse IgG1 CC39 HB-274 WC3, bovine mouse IgG1 CC21 HB-288 WC4, bovine mouse IgG1 CC55 HB-288 WC4, bovine mouse IgG1 CC57 HB-268 Yersinia pestis, F1 antigen< | Very late antigen 4 (VLA-4), mouse | rat/mouse | lgG2b | R1-2 | HB-227 |
| Vesicular stomatitis virus surface glycoprotein mouse IgG1 II-Hybridoma CRL-2700 v-fms oncogene peptide (synthetic) mouse IgG1 and 2b (kappa) 290-4E10 CRL-2662 Vitamin B6 mouse IgG1 E6(2)2 HB-8172¹ Vitamin B6 mouse IgG1 XVI E6E6G10 HB-9496¹ Vitamin D3 receptor, pig mouse IgG1 B6H12.2 HB-9771¹ Vitonectin receptor (VnR), human mouse IgG1 B6H12.2 HB-9771¹ Vulva, cancer human IgG4 VLN3G2 HB-8636¹ Vulva, cancer human IgG6 VLN6H2 HB-8633¹ WC1, bovine mouse IgG1 CC39 HB-265 WC1, bovine mouse IgG1 CC39 HB-265 WC1, bovine mouse IgG1 CC39 HB-274 WC1, bovine mouse IgG1 CC39 HB-274 WC3, bovine MC3 bovine B cell antigen (BoWC3) mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgA F1-3G8-1 HB-192 Yers in a pestis, F1 antigen mouse IgG1 CRL-1689 Yers in a pestis, F1 antigen mouse IgG1 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1; kappa H2.8 CRL-2684 ZP2 glycoprotein, mouse IgG2a IE-3 CRL-2683 ZP2 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | Very late antigen 4 (VLA-4), sheep | mouse | lgG2b | FW3-218-1 | HB-261 |
| Verfms oncogene peptide (synthetic) mouse lgG1 and 2b (kappa) 290-4E10 CRL-2662 | Very low density lipoprotein (VLDL) receptor | mouse | lgG1 | IgG-6A6 | CRL-2197 |
| Vitamin B6 mouse IgG1 E6(2)2 HB-8172¹ Vitamin D3 receptor, pig mouse IgG1 XVI E6E6G10 HB-9496¹ Vitonectin receptor (VnR), human mouse IgG1 B6H12.2 HB-977¹¹ Vulva, cancer human IgG4 VLN3G2 HB-8636¹ Vulva, cancer human IgG2 VLN6H2 HB-8633¹ WC1, bovine mouse IgG2a CC15 HB-265 WC1, bovine mouse IgG1 CC39 HB-274 WC1, bovine mouse IgG1 CC39 HB-274 WC3 bovine B cell antigen (BoWC3) mouse IgG1 CC21 HB-288 WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC57 HB-288 WC4, bovine mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgG2a; kappa 2D12 CRL-1689 Yersinia pestis, F1 antigen mouse IgG1 (kappa) H1.6 | Vesicular stomatitis virus surface glycoprotein | mouse | lgG1 | I1-Hybridoma | CRL-2700 |
| Witamin D3 receptor, pig mouse IgG1 XVI E6E6G10 HB-9496¹ Vitonectin receptor (VnR), human mouse IgG1 B6H12.2 HB-9771¹ Vulva, cancer human IgG4 VLN3G2 HB-8636¹ Vulva, cancer human IgG VLN6H2 HB-8633¹ WC1, bovine mouse IgG2a CC15 HB-265 WC1, bovine mouse IgG1 CC39 HB-274 WC1, bovine mouse IgG1 IL-A29 CRL-1874 WC3 bovine B cell antigen (BoWC3) mouse IgG1 CC21 HB-288 WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgG2a; kappa 2D12 CRL-1689 Yersinia pestis, F1 antigen mouse IgG1 240-13D10 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-25672 ZP1 glycoprotein, mouse rat/mouse | v-fms oncogene peptide (synthetic) | mouse | IgG1 and 2b (kappa) | 290-4E10 | CRL-2662 |
| Wittonectin receptor (VnR), human mouse IgG1 B6H12.2 HB-9771† Vulva, cancer human IgG4 VLN3G2 HB-8636† Vulva, cancer human IgG VLN6H2 HB-8633† WC1, bovine mouse IgG2a CC15 HB-265 WC1, bovine mouse IgG1 CC39 HB-274 WC1, bovine mouse IgG1 IL-A29 CRL-1874 WC3, bovine B cell antigen (BoWC3) mouse IgG1 CC21 HB-288 WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC57 HB-282 WC4, bovine mouse IgG1 CC57 HB-282 WC4, bovine mouse IgG1 CC57 HB-288 WC4, bovine mouse IgG1 CC57 HB-288 WC4, bovine mouse IgG2a; kappa 2D12 CRL-1689 Yellow fever virus mouse IgG2a; kappa 2D12 CRL-1689 < | Vitamin B6 | mouse | lgG1 | E6(2)2 | HB-8172 [†] |
| Vulva, cancerhumanIgG4VLN3G2HB-8636†Vulva, cancerhumanIgGVLN6H2HB-8633†WC1, bovinemouseIgG2aCC15HB-265WC1, bovinemouseIgG1CC39HB-274WC1, bovinemouseIgG1IL-A29CRL-1874WC3, bovine B cell antigen (BoWC3)mouseIgG1CC21HB-288WC4, bovinemouseIgG1CC55HB-282WC4, bovinemouseIgG1CC57HB-268Yellow fever virusmouseIgG2a; kappa2D12CRL-1689Yersinia pestis, F1 antigenmouseIgGAF1-3G8-1HB-192Yersinia pestis, pestis, F1 antigenmouseIgG1240-13D10CRL-2672Zonae pellucidae 1 (ZP1), humanmouseIgG1 (kappa)H1.6CRL-2567ZP1 glycoprotein, mouserat/mouseIgG2aM1.4CRL-2464ZP2 glycoprotein, humanmouseIgG2aM1.4CRL-2688ZP2 glycoprotein, mouserat/mouseIgG2aIE-3CRL-2688ZP2 glycoprotein, mouserat/mouseIgG2aIE-3CRL-2668ZP3 glycoprotein, humanmouseIgG1; kappaH3.1CRL-2569 | Vitamin D3 receptor, pig | mouse | lgG1 | XVI E6E6G10 | HB-9496 [†] |
| Vulva, cancerhumanIgGVLN6H2HB-8633†WC1, bovinemouseIgG2aCC15HB-265WC1, bovinemouseIgG1CC39HB-274WC1, bovinemouseIgG1IL-A29CRL-1874WC3 bovine B cell antigen (BoWC3)mouseIgG1CC21HB-288WC4, bovinemouseIgG1CC55HB-282WC4, bovinemouseIgG1CC57HB-268Yellow fever virusmouseIgG2a; kappa2D12CRL-1689Yersinia pestis, F1 antigenmouseIgAF1-3G8-1HB-192Yers (c-yes) oncogene peptide, syntheticmouseIgG1240-13D10CRL-2672Zonae pellucidae 1 (ZP1), humanmouseIgG1 (kappa)H1.6CRL-2567ZP1 glycoprotein, mouserat/mouseIgG2aM1.4CRL-2464ZP2 glycoprotein, humanmouseIgG2aIE-3CRL-2568ZP2 glycoprotein, mouserat/mouseIgG2aIE-3CRL-2463ZP3 glycoprotein, humanmouseIgG1; kappaH3.1CRL-2569 | Vitonectin receptor (VnR), human | mouse | lgG1 | B6H12.2 | HB-9771 [†] |
| WC1, bovine mouse IgG2a CC15 HB-265 WC1, bovine mouse IgG1 CC39 HB-274 WC1, bovine mouse IgG1 IL-A29 CRL-1874 WC3 bovine B cell antigen (BoWC3) mouse IgG1 CC21 HB-288 WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgG2a; kappa 2D12 CRL-1689 Yersinia pestis, F1 antigen mouse IgA F1-3G8-1 HB-192 Yers (c-yes) oncogene peptide, synthetic mouse IgG1 240-13D10 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-2567 ZP1 glycoprotein, mouse rat/mouse IgG2a M1.4 CRL-2464 ZP2 glycoprotein, human mouse IgG2a IE-3 CRL-2463 ZP3 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | Vulva, cancer | human | lgG4 | VLN3G2 | HB-8636 [†] |
| WC1, bovine mouse IgG1 CC39 HB-274 WC1, bovine mouse IgG1 IL-A29 CRL-1874 WC3 bovine B cell antigen (BoWC3) mouse IgG1 CC21 HB-288 WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgG2a; kappa 2D12 CRL-1689 Yersinia pestis, F1 antigen mouse IgA F1-3G8-1 HB-192 Yersinia pestis, F1 antigen mouse IgG1 240-13D10 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-2672 ZONae pellucidae 1 (ZP1), human mouse IgG2a M1.4 CRL-2567 ZP1 glycoprotein, mouse rat/mouse IgG3; kappa H2.8 CRL-2464 ZP2 glycoprotein, human mouse IgG2a IE-3 CRL-2463 ZP3 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | Vulva, cancer | human | lgG | VLN6H2 | HB-8633 [†] |
| WC1, bovine mouse IgG1 IL-A29 CRL-1874 WC3 bovine B cell antigen (BoWC3) mouse IgG1 CC21 HB-288 WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgG2a; kappa 2D12 CRL-1689 Yersinia pestis, F1 antigen mouse IgA F1-3G8-1 HB-192 Yers (c-yes) oncogene peptide, synthetic mouse IgG1 240-13D10 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-2567 ZP1 glycoprotein, mouse rat/mouse IgG2a M1.4 CRL-2464 ZP2 glycoprotein, human mouse IgG2a IE-3 CRL-2568 ZP2 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | WC1, bovine | mouse | lgG2a | CC15 | HB-265 |
| WC3 bovine B cell antigen (BoWC3) mouse IgG1 CC21 HB-288 WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgG2a; kappa 2D12 CRL-1689 Yersinia pestis, F1 antigen mouse IgA F1-3G8-1 HB-192 yes (c-yes) oncogene peptide, synthetic mouse IgG1 240-13D10 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-2567 ZP1 glycoprotein, mouse rat/mouse IgG2a M1.4 CRL-2464 ZP2 glycoprotein, human mouse IgG2a IE-3 CRL-2568 ZP2 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | WC1, bovine | mouse | lgG1 | CC39 | HB-274 |
| WC4, bovine mouse IgG1 CC55 HB-282 WC4, bovine mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgG2a; kappa 2D12 CRL-1689 Yersinia pestis, F1 antigen mouse IgA F1-3G8-1 HB-192 yes (c-yes) oncogene peptide, synthetic mouse IgG1 240-13D10 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-2567 ZP1 glycoprotein, mouse rat/mouse IgG2a M1.4 CRL-2464 ZP2 glycoprotein, human mouse IgG2a H2.8 CRL-2568 ZP2 glycoprotein, mouse rat/mouse IgG2a IE-3 CRL-2463 ZP3 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | WC1, bovine | mouse | lgG1 | IL-A29 | CRL-1874 |
| WC4, bovine mouse IgG1 CC57 HB-268 Yellow fever virus mouse IgG2a; kappa 2D12 CRL-1689 Yersinia pestis, F1 antigen mouse IgA F1-3G8-1 HB-192 yes (c-yes) oncogene peptide, synthetic mouse IgG1 240-13D10 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-2567 ZP1 glycoprotein, mouse rat/mouse IgG2a M1.4 CRL-2464 ZP2 glycoprotein, human mouse IgG1; kappa H2.8 CRL-2568 ZP2 glycoprotein, mouse rat/mouse IgG2a IE-3 CRL-2463 ZP3 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | WC3 bovine B cell antigen (BoWC3) | mouse | lgG1 | CC21 | HB-288 |
| Yellow fever virusmouseIgG2a; kappa2D12CRL-1689Yersinia pestis, F1 antigenmouseIgAF1-3G8-1HB-192yes (c-yes) oncogene peptide, syntheticmouseIgG1240-13D10CRL-2672Zonae pellucidae 1 (ZP1), humanmouseIgG1 (kappa)H1.6CRL-2567ZP1 glycoprotein, mouserat/mouseIgG2aM1.4CRL-2464ZP2 glycoprotein, humanmouseIgG1; kappaH2.8CRL-2568ZP2 glycoprotein, mouserat/mouseIgG2aIE-3CRL-2463ZP3 glycoprotein, humanmouseIgG1; kappaH3.1CRL-2569 | WC4, bovine | mouse | lgG1 | CC55 | HB-282 |
| Yersinia pestis, F1 antigenmouseIgAF1-3G8-1HB-192yes (c-yes) oncogene peptide, syntheticmouseIgG1240-13D10CRL-2672Zonae pellucidae 1 (ZP1), humanmouseIgG1 (kappa)H1.6CRL-2567ZP1 glycoprotein, mouserat/mouseIgG2aM1.4CRL-2464ZP2 glycoprotein, humanmouseIgG1; kappaH2.8CRL-2568ZP2 glycoprotein, mouserat/mouseIgG2aIE-3CRL-2463ZP3 glycoprotein, humanmouseIgG1; kappaH3.1CRL-2569 | WC4, bovine | mouse | lgG1 | CC57 | HB-268 |
| yes (c-yes) oncogene peptide, synthetic mouse IgG1 240-13D10 CRL-2672 Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-2567 ZP1 glycoprotein, mouse IgG2a M1.4 CRL-2464 ZP2 glycoprotein, human mouse IgG1; kappa H2.8 CRL-2568 ZP2 glycoprotein, mouse IgG2a IE-3 CRL-2463 ZP3 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | Yellow fever virus | mouse | IgG2a; kappa | 2D12 | CRL-1689 |
| Zonae pellucidae 1 (ZP1), human mouse IgG1 (kappa) H1.6 CRL-2567 ZP1 glycoprotein, mouse rat/mouse IgG2a M1.4 CRL-2464 ZP2 glycoprotein, human mouse IgG1; kappa H2.8 CRL-2568 ZP2 glycoprotein, mouse rat/mouse IgG2a IE-3 CRL-2463 ZP3 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | Yersinia pestis, F1 antigen | mouse | IgA | F1-3G8-1 | HB-192 |
| ZP1 glycoprotein, mouse rat/mouse IgG2a M1.4 CRL-2464 ZP2 glycoprotein, human mouse IgG1; kappa H2.8 CRL-2568 ZP2 glycoprotein, mouse rat/mouse IgG2a IE-3 CRL-2463 ZP3 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | yes (c-yes) oncogene peptide, synthetic | mouse | | 240-13D10 | CRL-2672 |
| ZP2 glycoprotein, humanmouseIgG1; kappaH2.8CRL-2568ZP2 glycoprotein, mouserat/mouseIgG2aIE-3CRL-2463ZP3 glycoprotein, humanmouseIgG1; kappaH3.1CRL-2569 | Zonae pellucidae 1 (ZP1), human | mouse | lgG1 (kappa) | H1.6 | CRL-2567 |
| ZP2 glycoprotein, mouserat/mouselgG2aIE-3CRL-2463ZP3 glycoprotein, humanmouselgG1; kappaH3.1CRL-2569 | ZP1 glycoprotein, mouse | rat/mouse | lgG2a | M1.4 | CRL-2464 |
| ZP3 glycoprotein, human mouse IgG1; kappa H3.1 CRL-2569 | ZP2 glycoprotein, human | mouse | lgG1; kappa | H2.8 | CRL-2568 |
| 3, 1 | ZP2 glycoprotein, mouse | rat/mouse | lgG2a | IE-3 | CRL-2463 |
| ZP3 glycoprotein, mouse rat/mouse IgG2a IE-10 CRL-2462 | ZP3 glycoprotein, human | mouse | lgG1; kappa | H3.1 | CRL-2569 |
| | ZP3 glycoprotein, mouse | rat/mouse | lgG2a | IE-10 | CRL-2462 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



ATCC has approximately 1,100 tumor cell lines from a variety of species. This list includes tumor cells from primary sites or from sources in which the primary/metastatic status is unknown. They are listed by disease state, which is described with varying degrees of specificity (ATCC reports the description provided by the depositor). Cell lines that are known to be from metastatic sites are given in the following list starting on page 170.

For more information on a cell line, see the main list starting on page 30 or use the catalogue number to find the entry in the cell biology section of the ATCC online catalog.

| Disease | Source | Species | Name | ATCC® No. |
|----------------|------------------|----------|-----------------|------------------------|
| | | | | |
| Adenocarcinoma | cervix | human | HeLa | CCL-2 |
| Adenocarcinoma | cervix | human | HeLa 229 | CCL-2.1 |
| Adenocarcinoma | cervix | human | HeLa S3 | CCL-2.2 |
| Adenocarcinoma | cervix | human | H1HeLa | CRL-1958 |
| Adenocarcinoma | cervix | human | Hs 588.T | CRL-7850* |
| Adenocarcinoma | cervix | human | GH329 | CRL-13002 [†] |
| Adenocarcinoma | cervix | human | GH354 | CRL-13003 [†] |
| Adenocarcinoma | cervix | human | HeLa NR1 | CRL-13011 [†] |
| Adenocarcinoma | colon | human | NCI-H548 | CCL-249 |
| Adenocarcinoma | colon | human | Hs 255.T | CRL-7213* |
| Adenocarcinoma | colon | marmoset | TAC-1 | CRL-10632 [†] |
| Adenocarcinoma | duodenum | human | HuTu 80 | HTB-40 |
| Adenocarcinoma | intestine, small | rat | IA-XsSBR | CRL-1677 |
| Adenocarcinoma | kidney | human | A704 | CRL-7911* |
| Adenocarcinoma | kidney | human | A-704 | HTB-45 |
| Adenocarcinoma | lung | human | NCI-H1373 | CRL-5866 |
| Adenocarcinoma | lung | human | NCI-H1395 | CRL-5868 |
| Adenocarcinoma | lung | human | Hs 618.T | CRL-7380* |
| Adenocarcinoma | lung | human | SK-LU-1 | HTB-57 |
| Adenocarcinoma | lung | human | HCC2935 | CRL-2869 |
| Adenocarcinoma | lung | human | HCC4006 | CRL-2871 |
| Adenocarcinoma | lung | human | HCC827 | CRL-2868 |
| Adenocarcinoma | mammary gland | human | Hs 274.T | CRL-7222* |
| Adenocarcinoma | mammary gland | human | Hs 280.T | CRL-7226* |
| Adenocarcinoma | mammary gland | human | Hs 281.T | CRL-7227* |
| Adenocarcinoma | mammary gland | human | Hs 343.T | CRL-7245* |
| Adenocarcinoma | mammary gland | human | Hs 362.T | CRL-7253* |
| Adenocarcinoma | mammary gland | human | Hs 739.T | CRL-7477* |
| Adenocarcinoma | mammary gland | human | Hs 741.T | CRL-7480* |
| Adenocarcinoma | mammary gland | mouse | JC | CRL-2116 |
| Adenocarcinoma | mammary gland | rat | 13762 MAT B III | CRL-1666 |
| Adenocarcinoma | mammary gland | rat | NMU | CRL-1743 |
| Adenocarcinoma | mammary gland | rat | RBA | CRL-1747 |
| Adenocarcinoma | mammary gland | rat | SMT/2A LNM | CRL-6602* |
| Adenocarcinoma | ovary | human | Caov-3 | HTB-75 |
| Adenocarcinoma | pancreas | human | BxPC-3 | CRL-1687 |
| Adenocarcinoma | pancreas | human | HPAF-II | CRL-1997 |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. earch use only. Not intended for use in humans, animals or for diagnostics.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Source | Species | Name | ATCC® No. |
|--|-----------------------|-------------------|----------------|------------------------|
| Adenocarcinoma | pancreas | human | HPAC | CRL-2119 |
| Adenocarcinoma | pancreas | human | Panc 03.27 | CRL-2549 |
| Adenocarcinoma | pancreas | human | Panc 08.13 | CRL-2551 |
| Adenocarcinoma | pancreas | human | Panc 02.03 | CRL-2553 |
| Adenocarcinoma | pancreas | human | Panc 02.13 | CRL-2554 |
| Adenocarcinoma | pancreas | human | Panc 04.03 | CRL-2555 |
| Adenocarcinoma | pancreas | human | Panc 05.04 | CRL-2557 |
| Adenocarcinoma | pancreas | human | Capan-2 | HTB-80 |
| Adenocarcinoma | pancreas | mouse | LTPA | CRL-2389 |
| Adenocarcinoma | prostate | mouse, transgenic | TRAMP-C1 | CRL-2730 |
| Adenocarcinoma | prostate | mouse, transgenic | TRAMP-C2 | CRL-2731 |
| Adenocarcinoma | prostate; transfected | human | CA-HPV-10 | CRL-2220 |
| Adenocarcinoma | rectum | human | SW837 | CCL-235 |
| Adenocarcinoma | salivary gland, | mouse | WR21 | CRL-2189 |
| Adenocarcinoma | submandibular | mouse | WNZI | CNL-2109 |
| Adenocarcinoma | unknown | human | TE 206.T | CRL-7758* |
| Adenocarcinoma | uterus, endometrium | human | KLE | CRL-1622 |
| Adenocarcinoma | uterus, endometrium | human | HEC-1-A | HTB-112 |
| Adenocarcinoma | uterus, endometrium | human | HEC-1-B | HTB-113 |
| Adenocarcinoma, bronchogenic | lung | human | Hs 229.T | CRL-7194* |
| Adenocarcinoma, colorectal | cecum | human | NCI-H716 | CCL-251 |
| Adenocarcinoma, colorectal | cecum | human | NCI-H747 | CCL-252 |
| Adenocarcinoma, colorectal | cecum | human | NCI-H508 | CCL-253 |
| Adenocarcinoma, colorectal | cecum | human | NCI-H498 | CCL-254 |
| Adenocarcinoma, colorectal | colon | guinea pig | GPC-16 | CCL-242 |
| Adenocarcinoma, colorectal | colon | human | WiDr | CCL-218 |
| Adenocarcinoma, colorectal | colon | human | COLO 320DM | CCL-220 |
| Adenocarcinoma, colorectal | colon | human | COLO 320HSR | CCL-220.1 |
| Adenocarcinoma, colorectal | colon | human | DLD-1 | CCL-221 |
| Adenocarcinoma, colorectal | colon | human | HCT-15 | CCL-225 |
| Adenocarcinoma, colorectal | colon | human | SW480 | CCL-228 |
| Adenocarcinoma, colorectal | colon | human | SW403 | CCL-228 |
| Adenocarcinoma, colorectal | colon | human | SW48 | CCL-231 |
| <u>'</u> | colon | | SW1116 | CCL-231 |
| Adenocarcinoma, colorectal | | human | SW948 | CCL-233 |
| Adenocarcinoma, colorectal | colon | human | | |
| Adenocarcinoma, colorectal | colon | human | SW1417 | CCL-238 |
| Adenocarcinoma, colorectal | colon | human | LS123 | CCL-255 |
| Adenocarcinoma, colorectal | colon | human | LS 180 | CL-187 |
| Adenocarcinoma, colorectal | colon | human | LS 174T | CL-188 |
| Adenocarcinoma, colorectal | colon | human | C2BBe1 | CRL-2102 |
| Adenocarcinoma, colorectal | colon | human | Hs 257.T | CRL-7214* |
| Adenocarcinoma, colorectal | colon | human | Hs 587.Int | CRL-7352* |
| Adenocarcinoma, colorectal | colon | human | Caco-2 | HTB-37 |
| Adenocarcinoma, colorectal | colon | human | HT-29 | HTB-38 |
| Adenocarcinoma, colorectal | rectum | human | SW1463 | CCL-234 |
| Adenocarcinoma, colorectal | rectum | human | Hs 200.T | CRL-7159* |
| Adenocarcinoma, colorectal | rectum | human | Hs 219.T | CRL-7184* |
| Adenocarcinoma, ductal; cystic fibrosis | pancreas | human | CFPAC-1 | CRL-1918 |
| Adenocarcinoma, ductal | pancreas | human | PL45 | CRL-2558 |
| Adenocarcinoma, gastric | stomach | human | AGS | CRL-1739 |
| Adenocarcinoma, ileocecal | colon | human | HCT-8 (HRT-18) | CCL-244 |
| colorectal | | | | |
| Adenocarcinoma, large cell, | lung | human | NCI-H1581 | CRL-5878 |
| non-small cell lung cancer | OVORV | human | TOV 21C | CDI 11720+ |
| Adenocarcinoma, malignant, clear cell carcinoma | ovary | human | TOV-21G | CRL-11730 [†] |
| Adenocarcinoma, malignant, endometrioid carcinoma | ovary | human | TOV-112D | CRL-11731 [†] |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Source | Species | Name | ATCC® No. |
|---|----------------------|-------------------|--------------|-----------|
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H23 | CRL-5800 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H522 | CRL-5810 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H1435 | CRL-5870 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H1563 | CRL-5875 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H1651 | CRL-5884 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H1734 | CRL-5891 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H1793 | CRL-5896 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H1838 | CRL-5899 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H1975 | CRL-5908 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H2073 | CRL-5918 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H2085 | CRL-5921 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H2228 | CRL-5935 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H2342 | CRL-5941 |
| Adenocarcinoma, non-small cell lung cancer | lung | human | NCI-H2347 | CRL-5942 |
| Adenocarcinoma, renal | kidney | mouse | RAG | CCL-142 |
| Adenocarcinoma, renal cell | kidney | human | ACHN | CRL-1611 |
| Adenocarcinoma, renal cell | kidney | human | 786-O | CRL-1932 |
| denocarcinoma, renal cell | kidney | human | 769-P | CRL-1933 |
| Adenocarcinoma | pancreas | human | Panc 10.05 | CRL-2547 |
| Adenocarcinoma, scirrhous | mammary gland | human | Hs 742.T | CRL-7482* |
| Adenocarcinoma, squamous cell carcinoma; mixed small cell lung cancer | lung | human | NCI-H2066 | CRL-5917 |
| Adenocarcinoma, squamous cell carcinoma; mixed small cell lung cancer | lung | human | NCI-H2286 | CRL-5938 |
| Adenocarcinoma, squamous cell, non-small cell lung cancer | lung | human | NCI-H1703 | CRL-5889 |
| Adenoma | lung | mouse | LA-4 | CCL-196 |
| denoma | pancreas, alpha cell | mouse, transgenic | αTC1 Clone 9 | CRL-2350 |
| denoma | pancreas, beta cell | mouse, transgenic | NIT-2 | CRL-2364 |
| denoma | pituitary, anterior | rat | RC-4B/C | CRL-1903 |
| denomatosis, hereditary | skin | human | 182-PF SK | CRL-1532 |
| ndenomatosis, hereditary (Gardner's variant) | skin | human | 166-ME SK | CRL-1533 |
| angiomyolipoma | kidney | human | SV7tert | CRL-2461 |
| Astrocytoma | brain | human | CCF-STTG1 | CRL-1718 |
| Astrocytoma | brain | human | SW 1088 | HTB-12 |
| Astrocytoma | brain | human | SW 1783 | HTB-13 |
| Cancer | breast, nipple | human | HT 762.T | CRL-7789* |
| Cancer | connective tissue | dog | CF17.T | CRL-6219* |
| Cancer | connective tissue | dog | CF21.T | CRL-6220* |
| Cancer | connective tissue | dog | CF24.T | CRL-6221* |
| Cancer | connective tissue | mouse | MM36T(C) | CRL-6411* |
| Cancer | connective tissue | mouse | MM37T | CRL-6414* |
| Cancer | lung | human | Hs 573.T | CRL-7343* |
| | | | | |



| Disease | Source | Species | Name | ATCC® No. |
|-----------------------------|---------------------------------------|----------------|---------------|-----------------------|
| Cancer | mammary gland | dog | CF34.Mg | CRL-6228* |
| Cancer | mammary gland | dog | CF35.Mg | CRL-6229* |
| Cancer | mammary gland | dog | CF41.Mg | CRL-6232* |
| Cancer | mammary gland | dog | CF45B.Mg | CRL-6237* |
| Cancer | mammary gland | human | Hs 190.T | CRL-7145* |
| Cancer | mammary gland | human | Hs 319.T | CRL-7236* |
| Cancer | mammary gland | human | Hs 329.T | CRL-7242* |
| Cancer | mammary gland | human | Hs 344.T | CRL-7246* |
| Cancer | mammary gland | human | Hs 350.T | CRL-7248* |
| Cancer | mammary gland | human | Hs 371.T | CRL-7256* |
| Cancer | mammary gland | human | Hs 748.T | CRL-7486* |
| | | | Hs 841.T | CRL-7460 CRL-7574* |
| Cancer | mammary gland | human | | |
| Cancer | mammary gland | human | Hs 849.T | CRL-7583* |
| Cancer | mammary gland | human | Hs 851.T | CRL-7584* |
| Cancer | mammary gland | human | Hs 861.T | CRL-7596* |
| Cancer | mammary gland | human | Hs 905.T | CRL-7652* |
| Cancer | mammary gland | human | Hs 479.T | CRL-7813* |
| ancer | mammary gland | monkey, Rhesus | CMMT | CRL-6299* |
| Cancer | mammary gland | mouse | MM2MT | CRL-6373* |
| Cancer | mammary gland | mouse | MM2MTC | CRL-6374* |
| Cancer | mammary gland | mouse | MM2SCT | CRL-6375* |
| ancer | mammary gland | mouse | MM5MTC | CRL-6378* |
| Cancer | mammary gland | mouse | MM5MTM | CRL-6379* |
| Cancer | mammary gland | mouse | MM5.1 | CRL-6380* |
| Cancer | mammary gland | mouse | MM5/C1 | CRL-6444* |
| Cancer | mammary gland | mouse | RIIIMT | CRL-6449* |
| Cancer | mammary gland | mouse | +/+ MGT | CRL-6468* |
| Cancer | mammary gland | mouse | MM5MT | CRL-6590* |
| Cancer | | rat | Rn1T | CRL-6598* |
| Zancer Zancer | mammary gland | | Rn2T | CRL-6599* |
| Cancer | mammary gland mixed connective and | rat mouse | +/+ SCT | CRL-6469* |
| | soft tissue | | | |
| Cancer | prostate | rat | R-3327-AT-1 | JHU-29 |
| Cancer | prostate | rat | R3327-G | JHU-3 |
| Cancer | prostate | rat | R-3327-AT-2.1 | JHU-30 |
| Cancer | prostate | rat | R-3327-AT-3.1 | JHU-31 |
| Cancer | prostate | rat | MAT-Lu | JHU-4 |
| Cancer | unknown | mouse | CFZT(A) | CRL-6338* |
| Cancer | unknown | | CFZT(B) | CRL-6339* |
| | unknown | mouse | | |
| Cancer | | mouse | MM14.OT | CRL-6384* |
| Cancer | unknown | mouse | MM43T | CRL-6418* |
| Cancer | unknown | mouse | MM15OT | CRL-6438* |
| Cancer, colorectal | colon | human | Hs 675.T | CRL-7400* |
| Cancer, non-small cell lung | lung | human | NCI-H2135 | CRL-5926 |
| Cancer, non-small cell lung | lung | human | NCI-H2172 | CRL-5930 |
| Cancer, non-small cell lung | lung | human | NCI-H2444 | CRL-5945 |
| Carcinoid | lung | human | NCI-H835 | CRL-5843 |
| Carcinoid | lung | human | UMC-11 | CRL-5975 |
| Carcinoid | lung, bronchus | human | NCI-H727 | CRL-5815 |
| Carcinoid, atypical | lung | human | NCI-H720 | CRL-5838 |
| Carcinoma | adrenal gland, cortex | human | NCI-H295R | CRL-2128 |
| Carcinoma | bladder, urinary | human | Hs 195.T | CRL-7150* |
| Carcinoma | bladder, urinary | human | Hs 228.T | CRL-7193* |
| Carcinoma | bladder, urinary | human | Hs 172.T | CRL-7833* |
| Carcinoma | bladder, urinary | human | 5637 | HTB-9 |
| Carcinoma | bladder, urinary | human | HT-1376 | CRL-1472 |
| | | | | |
| Carcinoma | bladder, urinary | human | HT-1197 | CRL-1473 |
| Carcinoma | cervix | human | C-41 | CRL-1594 |
| Carcinoma | cervix | human | C-4 II | CRL-1595 |
| Carcinoma | cervix | human human | DoTc2 4510 | CRL-7920* |
| | cervix | | C-33 A | HTB-31 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Source | Species | Name | ATCC® No. |
|---|---|-------------------|----------------------------------|------------------------|
| Carcinoma | colon | mouse | CT26.WT | CRL-2638 |
| Carcinoma | colon | mouse | CT26.CL25 | CRL-2639 |
| Carcinoma | embryo | mouse | NFPE | CRL-2069 |
| Carcinoma | embryo | mouse | PFHR 9 | CRL-2423 |
| Carcinoma | embryo, yolk sac | rat | L2-RYC | CRL-2180 |
| Carcinoma | embryonal stem cell | mouse | ES-E14TG2a | CRL-1821 |
| Carcinoma | embryonal stem cell, germ line competent | mouse | ES-D3 GL | SCRC-1003 |
| Carcinoma | kidney | human | A-498 | HTB-44 |
| Carcinoma | lung | human | A549 | CCL-185 |
| Carcinoma | lung | human | A-427 | HTB-53 |
| Carcinoma | mammary gland | human | Hs 540.T | CRL-7316* |
| Carcinoma | mammary gland | human | Hs 566(B).T | CRL-7336* |
| Carcinoma | mammary gland | human | Hs 605.T | CRL-7365* |
| Carcinoma | mammary gland | human | Hs 606 | CRL-7368* |
| Carcinoma | mammary gland | human | BT-20 | HTB-19 |
| Carcinoma | mammary gland | mouse | CMH1a | CRL-8399 [†] |
| Carcinoma | mammary gland | mouse | CSMαβ6C | CRL-8400 [†] |
| Carcinoma | mammary gland | | СЅМαβ1Н | CRL-8400 ⁺ |
| Carcinoma Carcinoma | ovary | mouse human | Съмαртн Нs 38.T | CRL-8401* |
| | | | | |
| Carcinoma | ovary | human | Hs 571.T | CRL-7846* |
| Carcinoma | pancreas | human | MIA PaCa-2 | CRL-1420 |
| Carcinoma | pancreas | rat | DSL-6A/C1 | CRL-2132 |
| Carcinoma | pancreas | rat | DSL-6B/C2 | CRL-2133 |
| Carcinoma | prostate | human | 22Rv1 | CRL-2505 |
| Carcinoma | salivary gland, submandibular | mouse | SCA-9 clone 15 | CRL-1734 |
| Carcinoma | stomach | human | Hs 740.T | CRL-7870* |
| Carcinoma | thyroid, medulla, C cell | mouse | MTC-M | CRL-1806 |
| Carcinoma | unknown | mouse | Ehrlich-Lettre ascites, strain E | CCL-77 |
| Carcinoma | unknown | rat | LLC-WRC 256 | CCL-38 |
| Carcinoma | uterus, endometrium | human | RL95-2 | CRL-1671 |
| Carcinoma | yolk sac, parietal endoderm | mouse | PYS-2 | CRL-2745 |
| Carcinoma, acinar cell | pancreas | mouse, transgenic | TGP49 | CRL-2136 |
| Carcinoma, acinar cell | pancreas | mouse, transgenic | TGP47 | CRL-2141 |
| Carcinoma, adenos quamous | lung | human | NCI-H596 | HTB-178 |
| Carcinoma, adrenocortical | adrenal gland, cortex | human | NCI-H295 | CRL-10296 [†] |
| Carcinoma, alveolar cell | lung | human | SW 1573 | CRL-2170 |
| Carcinoma, basal cell | skin | human | TE 354.T | CRL-7762* |
| Carcinoma, bronchioalveolar, | lung, bronchiole, | human | NCI-H358 | CRL-7702 CRL-5807 |
| non-small cell lung cancer | alveolus | numan | NCI-FI338 | CRL-3607 |
| Carcinoma, classic small cell lung cancer | lung | human | NCI-H1688 | CCL-257 |
| Carcinoma, classic small cell lung cancer | lung | human | NCI-H1417 | CRL-5869 |
| Carcinoma, classic small cell lung cancer | lung | human | NCI-H1672 | CRL-5886 |
| Carcinoma, classic small cell lung cancer | lung | human | NCI-H1836 | CRL-5898 |
| Carcinoma, clear cell | kidney | human | Caki-2 | HTB-47 |
| Carcinoma, clear cell | ovary | human | ES-2 | CRL-1978 |
| Carcinoma, colorectal | cecum | human | SNU-C2B | CCL-250 |
| Carcinoma, colorectal | cecum | human | SNU-C2A | CCL-250.1 |
| Carcinoma, colorectal | cecum | human | LS513 | CRL-2134 |
| <u> </u> | | | LS1034 | |
| Carcinoma, colorectal | cecum | human | | CRL-2158 |
| Carcinoma, colorectal | cecum | human | LS411N | CRL-2159 |
| Carcinoma, colorectal | colon | human | HCT 116 | CCL-247 |
| Carcinoma, colorectal | colon | human | ATRFLOX | CRL-2780 |
| Carcinoma, colorectal | rectum | human | Hs 722.T | CRL-7456* |
| Carcinoma, ductal | mammary gland | human | UACC-812 | CRL-1897 |



| Disease | Source | Species | Name | ATCC® No. |
|--|---------------------------------|----------------|----------------|-----------|
| Carcinoma, ductal | mammary gland | human | HCC1954 | CRL-2338 |
| Carcinoma, ductal | mammary gland | human | Hs 574.T | CRL-7345* |
| Carcinoma, ductal | mammary gland | human | BT-483 | HTB-121 |
| Carcinoma, ductal | mammary gland | human | BT-549 | HTB-122 |
| Carcinoma, ductal | mammary gland | human | DU4475 | HTB-123 |
| Carcinoma, ductal | mammary gland | human | Hs 578T | HTB-126 |
| Carcinoma, ductal | mammary gland | human | BT-474 | HTB-20 |
| Carcinoma, embryonal | testis | human | Cates-1B | HTB-104 |
| Carcinoma, embryonal, testicular teratoma | testis | mouse | F9 | CRL-1720 |
| Carcinoma, epidermoid | epidermis | human | A-431 | CRL-1555 |
| Carcinoma, epidermoid | epidermis | human | A431NS | CRL-2592 |
| Carcinoma, epidermoid | epidermis | human | A253 | CRL-7902* |
| Carcinoma, epidermoid | lung | human | HLF-a | CCL-199 |
| Carcinoma, epidermoid | salivary gland, submaxillary | human | A-253 | HTB-41 |
| Carcinoma, epithelioid | pancreas, duct | human | PANC-1 | CRL-1469 |
| Carcinoma, gastric | stomach | human | SNU-1 | CRL-5971 |
| Carcinoma, hepatocellular | liver | chicken | LMH | CRL-2117 |
| Carcinoma, hepatocellular | liver | chicken | LMH/2A | CRL-2118 |
| Carcinoma, hepatocellular | liver | human | C3A | CRL-2118 |
| Carcinoma, hepatocellular | liver | human | SNU-398 | CRL-2233 |
| Carcinoma, hepatocellular | liver | human | SNU-449 | CRL-2233 |
| Carcinoma, hepatocellular | liver | human | SNU-182 | CRL-2234 |
| Carcinoma, hepatocellular | | | SNU-475 | CRL-2235 |
| Carcinoma, nepatocellular | liver liver | human human | | HB-8064 |
| | | | Hep 3B2.1-7 | |
| Carcinoma, hepatocellular | liver | human | Hep G2 | HB-8065 |
| Carcinoma, hepatocellular | liver | topminnow | PLHC-1 | CRL-2406 |
| Carcinoma, large cell, neuro- endocrine, non-small cell | lung | human | NCI-H810 | CRL-5816 |
| lung cancer | | | | |
| Carcinoma, Lewis lung | lung | mouse | LL/2 (LLC1) | CRL-1642 |
| Carcinoma, malignant | prostate | rat | AT3B-1 | CRL-2375 |
| Carcinoma, malignant | prostate | rat | MAT-Ly-Lu-B-2 | CRL-2376 |
| Carcinoma, mammary | breast | mouse | EMT6 | CRL-2755 |
| Carcinoma, medulla | thyroid | human | TT | CRL-1803 |
| Carcinoma, medullary thyroid | thyroid | rat | 6-23 (Clone 6) | CRL-1607 |
| Carcinoma, mucoepidermoid | lung | human | NCI-H292 | CRL-1848 |
| pulmonary | 1 | | NGLUMA | 661.256 |
| Carcinoma, non-small cell lung cancer | lung | human | NCI-H2126 | CCL-256 |
| Carcinoma, papilloma virus induced | unknown | rabbit | VX7 | CRL-6504* |
| Carcinoma, pleomorphic hepatocellular | liver | human | SNU-387 | CRL-2237 |
| Carcinoma, pleomorphic hepatocellular | liver | human | SNU-423 | CRL-2238 |
| Carcinoma, polyploid | rectum | mouse | CMT-93 | CCL-223 |
| Carcinoma, primary acantholytic squamous cell | mammary gland | human | HCC1806 | CRL-2335 |
| Carcinoma, primary ductal | mammary gland | human | UACC-893 | CRL-1902 |
| Carcinoma, primary ductal | mammary gland | human | HCC38 | CRL-2314 |
| Carcinoma, primary ductal | mammary gland | human | HCC70 | CRL-2315 |
| Carcinoma, primary ductal | mammary gland | human | HCC202 | CRL-2316 |
| Carcinoma, primary ductal | mammary gland | human | HCC1143 | CRL-2321 |
| Carcinoma, primary ductal | mammary gland | human | HCC1187 | CRL-2322 |
| Carcinoma, primary ductal | mammary gland | human | HCC1395 | CRL-2324 |
| Carcinoma, primary ductal | mammary gland | human | HCC1419 | CRL-2324 |
| Carcinoma, primary ductal | mammary gland | human | HCC1500 | CRL-2329 |
| · · · · · · · · · · · · · · · · · · · | | | HCC1599 | |
| Carcinoma, primary ductal | mammary gland | human | | CRL-2331 |
| Carcinoma, primary ductal | mammary gland | human | HCC1937 | CRL-2336 |
| Carcinoma, primary ductal | mammary gland | human | HCC2157 | CRL-2340 |
| | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Source | Species | Name | ATCC® No. |
|--|--|-------------------|-------------|------------------------|
| Carcinoma, primary ductal | mammary gland | human | HCC2218 | CRL-2343 |
| Carcinoma, primary metaplastic | mammary gland | human | HCC1569 | CRL-2330 |
| Carcinoma, primary small cell | adrenal gland, cortex | human | SW-13 | CCL-105 |
| Carcinoma, probably lung anaplastic | unknown | human | Calu-6 | HTB-56 |
| Carcinoma, small cell lung cancer | lung | human | DMS 79 | CRL-2049 |
| Carcinoma, small cell lung cancer | lung | human | DMS 53 | CRL-2062 |
| Carcinoma, small cell lung cancer | lung | human | DMS 114 | CRL-2066 |
| Carcinoma, small cell lung cancer | lung | human | SW 1271 | CRL-2177 |
| Carcinoma, small cell lung cancer | lung | human | NCI-H2227 | CRL-5934 |
| Carcinoma, small cell lung cancer | lung | human | NCI-H1963 | CRL-5982 |
| Carcinoma, small cell lung cancer, | lung | human | SHP-77 | CRL-2195 |
| large cell, variant | lang | Haman | 5111 77 | CILE 2195 |
| Carcinoma, small cell lung cancer, | lung | human | H69AR | CRL-11351 [†] |
| | lung | Human | HOSAN | CRE-11331 |
| multidrug resistant Carcinoma, squamous cell | comity | human | SW756 | CRL-10302 [†] |
| · • | cervix | human | | |
| Carcinoma, squamous cell | cervix | human | SiHa | HTB-35 |
| Carcinoma, squamous cell | lung | human | NCI-H2170 | CRL-5928 |
| Carcinoma, squamous cell | lung | human | NCI-H520 | HTB-182 |
| Carcinoma, squamous cell | lung | human | SW 900 | HTB-59 |
| Carcinoma, squamous cell | lung | mouse | KLN 205 | CRL-1453 |
| Carcinoma, squamous cell | nasal | rat | FAT 7 | CRL-2109 |
| Carcinoma, squamous cell | pharynx | human | FaDu | HTB-43 |
| Carcinoma, squamous cell | thyroid | human | SW579 | HTB-107 |
| Carcinoma, squamous cell | tongue | human | SCC-15 | CRL-1623 |
| Carcinoma, squamous cell | tongue | human | SCC-4 | CRL-1624 |
| Carcinoma, squamous cell | tongue | human | SCC-25 | CRL-1628 |
| Carcinoma, squamous cell | tongue | human | SCC-9 | CRL-1629 |
| Carcinoma, squamous cell | tongue | human | CAL 27 | CRL-2095 |
| Carcinoma, squamous cell | vulva | human | SW 954 | HTB-117 |
| Carcinoma, transitional cell | bladder, urinary | human | UM-UC-3 | CRL-1749 |
| Carcinoma, transitional cell | bladder, urinary | human | SW 780 | CRL-2169 |
| Carcinoma, transitional cell | bladder, urinary | human | J82 | HTB-1 |
| Carcinoma, transitional cell | bladder, urinary | human | SCaBER | HTB-3 |
| Carcinoma, transitional cell | bladder, urinary | human | T24 | HTB-4 |
| Carcinoma, transitional cell | bladder, urinary | human | TCCSUP | HTB-5 |
| Carcinoma, transitional cell | ureter | human | Hs 789.T | CRL-7886* |
| Carcinoma, transitional cell | urethra | human | Hs 769.T | CRL-7882* |
| Chondrosarcoma | bone | human | Hs 819.T | CRL-7891* |
| Chondrosarcoma | bone | human | SW 1353 | HTB-94 |
| Choriocarcinoma | placenta | human | BeWo | CCL-98 |
| Choriocarcinoma | <u> </u> | | JAR | HTB-144 |
| | placenta | human | JEG-3 | **** |
| Choriocarcinoma | placenta | human | | HTB-36 |
| Dermatofibrosarcoma | skin | human | Hs 357.T | CRL-7252* |
| Dermatofibrosarcoma | skin | human | Hs 941.T | CRL-7692* |
| Dermatofibrosarcoma protuberans | skin | human | Hs 295.T | CRL-7233* |
| Dermatofibrosarcoma protuberans | skin | human | Hs 63.T | CRL-7043* |
| Endothelioma | brain, cerebral cortex; transformed | mouse | bEnd.3 | CRL-2299 |
| Erythroleukemia | bone marrow | cat | F25 | CRL-6566* |
| Erythroleukemia | bone marrow, erythroblast | human | TF-1 | CRL-2003 |
| Erythroleukemia | bone marrow, | human | TF-1a | CRL-2451 |
| Erythroleukemia | erythroblast bone marrow, | human | TF-1.CN5a.1 | CRL-2512 |
| Switch and a colonial - | erythroblast | he.: | LIEL 02.1.7 | TID 100 |
| Erythroleukemia | bone marrow, erythroblast | human | HEL 92.1.7 | TIB-180 |
| Fibroma | connective tissue | gerbil, Mongolian | IMR-33 | CCL-146 |
| Fibromatosis | mixed connective and soft tissue | human | TE 115.T | CRL-7744* |
| Fibrosarcoma | bladder (adjacent) | mouse | MM45T.Bl | CRL-6420* |
| | Diadae. (dajaceire) | | | 5.1L 0 120 |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.



| Disease | Source | Species | Name | ATCC® No. |
|---|---------------------------|------------------|----------------|------------------------|
| Fibrosarcoma | connective tissue | cat | FC77.T | CRL-6105* |
| Fibrosarcoma | connective tissue | cat | FC81.T | CRL-6108* |
| ibrosarcoma | connective tissue | cat | FC94.T | CRL-6113* |
| Fibrosarcoma | connective tissue | human | HT-1080 | CCL-121 |
| Fibrosarcoma | connective tissue | human | Hs 778(A).T | CRL-7508* |
| Fibrosarcoma | connective tissue | human | Hs 778(B).T | CRL-7509* |
| Fibrosarcoma | connective tissue | human | Hs 15.T | CRL-7824* |
| Fibrosarcoma | connective tissue | human | SW 684 | HTB-91 |
| Fibrosarcoma | connective tissue | mouse | HSDM,C, | CCL-148 |
| Fibrosarcoma | connective tissue | | MM47T | CRL-6424* |
| | | mouse | MM45T.Li | CRL-6421* |
| Fibrosarcoma | liver (adjacent) | mouse | Hs 93.T | CRL-7062* |
| Fibrosarcoma | mixed connective | human | П\$ 93.1 | CRL-7062" |
| ••• | and soft tissue | | 5604.6 | CD1 44.0=V |
| -ibrosarcoma | spleen | cat | FC81.Sp | CRL-6107* |
| ibrosarcoma | spleen | cat | FC83.Sp | CRL-6110* |
| ibrosarcoma | spleen | mouse | MM45T.Sp | CRL-6422* |
| ibrosarcoma | spleen | mouse | MM52.Sp | CRL-6428* |
| ibrosarcoma | spleen | mouse | MM53.Sp | CRL-6430* |
| ibrosarcoma | thymus | cat | FC81.Thy | CRL-6109* |
| Fibrosarcoma | unknown | human | Hs 868.T | CRL-7604* |
| ibrosarcoma | unknown | mouse | WEHI-13VAR | CRL-2148 |
| ibrosarcoma | unknown | mouse | MM46T | CRL-6423* |
| ibrosarcoma | unknown | mouse | MM48T | CRL-6425* |
| ibrosarcoma | unknown | mouse | MM49T | CRL-6426* |
| ibrosarcoma | unknown | mouse | MM52.T | CRL-6429* |
| ibrosarcoma | unknown | mouse | Sal/N | CRL-2544 |
| Fibrosarcoma | unknown | mouse | TM-7 | CRL-2798 |
| ibrosarcoma | unknown | mouse | MC17-51 | CRL-2799 |
| Fibrosarcoma | unknown | mouse | MN-11 | CRL-2800 |
| Fibrosarcoma | unknown | | TM-34 | CRL-2801 |
| | unknown | mouse | MiF-6 | CRL-2801 |
| Fibrosarcoma | | mouse | | |
| -ibrosarcoma | unknown | mouse | TM-28 | CRL-2803 |
| -ibrosarcoma | unknown | mouse | M-7 | CRL-2804 |
| -ibrosarcoma | unknown | mouse | MT-6 | CRL-2805 |
| Fibrosarcoma | unknown | quail, Japanese | QT6 | CRL-1708 |
| ibrosarcoma, chemically induced | muscle | quail, Japanese | QM7 | CRL-1962 |
| Fibrosarcoma, malignant, dibenzanthracene induced | ascites | mouse | Sal | CRL-2543 |
| Fibrosarcoma, methylcholanthracene induced | unknown | mouse | WEHI 164 | CRL-1751 |
| ibrosarcoma, methylcholanthrocene induced | unknown | mouse | MC57G | CRL-2295 |
| Glioblastoma | brain | human | A172 | CRL-1620 |
| Glioblastoma | brain | human | U-138 MG | HTB-16 |
| Glioblastoma | brain, glial cell | human | DBTRG-05MG | CRL-2020 |
| Glioblastoma | brain | human | LN-18 | CRL-2610 |
| Glioblastoma | brain | human | LN-229 | CRL-2611 |
| Glioblastoma, astrocytoma | brain | human | U-87 MG | HTB-14 |
| Glioblastoma, astrocytoma | brain | human | U-118 MG | HTB-15 |
| Glioblastoma, malignant | | | | |
| . 3 | brain, glial cell | human | M059K | CRL-2365 |
| Glioblastoma, malignant | brain, glial cell | human | M059J | CRL-2366 |
| Glioblastoma, multiforme | brain | human | T98G | CRL-1690 |
| Glioblastoma, neuroblastoma | brain, glial cell, neuron | mouse/rat hybrid | NG108-15 | HB-12317 [†] |
| Glioblastoma, p53 expression | brain | human | LNZTA3WT4 | CRL-11543 [†] |
| Glioblastoma, p53 expression | brain | human | LNZTA3WT11 | CRL-11544 [†] |
| Glioma | brain | human | Hs 683 | HTB-138 |
| Glioma | brain | rat | C ₆ | CCL-107 |
| Glioma, undifferentiated malignant | brain, fetal | rat | F98 | CRL-2397 |
| Glioma, undifferentiated malignant | brain, fetal | rat | RG2 | CRL-2433 |
| Gliosarcoma, expresses beta | brain | rat | C6/LacZ | CRL-2199 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Source | Species | Name | ATCC® No. |
|---|----------------------------------|--------------------|--------------------------------|------------------------|
| Gliosarcoma, expresses beta galactosidase | brain | rat | 9L/lacZ | CRL-2200 |
| Gliosarcoma, expresses beta galactosidase | brain | rat | C6/lacZ7 | CRL-2303 |
| Glomangioma | kidney, glomus | human | glomotel | CRL-2597 |
| Granuloma, eosinophilic | bone | human | Hs 454.T | CRL-7802* |
| Granuloma, noncaseating | lymph node | human | Hs 697.Ln | CRL-7434* |
| Granuloma, periostitis | bone | human | Hs 709.T | CRL-7453* |
| Hemangioendothelioma | unknown | | EOMA | CRL-2586 |
| | | mouse | | |
| Hemangioendothelioma; expresses GFP | unknown | mouse | EOMA-GFP | CRL-2587 |
| lepatoma | liver | mouse | Hepa 1-6 | CRL-1830 |
| Hepatoma | liver | mouse | Hepa-1c1c7 | CRL-2026 |
| Hepatoma | liver | mouse | BpRcl | CRL-2217 |
| lepatoma | liver | mouse | tao BpRcl | CRL-2218 |
| Hepatoma | liver | rat | MH ₁ C ₁ | CCL-144 |
| | liver | rat | H-4-II-E | CRL-1548 |
| lepatoma | liver | rat | H4TG | CRL-1578 |
| | liver | rat | H4-II-E-C3 | CRL-1600 |
| Hepatoma | liver | trout, rainbow | RTH-149 | CRL-1710 |
| Hepatoma | liver | woodchuck, Eastern | WCH-17 | CRL-2082 |
| lepatoma | liver, Alexander cells | human | PLC/PRF/5 | CRL-8024 [†] |
| Hepatoma; deficient in aryl | liver | mouse | c37 (B7IFi1) | CRL-2711 |
| hydrocarbon hydoxylase activity | livei | mouse | C37 (B/1111) | CILL 27 11 |
| Hepatoma; deficient in aryl | liver | mouse | c1 (B6NLxv1c2) | CRL-2716 |
| hydrocarbon hydoxylase activity | | | e: (56:12/t/162) | 0.12.27.10 |
| Hepatoma; lacks functional aryl | liver | mouse | c4 (B13NBii1) | CRL-2717 |
| hydrocarbon receptor | iivei | mouse | C4 (B13NBII1) | CHE 27 17 |
| nuclear translocator protein | | | | |
| Hepatoma, Morris Hepatoma 7777 | liver | rat | McA-RH7777 | CRL-1601 |
| | | rat | | |
| Hepatoma, Morris Hepatoma 8994 | liver | rat | McA-RH8994 | CRL-1602 |
| Hepatoma, Novikoff Hepatoma | liver | rat | N1-S1 Fudr | CRL-1603 |
| Hepatoma, Novikoff Hepatoma | liver | rat | N1-S1 | CRL-1604 |
| Hepatoma; reduced levels of aryl | liver | mouse | c12 (B15ECiii2) | CRL-2710 |
| AHR mRNA and protein | liven | | T(2) | CDL 2712 |
| Hepatoma; reduced levels of aryl | liver | mouse | vT{2} | CRL-2712 |
| hydrocarbon hydroxylase | 1. | | 25 (D166D:1 2) | CDL 274.5 |
| Hepatoma; reduced levels of aryl | liver | mouse | c35 (B16GBi1c3) | CRL-2715 |
| hydrocarbon hydroxylase | | | | CD1 ===== |
| Histiocytoma | connective tissue | human | Hs 856.T | CRL-7593* |
| Histiocytoma, fibrous, malignant | unknown | mouse | p53NiS1 | CRL-2619 |
| Histiocytosis, chronically infected with Ehrlichia canis | macrophage | dog | DH82ECOK | CRL-10390 [†] |
| Histiocytosis, malignant | macrophage | dog | DH82 | CRL-10389 [†] |
| Hodgkin's disease | lymphoblast, peripheral blood | human | RPMI 6666 | CCL-113 |
| Hypernephroma | kidney | human | SW 156 | CRL-2175 |
| nsulinoma | pancreas, beta cell | mouse, transgenic | β-TC-6 | CRL-11506 [†] |
| Insulinoma | pancreas, islet of | mouse, transgenic | NIT-1 | CRL-2055 |
| neulinoma, produces insulin and | Langerhans | vot | DIM m FF | CDI 1100F† |
| Insulinoma; produces insulin and | pancreas, islet of | rat | RIN-m5F | CRL-11605 [†] |
| and L-dopa decarboxylase but not somatostatin | Langerhans | | | |
| nsulinoma; produces insulin and L-dopa-decarboxylase but not somatostatin | pancreas, islet of Langerhans | rat | RIN-5F | CRL-2058 |
| Insulinoma; produces insulin and somatostatin | pancreas, islet of Langerhans | rat | RIN-m | CRL-2057 |
| Insulinoma; produce somatostatin and L-dopa-decarboxylase but not insulin | pancreas, islet of Langerhan | rat | RIN-14B | CRL-2059 |



| Disease | Source | Species | Name | ATCC® No. |
|---|------------------------------------|------------------------|------------------------------|------------------------|
| Interscapular tumor | possibly basal cell | bat, mouse-eared | Mvi/lt | CRL-6012* |
| Keratoacanthoma | skin | human | Hs 892.T | CRL-7630* |
| Keratoacanthoma, malignant | skin | human | Hs 898.T | CRL-7641* |
| acanthocytosis | | | | |
| _eiomyoblastoma, renal | kidney | human | G-402 | CRL-1440 |
| _eiomyosarcoma | muscle | human | TE 149.T | CRL-7751* |
| _eiomyosarcoma | connective tissue | human | Hs 5.T | CRL-7822* |
| Leiomyosarcoma | smooth muscle, ductus deferens | hamster, Syrian golden | DDT ₁ MF-2 | CRL-1701 |
| _eiomyosarcoma | uterus | human | SK-UT-1 | HTB-114 |
| _eiomyosarcoma | uterus, endometrium | human | SK-UT-1B | HTB-115 |
| eiomyosarcoma | vulva | human | SK-LMS-1 | HTB-88 |
| eukemia | B lymphocyte | mouse | CW13.20-3B3 (clone of BCL 1) | CRL-1669 |
| .eukemia | basophil, peripheral blood | rat | RBL-1 | CRL-1378 |
| Leukemia | basophil, peripheral blood | rat | RBL-2H3 | CRL-2256 |
| _eukemia | erythroblast, spleen | mouse | BB88 | TIB-55 |
| _eukemia | erythroblast, spleen | mouse | D1B | TIB-56 |
| Leukemia | lymph node | bovine | 2FLB.Ln | CRL-6045* |
| Leukemia | myelomonocyte, macrophage-like | mouse | WEHI-3 | TIB-68 |
| _eukemia | spleen | mouse | T27A | TIB-57 |
| _eukemia | spleen | mouse | D2N | TIB-58 |
| .eukemia | spleen | mouse | BC16A | TIB-59 |
| _eukemia | spleen | mouse | BC3A | TIB-60 |
| eukemia, acute lymphoblastic | B lymphoblast | human | SUP-B15 | CRL-1929 |
| eukemia, acute lymphoblastic | B lymphoblast, peripheral blood | human | CCRF-SB | CCL-120 |
| Leukemia, acute lymphoblastic | B lymphoblast, peripheral blood | human | 8E5 | CRL-8993 [†] |
| eukemia, acute lymphoblastic | bone marrow, myeloblast | human | KG-1 | CCL-246 |
| eukemia, acute lymphoblastic | bone marrow, myeloblast | human | KG-1 | CRL-8031 [†] |
| eukemia, acute lymphoblastic | bone marrow, promyeloblast | human | KG-1a | CCL-246.1 |
| eukemia, acute lymphoblastic | T lymphoblast | human | TALL-104 | CRL-11386 [†] |
| eukemia, acute lymphoblastic | T lymphoblast | human | MOLT-4 | CRL-1582 |
| eukemia, acute lymphoblastic | T lymphoblast, peripheral blood | human | CCRF-CEM | CCL-119 |
| Leukemia, acute lymphoblastic | T lymphoblast, peripheral blood | human | CCRF-HSB-2 | CCL-120.1 |
| Leukemia, acute lymphoblastic | T lymphoblast, peripheral blood | human | MOLT-3 | CRL-1552 |
| Leukemia, acute lymphoblastic | T lymphoblast, peripheral blood | human | CEM/C2 | CRL-2264 |
| Leukemia, acute lymphoblastic | T lymphoblast, peripheral blood | human | CEM/C1 | CRL-2265 |
| Leukemia, acute lymphoblastic t(16;20) translocation | T lymphocyte, peripheral blood | human | Loucy | CRL-2629 |
| Leukemia, acute lymphoblastic, t(4;11) translocation | bone marrow | human | RS4;11 | CRL-1873 |
| Leukemia, acute lymphocytic (non-T, non-B) | unknown | human | Reh | CRL-8286 [†] |
| Leukemia, acute monocytic | monocyte | human | THP-1 | TIB-202 |
| Leukemia, acute monocytic | monocyte, peripheral blood | human | AML-193 | CRL-9589 [†] |
| Leukemia, acute myeloblastic | peripheral blood | human | Kasumi-1 | CRL-2724 |
| Leukemia, acute myeloblastic | peripheral blood | human | Kasumi-3 | CRL-2725 |
| Leukemia, acute myelogenous | peripheral blood, | human | BDCM | CRL-2740 |
| | B lymphoblast | · · · · | - | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Source | Species | Name | ATCC® No. |
|--|------------------------------------|----------------|----------------------------|------------------------|
| Leukemia, acute myeloid | unknown | mouse | C1498 | TIB-49 |
| Leukemia, acute myeloid | peripheral blood | human | AML14.3D10/CCCKR3 Clone 16 | CRI -12079† |
| Leukemia, acute myeloid, subtype M2 | peripheral blood | human | Kasumi-6 | CRL-2775 |
| Leukemia, acute promyelocytic | promyeloblast, | human | HL-60 | CCL-240 |
| | peripheral blood | | | |
| Leukemia, acute promyelocytic | promyeloblast, peripheral blood | human | Clone 15 HL-60 | CRL-1964 |
| Leukemia, acute promyelocytic | promyeloblast, peripheral blood | human | HL-60/MX2 | CRL-2257 |
| Leukemia, acute promyelocytic | promyeloblast, peripheral blood | human | HL-60/MX1 | CRL-2258 |
| _eukemia, acute T cell | T lymphocyte | human | J.CaM1.6 | CRL-2063 |
| Leukemia, acute T cell | T lymphocyte | human | Jurkat, Clone E6-1 | TIB-152 |
| Leukemia, acute T cell | T lymphocyte | human | J.RT3-T3.5 | TIB-152 |
| · | | | | CRL-10915 [†] |
| eukemia, acute T cell, CD4 negative | T lymphoblast | human | D1.1 | |
| Leukemia, acute T cell, CD45 deficient | T lymphocyte | human | J45.01 | CRL-1990 |
| eukemia, biphenotypic B myelomonocytic | peripheral blood | human | MV-4-11 | CRL-9591 [†] |
| eukemia, chronic myeloblastic | peripheral blood | human | Kasumi-4 | CRL-2726 |
| Leukemia, chronic myelogenous | basophil, peripheral blood | human | KU812 | CRL-2099 |
| eukemia, chronic myelogenous | basophil, peripheral blood | human | KU812E | CRL-2100 |
| eukemia, chronic myelogenous | basophil, peripheral blood | human | KU812F | CRL-2101 |
| eukemia, chronic myelogenous | bone marrow, megakaryoblast | human | MEG-01 | CRL-2021 |
| eukemia, hairy cell | B lymphoblast, peripheral blood | human | Мо-В | CCL-245 |
| eukemia, hairy cell | T lymphocyte | human | Мо | CRL-8066 [†] |
| eukemia, lymphoblastic | T lymphoblast | human | SUP-T1 | CRL-1942 |
| eukemia, lymphocytic | unknown | mouse | L1210 | CCL-219 |
| eukemia, lymphoma | B lymphocyte | mouse | BCL, clone 5B,b | TIB-197 |
| _eukemia, lymphoma | pre-B lymphoblast | human | JM1 | CRL-10423 [†] |
| Leukemia, myeloid | myeloblast | mouse | M1 | TIB-192 |
| Leukemia, myeloid, virus induced | peripheral blood | mouse | M-NFS-60 | CRL-1838 |
| Leukemia, myelomonoblastic | monoblast, peripheral blood | human | GDM-1 | CRL-2627 |
| _eukemia, myelomonocytic | lymphoblast | human | CESS | TIB-190 |
| Leukemia, plasma cell | B lymphoblast, peripheral blood | human | ARH-77 | CRL-1621 |
| iposarcoma | connective tissue | human | SW 872 | HTB-92 |
| Lymphogranulomatosis | lymph node | human | Hs 268.T | CRL-7218* |
| ymphoma | B lymphoblast | human | 1A2 | CRL-8119 [†] |
| ymphoma | B lymphocyte | monkey, Rhesus | LCL 8664 | CRL-1805 [†] |
| ymphoma | B lymphocyte | mouse | WEHI-231 | CRL-1702 |
| ymphoma | B lymphocyte | mouse | WEHI-231 | CRL-1704 |
| Lymphoma | B lymphocyte | mouse | 2PK-3 | TIB-203 |
| ymphoma | B lymphocyte | mouse | CH1 | TIB-203 |
| ymphoma .ymphoma | B lymphocyte, spleen | mouse | RAW 8.1 | TIB-50 |
| ymphoma | bursa | chicken | DT40 | CRL-2111 |
| .ymphoma .ymphoma | | chicken | DT95 | CRL-2111 CRL-2112 |
| .ymphoma .ymphoma | bursa lymph node | | Hs 313.T | CRL-2112 CRL-7235* |
| <u>, , </u> | · · · | human | | |
| Lymphoma | lymph node | human | Hs 777.T | CRL-7507* |
| _ymphoma | lymph node, cervical | human | Hs 602 | HTB-142 |
| _ymphoma | lymph node, submandibular | cat | F ₁ B | CRL-6168* |
| ymphoma | lymphoblast | cat | FL74-UCD-1 | CRL-8012 [†] |
| _ymphoma | monocyte/macrophage | mouse | P388D ₁ | CCL-46 |
| Lymphoma | monocyte/macrophage | mouse | NCTC 3749 | CCL-46.1 |



| Disease | Source | Species | Name | ATCC® No. |
|----------------------------|-------------------------|---------|-----------------------------------|------------------------|
| _ymphoma | monocyte/macrophage | mouse | PU5-1.8 (PU5-1R) | TIB-61 |
| ymphoma | monocyte/macrophage | mouse | P388D ₁ (IL-1) | TIB-63 |
| ymphoma | pre-B lymphoblast | mouse | NFS-5 C-1 | CRL-1693 |
| ymphoma | pre-B lymphoblast | mouse | NFS-25 C-3 | CRL-1695 |
| ymphoma | pro-B lymphoblast | mouse | NFS-70 C-10 | CRL-1694 |
| ymphoma | spleen | cat | FC16.Sp | CRL-6174* |
| ymphoma | spleen | mouse | LBRM-33-1A5 | CRL-8079 [†] |
| ymphoma | spleen | mouse | RAW 309F.1.1 | TIB-51 |
| ymphoma | T lymphocyte | human | H9/HTLV-IIIB | CRL-8543 [†] |
| ymphoma | T lymphocyte | mouse | E.G7-OVA | CRL-2113 |
| ymphoma | T lymphocyte | mouse | TK-1 | CRL-2396 |
| ymphoma | T lymphocyte | mouse | S1A(Thy-1 ⁻ b) | TIB-231 |
| ymphoma | T lymphocyte | mouse | BW5147(T200 ⁻ a)5.2 | TIB-233 |
| ymphoma | T lymphocyte | mouse | S1A.TB.4.8.2 | TIB-27 |
| ymphoma | T lymphocyte | mouse | S49.1 | TIB-28 |
| ymphoma | T lymphocyte | mouse | S49.1H.1AG.6/2 | TIB-29 |
| ymphoma | T lymphocyte | mouse | S49.1TB.2 | TIB-30 |
| ymphoma | T lymphocyte | mouse | S49.1TB.4 DEX R.63 | TIB-33 |
| ymphoma | T lymphocyte | mouse | S49.1G.3 | TIB-34 |
| ymphoma | T lymphocyte | mouse | S49.1G.3 PHA.100/0 | TIB-35 |
| ymphoma | T lymphocyte | mouse | S49 (Thy-1-a) | TIB-36 |
| ymphoma | T lymphocyte | mouse | TIMI.4G.1.3 | TIB-38 |
| ymphoma | T lymphocyte | mouse | EL4 | TIB-39 |
| ymphoma | T lymphocyte | mouse | EL4.BU.1.OUA ^r .1.1 | TIB-41 |
| ymphoma | T lymphocyte, B | mouse | WEHI 22.1 | TIB-54 |
| | lymphocyte, thymus | | | |
| ymphoma | T lymphocyte, cutaneous | human | HuT 78 | TIB-161 |
| ymphoma | T lymphocyte, thymus | mouse | BW5147.3(Thy-1 ⁻ e).10 | TIB-234 |
| ymphoma | T lymphocyte, thymus | mouse | R1.1 | TIB-42 |
| ymphoma | T lymphocyte, thymus | mouse | R1E/TL8x.1 | TIB-43 |
| ymphoma | T lymphocyte, thymus | mouse | R1.G1 | TIB-44 |
| ymphoma | T lymphocyte, thymus | mouse | R1E/TL8x.1.G1.OUA ^r .1 | TIB-45 |
| ymphoma | T lymphocyte, thymus | mouse | BW5147.3 | TIB-47 |
| ymphoma | T lymphocyte, thymus | mouse | WEHI 7.1 | TIB-53 |
| ymphoma | thymus | mouse | L5178-R (LY-R) | CRL-1722 |
| ymphoma | thymus | mouse | L5178-S (LY-S) | CRL-1723 |
| ymphoma | thymus | mouse | EL4.IL-2 | TIB-181 |
| ymphoma | thymus | mouse | TIMI.4 | TIB-37 |
| ymphoma | unknown | cat | FeLV-3281 | CRL-9116 [†] |
| ymphoma | unknown | human | HT 1417 | CRL-7797* |
| ymphoma | unknown | mouse | L5178Y TK+/- (clone 3.7.2C) | CRL-9518 [†] |
| ymphoma | unknown | mouse | WR19L | TIB-52 |
| ymphoma, AMLV-transformed | pre-B lymphoblast | mouse | ABE-8.1/2 | TIB-205 |
| ymphoma, B cell | peritoneal effusion | human | JSC-1 | CRL-2769 |
| | (metastatic site: | | | |
| | peritoneal cavity) | | | |
| ymphoma, body cavity based | B lymphoblast, | human | BCP-1 | CRL-2294 |
| | peripheral blood | | | |
| ymphoma, Burkitt's | ascites, B lymphocyte | human | 2B8 | CRL-12569 [†] |
| ymphoma, Burkitt's | B lymphoblast, | human | Daudi | CCL-213 |
| ymphoma, Burkitt's | B lymphoblast, | human | NC-37 | CCL-214 |
| | peripheral blood | | | |
| ymphoma, Burkitt's | B lymphocyte | human | EB-3 | CCL-85 |
| ymphoma, Burkitt's | B lymphocyte | human | Raji | CCL-86 |
| ymphoma, Burkitt's | B lymphocyte | human | Jiyoye | CCL-87 |
| ymphoma, Burkitt's | B lymphocyte | human | NAMALWA | CRL-1432 |
| ymphoma, Burkitt's | B lymphocyte | human | HS-Sultan | CRL-1484 |
| ymphoma, Burkitt's | B lymphocyte | human | CA46 | CRL-1648 |
| ymphoma, Burkitt's | B lymphocyte | human | GA-10 | CRL-2392 |
| ymphoma, Burkitt's | B lymphocyte | human | GA-10 (Clone 4) | CRL-2393 |
| ymphoma, Burkitt's | B lymphocyte | human | GA-10 (Clone 20) | CRL-2394 |
| , , , ,,,,, ,,,, | - / i: : -/ | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Source | Species | Name | ATCC® No. |
|---|--|---------|-----------------------|------------------------|
| Lymphoma, Burkitt's | kidney, B cell | human | 20B8 | CRL-12582 [†] |
| Lymphoma, Burkitt's | kidney, B cell | human | HKB-11 | CRL-12568 [†] |
| Lymphoma, Burkitt's | kidney, peripheral blood, somatic cell hybrid | human | 1G2 | CRL-13005 [†] |
| Lymphoma, Burkitt's | lymph node | human | 2F7 | CRL-10237 [†] |
| Lymphoma, Burkitt's | upper maxilla | human | EB1 | HTB-60 |
| Lymphoma, Burkitt's (American) | B lymphocyte | human | Ramos (RA 1) | CRL-1596 |
| Lymphoma, Burkitt's (American) | B lymphocyte | human | Ramos.2G6.4C10 | CRL-1923 |
| Lymphoma, cutaneous | T lymphocyte, peripheral blood | human | H9 | HTB-176 |
| Lymphoma, cutaneous T cell | T lymphocyte, peripheral blood | human | НН | CRL-2105 |
| Lymphoma, cutaneous T cell, mycosis fungoides | T lymphocyte, peripheral blood | human | MJ | CRL-8294 [†] |
| Lymphoma, diffuse large cell, | B lymphocyte, | human | Toledo | CRL-2631 |
| non-Hodgkin's B cell | peripheral blood | naman | Toledo | CILE 2051 |
| Lymphoma, EBV and KSHV positive | B lymphoblast | human | BC-1 | CRL-2230 |
| Lymphoma, EBV and KSHV positive | B lymphoblast | human | BC-2 | CRL-2231 |
| Lymphoma, histiocytic | macrophage | human | U-937 | CRL-1593.2 |
| Lymphoma, histiocytic; neomycin | macrophage | human | TUR | CRL-2367 |
| resistant | | | | |
| Lymphoma, Hodgkin's disease | lymph node | human | Hs 604.T | CRL-7362* |
| Lymphoma, Hodgkin's disease | lymph node | human | Hs 751.T | CRL-7488* |
| Lymphoma, Hodgkin's disease | lymph node | human | Hs 445 | HTB-146 |
| Lymphoma, Hodgkin's disease | lymph node, spleen | human | Hs 611.T | CRL-7373* |
| Lymphoma, Hodgkin's disease | lymph node, thymus | human | Hs 616.T | CRL-7378* |
| Lymphoma, KSHV positive | B lymphoblast | human | BC-3 | CRL-2277 |
| Lymphoma, large cell | B lymphoblast | human | DB | CRL-2289 |
| Lymphoma, lymphocytic | lymph node | human | Hs 505.T | CRL-7306* |
| Lymphoma, lymphocytic | lymph node | human | Hs 491.T | CRL-7818* |
| Lymphoma, lymphocytic | spleen | human | Hs 518.T | CRL-7313* |
| Lymphoma, methylnitrosourea induced | pre-B lymphoblast | mouse | 70Z/3 | TIB-158 |
| Lymphoma, Mo-MuLV induced | unknown | mouse | YAC-1 | TIB-160 |
| Lymphoma, mycosis fungoides | T lymphocyte, cutaneous | human | HuT 102 | TIB-162 |
| Lymphoma, possible Burkitt's | lymph node | human | TE 161.T | CRL-7753* |
| Lymphoma, radiation induced | T lymphocyte | mouse | LBRM TG6 | CRL-1778 |
| Lymphoma, radiation induced | T lymphocyte | mouse | LBRM-33 clone 4A2 | TIB-155 |
| Lymphosarcoma | B lymphocyte | bovine | BL3.1 | CRL-2306 |
| Lymphosarcoma | bone marrow | bovine | LB9.Bm | CRL-6053* |
| Lymphosarcoma | bone marrow | bovine | LB10.Bm | CRL-6060* |
| Lymphosarcoma | lymph node | human | TE 175.T | CRL-7755* |
| Lymphosarcoma | mixed spleen, thymus, and bone marrow | bovine | LB9.Sp/Thy/Bm | CRL-6052* |
| Lymphosarcoma | spleen | bovine | LB9.Sp | CRL-6058* |
| Lymphosarcoma | spleen | bovine | LB10.Sp | CRL-6063* |
| Lymphosarcoma | spleen | bovine | LB11.Sp | CRL-6067* |
| Lymphosarcoma | thymus | bovine | LB9.Thy | CRL-6059* |
| Lymphosarcoma | thymus | bovine | LB10.Thy | CRL-6064* |
| Lymphosarcoma | thymus | bovine | LB11.Thy | CRL-6068* |
| Lymphosarcoma | unknown | mouse | MB III (de Bruyn-Gey) | CCL-32 |
| Lymphosarcoma, leukemia | B lymphocyte | bovine | BL-3 | CRL-8037 [†] |
| Mastocytoma Madulla blastoma | mast cell | mouse | P815 | TIB-64 |
| Medulloblastoma | brain, cerebellum | human | D341 Med | HTB-187 |
| Medulloblastoma, desmoplastic cerebellar | brain, cerebellum | human | Daoy | HTB-186 |
| Melanoma | skin | human | WM-115 | CRL-1675 |
| Melanoma | skin | human | Hs 600.T | CRL-7360* |
| Melanoma | skin | human | Hs 688(A).T | CRL-7425* |
| Melanoma | skin | human | Hs 839.T | CRL-7572* |
| Melanoma | skin | human | Hs 852.T | CRL-7585* |
| | | | | |



| Disease | Source | Species | Name | ATCC® No. |
|--|---|------------------------|--------------------------------------|------------------------------------|
| Melanoma | skin | human | Hs 906(A).T | CRL-7653* |
| Melanoma | skin | human | Hs 906(B).T | CRL-7654* |
| Melanoma | skin | human | Hs 908.Sk | CRL-7658* |
| Melanoma | skin | human | Hs 936.T | CRL-7686* |
| Melanoma | skin | human | Hs 936.T(C1) | CRL-7687* |
| Melanoma | skin | human | Hs 939.T | CRL-7690* |
| Melanoma | skin | human | A101D | CRL-7898* |
| Melanoma | skin | human | CHL-1 | CRL-9446 [†] |
| Melanoma | skin | human | HMCB (Human Melanoma Cell Bowles) | CRL-9607 [†] |
| Melanoma | skin | mouse | B16-F0 | CRL-6322* |
| Melanoma | skin | mouse | B16-F1 | CRL-6323* |
| Melanoma | skin | mouse | B16-F10 | CRL-6475* |
| Melanoma | skin, melanocyte | mouse | Clone M-3 | CCL-53.1 |
| Melanoma, amelanotic | skin | human | C32TG | CRL-1579 |
| Melanoma, amelanotic | skin | human | C32 | CRL-1585 |
| Melanoma, malignant | connective tissue | human | Hs 934.T | CRL-7684* |
| Melanoma, malignant | connective tissue | human | Hs 935.T | CRL-7685* |
| Welanoma, malignant | skin | human | G-361 | CRL-1424 |
| Melanoma, malignant | skin | human | A-375 | CRL-1619 |
| Melanoma, malignant | skin | human | A375.S2 | CRL-1872 |
| Melanoma, malignant | skin | human | COLO 829 | CRL-1974 |
| Melanoma, malignant | skin | human | Hs 940.T | CRL-7691* |
| Melanoma, malignant | skin | human | HT-144 | HTB-63 |
| <u> </u> | skin | human | Malme-3M | HTB-64 |
| Melanoma, malignant | | | | HTB-66 |
| Melanoma, malignant | skin skin | human | RPMI-7951 | |
| Melanoma, malignant | | human | SK-MEL-5 | HTB-70 |
| Melanoma, malignant | skin | human | SK-MEL-24 | HTB-71 |
| Melanoma, malignant | skin | human | SK-MEL-28 | HTB-72 |
| Melanoma, malignant | skin | human | SK-MEL-31 | HTB-73 |
| Melanoma, melanotic | skin | hamster, Syrian golden | RPMI 1846 | CCL-49 |
| Melanoma, nodular, in vertical growth phase | | human | WM278 | CRL-2809 |
| Melanoma, nodular, in vertical growth phase | skin, melanocyte; from lung metastases in mice | human | 451Lu | CRL-2813 |
| Melanoma, primary superficial, in radial growth phase/vertical growth phase | skin | human | WM1552C | CRL-2808 |
| Melanoma, primary superficial, in radial growth phase/vertical growth phase | skin, melanocyte | human | WM35 | CRL-2807 |
| Melanoma, primary superficial, in vertical growth phase | skin, melanocyte | human | WM793B | CRL-2806 |
| Melanoma, primary superficial, in | skin, melanocyte; from lung | | | |
| vertical growth phase | metastases in mice | human | 1205Lu | CRL-2812 |
| Melanoma, primary, in vertical growth phase | | human | WM39 | CRL-2811 |
| Melanoma, transfected to express | skin | human | A7 | CRL-2500 |
| filamin-1 | | | • | |
| Neuroblastoma | brain | human | CHP-212 | CRL-2273 |
| Neuroblastoma | brain, neuroblast | human | IMR-32 | CCL-127 |
| Neuroblastoma Neuroblastoma | brain, neuroblast | mouse | Neuro-2a | CCL-131 |
| Neuroblastoma | brain, neuroblast | mouse | NB41A3 | CCL-147 |
| Neuroblastoma | brain, neuroblast | mouse | N1E-115 | CRL-2263 |
| Neuroblastoma | central nervous system; | rat | B35 | CRL-2754 |
| | nitrosoethylurea-induced | | | |
| Neuroglioma | brain | human | H4 | HTB-148 |
| Osteoma, benign osteoid | bone | human | Hs 900.T | CRL-7646* |
| Osteoma, benign osteoid | bone | human | Hs 903.T | CRL-7649* |
| Osteoma, benign osteoid | bone | human | Hs 919.T | CRL-7672* |
| | | d = == | D17 | CRL-6248* |
| Osteosarcoma | bone | dog | | |
| Osteosarcoma | bone bone | dog | D22 | CRL-6250* |
| Osteosarcoma Osteosarcoma | | dog dog | D22 D17 | CRL-6250* CRL-8468 [†] |
| Osteosarcoma Osteosarcoma Osteosarcoma Osteosarcoma Osteosarcoma | bone | dog | D22 | CRL-6250* |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Source | Species | Name | ATCC® No. |
|--------------------------------------|-------------------------|--------------------|-------------------------|-----------------------|
| Osteosarcoma | bone | human | MG-63 | CRL-1427 |
| Osteosarcoma | bone | human | HOS | CRL-1543 |
| Osteosarcoma | bone | human | KHOS/NP (R-970-5) | CRL-1544 |
| Osteosarcoma | bone | human | KHOS-240S | CRL-1545 |
| Osteosarcoma | bone | human | KHOS-321H | CRL-1546 |
| Osteosarcoma | bone | human | MNNG/HOS (CI #5) | CRL-1547 |
| Osteosarcoma | bone | human | Hs 3.T | CRL-7005* |
| Osteosarcoma | bone | human | Hs 39.T | CRL-7023* |
| Osteosarcoma | bone | human | Hs 184.T | CRL-7134* |
| Osteosarcoma | bone | human | Hs 188.T | CRL-7140* |
| Osteosarcoma | bone | human | Hs 387.T | CRL-7263* |
| Osteosarcoma | bone | human | Hs 704.T | CRL-7444* |
| Osteosarcoma | bone | human | Hs 707(A).T | CRL-7448* |
| Osteosarcoma | bone | human | Hs 735.T | CRL-7471* |
| Osteosarcoma | bone | human | Hs 755(B).T | CRL-7489* |
| Osteosarcoma | bone | human | Hs 781.T | CRL-7511* |
| Osteosarcoma | bone | human | Hs 792(B).T | CRL-7521* |
| Osteosarcoma | bone | human | Hs 805.T | CRL-7537* |
| Osteosarcoma | bone | human | Hs 811.T | CRL-7543* |
| Osteosarcoma | bone | human | Hs 866.T | CRL-7602* |
| Osteosarcoma | bone | human | Hs 870.T | CRL-7606* |
| Osteosarcoma | bone | human | Hs 871.T | CRL-7609* |
| Osteosarcoma | bone | human | Hs 889.T | CRL-7626* |
| Osteosarcoma | bone | human | Hs 890.T | CRL-7628* |
| Osteosarcoma | bone | human | Murphy | CRL-7722* |
| Osteosarcoma | bone | human | R-970-5 | CRL-7723* |
| Osteosarcoma | bone | human | TE 417.T | CRL-7765* |
| Osteosarcoma | bone | human | TE 418.T | CRL-7766* |
| Osteosarcoma | bone | human | TO 203.T | CRL-7780* |
| Osteosarcoma | bone | human | HT 728.T | CRL-7783* |
| Osteosarcoma | bone | human | Hs 14.T | CRL-7823* |
| Osteosarcoma | bone | human | T1-73 | CRL-7943* |
| Osteosarcoma | bone | human | 143B | CRL-8303 [†] |
| Osteosarcoma | bone | human | 143B PML BK TK | CRL-8304 [†] |
| Osteosarcoma | bone | human | Saos-2 | HTB-85 |
| Osteosarcoma | bone | human | U-2 OS | HTB-96 |
| Osteosarcoma | bone | rat | UMR-106 | CRL-1661 |
| Osteosarcoma | bone | rat | UMR-108 | CRL-1663 |
| Osteosarcoma | bone, connective tissue | dog | CF11.T | CRL-6217* |
| Osteosarcoma | bone, connective tissue | human | Hs 88.T | CRL-7060* |
| Osteosarcoma | bone, connective tissue | human | Hs 864.T | CRL-7600* |
| Osteosarcoma | thymus | cat | FC95.Thy | CRL-6114* |
| Osteosarcoma, multipotential sarcoma | bone | human | SJSA-1 | CRL-2098 |
| Papilloma | pharynx | human | Hs 840.T | CRL-7573* |
| Papilloma | skin | rabbit, cottontail | CTPS | CRL-6496* |
| Papilloma, squamous | skin | human | Hs 416.T | CRL-7289* |
| Papilloma, transitional cell | bladder, urinary | human | RT4 | HTB-2 |
| Pheochromocytoma | adrenal gland | rat | PC-12 | CRL-1721 |
| Pheochromocytoma | adrenal gland | rat | PC-12 | CRL-1721 |
| Plasmacytoma, myeloma | B lymphoblast | human | U266B1 | TIB-196 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | MOPC-31C | CCL-130 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | MPC-11 | CCL-167 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | P1.17 | TIB-10 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | C1.18.4 | TIB-11 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | HOPC 1F/12 | TIB-13 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | MPC 11 OUA ^r | TIB-15 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | XC1.5/51 | TIB-16 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | XS63 | TIB-17 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | S194/5.XXO-1 | TIB-19 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | MOPC 315 | TIB-23 |
| Plasmacytoma, myeloma | B lymphocyte | mouse | J558 | TIB-6 |



| Disease | Source | Species | Name | ATCC® No. |
|--|-----------------------------------|---------|----------------|-----------------------|
| Plasmacytoma, myeloma | B lymphocyte | mouse | P3.6.2.8.1 | TIB-8 |
| Plasmacytoma, myeloma | B lymphocyte, peripheral blood | human | RPMI 8226 | CCL-155 |
| Plasmacytoma, myeloma | bone marrow, B lymphocyte | human | NCI-H929 | CRL-9068 [†] |
| Primitive neuroectodermal, malignant | retroperitoneal | human | SK-PN-DW | CRL-2139 |
| Retinoblastoma | eye, retina | human | WERI-Rb-1 | HTB-169 |
| Retinoblastoma | eye, retina | human | Y79 | HTB-18 |
| Rhabdomyosarcoma | connective tissue | human | TE 441.T | CRL-7767* |
| Rhabdomyosarcoma | connective tissue | human | TE 617.T | CRL-7774* |
| Rhabdomyosarcoma | connective tissue | human | Hs 729.T | CRL-7862* |
| Rhabdomyosarcoma | mixed connective and soft | human | TE 381.T | CRL-7763* |
| Rhabdomyosarcoma | muscle | human | RD | CCL-136 |
| Rhabdomyosarcoma | muscle | human | A-673 | CRL-1598 |
| Rhabdomyosarcoma | muscle | human | Hs 729 | HTB-153 |
| Rhabdomyosarcoma | muscle | human | A-204 | HTB-82 |
| Rhabdomyosarcoma | muscle, skeletal | human | Hs 94.T | CRL-7064* |
| Rhabdomyosarcoma | unknown | human | TE 159.T | CRL-7752* |
| Rhabdomyosarcoma | unknown | human | TE 125.T | CRL-7945* |
| Rhabdomyosarcoma, renal | kidney | human | Hs 926.T | CRL-7678* |
| Sarcoma | connective tissue | cat | FC100.T | CRL-6115* |
| Sarcoma | connective tissue | mouse | EHS | CRL-2108 |
| Sarcoma | spleen | cat | FC100.Sp | CRL-6116* |
| Sarcoma | unknown | mouse | CCRF S-180 II | CCL-8 |
| Sarcoma | unknown | mouse | Sarcoma 180 | TIB-66 |
| Sarcoma | unknown | rat | Jensen Sarcoma | CCL-45 |
| Sarcoma | unknown | rat | RR1022 | CCL-47 |
| Sarcoma (anaplastic osteosarcoma | bone | human | SK-ES-1 | HTB-86 |
| or Ewing's sarcoma) | | | | |
| Sarcoma or lymphoma | lung | human | Hs 57.T | CRL-7037* |
| Sarcoma, Ewing's | bone | human | Hs 822.T | CRL-7556* |
| Sarcoma, Ewing's | bone | human | Hs 863.T | CRL-7598* |
| Sarcoma, Ewing's | bone | human | RD-ES | HTB-166 |
| Sarcoma, giant cell | bone | human | Hs 706.T | CRL-7447* |
| Sarcoma, giant cell | bone | human | Hs 737.T | CRL-7473* |
| Sarcoma, giant cell | bone | human | Hs 821.T | CRL-7554* |
| Sarcoma, giant cell | bone | human | Hs 846.T | CRL-7579* |
| Sarcoma, giant cell | bone | human | Hs 883.T | CRL-7617* |
| Sarcoma, giant cell | connective tissue | human | Hs 127.T | CRL-7081* |
| Sarcoma, giant cell | vertebral column | human | Hs 814.T | CRL-7547* |
| Sarcoma; heterozygous for tuberin; tuberous sclerosis model | unknown, cutaneous | mouse | tsc2 ang1 | CRL-2620 |
| Sarcoma, pagetoid | skin | human | Hs 925.T | CRL-7677* |
| Sarcoma, reticulum cell | bone marrow | cat | FC11.BM | CRL-6088* |
| Sarcoma, reticulum cell | B lymphocyte | mouse | A20 | TIB-208 |
| Sarcoma, reticulum cell | B lymphocyte | mouse | X16C8.5 | TIB-209 |
| Sarcoma, reticulum cell | lymph node | human | Hs 324.T | CRL-7239* |
| Sarcoma, reticulum cell | monocyte/macrophage | mouse | J774A.1 | TIB-67 |
| Sarcoma, spindle cell | connective tissue | human | Hs 132.T | CRL-7085* |
| Sarcoma, synovial | connective tissue | human | Hs 701.T | CRL-7440* |
| Sarcoma, synovial | synovium | human | SW 982 | HTB-93 |
| Sarcoma, uterine | uterus | human | MES-SA | CRL-1976 |
| Sarcoma, uterine | uterus | human | MES-SA/Dx5 | CRL-1977 |
| Sarcoma, uterine | uterus | human | MES-SA/MX2 | CRL-2274 |
| Schwannoma | Schwann cell | rat | RT4-D6P2T | CRL-2768 |
| Teratocarcinoma | stem cell, nullipotent | human | NCCIT | CRL-2073 |
| Teratocarcinoma | testis | mouse | NULLI-SCC1 | CRL-1566 |
| Teratocarcinoma, carcinoma | embryo | mouse | P19 | CRL-1825 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Source | Species | Name | ATCC® No. |
|--|-------------------------------------|-------------------|--------------------------------|------------------------|
| Teratocarcinoma, carcinoma | embryonal stem cell, nullipotent | mouse | NE | CRL-2070 |
| Teratocarcinoma, carcinoma | embryonal stem cell, nullipotent | mouse | NF-1 | CRL-2075 |
| Teratocarcinoma, carcinoma | embryonal stem cell, pluripotent | mouse | SCC-PSA1 | CRL-1535 |
| Teratoma | keratinocyte | mouse | XB-2 | CL-177 |
| Teratoma | ovary | human | TE 84.T | CRL-7944* |
| Teratoma, sacrococcygeal | bone | human | TE 76.T | CRL-7732* |
| Teratoma, sacrococcygeal | bone | human | TE 130.T | CRL-7746* |
| Tumor | bladder, urinary | rat | NBT-II | CRL-1655 |
| Tumor | lung, transformed | mouse | TC-1 | JHU-1 |
| Tumor | mammary gland | mouse | 4T1 | CRL-2539 |
| Tumor | mammary gland | mouse | MMT 060562 | CCL-51 |
| Tumor | mammary gland | mouse | C127I | CRL-1616 |
| Tumor | mammary gland | mouse | C127:LT | CRL-1804 |
| Tumor | pancreas, exocrine | rat | AR42J | CRL-1492 |
| Tumor | pancreas, exocrine | rat | ARIP | CRL-1492 CRL-1674 |
| Tumor | pituitary | mouse | AtT-20 | CCL-89 |
| Tumor | pituitary | mouse | AtT-20/D16v-F2 | CRL-1795 |
| Tumor | pituitary | rat | GH. | CCL-82 |
| Tumor | pituitary | rat | GH, | CCL-82.1 |
| Tumor | | | 3 | CCL-82.1 |
| | pituitary | rat | GH ₄ C ₁ | |
| Tumor | pituitary | rat | MMQ MM7.11.5p | CRL-10609 [†] |
| Tumor | spleen | mouse | MM7-11.Sp | CRL-6381* |
| Tumor | unknown | dog | A-72 | CRL-1542 |
| Tumor, AMLV induced | monocyte | mouse | WEHI-274.1 | CRL-1679 |
| Tumor, AMLV induced | monocyte | mouse | WEHI-265.1 | TIB-204 |
| Tumor, AMLV induced | monocyte/macrophage | mouse | RAW 309 Cr.1 | TIB-69 |
| Tumor, AMLV induced | monocyte/macrophage | mouse | WR19M.1 | TIB-70 |
| Tumor, AMLV induced | monocyte/macrophage | mouse | RAW 264.7 | TIB-71 |
| Tumor, DMBA induced | unknown | rat | Rn6T | CRL-6601* |
| Tumor, acinar cell | pancreas | mouse | 266-6 | CRL-2151 |
| Tumor, chemically induced | unknown | rat | Rn 3T | CRL-6511* |
| Tumor, chemically induced | unknown | rat | Rn 4T | CRL-6512* |
| Tumor, glucose-stimulated insulin release | pituitary | mouse | AtT-20ins (CGT-6) | CRL-11285 [†] |
| Tumor, islet cell, insulinoma | pancreas | mouse, transgenic | TGP61 | CRL-2135 |
| Tumor, islet cell, insulinoma | pancreas | mouse, transgenic | TGP52 | CRL-2140 |
| Fumor, Leydig cell | testis | mouse | I-10 | CCL-83 |
| Tumor, Leydig cell | testis | mouse | MLTC-1 | CRL-2065 |
| Tumor, Leydig cell | testis | rat | LC-540 | CCL-43 |
| Tumor, Leydig cell | testis | rat | R2C | CCL-97 |
| Tumor, malignant primitive neuroectodermal | brain, cerebellum | human | PFSK-1 | CRL-2060 |
| Tumor, nonneoplastic | oral | human | Hs 53.T | CRL-7033* |
| Tumor, premalignant | mammary gland | mouse | CL-S1 | CRL-1615 |
| Tumor, rhabdoid | kidney | human | G-401 | CRL-1441 |
| Tumor, small cell | pancreas | mouse, transgenic | TGP55 | CRL-2150 |
| Tumor, smooth muscle-like, | brain | mouse | BC ₃ H1 | CRL-1443 |
| methylnitrosourea induced | | | | |
| Xanthogranuloma | skin | human | Hs 156.T | CRL-7102* |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



These tumor cells are known to be from metastatic sites. They are listed by disease state and primary site as provided by the depositor. Cell lines that are not from metastatic sites or whose primary/metastatic status is unknown are listed in the previous index starting on page 153.

For more information on a cell line, see the main list starting on page 30 or use the catalogue number to find the entry in the cell biology section of the ATCC online catalog.

| Disease | Primary Site | Metastatic Site | Species | Name | ATCC® No. |
|----------------------------|---------------------|--------------------------|------------|-------------|-----------|
| Adenocarcinoma | colon | connective tissue, trunk | human | Hs 698.T | CRL-7435* |
| Adenocarcinoma | colon | ovary | human | SW 626 | HTB-78 |
| Adenocarcinoma | colon | peritoneum | human | SNU-C1 | CRL-5972 |
| Adenocarcinoma | liver | ascites | human | SK-HEP-1 | HTB-52 |
| Adenocarcinoma | lung | lymph node | human | NCI-H1648 | CRL-5882 |
| Adenocarcinoma | lung | lymph node | human | NCI-H1819 | CRL-5897 |
| Adenocarcinoma | lung | lymph node | human | NCI-H2009 | CRL-5911 |
| Adenocarcinoma | lung | pleural effusion | human | NCI-H1355 | CRL-5865 |
| Adenocarcinoma | lung | pleural effusion | human | NCI-H1792 | CRL-5895 |
| Adenocarcinoma | lung | pleural effusion | human | NCI-H676B | HTB-179 |
| Adenocarcinoma | lung | pleural effusion | human | Calu-3 | HTB-55 |
| Adenocarcinoma | lung | soft tissue | human | NCI-H1573 | CRL-5877 |
| Adenocarcinoma | mammary gland | brain | human | MDA-MB-361 | HTB-27 |
| Adenocarcinoma | mammary gland | pleural effusion | human | HCC1428 | CRL-2327 |
| Adenocarcinoma | mammary gland | pleural effusion | human | AU565 | CRL-2351 |
| Adenocarcinoma | mammary gland | pleural effusion | human | MDA-MB-415 | HTB-128 |
| Adenocarcinoma | mammary gland | pleural effusion | human | MDA-MB-436 | HTB-130 |
| Adenocarcinoma | mammary gland | pleural effusion | human | MDA-MB-468 | HTB-132 |
| Adenocarcinoma | mammary gland | pleural effusion | human | CAMA-1 | HTB-21 |
| Adenocarcinoma | mammary gland | pleural effusion | human | MCF7 | HTB-22 |
| Adenocarcinoma | mammary gland | pleural effusion | human | MDA-MB-231 | HTB-26 |
| Adenocarcinoma | mammary gland | pleural effusion | human | SK-BR-3 | HTB-30 |
| Adenocarcinoma | ovary | ascites | human | NIH:OVCAR-3 | HTB-161 |
| Adenocarcinoma | ovary | ascites | human | SK-OV-3 | HTB-77 |
| Adenocarcinoma | ovary | fallopian tube | human | Caov-4 | HTB-76 |
| Adenocarcinoma | pancreas | ascites | human | AsPC-1 | CRL-1682 |
| Adenocarcinoma | pancreas | liver | human | Capan-1 | HTB-79 |
| Adenocarcinoma | pancreas | spleen | human | SW 1990 | CRL-2172 |
| Adenocarcinoma | prostate | bone | human | PC-3 | CRL-1435 |
| Adenocarcinoma | prostate | bone | human | MDA PCa 2b | CRL-2422 |
| Adenocarcinoma | prostate | prostate | mouse, | TRAMP-C3 | CRL-2732 |
| | | | transgenic | | |
| Adenocarcinoma | unknown | bone | human | Hs 696 | HTB-151 |
| adenocarcinoma | uterus, endometrium | lymph node | human | AN3 CA | HTB-111 |
| Adenocarcinoma, | lung | pleural effusion | human | NCI-H1650 | CRL-5883 |
| bronchoalveolar carcinoma | - | | | | |
| Adenocarcinoma, | lung | pleural effusion | human | NCI-H1666 | CRL-5885 |
| bronchoalveolar carcinoma | - | | | | |
| Adenocarcinoma, | lung | pleural effusion | human | NCI-H1781 | CRL-5894 |
| bronchoalveolar carcinoma | - | | | | |
| Adenocarcinoma, colorectal | colon | ascites | human | COLO 205 | CCL-222 |
| Adenocarcinoma, colorectal | COION | ascites | Hullian | COLO 203 | CCL-222 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Primary Site | Metastatic Site | Species | Name | ATCC® No. |
|--|----------------|-------------------------------------|----------------|-----------------------|------------------------|
| Adenocarcinoma, colorectal | colon | lymph node | human | SW620 | CCL-227 |
| Adenocarcinoma, colorectal | colon | lymph node, left supraclavicular | human | LoVo | CCL-229 |
| Adenocarcinoma, colorectal | colon | ascites | human | SK-CO-1 | HTB-39 |
| Adenocarcinoma, malignant | ovary | ascites | human | OV-90 | CRL-11732 [†] |
| papillary serous | | | | | |
| Adenocarcinoma, non-small cell lung cancer | lung | ascites | human | NCI-H2405 | CRL-5944 |
| Adenocarcinoma, non-small cell lung cancer | lung | liver | human | NCI-H1755 | CRL-5892 |
| Adenocarcinoma, non-small cell lung cancer | lung | lymph node | human | NCI-H838 | CRL-5844 |
| Adenocarcinoma, non-small | lung | lymph node | human | NCI-H920 | CRL-5850 |
| cell lung cancer Adenocarcinoma, non-small | lung | lymph node | human | NCI-H1568 | CRL-5876 |
| cell lung cancer | | | | | |
| Adenocarcinoma, non-small cell lung cancer | lung | lymph node | human | NCI-H1623 | CRL-5881 |
| Adenocarcinoma, non-small cell lung cancer | lung | lymph node | human | NCI-H1693 | CRL-5887 |
| Adenocarcinoma, non-small cell lung cancer | lung | lymph node | human | NCI-H1993 | CRL-5909 |
| Adenocarcinoma, non-small | lung | lymph node | human | NCI-H2023 | CRL-5912 |
| cell lung cancer Adenocarcinoma, non-small | lung | lymph node | human | NCI-H2030 | CRL-5914 |
| cell lung cancer Adenocarcinoma, non-small | lung | lymph node | human | NCI-H2087 | CRL-5922 |
| cell lung cancer Adenocarcinoma, non-small | lung | lymph node | human | NCI-H2291 | CRL-5939 |
| cell lung cancer | 9 | ур | | | |
| Adenocarcinoma, non-small cell lung cancer | lung | pleural effusion | human | NCI-H969 | CRL-5852 |
| Adenocarcinoma, non-small cell lung cancer | lung | pleural effusion | human | NCI-H1437 | CRL-5872 |
| Adenocarcinoma, non-small cell lung cancer | lung | pleural effusion | human | NCI-H2122 | CRL-5985 |
| Adenocarcinoma, non-small | lung | soft tissue | human | NCI-H1944 | CRL-5907 |
| cell lung cancer | lung | lymph node | human | NCI-H1404 | CRL-5819 |
| denocarcinoma, papillary | lung | lymph node | human human | NCI-H1404 NCI-H820 | HTB-181 |
| Adenocarcinoma, papillary | lung | pericardial fluid | human | NCI-H441 | HTB-174 |
| Carcinoma | cervix | lymph node | human | HT-3 | HTB-32 |
| Carcinoma | kidney | lymph node | human | Hs 891.T | CRL-7629* |
| Carcinoma | mammary gland | pleural effusion | human | MB 157 | CRL-7721* |
| Carcinoma | mammary gland | pleural effusion | human | MDA-MB-330 | HTB-127 |
| Carcinoma | mammary gland | pleural effusion | human | MDA-MB-453 | HTB-131 |
| Carcinoma | mammary gland | pleural effusion | human | MDA-MB-157 | HTB-24 |
| Carcinoma | pancreas | lymph node | human | Hs 766T | HTB-134 |
| Carcinoma | pharynx | pleural effusion | human | Detroit 562 | CCL-138 |
| Carcinoma | prostate | brain | human | DU 145 | HTB-81 |
| Carcinoma | prostate | lymph node, left | human | LNCaP clone FGC | CRL-1740 |
| | prostate | supraclavicular | manian | | |
| Carcinoma | rectum | liver | human | NCI-H630 | CRL-5833 |
| Carcinoma | unknown | omentum | human | Hs 904.T | CRL-7651* |
| Carcinoma | vulva | lymph node | human | SW 962 | HTB-118 |
| Carcinoma, extrapulmonary small cell; neuroendocrine | prostate | lymph node | human | NCI-H660 | CRL-5813 |
| Carcinoma, bronchioalveolar, | lung | lymph node | human | NCI-H650 | CRL-5835 |
| non-small cell lung cancer Carcinoma, bronchogenic | lung, bronchus | subcutaneous | human | ChaGo-K-1 | HTB-168 |
| za. ciriorna, pronenogenie | iang, bronchus | Jaseatarieous | Haman | CHUGO IC I | 1110 100 |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. bry research use only. Not intended for use in humans, animals or for diagnostics.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trade-



| Disease | Primary Site | Metastatic Site | Species | Name | ATCC® No. |
|---|------------------------------|------------------|---------|----------------|-----------|
| Carcinoma, classic small cell lung cancer | lung | ascites | human | NCI-H1694 | CRL-5888 |
| Carcinoma, classic small cell lung cancer | lung | bone marrow | human | NCI-H711 | CRL-5836 |
| Carcinoma, classic small cell lung cancer | lung | bone marrow | human | NCI-H719 | CRL-5837 |
| Carcinoma, classic small cell | lung | bone marrow | human | NCI-H1092 | CRL-5855 |
| lung cancer Carcinoma, classic small cell | lung | bone marrow | human | NCI-H1284 | CRL-5861 |
| lung cancer Carcinoma, classic small cell lung cancer | lung | brain | human | NCI-H250 | CRL-5828 |
| Carcinoma, classic small cell lung cancer | lung | lymph node | human | NCI-H889 | CRL-5817 |
| Carcinoma, classic small cell lung cancer | lung | lymph node | human | NCI-H740 | CRL-5840 |
| Carcinoma, classic small cell lung cancer | lung | lymph node | human | NCI-H748 | CRL-5841 |
| Carcinoma, classic small cell lung cancer | lung | lymph node | human | NCI-H1105 | CRL-5856 |
| Carcinoma, classic small cell lung cancer | lung | lymph node | human | NCI-H1436 | CRL-5871 |
| Carcinoma, classic small cell lung cancer | lung | lymph node | human | NCI-H1876 | CRL-5902 |
| Carcinoma, classic small cell lung cancer | lung | lymph node | human | NCI-H1930 | CRL-5906 |
| Carcinoma, classic small cell lung cancer | lung | lymph node | human | NCI-H1994 | CRL-5910 |
| Carcinoma, classic small cell lung cancer | lung | lymph node | human | NCI-H2059 | CRL-5916 |
| Carcinoma, classic small cell lung cancer | lung | pleural effusion | human | NCI-H187 | CRL-5804 |
| Carcinoma, classic small cell lung cancer | lung | pleural effusion | human | NCI-H378 | CRL-5808 |
| Carcinoma, classic small cell lung cancer | lung | pleural effusion | human | NCI-H60 | CRL-5821 |
| Carcinoma, classic small cell lung cancer | lung | pleural effusion | human | NCI-H220 | CRL-5825 |
| Carcinoma, classic small cell lung cancer | lung | pleural effusion | human | NCI-H847 | CRL-5846 |
| Carcinoma, classic small cell | lung | pleural effusion | human | NCI-H865 | CRL-5849 |
| Carcinoma, classic small cell lung cancer | lung | pleural effusion | human | NCI-H1304 | CRL-5862 |
| Carcinoma, classic small cell lung cancer | lung | pleural effusion | human | NCI-H2081 | CRL-5920 |
| Carcinoma, classic small cell lung cancer | lung | soft tissue | human | NCI-H774 | CRL-5842 |
| Carcinoma, clear cell | kidney | skin | human | Caki-1 | HTB-46 |
| Carcinoma, colorectal | colon | lung | human | T84 | CCL-248 |
| Carcinoma, ductal | mammary gland | lymph node | human | HCC1008 | CRL-2320 |
| Carcinoma, ductal | mammary gland | pleural effusion | human | MDA-MB-435S | HTB-129 |
| Carcinoma, ductal | mammary gland | pleural effusion | human | T-47D | HTB-133 |
| Carcinoma, ductal | mammary gland | pleural effusion | human | MDA-MB-134-VI | HTB-23 |
| Carcinoma, ductal | mammary gland | pleural effusion | human | MDA-MB-175-VII | HTB-25 |
| Carcinoma, ductal | mammary gland, epithelium | ascites | human | ZR-75-1 | CRL-1500 |
| Carcinoma, ductal | mammary gland, epithelium | ascites | human | ZR-75-30 | CRL-1504 |
| Carcinoma, ductal | pancreas | liver | human | SU.86.86 | CRL-1837 |
| | | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Primary Site | Metastatic Site | Species | Name | ATCC® No. |
|--|--------------|------------------------|---------|---------------|-----------|
| Carcinoma, embryonal malignant | unknown | lung | human | Tera-1 | HTB-105 |
| Carcinoma, embryonal malignant | unknown | lung | human | Tera-2 | HTB-106 |
| Carcinoma, epidermoid | unknown | lymph nodes | human | A388 | CRL-7905* |
| Carcinoma, epidermoid | cervix | lymph node | human | MS751 | HTB-34 |
| Carcinoma, epidermoid | cervix | mesentery, small bowel | human | Ca Ski | CRL-1550 |
| Carcinoma, epidermoid | cervix | omentum | human | ME-180 | HTB-33 |
| Carcinoma, epidermoid | lung | pleura | human | Calu-1 | HTB-54 |
| Carcinoma, epidermoid | lung | pleural effusion | human | Hs 284.Pe | CRL-7228* |
| Carcinoma, epithelioid | bone | bone marrow | human | VA-ES-BJ | CRL-2138 |
| Carcinoma, gastric | stomach | ascites | human | SNU-5 | CRL-5973 |
| Carcinoma, gastric | stomach | ascites | human | SNU-16 | CRL-5974 |
| Carcinoma, gastric | stomach | liver | human | NCI-N87 | CRL-5822 |
| Carcinoma, gastric | stomach | muscle | human | Hs 746T | HTB-135 |
| Carcinoma, gastric | stomach | pleural effusion | human | KATO III | HTB-103 |
| Carcinoma, intestinal | unknown | lymph node | human | Hs 692(A).T | CRL-7428* |
| Carcinoma, large cell | lung | pleural effusion | human | NCI-H460 | HTB-177 |
| Carcinoma, large cell | lung | lymph node | human | NCI-H661 | HTB-183 |
| lung cancer | | , · | | | |
| Carcinoma, large cell neuroendocrine | lung | lymph node | human | NCI-H1299 | CRL-5803 |
| Carcinoma, large cell neuroendocrine | lung | lymph node | human | NCI-H1155 | CRL-5818 |
| Carcinoma, large cell neuroendocrine | lung | lymph node | human | NCI-H2106 | CRL-5923 |
| Carcinoma, large cell poorly differentiatied | lung | brain | human | NCI-H1915 | CRL-5904 |
| Carcinoma, malignant pluripotent embryonal; neuroendocrine | testis | lung | human | NTERA-2 cl.D1 | CRL-1973 |
| Carcinoma, mixed adenosquamous | lung | pleural effusion | human | NCI-H647 | CRL-5834 |
| Carcinoma, neuroendocrine, non-small cell lung cancer | lung | lymph node | human | NCI-H1770 | CRL-5893 |
| Carcinoma, neuroendocrine, squamous cell | lung | lymph node | human | NCI-H1385 | CRL-5867 |
| Carcinoma, small cell lung cancer | lung | bone marrow | human | NCI-H211 | CRL-5824 |
| Carcinoma, small cell lung cancer | lung | bone marrow | human | NCI-H1238 | CRL-5859 |
| Carcinoma, small cell lung | lung | bone marrow | human | NCI-H1618 | CRL-5879 |
| cancer Carcinoma, small cell lung cancer | lung | bone marrow | human | NCI-H1882 | CRL-5903 |
| Carcinoma, small cell lung | lung | bone marrow | human | NCI-H2195 | CRL-5931 |
| cancer Carcinoma, small cell lung | lung | bone marrow | human | NCI-H2196 | CRL-5932 |
| cancer Carcinoma, small cell lung | lung | bone marrow | human | NCI-H2107 | CRL-5983 |
| cancer Carcinoma, small cell lung | lung | bone marrow | human | NCI-H2108 | CRL-5984 |
| cancer Carcinoma, small cell lung | lung | bone marrow | human | NCI-H209 | HTB-172 |
| cancer Carcinoma, small cell lung | lung | bone marrow | human | NCI-H146 | HTB-173 |
| cancer Carcinoma, small cell lung | lung | bone marrow | human | NCI-H345 | HTB-180 |
| cancer Carcinoma, small cell lung | lung | cervix | human | NCI-H1870 | CRL-5901 |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. ry research use only. Not intended for use in humans, animals or for diagnostics.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trade-



| Disease | Primary Site | Metastatic Site | Species | Name | ATCC® No. |
|---|----------------------------------|---------------------|---------|-------------|------------------------|
| Carcinoma, small cell lung | lung | cervix | human | NCI-H1341 | CRL-5864 |
| cancer Carcinoma, small cell lung | lung | liver | human | DMS 153 | CRL-2064 |
| cancer Carcinoma, small cell lung | lung | liver | human | NCI-H735 | CRL-5978 |
| cancer Carcinoma, small cell lung | lung | lymph node | human | NCI-H1184 | CRL-5858 |
| cancer Carcinoma, small cell lung | lung | lymph node | human | NCI-H1926 | CRL-5905 |
| Cancer Carcinoma, small cell lung | lung | lymph node | human | NCI-H2029 | CRL-5913 |
| cancer Carcinoma, small cell lung cancer | lung | lymph node | human | NCI-H2141 | CRL-5927 |
| Caricer Carcinoma, small cell lung cancer | lung | lymph node | human | NCI-H2198 | CRL-5933 |
| Caricer Carcinoma, small cell lung cancer | lung | lymph node | human | NCI-H2330 | CRL-5940 |
| Carcinoma, small cell lung cancer | lung | pleural effusion | human | NCI-H1048 | CRL-5853 |
| Carcinoma, small cell lung cancer | lung | pleural effusion | human | NCI-H1522 | CRL-5874 |
| Carcinoma, small cell lung cancer | lung | pleural effusion | human | NCI-H2171 | CRL-5929 |
| Carcinoma, small cell lung cancer | lung | pleural effusion | human | NCI-H69 | HTB-119 |
| Carcinoma, small cell lung cancer | lung | pleural effusion | human | NCI-H128 | HTB-120 |
| Carcinoma, small cell lung cancer | lung | pleural effusion | human | NCI-H446 | HTB-171 |
| Carcinoma, small cell lung cancer | lung | pleural effusion | human | NCI-H82 | HTB-175 |
| Carcinoma, small cell lung cancer | unknown | adrenal gland | human | NCI-H510A | HTB-184 |
| Carcinoma, squamous cell | lung | pleural effusion | human | NCI-H1869 | CRL-5900 |
| Carcinoma, squamous cell | lung | pleural effusion | human | SK-MES-1 | HTB-58 |
| Carcinoma, squamous cell | nasal septum | pleural effusion | human | RPMI 2650 | CCL-30 |
| Carcinoma, squamous cell mesothelioma | lung, pleura | pleural effusion | human | NCI-H226 | CRL-5826 |
| Carcinoma, variant small cell lung cancer | lung | bone marrow | human | NCI-H526 | CRL-5811 |
| Carcinoma, variant small cell lung cancer | lung | lymph node | human | NCI-H524 | CRL-5831 |
| Carcinoma, variant small cell lung cancer | lung | lymph node | human | NCI-H841 | CRL-5845 |
| Carcinoma, variant small cell lung cancer | lung | pleural effusion | human | NCI-H196 | CRL-5823 |
| ibrosarcoma | connective tissue | lung or bronchus | human | Hs 913(B).T | CRL-7664* |
| ibrosarcoma | connective tissue | lung or bronchus | human | Hs 913(C).T | CRL-7665* |
| ibrosarcoma | connective tissue | lymph node | human | Hs 414.T | CRL-7287* |
| ibrosarcoma | unknown | lung | human | Hs 913T | HTB-152 |
| ibrosarcoma | unknown | lung or bronchus | human | Hs 913(D).T | CRL-7666* |
| ibrosarcoma | unknown | lung or bronchus | human | Hs 913(F).T | CRL-7668* |
| listiocytoma, fibrous | unknown | lung | human | GCT | TIB-223 |
| eukemia, chronic myelogenous | bone marrow, undifferentiated | pleural effusion | human | K-562 | CCL-243 |
| | granulocyte | | | | |
| Lymphangiectasia | B lymphocyte | pleural effusion | human | DS-1 | CRL-11102 [†] |
| Lymphoma, B cell | B lymphoblast | peritoneal effusion | human | JSC-1 | JHU-32 |
| Lymphoma, Burkitt's | B lymphoblast | ascites | human | ST486 | CRL-1647 |
| Lymphoma, Burkitt's | B lymphoblast | ascites | human | P3HR-1 | HTB-62 |
| | | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Disease | Primary Site | Metastatic Site | Species | Name | ATCC® No. |
|--|----------------------|----------------------------|------------------|------------------------|------------------------|
| Lymphoma, Burkitt's | B lymphocyte | ovary | human | EB2 | HTB-61 |
| Lymphoma, diffuse large cell non-Hodgkin's | B lymphocyte | pleural effusion | human | Pfeiffer | CRL-2632 |
| Lymphoma, diffuse mixed | B lymphoblast | ascites | human | HT | CRL-2260 |
| Lymphoma, Hodgkin's disease | lymph node | skin | human | TO 175.T | CRL-7779* |
| Lymphoma, large cell | unknown | pleural effusion | human | SR | CRL-2262 |
| immunoblastic | | | | | |
| Lymphoma, non-Hodgkin's | B lymphoblast | ascites | human | RL | CRL-2261 |
| Lymphoma, non-Hodgkin's B cell | unknown | lymph node | human | Farage | CRL-2630 |
| Lymphoma, undifferentiated | B lymphoblast | ascites | human | MC116 | CRL-1649 |
| Medulloblastoma | brain, cerebellum | ascites, peritoneum | human | D283 Med | HTB-185 |
| Melanoma | skin | lung | human | Hs 895.T | CRL-7637* |
| Melanoma | skin | lymph node | human | Hs 944.T | CRL-7693* |
| Melanoma | skin | lymph node, neck | human | Hs 834.T | CRL-7568* |
| Melanoma | skin | pleural effusion | human | SH-4 | CRL-7724* |
| Melanoma | skin | skin | human | WM-266-4 | CRL-1676 |
| Melanoma, amelanotic | intestines, pancreas | bone, pelvis | human | Hs 700T | HTB-147 |
| Melanoma, amelanotic | skin | lymph node | human | Hs 695T | HTB-137 |
| Melanoma, amelanotic | skin | lymph node | human | Hs 294T | HTB-140 |
| Melanoma, inquinal | skin | lymph node | human | Hs 688(B).T | CRL-7426* |
| Melanoma, malignant | skin | lymph node | human | A2058 | CRL-11147 [†] |
| Melanoma, malignant | skin | lymph node | human | MeWo | HTB-65 |
| Melanoma, malignant | skin | lymph node | human | SK-MEL-3 | HTB-69 |
| Melanoma, malignant | skin | skin metastasis | human | SK-MEL-2 | HTB-68 |
| Melanoma, malignant | skin | thoracic duct | human | SK-MEL-1 | HTB-67 |
| Mesothelioma | pleura | pleural effusion | human | NCI-H28 | CRL-5820 |
| Mesothelioma | pleura | pleural effusion | human | NCI-H2052 | CRL-5915 |
| Mesothelioma | unknown | pleural effusion | human | NCI-H2032 NCI-H2452 | CRL-5915 |
| Mesothelioma, biphasic | | pleural effusion | human | MSTO-211H | CRL-3946 CRL-2081 |
| Neuroblastoma | lung brain | bone marrow | human | SH-SY5Y | CRL-2266 |
| Neuroblastoma | | | | BE(2)-M17 | CRL-2266 |
| Neuroblastoma | brain brain | bone marrow bone marrow | human human | BE(2)-C | CRL-2267 CRL-2268 |
| Neuroblastoma | | | | | |
| | brain | bone marrow | human | SK-N-BE(2) | CRL-2271 |
| Neuroblastoma | brain | bone marrow | human | SK-N-SH | HTB-11 CRL-2137 |
| Neuroblastoma, embryonal | brain, neuroblast | bone marrow | human | SK-N-AS | |
| Neuroblastoma, embryonal | brain, neuroblast | bone marrow | human | SK-N-FI | CRL-2142 |
| Neuroblastoma, embryonal | brain, neuroblast | bone marrow | human | SK-N-DZ | CRL-2149 |
| Neuroepithelioma | brain | supraorbital area | human | MC-IXC | CRL-2270 |
| Neuroepithelioma | brain | supraorbital area | human | SK-N-MC | HTB-10 |
| Non-small cell lung cancer | lung | pleural effusion | human | NCI-H2110 | CRL-5924 |
| Osteosarcoma | bone | lung | dog | D-17 | CCL-183 |
| Osteosarcoma | bone | lung | human | Hs 860.T | CRL-7595* |
| Osteosarcoma | bone | lung | human | Hs 888.T | CRL-7622* |
| Osteosarcoma | bone | lung | human | Hs 894(A).T | CRL-7631* |
| Osteosarcoma | bone | lung | human | Hs 894(B).T | CRL-7632* |
| Osteosarcoma | bone | lung | human | Hs 894(C).T | CRL-7633* |
| Osteosarcoma | bone | lung | human | Hs 894(D).T | CRL-7634* |
| Osteosarcoma | bone | lung | human | Hs 899(A).T | CRL-7642* |
| Osteosarcoma | bone | lung | human | Hs 899(B).T | CRL-7643* |
| Osteosarcoma | bone | lung | human | Hs 899(C).T | CRL-7644* |
| Osteosarcoma | bone | lung | human | Hs 899(D).Lu | CRL-7645* |
| Osteosarcoma | bone | lymph node, cervical | human | Hs 792(A).T | CRL-7520* |
| Osteosarcoma | bone, femur | bone | human | Hs 845.T | CRL-7577* |
| Rhabdomyosarcoma | muscle | bone marrow | human | SJRH30 | CRL-2061 |
| Teratocarcinoma | ovary | ascites | human | PA-1 | CRL-1572 |
| Tumor | unknown | spleen | viper, Russell's | VSW | CCL-129 |
| Tumor, Wilms' | kidney | pleural effusion | human | SK-NEP-1 | HTB-48 |
| | • | * | | | |



Tumor/Normal Matched Cell Line Pairs

Matched cell line pairs provide a valuable resource for cancer studies. The first section lists the tumor and normal cell lines established from the same patient. The second section lists the primary and metastatic cell lines from the same patient. For more information on a cell line, see the main index starting on page 30 or use the catalogue number to find the entry in the cell biology section of the ATCC online catalog.

| Tissue Source (Tumor) | Name | ATCC® No. | Tissue Source (Normal) | Name | ATCC® No. |
|---|---|--|--|--|--|
| es from the Same Individual | | | | | |
| luna | NCI-H1395 | CRL-5868 | B lymphoblast | NCI-BL1395 | CRL-5957 |
| lymph node metastasis; lung primary | NCI-H2009 | CRL-5911 | B lymphoblast | NCI-BL2028 | CRL-5962 |
| lymph node metastasis; lung primary | NCI-H2087 | CRL-5922 | B lymphoblast | NCI-BL2087 | CRL-5965 |
| pleural effusion metastasis; lung primary | NCI-H2126 | CCL-256 | B lymphoblast | NCI-BL2126 | CCL-256.1 |
| pleural effusion metastasis; lung primary | NCI-H1437 | CRL-5872 | B lymphoblast | NCI-BL1437 | CRL-5958 |
| pleural effusion metastasis; lung primary | NCI-H2122 | CRL-5985 | B lymphoblast | NCI-BL2122 | CRL-5967 |
| mammary gland | Hs 742.T | CRL-7482* | skin | Hs 742.Sk | CRL-7481* |
| mammary gland | Hs 605.T | CRL-7365* | skin | Hs 605.Sk | CRL-7364* |
| mammary gland | Hs 606 | CRL-7368* | skin | Hs 606.Sk | CRL-7367* |
| skin | TE 354.T | CRL-7762* | skin | TE 353.Sk | CRL-7761* |
| lung | NCI-H1672 | CRL-5886 | B lymphoblast | NCI-BL1672 | CRL-5959 |
| lymph node metastasis; mammary gland primary | HCC1008 | CRL-2320 | B lymphoblast | HCC1007 BL | CRL-2319 |
| mammary gland | HCC1954 | CRL-2338 | B lymphoblast | HCC1954 BL | CRL-2339 |
| mammary gland | Hs 574.T | CRL-7345* | skin | Hs 574.Sk | CRL-7346* |
| mammary gland | Hs 578T | HTB-126 | mammary gland | Hs 578Bst | HTB-125 |
| lymph node metastasis; lung primary | NCI-H1770 | CRL-5893 | B lymphoblast | NCI-BL1770 | CRL-5960 |
| mammary gland | HCC38 | CRL-2314 | B lymphoblast | HCC38 BL | CRL-2346 |
| mammary gland | HCC1143 | CRL-2321 | B lymphoblast | HCC1143 BL | CRL-2362 |
| mammary gland | HCC1187 | CRL-2322 | B lymphoblast | HCC1187 BL | CRL-2323 |
| mammary gland | HCC1395 | CRL-2324 | B lymphoblast | HCC1395 BL | CRL-2325 |
| mammary gland | HCC1599 | CRL-2331 | B lymphoblast | HCC1599 BL | CRL-2332 |
| mammary gland | HCC1937 | CRL-2336 | B lymphoblast | HCC1937 BL | CRL-2337 |
| mammary gland | HCC2157 | CRL-2340 | B lymphoblast | HCC2157 BL | CRL-2341 |
| mammary gland | HCC2218 | CRL-2343 | B lymphoblast | HCC2218 BL | CRL-2363 |
| bone marrow metastasis; | NCI-H2195 | CRL-5931 | B lymphoblast | NCI-BL2195 | CRL-5956 |
| lung primary | | | | | |
| bone marrow metastasis; | NCI-H2107 | CRL-5983 | B lymphoblast | NCI-BL2107 | CRL-5966 |
| lung primary | | | | | |
| bone marrow metastasis; | NCI-H209 | HTB-172 | B lymphoblast | NCI-BL209 | CRL-5948 |
| lung primary | | | | | |
| lymph node metastasis; | NCI-H1184 | CRL-5858 | B lymphoblast | NCI-BL1184 | CRL-5949 |
| | lung lymph node metastasis; lung primary lymph node metastasis; lung primary pleural effusion metastasis; lung primary mammary gland mammary gland mammary gland skin lung lymph node metastasis; mammary gland primary mammary gland | lung NCI-H1395 lymph node metastasis; NCI-H2009 lung primary lymph node metastasis; NCI-H2087 lung primary pleural effusion metastasis; NCI-H2126 lung primary pleural effusion metastasis; NCI-H2126 lung primary pleural effusion metastasis; NCI-H2122 lung primary pleural effusion metastasis; NCI-H2122 lung primary mammary gland Hs 605.T mammary gland Hs 606 skin TE 354.T lung NCI-H1672 lymph node metastasis; HCC1008 mammary gland HcC1954 mammary gland Hs 574.T mammary gland Hs 578T lymph node metastasis; NCI-H1770 lung primary mammary gland HCC138 mammary gland HCC1143 mammary gland HCC1143 mammary gland HCC1187 mammary gland HCC1395 mammary gland HCC1395 mammary gland HCC1599 mammary gland HCC1599 mammary gland HCC157 mammary gland HCC2187 mammary gland HCC2187 lung primary bone marrow metastasis; NCI-H2107 lung primary bone marrow metastasis; NCI-H2107 lung primary lymph node metastasis; NCI-H209 lung primary lymph node metastasis; NCI-H209 lung primary lymph node metastasis; NCI-H209 | lung NCI-H1395 CRL-5868 lymph node metastasis; NCI-H2009 CRL-5911 lung primary lymph node metastasis; NCI-H2087 CRL-5922 lung primary pleural effusion metastasis; NCI-H2126 CCL-256 lung primary pleural effusion metastasis; NCI-H2126 CRL-5985 lung primary pleural effusion metastasis; NCI-H2122 CRL-5985 lung primary pleural effusion metastasis; NCI-H2122 CRL-5985 lung primary mammary gland Hs 742.T CRL-7482* mammary gland Hs 605.T CRL-7365* mammary gland Hs 606 CRL-7368* skin TE 354.T CRL-7762* lung NCI-H1672 CRL-5886 lymph node metastasis; HCC1008 CRL-2320 mammary gland Hs 574.T CRL-7345* mammary gland Hs 578T HTB-126 lymph node metastasis; NCI-H1770 CRL-5893 lung primary mammary gland HCC188 CRL-2314 mammary gland HCC1143 CRL-2321 mammary gland HCC1187 CRL-2322 mammary gland HCC1187 CRL-2324 mammary gland HCC1187 CRL-2324 mammary gland HCC1937 CRL-2331 mammary gland HCC1937 CRL-2336 mammary gland HCC1937 CRL-2336 mammary gland HCC218 CRL-2343 bone marrow metastasis; NCI-H2195 CRL-5981 lung primary bone marrow metastasis; NCI-H2107 CRL-5983 lung primary bone marrow metastasis; NCI-H209 HTB-172 lung primary lymph node metastasis; NCI-H209 HTB-172 | lung NCI-H1395 CRL-5868 B lymphoblast lymph node metastasis; NCI-H2009 CRL-5911 B lymphoblast lung primary leural effusion metastasis; NCI-H2087 CRL-5922 B lymphoblast lung primary pleural effusion metastasis; NCI-H2126 CCL-256 B lymphoblast lung primary pleural effusion metastasis; NCI-H1437 CRL-5872 B lymphoblast lung primary pleural effusion metastasis; NCI-H1437 CRL-5872 B lymphoblast lung primary pleural effusion metastasis; NCI-H1437 CRL-5872 B lymphoblast lung primary pleural effusion metastasis; NCI-H2122 CRL-5985 B lymphoblast lung primary mammary gland Hs 605.T CRL-7365* skin mammary gland Hs 606. CRL-7368* skin mammary gland Hs 606 CRL-7368* skin lung mammary gland Hs 606 CRL-7368* skin lung NCI-H1672 CRL-5886 B lymphoblast lung hoode metastasis; HCC1008 CRL-2320 B lymphoblast mammary gland Hs 574.T CRL-7345* skin mammary gland Hs 574.T CRL-7345* skin mammary gland Hs 578.T HTB-126 mammary gland lymph node metastasis; NCI-H1770 CRL-5893 B lymphoblast lung primary mammary gland HCC1185 CRL-2321 B lymphoblast mammary gland HCC1187 CRL-2321 B lymphoblast mammary gland HCC1187 CRL-2321 B lymphoblast mammary gland HCC1187 CRL-2322 B lymphoblast mammary gland HCC1187 CRL-2321 B lymphoblast mammary gland HCC1187 CRL-2340 B lymphoblast lung primary bone marrow metastasis; NCI-H2107 CRL-5983 B lymphoblast lung primary | lung NCI-H1395 CRL-5868 B lymphoblast NCI-BL1395 lymph node metastasis; NCI-H2009 CRL-5911 B lymphoblast NCI-BL2028 lung primary lymph node metastasis; NCI-H2087 CRL-5922 B lymphoblast NCI-BL2087 lung primary pleural effusion metastasis; NCI-H2126 CCL-256 B lymphoblast NCI-BL2126 lung primary pleural effusion metastasis; NCI-H2126 CCL-256 B lymphoblast NCI-BL2126 lung primary pleural effusion metastasis; NCI-H2126 CRL-5872 B lymphoblast NCI-BL2126 lung primary pleural effusion metastasis; NCI-H2122 CRL-5875 B lymphoblast NCI-BL2122 lung primary pleural effusion metastasis; NCI-H2122 CRL-5885 B lymphoblast NCI-BL2122 lung primary mammary gland Hs 742.T CRL-7482* skin Hs 605.Sk mammary gland Hs 605.T CRL-7368* skin Hs 605.Sk mammary gland Hs 606 CRL-7368* skin Hs 605.Sk lung NCI-H1672 CRL-5886 B lymphoblast NCI-BL1672 lymph node metastasis; HCC1008 CRL-2320 B lymphoblast NCI-BL1672 lymph node metastasis; HCC1008 CRL-2320 B lymphoblast HCC1097 BL mammary gland Hs 574.T CRL-7348* skin Hs 674.Sk mammary gland Hs 574.T CRL-5893 B lymphoblast HCC1097 BL mammary gland Hs 574.T CRL-5893 B lymphoblast HCC104 BL mammary gland Hs 574.T CRL-5893 B lymphoblast HCC1143 BL mammary gland HCC1143 CRL-2321 B lymphoblast HCC1143 BL mammary gland HCC1143 CRL-2321 B lymphoblast HCC1147 BL mammary gland HCC1143 CRL-2321 B lymphoblast HCC1147 BL mammary gland HCC1147 CRL-3231 B lymphoblast HCC1147 BL mammary gland HCC1147 CRL-3231 B lymphoblast HCC1147 BL mammary gland HCC1187 CRL-3234 B lymphoblast HCC11937 BL mammary gland HCC11937 CRL-3234 B lymphoblast HCC11937 BL mammary gland HCC11937 CRL-3240 B lymphoblast HCC11937 BL mammary gland HCC11937 CRL-3240 B lymphoblast HCC11937 BL mammary gland HCC1218 CRL-3240 B lymphoblast HCC11937 BL mammary gland HCC |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



Tumor/Normal Matched Cell Line Pairs

| Cancer Type | Tissue Source (Tumor) | Name | ATCC® No. | Tissue Source (Normal) | Name | ATCC® No. |
|-----------------------------------|--|-------------|-----------|------------------------------------|------------|-----------|
| Carcinoma; small cell lung cancer | pleural effusion metastasis; lung primary | NCI-H2171 | CRL-5929 | B lymphoblast | NCI-BL2171 | CRL-5969 |
| Carcinoma; small cell lung cancer | pleural effusion metastasis; lung primary | NCI-H128 | HTB-120 | B lymphoblast | NCI-BL128 | CRL-5947 |
| Carcinoma; transitional cell | ureter | Hs 789.T | CRL-7886* | skin | Hs 789.Sk | CRL-7518* |
| Melanoma | lung metastasis; skin primary | Hs 895.T | CRL-7637* | skin | Hs 895.Sk | CRL-7636* |
| Melanoma; malignant | skin | COLO 829 | CRL-1974 | B lymphoblast | COLO 829BL | CRL-1980 |
| Mesothelioma | pleural effusion metastasis; pleura primary | NCI-H2052 | CRL-5915 | B lymphoblast | NCI-BL2052 | CRL-5963 |
| Osteofication; heterophilic | bone | Hs 820.T | CRL-7552* | skin | Hs 820.Sk | CRL-7551* |
| Osteoma; benign osteoid | bone | Hs 919.T | CRL-7672* | skin | TE 353.Sk | CRL-7761* |
| Osteosarcoma | bone | Hs 704.T | CRL-7444* | skin | Hs 704.Sk | CRL-7443* |
| Osteosarcoma | bone | Hs 707(A).T | CRL-7448* | skin, connective tissue; keloid | KEL FIB | CRL-1762 |
| Osteosarcoma | bone | Hs 889.T | CRL-7626* | skin | Hs 889.Sk | CRL-7625* |
| Osteosarcoma | bone | Hs 890.T | CRL-7628* | skin | Hs 890.Sk | CRL-7627* |
| Osteosarcoma | lung metastasis; bone primary | Hs 860.T | CRL-7595* | skin | Hs 791.Sk | CRL-7519* |
| Osteosarcoma | lung metastasis; bone primary | Hs 888.T | CRL-7622* | lung | Hs888Lu | CCL-211 |
| Periostitis; granuloma | bone | Hs 709.T | CRL-7453* | skin | Hs 709.Sk | CRL-7452* |
| Sarcoma; giant cell | bone | Hs 821.T | CRL-7554* | skin | Hs 821.Sk | CRL-7553* |
| Sarcoma; giant cell | vertebral column | Hs 814.T | CRL-7547* | skin | Hs 814.Sk | CRL-7546* |
| Sarcoma; pagetoid | skin | Hs 925.T | CRL-7677* | skin | Hs 925.Sk | CRL-7676* |

Primary and Metastatic Cell Lines from the Same Individual

| Primary Cell Line | | | | Metastatic Cell Li | Metastatic Cell Line | | | |
|----------------------------|---------|-------------|-----------|--------------------|----------------------|-----------|--|--|
| Disease | Source | Name | ATCC No. | Metastatic Site | Name | ATCC No. | | |
| Adenocarcinoma; colorectal | colon | SW480 | CCL-228 | lymph node | SW620 | CCL-227 | | |
| Adenocarcinoma; gastric | stomach | RF-1 | CRL-1864 | ascites | RF-48 | CRL-1863 | | |
| Melanoma | skin | WM-115 | CRL-1675 | skin | WM-266-4 | CRL-1676 | | |
| Melanoma | skin | Hs 688(A).T | CRL-7425* | lymph node | Hs 688(B).T | CRL-7426* | | |



Stem Cells

ATCC established the Stem Cell Center in the year 2000 to support researchers in the growing field of stem cells. Today the Center diligently maintains and distributes one of the largest stem cell collections available — approximately 70 cell lines, including embryonic and somatic stem cells, embryonal carcinoma cells as well as mouse and human feeder cell lines. For more information visit the ATCC Stem Cell Center web pages at stemcells.atcc.org.

| Product name | Description | Uses | ATCC® No. | |
|----------------------|---|--|-----------|--|
| Human embryonic stem | cells | | | |
| BG01V | Variant of human embryonic stem cell line BG01 | BG01V is easier to grow than most human ES lines; ideal for start-up stem cell research, eligible for U.S. government and private funding. | SCRC-2002 | |
| Mouse embryonic stem | cells | | | |
| ES-C57BL/6 | Strain C57BL/6; wild type cell line derived from inbred C57B/6 | Germline-competent; complete genome sequenced and annotated; use with feeder cells C57BL/6 for genomic background consistency | SCRC-1002 | |
| ES-D3 GL | Strain 129S2/SvPas; wild type cell line derived from 129 sub-strain | Germline-competent | SCRC-1003 | |
| J1 | Strain 129S4/Jae; wild type cell line derived from 129 sub-strain | Germline-competent | SCRC-1010 | |
| R1 | Strain 129X1 x 129S1; wild type cell line derived from 129 sub-strain | Germline-competent | SCRC-1011 | |
| RW.4 | Strain 129X1 / SvJ; wild type cell line derived from 129 sub-strain | Germline-competent | SCRC-1018 | |
| R1/E | Strain 129X1 x 129S1; wild type cell line; sub-clone of R1 line | Germline-competent | SCRC-1036 | |
| 7AC5/EYFP | Strain 129X1 x 129S1; modified R1 line; constitutive YFP expression; puromycin-resistant | Germline-competent; recommended for gene targeting and transgenics | SCRC-1033 | |
| AINV15 | Strain 129P2/OlaHsd; rtTA and HPRT cell line for targeting of plox constructs | Modified in vitro line; recommended for gene targeting | SCRC-1029 | |
| G-Olig2 | Strain 129X1/SvJ; lineage-specific GFP expression | Modified in vitro line; useful for differentiation studies | SCRC-1037 | |
| CE-1 | Strain 129S2/SvPas; cassette exchange for double lox targeting; hygromycin-resistant | Modified in vitro line; useful for gene targeting; good for selection of transfected cells | SCRC-1038 | |
| CE-3 | Strain 129S2/SvPas; cassette exchange for double lox targeting; puromycin-resistant; constitutive GFP expression | Modified in vitro line; useful for gene targeting studies; good for selection of transfected cells | SCRC-1039 | |
| ES-D3 | Strain 129S4/Jae; pluripotent | In vitro line | CRL-1934 | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



Stem Cells

| roduct name | Description | Uses | ATCC® No. |
|------------------------|--|---|-------------|
| Human embryonal carcir | noma (EC) cells | | |
| NTERA-2 | Pluripotent line derived from a xenograft tumor of Tera-2 | Commonly-used reference standard for human ESC markers*; used routinely at ATCC | CRL-1973 |
| NCCIT | Teratocarcinoma; nullipotent; pluripotent | Use as positive or negative controls for ESC markers depending on assay | CRL-2073 |
| Tera-1 | Teratocarcinoma; nullipotent; | Use as positive or negative controls for ESC markers depending on assay | HTB-105 |
| Tera-2 | Teratocarcinoma; nullipotent; pluripotent | Use as positive or negative controls for ESC markers depending on assay | HTB-106 |
| Mouse embryonal carcin | oma (FC) cells | | |
| F9 | Strain 129; testicular teratoma; pluripotent | Useful for endoderm differentiation studies | CRL-1720 |
| NULLI-SCC1 | Strain 129; teratocarcinoma; nul- lipotent control | Line does not differentiate; use as nullipotent control | CRL-1566 |
| NFPE | Strain BALB/c; derived from NF-1 EC line | Useful for endoderm differentiation studies | CRL-2069 |
| P19 | Strain C3H/He; teratocarcinoma; pluripotent | Useful for neuronal (and possibly muscle) differentiation studies | CRL-1825 |
| Mouse progenitor cells | | | |
| SFME | Strain BALB/c; neural stem cells | Use for lineage-specific differentiation studies | CRL-9392 |
| EML Cell line, clone 1 | Strain BDFI; bone marrow; lympho- hematopoietic progenitor cell line | Use for lineage-specific differentiation studies | CRL-11691 |
| D1 ORL UVA | Strain BALB/c; bone marrow; multi- potent stromal precursor | Use for lineage-specific differentiation studies | CRL-12424 |
| Mouse Fibroblasts | | | |
| MEF (CF-1) IRR | Strain CF-1; CF-1 embryonic fibro- blasts, irradiated | Outbred, hardier line: supports mouse and human ESC cultures | SCRC-1040.1 |
| MEF (CF-1) MITC | Strain CF-1; CF-1 embryonic fibro- blasts, mitomycin-C treated | Outbred, hardier line: supports mouse and human ESC cultures | SCRC-1040.2 |
| MEF (CF-1) | Strain CF-1; CF-1 embryonic fibro- blasts | Use to grow feeder cells for human and mouse ESC cultures | SCRC-1040 |
| MEF (C57BL/6) IRR | Strain C57BL/6; C57BL/6 embryonic fibroblasts, irradiated | Supports mouse ESC cultures; ideal for use with SCRC- 1002 | SCRC-1008.1 |
| MEF (C57BL/6) MITC | Strain C57BL/6; C57BL/6 embryonic fibroblasts, mitomycin-C treated | Supports mouse ESC cultures; ideal for use with SCRC- 1002 | SCRC-1008.2 |
| MEF (C57BL/6) | Strain C57BL/6; C57BL/6 embryonic fibroblasts | Use to grow feeder cells for mouse ESC cultures; ideal for use with SCRC-1002 | SCRC-1008 |
| MEF (DR4) IRR | Strain DR4; DR4 embryonic fibroblasts, irradiated; resistant to commonly used concentrations of puromycin, hygromycin, G418, and 6-thioguanine | Supports mouse ESC cultures; good for antibiotic selection of transfected ESCs | SCRC-1045.1 |
| MEF (DR4) MITC | Strain DR4; DR4 embryonic fibroblasts, mitomycin-C treated; resistant to commonly used concentrations of puromycin, hygromycin, G418, and 6-thioguanine | Supports mouse ESC cultures: good for antibiotic selection of transfected ESCs | SCRC-1045.2 |
| MEF (DR4) | Strain DR4; DR4 embryonic fibroblasts; resistant to commonly used concentrations of puromycin, hygromycin, G418, and 6-thiogua- nine | Use to grow feeder cells for gene targeting with mouse ESC culture; good for antibiotic selection of transfected ESCs | SCRC-1045 |



Stem Cells

| irradiated Strain ICR; ICR embryonic fibroblasts, mitomycin-C treated MEF (ICR) Strain ICR; ICR embryonic fibroblasts, mitomycin-C treated MEF (ICR) Strain ICR; ICR embryonic fibroblasts Strain SIM; embryonic fibroblasts derived cell line STO IRR Strain SIM; STO embryonic fibroblasts Strain SIM; STO embryonic fibroblasts HEF-1 foreskin fibroblasts, irradiated Human Fibroblasts HFF-1 foreskin fibroblasts, mitomycin-C treated HFF-1 foreskin fibroblasts, newborn HFF-1 HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 foreskin fibroblasts HFF-2 foreskin fibroblasts HFF-2 foreskin fibroblasts HFF-3 foreskin fibroblasts HFF-1 WHFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 foreskin fibroblasts HFF-3 foreskin fibroblasts HFF-4 WHFF-1 WHFF-1 foreskin fibroblasts, mitomycin-C treated HFF-2 foreskin fibroblasts Use to grow feeder cells for human ESC culture SCRC-1041.2 Supports human ESC culture SCRC-1042.2 Support Sulture SCRC-1041.2 Support Sulture | Product name | Description | Uses | ATCC® No. |
|--|-----------------------|--|--|-------------|
| MEF (ICR) Strain ICR; ICR embryonic fibroblasts derived cell line STO Strain SIM; embryonic fibroblast- derived cell line STO IRR Strain SIM; STO embryonic fibro- blasts, irradiated Human Fibroblasts HFF-1 foreskin fibroblasts, irradiated HFF-1 foreskin fibroblasts, mitomy- cin-C treated HFF-2 foreskin fibroblasts, mitomy- cin-C treate | MEF (ICR) IRR | | Supports mouse and some human ESC culture | SCRC-1046.1 |
| STO Strain SIM; embryonic fibroblast- derived cell line STO IRR Strain SIM; STO embryonic fibro- blasts, irradiated Human Fibroblasts HFF-1 foreskin fibroblasts, mitomy- cin-C treated HFF-2 foreskin fibroblasts, mitomy- cin-C treated HFF-2 foreskin fibroblasts, mitomy- cin-C treated HFF-2 foreskin fibroblasts HFF-2 foreskin fibroblasts HFF-2 foreskin fibroblasts, mitomy- cin-C treated HFF-2 foreskin fibroblasts HFF-2 foreskin fibroblasts, mitomy- cin-C treated HFF-2 foreskin fibroblasts Supports human ESC culture SCRC-1041.2 Supports human ESC culture SCRC-1041.2 SUPPORTS human ESC culture SCRC-1041.2 SUPPORTS human ESC culture SCRC-1042.2 SUPPORTS human ESC cultur | MEF (ICR) MITC | | Supports mouse and some human ESC culture | SCRC-1046.2 |
| STO IRR Strain SIM; STO embryonic fibroblasts, irradiated Human Fibroblasts HeFF-1 foreskin fibroblasts, irradiated Supports human ESC culture SCRC-1041.1 HFF-1 MITC HFF-1 foreskin fibroblasts, mitomycin-C treated HFF-1 foreskin fibroblasts, mewborn HFF-2 MITC HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 MITC HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 MITC HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 MITC HFF-2 foreskin fibroblasts witomycin-C treated HFF-3 MITC HFF-2 foreskin fibroblasts witomycin-C treated HFF-2 MITC HFF-2 foreskin fibroblasts Supports human ESC culture SCRC-1041.2 Supports human ESC culture SCRC-1042.2 Use to grow feeder cells for human ESC culture SCRC-1042.2 Support Cells 3T3-Swiss albino Strain: Swiss albino; mouse embryonic fibroblast-derived cell line 3T3-Swiss albino, IRR Strain: Swiss albino; mouse attain swiss albino; mouse att | MEF (ICR) | Strain ICR; ICR embryonic fibroblasts | 5 | SCRC-1046 |
| Human Fibroblasts HFF-1 foreskin fibroblasts, irradiated HFF-1 foreskin fibroblasts, mitomy-cin-C treated HFF-1 foreskin fibroblasts, mitomy-cin-C treated HFF-1 foreskin fibroblasts, newborn HFF-1 foreskin fibroblasts, newborn HFF-1 foreskin fibroblasts, newborn HFF-2 foreskin fibroblasts, mitomy-cin-C treated HFF-2 foreskin fibroblasts HFF-2 foreskin fibroblasts Use to grow feeder cells for human ESC culture SCRC-1041.2 Supports human ESC culture SCRC-1042.2 Support cells ST3-Swiss albino Strain: Swiss albino; mouse embry-onic fibroblasts Strain: Swiss albino; mouse aT3-Swiss albino, mouse at3-Swiss albino; mouse at3-Swiss albino embryonic fibroblasts, irradiated OP9 Strain: (C57Bl/6 x C3H); mouse bone marrow; stroma C166 Strain: (MMRI/GSF x CD-1); mouse yolk sac; endothelial C166-GFP Strain: (MMRI/GSF x CD-1); mouse yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture SCRC-1041.2 Supports human ESC culture Supports h | STO | | Use to grow feeder cells for mouse ESC culture | CRL-1503 |
| HFF-1 IRR HFF-1 foreskin fibroblasts, irradiated HFF-1 MITC HFF-1 foreskin fibroblasts, mitomycin-C treated HFF-1 foreskin fibroblasts, mitomycin-C treated HFF-1 foreskin fibroblasts, newborn HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 MITC HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 MITC HFF-2 foreskin fibroblasts witomycin-C treated HFF-2 MITC HFF-2 foreskin fibroblasts Wiss albino; mouse embrycin-C treated HFF-2 hff-2 with salbino; mouse embrycin-C treated Wiss albino; mouse embrycin-C treated Wiss albino with salbino; mouse embrycinic fibroblasts wiss albino; mouse embrycinic fibroblast-derived cell line Wiss albino, IRR Strain: Swiss albino; mouse 3T3-Swiss albino, IRR Strain: Swiss albino; mouse 3T3-Swiss albino embryonic fibroblasts, irradiated Wiss albino; mouse bone marrow; stroma Wiss albino; mouse bone wiss albino; mouse wiss albino; wiss albino; mouse wis | STO IRR | | Supports mouse ESC culture | 56-X |
| HFF-1 MITC HFF-1 foreskin fibroblasts, mitomycin-C treated HFF-1 HFF-1 foreskin fibroblasts, newborn HFF-2 foreskin fibroblasts, newborn HFF-2 MITC HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 foreskin fibroblasts HFF-2 foreskin fibroblasts Use to grow feeder cells for human ESC culture SCRC-1042.2 Support Cells Strain: Swiss albino; mouse embryonic fibroblast-derived cell line Strain: Swiss albino; mouse at 373-Swiss albino, lRR Strain: Swiss albino; mouse at 373-Swiss albino; mouse at 373-Swiss albino embryonic fibroblasts, irradiated OP9 Strain: (C57BI/6 x C3H); mouse bone marrow; stroma C166 Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial C166-GFP Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture CRL-2581 Use for hematopoietic cell culture CRL-2583 CRC-1041.2 Supports human ESC culture SCRC-1042.2 Use for hematopoietic cell culture Use for hematopoietic cell culture CRL-2749 Use for hematopoietic cell culture CRL-2581 Volume of the matopoietic cell culture CRL-2583 Volume of the matopoietic cell culture CRL-2583 Volume of the matopoietic cell culture CRL-2583 | Human Fibroblasts | | | |
| cin-C treated HFF-1 HFF-1 foreskin fibroblasts, newborn Use to grow feeder cells for human ESC culture SCRC-1041 HFF-2 MITC HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 HFF-2 HFF-2 foreskin fibroblasts Use to grow feeder cells for human ESC culture SCRC-1042.2 Support Cells 3T3-Swiss albino Strain: Swiss albino; mouse embryonic fibroblast-derived cell line 3T3-Swiss albino, IRR Strain: Swiss albino; mouse 3T3-Swiss albino embryonic fibroblasts, irradiated OP9 Strain: (C57BI/6 x C3H); mouse bone marrow; stroma C166 Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial C166-GFP Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture SCRC-1007 | HFF-1 IRR | HFF-1 foreskin fibroblasts, irradiated | Supports human ESC culture | SCRC-1041.1 |
| HFF-2 MITC HFF-2 foreskin fibroblasts, mitomycin-C treated HFF-2 HFF-2 foreskin fibroblasts HFF-2 foreskin fibroblasts Use to grow feeder cells for human ESC culture SCRC-1042.2 Support Cells 3T3-Swiss albino Strain: Swiss albino; mouse embryonic fibroblasts, irradiated OP9 Strain: (C57BI/6 x C3H); mouse bone marrow; stroma C166 Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use to grow feeder cells for human ESC culture SCRC-1042.2 Supports human ESC culture SCRC-1042.2 Supports human ESC culture SCRC-1042.2 Supports human ESC culture SCRC-1042.2 Use for hematopoietic cell culture Use for hematopoietic cell culture CRL-92 Use for hematopoietic cell culture CRL-2749 Use for hematopoietic cell culture CRL-2581 Use for hematopoietic cell culture CRL-2583 | HFF-1 MITC | | Supports human ESC culture | SCRC-1041.2 |
| cin-C treated HFF-2 HFF-2 foreskin fibroblasts Use to grow feeder cells for human ESC culture SCRC-1042 Support Cells 3T3-Swiss albino Strain: Swiss albino; mouse embryonic fibroblast-derived cell line 3T3-Swiss albino, IRR Strain: Swiss albino; mouse 3T3-Swiss albino embryonic fibroblasts, irradiated OP9 Strain: (C57BI/6 x C3H); mouse bone marrow; stroma C166 Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial C166-GFP Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture CRL-2581 Use for hematopoietic cell culture CRL-2583 | HFF-1 | HFF-1 foreskin fibroblasts, newborn | Use to grow feeder cells for human ESC culture | SCRC-1041 |
| Support Cells 3T3-Swiss albino Strain: Swiss albino; mouse embry- onic fibroblast-derived cell line 3T3-Swiss albino, IRR Strain: Swiss albino; mouse 3T3- Swiss albino embryonic fibroblasts, irradiated OP9 Strain: (C57BI/6 x C3H); mouse bone marrow; stroma C166 Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial C166-GFP Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture CRL-2749 Use for hematopoietic cell culture CRL-2581 Use for hematopoietic cell culture CRL-2583 | HFF-2 MITC | | Supports human ESC culture | SCRC-1042.2 |
| Strain: Swiss albino, IRR Strain: Swiss albino; mouse embry- onic fibroblast-derived cell line 3T3-Swiss albino, IRR Strain: Swiss albino; mouse 3T3- Swiss albino embryonic fibroblasts, irradiated OP9 Strain: (C57BI/6 x C3H); mouse bone marrow; stroma C166 Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial C166-GFP Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture CRL-92 Use for hematopoietic cell culture CRL-2749 Use for hematopoietic cell culture CRL-2749 Use for hematopoietic cell culture CRL-2581 Use for hematopoietic cell culture CRL-2583 | HFF-2 | HFF-2 foreskin fibroblasts | Use to grow feeder cells for human ESC culture | SCRC-1042 |
| onic fibroblast-derived cell line 3T3-Swiss albino, IRR Strain: Swiss albino; mouse 3T3- Swiss albino embryonic fibroblasts, irradiated OP9 Strain: (C57BI/6 x C3H); mouse bone marrow; stroma C166 Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial C166-GFP Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture CRL-2581 Use for hematopoietic cell culture CRL-2583 Use for hematopoietic cell culture CRL-2583 | Support Cells | | | |
| Swiss albino embryonic fibroblasts, irradiated OP9 Strain: (C57BI/6 x C3H); mouse bone marrow; stroma C166 Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial C166-GFP Strain: (NMRI/GSF x CD-1); mouse yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture CRL-2581 | 3T3-Swiss albino | | Use for hematopoietic cell culture | CRL-92 |
| marrow; stroma C166 Strain: (NMRI/GSF x CD-1); mouse Use for hematopoietic cell culture CRL-2581 yolk sac; endothelial C166-GFP Strain: (NMRI/GSF x CD-1); mouse Use for hematopoietic cell culture CRL-2583 yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture SCRC-1007 | 3T3-Swiss albino, IRR | Swiss albino embryonic fibroblasts, | Use for hematopoietic cell culture | 48-X |
| yolk sac; endothelial C166-GFP Strain: (NMRI/GSF x CD-1); mouse Use for hematopoietic cell culture CRL-2583 yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture SCRC-1007 | OP9 | | Use for hematopoietic cell culture | CRL-2749 |
| yolk sac; endothelial; GFP expressing AFT024 Mouse embryonic liver Use for hematopoietic cell culture SCRC-1007 | C166 | * | Use for hematopoietic cell culture | CRL-2581 |
| , | C166-GFP | , ,, | Use for hematopoietic cell culture | CRL-2583 |
| AFT024 IRR AFT024 irradiated Use for hematopoietic cell culture SCRC-1007.1 | AFT024 | Mouse embryonic liver | Use for hematopoietic cell culture | SCRC-1007 |
| | AFT024 IRR | AFT024 irradiated | Use for hematopoietic cell culture | SCRC-1007.1 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



Cell lines have many applications as phenotypic or process models,

tools for production or expression, and dozens of other utilities. This

index represents a sample of published applications for ATCC cell lines.

References can be found in each cell line description in the cell biology

section of the ATCC online catalog.

| Application | Species | Name | ATCC® No. |
|---|------------------------|-------------------------|------------------------|
| Transfected and Expressing | | | |
| CTLA4lq fusion protein | hamster, Chinese | CTLA4 lg-24 | CRL-10762 [†] |
| Granulocyte colony stimulating factor (G-CSF) | chicken | Con A-C1-VICK | CRL-12135 [†] |
| Granulocyte colony stimulating factor (G-CSF) | chicken | ConA-B1-VICK | CRL-12357 [†] |
| HER2/neu | mouse | B104-1-1 | CRL-1887 |
| HER2/neu | mouse | DHFR-G8 | CRL-1915 |
| Human 5HT1D receptor | mouse | Ltk-11 | CRL-10422 [†] |
| Human 5HT2 receptor | mouse | L-NGC-5HT2 | CRL-10287 [†] |
| Human adrenergic alpha1B receptor | mouse | L-α-1b | CRL-11139 [†] |
| Human CD36 | hamster, Chinese | CHO-CD36 | CRL-2092 |
| Human colony stimulating factor (M-CSF) | hamster, Chinese | 5/9 m α3-18 | CRL-10154 [†] |
| Human CR1 | hamster, Chinese | 35.6 | CRL-10052 [†] |
| Human dopamine D2 receptor | mouse | A9 L hD2 S.C. 18 | CRL-10225 [†] |
| Human erythropoietin | hamster, Syrian golden | BHK21-pcDNA3.1-HC | CRL-13001 [†] |
| Human gamma interferon | hamster, Chinese | HIIF-D | CRL-8200 [†] |
| Human glycosylation inhibiting factor (GIF) | human/human | 31E9 | HB-11052 [†] |
| Human ICAM-1 | hamster, Chinese | CHO-ICAM-1 | CRL-2093 |
| Human pluripotent hematopoietic colony- | human | 1A6 | CRL-2742 |
| stimulating factor (p-CSF) | | | |
| Human tissue plasminogen activator (t-PA) | hamster, Chinese | CHO 1-15 ₅₀₀ | CRL-9606 [†] |
| IgE binding factor | rat (T cell)/mouse | 23B6 | HB-8521 [†] |
| (lymphoma) | | | |
| Mouse c- <i>myc</i> protein | hamster, Chinese | DUKX B1 | CRL-9010 [†] |
| Neuroleukin | hamster, Chinese | CHO-1C6 | CRL-1793 |
| P element transposase | Drosophila | L-2/M δ 2-3 | CRL-10191 [†] |
| p97 melanoma associated antigen | mouse | MTKP 97-12 | CRL-8985 [†] |
| Rat GABAA receptor | human | WSS-1 | CRL-2029 |
| Rat m1 muscarinic acetylcholine receptor | hamster, Chinese | M1WT2 | CRL-1984 |
| Rat m1 muscarinic acetylcholine receptor | hamster, Chinese | M1WT3 | CRL-1985 |
| Rat m1 muscarinic acetylcholine receptor | hamster, Chinese | M1WT5 | CRL-1986 |
| Rat m3 muscarinic acetylcholine receptor | hamster, Chinese | M3WT4 | CRL-1981 |
| Rat m3 muscarinic acetylcholine receptor | hamster, Chinese | M3WT5 | CRL-1982 |
| Rat m3 muscarinic acetylcholine receptor | hamster, Chinese | M3WT8 | CRL-1983 |
| Soluble CHE-Fc | human | 293/CHE-Fc | CRL-2368 |
| Soluble suppression factor (SSF) | human (T cell)/human | HM2 | HB-8587 [†] |
| | (T cell leukemia) | | |
| Wnt-3A conditioned medium | mouse | L Wnt-3A | CRL-2647 |
| Control for L Wnt-3A cells | mouse | L Cells | CRL-2648 |
| Retroviral Packaging Lines | | | |
| Amphotropic retroviral packaging line | dog | DAN | CRL-2130 |
| Amphotropic retroviral packaging line | human | Bing | CRL-11554 [†] |
| Amphotropic retroviral packaging line | human | 2A | CRL-12013 [†] |
| Amphotropic retroviral packaging line | human | ProPakA.6 | CRL-12006 [†] |
| Amphotropic retroviral packaging line | human | ProPak-A.52 Clone #52 | CRL-12479 [†] |
| Amphotropic retroviral packaging line | mouse | PT67 | CRL-12284 [†] |
| Amphotropic retroviral packaging line | mouse | PA317 LXSN 16E6E7 | CRL-2203 |
| Amphotropic retroviral packaging line | mouse | PA317 LXSN 16E6 | CRL-2204 |
| | | | <u> </u> |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.



| Application | Species | Name | ATCC® No. |
|--|--------------------------------------|-----------------------|------------------------------------|
| Amphotropic retroviral packaging line | mouse | PA317 LXSN 16E7 | CRL-2205 |
| Amphotropic retroviral packaging line | mouse | PA317 LXSN 6E6 | CRL-2205 |
| Amphotropic retroviral packaging line | mouse | PA317 LXSN 6E7 | CRL-2207 |
| Amphotropic retroviral packaging line Amphotropic retroviral packaging line | | PA317 LA3N 0E7 | CRL-9078 [†] |
| Amphotropic retroviral packaging line Amphotropic retroviral packaging line | mouse mouse | GP+envAM-12 | CRL-96/1 [†] |
| Ecotropic retroviral packaging line | human | BOSC 23 | CRL-11270† |
| | | GP+E-86 | CRL-9642 [†] |
| Ecotropic retroviral packaging line | mouse | | |
| MoMuLV retroviral packaging line | mouse | Wgd5 | CRL-1817 |
| Polytropic retroviral packaging cell line | human | HP | CRL-12012 [†] |
| Retroviral packaging line | dog | DSDh | CRL-2131 |
| Retroviral packaging line | mouse | PG13 | CRL-10686 [†] |
| Xenotropic retroviral packaging cell line | human | HX | CRL-12011 [†] |
| Xenotropic retroviral packaging line | human | ProPak-X.36 | CRL-12007 [†] |
| Recombinant Retroviral Expression | | | |
| Amphotropic control retrovirus; g418 resistant | mouse | PA317 LXSN | CRL-2202 |
| Retrovirus containing adenovirus 12S E1A gene | mouse | Psi2 12S6 | CRL-1808 |
| Retrovirus containing adenovirus 13S E1A gene | mouse | Psi2 13s1 | CRL-1809 |
| Retrovirus containing beta galactosidase gene | mouse | CRE BAG 2 | CRL-1858 |
| Retrovirus containing beta galactosidase gene | mouse | Ψ 2 BAG α | CRL-9560 [†] |
| Retrovirus containing human alkaline phosphatase gene | mouse | ψ 2 DAP | CRL-1949 |
| Retrovirus containing human cyclin E-L gene | mouse | PA317 cyclin E-L | CRL-2187 |
| | mouse | | |
| Retrovirus containing human cyclin E-S gene | mouse | PA317 cyclin E-S | CRL-2188 |
| Retrovirus containing vHa-ras oncogene | mouse | Raszip 6 | CRL-1917 |
| Retrovirus with a neomycin resistant gene | mouse | PG13/LN c8 | CRL-10685 [†] |
| SNV helper virus | dog | DSN | CRL-9939 [†] |
| Genetic Defects | | | |
| Defective in nucleotide excision repair | hamster, Chinese | UV41 | CRL-1860 |
| Defective in nucleotide excision repair | hamster, Chinese | UV20 | CRL-1862 |
| Defective in nucleotide excision repair | hamster, Chinese | UV5 | CRL-1865 |
| Defective in nucleotide excision repair | hamster, Chinese | UV24 | CRL-1866 |
| Defective in nucleotide excision repair | hamster, Chinese | UV135 | CRL-1867 |
| Defective in single strand break repair | hamster, Chinese | EM9 | CRL-1861 |
| Deficient for Src, Yes, and Fyn; immortalized with SV40 large T antigen | mouse | SYF | CRL-2459 |
| Deficient for Yes and Fyn; immortalized with | mouse | Src++ | CRL-2497 |
| SV40 large T antigen Deficient for Yes and Fyn; immortalized with | | CVF C | CDI 2400 |
| Deficient for Yes and Fyn; immortalized with SV40 large T antigen | mouse | SYF + c-Src | CRL-2498 |
| Deficient in dihydrofolate reductase | hamster, Chinese | CHO/dhFr | CRL-9096 [†] |
| Galactosyltransferase I deficient | hamster, Chinese | pgsB-618 | CRL-2241 |
| Galactosyltransferase I deficient | hamster, Chinese | pgsB-650 | CRL-2243 |
| Heparin sulfate deficient | hamster, Chinese | pgsD-677 | CRL-2244 |
| Heparin sulfate N-sulfotransferase deficient | hamster, Chinese | pgsE-606 | CRL-2246 |
| Ku autoantigen mutant | hamster, Chinese | xrs5 | CRL-2348 |
| Lacks GlcNAc glycosyl transferase function | hamster, Chinese | Lec1 | CRL-2346 CRL-1735 |
| Methotrexate resistant | hamster, Chinese | LA 3-5 | CRL-1/35 CRL-10101 [†] |
| Proline auxotroph | hamster, Chinese | Pro ⁻ 5 | CRL-1781 |
| Reduced transport of CMP-sialic acid into Golgi | hamster, Chinese | | CRL-1781 CRL-1736 |
| | <u> </u> | Lec2 | |
| Reduced transport of UDP-galactose into Golgi | hamster, Chinese | Lec8 | CRL-1737 |
| Sulfate transporter deficient Xylosyltransferase I deficient | hamster, Chinese hamster, Chinese | pgsC-605 pgsA-745 | CRL-2245 CRL-2242 |
| Ayiosyidalisielase i delicielit | namster, Chinese | рузн-743 | CNL-2242 |
| Signal Transduction Model Systems | | | |
| Apoptosis | | 111.40 | CDL 0440 |
| Brain; glioblastoma; p53+, p16-, p14ARF- | human | LN-18 | CRL-2610 |
| Brain; glioblastoma; p53+, p16-, p14ARF- | human | LN-229 | CRL-2611 |
| Colon; carcinoma; negligible p53 expression | human | RKO-E6 | CRL-2578 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Application | Species | Name | ATCC® No. |
|---|------------------------|--------------------|------------------------|
| Colon; carcinoma; overexpression of GADD4 | human | RKO-AS45-1 | CRL-2579 |
| Colon; Carcinoma; overexpression of GADD4 | numan | RKU-A545-1 | CRL-25/9 |
| Colon; carcinoma; control for RKO-E6 and RKO-AS45-1 cell lines | human | RKO | CRL-2577 |
| Embryo; null for cytochrome c | mouse | Cyt c-/- | CRL-2613 |
| Pituitary; nonfunctioning plurihormonal adenoma | human | HP75 | CRL-2506 |
| T lymphocyte; caspase-8 mutant | human | 19.2 | CRL-2571 |
| T lymphocyte; FADD mutant | human | I 2.1 | CRL-2572 |
| T lymphocyte; control for I 9.2 and I 2.1 | human | A3 | CRL-2570 |
| IL-3 signaling pathway | | | |
| Bone marrow; erythroblast | human | TF-1 | CRL-2003 |
| Bone marrow; erythroblast; control cell line for TF-1 | human | TF-1a | CRL-2451 |
| Integrin signaling | | | |
| Embryo; null for both FAK and p53 | mouse | FAK-/- | CRL-2644 |
| Embryo; positive for FAK but null for p53 | mouse | FAK+/+ | CRL-2645 |
| T cell receptor | | | |
| T lymphocyte; PLC-gamma1 negative | human | J.γ1 | CRL-2678 |
| T lymphocyte; transfected with PLC-gamma1 | human | J.γ1.WT | CRL-2679 |
| expression vector; control for J.γ1 cells | | - | |
| T lymphocyte; transfected with ZAP-70 expression vector; control for P116 cells | human | P116.cl39 | CRL-2677 |
| T lymphocyte; ZAP-70 negative; model for T cell | human | P116 | CRL-2676 |
| receptor signaling | | | |
| | | | |
| Transfection Hosts | | | |
| Kidney; highly transfective | human | 293T/17 | CRL-11268 [†] |
| Liver; hepatocellular carcinoma; transfected with | human | HEP G2/2.2.1 | CRL-11997 [†] |
| a CYP7 minigene/luciferase construct | | | |
| Tumor, adenovirus 12 induced; transfection host; | hamster, Syrian golden | MCB3901 | CRL-9595 [†] |
| exogenous gene expression | | | |
| | | | |
| Assay Systems | | | |
| Androgen agonist/antagonist; luciferase responsive | human | MDA-kb2 | CRL-2713 |
| Carcinogens and mutagens | human | MCL-5 | CRL-10575 [†] |
| Carcinogens and mutagens | human | AHH-1 | CRL-8146 [†] |
| Drug resistance in ovarian cancer | human | NIH:OVCAR-3 | HTB-161 |
| Models | | | |
| Low density lipoprotein receptor-related protein (LF | PP) model | | |
| Embryo; SV40 transformed | mouse | MEF-1 | CRL-2214 |
| Embryo; LRP deficient | mouse | PEA 10 | CRL-2215 |
| Embryo; LRP deficient | mouse | PEA 13 | CRL-2216 |
| Microvascular endothelial cell model | mouse | 1 11 11 11 | CITE 2210 |
| Hemangioendothelioma | mouse | EOMA | CRL-2586 |
| Hemangioendothelioma; expresses GFP | mouse | EOMA-GFP | CRL-2587 |
| Cre-Lox recombination model | mouse | LOWIN GIT | CIL 250/ |
| Embryo; SV40 large T antigen transfected | mouse | MB19tsA, clone 2B2 | CRL-2308 |
| Control for MBI9tsA, clone 2B2 | mouse | MB16tsA, clone 1B5 | CRL-2307 |
| Metastatic tumor model | | moroto, gelone 100 | CIL 2507 |
| Mammary gland tumor | mouse | 4T1 | CRL-2539 |
| DNA damage recognition and repair | | | |
| Brain, glial cell; malignant glioblastoma | human | M059K | CRL-2365 |
| Brain, glial cell; malignant glioblastoma | human | M059J | CRL-2366 |
| In vivo glioma models | | | |
| Brain; gliosarcoma; expresses beta galactosidase | rat | C6/LacZ | CRL-2199 |
| Brain; gliosarcoma; expresses beta galactosidase | rat | 9L/lacZ | CRL-2200 |
| Brain; gliosarcoma; expresses beta galactosidase | rat | C6/lacZ7 | CRL-2303 |
| Brain; undifferentiated malignant glioma | rat; fetal | F98 | CRL-2397 |
| Brain; undifferentiated malignant glioma | rat; fetal | RG2 | CRL-2433 |
| Immunotherapy protocols | , | | |
| Ascites; malignant fibrosarcoma; dibenzanthracene | mouse | Sal | CRL-2543 |
| , | | | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Application | Species | Name | ATCC® No. |
|---|----------------|----------------------------------|-------------------------|
| nduced | | | |
| Tolon; carcinoma | mouse | CT26.WT | CRL-2638 |
| Colon; carcinoma | mouse | CT26.CL25 | CRL-2639 |
| 201011, carellionia | mouse | C120.C223 | CILE 2007 |
| eeder Layer Cell Lines | | 116 - | CD1 44000± |
| Bone marrow; stroma; HPV-16 E6/E7 transformed | human | HS-5 | CRL-11882 [†] |
| Mammary gland tumor | rat | LA7 | CRL-2283 |
| Embryo | mouse | 3T3-Swiss albino | CCL-92 |
| ung Embryo | human mouse | MRC-5 STO | CCL-171 CRL-1503 |
| indiyo | mouse | 310 | CILE 1303 |
| Hybridoma Fusion Partners | | | CDL 0400± |
| 3 cell | human | 36 | CRL-8193 [†] |
| 3 cell | human | A6 | CRL-8192 [†] |
| 3 cell | human | F3B6 | HB-8785 [†] |
| 3 cell | human | GK-5 | CRL-1834 |
| 3 cell | human | HuNS1 | CRL-8644 [†] |
| 3 cell | human | K6H6/B5 | CRL-1823 |
| 3 cell | human | KR-12 | CRL-8658 [†] |
| 3 cell | human | LTR228 | HB-8502 [†] |
| 3 cell | human | MC/CAR | CRL-8083 [†] |
| 3 cell | human | MC/CAR-Z2 | CRL-8147 [†] |
| 3 cell | human | SHM-D33 | CRL-1668 |
| 3 cell | human | SKO-007 | CRL-8033-1 [†] |
| 3 cell | human | SKO-007 [clone J3] | CRL-8033-2 [†] |
| 3 cell | human | WI-L2-729HF2 | CRL-8062 [†] |
| 3 cell | human | WIL2-NS | CRL-8155 [†] |
| 3 cell | human | WIL2-S | CRL-8885 [†] |
| 3 cell | mouse | 45.6.TG1.7 | CRL-1608 |
| 3 cell | mouse | FO | CRL-1646 |
| B cell | mouse | FOX-NY | CRL-1732 |
| 3 cell | mouse | P3/NSI/1-Ag4-1 (NS-1) | TIB-18 |
| 3 cell | mouse | P3X63Ag8 | TIB-9 |
| 3 cell | mouse | P3X63Ag8.653 | CRL-1580 |
| 3 cell | mouse | P3X63Ag8U.1 | CRL-1597 |
| 3 cell | mouse | RPC5.4 | TIB-12 |
| 3 cell | mouse | S194/5.XXO.BU.1 | TIB-20 |
| 3 cell | mouse | Sp2/01-Ag | CRL-8006 [†] |
| 3 cell | mouse | Sp2/0-Ag14 | CRL-1581 |
| 3 cell | mouse | Sp2/0-Ag14 | CRL-8287 [†] |
| 3 cell | mouse | Sp2/mIL-6 | CRL-2016 |
| 3 cell | rat | Y3-Ag 1.2.3 | CRL-1631 |
| 3 cell | rat | YB2/0 | CRL-1662 |
| Γ cell | human | CEM-CM3 | TIB-195 |
| Γ cell | mouse | AKR1.G.1.OVA ^R .1.26 | TIB-232 |
| Γ cell | mouse | BW5147.G.1.4 | TIB-48 |
| Γ cell | mouse | BW5147.G.1.4.OUA ^R .1 | CRL-1588 |
| Γ cell | mouse | EL4.BU | TIB-40 |
| 「cell | rat | C58(NT)D.1.G.OVA ^R .1 | TIB-236 |
| Factor Assay Systems | | | |
| Ciliary neurotrophic factor (CNTF) | human | TF-1.CN5a.1 | CRL-2512 |
| Colony stimulating factor (CSF) | human | KG-1 | CCL-246 |
| Control for KG-1, does not respond to CSF | human | KG-1a | CCL-246.1 |
| Fibroblast growth factor (FGF) | bovine | FBHE | CRL-1395 |
| Fibroblast growth factor (FGF) | | SR-4987 | CRL-1395 |
| | mouse | | |
| Human bone morphogenetic protein-2 (rhBMP-2) L-1 | mouse | W-20-17 A375.S2 | CRL-2623 CRL-1872 |
| | human | A3/3.32 | CRL-10/2 |
| | mausa | D10 C / 1 | TID 224 |
| L-1 L-1 L-2 and IL-4 (BSF-1) | mouse mouse | D10.G4.1 HT-2 clone A5E | TIB-224 CRL-1841 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| | Starting Phenotye | Ending Phenotype | Tissue/Disease | Name | ATCC® No. |
|-------------------------|---|---|---|------------------------|--|
| Differentiati | ng | | | | |
| Bone | | | | | |
| mouse | preosteoblast | osteoblast | bone, calvaria | MC3T3-E1 Subclone 4 | CRL-2593 |
| mouse | preosteoblast | osteoblast | bone, calvaria | MC3T3-E1 Subclone 14 | CRL-2594 |
| mouse | preosteoblast | control for MC3T3-E1 | bone, calvaria | MC3T3-E1 Subclone 24 | CRL-2595 |
| | ' | Subclones 4 and 14 | | | |
| mouse | preosteoblast | control for MC3T3-E1 Subclones 4 and 14 | bone, calvaria | MC3T3-E1 Subclone 30 | CRL-2596 |
| numan | preosteoblast; SV40 large T antigen transfect | osteoblast ed | bone | hFOB 1.19 | CRL-11372 [†] |
| mouse | stromal precursor; multipotent | osteocytes, chondrocytes, and adipocytes | bone marrow | D1 ORL UVA | CRL-12424 [†] |
| mouse | osteoblast | adipocyte | bone marrow | 7F2 | CRL-12557 [†] |
| Breast | | L X | | | |
| numan | malignant breast tumor cells | mature breast cell phenotype | adenocarcinoma; mammary gland | AU565 | CRL-2351 |
| Endothelial | | | | | |
| mouse | endothelial | endothelial cell differentiation | yolk sac | C166 | CRL-2581 |
| nouse | endothelial | endothelial cell differentiation | yolk sac | C166-GFP | CRL-2583 |
| mouse | testicular teratoma | parietal endoderm | embryonal carcinoma | F9 | CRL-1720 |
| Epithelial | | | , | | |
| numan | bronchus; viral immortalized | squamous differentiation | lung | BEAS-2B | CRL-9609 [†] |
| human | colon epithelium | enterocytic differentiation; expresses etinoic acid binding proteins I and II; keratin positive | colon | Caco-2 | HTB-37 |
| mouse | hepatocyte, tsSV-40 immortalized | various phenotypes; induction of liver transcription factor; increase in albumin mRNA | liver | H2.35 | CRL-1995 |
| rat | lung epithelium | squamous epithelium (nonkeratinized) | lung | RL-65 | CRL-10354 [†] |
| Hematopoie | tic | (Horikeratiinizea) | | | |
| numan | promyelocyte | granulocyte, monocyte, or macrophage | acute promyelocytic leukemia | HL-60 | CCL-240 |
| human | histiocyte/monocyte | macrophage | histiocytic lymphoma | U-937 | CRL-1593.2 |
| numan | erythroblast | macrophage-like | erythroleukemia, bone | TF-1 | CRL-2003 |
| | c., o b | mac.op.iage inte | marrow | | C.12 2000 |
| numan | monoblast | macrophage-like | peripheral blood | GDM-1 | CRL-2627 |
| numan | erythroblast | macrophage-like | bone marrow; erythro- leukemia | HEL 92.1.7 | TIB-180 |
| human | monocyte | macrophage | acute monocytic | THP-1 | TIB-202 |
| mouse | erythroblast | hemoglobin synthesis, erythroid differentiation | leukemia spleen, leukemia | BB88 | TIB-55 |
| mouse | erythroblast | hemoglobin synthesis, | spleen, leukemia | D1B | TIB-56 |
| mouse | neutrophil progenitor | erythroid differentiation neutrophil | bone marrow Clone 2.1 | MPRO Cell Line, | CRL-11422 [†] |
| mouse | lymphohematopoietic | B-lymphocyte, erythrocyte, | bone marrow | EML Cell Line, Clone 1 | CRL-11691 [†] |
| | stem cell | neutrophil, macrophage, mast cell, megakaryocyte | | | |
| Muscle | | , J , , , | | | |
| mouse | fibroblast | myoblast | embryo | C3H/10T1/2, Clone 8 | CCL-226 |
| Veural | | , | . , . | | |
| | fibroblast | neurons | embryonal carcinoma | NTERA-2 cl.D1 | CRL-1973 |
| | | | | | |
| human | teratocarcinoma | neural and glial-like cells | embryonal carcinoma | (NT2/D1) P19 | CRL-1825 |
| human mouse | teratocarcinoma fibroblast | neural and glial-like cells | embryonal carcinoma embryo | P19 | CRL-1825 CRL-9391 [†] |
| mouse mouse mouse | teratocarcinoma fibroblast neural stem cell | neural and glial-like cells astrocyte astrocyte | embryonal carcinoma embryo embryo | | CRL-1825 CRL-9391 [†] CRL-9392 [†] |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No.CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



Neurobiology

ATCC cells for neurobiology include tumor and normal cells (from

human and other species) and hybridomas whose monoclonal antibod-

ies target neural proteins. For more information on a cell line, see the

main list starting on page 30 or use the catalogue number to find the

entry in the cell biology section of the online catalog.

| Species | Tissue Source | Cell Type | Appearance | Name | ATCC® No |
|---------------|--|----------------|--------------------|------------|------------------------|
| | | | | | |
| Glioma cells | | | | | |
| human | brain | astroglia | fibroblast | SVG p12 | CRL-8621* |
| human | brain; astrocytoma | | astrocytic | CCF-STTG1 | CRL-1718 |
| human | brain; astrocytoma | | fibroblast | SW 1088 | HTB-12 |
| human | brain; astrocytoma | | fibroblast | SW 1783 | HTB-13 |
| human | brain; cerebrum; right temporal lobe; | | epithelial | LN-18 | CRL-2610 |
| | glioblastoma; glioma | | | | |
| human | brain; glioblastoma | | glial | LNZTA3WT4 | CRL-11543 [†] |
| human | brain; glioblastoma | | glial | LNZTA3WT11 | CRL-11544 [†] |
| human | brain; glioblastoma | | epithelial | A172 | CRL-1620 |
| human | brain; glioblastoma | glial cell | fibroblast | DBTRG-05MG | CRL-2020 |
| human | brain; glioblastoma | - | polygonal | U-138 MG | HTB-16 |
| human | brain; glioblastoma multiforme | | fibroblast (glial) | T98G | CRL-1690 |
| human | brain; glioblastoma; astrocytoma | | epithelial | U-87 MG | HTB-14 |
| human | brain; glioblastoma; astrocytoma | | mixed | U-118 MG | HTB-15 |
| human | brain; glioma | | fibroblast | Hs 683 | HTB-138 |
| human | brain; malignant glioblastoma; glioma | glial cell | fibroblast | M059K | CRL-2365 |
| human | brain; malignant glioblastoma; glioma | glial cell | fibroblast | M059J | CRL-2366 |
| human | brain; neuroglioma | | epithelial | H4 | HTB-148 |
| human | brain, right frontal parietal-occipital | | epithelial | LN-229 | CRL-2611 |
| | cortex; glioblastoma | | · | | |
| Medulloblast | oma-derived cells | | | | |
| human | brain, cerebellum; medulloblastoma | | spheroid | D341 Med | HTB-187 |
| human | brain, cerebellum; medulloblastoma; | | polygonal | Daoy | HTB-186 |
| | desmoplastic cerebellar | | . ,3 | , | |
| human | brain, cerebellum; medulloblastoma; | | epithelial | D283 Med | HTB-185 |
| | metastatic sites: ascites and peritoneum | | | | |
| Tumor cells n | netastatic to brain | | | | |
| human | lung; carcinoma; classic small cell lung | | | NCI-H250 | CRL-5828 |
| - | cancer | | | | |
| human | lung; large cell carcinoma | | | NCI-H1915 | CRL-5904 |
| human | mammary gland; adenocarcinoma | | epithelial | MDA-MB-361 | HTB-27 |
| | , g, | | sla | | |
| human | prostate; carcinoma | | epithelial | DU 145 | HTB-81 |
| Neuroendocr | | | | | |
| human | lung; carcinoma; non-small | neuroendocrine | | NCI-H1770 | CRL-5893 |
| | cell lung cancer | | | | |
| human | lung; extrapulmonary small | neuroendocrine | epithelial | NCI-H660 | CRL-5813 |
| | cell carcinoma; metastatic | | | | |
| | site: lymph node | | | | |
| human | lung; large cell carcinoma; metastatic | neuroendocrine | epithelial | NCI-H1299 | CRL-5803 |
| | site: lymph node | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



Neurobiology

| Species | Tissue Source | Cell Type | Appearance | Name | ATCC® No |
|-------------|---|----------------------------------|------------------------|---------------------------------------|-----------|
| human | lung; large cell carcinoma; metastatic site: lymph node | neuroendocrine | epithelial | NCI-H1155 | CRL-5818 |
| human | lung; large cell carcinoma; metastatic site: lymph node | neuroendocrine | | NCI-H2106 | CRL-5923 |
| human | lung; large cell carcinoma; non-small cell lung cancer | neuroendocrine | epithelial | NCI-H810 | CRL-5816 |
| human | neuroectodermal tumor; retroperitoneal embryonal tumor | | epithelial | SK-PN-DW | CRL-2139 |
| human | testis; malignant carcinoma; pluripotent embryonal; metastatic site: lung | neuroendocrine | fibroblast | NTERA-2 cl.D1 | CRL-1973 |
| Nontumor ne | uronal-like cells | | | | |
| human | brain | cortical neuron | neuronal | HCN-1A | CRL-10442 |
| human | brain | cortical neuron | neuronal | HCN-2 | CRL-10742 |
| | ma-derived cells | | <u> </u> | | |
| human | eye (retina); retinoblastoma | | lymphoblast | WERI-Rb-1 | HTB-169 |
| human | eye (retina); retinoblastoma | | epithelial | Y79 | HTB-18 |
| | ed neuronal-like cells | | срински | 17.2 | 1110 10 |
| | | | fibroblast | PFSK-1 | CRL-2060 |
| human | brain, cerebellum; malignant primitive neuroectodermal tumor | | | | |
| human | brain; embryonal neuroblastoma; metastatic site: bone marrow | neuroblast | epithelial | SK-N-DZ | CRL-2149 |
| human | brain; embryonal neuroblastoma; metastatic site: bone marrow | neuroblast | epithelial | SK-N-AS | CRL-2137 |
| human | brain; embryonal neuroblastoma; metastatic site: bone marrow | neuroblast | epithelial | SK-N-FI | CRL-2142 |
| human | brain; neuroblastoma | neuroblast | fibroblast; neuroblast | IMR-32 | CCL-127 |
| human | brain; neuroblastoma | | neuroblast | CHP-212 | CRL-2273 |
| human | brain; neuroblastoma; metastatic site: bone marrow | | epithelial | SH-SY5Y | CRL-2266 |
| human | brain; neuroblastoma; metastatic site: | | neuroblast | BE(2)-M17 | CRL-2267 |
| human | brain; neuroblastoma; metastatic site: bone marrow | | neuroblast | BE(2)-C | CRL-2268 |
| human | brain; neuroblastoma; metastatic site: bone marrow | | neuroblast | SK-N-BE(2) | CRL-2271 |
| human | brain; neuroblastoma; metastatic site: bone marrow | | epithelial | SK-N-SH | HTB-11 |
| human | brain; neuroepithelioma; metastatic site: supraorbital area | | fibroblast | MC-IXC | CRL-2270 |
| human | brain; neuroepithelioma; metastatic site: supraorbital area | | epithelial | SK-N-MC | HTB-10 |
| Namba | -0- | | | | |
| Nonhuman C | | allal astro -: +- | ulial astuaci to | DC 4 (C±1-) | CDI 2022 |
| cat | brain | glial, astrocyte | glial, astrocyte | PG-4 (S ⁺ L ⁻) | CRL-2032 |
| cat | brain | glial, astrocyte | glial, astrocyte | G355-5 | CRL-2033 |
| crayfish | brain; cerebral ganglion | dendritic | dendritic | OLGA-PH-J/92 | CRL-2576 |
| ferret | brain | | fibroblast | Mpf | CRL-1656 |
| mouse | brain | neuron | round | CATH.a | CRL-11179 |
| mouse | brain | smooth muscle-like tumor | fibroblast | BC3H1 | CRL-1443 |
| mouse | brain | microglia; macrophage | macrophage | EOC 2 | CRL-2467 |
| mouse | brain | microglia; macrophage | macrophage | EOC 13.31 | CRL-2468 |
| mouse | brain | microglia; macrophage | macrophage | EOC 20 | CRL-2469 |
| mouse | brain, cerebellum | astrocyte, type III phenotype | neuronal | C8-D30 | CRL-2534 |
| mouse | brain, cerebellum | astrocyte, type II phenotype | neuronal | C8-S | CRL-2535 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



Neurobiology

| Species | Tissue Source | Cell Type | Appearance | Name | ATCC® No. |
|-----------------|---|--------------------------------|-------------------------------------|----------------------|-----------------------|
| mouse | brain, cerebellum | microglial | neuronal | C8-B4 | CRL-2540 |
| mouse | brain, cerebellum | astrocyte, type I phenotype | neuronal | C8-D1A | CRL-2541 |
| mouse | brain, cerebral cortex; endothelioma | endothelial | endothelial | bEnd.3 | CRL-2299 |
| mouse | brain; neuroblastoma | neuroblast | neuronal and amoeboid | Neuro-2a | CCL-131 |
| mouse | brain; neuroblastoma | neuroblast | neuroblast with elongated processes | NB41A3 | CCL-147 |
| mouse | brain; neuroblastoma | neuroblast | fibroblast | N1E-115 | CRL-2263 |
| mouse/rat | brain; neuroblastoma/glioma hybrid | glial cell; neuron | flat; round | NG108-15 | HB-12317 [†] |
| quail, Japanese | neuroretina | neuronal | neuronal | QNR/D | CRL-2532 |
| quail, Japanese | neuroretina | astroglial | astroglial | QNR/K2 | CRL-2533 |
| rat | adrenal gland; pheochromocytoma | polygonal | polygonal | PC-12 | CRL-1721 |
| rat | brain; cortex | astrocyte, type 1 phenotype | fibroblast | CTX TNA2 | CRL-2006 |
| rat | brain; diencephalon | astrocyte, type 1 phenotype | fibroblast | DI TNC ₁ | CRL-2005 |
| rat | brain; glioma | glial cell | fibroblast | C6 | CCL-107 |
| rat | brain; gliosarcoma | glial cell | fibroblast | C6/LacZ | CRL-2199 |
| rat | brain; gliosarcoma | glial cell | fibroblast | 9L/lacZ | CRL-2200 |
| rat | brain; gliosarcoma | glial cell | fibroblast | C6/lacZ7 | CRL-2303 |
| rat | brain; undifferentiated malignant glioma | | glial | F98 | CRL-2397 |
| rat | brain; undifferentiated malignant glioma | | glial | RG2 | CRL-2433 |
| rat | hippocampus | | fibroblast | H19-7/IGF-IR | CRL-2526 |
| rat | jejunum, myenteric plexus | enteroglial | glial | EGC/PK060399 egfr | CRL-2690 |
| sheep | brain, choroid plexus | | fibroblast | SCP | CRL-1700 |
| sheep | brain | | fibroblast | OA1 | CRL-6538 |

Hybridomas

| Antigenic Specificity | B Cell/Myeloma | Isotype | Name | ATCC® No. |
|---|----------------|--------------|------------|----------------------|
| | | | | |
| Acetylcholine receptor (AChR) alpha subunit | rat/mouse | lgG1 | mAb35 | TIB-175 |
| Acetylcholine receptor (AChR) alpha subunit | rat/rat | lgG2a | mAb64 | HB-8987 [†] |
| Acetylcholine receptor (AChR) main immunogenic | rat/mouse | lgG1 | mAb 35 | HB-8857 [†] |
| region of the alpha subunit | | | | |
| Acetylcholine receptor, neuronal, chicken and rat | rat/mouse | lgG2a | mAb 270 | HB-189 |
| Astrocyte protein, human | mouse/mouse | IgM | J1-31 | CRL-2253 |
| Astrocytoma cell line, gp120 glycoprotein, human | mouse/mouse | lgG1 | S5 | HB-9255 [†] |
| Astrocytoma cell line, gp90 glycoprotein, human | mouse/mouse | lgG2a | G253 | HB-9706 [†] |
| Astrocytoma cell line, Thy-1 antigen, human | mouse/mouse | lgG1 | K117 | HB-8553 [†] |
| Clathrin (light chain, 36000 dalton), bovine brain | mouse/mouse | lgG1 | CVC.1 | TIB-135 |
| Clathrin (light chain, 36000 dalton), bovine brain | mouse/mouse | lgG2a | CVC.7 | TIB-137 |
| Clathrin, bovine brain | mouse/mouse | IgM | CVC.4 | TIB-138 |
| Ganglioside associated with neuronal cells, endocrine | mouse/mouse | lgM; kappa | 3G5 | CRL-1814 |
| cells, and T lymphocytes | | | | |
| Neuroblastoma, human | mouse/mouse | IgM | PI 153/3 | TIB-198 |
| Medullary thymic epithelium, mouse | rat/mouse | IgM | MD2 | HB-229 |
| Nerve growth factor (NGF) receptor, primate | mouse/mouse | lgG1 | 200-3-G6-4 | HB-8737 [†] |
| Nicotinic acetylcholine receptor, Torpedo californica | mouse/mouse | lgG1 | 88B | CRL-1967 |
| Oxytocin-neurophysin (NP-OT), rat | mouse/mouse | lgG2a; kappa | PS 67 | CRL-1797 |
| Oxytocin-neurophysin (NP-OT), rat | mouse/mouse | IgG2b; kappa | PS 60 | CRL-1800 |
| Oxytocin-neurophysin (NP-OT), rat | mouse/mouse | IgG2b; kappa | PS 38 | CRL-1950 |
| Rat neural antigen 2: astrocytes, ependymal cell | mouse/mouse | lgG2a | RAN-2 | TIB-119 |
| Vasopressin-neurophysin (NP-AVP), rat | mouse/mouse | IgG2b; kappa | PS 45 | CRL-1798 |
| Vasopressin-neurophysin (NP-AVP), rat | mouse/mouse | lgG2b; kappa | PS 41 | CRL-1799 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



Genetic Variant Fibroblasts

The following list contains human skin fibroblast cell lines from individuals with genetic disorders and other disease states. In most cases the cell lines were developed at ATCC from skin biopsies. Skin fibroblast lines have a finite life expectancy and thus supplies may be limited. For more information on a cell line, see the main list starting on page 30 or use the catalogue number to find the entry in the cell biology section of the ATCC online catalog.

| Acanthocytosis Hs 859.T CRL-7594* Aspartoacylase deficiency; possible Canavan disease; foreskin Hs68 CRL-1635 Chronic dermatitis Hs 483.T CRL-7814* Citrullinemia CL-76 Cockayne syndrome Tep Be CRL-1336 Cri du Chat syndrome C 211 CCL-76 Cockayne syndrome C 211 CCL-78 Cri du Chat syndrome C 211 CCL-123 Cri du Chat syndrome C | Condition | Name | ATCC® No. | |
|--|--|-------------|-----------|--|
| Aspartacylase deficiency; possible Canavan disease; foreskin Hs 483.T CR. 1-635 Chronic dermatitis Hs 483.T CR. 7814* Citrullinemia CCL-76 Cockayne syndrome Tep Be CR. 1-326 Ci du Chat syndrome Cri | Acanthocytosis | Hs 859.T | CRL-7594* | |
| Chronic dermatitis | | | | |
| Citrullinemia Citrullinemia CCL-76 Cockayne syndrome Tep Be CR.1336 Cri du Chat syndrome C 211 CCL-123 Cri du Chat syndrome Cri du Chat CCL-90 Cystic fibrosis CCD-1865k CRL-1563 Darier-White disease Lei Cap CRL-1098 DiGeorge syndrome Hs 610.5k CRL-3722* Down syndrome Detroit 529 CCL-66 Down syndrome Detroit 539 CCL-84 Down syndrome Detroit 539 CCL-84 Down syndrome, foreskin Detroit 532 CCL-54 Ehlers-Danlos syndrome Ron Har CRL-1131 Ehlers-Danlos syndrome Mar Ton CRL-1219 Ehlers-Danlos syndrome Mar Ton CRL-1223 Ehlers-Danlos syndrome Ga Va CRL-1323 Ehlers-Danlos syndrome Ga Va CRL-1324 Ehlers-Danlos syndrome (variant type) Be Mon CRL-1342 Ehlers-Danlos syndrome (variant type) Be R CRL-1365 Ehlers-Danlos syndrome, possible heterozygote Em | · · · · · · · · · · · · · · · · · · · | | | |
| Cockayne syndrome Cri du Chat syndrome Cystic fibrosis CCD-186Sk CRL-1563 Darier-White disease Lei Cap CRL-1098 DiGeorge syndrome Hs 610.5k CRL-7372* Down syndrome Detroit 529 CCL-66 Down syndrome Detroit 539 CCL-84 Down syndrome Detroit 532 CCL-54 Ehlers-Danlos syndrome Ron Har CRL-1311 Ehlers-Danlos syndrome Ron Har CRL-1131 Ehlers-Danlos syndrome Ron Har CRL-1219 Ehlers-Danlos syndrome Ror CRL-1252 Ehlers-Danlos syndrome Ror CRL-1252 Ehlers-Danlos syndrome Ror CRL-1344 Ehlers-Danlos syndrome Ror CRL-1344 Ehlers-Danlos syndrome (variant type) Ror CRL-1344 Ehlers-Danlos syndrome (variant type) Be CRL-1365 Ehlers-Danlos syndrome (variant type) Be CRL-1379 Ehlers-Danlos syndrome (variant type) Be CRL-1365 Ehlers-Danlos syndrome (variant type) Be CRL-1379 Ehlers-Danlos syndrome (variant type) Be CRL-1365 Ehlers-Danlos syndrome (variant type) Be CRL-1365 Ehlers-Danlos syndrome (variant type) Be CRL-1379 Ehlers-Danlos syndrome (variant type) Be CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1188 Ehlers-Danlos syndrome, possible heterozygote Bellers-Danlos syndrome, possible heterozygote Bellers- | Citrullinemia | | | |
| Cri du Chat syndrome Cri du Chat yndrome Cri du Chat yndrome Cystic fibrosis CCD-1865k CRL-1563 Darier-White disease Lei Cap CRL-1098 DiGeorge syndrome Detroit 529 CCL-66 Down syndrome Detroit 539 Down syndrome Detroit 539 CCL-84 Down syndrome Detroit 532 Down syndrome Detroit 532 Down syndrome Detroit 532 CCL-66 Down syndrome Detroit 532 CCL-84 Down syndrome Detroit 532 CCL-54 Elhiers-Danlos syndrome Bi Fin CRL-1219 Elhiers-Danlos syndrome Bi Fin CRL-1219 Elhiers-Danlos syndrome Bi Fin CRL-1219 Elhiers-Danlos syndrome Bi Fin CRL-1273 Elhiers-Danlos syndrome Wo Fel CRL-1273 Elhiers-Danlos syndrome Ga Va CRL-1344 Elhiers-Danlos syndrome (variant type) EB CRL-1365 Elhiers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Elhiers-Danlos syndrome, possible heterozygote Em Ar CRL-1132 Elhiers-Danlos syndrome, possible heterozygote Elhiers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1332 Elhiers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Elhiers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Elhiers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Elhiers-Danlos syndrome, type I (autosomal dominant type) Elhiers-Danlos syndrome, | Cockayne syndrome | | | |
| Cri du Chat syndrome Cri du Chat CCL-90 Cystic fibrosis CCD-186Sk CRL-1563 Darier-White disease Lei Cap CRL-1098 DiGeorge syndrome Hs 610.5k CRL-7372* Down syndrome Detroit 529 CCL-66 Down syndrome Detroit 539 CCL-84 Down syndrome (foreskin Detroit 532 CCL-54 Ehlers-Danios syndrome Ron Har CRL-1131 Ehlers-Danios syndrome Bi Fin CRL-1219 Ehlers-Danios syndrome Mar Ton CRL-1219 Ehlers-Danios syndrome Wo Fel CRL-1219 Ehlers-Danios syndrome Ga Va CRL-1273 Ehlers-Danios syndrome (variant type) Me Mon CRL-1394 Ehlers-Danios syndrome (variant type) EB CRL-1342 Ehlers-Danios syndrome (variant type) Bi GRL-1379 Ehlers-Danios syndrome (variant type) Bi GRL-1379 Ehlers-Danios syndrome (variant type) Bi GRL-13816 Ehlers-Danios syndrome, possible heterozygote Em Ar CRL-1326 Ehlers-Danios syndrome, possible heterozygote Em Ar CRL-1326 Ehlers-Danios syndrome, possible heterozygote Ga Per CRL-1326 Ehlers-Danios syndrome, possible heterozygote Jo Per CRL-1327 | | · | | |
| Cystic fibrosis CCD-1865k CRL-1563 Darier-White disease Lel Cap CRL-1098 DiGeorge syndrome Hs 610.5k CRL-7372* Down syndrome Detroit 529 CCL-66 Down syndrome Detroit 539 CCL-64 Down syndrome (roreskin Detroit 532 CCL-54 Ehlers-Danlos syndrome Ron Har CRL-1131 Ehlers-Danlos syndrome Bi Fin CRL-1219 Ehlers-Danlos syndrome Mar Ton CRL-1252 Ehlers-Danlos syndrome Wo Fel CRL-1273 Ehlers-Danlos syndrome Ga Va CRL-1394 Ehlers-Danlos syndrome (variant type) BB R CRL-1394 Ehlers-Danlos syndrome (variant type) EB CRL-1342 Ehlers-Danlos syndrome (variant type) BB CRL-1381 Ehlers-Danlos syndrome (variant type) Go Je CRL-1381 Ehlers-Danlos syndrome (variant type) Go Je CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1382 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Ga Per CRL-1327 Ehlers-Danlos syndrome, possible heterozygote Ga Per CRL-1327 Ehlers-Danlos syndrome, type | , | Cri du Chat | CCL-90 | |
| Darier-White disease DiGeorge syndrome Hs 610.5k CRL-7372* Down syndrome Detroit 529 CCL-66 Down syndrome Detroit 529 Down syndrome Detroit 539 Down syndrome Detroit 539 Detroit 539 Detroit 539 Detroit 532 CCL-84 Down syndrome Detroit 532 CCL-54 Ehlers-Danlos syndrome Ron Har CRL-131 Ehlers-Danlos syndrome Bi Fin CRL-1219 Ehlers-Danlos syndrome Bi Fin CRL-1219 Ehlers-Danlos syndrome Mar Ton CRL-1252 Ehlers-Danlos syndrome Wo Fel CRL-1273 Ehlers-Danlos syndrome Ga Va CRL-1344 Ehlers-Danlos syndrome Wo Fel CRL-1342 Ehlers-Danlos syndrome (variant type) BB CRL-1365 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1188 Ehlers-Danlos syndrome, possible heterozygote Bm Ar CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Bn Ar CRL-1336 Ehlers-Danlos syndrome, possible heterozygote Bn Ar CRL-1336 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1324 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1324 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1324 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1318 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1324 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1344 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1340 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1341 Ehlers-Danlos syndrome, p | | | | |
| DiGeorge syndrome DiGeorge syndrome Detroit 529 CCL-66 Down syndrome Detroit 539 CCL-84 Down syndrome Detroit 539 CCL-84 Down syndrome Detroit 539 CCL-84 Down syndrome Down syndrome His 52.5k CRL-7031* Down syndrome Ron Har CRL-1131 Ehlers-Danlos syndrome Ron Har CRL-1131 Ehlers-Danlos syndrome Bi Fin CRL-1219 Ehlers-Danlos syndrome Mar Ton CRL-1252 Ehlers-Danlos syndrome More Wo Fel CRL-1273 Ehlers-Danlos syndrome Ga Va CRL-1344 Ehlers-Danlos syndrome CRL-1345 Ehlers-Danlos syndrome Ga Va CRL-1342 Ehlers-Danlos syndrome (variant type) BB CRL-1365 Ehlers-Danlos syndrome (variant type) BB CRL-1365 Ehlers-Danlos syndrome (variant type) BB CRL-1365 Ehlers-Danlos syndrome (variant type) BB CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1188 Ehlers-Danlos syndrome, possible heterozygote Bhlers-Danlos syndrome, presumed heterozygote Bhlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1327 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1324 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1130 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin C | , | | | |
| Down syndrome Detroit 529 CCL-66 Down syndrome Detroit 539 CCL-84 Down syndrome Hs 52.5k CRL-7031* Down syndrome Hs 52.5k CRL-7031* Down syndrome Brown Syndrome Brown Syndrome Brown Syndrome Brown Syndrome Ron Har CRL-1131 Ehlers-Danlos syndrome Brin CRL-1219 Ehlers-Danlos syndrome Brin CRL-1219 Ehlers-Danlos syndrome Mar Ton CRL-1252 Ehlers-Danlos syndrome Wo Fel CRL-1273 Ehlers-Danlos syndrome Ga Va CRL-1394 Ehlers-Danlos syndrome Wo Fel CRL-1394 Ehlers-Danlos syndrome (variant type) Me Mon CRL-1394 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) B CRL-1379 Ehlers-Danlos syndrome (variant type) Go Je CRL-1379 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Gam Per CRL-1326 Ehlers-Danlos syndrome, possible heterozygote No Per CRL-1327 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1332 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1336 Ehle | DiGeorge syndrome | | CRL-7372* | |
| Down syndrome Hs 52.Sk CR7031* Down syndrome, foreskin Detroit 532 CCL-54 Ehlers-Danlos syndrome Rowner R | | Detroit 529 | CCL-66 | |
| Down syndrome Down syndrome; foreskin Down syndrome; foreskin Down syndrome; foreskin Down syndrome; foreskin Down syndrome Ron Har CRL-1131 Ehlers-Danlos syndrome Bi Fin CRL-1219 Ehlers-Danlos syndrome Mar Ton CRL-1252 Ehlers-Danlos syndrome Mar Ton CRL-1273 Ehlers-Danlos syndrome Ga Va CRL-1394 Ehlers-Danlos syndrome (variant type) Me Mon CRL-1342 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) Da Hol CRL-1379 Ehlers-Danlos syndrome (variant type) Da Hol CRL-1379 Ehlers-Danlos syndrome (variant type) CG Je CRL-1381 Ehlers-Danlos syndrome (variant type) CG Je CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Do Per CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Do Per CRL-1327 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1130 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1136 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1347 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1347 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1347 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1347 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1337 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1337 Ehlers-Danlos syndrome, type I (au | | Detroit 539 | CCL-84 | |
| Ehlers-Danlos syndrome Bi Fin CRL-1219 Ehlers-Danlos syndrome Mar Ton CRL-1252 Ehlers-Danlos syndrome Wo Fel CRL-1273 Ehlers-Danlos syndrome Wo Fel CRL-1273 Ehlers-Danlos syndrome Ga Va Ehlers-Danlos syndrome Ga Va Ehlers-Danlos syndrome (variant type) EB CRL-1394 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) BB CRL-1379 Ehlers-Danlos syndrome (variant type) BB CRL-1379 Ehlers-Danlos syndrome (variant type) BB CRL-1379 Ehlers-Danlos syndrome (variant type) Go Je CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Bhers-Danlos syndrome, possible heterozygote Ar Ehlers-Danlos syndrome, possible heterozygote Gap Per CRL-1327 Ehlers-Danlos syndrome, possible heterozygote Gap Per CRL-1332 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Ar Vin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1181 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal domi | <u> </u> | Hs 52.Sk | CRL-7031* | |
| Ehlers-Danlos syndrome Bi Fin CRL-1219 Ehlers-Danlos syndrome Mar Ton CRL-1252 Ehlers-Danlos syndrome Wo Fel CRL-1273 Ehlers-Danlos syndrome Wo Fel CRL-1273 Ehlers-Danlos syndrome Ga Va Ehlers-Danlos syndrome Ga Va Ehlers-Danlos syndrome (variant type) EB CRL-1394 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) BB CRL-1379 Ehlers-Danlos syndrome (variant type) BB CRL-1379 Ehlers-Danlos syndrome (variant type) BB CRL-1379 Ehlers-Danlos syndrome (variant type) Go Je CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Bhers-Danlos syndrome, possible heterozygote Ar Ehlers-Danlos syndrome, possible heterozygote Gap Per CRL-1327 Ehlers-Danlos syndrome, possible heterozygote Gap Per CRL-1332 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Ar Vin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1181 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1134 Ehlers-Danlos syndrome, type I (autosomal domi | | Detroit 532 | CCL-54 | |
| Ehlers-Danlos syndrome Ehlers-Danlos syndrome Wo Fel CRL-1273 Ehlers-Danlos syndrome Ga Va CRL-1394 Ehlers-Danlos syndrome (variant type) Me Mon CRL-1342 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) BB CRL-1365 Ehlers-Danlos syndrome (variant type) BB CRL-1379 Ehlers-Danlos syndrome (variant type) Go Je CRL-1379 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Bhlers-Danlos syndrome, possible heterozygote Aper CRL-1327 Ehlers-Danlos syndrome, possible heterozygote Aper CRL-1332 Ehlers-Danlos syndrome, possible heterozygote Aper CRL-1335 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1324 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1140 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type II Al Hot CRL-1341 Ehlers-Danlos syndrome, type II Al Hot CRL-13 | | Ron Har | CRL-1131 | |
| Ehlers-Danlos syndrome Ehlers-Danlos syndrome Wo Fel CRL-1273 Ehlers-Danlos syndrome Ga Va CRL-1394 Ehlers-Danlos syndrome (variant type) Me Mon CRL-1342 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) BB CRL-1365 Ehlers-Danlos syndrome (variant type) BB CRL-1379 Ehlers-Danlos syndrome (variant type) Go Je CRL-1379 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Bhlers-Danlos syndrome, possible heterozygote Aper CRL-1327 Ehlers-Danlos syndrome, possible heterozygote Aper CRL-1332 Ehlers-Danlos syndrome, possible heterozygote Aper CRL-1335 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1324 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1140 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Al Ke CRL-1341 Ehlers-Danlos syndrome, type II Al Hot CRL-1341 Ehlers-Danlos syndrome, type II Al Hot CRL-13 | Ehlers-Danlos syndrome | Bi Fin | CRL-1219 | |
| Ehlers-Danlos syndrome Ga Va Ehlers-Danlos syndrome Ga Va Ehlers-Danlos syndrome (variant type) EB CRL-1342 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) Da Hol CRL-1379 Ehlers-Danlos syndrome (variant type) Go Je CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote An OPer CRL-1327 Ehlers-Danlos syndrome, possible heterozygote An OPer CRL-1327 Ehlers-Danlos syndrome, possible heterozygote An CRL-1332 Ehlers-Danlos syndrome, possible heterozygote An Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1130 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1146 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1344 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1344 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1344 Ehlers-Danlos syndrome, type I (autosomal dominant type) Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | Ehlers-Danlos syndrome | Mar Ton | CRL-1252 | |
| Ehlers-Danlos syndrome (variant type) EB CRL-1342 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) Da Hol CRL-1379 Ehlers-Danlos syndrome (variant type) Go Je CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Gam Per CRL-1326 Ehlers-Danlos syndrome, possible heterozygote No Per CRL-1327 Ehlers-Danlos syndrome, possible heterozygote Jo Per CRL-1332 Ehlers-Danlos syndrome, possible heterozygote Gap Per CRL-1335 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1334 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1130 Ehlers-Danlos syndrome, type I (autosomal dominant type) Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1188 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1347 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1347 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1347 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | | Wo Fel | CRL-1273 | |
| Ehlers-Danlos syndrome (variant type) EB CRL-1342 Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) Da Hol CRL-1379 Ehlers-Danlos syndrome (variant type) Go Je CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Gam Per CRL-1326 Ehlers-Danlos syndrome, possible heterozygote No Per CRL-1327 Ehlers-Danlos syndrome, possible heterozygote Jo Per CRL-1332 Ehlers-Danlos syndrome, possible heterozygote Gap Per CRL-1335 Ehlers-Danlos syndrome, possible heterozygote Ar Ke-2 CRL-1334 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1130 Ehlers-Danlos syndrome, type I (autosomal dominant type) Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1188 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1347 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1347 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1347 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | Ehlers-Danlos syndrome | Ga Va | CRL-1394 | |
| Ehlers-Danlos syndrome (variant type) EB CRL-1365 Ehlers-Danlos syndrome (variant type) Da Hol CRL-1379 Ehlers-Danlos syndrome (variant type) Go Je CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1326 Ehlers-Danlos syndrome, possible heterozygote No Per CRL-1327 Ehlers-Danlos syndrome, possible heterozygote In Sper CRL-1327 Ehlers-Danlos syndrome, possible heterozygote In Sper CRL-1332 Ehlers-Danlos syndrome, possible heterozygote In Sper CRL-1332 Ehlers-Danlos syndrome, possible heterozygote In Sper CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote In Sper CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote In Sper CRL-1324 Ehlers-Danlos syndrome, presumed heterozygote In Sper CRL-1324 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1388 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1215 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1215 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) In Sper CRL-1344 Ehlers-Danlos syndrome, type II In Sper CRL-1337 Ehlers-Danlos syndrome, type II (hemorrhagic type) In Sper CRL-1337 Ehlers-Danlos syndrome, type II (hemorrhagic type) In Sper CRL-1376 | | Me Mon | CRL-1342 | |
| Ehlers-Danlos syndrome (variant type) Ehlers-Danlos syndrome (variant type) Ehlers-Danlos syndrome (variant type) Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote No Per CRL-1326 Ehlers-Danlos syndrome, possible heterozygote Jo Per CRL-1332 Ehlers-Danlos syndrome, possible heterozygote Gap Per CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1325 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1130 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lu Vin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1140 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1347 Ehlers-Danlos syndrome, type II Ro Dow CRL-1337 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | | | | |
| Ehlers-Danlos syndrome (variant type) Go Je CRL-1381 Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Gap Per CRL-1332 Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1335 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1130 Ehlers-Danlos syndrome, type I (autosomal dominant type) Mar Vin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Fhlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1344 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type I (hemorrhagic type) In Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | Ehlers-Danlos syndrome (variant type) | Da Hol | CRL-1379 | |
| Ehlers-Danlos syndrome, possible heterozygote Em Ar CRL-1168 Ehlers-Danlos syndrome, possible heterozygote Enlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1344 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type II Enlers-Danlos syndrome, type II Enlers-Danlo | | Go Je | CRL-1381 | |
| Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type II Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | | Em Ar | CRL-1168 | |
| Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type II Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | Ehlers-Danlos syndrome, possible heterozygote | Gam Per | CRL-1326 | |
| Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, possible heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type II Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | | No Per | CRL-1327 | |
| Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1324 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1130 Ehlers-Danlos syndrome, type I (autosomal dominant type) Mar Vin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lu Vin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Jay Sen CRL-1215 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type II Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | | Jo Per | CRL-1332 | |
| Ehlers-Danlos syndrome, presumed heterozygote Ar Ke-2 CRL-1324 Ehlers-Danlos syndrome, presumed heterozygote Al Ke CRL-1325 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lo Ren CRL-1130 Ehlers-Danlos syndrome, type I (autosomal dominant type) Mar Vin CRL-1138 Ehlers-Danlos syndrome, type I (autosomal dominant type) Lu Vin CRL-1144 Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Jay Sen CRL-1215 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type II Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | Ehlers-Danlos syndrome, possible heterozygote | Gap Per | CRL-1335 | |
| Ehlers-Danlos syndrome, presumed heterozygote Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 Ehlers-Danlos syndrome, type II Ad Hot CRL-1344 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | | Ar Ke-2 | CRL-1324 | |
| Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type II Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II Ro Dow CRL-1337 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | | Al Ke | CRL-1325 | |
| Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type II Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II Ro Dow CRL-1337 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | Ehlers-Danlos syndrome, type I (autosomal dominant type) | Lo Ren | CRL-1130 | |
| Ehlers-Danlos syndrome, type I (autosomal dominant type) Ehlers-Danlos syndrome, type I (autosomal dominant type) Bo Gin CRL-1180 Ehlers-Danlos syndrome, type I (autosomal dominant type) Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-1 CRL-1341 Ehlers-Danlos syndrome, type I (autosomal dominant type) Pa Kel-2 CRL-1344 Ehlers-Danlos syndrome, type II Ad Hot CRL-1227 Ehlers-Danlos syndrome, type II Ro Dow CRL-1337 Ehlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | | Mar Vin | CRL-1138 | |
| Ehlers-Danlos syndrome, type I (autosomal dominant type) Ehlers-Danlos syndrome, type II Ehlers-Danlos syndrome, type II Ehlers-Danlos syndrome, type II Ehlers-Danlos syndrome, type II Ehlers-Danlos syndrome, type II (hemorrhagic type) Enlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1215 CRL-1215 CRL-1341 CRL-1341 Enlers-Danlos syndrome, type II Ro Dow CRL-1337 CRL-1176 | | Lu Vin | CRL-1144 | |
| Ehlers-Danlos syndrome, type I (autosomal dominant type) Ehlers-Danlos syndrome, type II Ehlers-Danlos syndrome, type II Ehlers-Danlos syndrome, type II Ehlers-Danlos syndrome, type II Ehlers-Danlos syndrome, type II (hemorrhagic type) Enlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1215 CRL-1341 CRL-1344 CRL-1327 Enlers-Danlos syndrome, type II (hemorrhagic type) Ja Bos CRL-1176 | Ehlers-Danlos syndrome, type I (autosomal dominant type) | Bo Gin | CRL-1180 | |
| Ehlers-Danlos syndrome, type I (autosomal dominant type)Pa Kel-2CRL-1344Ehlers-Danlos syndrome, type IIAd HotCRL-1227Ehlers-Danlos syndrome, type IIRo DowCRL-1337Ehlers-Danlos syndrome, type II (hemorrhagic type)Ja BosCRL-1176 | | Jay Sen | CRL-1215 | |
| Ehlers-Danlos syndrome, type I (autosomal dominant type)Pa Kel-2CRL-1344Ehlers-Danlos syndrome, type IIAd HotCRL-1227Ehlers-Danlos syndrome, type IIRo DowCRL-1337Ehlers-Danlos syndrome, type II (hemorrhagic type)Ja BosCRL-1176 | Ehlers-Danlos syndrome, type I (autosomal dominant type) | Pa Kel-1 | CRL-1341 | |
| Ehlers-Danlos syndrome, type IIAd HotCRL-1227Ehlers-Danlos syndrome, type IIRo DowCRL-1337Ehlers-Danlos syndrome, type II (hemorrhagic type)Ja BosCRL-1176 | | Pa Kel-2 | CRL-1344 | |
| Ehlers-Danlos syndrome, type IIRo DowCRL-1337Ehlers-Danlos syndrome, type II (hemorrhagic type)Ja BosCRL-1176 | | Ad Hot | CRL-1227 | |
| | | Ro Dow | CRL-1337 | |
| | Ehlers-Danlos syndrome, type II (hemorrhagic type) | Ja Bos | CRL-1176 | |
| | Ehlers-Danlos syndrome, type II (hemorrhagic type) | Fe Bos | CRL-1177 | |

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line. These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.



Genetic Variant Fibroblasts

| Condition | Name | ATCC® No. |
|--|---------------------|----------------------|
| | | |
| Ehlers-Danlos syndrome, type III | Ray Hot | CRL-1226 |
| Ehlers-Danlos syndrome, type III | Or De | CRL-1366 |
| Ehlers-Danlos syndrome, type IV | Lu Rob | CRL-1397 |
| Ehlers-Danlos syndrome, type V | Da Mo | CRL-1383 |
| Ehlers-Danlos syndrome, type VI (hemorrhagic type) | La Bel | CRL-1179 |
| Ehlers-Danlos syndrome, type VI (hemorrhagic type) | La Bel II | CRL-1195 |
| Ehlers-Danlos syndrome, type VII (arthrochalasia type) | Ma San | CRL-1148 |
| Ehlers-Danlos syndrome, type VII (arthrochalasia type) | El Don | CRL-1149 |
| Ehlers-Danlos syndrome, type VII (arthrochalasia type) | Mel Neg | CRL-1193 |
| Epidermolysis bullosa simplex | НВ | CRL-7729* |
| Fanconi's anemia | HG-261 | CCL-122 |
| Galactosemia | Detroit 510 | CCL-72 |
| Galactosemia; galactose-1-phosphate uridyl transferase deficient | CHP 3 (M.W.) | CCL-132 |
| Galactosemia; galactose-1-phosphate uridyl transferase deficient | CHP 4 | CCL-133 |
| Gardner's syndrome | GS-109-V-20 | CRL-1610 |
| Gardner's syndrome | GS-109-V-34 | CRL-1613 |
| Gardner's syndrome | GS-109-V-63 | CRL-1614 |
| Gardner's syndrome | GS-109-V-21 | CRL-1643 |
| Gardner's syndrome | GS-109-IV-8 | CRL-1672 |
| Hereditary adenomatosis | 182-PF SK | CRL-1532 |
| Hereditary adenomatosis (Gardner's variant) | 166-ME SK | CRL-1533 |
| Klinefelter syndrome | Dempsey | CCL-28 |
| Lesch-Nyhan syndrome | Sal Mat | CRL-1110 |
| Marfan syndrome | Ce Geg | CRL-1173 |
| Marfan syndrome Marfan syndrome | | CRL-1173 |
| | Le Ana | |
| Marfan syndrome | De Te | CRL-1249 |
| Marfan syndrome | May Roy | CRL-1250 |
| Marfan syndrome | Mar Nol | CRL-1257 |
| Marfan syndrome | Ra Bot | CRL-1265 |
| Marfan syndrome | An Zan | CRL-1266 |
| Marfan syndrome | Wa Fen | CRL-1271 |
| Marfan syndrome | Ra Lot | CRL-1289 |
| Methylmalonicacidemia | Amdur II | CCL-124 |
| Osteogenesis imperfecta | Per Sel | CRL-1107 |
| Osteogenesis imperfecta | Am Ric | CRL-1129 |
| Osteogenesis imperfecta | RSOI | CRL-1419 |
| Osteogenesis imperfecta (congenita) | Tal Jo | CRL-1267 |
| Osteogenesis imperfecta (congenita) | Ba Pot | CRL-1280 |
| Osteogenesis imperfecta (congenita) | Ran De | CRL-1287 |
| Osteogenesis imperfecta (congenita) | Me Jon | CRL-1288 |
| Osteogenesis imperfecta (congenita) | Ru Ra | CRL-1315 |
| Osteogenesis imperfecta (severe congenita) | Tu To | CRL-1298 |
| Osteogenesis imperfecta (tarda) | Wo Jo | CRL-1247 |
| Osteogenesis imperfecta (tarda) | Ro Bon | CRL-1248 |
| Osteogenesis imperfecta (tarda) | Da Bon | CRL-1251 |
| Osteogenesis imperfecta (tarda) | Am Coo | CRL-1286 |
| Osteogenesis imperfecta (tarda) | Ja Coo | CRL-1294 |
| Osteogenesis imperfecta; fetus | Os Te | CRL-1262 |
| Osteoporosis | Ber Lin | CRL-1132 |
| Osteoporosis | Be Sal | CRL-1140 |
| Poikiloderma | Ce Wal | CRL-1351 |
| Porokeratosis | Ro Shi | CRL-1310 |
| Pseudoachondroplasia (autosomal dominant) | Sar Nis | CRL-1231 |
| Stiff Skin syndrome | Ne Loc | CRL-1205 |
| Stiff Skin syndrome | He We | CRL-1338 |
| Stiff Skin syndrome | Da Cav | CRL-1388 |
| Turner syndrome | Da Cav Detroit 525 | CCL-65 |
| Xeroderma pigmentosum | XP17BE | CRL-1360 |
| Xeroderma pigmentosum Xeroderma pigmentosum | A68177 | CRL-7714* |
| Xeroderma pigmentosum, presumed heterozygote | Lo Wen | CRL-7714" CRL-1159 |
| Xeroderma pigmentosum, presumed heterozygote | Ce Ar | CRL-1159 CRL-1165 |
| легоченна рідіненкозині, ріезиней несегодудосе | Ce Ai | CNE-1103 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



Genetic Variant Fibroblasts

| Condition | Name | ATCC® No. | |
|--|---------|-----------|--|
| Xeroderma pigmentosum, presumed heterozygote | Be Ar | CRL-1167 | |
| Xeroderma pigmentosum, presumed heterozygote | Win Mec | CRL-1172 | |
| Xeroderma pigmentosum, presumed heterozygote | Be Tim | CRL-1254 | |
| Xeroderma pigmentosum, presumed heterozygote | Ro Vid | CRL-1308 | |
| Xerederma pigmentosum, presumed heterozygot | HTZ17BE | CRL-1361 | |



Immortalized Cells

Primary cells that have been immortalized with hTERT (human telomerase reverse transcriptase protein) enable use of the same consistent cell material throughout a research project without having to establish new cultures. These hTERT-immortalized cell lines are tested for extended proliferative capacity, stable genotype, the presence of selected markers and the continued expression of the hTERT protein.

These products are subject to a limited license agreement from ATCC. For more information visit the cell immortalization page of the ATCC website at www.lgcpromochem.com/atcc.

| Name | Description | ATCC® No. |
|--------------------|------------------------------------|-----------|
| | | |
| CHON-001 | human bone cartilage fibroblast | CRL-2846 |
| CHON-002 | human bone cartilage fibroblast | CRL-2847 |
| BJ-5ta | human foreskin fibroblast | CRL-4001 |
| hTERT-HME1 (ME16C) | human mammary epithelium | CRL-4010 |
| hTERT RPE-1 | human retinal pigmented epithelium | CRL-4000 |
| T HESCs | human endometrium fibroblast-like | CRL-4003 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



This index groups ATCC cell lines by their expression of, or response to, specific genes, gene products or bioactive compounds (such as serotonin). The index was developed based on information supplied by the depositor at the time of deposit and supplemented with data from the scientific literature. This information has not been verified by ATCC. It is provided as a service to the scientific community and is not intended to be comprehensive.

The National Center for Biotechnology Information (NCBI) Entrez Gene database (www.ncbi.nlm.nih.gov/entrez) was used to organize and arrange this index. Whenever possible, the Gene Symbol and GenelD are provided. Entrez Gene was selected because it provides a curated, universal reference point for all genes and their protein products with ties to other relevant NCBI databases.

The groupings are listed alphabetically by the name of the gene/protein/compound. Human, mouse, rat and bovine gene information is provided. For other species, information on the human homolog is provided where possible. Hybridoma lines which express monoclonal antibodies to the gene/protein/compound are listed last within each grouping in purple.

The information on cell lines for specific genes, proteins, or compounds was current at the time of deposit. However, new information on gene structure, mRNA transcription, and protein expression rapidly renders this data incomplete. For example, 'acid phosphatase' was cited as a product for six of our cell lines by their various depositors prior to the discovery that there are at least seven different forms of this enzyme. On the other hand, acid phosphatase from prostate (symbol ACPP) was specifically identified for two other cell lines.

The index provides information in the following fields:

- Name (lists the name of the gene or bioactive compound)
- Gene symbol
- GenelD
- Cell line name
- Catalogue number of the cell line
- Species of the cell line or hybridoma
- Expresses, + or -

P = product

A = antigen

O = oncogene

R = receptor

MAb = monoclonal antibody against the gene product or bioactive compound

Comments

In the 'Expresses' column, the + or – symbol may refer to the expression of either the mRNA or the protein product of the gene. Additionally, O+ or O– for an oncogene may mean either expression of the mRNA/protein or it may mean 'activation/deactivation' of the oncogene protein product. Any information on specific sequence mutations is listed in the comments section. For more information as well as relevant references, please look up the cell line (by catalogue number) on the ATCC website.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|------------------------|-----------------------------|-------------|---|
| | | | • | |
| Abelson murine leukemia virus | TID 51 | | D . | |
| RAW 309F.1.1 RAW 309 Cr.1 | TIB-51 | mouse | P+ | |
| | TIB-69 TIB-70 | mouse | P+ | |
| WR19M.1 Abelson murine leukemia virus, 16-kl | | mouse | P+ | |
| CDR1 | HB-213 | rat/mouse | MAb | Anti mouse Abelson leukemia antigen |
| v-abl Abelson murine leukemia viral | | | IVIAD | Anti mouse Abeison leukenila antigen |
| v-uoi Abeison munne leukeima viiai | | (arg, Abelson-related gene) | · ARI 2. 27 | |
| COLO 201 | CCL-224 | human | 0- | |
| DLD-1 | CCL-221 | human | 0- | |
| HT-29 | HTB-38 | human | 0- | |
| LoVo | CCL-229 | human | 0- | |
| LS 174T | CL-188 | human | 0- | |
| MSTO-211H | CRL-2081 | human | 0+ | v-abl |
| NCI-H23 | CRL-5800 | human | 0+ | v-abl |
| SK-CO-1 | HTB-39 | human | 0- | |
| SW1116 | CCL-233 | human | 0- | |
| SW1417 | CCL-238 | human | 0- | |
| SW480 | CCL-228 | human | 0- | |
| SW620 | CCL-227 | human | 0- | |
| SW948 | CCL-237 | human | 0- | |
| 310-29F7 | CRL-2656 | mouse/mouse | MAb | Anti abl oncogene peptide, synthetic |
| 311-3D4 | CRL-2657 | mouse/mouse | MAb | Anti <i>abl</i> oncogene peptide, synthetic |
| 312-13E8 | CRL-2658 | mouse/mouse | MAb | Anti <i>abl</i> oncogene peptide, synthetic |
| Acetylated low density lipoprotein (L | DP). See Scavenger red | eptor class F, member 1. | | |
| Acetylcholine, neuronal | | | | |
| mAb270 | HB-189 | rat/mouse | MAb | Anti chicken and rat neuronal receptor |
| Acetylcholine receptor, muscarinic. So | ee Cholinergic recepto | r, muscarinic. | | |
| Acetylcholinesterase: Ache, 11423 | | | | |
| N1E-115 | CRL-2263 | mouse | P+ | |
| NB41A3 | CCL-147 | mouse | P+ | |
| Neuro-2a | CCL-131 | mouse | P+ | |
| Acetylcholinesterase (YT blood grou | p): ACHE, 43 | | | |
| AE-1 | HB-72 | mouse/mouse | MAb | Anti human acetylcholinesterase |
| AE-2 | HB-73 | mouse/mouse | MAb | Anti human acetylcholinesterase |
| Acid phosphatase (seven different fo | | | | |
| CCD 1103 KIDTr | CRL-2304 | human | P+ | |
| CCD 1105 KIDTr | CRL-2305 | human | P+ | |
| CCF-STTG1 | CRL-1718 | human | P+ | |
| HK-2 | CRL-2190 | human | P+ | |
| MEG-01 | CRL-2021 | human | P+ | |
| PC-3 | CRL-1435 | human | P+ | |
| Acid phosphatase, prostate: ACPP, 5 5 | | | | |
| LNCaP clone FGC | CRL-1740 | human | P+ | |
| RLTM01 | HB-8526 [†] | mouse/mouse | MAb | Anti human acid PAP |
| RLTM02 | HB-8523 [†] | mouse/mouse | MAb | Anti human acid PAP |
| Actin (over 100 actins) | | <u> </u> | | |
| MDA-MB-330 | HTB-127 | human | P+ | |
| MDA-MB-435S | HTB-129 | human | P+ | |
| MDA-MB-436 | HTB-130 | human | P+ | |
| SV40 MES 13 | CRL-1927 | mouse | P+ | |
| RL-65 | CRL-10354 [†] | rat | P+ | A1 1 |
| SV40LT-SMC Clone H | CRL-2018 | rat | P+ | Alpha actin |
| ACTIV | HB-80 | mouse/mouse | MAb | Anti actin from prokaryotic organisms |
| ACT IV | HB-81 | mouse/mouse | MAb | Anti actin from prokaryotic organisms |
| Actinin, alpha 1: ACTN1, 87 OR | | | | |
| alpha 2: ACTN2, 88 OR | | | | |
| alpha 3: ACTN3, 89 OR | | | | |
| alpha 4: ACTN4, 81 | | | | |
| G-3-5 | CRL-2252 | mouse/mouse | MAb | Anti human alpha actinin |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|--------------------------------|------------------------------|-----------------|--|
| | | <u> </u> | | |
| daptor-related protein complex | | | | |
| AP.6 | CRL-2227 | mouse/mouse | MAb | Reacts with many species |
| Adaptor-related protein complex | | | | |
| mh [mocha] | CRL-2709 | mouse | P- | Deficient |
| denocarcinoma-associated antig | | | | |
| CFPAC-1 | CRL-1918 | human | P+ | |
| denomatosis polyposis coli: APC, | | | | |
| LS1034 | CRL-2158 | human | 0+ | Mutated, deletion, GAAAAGATT – GATT at codon 1309 |
| denosine A1 receptor: Adora1, 1 | | | | |
| A2a receptor: Adora2a | | | | |
| A2b receptor: Adora2 b | | | | |
| A3 receptor: Adora3, 1 | | | | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| denovirus 12, early region protei | ns | | | |
| MCB3901 | CRL-9595 [†] | Syrian golden hamster | P+ | |
| denylate phosphokinase | | | | |
| BC ₃ H1 | CRL-1443 | mouse | P+ | |
| drenergic alpha 1A receptor: ADI | RA1A, 148 | | | |
| mAb 35 | HB-8857 [†] | rat/mouse | MAb | Reacts with a variety of species |
| mAb35 | TIB-175 | rat/mouse | MAb | Reacts with a variety of species |
| mAb64 | HB-8987 [†] | rat/rat | MAb | Reacts with a variety of species |
| drenergic alpha 1A receptor: ADI | RA1A , 148 OR | | | , , |
| alpha 1B receptor: ADI | RA1B, 147 OR | | | |
| alpha 1D receptor: AD | PRA1D, 146 (human: ham | nster genes not yet curated) | | |
| DDT, MF-2 | CRL-1701 | Syrian golden | R+ | |
| | | hamster | | |
| drenergic alpha 1B receptor: ADI | RA1B.147 | Harrister | | |
| L-α-1b | CRL-11139 [†] | mouse | R+ (human) | |
| drenergic alpha 2A receptor: AD I | | | () | |
| alpha 2B receptor: ADF | | | | |
| | | sum genes not yet curated) | | |
| OK | CRL-1840 | opossum | R+ | |
| drenergic alpha 2A receptor : AD | | ороззин | 111 | |
| HT-29 | HTB-38 | human | R+ | |
| drenergic beta 2 receptor, surface | | | INT | |
| | | | D. | Coupled to adept levelace |
| DDT ₁ MF-2 | CRL-1701 | Syrian golden hamster | R+ | Coupled to adenyl cyclase |
| dronocorticotronic harmana (AC | TU) product Car Cart' | | | |
| drenocorticotropic hormone (AC | | | in-n-n-mat-1 C5 | 12 -150\-ANDED 200 |
| anyl (membrane) aminopeptida | | | | 713, p150): ANPEP, 290 |
| SUP-B15 | CRL-1929 | human | A+ | |
| bumin: ALB, 213 | CDL 107111 | | D : | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| THLE-3 | CRL-11233 [†] | human | P+ | |
| oumin: Alb1, 11657 | | | | |
| AML12 | CRL-2254 | mouse | P+ | |
| Hepa 1-6 | CRL-1830 | mouse | P+ | |
| oumin: Alb, 24186 | | | | |
| H4-II-E-C3 | CRL-1600 | rat | P+ | |
| MH ₁ C ₁ | CCL-144 | rat | P+ | |
| dosterone | | | | |
| NCI-H295R | CRL-2128 | human | P+ | |
| A2E11 | CRL-1846 | mouse/mouse | Mab | Anti aldosterone |
| lkaline phosphatase, intestinal: A | | | | |
| | kidney: ALPL, 249 OR | | | |
| | egan isozyme): ALPP, 25 | 0 | | |
| 3A(tPA-30-1) | CRL-1583 | human | P+ | |
| | CCL-244 | human | P+ | |
| HCT-8 (HRT-18) | CCL-244 | | | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product of the produc$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---------------------------------------|-------------|------------|--------------------------|
| | | | | |
| Alkaline phosphatase continued | CDL 11272† | In comment | D. | |
| hFOB 1.19 | CRL-11372 [†] | human | P+ | |
| HK-2 | CRL-2190 | human | P+ | |
| MEG-01 | CRL-2021 | human | P- | |
| NCCIT | CRL-2073 | human | P+ | |
| ψ2 DAP | CRL-1949 | mouse | P+ (human) | Human transducing vector |
| Ilkaline phosphatase 1: Akp1, 109 | | | | |
| 2: liver: Akp 2 | | | | |
| | not Mn requiring: Akp3, ' | 11648 OR | | |
| 4: Akp4: 10 9 | | | | |
| 5: Akp5, 116 | | | | |
| 7F2 | CRL-12557 [†] | mouse | P+ | |
| NE | CRL-2070 | mouse | P+ | |
| RLE-6TN | CRL-2300 | mouse | P- | |
| W-20-17 | CRL-2623 | mouse | P+ | |
| lkaline phosphatase (zebrafish ge | · · · · · · · · · · · · · · · · · · · | | | |
| ZFL | CRL-2643 | zebrafish | P+ | |
| lpha-1 acid glycoprotein | | | | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| lpha-1 antichymotrypsin. See Ser | | | | |
| lpha-1 antitrypsin (over seven isc | | | | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| Hepa 1-6 | CRL-1830 | mouse | P+ | |
| AML12 | CRL-2254 | mouse | P+ | |
| Alpha chemokines. See Chemokine | | | | |
| Alpha-fetoprotein: AFP, 174 | • | | | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| THLE-3 | CRL-11233 [†] | human | P- | |
| OM 3-1.1 | HB-134 | mouse/mouse | Mab | Anti human AFP |
| Ipha-fetoprotein: Afp, 11576 | | | | |
| Hepa 1-6 | CRL-1830 | mouse | P+ | |
| Alpha-fetoprotein: Afp, 24177 | C.12 1030 | | | |
| L2-RYC | CRL-2180 | rat | P- | |
| McA-RH7777 | CRL-1601 | rat | P+ | |
| McA-RH8994 | CRL-1602 | rat | P+ | |
| Ipha-2-HS glycoprotein | CNL-1002 | ιαι | ГT | |
| C3A | CRL-10741 [†] | human | P+ | |
| | | human | | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| lpha-2-macroglobulin: A2M, 2 | CDL 40744+ | In comment | D. | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| lpha-2-macroglobulin: A2m, 241 | | | | |
| DITNC, | CRL-2005 | rat | P+ | |
| CTX TNA2 | CRL-2006 | rat | P+ | |
| lveolar surfactant protein (ASP). S | | | | |
| minobutyric acid, gamma. See Ga | | | | |
| mylase (more than five amylases |) | | | |
| Hepa 1-6 | CRL-1830 | mouse | P+ | |
| AR42J | CRL-1492 | rat | P+ | |
| Amylase, alpha 1A; salivary: AMY1 | A, 276 OR | | | |
| alpha 1B; salivary: AMY1 | | | | |
| alpha 1C; salivary: AMY1 | | | | |
| aipila ic, salivaly. Aivi i | C, 27 0 | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|-----------------------------|----------------------------------|--------------------|--------------------------------------|
| Androgen receptor (dihydrotestos | sterone receptor, testicula | r feminization, spinal and bulba | ar muscular atroph | ny, Kennedy disease): AR, 367 |
| 22Rv1 | CRL-2505 | human | R+ | Responsive |
| LNCaP clone FGC | CRL-1740 | human | R+ | Responsive |
| MDA-kb2 | CRL-2713 | human | R+ | |
| MDA PCa 2b | CRL-2422 | human | R+ | Sensitive |
| NIH:OVCAR-3 | HTB-161 | human | R+ | |
| PWR-1E | CRL-11611 [†] | human | R+ | Responsive |
| RWPE-1 | CRL-11609 [†] | human | R+ | Responsive |
| RWPE-2 | CRL-11610 [†] | human | R+ | Responsive |
| T-47D | HTB-133 | human | R+ | |
| ndrogen receptor: Ar, 11835 | | | | |
| TM3 | CRL-1714 | mouse | R+ | |
| TM4 | CRL-1715 | mouse | R+ | |
| ndrogen receptor: Ar, 24208 | | | | |
| NMU | CRL-1743 | rat | R+ | |
| RBA | CRL-1747 | rat | R+ | |
| ndrogen receptor (hamster gene | | 140 | | |
| DDT, MF-2 | CRL-1701 | Syrian golden hamster | R+ | Responsive |
| ngiogenesis inhibiting factor | CAL 1701 | Syrian golden hamstel | | перриниче |
| LNZTA3WT11 | CRL-11544 [†] | human | P+ | |
| LNZTA3WT4 | CRL-11543 [†] | human | P+ | |
| ngiotensin I converting enzyme | | | | |
| α -ACE 3.1.1 | HB-8191 [†] | mouse/mouse | MAb | Anti mouse, bovine, and human ACE |
| ngiotensin converting enzyme: | | mouse/mouse | IVII (IS | And mode, bovine, and naman Act |
| C166 | CRL-2581 | mouse | P+ | |
| EOMA | CRL-2586 | mouse | P+ | |
| α-ACE 3.1.1 | HB-8191 [†] | mouse/mouse | MAb | Anti mouse, bovine, and human ACE |
| ngiotensin converting enzyme (k | | | IVIAD | Anti mouse, bovine, and numan Act |
| CPAE | CCL-209 | bovine | P+ | |
| CPA 47 | CRL-1733 | bovine | P+ | |
| ngiotensin II receptor, type 2: Ag | | DOVINE | ГТ | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| nnexin A1: ANXA1, 301 | CNL-2203 | illouse | INT | |
| EH17a | CRL-2209 | mouse/mouse | MAb | Anti human annexin I |
| nnexin A1: ANXA1, 301 AND | CNL-2209 | mouse/mouse | IVIAD | Antinumanamexim |
| A2: ANXA2, 302 | | | | |
| EH7a | CRL-2194 | mouse/mouse | MAb | Anti human annexin I and human |
| EH7a | CNL-2194 | mouse/mouse | IVIAD | annexin II |
| polipoprotein A-l: APOA1, 335 | | | | aillexIII II |
| A5.4 | CRL-2275 | mouse/mouse | MAb | Anti human Ano A I |
| polipoprotein E: APOE, 348 | CNL-22/3 | mouse/mouse | IVIAU | Anti human Apo-A-I |
| WU E-14 | CRL-2255 | mouse/mouse | MAb | Anti human ADOE |
| WU E-14 WU E-4 | | mouse/mouse | | Anti human APOE |
| | CRL-2247 | mouse/mouse | MAb | Anti human APOE |
| oomucin. See Mucin 5. | | | | |
| rginine vasopressin: Avp, 24221 | CDI 1700 | mouse/m= | MAA | Antirot ND AVD |
| PS 41 PS 45 | CRL-1799 | mouse/mouse | MAb | Anti rat NP-AVP |
| | CRL-1798 | mouse/mouse | MAb | Anti rat NP-AVP |
| ryl-hydrocarbon receptor: Ahr, 1 | | | D : | |
| BpRcl | CRL-2217 | mouse | R+ | |
| Hepa-1c1c7 | CRL-2026 | mouse | R+ | |
| tao BpRcl | CRL-2218 | mouse | R+ | |
| ryl-hydrocarbon receptor (specie | | | | |
| PLHC-1 | CRL-2406 | topminnow | R+ | |
| yl hydrocarbon hydroxylase. See | | | | |
| TP binding cassette, sub-familyB | | BCB, 5243 | | |
| ES-2 | CRL-1978 | human | P+ | |
| rial natriuretic peptide (ANP). Se | e Natriuretic peptide rece | eptor. | | |
| cell growth factor 1 (12kD): BCG | | • | | |
| 11B11 | HB-188 | rat/mouse | MAb | Anti mouse BCGF-1 |
| | | | | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

^{*} Part of the NBL collection; see page 12. $\,^+$ Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Nan | neID ne ATCC® No. | Species | Expresses | Comments |
|--|---|---|-------------------------------------|--|
| | ATCC NO. | эресіез | Lxpresses | Comments |
| 3 cell stimulating factor | | | | |
| Cl. Ly1+2-/9 | CRL-8179 [†] | mouse | P+ | |
| 11B11 | HB-188 | rat/mouse | MAb | Anti mouse BSF-1 |
| 37-1. See CD80 (B7-1). | | | | |
| 37.2. See CD86 (B7-2). | | | | |
| Seta-endorphin. See Pro | | | | |
| | Galactosidase, beta 1. | | | |
| Beta-lipoprotein. <i>See</i> Li _l | | | | |
| Beta-2-microglobulin: E | | | | |
| HEL 92.1.7 | TIB-180 | human | P+ | |
| LS1034 | CRL-2158 | human | P+ | |
| LS513 | CRL-2134 | human | P+ | |
| SUP-T1 | CRL-1942 | human | P+ | |
| U-937 | CRL-1593.2 [†] | human | P+ | |
| J26 | CRL-1802 | mouse | P+ (human) | |
| BBM.1 | HB-28 | mouse/mouse | MAb | Anti human beta-2-microglobulir |
| L368 | HB-149 | mouse/mouse | MAb | Anti human beta-2-microglobulir |
| Beta-2-microglobulin: E | | | | |
| 4C9 | CRL-2437 | mouse/mouse | MAb | Anti rat beta-2-microglobulin |
| one gamma carboxyg | lutamate protein 1: Bglap1, 12096 | OK | | |
| | protein 2: Bglap2, 12097 | | | |
| MC3T3-E1 S | | mouse | P+ | |
| MC3T3-E1 S | | mouse | P- | |
| MC3T3-E1 S | | mouse | P- | |
| MC3T3-E1 S | | mouse | P+ | |
| | hormone. See Vitamin D. | | | |
| | . See Secreted phosphoprotein 1 (o | steopontin, bone sialoprotei | n I, early I-lymphocyte | e activation 1). |
| | eptidase): Enpep, 13809 | | | |
| 2E8 | TIB-239 | mouse | A+ | |
| 3P-4 | LITE | | | |
| MCF7 | HTB-22 | human | P+ | |
| BP-5 | LITE 22 | h | D.: | |
| MCF7 | HTB-22 | human | P+ | |
| | ee Membrane-spanning 4-domains. ee Tumor necrosis factor receptor su | | | |
| | | iperiamily, member 5. | | |
| | | | | |
| Bradykinin receptor B1: | :BDKRB1,623 OR | | | |
| Bradykinin receptor B1: receptor B2: | : BDKRB1, 623 OR : BDKRB2 , 624 | human | D i | Sansitiva |
| Bradykinin receptor B1: receptor B2: HGF-1 | : BDKRB1,623 OR : BDKRB2,624 CRL-2014 | human | R+ | Sensitive |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 ta: Bdkrb, 12061 OR | human | R+ | Sensitive |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 ta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 | | | Sensitive |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 ta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 CRL-2263 | human mouse | R+ R+ | Sensitive |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early o | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 | mouse | R+ | |
| receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Brast cancer 1, early of | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 | mouse human | R+ O+ | Insertion C at nucleotide 5382 |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early or HCC1937 HCC1937 BL | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 | mouse | R+ | |
| receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early of HCC1937 HCC1937 BL Breast cancer 2, early of | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 | mouse human human | R+ O+ O+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| radykinin receptor B1: receptor B2: HGF-1 radykinin receptor, be receptor, be N1E-115 reast cancer 1, early or HCC1937 HCC1937 BL reast cancer 2, early or PL45 | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 | mouse human | R+ O+ | Insertion C at nucleotide 5382 |
| radykinin receptor B1: receptor B2: HGF-1 radykinin receptor, be receptor, be N1E-115 reast cancer 1, early or HCC1937 HCC1937 BL reast cancer 2, early or PL45 | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 | mouse human human human | R+ O+ O+ O+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early of HCC1937 HCC1937 BL Breast cancer 2, early of PL45 C19 steroids NCI-H295R | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 | mouse human human | R+ O+ O+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| receptor B1: receptor B2: HGF-1 redykinin receptor, be receptor, be receptor, be N1E-115 reast cancer 1, early or HCC1937 HCC1937 BL reast cancer 2, early or PL45 T9 steroids NCI-H295R | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 | mouse human human human human | R+ O+ O+ P+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| receptor B1: receptor B2: HGF-1 radykinin receptor, be receptor, be N1E-115 reast cancer 1, early or HCC1937 HCC1937 BL reast cancer 2, early or PL45 19 steroids NCI-H295R 3 activator C3A | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 CRL-2128 | human human human human human | R+ O+ O+ P+ P+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| radykinin receptor B1: receptor B2: HGF-1 radykinin receptor, be receptor, be N1E-115 reast cancer 1, early or HCC1937 HCC1937 BL reast cancer 2, early or PL45 19 steroids NCI-H295R 3 activator C3A Hep 3B2.1-7 | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 CRL-2128 | human human human human human human human human | R+ O+ O+ P+ P+ P+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| receptor B1: receptor B2: HGF-1 radykinin receptor, be receptor, be N1E-115 receptor, be N1E- | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 CRL-2128 | human human human human human | R+ O+ O+ P+ P+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early of HCC1937 HCC1937 BL Breast cancer 2, early of PL45 C19 steroids NCI-H295R C3 activator C3A Hep 3B2.1-7 Hep G2 CA19-9 | EBDKRB1, 623 OR EBDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 CRL-2128 CRL-10741† HB-8064† HB-8065† | human human human human human human human human human | R+ O+ O+ P+ P+ P+ P+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early or HCC1937 HCC1937 BL Breast cancer 2, early or PL45 C19 steroids NCI-H295R C3 activator C3A Hep 3B2.1-7 Hep G2 CA19-9 CFPAC-1 | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 CRL-2128 CRL-10741† HB-8064† HB-8065† | human | R+ O+ O+ P+ P+ P+ A+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early or HCC1937 HCC1937 BL Breast cancer 2, early or PL45 E19 steroids NCI-H295R E3 activator C3A Hep 3B2.1-7 Hep G2 EA19-9 CFPAC-1 NCI-H498 | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 CRL-2128 CRL-10741† HB-8064† HB-8065† CRL-1918 CCL-254 | human | R+ O+ O+ O+ P+ P+ P+ A+ A+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early or HCC1937 HCC1937 BL Breast cancer 2, early or PL45 C19 steroids NCI-H295R C3 activator C3A Hep 3B2.1-7 Hep G2 CA19-9 CFPAC-1 NCI-H498 NCI-H508 | EBDKRB1,623 OR EBDKRB2,624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 Inset: BRCA1,672 CRL-2336 CRL-2337 Inset: BRCA2,675 CRL-2558 CRL-2128 CRL-10741† HB-8064† HB-8065† CRL-1918 CCL-254 CCL-253 | human | R+ O+ O+ O+ P+ P+ P+ A+ A+ A+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early or HCC1937 HCC1937 BL Breast cancer 2, early or PL45 C19 steroids NCI-H295R C3 activator C3A Hep 3B2.1-7 Hep G2 CA19-9 CFPAC-1 NCI-H498 NCI-H508 NCI-H508 NCI-H508 | EBDKRB1, 623 OR EBDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 CRL-2263 Inset: BRCA1, 672 CRL-2336 CRL-2337 Inset: BRCA2, 675 CRL-2128 CRL-10741† HB-8064† HB-8065† CRL-1918 CCL-254 CCL-253 CCL-251 | human | R+ O+ O+ O+ P+ P+ P+ A+ A+ A+ A- | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| Bradykinin receptor B1: receptor B2: HGF-1 Bradykinin receptor, be receptor, be N1E-115 Breast cancer 1, early of HCC1937 HCC1937 BL Breast cancer 2, early of PL45 E19 steroids NCI-H295R E3 activator C3A Hep 3B2.1-7 Hep G2 EA19-9 CFPAC-1 NCI-H498 NCI-H508 NCI-H716 NCI-H747 | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 CRL-2128 CRL-10741† HB-8064† HB-8065† CRL-1918 CCL-254 CCL-253 CCL-251 CCL-252 | human | R+ O+ O+ O+ P+ P+ P+ A+ A+ A+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| radykinin receptor B1: receptor B2: HGF-1 radykinin receptor, be receptor, be N1E-115 reast cancer 1, early or HCC1937 HCC1937 BL reast cancer 2, early or PL45 19 steroids NCI-H295R 3 activator C3A Hep 3B2.1-7 Hep G2 A19-9 CFPAC-1 NCI-H498 NCI-H508 NCI-H716 NCI-H747 Calcitonin receptor: CA | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR tta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 CRL-2128 CRL-10741† HB-8064† HB-8065† CRL-1918 CCL-254 CCL-253 CCL-251 CCL-252 | human | R+ O+ O+ O+ P+ P+ P+ A+ A+ A+ A- A+ | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |
| radykinin receptor B1: receptor B2: HGF-1 radykinin receptor, be receptor, be N1E-115 reast cancer 1, early or HCC1937 HCC1937 BL reast cancer 2, early or PL45 19 steroids NCI-H295R 3 activator C3A Hep 3B2.1-7 Hep G2 A19-9 CFPAC-1 NCI-H498 NCI-H508 NCI-H508 NCI-H716 NCI-H747 | : BDKRB1, 623 OR : BDKRB2, 624 CRL-2014 tta: Bdkrb, 12061 OR ta 2: Bdkrb2, 12062 CRL-2263 nset: BRCA1, 672 CRL-2336 CRL-2337 nset: BRCA2, 675 CRL-2558 CRL-2128 CRL-10741† HB-8064† HB-8065† CRL-1918 CCL-254 CCL-253 CCL-251 CCL-252 | human | R+ O+ O+ O+ P+ P+ P+ A+ A+ A+ A- | Insertion C at nucleotide 5382 Insertion C at nucleotide 5382 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| lame: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|-----------------------|-------------|-----------|----------------------|
| | | | | |
| Calcitonin/calcitonin-related polyp | | | D : | |
| DMS 153 | CRL-2064 | human | P+ | |
| DMS 53 | CRL-2062 | human | P+ | |
| DMS 79 | CRL-2049 | human | P+ | |
| TT | CRL-1803 | human | P+ | Produces high levels |
| alcitonin/calcitonin-related polyp | | | | |
| MTC-M | CRL-1806 | mouse | P+ | |
| alcitonin/calcitonin-related polyp | | | | |
| 6-23 (Clone 6) | CRL-1607 | rat | P+ | |
| rcinoembryonic antigen (CEA) (a | | | | |
| AsPC-1 | CRL-1682 | human | P+ | |
| BxPC-3 | CRL-1687 | human | P+ | |
| CFPAC-1 | CRL-1918 | human | P+ | |
| COLO 205 | CCL-222 | human | P+ | |
| DLD-1 | CCL-221 | human | P+ | |
| HCT 116 | CCL-247 | human | P+ | |
| HCT-15 | CCL-225 | human | P+ | |
| HT-29 | HTB-38 | human | P+ | |
| HCT-8 (HRT-18) | CCL-244 | human | P+ | |
| LoVo | CCL-229 | human | P+ | |
| LS1034 | CRL-2158 | human | A+ | |
| LS123 | CCL-255 | human | P+ | |
| LS 174T | CL-188 | human | P+ | |
| LS 180 | CL-187 | human | P+ | |
| LS411N | CRL-2159 | human | A+ | |
| LS513 | CRL-2134 | human | A+ | |
| NCI-H498 | CCL-254 | human | P+ | |
| NCI-H508 | CCL-253 | human | P+ | |
| NCI-H548 | CCL-249 | human | P+ | |
| NCI-H747 | CCL-249 | human | P+ | |
| NCI-N87 | CRL-5822 | | | |
| | | human | A+ | |
| SNU-1 | CRL-5971 | human | A+ | |
| SNU-16 | CRL-5974 | human | A+ | |
| SNU-5 | CRL-5973 | human | A+ | |
| RF-1 | CRL-1864 | human | P+ | |
| SNU-C2B | CCL-250 | human | P+ | |
| SNU-C2A | CCL-250.1 | human | P+ | |
| SU.86.86 | CRL-1837 | human | P+ | |
| SW1116 | CCL-233 | human | P+ | |
| SW1417 | CCL-238 | human | P+ | |
| SW1463 | CCL-234 | human | P+ | |
| SW403 | CCL-230 | human | P+ | |
| SW48 | CCL-231 | human | P+ | |
| SW480 | CCL-228 | human | P+ | |
| SW620 | CCL-227 | human | P+ | |
| SW837 | CCL-235 | human | P+ | |
| SW948 | CCL-237 | human | P+ | |
| T84 | CCL-248 | human | P+ | |
| TT | CRL-1803 | human | P+ | |
| WiDr | CCL-218 | human | P+ | |
| 1116NS-3d | CRL-8019 [†] | mouse/mouse | MAb | Anti CEA |
| T84.66A3.1A.1F2 | HB-8747 | mouse/mouse | MAb | Anti CEA |
| seinase (stromelysin). See Matrix | | | | |
| techolamines | ctanoproteniase s. | | | |
| PC-12 | CRL-1721 | rat | P+ | |
| thepsin L: Ctsl, 13039 | CIL 1/21 | iuc | 1.1 | |
| EOMA | CDI 2506 | mouro | P+ | |
| EONA | CRL-2586 | mouse | Γ† | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|------------------------------------|----------------|-----------|-------------------------|
| | | Species | LAPIESSES | Comments |
| 1A antigen, a polypeptide: CD1 | | | | |
| 1B antigen, b polypeptide: CD | | | | |
| 1C antigen, c polypeptide: CD 1 | | | | |
| 1D antigen, d polypeptide: CD | | | | |
| 1E antigen, e polypeptide: CD1 | E, 913 | | | |
| MOLT-3 | CRL-1552 | human | A+ | |
| MOLT-4 | CRL-1582 | human | A+ | |
| NK-92 | CRL-2407 | human | A- | |
| NK-92CI | CRL-2409 | human | A- | |
| NK-92MI | CRL-2408 | human | A- | |
| OKT 6 | CRL-8020 [†] | mouse/mouse | MAb | Anti human CD1 |
| 1 antigen complex: Cd1, 1133 | 4 OR | | | |
| 1d1 antigen: Cd1d1, 12479 | | | | |
| 15C6 | HB-326 | rat/mouse | MAb | Anti mouse CD1.1 |
| 15F7 | HB-322 | rat/mouse | MAb | Anti mouse CD1.1 |
| 19F8 | HB-321 | rat/mouse | MAb | Anti mouse CD1.1 |
| 20H2 | HB-323 | rat/mouse | MAb | Anti mouse CD1.1 |
| 4C4 | HB-327 | rat/mouse | MAb | Anti mouse CD1.1 |
| 1 (species not yet curated) | | | | |
| 76-7-4 | HB-140 | mouse/mouse | MAb | Anti pig CD1 |
| CC20 | HB-267 | mouse/mouse | MAb | Anti bovine CD1 (CD1w2) |
| 1A antigen, a polypeptide: CD 1 | | ase/iniouse | .7010 | , 20 vine CD1 (CD1W2) |
| SUP-B15 | CRL-1929 | human | A- | |
| SUP-T1 | CRL-1942 | human | A+ | |
| 2 antigen (p50), sheep red bloo | | | Д | |
| BC-3 | CRL-2277 | human | A- | |
| DS-1 | CRL-2277 CRL-11102† | human | A+/- | |
| | | | | |
| HH | CRL-2105 | human | A+ | |
| J45.01 | CRL-1990 | human | A+ | |
| MJ | CRL-8294 [†] | human | A+ | |
| MOLT-4 | CRL-1582 | human | A+ | |
| NK-92 | CRL-2407 | human | A+ | |
| NK-92CI | CRL-2409 | human | A+ | |
| NK-92MI | CRL-2408 | human | A+ | |
| SUP-B15 | CRL-1929 | human | A- | |
| SUP-T1 [VB] | CRL-1942 | human | A- | |
| TALL-104 | CRL-11386 [†] | human | A+ | |
| 35.1 | HB-222 | mouse/mouse | MAb | Anti human CD2 |
| OKT 11 | CRL-8027 [†] | mouse/mouse | MAb | Anti human CD2 |
| TM1 | HB-169 | mouse/mouse | MAb | Anti human CD2 |
| TS2/18.1.1 | HB-195 | mouse/mouse | MAb | Anti human CD2 |
| 2 (species not yet curated) | | | | |
| 36F-18C | HB-285 | mouse/mouse | MAb | Anti sheep CD2 |
| CC42 | HB-272 | mouse/mouse | MAb | Anti bovine CD2 |
| IL-A42 | CRL-1870 | mouse/mouse | MAb | Anti bovine CD2 |
| 3D antigen, delta polypeptide | (TiT3 complex): CD3D, 91 | 5 OR | | |
| 3E antigen, epsilon polypeptid | e (TiT3 complex): CD3E, 9 | 916 OR | | |
| 3G antigen, gamma polypeption | de (TiT3 complex): CD3G, | 917 | | |
| BC-3 | CRL-2277 | human | A- | |
| DS-1 | CRL-11102 [†] | human | A+/- | |
| HH | CRL-2105 | human | A+ | |
| J45.01 | CRL-1990 | human | A+ | |
| Jurkat, Clone E6-1 | TIB-152 | human | A+ | |
| J.RT3-T3.5 | TIB-153 | human | A- | |
| MJ | CRL-8294 [†] | human | A+ | |
| NK-92 | CRL-2407 | human | A+ A- | |
| NK-92CI | CRL-2407 CRL-2409 | human | A- A- | |
| NK-92MI | | | | |
| | CRL-2408 | human | A- | |
| SUP-B15 | CRL-1929 | human | A- | |
| SUP-T1 TALL-104 | CRL-1942 CRL-11386 [†] | human human | A+ A+ | |
| | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| | Symbol, GenelD Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---------|--|------------------------------------|--------------------|-----------|--|
| | Cell Line Name | AICC® NO. | species | Expresses | Comments |
| | 38.1 | HB-231 | mouse/mouse | MAb | Anti human CD3 |
| | OKT 3 | CRL-8001 [†] | mouse/mouse | MAb | Anti human CD3 |
| D3E an | tigen, epsilon polypeptid | e (TiT3 complex): CD3E, 916 | | | |
| | BC3 | HB-10166 [†] | mouse/mouse | MAb | Anti human CD3, epsilon chair |
| D3 (cat | gene not yet curated) | | | | |
| | MYA-1 | CRL-2417 | cat | A+ | |
| D3 ant | igen, delta polypeptide: C | | | | |
| | epsilon polypeptide | | | | |
| | gamma polypeptide | | | | |
| | 145-2C11 | CRL-1975 | Armenian hamster/ | MAb | Anti mouse CD3 |
| 224 | | | mouse | | |
| D3A | MOLT 4 | CDL 1502 | I | Δ. | |
| | MOLT-4 | CRL-1582 | human | A+ | |
|) 2 D | Reh | CRL-8286 [†] | human | A+ | |
|)3B | CCRF-CEM | CCL-119 | human | Λ.μ. | |
| | MOLT-4 | CRL-119 | human human | A+ A+ | |
| | Reh | CRL-1362 CRL-8286 [†] | human | A+ A+ | |
| 3C | NCII | CNL-0200 | numan | A f | |
| .50 | MOLT-4 | CRL-1582 | human | A+ | |
| | Reh | CRL-8286 [†] | human | A+ | |
|)4 ant | igen (p55): CD4, 920 | | | | |
| | 8E5 | CRL-8993 [†] | human | A+ | |
| | BC-3 | CRL-2277 | human | A- | |
| | C8-B4 | CRL-2540 | human | A+ | |
| | CCRF-CEM | CCL-119 | human | A+ | |
| | D1.1 | CRL-10915 [†] | human | A- | |
| | DS-1 | CRL-11102 [†] | human | A- | |
| | H9 | HTB-176 | human | A+ | |
| | HH | CRL-2105 | human | A+ | |
| | HuT 102 | TIB-162 | human | A+ | |
| | HuT 78 | TIB-161 | human | A+ | |
| | MJ | CRL-8294 [†] | human | A+ | |
| | MOLT-3 | CRL-1552 | human | A+ | |
| | MOLT-4 | CRL-1582 | human | A+ | |
| | MV-4-11 | CRL-9591 [†] | human | A+ | |
| | NK-92 | CRL-2407 | human | A- | |
| | NK-92CI | CRL-2409 | human | A- | |
| | NK-92MI | CRL-2408 | human | A- | |
| | Reh | CRL-8286 [†] | human | A+ | |
| | SUP-B15 | CRL-1929 | human | A- | |
| | SUP-T1 | CRL-1942 | human | A+ | |
| | TALL-104 | CRL-11386 [†] | human | A- | And house - CD4 |
| 1 254 | OKT 4 | CRL-8002 [†] | mouse/mouse | MAb | Anti human CD4 |
| 4 ant | igen: Cd4, 12504 | TID 222 | mouro | Λ. | |
| | AKR1.G.1.OVA ^R .1.26 GK1.5 | TIB-232 TIB-207 | mouse rat/mouse | MAb | Anti mouse CD4 |
| 1 ant | igen (species not yet cura | | rat/mouse | IVIAD | Anti mouse CD4 |
| → ant | MYA-1 | CRL-2417 | cat | A+ | |
| | 17D | HB-262 | mouse/mouse | MAb | Anti sheep CD4 |
| | 74-12-4 | HB-147 | mouse/mouse | MAb | Anti pig CD4a |
| | CC30 | HB-270 | mouse/mouse | MAb | Anti bovine CD4 (BoCD4) |
| | CC8 | HB-280 | mouse/mouse | MAb | Anti bovine CD4 (BoCD4) |
| | IL-A11 | CRL-1879 | mouse/mouse | MAb | Anti bovine CD4 (BoCD4) Anti bovine CD4 (BoCD4) |
| 5 ant | igen (p56-62): CD5, 921 | 52 .5/ > | 5450,6450 | | 25 |
| | 8E5 | CRL-8993 [†] | human | A+ | |
| | BC-3 | CRL-2277 | human | A- | |
| | CCRF-CEM | CCL-119 | human | A+ | |
| | CCRF-HSB-2 | CCL-120.1 | human | A+ | |
| | DS-1 | CRL-11102 [†] | human | A- | |
| | MOLT-3 | CRL-1552 | human | A+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|------------------------------------|--------------|-----------|--|
| Cell Lille Name | AICC NO. | Species | Expresses | Comments |
| 95 antigen (p56-62) continued | | | | |
| MOLT-4 | CRL-1582 | human | A+ | |
| NK-92 | CRL-2407 | human | A- | |
| NK-92CI | CRL-2409 | human | A- | |
| NK-92MI | CRL-2408 | human | A- | |
| SUP-B15 | CRL-1929 | human | A- | |
| SUP-T1 | CRL-1942 | human | A+ | |
| OKT 1 | CRL-8000 [†] | mouse/mouse | MAb | Anti human CD5 |
| 5 antigen: Cd5, 12507 | | | | |
| AMJ2-C11 | CRL-2456 | mouse | A- | Lyt 1 |
| AMJ2-C8 | CRL-2455 | mouse | A- | Lyt 1 |
| NFS-25 C-3 | CRL-1695 | mouse | A+ | , |
| NFS-5 C-1 | CRL-1693 | mouse | A+ | |
| NFS-70 C-10 | CRL-1694 | mouse | A+ | |
| PMJ2-PC | CRL-2457 | mouse | A- | Lyt 1.1; Lyt 1.2 |
| PMJ2-R | CRL-2458 | mouse | A- | Lyt 1.1; Lyt 1.2 |
| 53-7.313 | TIB-104 | rat/mouse | MAb | Anti mouse LYT 1 (all alleles |
| 5 antigen (p56-62): CD5, 280745 | | ray mouse | 111110 | And mode Erri (an alleles |
| CC29 | HB-269 | mouse/mouse | MAb | Anti bovine CD5 (BoCD5) |
| CC17 | HB-281 | mouse/mouse | MAb | Anti bovine CD5 (BoCD5) Anti bovine CD5 (BoCD5) |
| 06 antigen: CD6, 923 | 110 201 | mouse, mouse | 111110 | Sovine CD3 (BOCD3) |
| MOLT-4 | CRL-1582 | human | A+ | |
| 12.1 | HB-228 | mouse/mouse | MAb | Anti human CD6 |
| 3Pt12B8 | HB-8136 [†] | mouse/mouse | MAb | Anti human CD6 |
| 6 antigen: CD6, 282881 | ПБ-0130 | mouse/mouse | IVIAD | Anti numan CDo |
| CC38 | LID 266 | mouso/mouso | MAb | Anti havina CD6 (PaCD6) |
| | HB-266 | mouse/mouse | IVIAD | Anti bovine CD6 (BoCD6) |
| 7 antigen (p41): CD7, 924 | CCL 110 | ha.a.a | Λ. | |
| CCRF-CEM | CCL-119 | human | A+ | |
| CCRF-HSB-2 | CCL-120.1 | human | A+ | |
| DS-1 | CRL-11102 [†] | human | A- | |
| K-562 | CCL-243 | human | A+ | |
| MOLT-3 | CRL-1552 | human | A+ | |
| MOLT-4 | CRL-1582 | human | A+ | |
| SUP-T1 | CRL-1942 | human | A+ | |
| T1 (174 x CEM.T1) | CRL-1991 | human | A+ | |
| T2 (174 x CEM.T2) | CRL-1992 | human | A+ | |
| NK-92 | CRL-2407 | human | A+ | |
| NK-92MI | CRL-2408 | human | A+ | |
| NK-92CI | CRL-2409 | human | A+ | |
| TALL-104 | CRL-11386 [†] | human | A+ | |
| T3-3A1 | HB-2 | mouse/mouse | MAb | Anti human CD7 |
| 08 antigen, alpha polypeptide (p32 | 2): CD8A , 925 OR | | | |
| beta polypeptide 1 (p3 | 7): CD8B1,926 | | | |
| BC-3 | CRL-2277 | human | A- | |
| DS-1 | CRL-11102 [†] | human | A- | |
| НН | CRL-2105 | human | A- | |
| NK-92 | CRL-2407 | human | A- | |
| NK-92CI | CRL-2409 | human | A- | |
| NK-92MI | CRL-2408 | human | A- | |
| SUP-B15 | CRL-1929 | human | A- | |
| SUP-T1 | CRL-1942 | human | A+ | |
| TALL-104 | CRL-1342 CRL-11386 [†] | human | A+ | |
| 51.1 | HB-230 | mouse/mouse | MAb | Anti human CD8 |
| OKT 8 | CRL-8014 [†] | mouse/mouse | MAb | Anti human CD8 |
| S6F1 | HB-9579 [†] | | MAb | Anti human CD8 Anti human CD8 |
| 36F I 98 antigen, alpha chain: Cd8a, 125 | | mouse/mouse | MAD | ATTUTTUTTI CDÖ |
| AKR1.G.1.OVAR.1.26 | TIB-232 | mouse | A+ | Lyt-2 |
| | | | | |
| 116-13.1 | HB-129 | mouse/mouse | MAb | Anti mouse Lyt 2 |
| 2.43 | TIB-210 | rat/mouse | MAb | Anti mouse Lyt 2.2 |
| 3.155 | TIB-211 | rat/mouse | MAb | Anti mouse Lyt 2 (all alleles) |
| 41-3.48 | HB-130 | mouse/mouse | MAb | Anti mouse Lyt 2.2 |
| | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|-------------------------------|--------------|-----------|------------------------------------|
| 53-6.72 | TIB-105 | rat/mouse | MAb | Anti mouse Lyt 2 (all alleles) |
| 83-12-5 | CRL-1971 | mouse/mouse | MAb | Anti mouse Lyt 2.2 (CD8 alpha 2.2) |
| HO-2.2 | TIB-150 | mouse/mouse | MAb | Anti mouse Lyt 2.2 |
| 08 antigen, alpha chain: Cd8a, 1 beta chain: Cd8b, 12 | | | | |
| TK-1 | CRL-2396 | mouse | A+ | |
| 36.5 | CRL-11116 [†] | mouse | A- | |
| 08 antigen, alpha polypeptide (p | o32): CD8A: 281060 | | | |
| CC58 | HB-275 | mouse/mouse | MAb | Anti bovine CD8 (BoCD8) |
| CC63 | HB-264 | mouse/mouse | MAb | Anti bovine CD8 (BoCD8) |
| IL-A51 | CRL-1871 | mouse/mouse | MAb | Anti bovine CD8 (BoCD8) |
| D8 antigen (species not yet cura | ted) | | | |
| MYA-1 | CRL-2417 | cat | A- | Feline CD8– |
| 09 antigen (p24): CD9, 928 | | | | |
| RS4 | CRL-1873 | human | A+ | |
| D9 antigen: Cd9 12527 | | | | |
| KMC8.8 | CRL-2212 | rat/mouse | MAb | Anti mouse CD9 |
| D10. <i>See</i> Membrane metallo-end | lopeptidase. | | | |
| D11a. See Integrin, alpha L. | | | | |
| D11b. See Integrin, alpha M. | | | | |
| D11b/CD18. See Integrin, alpha ለ | A AND Integrin, beta 2. | | | |
| D11c. See Integrin, alpha X. | | | | |
| D13. <i>See</i> Alanyl (membrane) ami | nopeptidase. | | | |
| D14 antigen: CD14, 929 | | | | |
| NK-92 | CRL-2407 | human | A- | |
| NK-92CI | CRL-2409 | human | A- | |
| NK-92MI | CRL-2408 | human | A- | |
| 26ic | HB-246 | mouse/mouse | MAb | Anti human CD14 |
| 3C10 | TIB-228 | mouse/mouse | MAb | Anti human CD14 |
| 60bca | HB-247 | mouse/mouse | MAb | Anti human CD14 |
| D15 | | | | |
| AML-193 | CRL-9589 [†] | human | A+ | |
| MV-4-11 | CRL-9591 [†] | human | A+ | |
| SUP-B15 | CRL-1929 | human | A- | |
| D16. See Fc fragment of IgG, low | affinity Illa, receptor for (| CD16). | | |
| D 18. See Integrin, beta 2. | | | | |
| D19 antigen: CD19, 930 | | | | |
| 29SR | CRL-2262 | human | A- | |
| ARH-77 | CRL-1621 | human | A+ | |
| BC-3 | CRL-2277 | human | A- | |
| DB | CRL-2289 | human | A+ | |
| Farage | CRL-2630 | human | A+ | |
| GA-10 | CRL-2392 | human | A+ | |
| HS-Sultan | CRL-1484 | human | A+ | |
| HT | CRL-2260 | human | A+ | |
| IM-9 | CCL-159 | human | A+ | |
| JM1 | CRL-10423 [†] | human | A+ | |
| MC/CAR | CRL-8083 [†] | human | A+ | |
| NK-92 | CRL-2407 | human | A- | |
| NK-92CI | CRL-2409 | human | A- | |
| NK-92MI | CRL-2408 | human | A- | |
| Pfeiffer | CRL-2632 | human | A+ | |
| RL | CRL-2261 | human | A+ | |
| RPMI 8226 | CCL-155 | human | A- | |
| Toledo | CRL-2631 | human | A+ | |
| D19 antigen: Cd19, 12478 | | | | |
| 1D3 | HB-305 | rat/mouse | MAb | Anti mouse CD19 |
| D20. See Membrane-spanning 4- | | 744 0450 | | |
| D21. See Complement compone | | receptor 2. | | |
| D22 antigen: CD22, 933 | (34) Epstern barr virus) | . cccptor 2. | | |
| 29SR | CRL-2262 | human | A- | |
| 27JN | CNL-ZZUZ | Human | Λ- | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product of the produc$

^{*}Part of the NBL collection; see page 12. †Patent item; see page 12.

See the ATCC online catalogue for the complete description of a cell line.
research use only, Not intended for use in humans, animals or for diagnostics.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|--|---|--|---|
| CD22ti | | - | - | |
| D22 antigen continued | CDL 2277 | h | Λ | |
| BC-3 | CRL-2277 | human | A- | |
| DB | CRL-2289 | human | A+ | |
| Farage | CRL-2630 | human | A+ | |
| HT | CRL-2260 | human | A+ | |
| RL | CRL-2261 | human | A+ | |
| D22 antigen: Cd22, 12483 | | | | |
| Cy34.1.2 | TIB-163 | mouse/mouse | MAb | Anti mouse LYB 8.2 |
| D23. See Fc fragment of IgE, low a | | | | |
| D24 antigen (small cell lung carci | <u> </u> | | | |
| RS4 | CRL-1873 | human | A+ | |
| D25. See Interleukin 2 receptor, al | pha. | | | |
| D28 antigen (Tp44): CD28, 940 | | | | |
| ARH-77 | CRL-1621 | human | A+ | |
| HS-Sultan | CRL-1484 | human | A- | |
| J45.01 | CRL-1990 | human | A+ | |
| MC/CAR | CRL-8083 [†] | human | A- | |
| NK-92 | CRL-2407 | human | A+ | |
| NK-92CI | CRL-2409 | human | A+ | |
| NK-92MI | CRL-2408 | human | A+ | |
| RPMI 8226 | CCL-155 | human | A+ | |
| :D28 antigen: Cd28, 12487 | | | | |
| PV1 | HB-12352 | Armenian hamster/ | MAb | Anti mouse CD28 |
| | | mouse | | |
| D29. See Integrin, beta 1. | | | | |
| D30. See Tumor necrosis factor re | contar cun orfamily man | abor 9 | | |
| D30.3ee fulfior flectosis factor re | | | | |
| TD 21 Con Platalet/and etholial coll | adhasian malasula (CD) | 21 antigon) | | |
| D 31. See Platelet/endothelial cell | | | | |
| D32. See Fc fragment of IgG, low a | | | | |
| D32. <i>See</i> Fc fragment of IgG, low a D33 antigen: CD33, 945 | affinity IIa, receptor for (C | D32). | | |
| D32. See Fc fragment of IgG, low a D33 antigen: CD33, 945 SUP-B15 | affinity IIa, receptor for (C CRL-1929 | D32). | A- | |
| D32. See Fc fragment of IgG, low a D33 antigen: CD33, 945 SUP-B15 M195 | affinity IIa, receptor for (C | D32). | A- MAb | Anti human myeloid leukemia (CD33) |
| D32. See Fc fragment of IgG, low a D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 | affinity IIa, receptor for (C CRL-1929 HB-10306 | D32). human mouse/mouse | MAb | Anti human myeloid leukemia (CD33) |
| D32. See Fc fragment of IgG, low a D33 antigen: CD33, 945 SUP-B15 | affinity IIa, receptor for (C CRL-1929 HB-10306 CRL-2392 | D32). | | Anti human myeloid leukemia (CD33) |
| D32. See Fc fragment of IgG, low a D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 | affinity IIa, receptor for (C CRL-1929 HB-10306 | D32). human mouse/mouse | MAb | Anti human myeloid leukemia (CD33) |
| D32. See Fc fragment of IgG, low a D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 | affinity IIa, receptor for (C CRL-1929 HB-10306 CRL-2392 | human mouse/mouse human | MAb A- | Anti human myeloid leukemia (CD33) |
| D32. See Fc fragment of IgG, low a D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 | CRL-1929 HB-10306 CRL-2392 CRL-2407 | human mouse/mouse human human | MAb A- A- | Anti human myeloid leukemia (CD33) |
| D32. See Fc fragment of IgG, low a D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 | human mouse/mouse human human human human | MAb A- A- A- A- A- | Anti human myeloid leukemia (CD33) |
| D32. See Fc fragment of IgG, low at D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 | human mouse/mouse human human human human human human human | A- A- A- A- A- A+ | |
| D32. See Fc fragment of IgG, low at D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 | human mouse/mouse human human human human | MAb A- A- A- A- A- | Anti human myeloid leukemia (CD33) Anti human CD34 |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 | human mouse/mouse human human human human human human human | A- A- A- A- A- A+ | |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. | human mouse/mouse human human human human human human human mouse/mouse | A- A- A- A- A- A+ MAb | |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 | human mouse/mouse human | A- A- A- A- A- A+ MAb | |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 | human mouse/mouse human mouse/mouse | A- A- A- A- A- A+ MAb | |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 | human mouse/mouse human human human human human human human human mouse/mouse human human | MAb A- A- A- A- A+ MAb A- A+ A- A+ A- | |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 | human mouse/mouse human human human human human human human human mouse/mouse human human human human | MAb A- A- A- A+ MAb A- A+ A- A+ A- A+ A- A+ | |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 | human mouse/mouse human human human human human human human human mouse/mouse human human human human human human human | MAb A- A- A- A- A+ MAb A- A+ A+ A- A+ A- A+ A+ | |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 | human mouse/mouse human human human human human human human human mouse/mouse human human human human | MAb A- A- A- A+ MAb A- A+ A- A+ A- A+ A- A+ A- A+ A- | |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† | human mouse/mouse human human human human human human human human mouse/mouse human human human human human human human | MAb A- A- A- A- A+ MAb A- A+ A+ A- A+ A- A+ A+ | |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer: D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 | human mouse/mouse human human human human human human human human mouse/mouse human | MAb A- A- A- A+ MAb A- A+ A- A+ A- A+ A- A+ A- A+ A- | |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer: D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† | human mouse/mouse human | MAb A- A- A- A+ MAb A- A+ A- A+ A- A+ A- A+ A- A+ A- A+ | |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† | human mouse/mouse human | MAb A- A- A- A+ MAb A- A+ A- A+ A- A+ A+ A- A+ A+ A- A+ A+ A+ A+ A+ | |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 Pfeiffer RPMI 8226 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-2632 CCL-155 | human mouse/mouse human | MAb A- A- A- A- A+ MAb A- A+ A- A+ A- A+ A+ A- A+ A+ A+ A+ A+ A+ A+ | |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 Pfeiffer RPMI 8226 SUP-B15 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-1630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-2632 CCL-155 CRL-1929 | human mouse/mouse human | MAb A- A- A- A- A+ MAb A- A+ A- A+ A- A+ A+ A- A+ A+ A+ A+ A+ A+ A+ A+ A+ | |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 Pfeiffer RPMI 8226 SUP-B15 SUP-T1 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-2632 CCL-155 CRL-1929 CRL-1942 | human mouse/mouse human | MAb A- A- A- A- A+ MAb A- A+ A- A+ A- A+ | |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 Pfeiffer RPMI 8226 SUP-B15 SUP-T1 TF-1a | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 At (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-9068† CRL-2632 CCL-155 CRL-1929 CRL-1942 CRL-1942 CRL-2451 | human mouse/mouse human | MAb A- A- A- A- A+ MAb A- A+ A- A+ A- A+ | |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 Pfeiffer RPMI 8226 SUP-B15 SUP-T1 TF-1a Toledo | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 At (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-9068† CRL-2632 CCL-155 CRL-1929 CRL-1942 CRL-2451 CRL-2631 | human mouse/mouse human | MAb A- A- A- A- A+ MAb A- A+ A- A+ A- A+ A+ A- A+ | Anti human CD34 |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 Pfeiffer RPMI 8226 SUP-B15 SUP-T1 TF-1a Toledo OKT 10 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-968† CRL-2632 CCL-155 CRL-1929 CRL-1942 CRL-2631 CRL-2631 CRL-2631 CRL-2631 | human mouse/mouse human | MAb A- A- A- A- A+ MAb A- A+ A- A+ A- A+ A+ A- A+ | Anti human CD34 Anti human CD38 |
| D32. See Fc fragment of IgG, low a SUP-B15 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 Pfeiffer RPMI 8226 SUP-B15 SUP-T1 TF-1a Toledo OKT 10 THB-7 | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-9068† CRL-1929 CRL-1929 CRL-1942 CRL-2451 CRL-2631 CRL-2631 CRL-2631 CRL-28022 HB-136 | human mouse/mouse human | MAb A- A- A- A- A+ MAb A- A+ A- A+ A- A+ A+ A- A+ | Anti human CD34 |
| CD32. See Fc fragment of IgG, low according to the IgG, low according to IgG, low accord | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-9068† CRL-1929 CRL-1929 CRL-1942 CRL-2451 CRL-2631 CRL-2631 CRL-2631 CRL-2631 CRL-8022 HB-136 whate diphosphohydrolas | human mouse/mouse human | MAb A- A- A- A- A+ MAb A- A+ A- A+ A- A+ | Anti human CD34 Anti human CD38 |
| D32. See Fc fragment of IgG, low at D33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 Pfeiffer RPMI 8226 SUP-B15 SUP-T1 TF-1a Toledo OKT 10 THB-7 D39. See Ectonucleoside triphosp | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-9068† CRL-2631 CRL-1929 CRL-1942 CRL-2631 CRL-2631 CRL-2631 CRL-2631 CRL-8022 HB-136 whate diphosphohydrolast | human | MAb A- A- A- A- A- A+ MAb A- A+ A- A+ A- A+ A+ A- A+ | Anti human CD34 Anti human CD38 |
| D32. See Fc fragment of IgG, low at D33 antigen: CD33, 945 SUP-B15 M195 D34 antigen: CD34, 947 GA-10 NK-92 NK-92CI NK-92MI TF-1a AC133.1 D35. See Complement componer D38 antigen (p45): CD38, 952 ARH-77 BC-3 DS-1 Farage HS-Sultan IM-9 MC/CAR NCI-H929 Pfeiffer RPMI 8226 SUP-B15 SUP-T1 TF-1a Toledo OKT 10 THB-7 D33. See Ectonucleoside triphosp | CRL-1929 HB-10306 CRL-2392 CRL-2407 CRL-2409 CRL-2408 CRL-2451 HB-12346 at (3b/4b) receptor 1. CRL-1621 CRL-2277 CRL-11102 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-9068† CRL-9068† CRL-2631 CRL-1929 CRL-1942 CRL-2631 CRL-2631 CRL-2631 CRL-2631 CRL-8022 HB-136 whate diphosphohydrolast | human | MAb A- A- A- A- A- A+ MAb A- A+ A- A+ A- A+ A+ A- A+ | Anti human CD34 Anti human CD38 |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| lame: Symbol, GeneID | ATCC® N - | C: | F | C |
|--|---|---|--|--------------------------------------|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| | | | | |
| Farage | CRL-2630 | human | A+ | |
| FW11-10-3 | HB-257 | mouse/mouse | MAb | Anti human CD44, V4 variant |
| FW11-24-17-36 | HB-258 | mouse/mouse | MAb | Anti human CD44, V9 variant |
| FW11-9-2 | HB-256 | mouse/mouse | MAb | Anti human CD44, V6 variant |
| Hermes-3 | HB-9480 [†] | mouse/mouse | MAb | Anti human CD44 |
| D44 antigen: Cd4, 12505 | | | | |
| KM114 | TIB-242 | rat/mouse | MAb | Anti mouse CD44 |
| KM201 | TIB-240 | rat/mouse | MAb | Anti mouse CD44 |
| KM703 | CRL-1896 | rat/mouse | MAb | Anti mouse CD44 |
| KM81 | TIB-241 | rat/mouse | MAb | Anti mouse CD44 |
| LYK-1 | HB-306 | rat/mouse | MAb | Anti mouse CD44, isoforms expressing |
| | | | | variable exon V10 |
| LYK-12 | HB-316 | rat/mouse | MAb | Anti mouse CD44 |
| LYK-16 | HB-319 | rat/mouse | MAb | Anti mouse CD44 |
| LYK-5 | HB-310 | rat/mouse | MAb | Anti mouse CD44 |
| LYK-7 | HB-311 | rat/mouse | MAb | Anti mouse CD44, isoforms expressing |
| LII(-/ | וו כ-טוו | ray mouse | INIAU | variable exon V10 |
| LYK-8 | UD 212 | rat/mouse | MAb | Anti mouse CD44, isoforms expressing |
| LI N-O | HB-312 | | IVIAD | And mouse CD44, isolorins expressing |
| 12/// 0 | 110.040 | variable exon V10 | | |
| LYK-9 | HB-313 | rat/mouse | MAb | Anti mouse CD44, isoforms expressing |
| | | variable exon V10 | | |
| D45. See Protein tyrosine phospha | | | | |
| D47 antigen (Rh-related antigen, i | | | | |
| B6H12.2 | HB-9771 [†] | mouse/mouse | MAb | Anti human CD47 |
| D49a. See Integrin, alpha 1. | | | | |
| D49d. See Integrin, alpha 4. | | | | |
| | | | | |
| D49e. See Integrin, alpha 5. | | | | |
| D49e. <i>See</i> Integrin, alpha 5. D54 <i>See</i> Intercellular adhesion mo | olecule 1 (ICAM1) | | | |
| D54. See Intercellular adhesion mo | | | | |
| D54. See Intercellular adhesion mo D56. See Neural cell adhesion mole | | | | |
| D54. See Intercellular adhesion mo D56. See Neural cell adhesion mole D57 antigen: CD57, 964 | ecule 1 (NCAM1). | homan | A. | |
| D54. See Intercellular adhesion mo D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 | ecule 1 (NCAM1). CRL-2066 | human | A+ | |
| D54. See Intercellular adhesion mo D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 | CRL-2066 CRL-2064 | human | A+ | |
| D54. See Intercellular adhesion mo D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 | CRL-2066 CRL-2064 CRL-2062 | human human | A+ A+ | |
| D54. See Intercellular adhesion mo D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 | human | A+ A+ A+ | |
| D54. See Intercellular adhesion mo D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 | CRL-2066 CRL-2064 CRL-2062 | human human | A+ A+ | |
| D54. See Intercellular adhesion mo D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 | human human human | A+ A+ A+ | Anti human CD57 |
| D54. See Intercellular adhesion mol D56. See Neural cell adhesion mol D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 | human human human human mouse/mouse | A+ A+ A+ A+ | Anti human CD57 |
| D54. See Intercellular adhesion mol D56. See Neural cell adhesion mol D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 | human human human human mouse/mouse | A+ A+ A+ A+ MAb | Anti human CD57 |
| D54. See Intercellular adhesion mod D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 | human human human human mouse/mouse CD58, 965 human | A+ A+ A+ A+ MAb | |
| D54. See Intercellular adhesion mod D56. See Neural cell adhesion mod D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 | human human human human mouse/mouse | A+ A+ A+ A+ MAb | Anti human CD57 Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 | human human human human mouse/mouse CD58, 965 human | A+ A+ A+ A+ MAb | |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 | human human human human mouse/mouse CD58, 965 human | A+ A+ A+ A+ MAb | |
| D54. See Intercellular adhesion model. D56. See Neural cell adhesion model. D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 | human human human human mouse/mouse CD58, 965 human | A+ A+ A+ A+ MAb | |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 | human human human human mouse/mouse CD58, 965 human | A+ A+ A+ A+ MAb | |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 | human human human human mouse/mouse CD58, 965 human | A+ A+ A+ A+ MAb | |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. D71. See Transferrin receptor. | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 | human human human human mouse/mouse CD58, 965 human | A+ A+ A+ MAb A+ MAb | |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 | human human human human mouse/mouse CD58, 965 human | A+ A+ A+ MAb A+ MAb | |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 | human human human human mouse/mouse CD58, 965 human mouse/mouse | A+ A+ A+ MAb A+ MAb | |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse/mouse | A+ A+ A+ MAb A+ MAb | |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse mouse | A+ A+ A+ MAb A+ MAb A+ A+ A+ A+ A+ A+ | |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse | A+ A+ A+ MAb A+ MAb A+ A+ A+ A+ A+ A+ | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin E. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 TIB-165 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse | A+ A+ A+ MAb A+ MAb A+ MAb | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 D77 GA-10 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 TIB-165 CRL-2392 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse human human mouse/mouse | A+ A+ A+ MAb A+ MAb A+ MAb A+ A+ A+ A+ A+ A+ A+ A+ | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 D77 GA-10 GA-10 (Clone 4) | CRL-2630 CRL-1695 CRL-1694 TIB-165 CRL-2392 CRL-2396 CRL-2393 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse human human human | A+ A+ A+ MAb A+ MAb A+ MAb A+ | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin L. D 62P. See Selectin P. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 D77 GA-10 GA-10 (Clone 4) GA-10 (Clone 20) | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 TIB-165 CRL-2392 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse human human mouse/mouse | A+ A+ A+ MAb A+ MAb A+ MAb A+ A+ A+ A+ A+ A+ A+ A+ | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin E. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 D77 GA-10 GA-10 (Clone 4) GA-10 (Clone 20) D80 antigen: Cd80, 12519 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 TIB-165 CRL-2392 CRL-2393 CRL-2394 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse mouse human human human human | A+ A+ A+ MAb A+ MAb A+ MAb A+ | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin E. D62L. See Transferrin receptor. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 D77 GA-10 GA-10 (Clone 4) GA-10 (Clone 20) D80 antigen: Cd80, 12519 C1498 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 TIB-165 CRL-2392 CRL-2393 CRL-2394 TIB-49 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse mouse human human human human human human mouse | A+ A+ A+ MAb A+ MAb A+ MAb A+ | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin E. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 D77 GA-10 GA-10 (Clone 4) GA-10 (Clone 20) D80 antigen: Cd80, 12519 C1498 EOC 13.31 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 TIB-165 CRL-2392 CRL-2393 CRL-2394 TIB-49 CRL-2468 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse mouse human human human human | A+ A+ A+ MAb A+ MAb A+ MAb A+ | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin E. D62L. See Transferrin receptor. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 D77 GA-10 GA-10 (Clone 4) GA-10 (Clone 20) D80 antigen: Cd80, 12519 C1498 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 TIB-165 CRL-2392 CRL-2393 CRL-2394 TIB-49 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse mouse human human human human human human mouse | A+ A+ A+ MAb A+ MAb A+ MAb A+ | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D 61. See Integrin, beta 3. D62E. See Selectin E. D62L. See Selectin E. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 D77 GA-10 GA-10 (Clone 4) GA-10 (Clone 20) D80 antigen: Cd80, 12519 C1498 EOC 13.31 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 TIB-165 CRL-2392 CRL-2393 CRL-2394 TIB-49 CRL-2468 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse human human human human human human mouse mouse mouse | A+ A+ A+ MAb A+ MAb A+ MAb A+ | Anti human CD58 |
| D54. See Intercellular adhesion mole D56. See Neural cell adhesion mole D56. See Neural cell adhesion mole D57 antigen: CD57, 964 DMS 114 DMS 153 DMS 53 DMS 79 SHP-77 HNK-1 D58 antigen (lymphocyte function Farage TS2/9.1.4.3 D61. See Integrin, beta 3. D62E. See Selectin E. D62E. See Selectin E. D71. See Transferrin receptor. D72 antigen: Cd72, 12517 NFS-25 C-3 NFS-5 C-1 NFS-70 C-10 10-1.D.2 D77 GA-10 GA-10 (Clone 4) GA-10 (Clone 20) D80 antigen: Cd80, 12519 C1498 EOC 13.31 EOC 2 | CRL-2066 CRL-2064 CRL-2062 CRL-2049 CRL-2195 TIB-200 n-associated antigen 3): CRL-2630 HB-205 CRL-1695 CRL-1693 CRL-1694 TIB-165 CRL-2392 CRL-2393 CRL-2394 TIB-49 CRL-2468 CRL-2467 | human human human human human mouse/mouse CD58, 965 human mouse/mouse mouse mouse mouse mouse human human human human human mouse | A+ A+ A+ MAb A+ MAb A+ MAb A+ | Anti human CD58 |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product is a product of the product$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| ame: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|----------------------------------|------------------------------|-----------|---------------------------|
| Cell Lille Haille | AICC NO. | Species | Lxpresses | Comments |
| 986 antigen: Cd86, 12524 | | | | |
| EOC 13.31 | CRL-2468 | mouse | A+ | |
| EOC 2 | CRL-2467 | mouse | A+ | |
| EOC 20 | CRL-2469 | mouse | A- | |
| 2D10 | CRL-2226 | rat/mouse | MAb | Anti mouse B7-2 |
| GL1 | HB-253 | rat/mouse | MAb | Anti mouse B7-2 |
| 106. See Vascular cell adhesion | · , | | | |
| 15. See Colony stimulating fac | tor 1 receptor. | | | |
| 117. <i>See kit</i> . | | | | |
| 151 antigen: CD151,977 | | | | |
| 41-2 | CRL-2695 | mouse/mouse | MAb | Anti human CD151 |
| 50-6 | CRL-2696 | mouse/mouse | MAb | Anti human CD151 |
| 152 antigen: Cd152, 12477 | | | | |
| UC10-4F10-11 | HB-304 | Armenian hamster/ | MAb | Anti mouse CTLA-4 |
| | | mouse | | |
| 0154. See Tumor necrosis factor (| (ligand) superfamily, men | nber 5 (hyper-IgM syndrome). | | |
| 0164 antigen, sialomucin: CD16 4 | | | | |
| MCF-12A | CRL-10782 [†] | human | P+ | |
| MCF-12F | CRL-10783 [†] | human | P+ | |
| w14 | | | | |
| MEG-01 | CRL-2021 | human | A+ | |
| 0w128. See Interleukin 8 recepto | r, beta. | | | |
| ntromere protein B (80kD): CEN | PB, 1059 | | | |
| 2D-7 | HB-9667 [†] | mouse/mouse | MAb | Anti human CENP-B |
| ruloplasmin (ferroxidase): CP, 13 | | | | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| os. See fos. | 1.0 0000 | | | |
| nemokines, alpha | | | | |
| BEND | CRL-2398 | bovine | P+ | In response to interferor |
| olecystokinin: CCK, 885 | CHE 2370 | bovine | | in response to interrero |
| SK-PN-DW | CRL-2139 | human | P+ | |
| olecystokinin-8 | CIL 2137 | Haman | | |
| HCN-1A | CRL-10442 [†] | human | P+ | |
| HCN-2 | CRL-10742 [†] | human | P+ | |
| olesterol | CNL-10742 | Human | ГТ | |
| | CDI 2200 | maura | D. | |
| FL83B 2C5-6 | CRL-2390 HB-8995 [†] | mouse/mouse | P+ MAb | Anti cholesterol |
| | | mouse/mouse | IVIAD | Anti cholesteroi |
| oline acetyltransferase: Chat, 1 2 | | mauss | D. | |
| NB41A3 | CNC-147 | mouse | P+ | |
| olinergic receptor, muscarinic 1 | | mausa | D. | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| olinergic receptor, muscarinic 2 | | he. | D. | |
| HEL 299 | CCL-137 | human | R+ | |
| nolinergic receptor, muscarinic 2 | · | | D.: | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| nolinergic receptor, muscarinic 3 | | | | |
| M1WT2 | CRL-1984 | Chinese hamster | R+ (rat) | |
| M1WT3 | CRL-1985 | Chinese hamster | R+ (rat) | |
| M1WT5 | CRL-1986 | Chinese hamster | R+ (rat) | |
| M3WT4 | CRL-1981 | Chinese hamster | R+ (rat) | |
| M3WT5 | CRL-1982 | Chinese hamster | R+ (rat) | |
| M3WT8 | CRL-1983 | Chinese hamster | R+ (rat) | |
| nolinergic receptor, muscarinic 1 | | | | |
| muscarinic 2 | : CHRM2, 1129 OR | | | |
| muscarinic 3 | :CHRM3, 1131 | | | |
| DMS 53 | CRL-2062 | human | R+ | |
| NCI-N87 | CRL-5822 | human | R+ | |
| NCI-SNU-16 | CRL-5974 | human | R+ | |
| - | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|--|----------------------|-----------|--|
| | | Species | Expicases | Comments |
| holinergic receptor, muscarinic 1, | | 0.0 | | |
| | cardiac: Chrm2, 107850 | OR | | |
| 266-6 | cardiac: Chrm3, 12671 CRL-2151 | mouso | R+ | |
| BC,H1 | CRL-1443 | mouse mouse | R+ | |
| G-8 | CRL-1456 | mouse | R+ | Highly responsive |
| H7c2 (2-1) | CRL-1446 | mouse | R+ | Responsive |
| Chondroitin sulfate proteoglycan | | mouse | IV I | пезропыче |
| L2-RYC | CRL-2180 | rat | P+ | |
| horionic gonadotropin receptor. | | | | |
| horionic gonadotropin (hCG). See | | | | |
| horionic somatomammotropin h | | | | |
| h | ormone 2: CSH2, 1443 | | | |
| BeWo | CCL-98 | human | P+ | |
| JAR | HTB-144 | human | P+ | |
| JEG-3 | HTB-36 | human | P+ | |
| horoideremia (Rab escort proteir | 1): CHM, 1121 | | | |
| IgG-2F1 | CRL-2419 | mouse/mouse | MAb | Anti human REP-1 |
| -H-ras. See ras. | | | | |
| hromogranin A (parathyroid secr | etory protein 1): CHGA, 1 | 113 | | |
| HP75 | CRL-2506 | human | P+ | |
| HPAC | CRL-2119 | human | P- | |
| iliary neurotrophic factor recepto | <u> </u> | | | |
| TF-1 | CRL-2003 | human | R– | |
| TF-1.CN5a.1 | CRL-2512 | human | R+ | Responsive (alpha subunit of CNTF) |
| -kit. See kit. | | | | |
| Clathrin, brain | TID 407 | | | |
| CVC.4 | TIB-137 | mouse/mouse | MAb | Anti bovine brain clathrin |
| Clathrin, heavy polypeptide (Hc): C | | | | |
| TD.1 | CRL-2232 | mouse/mouse | MAb | Anti human clathrin, heavy chain |
| X22 | CRL-2228 | mouse/mouse | MAb | Anti human clathrin, heavy chain |
| Clathrin, light polypeptide (Lca): Cl | | | | |
| polypeptide (Lcb): C CON.1 | CRL-2229 | mausa/mausa | MAb | Anti human clathrin light chain |
| Clathrin, light polypeptide (Lca): Clathrin | | mouse/mouse | IVIAD | Anti human clathrin, light chain |
| chain B: CLTB, 2810 | | | | |
| CVC.1 | TIB-135 | mouse/mouse | MAb | Anti bovine clathrin, light chain |
| CVC.7 | TIB-133 | mouse/mouse | MAb | Anti bovine clathrin, light chain |
| -myb. See myb. | 110-130 | mouse/mouse | IVIAD | And bovine clatinii, light chain |
| :-myc. See myc. | | | | |
| Coagulation factor II (thrombin): F . | 2.2147 | | | |
| JO1-1 | HB-8638 [†] | mouse/mouse | MAb | Anti human abnormal prothrombin |
| Coagulation factor 2: F2, 29251 | 1.5 0000 | 1110 43 67 1110 43 6 | | 7 and Training agreement processing in |
| H4-II-E-C3 | CRL-1600 | rat | P+ | |
| Coagulation factor II (thrombin) re | | | | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| oagulation factor VIII, procoagula | nt component (hemoph | | | |
| HUV-EC-C | CRL-1730 | human | P+ | |
| MEG-01 | CRL-2021 | human | P+ | |
| Coagulation factor VIII: F8, 14069 | | | | |
| M2-10B4 | CRL-1972 | mouse | P- | |
| Coagulation factor VIII (species no | t yet curated) | | | |
| CPA 47 | CRL-1733 | bovine | P+ | |
| EJG | CRL-8659 [†] | bovine | P+ | |
| RF/6A | CRL-1780 | Rhesus monkey | P+ | |
| ollagen | | , | | |
| KEL FIB | CRL-1762 | human | P+ | |
| 3T6-Swiss albino | CCL-96 | mouse | P+ | |
| MC3T3-E1 Subclone 14 | | mouse | P+ | |
| | | | P+ | |
| MC3T3-E1 Subclone 24 | CRL-2595 | mouse | ГТ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product of the produc$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|------------------------|-----------------|----------------------|--------------------------|
| | | | | |
| Collagen continued | | | | |
| MC3T3-E1 Subclone 4 | CRL-2593 | mouse | P+ | |
| ollagen, bone type 1 | | | | |
| 1H11 | HB-10611 [†] | mouse/mouse | MAb | Anti collagen, bone type |
| llagen, type IV (six type IV collagens) | | | | |
| EHS | CRL-2108 | mouse | P+ | |
| F9 | CRL-1720 | mouse | P+ | |
| M2-10B4 | CRL-1972 | mouse | P+ | |
| PFHR 9 | CRL-2423 | mouse | P+ | |
| L2-RYC | CRL-2180 | rat | P+ | |
| NMU | CRL-1743 | rat | P+ | |
| ocollagen, type XVIII, alpha 1: Col18a | | | D : | |
| EOMA | CRL-2586 | mouse | P+ | |
| llagenase (ten collagenases) HIG-82 | CDL 1022 | In India | D : | |
| | CRL-1832 | rabbit | P+ | |
| olon antigen 3 | CCL 221 | hna = := | D : | |
| DLD-1 | CCL-221 | human | P+ | |
| olon specific antigen (CSAp) | CCL 227 | la coma a m | D. | |
| SW948 | CCL-237 | human | P+ | |
| WiDr | CCL-218 | human | P+ | |
| plonic mucin glycoprotein. See Mucin | 1. | | | |
| olony stimulating activity (CSA) | TID 222 | h | D : | |
| GCT | TIB-223 | human | P+ | |
| lony stimulating factor 1 (macropha | | h | D : | |
| HS-5 | CRL-11882 [†] | human | P+ | |
| MIA PaCa-2 SK-N-SH | CRL-1420 | human | P+ | |
| | HTB-11 | human | P+ | |
| 5/9 m α3-18 | CRL-10154 [†] | Chinese hamster | P+ (human) | Anti human CCF I |
| F1A3-23 F18 AF1 | HB-8207 [†] | mouse/mouse | MAb MAb | Anti human CSF-I |
| | HB-8208 [†] | mouse/mouse | IVIAD | Anti human CSF-I |
| ony stimulating factor 1 (macropha | | | D. | |
| LADMAC SR-4987 | CRL-2420 CRL-2028 | mouse mouse | P+ P+ | |
| ony stimulating factor 1 receptor, fo | | | | CE1D 1426 |
| DMS 79 | CRL-2049 | human | 0– | v-fms |
| MSTO-211H | CRL-2049 CRL-2081 | human | 0- | v-fms |
| NCI-H146 | HTB-173 | human | 0 - 0+ | v-fms |
| NCI-H146 | | human | O+ | V-IIIIS |
| NCI-H526 NCI-H69 | CRL-5811 HTB-119 | human | O+ | v-fms |
| NCI-H82 | HTB-119 | human | O+ | v-fms |
| NCI-N417 | CRL-5809 | human | O+ O+ | v-11115 |
| olony stimulating factor 1 receptor: C | | Hulliali | O+ | |
| EOC 13.31 | CRL-2468 | mouse | A+, R+ | Dependent |
| EOC 2 | CRL-2467 | mouse | A+, R+ | Dependent |
| EOC 20 | CRL-2469 | mouse | A+, R+ | Dependent |
| I-11.15 | CRL-2470 | mouse | A+, R+ | Dependent |
| I-13.35 | CRL-2470 | mouse | A+, R+ | Dependent |
| olony stimulating factor 2 (granulocy | | | 7117111 | Берепаен |
| HS-5 | CRL-11882 [†] | human | P+ | |
| Mo | CRL-8066 [†] | human | P+ | |
| SW480 | CCL-228 | human | P+ | |
| TALL-104 | CRL-11386 [†] | human | P+ | |
| VA-ES-BJ | CRL-2138 | human | P+ | |
| BVD2-23B6.4 | HB-9568 [†] | rat/mouse | MAb | Anti human GM-CSF |
| BVD2-21C11.3 | HB-9569 [†] | rat/mouse | MAb | Anti human GM-CSF |
| lony stimulating factor 3 (granulocy | | 7447110430 | | |
| HS-5 | CRL-11882 [†] | human | P+ | |
| plony stimulating factor 3 (granulocy | | | | |
| ConA-B1-VICK | CRL-12357 [†] | chicken | P+ | |
| Con A-C1-VICK | CRL-12135 [†] | chicken | P+ | |
| | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name: Symbol, GeneID | 17668 11 | | _ | |
|------------------------------------|----------------------------|-----------------------------|------------|---------------------------------------|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| CA46 | CRL-1648 | human | R+ | |
| CESS | TIB-190 | human | R+ | |
| Clone 15 HL-60 | CRL-1964 | human | R+ | |
| Daudi | CCL-213 | human | R+ | |
| HL-60 | CCL-240 | human | R+ | |
| MC116 | CRL-1649 | human | R– | |
| ST486 | CRL-1647 | human | R+ | |
| MH,C, | CCL-144 | rat | P+ | Components |
| Complement (C4) | | | | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| omplement component 1, q subc | omponent, receptor 1: C | 1qr1, 17064 | | |
| LADMAC | CRL-2420 | mouse | R+ | |
| omplement component 1, q subc | | | | |
| | | otide: C1QB, 713 OR | | |
| | | peptide: C1QG, 714 | | |
| 12A5B7 | HB-8328 [†] | mouse/mouse | MAb | Anti human complement C1q |
| 4A4B11 | HB-8327 [†] | mouse/mouse | MAb | Anti human complement C1q |
| omplement component 3a recept | | modac/modac | ITITAL | , and mannan complement CTq |
| DMS 114 | CRL-2066 | human | R+ | |
| DMS 114 | CRL-2066 CRL-2064 | human | R+ | |
| GDM-1 | CRL-2064 CRL-2627 | human | R+ | |
| U-937 | CRL-2627 CRL-1593.2 | | R+ | |
| | | human | K+ | |
| Complement component 3a recept | | | D : | |
| IC-21 | TIB-186 | mouse | R+ | |
| J774A.1 | TIB-67 | mouse | R+ | |
| RAW264.7γNO(-) | CRL-2278 | mouse | R+ | |
| P388D ₁ | TIB-63 | mouse | R+ | |
| PU5-1.8 | TIB-61 | mouse | R+ | |
| RAW 264.7 | TIB-71 | mouse | R+ | |
| WEHI-3 | TIB-68 | mouse | R+ | |
| WR19M.1 | TIB-70 | mouse | R+ | |
| 5C6 Clone 1 | CRL-1969 | rat/mouse | MAb | Anti mouse type 3 complement receptor |
| Complement component 3a recept | or 1: C3ar1, 84007 | | | |
| EGC/PK060399egfr | CRL-2690 | rat | R- | |
| Complement component (3b/4b) re | eceptor 1, including Kno | ps blood group system: CR1, | 1378 | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| MC/CAR | CRL-8083 [†] | human | R+ | |
| THP-1 | TIB-202 | human | R+ | |
| 35.6 | CRL-10052 [†] | Chinese hamster | P+ (human) | |
| Mab 543 | HB-8592 [†] | mouse/mouse | MAb | Anti human C3b, CD35 |
| Complement component (3d/Epste | ein Barr virus) receptor 2 | | <u> </u> | |
| 29SR | CRL-2262 | human | A- | |
| BC-3 | CRL-2277 | human | A- | |
| DB | CRL-2289 | human | A- | |
| Farage | CRL-2630 | human | A+ | |
| HT | CRL-2260 | human | A+ | |
| RL | CRL-2261 | human | A+ A+ | |
| THB-5 | HB-135 | | MAb | Anti human CD21 |
| | | mouse/mouse | IVIAD | And Hullian CDZ1 |
| CC51 | | mouso/mouso | MAh | Anti havina CD21 (PaCD21) |
| | HB-271 | mouse/mouse | MAb | Anti bovine CD21 (BoCD21) |
| orticotropin releasing hormone: C | | I | D.: | |
| COLO 320DM | CCL-220 | human | P+ | |
| COLO 320HSR | CCI-220.1 | human | P+ | |
| DMS 114 | CRL-2066 | human | P+ | |
| DMS 153 | CRL-2064 | human | P+ | |
| DMS 53 | CRL-2062 | human | P+ | |
| DMS 79 | CRL-2049 | human | P+ | |
| Corticotropin releasing hormone: C | rh, 12918 | | | |
| | | | | |
| AtT-20 AtT-20/D16v-F2 | CCL-89 | mouse | P+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product is a product of the product$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---------------------------------------|-----------------------------|------------------------------|--------------------------------------|
| | | ., | | |
| Corticotropin releasing hormone: | | | D. | |
| RC-4B/C | CRL-1903 | rat | P+ | |
| Cortisol (steroid) | CDL 2120 | h | D. | |
| NCI-H295R | CRL-2128 | human | P+ | |
| Coxsackie virus and adenovirus re | - | | **** | |
| RmcB | CRL-2379 | mouse/mouse | MAb | Anti human CAR |
| CR1 See Complement component | | | | |
| c-raf-1.See v-raf-1 murine leukemi | | | | |
| CRALBP: Cellular retinaldehyde-bi | nding protein 1. <i>See</i> Retir | naldehyde binding protein 1 | | |
| Creatine kinase, brain: CKB, 1152 | | | | |
| NCI-H146 | HTB-173 | human | P+ | |
| NCI-H187 | CRL-5804 | human | P+ | |
| NCI-H209 | HTB-172 | human | P+ | |
| NCI-H345 | HTB-180 | human | P+ | |
| NCI-H378 | CRL-5808 | human | P+ | |
| NCI-H446 | HTB-171 | human | P+ | |
| NCI-H526 | CRL-5811 | human | P+ | |
| NCI-H82 | HTB-175 | human | P+ | |
| NCI-N417 | CRL-5809 | human | P+ | |
| Creatine kinase, brain: CKB, 1152 | AND | | | |
| muscle: CKM [din | ner], 1158 | | | |
| CKMM 14.15 | HB-9419 [†] | rat/mouse | MAb | Anti human CK-MM and CK-MB |
| Creatine kinase, muscle: CKM, 115 | 58 | | | |
| CKMM 14.52 | HB-9421 [†] | rat/mouse | MAb | Anti human CK-MM |
| CKMM 14.5 | HB-9420 [†] | rat/mouse | MAb | Anti human CK-MM |
| Creatine kinase, muscle (species n | | | | |
| QM7 | CRL-1962 | Japanese quail | P+ | |
| Creatine phosphokinase (CPK) | CILE 1702 | supuriese quan | | |
| BC,H1 | CRL-1443 | mouse | P+ | |
| A-10 | CRL-1445 | rat | P+ | |
| A7r5 | CRL-1444 | rat | P+ | |
| | | | | |
| H9c2(2-1) L8 | CRL-1446 CRL-1769 | rat rat | P+ P+ | |
| | | | ГТ | |
| Crystallin, beta and gamma (five b | CRL-11421 [†] | | D : | |
| B-3 | | human | P+ | |
| CTLA-4. See Cytotoxic T-lymphocy | | The COVAL COVAL ASSO | | |
| Cyclin-dependent kinase inhibitor | | | | 14405 (114 1) 1 46 (114 1) |
| LN-18 | CRL-2610 | human | 0- | p14ARF– (deleted) and p16– (deleted) |
| LN-229 | CRL-2611 | human | 0- | p14ARF- (deleted) and p16- (deleted) |
| Cyclin-dependent kinase inhibitor | | | | |
| p53NiS1 | CRL-2619 | mouse | 0- | p16–; p19ARF+ |
| Cystic fibrosis transmembrane cor | | | y C, member 7): CFTR, | |
| BxPC-3 | CRL-1687 | human | | CFTR- |
| Capan-1 | HTB-79 | human | | CFTR+ |
| CFPAC-1 | CRL-1918 | human | | CFTR+ |
| NCI-H146 | HTB-173 | human | | mRNA CFTR+ |
| NCI-H345 | HTB-180 | human | | mRNA CFTR+ |
| NCI-H727 | CRL-5815 | human | | mRNA CFTR+ |
| mAb 13-1 | HB-10565 [†] | mouse/mouse | MAb | Anti human CFTR |
| mAB 24-2 | HB-11946 [†] | mouse/mouse | MAb | Anti human CFTR |
| mAB 24-1 | HB-11947 [†] | mouse/mouse | MAb | Anti human CFTR |
| Cystic fibrosis transmembrane cor | | | | |
| DSL-6A/C1 | CRL-2132 | rat | | CFTR+ |
| Cytochrome P450 (CYP) (106 fami | | | | |
| PLHC-1 | CRL-2406 | topminnow | P+ | |
| Cytochrome P450, 1a1: Cyp1a1, 2 | | | • • | |
| H-4-II-E | CRL-1548 | rat | P+ | Inducible |
| Cytochrome P450, 1a1 (species no | | iut | 1 1 | aucibic |
| ZFL | · · · · · · · · · · · · · · · · · · · | zohrafich | P+ | Inducible |
| ZFL Cytochrome P450IA1 | CRL-2643 | zebrafish | r+ | Inducible |
| • | CDI 2217 | mouss | D : | |
| BpRcl | CRL-2217 | mouse | P+ | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name | |
|--|--|
| tao BpRd | |
| Artokeratin 7 (CK7). See Keratin 7. Artokeratin 8 (CK8). See Keratin 8. Artokeratin 10 (CK10). See Keratin 10. Artokeratin 11 (CK11). See Keratin 11. Artokeratin 11 (CK11). See Keratin 11. Artokeratin 12 (CK18). See Keratin 14. Artokeratin 19 (CK19). See Keratin 19. Artokeratin 19. Artokeratin 19 (CK19). See Keratin 19. Artokeratin 19 (CK19). See Keratin 19. Artokeratin 19 (CK19). See Keratin 19. Artokeratin 19 (CK19). S | |
| \text{ytokeratin 8 (CK8). See Keratin 10. \text{ytokeratin 110. (CK10). See Keratin 10. \text{ytokeratin 11. (CK11). See Keratin 11. \text{ytokeratin 14. (CK14). See Keratin 14. \text{ytokeratin 14. (CK18). See Keratin 18. \text{ytokeratin 19 (CK18). See Keratin 18. \text{ytokeratin 19 (CK18). See Keratin 19. \text{ytokeratin 19 (CK19). See Keratin 19. \text{ytotexic T-lymphocyte-associated protein 4: CTLA4, 1493} ptouse-formula protein 4: P | |
| tokeratin 10 (CK10). See Keratin 11. tokeratin 11 (CK11). See Keratin 11. tokeratin 14 (CK114). See Keratin 18. tokeratin 18 (CK18). See Keratin 18. tokeratin 19 (CK19). See Keratin 19. totoxic T-lymphocyte-associated protein 4: CTLA4, 1493 A3.6810 HB-12318° mouse/mouse MAb Anti human CTLA-4 A3.4H2 HB-12319° mouse/mouse MAb Anti human P- ANOLT-3 CRL-2630 human P- ANOLT-3 CRL-1552 human P- ANOLT-3 CRL-1552 human P- ANOLT-4 CRL-1582 human P- ANOLT-4 CRL-1589 mouse P- ANOLT-4 CRL-1589 mouse P- ANOLT-5 CRL-2690 rat P- ANOLT-6 CRL-2573 rat P- ANOLT-7 CRL-1690 rat P- ANOLT-8 CRL-2573 rat P- ANOLT-9 CRL-2573 rat P- ANOLT-9 CRL-2573 rat P- ANOLT-9 CRL-2573 rat P- ANOLT-9 CRL-1580 human P- ANOLT-9 CRL-1685 human P- ANOLT-9 CRL-1885 human P- ANOLT-9 CRL-18804 human P- ANOLT-9 CRL-18804 human P- ANOLT-9 CRL-18804 human P- ANOLT-9 CRL-18804 human P- ANOLT- | |
| tokeratin 11 (CK11). See Keratin 11. tokeratin 14 (CK14). See Keratin 14. tokeratin 18 (CK18). See Keratin 18. tokeratin 19 (CK19). See Keratin 19. totoxic T-lymphocyte-associated protein 4: CTLA4, 1493 A 3.6B10 | |
| tokeratin 14 (CK14). See Keratin 18. tokeratin 18 (CK18). See Keratin 19. totoxic T-lymphocyte-associated protein 4: CTLA4, 1493 A3.6810 | |
| tokeratin 18 (CK18). See Keratin 19. tokeratin 19 (CK19). See Keratin 19. totoxic T-lymphocyte-associated protein 4: CTLA4, 1493 A3.6810 | |
| totoxic T-lymphocyte-associated protein 4: CTLA4, 1493 A3.6B10 | |
| totoxic T-lymphocyte-associated protein 4: CTLA4, 1493 A3.6B10 | |
| totoxic T-lymphocyte-associated protein 4: CTLA4, 1493 A3.6810 | |
| A3.6810 HB-12318† mouse/mouse MAb Anti human CTLA-4 A3.4H2 HB-12319† mouse/mouse MAb Anti human CTLA-4 CC-205.See Lymphocyte antigen 75. EC-205.See Lymphocyte antigen 75. Expyrucleotidyltransferase, terminal: DNTT, 1791 70Z/3 TIB-158 human P- Farage CRL-2630 human P- HuT 102 TIB-162 human P- HuT 102 TIB-162 human P- MOLT-3 CRL-1552 human P+ MOLT-4 CRL-1552 human P+ R54 CRL-1582 human P+ ESSIMIC CRL-1582 human P+ ESSIMIC CRL-189 mouse P- ESSIMIC Des, 64362 EGC/PK060399egfr CRL-2690 rat P- RL-65 CRL-10354† rat P+ ESSIMIC CRL-2573 rat P+ ESSIMIC Species not yet curated) QM7 CRL-2573 rat P+ ESSIMIC Species not yet curated) QM7 CRL-1962 Japanese quail P+ Hydrotestosterone receptor. See Androgen receptor. NA polymerase alpha. See Polymerase, alpha. Daya decarboxylase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H128 HTB-173 human P+ NCI-H146 HTB-173 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| A3.4H2 | |
| C-205. See Lymphocyte antigen 75. | |
| Time | |
| Tight Tigh | |
| Farage | |
| HuT 102 TIB-162 human P- Loucy CRL-2629 human P- MOLT-3 CRL-1552 human P+ MOLT-4 CRL-1582 human P+ RS4 CRL-1873 human P+ esmin: Des, 13346 WR21 CRL-2189 mouse P- esmin: Des, 64362 EGC/PK060399egfr CRL-2690 rat P+ RMC CRL-2573 rat P+ RMC CRL-2573 rat P+ esmin (species not yet curated) QM7 CRL-1962 Japanese quail P+ hydrotestosterone receptor. See Androgen receptor. WA polymerase alpha. See Polymerase, alpha. A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ NCI-H187 CRL-5804 human P+ | |
| Loucy CRL-2629 human P- MOLT-3 CRL-1552 human P+ MOLT-4 CRL-1582 human P+ RS4 CRL-1873 human P+ esmin: Des, 13346 WR21 CRL-2189 mouse P- esmin: Des, 64362 EGC/PK060399egfr CRL-2690 rat P+ RMC CRL-2573 rat P+ esmin (species not yet curated) QM7 CRL-1962 Japanese quail P+ hydrotestosterone receptor. See Androgen receptor. WA polymerase alpha. See Polymerase, alpha. pad decarboxylase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P- NCI-H187 CRL-5804 human P+ | |
| MOLT-3 | |
| MOLT-4 | |
| RS4 CRL-1873 human P+ esmin: Des, 13346 WR21 CRL-2189 mouse P- esmin: Des, 64362 EGC/PK060399egfr CRL-2690 rat P+ RL-65 CRL-10354† rat P+ RMC CRL-2573 rat P+ esmin (species not yet curated) QM7 CRL-1962 Japanese quail P+ hydrotestosterone receptor. See Androgen receptor. VA polymerase alpha. See Polymerase, alpha. Dapa decarboxylase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| WR21 | |
| WR21 CRL-2189 mouse P− esmin: Des, 64362 EGC/PK060399egfr CRL-2690 rat P− RL-65 CRL-10354† rat P+ RMC CRL-2573 rat P+ esmin (species not yet curated) P+ QM7 CRL-1962 Japanese quail P+ phydrotestosterone receptor. See Androgen receptor. P+ Apolymerase alpha. See Polymerase, alpha. See Polymerase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P− MSTO-211H CRL-2081 human P− NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| EGC/PK060399egfr CRL-2690 rat P+ RL-65 CRL-10354† rat P+ RMC CRL-2573 rat P+ esmin (species not yet curated) QM7 CRL-1962 Japanese quail P+ hydrotestosterone receptor. See Androgen receptor. VA polymerase alpha. See Polymerase, alpha. papa decarboxylase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| EGC/PK060399egfr CRL-2690 rat P- RL-65 CRL-10354† rat P+ RMC CRL-2573 rat P+ esmin (species not yet curated) Users in the common of the curated | |
| RL-65 CRL-10354 [†] rat P+ RMC CRL-2573 rat P+ esmin (species not yet curated) QM7 CRL-1962 Japanese quail P+ hydrotestosterone receptor. See Androgen receptor. NA polymerase alpha. See Polymerase, alpha. pa decarboxylase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| RMC CRL-2573 rat P+ rsmin (species not yet curated) QM7 CRL-1962 Japanese quail P+ rhydrotestosterone receptor. See Androgen receptor. NA polymerase alpha. See Polymerase, alpha. rpa decarboxylase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| smin (species not yet curated) QM7 CRL-1962 Japanese quail P+ nydrotestosterone receptor. See Androgen receptor. IA polymerase alpha. See Polymerase, alpha. pa decarboxylase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| QM7 CRL-1962 Japanese quail P+ nydrotestosterone receptor. See Androgen receptor. IA polymerase alpha. See Polymerase, alpha. pa decarboxylase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| As49 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ NCI-H187 CRL-5804 human P+ | |
| A polymerase alpha. See Polymerase, alpha. Apa decarboxylase (aromatic L-amino acid decarboxylase): DDC, 1644 A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| A549 CCL-185 human P- | |
| A549 CCL-185 human P- MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| MSTO-211H CRL-2081 human P- NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| NCI-H128 HTB-120 human P+ NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| NCI-H146 HTB-173 human P+ NCI-H187 CRL-5804 human P+ | |
| NCI-H187 CRL-5804 human P+ | |
| | |
| NCI-H209 HTB-172 human P+ | |
| NCI-H23 CRL-5800 human P- | |
| NCI-H28 CRL-5820 human P- | |
| NCI-H292 CRL-1848 human P- | |
| | |
| | |
| NCI-H378 CRL-5808 human P+ | |
| NCI-H446 HTB-171 human P- | |
| NCI-H510A HTB-184 human P+ | |
| NCI-H526 CRL-5811 human P– | |
| NCI-H548 CCL-249 human P+ | |
| NCI-H60 CRL-5821 human P+ | |
| NCI-H660 CRL-5813 human P+ | |
| NCI-H69 HTB-119 human P+ | |
| NCI-H716 CCL-251 human P+ | |
| NCI-H747 CCL-252 human P– | |
| NCI-H82 HTB-175 human P– | |
| NCI-N417 CRL-5809 human P– | |
| NCI-N87 CRL-5822 human P– | |
| SNU-1 CRL-5971 human P- | |
| SNU-5 CRL-5973 human P+ | |
| SNU-16 CRL-5974 human P+ | |
| SHP-77 CRL-2195 human P+ | |
| | |
| SNU-C2A CCL-250.1 human P+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| lame: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---|----------------------------------|----------------|-----------------------|
| | | · · | Lxpresses | Comments |
| opa decarboxylase (aromatic L-a | | | | |
| RIN-14B | CRL-2059 | rat | P+ | |
| RIN-5F | CRL-2058 | rat | P+ | |
| RIN-m RIN-m5F | CRL-2057 CRL-11605 [†] | rat | P+ | |
| | | rat | P+ | |
| NA polymerase epsilon. <i>See</i> Polyr Opamine | nerase, epsilon. | | | |
| PC-12 | CRL-1721 | rat | P+ | |
| opamine beta-hydroxylase (dopa | | | ГТ | |
| MC-IXC | CRL-2270 | human | P- | |
| SH-SY5Y | CRL-2266 | human | P+ | |
| SK-N-BE(2) | CRL-2271 | human | P+ | |
| SK-N-MC | HTB-10 | human | P+ | |
| SK-N-SH | HTB-11 | human | P+ | |
| opamine beta-hydroxylase: Dbh, | | | | |
| CATH.a | CRL-11179 [†] | mouse | P+ | |
| Oppamine 1A receptor: Dr1a, 243 | 16 OR | | | |
| receptor D2: Drd2, 243 | 18 OR | | | |
| receptor D3: Drd3, 292 | 238 OR | | | |
| receptor D4: Drd4, 254 | 32 OR | | | |
| receptor D5: Drd5, 251 | 95 | | | |
| MMQ | CRL-10609 [†] | rat | R+ | |
| opamine receptor D2: DRD2, 181 | | | | |
| A9 L hD2 S.C. 18 | CRL-10225 [†] | mouse | R+ (human) | |
| PC4. See MAD, mothers against d | ecapentaplegic homolog | 4. | | |
| 6/E7 | | | | |
| CCD 1102 KERTr | CRL-2310 | human | 0+ | |
| CCD 1103 KIDTr | CRL-2304 | human | 0+ | |
| CCD 1105 KIDTr | CRL-2305 | human | 0+ | |
| CCD 1106 KERTr | CRL-2309 | human | 0+ | |
| ctonucleotide pyrophosphatase/ | | | | |
| NCI-H929 | CRL-9068 [†] | human | A+ | |
| ctonucleoside triphosphate diph | | | Λ. | |
| Farage | CRL-2630 | human | A+ | |
| Toledo Pfeiffer | CRL-2631 | human | A- | |
| | CRL-2632 | human | A- | |
| GF-like module-containing, mucii | | | | |
| C8-B4 EOC 13.31 | CRL-2540 CRL-2468 | mouse | A+ ^+ | |
| EOC 13.31 | | mouse | A+ ^+ | |
| EOC 20 | CRL-2467 | mouse | A+ ^+/- | |
| PMJ2-PC | CRL-2469 | mouse | Δ+/- | |
| PMJ2-PC PMJ2-R | CRL-2457 CRL-2458 | mouse | A+ A+ | |
| F4/80 | HB-198 | mouse rat/mouse | MAb | Anti mouse macrophage |
| LAM-1. See Selectin E. | סלו־טוו | ray mouse | IVIAU | And mouse macrophage |
| ndorphin, beta. <i>See</i> Proopiomelar | occortin | | | |
| ndostatin. See Collagen, type XVII | | | | |
| ndothelial leukocyte adhesion m | | | | |
| nkephalin. <i>See</i> Preproenkephalin | | | | |
| nolase 2, (gamma, neuronal): ENC | | | | |
| D283 Med | HTB-185 | human | P+ | |
| | HTB-187 | human | P+ | |
| 1)341 Med | CRL-2020 | human | P+ | |
| D341 Med DBTRG-05MG | CITE 2020 | human | P+ | |
| DBTRG-05MG | CRI -10442† | | | |
| DBTRG-05MG HCN-1A | CRL-10442 [†] | | P⊥ | |
| DBTRG-05MG HCN-1A HCN-2 | CRL-10742 [†] | human | P+ P+ | |
| DBTRG-05MG HCN-1A HCN-2 MSTO-211H | CRL-10742 [†] CRL-2081 | human human | P+ | |
| DBTRG-05MG HCN-1A HCN-2 MSTO-211H NCI-H187 | CRL-10742 [†] CRL-2081 CRL-5804 | human human human | P+ P+ | |
| DBTRG-05MG HCN-1A HCN-2 MSTO-211H NCI-H187 NCI-H378 | CRL-10742 [†] CRL-2081 CRL-5804 CRL-5808 | human human human human | P+ P+ P+ | |
| DBTRG-05MG HCN-1A HCN-2 MSTO-211H NCI-H187 | CRL-10742 [†] CRL-2081 CRL-5804 | human human human | P+ P+ | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name Disinophil cationic protein (ECP). See I obsinophil derived neurotoxin (EDN). See I obsinophil major basic protein (MBP). Sesinophil peroxidase: EPX, 8288 Clone 15 HL-60 Didermal growth factor receptor (ery AU565 C2BBe1 Caco-2 DBTRG-05MG DMS 114 | See Ribonuclease, RNa See Proteoglycan 2, b CRL-1964 | ise A family 2. | Expresses | Comments |
|--|---|---|-----------------------------|--|
| osinophil derived neurotoxin (EDN) osinophil major basic protein (MBP). osinophil peroxidase: EPX, 8288 Clone 15 HL-60 oidermal growth factor receptor (ery AU565 C2BBe1 Caco-2 DBTRG-05MG DMS 114 | See Ribonuclease, RNa See Proteoglycan 2, b CRL-1964 rthroblastic leukemia CRL-2351 | ise A family 2. one marrow. | | |
| osinophil major basic protein (MBP). osinophil peroxidase: EPX, 8288 Clone 15 HL-60 oidermal growth factor receptor (ery AU565 C2BBe1 Caco-2 DBTRG-05MG DMS 114 | See Proteoglycan 2, b CRL-1964 rthroblastic leukemia CRL-2351 | one marrow. | | |
| osinophil peroxidase: EPX, 8288 Clone 15 HL-60 Didermal growth factor receptor (ery AU565 C2BBe1 Caco-2 DBTRG-05MG DMS 114 | CRL-1964 rthroblastic leukemia CRL-2351 | | | |
| Clone 15 HL-60 pidermal growth factor receptor (ery AU565 C2BBe1 Caco-2 DBTRG-05MG DMS 114 | rthroblastic leukemia CRL-2351 | human | | |
| oidermal growth factor receptor (ery AU565 C2BBe1 Caco-2 DBTRG-05MG DMS 114 | rthroblastic leukemia CRL-2351 | human | | |
| AU565 C2BBe1 Caco-2 DBTRG-05MG DMS 114 | CRL-2351 | | P+ | |
| C2BBe1 Caco-2 DBTRG-05MG DMS 114 | | viral (v- <i>erb</i> -b) oncogene homol | og, avian): EGFR , 1 | 956 |
| Caco-2 DBTRG-05MG DMS 114 | CDI 2102 | human | R+ | |
| DBTRG-05MG DMS 114 | ChL-2102 | human | R+ | |
| DMS 114 | HTB-37 | human | R+ | |
| | CRL-2020 | human | R+ | |
| DMC 1F2 | CRL-2066 | human | R+ | |
| DMS 153 | CRL-2064 | human | R+ | |
| DMS 53 | CRL-2062 | human | R+ | |
| DMS 79 | CRL-2049 | human | R+ | |
| FHs 74 Int | CCL-241 | human | R+ | |
| G-292, clone A141B1 | CRL-1423 | human | R+ | |
| НЕРМ | CRL-1486 | human | R+ | Responsive |
| HK-2 | CRL-2190 | human | R+ | Dependent on EGF |
| HPAC | CRL-2119 | human | R+ | Responsive |
| Hs 578Bst | HTB-125 | human | R+ | |
| MCF-10-2A | CRL-10781 [†] | human | R+ | |
| MCF 10F | CRL-10318 [†] | human | R+ | Responsive |
| MDA-MB-231 | HTB-26 | human | R+ | · |
| MDA-MB-330 | HTB-127 | human | R+ | |
| MDA-MB-468 | HTB-132 | human | R+ | |
| NCI-H23 | CRL-5800 | human | R+ | |
| NCI-H661 | HTB-183 | human | R– | |
| NCI-H69 | HTB-119 | human | R– | |
| NCI-H727 | CRL-5815 | human | R+ | Growth inhibited by EGF receptor antibodies. |
| NCI-H82 | HTB-175 | human | R– | |
| NCI-N417 | CRL-5809 | human | R+ | Expresses the EGF receptor and EGF receptor mRNA |
| Saos-2 | HTB-85 | human | R+ | |
| SNU-C2B | CCL-250 | human | R+ | |
| SW480 | CCL-228 | human | R+ | |
| WiDr | CCL-218 | human | R+ | |
| EGC/PK060399egfr | CRL-2690 | rat | R+ (human) | |
| 225 | HB-8508 [†] | mouse/mouse | MAb | Anti human EGF receptor |
| 455 | HB-8507 [†] | mouse/mouse | MAb | Anti human EGF receptor |
| 528 | HB-8509 [†] | mouse/mouse | MAb | Anti human EGF receptor |
| 579 | HB-8506 [†] | mouse/mouse | MAb | Anti human EGF receptor |
| Mab 108 | HB-9764 [†] | mouse/mouse | MAb | Anti human EGF receptor |
| Mab 9 | HB-9763 [†] | mouse/mouse | MAb | Anti human EGF receptor |
| pidermal growth factor receptor: Egf | | mouse/mouse | 1717.10 | . ard manual Edi Teceptor |
| TM3 | CRL-1714 | mouse | R+ | |
| pidermal growth factor receptor: Egf | | mouse | IV I | |
| FAT 7 | CRL-2109 | rat | R+ | |
| NRK-49F | CRL-2109 CRL-1570 | | R+ | |
| NRK-49F NRK-52E | CRL-1570 CRL-1571 | rat | | |
| | | rat | R+ | |
| oidermal growth factor receptor (spe 12MBr6 | CRL-1576 | African green monkey | D i | Dependent on EGF |
| 4MBr-5 | | <u> </u> | R+ | <u> </u> |
| | CCL-208 | Rhesus monkey | R+ | Dependent on EGF |
| oidermal growth factor: Egf, 13645 | CDI 1724 | mouss | D. | |
| SCA-9 clone 15 | CRL-1734 | mouse | P+ | |
| oithelial membrane antigen (EMA). S | ee Mucin 1, transmen | prane. | | |
| pithelial specific antigen | CDL 2212 | | A : | |
| CCD 1102 KERTr | CRL-2310 | human | A+ | |
| CCD 1106 KERTr | CRL-2309 | human | A+ | |
| ostein-Barr nuclear antigen 1 (EBNA- CV-1/EBNA-1 | CRL-10478 [†] | African green monkey | P+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Name: Symbol, GeneID | ATCCO N | . | _ | |
|---|------------------------|-----------------------------|---------------------|---|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| pstein-Barr virus (EBV) | | | | |
| 1A2 | CRL-8119 [†] | human | P+ | |
| CESS | TIB-190 | human | P+ | |
| E.H. IV (Elaine IV) | CCL-104 | human | P+ | |
| Jiyoye | CCL-87 | human | P+ | |
| RPMI 7666 | CCL-114 | human | P+ | |
| 72A1 | HB-168 | mouse/mouse | MAb | Anti EBV |
| pstein-Barr virus (EBV) receptor. Se | | | | |
| <i>-erb</i> -b2 erythroblastic leukemia vir | | 2, neuro/glioblastoma deriv | ed oncogene homolog | |
| AU565 | CRL-2351 | human | 0+ | her2/neu; overexpressed |
| HCC1008 | CRL-2320 | human | 0+ | her2/ <i>neu</i> |
| HCC1143 | CRL-2321 | human | 0- | her2/ <i>neu</i> |
| HCC1187 | CRL-2322 | human | 0- | her2/ <i>neu</i> |
| HCC1395 | CRL-2324 | human | 0- | her2/ <i>neu</i> |
| HCC1419 | CRL-2326 | human | 0+ | her2/neu; overexpressed |
| HCC1428 | CRL-2327 | human | 0- | her2/ <i>neu</i> |
| HCC1500 | CRL-2329 | human | 0- | her2/neu |
| HCC1569 | CRL-2330 | human | 0+ | her2/neu |
| HCC1599 | CRL-2331 | human | 0- | her2/neu |
| HCC1806 | CRL-2335 | human | 0- | her2/ <i>neu</i> |
| HCC1937 | CRL-2336 | human | 0- | her2/ <i>neu</i> |
| HCC1954 | CRL-2338 | human | 0+ | her2/neu; overexpressed |
| HCC202 | CRL-2316 | human | 0+ | her2/ <i>neu</i> |
| HCC2157 | CRL-2340 | human | 0+ | her2/ <i>neu</i> |
| HCC2218 | CRL-2343 | human | 0+ | her2/ <i>neu</i> |
| HCC38 | CRL-2314 | human | 0- | her2/ <i>neu</i> |
| HCC70 | CRL-2315 | human | 0- | her2/ <i>neu</i> |
| MSTO-211H | CRL-2081 | human | 0+ | v-erb B |
| NCI-H23 | CRL-5800 | human | 0+ | v- <i>erb</i> B |
| NCI-N87 | CRL-5822 | human | 0+ | c-erb-B2 |
| SNU-1 | CRL-5971 | human | 0+ | c- <i>erb</i> -B2 |
| SNU-16 | CRL-5974 | human | 0+ | c- <i>erb</i> -B2 |
| SNU-5 | CRL-5973 | human | 0+ | c- <i>erb</i> -B2 |
| OV-90 | CRL-11732 [†] | human | 0+ | her2/ <i>neu</i> |
| SK-BR-3 | HTB-30 | human | 0+ | HER2/c- <i>erb</i> -2; overexpresses |
| TOV-112D | CRL-11731 [†] | human | 0+ | her2/ <i>neu</i> |
| UACC-812 | CRL-1897 | human | 0+ | her2/neu; 15-fold amplification |
| UACC-893 | CRL-1902 | human | 0+ | her2/neu; 20-fold amplification |
| EGC/PK060399egfr | CRL-2690 | rat | O+ (human) | |
| 171-11B9 | CRL-2661 | mouse/mouse synthetic | MAb | Anti erb B (v- <i>erb</i> -B) oncogene peptide, |
| 172-12A4 | CRL-2660 | mouse/mouse synthetic | MAb | Anti erb B (v- <i>erb</i> -B) oncogene peptide, |
| 20.3 [TAb 250] | CRL-2655 | mouse/mouse | MAb | Anti human c- <i>erb</i> -B2 protein |
| Ab 21.1 | HB-11601 [†] | mouse/mouse | MAb | Anti human <i>erb</i> -B2 protein |
| Ab 23.1 | HB-11602 [†] | mouse/mouse | MAb | Anti human <i>erb</i> -B2 protein |
| A-HER2 | CRL-10463 [†] | mouse/mouse | MAb | Anti HER2 receptor |
| <i>-erb</i> -b2 erythroblastic leukemia vir | | 2, neuro/glioblastoma deriv | ed oncogene homolog | g (avian): Erbb2 , 13866 |
| B104-1-1 | CRL-1887 | mouse | 0+ | neu |
| rythropoietin: EPO, 2056 | | | | |
| 5F12 AD3 | HB-8209 [†] | mouse/mouse | MAb | Anti EPO |
| BF-11 | CRL-8164 [†] | rat/mouse | MAb | Anti human EPO |
| -selectin. See Selectin E. | | | | |
| stradiol | | | | |
| BeWo | CCL-98 | human | P+ | |
| ChaGo-K-1 | HTB-186 | human | P+ | |
| 7 beta Estradiol | | | | |
| DMS 114 | CRL-2066 | human | P+ | |
| DMS 153 | CRL-2064 | human | P+ | |
| DMS 53 | CRL-2062 | human | P+ | |
| | | | • | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| lame: Symbol, GeneID | | | _ | |
|---|--------------------------|----------------|-----------|---|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| striol | | | | |
| BeWo | CCL-98 | human | P+ | |
| strogen | | | | |
| BeWo | CCL-98 | human | P+ | |
| JAR | HTB-144 | human | P+ | |
| trogen (estradiol and others) | | | | |
| LC-540 | CCL-43 | rat | P+ | |
| trogen receptor 1: ESR1, 2099 | | | | |
| Capan-1 | HTB-79 | human | R+ | ER alpha |
| trogen receptor 1: ESR1, 2099 OF | | | | |
| receptor 2 (ER beta): ESR | | | | |
| BT-20 | HTB-19 | human | R- | |
| HCC1008 | CRL-2320 | human | R- | |
| HCC1143 HCC1395 | CRL-2321 CRL-2324 | human | R– R+ | |
| HCC1419 | CRL-2324 CRL-2326 | human human | R- | |
| HCC1500 | CRL-2326 CRL-2329 | human | R+ | |
| HCC1569 | CRL-2329 CRL-2330 | human | R- | |
| HCC1509 | CRL-2330 CRL-2331 | human | R- | |
| HCC1806 | CRL-2335 | human | R- | |
| HCC1937 | CRL-2336 | human | R- | |
| HCC1954 | CRL-2338 | human | R- | |
| HCC202 | CRL-2316 | human | R- | |
| HCC2157 | CRL-2340 | human | R– | |
| HCC2218 | CRL-2343 | human | R– | |
| HCC38 | CRL-2314 | human | R– | |
| HCC70 | CRL-2315 | human | R+ | |
| Hs 578Bst | HTB-125 | human | R- | |
| Hs 578T | HTB-126 | human | R- | |
| LNCaP clone FGC | CRL-1740 | human | R+ | |
| MCF7 | HTB-22 | human | R+ | |
| NIH:OVCAR-3 | HTB-161 | human | R+ | |
| RL95-2 | CRL-1671 | human | R+ | |
| T-47D | HTB-133 | human | R+ | |
| UACC-812 | CRL-1897 | human | R– | |
| UACC-893 | CRL-1902 | human | R– | |
| ZR-75-1 | CRL-1500 | human | R+ | |
| trogen receptor 1 (alpha): Esr1:1 | | | | |
| receptor 2 (beta): Esr2: 13 | | | | |
| TM3 | CRL-1714 | mouse | R+ | |
| TM4 | CRL-1715 | mouse | R+ | |
| trogen receptor (species not yet | | alai alvan | D | Funnassa lauritarrat |
| LMH | CRL-2117 | chicken | R+ | Expresses low level |
| LMH/2A | CRL-2118 | chicken | R+ | Responsive; expresses high levels |
| trone BeWo | CCI 00 | human | P+ | |
| | CCL-98 | human | r+ | |
| ocrine enzymes AR42J | CRL-1492 | rat | P+ | |
| AR42J ARIP | CRL-1492 CRL-1674 | rat | P+ P+ | Low levels |
| tracellular matrix (ECM) proteins | CNL-10/4 | ıaı | ГТ | LOW IEVEIS |
| BCE C/D-1b | CRL-2048 | bovine | P+ | |
| /80. See EGF-like module. | CITE ZUTO | DOVING | 1 1 | |
| ctor VIII. See Coagulation factor V | III. | | | |
| rnesyltransferase, CAAX box, alph | | | | |
| IgG-IB7 | CRL-2418 | mouse/mouse | MAb | Anti alpha subunit of farnesyltransferase |
| s. See Tumor necrosis factor recep | otor superfamily, member | er 6. | | , . |
| ERI (Fc of IgE) | , ,, | | | |
| 10P12 | CRL-2036 | mouse | R+ | FcERI (Fc of IgE) |
| | | | R+ | FcERI (Fc of IgE) |
| 10P2 | CRL-2034 | mouse | IΛT | r certi (i c or ige) |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product is a product of the product$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|---|------------------------------|------------|---|
| Cell Lille Name | AICC* NO. | Species | Lxpresses | Comments |
| cERI (Fc of IgE) continued | | | | |
| MC/9 | CRL-8306 [†] | mouse | R+ | FcERI (Fc of IgE) |
| RBL-1 | CRL-1378 | rat | R+ | FcERI (Fc of IgE) |
| RBL-2H3 | CRL-2256 | rat | R+ | FcERI (Fc of IgE) |
| fragment of IgA, receptor for: F | | | | |
| My 43.51 | HB-12128 [†] | mouse/mouse | MAb | Anti human Fc receptor for IgA |
| fragment of IgE, high affinity I, i | | peptide: FCER1G, 2207 | | |
| CT6-1D7 | CRL-2438 | mouse/mouse | MAb | Anti human Fc receptor for IgG |
| fragment of IgE, low affinity II, r | eceptor for (CD23A): FCE I | R2, 2208 | | |
| NK-92 | CRL-2407 | human | A- | |
| NK-92CI | CRL-2409 | human | A- | |
| NK-92MI | CRL-2408 | human | A- | |
| Pfeiffer | CRL-2632 | human | A- | |
| Ramos (RA 1) | CRL-1596 | human | A+, R+ | Responsive |
| Ramos.2G6.4C10 | CRL-1923 | human | A+, R+ | Responsive |
| Farage | CRL-2630 | human | A- | |
| Toledo | CRL-2631 | human | A- | |
| fragment of IgG, high affinity la | | R1A, 2209 | | |
| 32.2 | HB-9469 [†] | mouse/mouse | MAb | Anti human monocyte Fc receptor (high affinity, FcRI) |
| fragment of IgG, low affinity lla | , receptor for (CD32): FCG | R2A, 2212 OR | | |
| | , receptor for (CD32): FCG HB-217 | | NA A La | Anti human CD22 |
| IV.3 | | mouse/mouse | MAb | Anti human CD32 |
| fragment of IgG, low affinity Illa | | | | |
| • | o, receptor for (CD16): FCC | | | |
| NK-92 | CRL-2407 | human | A- | |
| NK-92CI | CRL-2409 | human | A- | |
| NK-92MI | CRL-2408 | human | A- | |
| TALL-104 | CRL-11386 [†] | human | A- | |
| receptor, IgG, low affinity IIb: Fo | | | | |
| NFS-25 C-3 | CRL-1695 | mouse | A+ | |
| NFS-5 C-1 | CRL-1693 | mouse | A+ | |
| NFS-70 C-10 | CRL-1694 | mouse | A+ | |
| receptor, IgG, low affinity III (mo | | | | |
| 2.4G2 | HB-197 | rat/mouse | MAb | Anti mouse Fc gamma receptor |
| receptor (FcR) (32 Fc receptors) | | | | |
| AMJ2-C11 | CRL-2456 | mouse | A+ | |
| AMJ2-C8 | CRL-2455 | mouse | A+ | |
| EOC 13.31 | CRL-2468 | mouse | A+ | |
| EOC 2 | CRL-2467 | mouse | A+ | |
| EOC 20 | CRL-2469 | mouse | A+ | |
| PMJ2-PC | CRL-2457 | mouse | A+ | |
| PMJ2-R | CRL-2458 | mouse | A+ | |
| rat heavy chain heterodimers | | | | |
| 1G3 | CRL-2434 | mouse/mouse | MAb | Anti FcRn heavy chain heterodimers |
| 2G3 | CRL-2435 | mouse/mouse | MAb | Anti FcRn heavy chain heterodimers |
| eline sarcoma oncogene: FES, 22 | | | | |
| DMS 79 | CRL-2049 | human | 0- | v-fes |
| MSTO-211H | CRL-2081 | human | 0- | v-fes |
| NCI-H146 | HTB-173 | human | 0- | |
| NCI-H526 | CRL-5811 | human | 0+ | |
| NCI-H69 | HTB-119 | human | 0+ | v-fes |
| NCI-H82 | HTB-175 | human | 0+ | v-fes |
| NCI-N417 | CRL-5809 | human | 0+ | |
| C166 | CRL-2581 | mouse | O+ (human) | fes (fps/fes) |
| etoprotein, alpha. See Alpha-feto | | | | · · |
| brinogen (six fibrinogens) | | | | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| | | | | Anti human fibrinogen |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|--|---|---|--|
| Fibroblast growth factor receptor | 1 (fms-related tyrosing ki | • | · · | |
| | | nase 2, Plemer syndrome): Fo ase, keratinocyte growth fact | | rial dysostosis 1 Crouzon |
| | , | ckson-Weiss syndrome): FGF | | ciai dysostosis 1, Crodzori |
| | | tophoric dwarfism): FGFR3, 2 | | |
| | 4: FGFR4. 2264 | tophone awamsmy. I di R3, 2 | 201 OK | |
| MDA-MB-134-VI | HTB-23 | human | R+ | Overexpresses |
| MDA MB 154 VI MDA-MB-453 | HTB-131 | human | R+ | Overexpresses |
| Fibronectin 1: FN1,2335 | 1110-131 | Hullian | IXT | Overexpresses |
| HK-2 | CRL-2190 | human | P+ | |
| LN-18 | CRL-2610 | human | P+ | |
| FHCR-1-2813/FDC-6 | HB-9018 [†] | mouse/mouse | MAb | Anti human fibronectin |
| HFN 36.3 | CRL-1605 | mouse/mouse | MAb | Anti human fibronectin |
| HFN 7.1 | CRL-1606 | mouse/mouse | MAb | Anti human fibronectin |
| P,NP/PFn | HB-91 | mouse/mouse | MAb | Anti human fibronectin |
| ibronectin 1: Fn1,14268 | 110 21 | mouse/mouse | IVIA | Antinamannoneem |
| NE | CRL-2070 | mouse | P+ | |
| WR21 | CRL-2070 CRL-2189 | mouse | P+ | |
| Fibronectin 1: Fn1, 25661 | CILL 2107 | mouse | | |
| RL-65 | CRL-10354 [†] | rat | P+ | |
| Fibronectin 1 (species not yet cura | | 146 | | |
| RF/6A | CRL-1780 | Rhesus monkey | P+ | |
| Filamin A, alpha (actin binding pro | | | • • | |
| B, beta (actin binding prot | | | | |
| C, gamma (actin binding p | | | | |
| A7 | CRL-2500 | human | P+ | |
| K506 binding protein 5: FKBP5, 2 | | | | |
| GSML | CRL-2699 | Guyanese squirrel | P+ | Elevated expression |
| GSIVIE | CILE 2000 | monkey | | Elevated expression |
| | in recentor | Попксу | | |
| fms. See Colony stimulating factor | | | | |
| Follicle stimulating hormone rece | | | | |
| FSHR-18 | CRL-2688 | mouse/mouse | MAb | Anti human FSH |
| FSHR-323 | CRL-2689 | mouse/mouse | MAb | Anti human FSH |
| Follicle stimulating hormone rece | | mouse/mouse | IVIA | And Hamairi Sii |
| TM4 | CRL-1715 | mouse | R+ | Responsive |
| Follicle stimulating hormone, beta | | | INT | Responsive |
| HP75 | CRL-2506 | human | P+ | |
| Follicle stimulating hormone, sub- | | numan | P+ | |
| RC-4B/C | CRL-1903 | | D. | |
| | | rat | P+ | |
| v-fos FBJ murine osteosarcoma vir | | · . | 0. | |
| COLO 201 | CCL-224 | human | 0+ | |
| DLD-1 | CCL-221 | human | 0+ | c-fos |
| LIEC 1 A | | | | |
| HEC-1-A | HTB-112 | human | 0+ | C-10S |
| HT-29 | HTB-38 | human | O+ | C-10S |
| HT-29 LoVo | HTB-38 CCL-229 | human human | O+ O+ | C-105 |
| HT-29 LoVo LS 174T | HTB-38 CCL-229 CL-188 | human human human | O+ O+ O+ | |
| HT-29 LoVo LS 174T MSTO-211H | HTB-38 CCL-229 CL-188 CRL-2081 | human human human human | O+ O+ O+ | c-fos |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 | human human human human human | 0+ 0+ 0+ 0- 0+ | |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 | human human human human human human | 0+ 0+ 0+ 0- 0- 0+ | |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 | human human human human human human human | 0+ 0+ 0+ 0- 0- 0+ 0+ | |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 SW480 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 CCL-228 | human | 0+ 0+ 0+ 0- 0+ 0+ 0+ 0+ | |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 SW480 SW620 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 CCL-228 CCL-227 | human human human human human human human | 0+ 0+ 0+ 0- 0+ 0+ 0+ 0+ 0+ | |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 SW480 SW620 SW948 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 CCL-228 CCL-227 CCL-237 | human | 0+ 0+ 0+ 0- 0+ 0+ 0+ 0+ 0+ 0+ | c-fos |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 SW480 SW620 SW620 SW948 411-14E10 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 CCL-228 CCL-227 | human | 0+ 0+ 0+ 0- 0+ 0+ 0+ 0+ 0+ 0+ 0+ MAb | |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 SW480 SW620 SW948 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 CCL-228 CCL-227 CCL-237 | human | 0+ 0+ 0+ 0- 0+ 0+ 0+ 0+ 0+ 0+ | c-fos |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 SW480 SW620 SW620 SW948 411-14E10 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 CCL-228 CCL-227 CCL-237 CRL-2663 CRL-2653 | human mouse/mouse | 0+ 0+ 0+ 0- 0+ 0+ 0+ 0+ 0+ 0+ 0+ MAb | Anti fos oncogene peptide, synthetic Anti fos oncogene peptide, synthetic |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 SW480 SW620 SW948 411-14E10 413-15D12 | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 CCL-228 CCL-227 CCL-237 CRL-2663 CRL-2653 | human mouse/mouse | 0+ 0+ 0+ 0- 0+ 0+ 0+ 0+ 0+ 0+ 0+ MAb | c-fos Anti fos oncogene peptide, synthetic |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 SW480 SW620 SW948 411-14E10 413-15D12 Fragile histidine triad gene: FHIT, | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 CCL-228 CCL-227 CCL-237 CRL-2663 CRL-2653 | human mouse/mouse mouse/mouse | O+ O+ O+ O- O+ O+ O+ O+ O+ O+ MAb MAb | Anti fos oncogene peptide, synthetic Anti fos oncogene peptide, synthetic |
| HT-29 LoVo LS 174T MSTO-211H SK-CO-1 SW1116 SW1417 SW480 SW620 SW948 411-14E10 413-15D12 Fragile histidine triad gene: FHIT, | HTB-38 CCL-229 CL-188 CRL-2081 HTB-39 CCL-233 CCL-238 CCL-227 CCL-227 CCL-237 CRL-2663 CRL-2653 2272 CRL-2327 | human mouse/mouse mouse/mouse | O+ O+ O+ O- O+ P- | c-fos Anti fos oncogene peptide, synthetic Anti fos oncogene peptide, synthetic Homozygous deletion |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

^{*} Part of the NBL collection; see page 12. $\,^+$ Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|-----------------------------|-----------------------------|-----------|--|
| | | - Species | | Comments |
| Fragile X mental retardation 1: FM | | | | |
| C13589 | CRL-2704 | human | | Mutated; 31 and 59 CGG-triplet repeats |
| Fyn proto-oncogene: Fyn, 14360 | | | | |
| SYF | CRL-2459 | mouse | 0- | |
| Galactosidase, beta 1: Glb 1, 1209 1 | | | | |
| CT26.CL25 | CRL-2639 | mouse | P+ | |
| Galactosidase, beta 1: Glb 1, 24395 | | | | |
| 9L/lacZ | CRL-2200 | rat | P+ | |
| C6/LacZ | CRL-2199 | rat | P+ | |
| C6/lacZ7 | CRL-2303 | rat | P+ | |
| Gamma-aminobutyric acid-A rece | ptor (GABA-A,Type 1 BzF | () (eight type-1 receptors) | | |
| CMVα1 WSS-1 | CRL-2029 | human | R+ (rat) | |
| Gamma-glutamyltransferase 1: GG | i T1, 2678 OR | | , | |
| glutamyltransferase 2: G 0 | | | | |
| HK-2 | CRL-2190 | human | P+ | |
| Gelatinase | CILL Z I JU | Haman | 1 1 | |
| HIG-82 | CRL-1832 | rabbit | P+ | |
| Glioma-associated oncogene hom | | | ı F | |
| | | human | 0.1 | Amplified 30 fold |
| SJRH30 | CRL-2061 | | 0+ | • |
| SJSA-1 | CRL-2098 | human | 0+ | Amplified 15 fold |
| Glial fibrillary acidic protein: GFAP | | | | |
| CCF-STTG1 | CRL-1718 | human | P+ | |
| D283 Med | HTB-185 | human | P- | |
| D341 Med | HTB-187 | human | P- | |
| Daoy | HTB-186 | human | P- | |
| DBTRG-05MG | CRL-2020 | human | P– | |
| HCN-1A | CRL-10442 [†] | human | P- | |
| LN-18 | CRL-2610 | human | P+ | |
| M059J | CRL-2366 | human | P- | |
| M059K | CRL-2365 | human | P- | |
| SVG p12 | CRL-8621 [†] | human | P+ | |
| Glial fibrillary acidic protein: Gfap, | | | | |
| C8-D1A | CRL-2541 | mouse | P+ | |
| C8-D30 | CRL-2534 | mouse | P+ | |
| C8-S | CRL-2535 | mouse | P+ | |
| Swiss SFME | CRL-9391 [†] | | P+ | |
| | | mouse | ГТ | |
| Glial fibrillary acidic protein: Gfap , | | wat | D : | |
| CTX TNA2 | CRL-2006 | rat | P+ | |
| DITNC ₁ | CRL-2005 | rat | P+ | |
| EGC/PK060399egfr | CRL-2690 | rat | P+ | |
| Glucagon: GCG, 2641 | | <u> </u> | | |
| DMS 114 | CRL-2066 | human | P+ | |
| DMS 53 | CRL-2062 | human | P+ | |
| Glucagon: Gcg, 14526 | | | | |
| αTC1 Clone 9 | CRL-2350 | mouse | P+ | |
| B-TC-6 | CRL-11506 [†] | mouse | P+ | |
| NIT-1 | CRL-2055 | mouse | P+/- | |
| Glucagon receptor: Gcgr, 14527 | | | | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| Glucagon receptor (species not ye | | | | |
| HIT-T15 | CRL-1777 | Syrian golden | R+ | Responsive |
| 113 | CILL 1777 | hamster | | esponsive |
| Glucocorticoid receptors. See Nucl | ear recentor subfamily 2 | | | |
| · | cai receptor subtattilly 3 | • | | |
| Glutamate | CDL 2540 | | D. | |
| C8-B4 | CRL-2540 | mouse | P+ | |
| Glutamate decarboxylase 2 (pancr | eatic isiets and brain, 651 | | , | |
| | | GAD2, 2572 (human ge | <u> </u> | |
| GAD-1 | HB-184 | mouse/mouse | MAb | Anti GAD (many species) |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---|---|-----------------------|---------------------------------------|
| | | <u> </u> | Expresses | Comments |
| ilucose-6-phosphate dehydrogenas | | | | |
| C _s denydrogenas | se 2, mitochondrial: Gp CCL-107 | rat | P+ | |
| Glycogen | CCL 107 | Tat | 11 | |
| FL83B | CRL-2390 | mouse | P+ | |
| Glycophorin | | | | |
| HEL 92.1.7 | TIB-180 | human | P+ | |
| G26.4.1C3/86 | HB-9893 [†] | mouse/mouse | MAb | Anti human glycophorin |
| Glycophorin A (includes MN blood g | group): GYPA, 2993 | | | |
| TF-1 | CRL-2003 | human | P- | |
| 10F7MN | HB-8162 [†] | mouse/mouse | MAb | Anti human glycophorin A type M and |
| | | type N | | |
| 6A7M | HB-8159 [†] | mouse/mouse | MAb | Anti human glycophorin A type M |
| 8A2N | HB-8161 [†] | mouse/mouse | MAb | Anti human glycophorin A type N |
| NN-3 | HB-8474 [†] | mouse/mouse | MAb | Anti human glycophorin A type N |
| NN-4 | HB-8473 [†] | mouse/mouse | MAb | Anti human glycophorin A type N |
| NN-5 | HB-8476 [†] | mouse/mouse | MAb | Anti human glycophorin A type N |
| ilycoprotein hormones, alpha polyp | | | | |
| ChaGo-K-1 | HTB-168 | human | P+ | |
| HP75 | CRL-2506 | human | P+ | Autilian TCII |
| TSHR-T5-51 | CRL-2680 | mouse/mouse | MAb | Anti human TSH receptor alpha |
| TSHR-R5T-44 TSHR-T5U-317 | CRL-2681 CRL-2682 | mouse/mouse | MAb MAb | Anti human TSH receptor alpha |
| TSHR-15U-317 Chorionic gonadotropin, beta polypo | | mouse/mouse | IVIAD | Anti human TSH receptor alpha |
| norionic gonadotropin, beta polypi Ca Ski | CRL-1550 | human | P+ | |
| Glycoprotein hormones, alpha polyp | | | P+ | |
| chorionic gonadotropin, beta polyj | | | | |
| 3A-sub E | CRL-1584 | human | P+ | At 40°C |
| 3A(tPA-30-1) | CRL-1583 | human | P+ | At 40°C |
| BeWo | CCL-98 | human | P+ | 711-10-0 |
| DMS 53 | CRL-2062 | human | P+ | |
| JAR | HTB-144 | human | P+ | |
| JEG-3 | HTB-36 | human | P+ | |
| MSTO-211H | CRL-2081 | human | P+ | |
| Gonadotropin-releasing hormone re | ceptor: Gnrhr, 81668 | | | |
| RC-4B/C | CRL-1903 | rat | R+ | Less than normal number |
| Gonadotropin-releasing hormone 1 | (leutinizing-releasing h | normone): GNRH1, 2796 | | |
| USASK/DSIL-LHRH-A | HB-9094 [†] | mouse/mouse | MAb | Anti carboxy terminal end of |
| | | | | gonadotropin-releasing hormone |
| p39. See Tumor necrosis factor (liga | ınd) superfamily, memk | oer 5. | | |
| GPIIIa, platelet. See Integrin, beta 3. | | | | |
| Granulocyte colony stimulating activ | | | | |
| PU5-1.8 (PU5-1R) | TIB-61 | mouse | P+ | |
| WEHI-3 | TIB-68 | mouse | P+ | |
| Granulocyte colony stimulating factor | | | | |
| Granulocyte macrophage colony stir | | | ctor 2 (granulocyte-n | nacrophage). |
| | | | | |
| | | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | | | |
| Hep 3B2.1-7 Growth factor receptor bound prote | in 2-associated protein | 2: Gab2, 14389 | | |
| Hep 3B2.1-7 Growth factor receptor bound prote Cl. Ly1+2/9 | in 2-associated proteir CRL-8179† | 2: Gab2, 14389 mouse | P+ | |
| Hep 3B2.1-7 Growth factor receptor bound prote Cl. Ly1+2-/9 Growth arrest and DNA-damage-ind | in 2-associated protein CRL-8179† lucible, alpha: GADD45 | 2: Gab2, 14389 mouse GA, 1647 | | |
| Hep 3B2.1-7 Frowth factor receptor bound prote CI.Ly1+2/9 | in 2-associated proteir CRL-8179† | 2: Gab2, 14389 mouse | P+ P+ | Overexpresses Gadd45 RNA and |
| Hep 3B2.1-7 Growth factor receptor bound prote CI. Ly1+2-/9 Growth arrest and DNA-damage-ind RKO-AS45-1 | in 2-associated protein CRL-8179† lucible, alpha: GADD45 | 2: Gab2, 14389 mouse GA, 1647 | | Overexpresses Gadd45 RNA and protein |
| Hep 3B2.1-7 Growth factor receptor bound prote CI. Ly1+2-/9 Growth arrest and DNA-damage-ind RKO-AS45-1 Growth hormone 1: GH1, 2688 | in 2-associated protein CRL-8179† Iucible, alpha: GADD45 CRL-2579 | 2: Gab2, 14389 mouse A, 1647 human | P+ | |
| Hep 3B2.1-7 Growth factor receptor bound prote CI. Ly1+2/9 Growth arrest and DNA-damage-ind RKO-AS45-1 Growth hormone 1: GH1, 2688 DMS 53 | in 2-associated protein CRL-8179† Iucible, alpha: GADD45 CRL-2579 CRL-2062 | 12: Gab 2, 14389 mouse 6 A, 1647 human | P+ P+ | protein |
| Hep 3B2.1-7 Growth factor receptor bound prote CI. Ly1+2/9 Growth arrest and DNA-damage-ind RKO-AS45-1 Growth hormone 1: GH1, 2688 DMS 53 HGH-B | in 2-associated protein CRL-8179† Iucible, alpha: GADD45 CRL-2579 | 2: Gab2, 14389 mouse A, 1647 human | P+ | |
| Hep 3B2.1-7 Growth factor receptor bound prote CI. Ly1+2/9 Growth arrest and DNA-damage-ind RKO-AS45-1 Growth hormone 1: GH1, 2688 DMS 53 HGH-B Growth hormone 1: Gh1, 24391 | cin 2-associated protein CRL-8179 [†] lucible, alpha: GADD45 CRL-2579 CRL-2062 HB-10596 [†] | n 2: Gab 2, 14389 mouse 6A, 1647 human human mouse/mouse | P+ P+ MAb | protein Anti human GH |
| Growth factor receptor bound prote CI. Ly1+2/9 Growth arrest and DNA-damage-ind RKO-AS45-1 Growth hormone 1: GH1, 2688 DMS 53 HGH-B Growth hormone 1: Gh1, 24391 GH ₁ | cin 2-associated protein CRL-8179 [†] lucible, alpha: GADD45 CRL-2579 CRL-2062 HB-10596 [†] CCL-82 | n 2: Gab 2, 14389 mouse GA, 1647 human human mouse/mouse | P+ P+ MAb P+ | protein Anti human GH Somatotrophin |
| Hep 3B2.1-7 Growth factor receptor bound prote CI. Ly1+2/9 Growth arrest and DNA-damage-ind RKO-AS45-1 Growth hormone 1: GH1, 2688 DMS 53 HGH-B Growth hormone 1: Gh1, 24391 | cin 2-associated protein CRL-8179 [†] lucible, alpha: GADD45 CRL-2579 CRL-2062 HB-10596 [†] | n 2: Gab 2, 14389 mouse 6A, 1647 human human mouse/mouse | P+ P+ MAb | protein Anti human GH |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product is a product of the product$

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|--------------------------|-------------------|------------|---------------------------------|
| | | | | |
| Growth hormone receptor: GHR, 2 | | | | |
| IM-9 | CCL-159 | human | R+ | |
| uanylate cyclase 2C (heat stable | | | | |
| Caco-2 | HTB-37 | human | R+ | |
| aptoglobin: HP, 3240 | | | | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| ras 1. See ras. | | | | |
| CG. See Glycoprotein hormones. | | | | |
| emochromatosis: HFE, 3077 | | | | |
| 1C3 | CRL-2441 | mouse/mouse | MAb | Anti human HFE |
| 2A11 | CRL-2442 | mouse/mouse | MAb | Anti human HFE |
| 2A5 | CRL-2444 | mouse/mouse | MAb | Anti human HFE |
| 2B7 | CRL-2443 | mouse/mouse | MAb | Anti human HFE |
| 3A5 | CRL-2440 | mouse/mouse | MAb | Anti human HFE |
| emoglobin | CILL ZTTO | mouse, mouse | 111110 | |
| BB88 | TIB-55 | mouse | P+ | |
| D1B | TIB-56 | | P+ P+ | |
| HEL 92.1.7 | TIB-180 | mouse | P+ | |
| | IID-18U | human | r+ | |
| eparan sulfate proteoglycan | CDL 2100 | | D : | |
| EHS | CRL-2108 | mouse | P+ | |
| L2-RYC | CRL-2180 | rat | P+ | |
| eparan sulfate proteoglycan 2 (p | | | | |
| PFHR 9 | CRL-2423 | mouse | P+ | |
| ER2 receptor. See erb. | | | | |
| er2/neu.See erb. | | | | |
| er3 | | | | |
| AU565 | CRL-2351 | human | 0+ | |
| r4 | | | | |
| AU565 | CRL-2351 | human | 0+ | |
| stamine | | | | |
| MC/9 | CRL-8306 [†] | mouse | P+ | |
| RBL-1 | CRL-1378 | rat | P+ | |
| RBL-2H3 | CRL-2256 | rat | P+ | |
| stamine receptor H 1: Hrh1, 154 | | | | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| e-1 | | | · · | |
| 29SR | CRL-2262 | human | A+ | |
| DB | CRL-2289 | human | A+ | |
| HT | CRL-2269 CRL-2260 | human | A+ | |
| | CRL-2261 | | | |
| RL | | human | A+ | |
| MG-CoA reductase. See 3-hydrox | ty-5-methylglutaryi-Coen | zyme A reductase. | | |
| NK-1. See CD57. | | | | |
| 5A | TID COO | | A : | |
| AKR1.G.1.OVA ^R .1.26 | TIB-232 | mouse | A+ | |
| Υ | | | | |
| TM4 | CRL-1715 | mouse | A+, P+ | |
| HY3-11.27 | HB-8116 [†] | mouse/mouse | MAb | Anti mammalian H-Y antigen |
| 12/44 | HB-9070 [†] | mouse/mouse | MAb | Anti mouse and human H-Y antige |
| 12/49 | HB-9071 [†] | mouse/mouse | MAb | Anti mouse and human H-Y antige |
| yaluronic acid | | | | |
| 3T6-Swiss albino | CCL-96 | mouse | P+ | |
| Hydroxy-3-methylglutaryl-Coen | | | | |
| A9 | CRL-1811 | mouse/mouse | MAb | Anti hamster and rat HMG-CoA |
| | 101 (51)5:51 | | | reductase |
| Hydroxytryptamine (serotonin) | | | | |
| Ltk-11 | CRL-10422 [†] | mouse | R+ (human) | |
| | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---|--|---------------------------------------|---------------------------------------|
| | | • | Expicases | Comments |
| 5-Hydroxytryptamine (seroton | | | | |
| | receptor 2B: HTR2B, 3357 | | | |
| L NCC FUT2 | receptor 2C: HTR2C, 3358 | | D. (h) | |
| L-NGC-5HT2 5-Hydroxytryptamine (seroton | CRL-10287 [†] | mouse | R+ (human) | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| 5-Hydroxytryptamine (seroton | | | | 7.0\ |
| o-nydroxytryptamine (seroton OK | CRL-1840 | | R+ | 7,8) |
| | | opossum | N+ | |
| 5-Hydroxytryptamine (seroton COLO 320DM | | la coma mon | D. | |
| COLO 320DM COLO 320HSR | CCL-220 CCL-220.1 | human human | P+ P+ | |
| CAM1. See Intercellular adhesi | | numan | r+ | |
| | · , | ************************************** | | |
| gE, low affinity (CD23). See Fc f L. See Interleukin. | ragment of ige, low affinity if | , receptor for (CD23A). | | |
| | | | | |
| nsulin (many species) | LID 125 | | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Antinovlin (many and sing) |
| AE9D6 | HB-125 | mouse/mouse | MAb | Anti insulin (many species) |
| BE3F9 | HB-133 | mouse/mouse | MAb | Anti insulin (many species) |
| CC9C10 | HB-123 | mouse/mouse | MAb | Anti insulin (many species) |
| CE9H9 | HB-127 | mouse/mouse | MAb | Anti insulin (many species) |
| CG7C7 | HB-126 | mouse/mouse | MAb | Anti insulin (many species) |
| DB9G8 | HB-124 | mouse/mouse | MAb | Anti insulin (many species) |
| nsulin II: Ins2, 16334 | 601 | | | |
| αTC1 Clone 9 | CRL-2350 | mouse | P- | |
| cβ-TC-6 | CRL-11506 [†] | mouse | P+ | |
| CW13.20-3B3 | CRL-1669 | mouse | P+ | |
| TGP55 | CRL-2150 | mouse | P+ | |
| NIT-1 | CRL-2055 | mouse | P+ | |
| NIT-2 | CRL-2364 | mouse | P+ | |
| nsulin 2: Ins2, 24506 | | | | |
| AtT-20ins | CRL-11285 [†] | mouse | P+ (rat) | |
| AR42J | CRL-1492 | rat | P+ | |
| ARIP | CRL-1674 | rat | P+ | |
| RIN-14B | CRL-2059 | rat | P- | |
| RIN-5F | CRL-2058 | rat | P+ | |
| RIN-m | CRL-2057 | rat | P+ | |
| RIN-m5F | CRL-11605 [†] | rat | P+ | |
| nsulin 2 (species not yet curat | ed) | | | |
| HIT-T15 | CRL-1777 | Syrian golden | P+ | |
| | | hamster | | |
| nsulin receptor: INSR, 3643 | | | | |
| C3A | CRL-10741 [†] | human | R+ | |
| Hep G2 | HB-8065 [†] | human | R+ | |
| IM-9 | CCL-159 | human | R+ | |
| MCF-10-2A | CRL-10781 [†] | human | R+ | |
| MCF 10F | CRL-10318 [†] | human | R+ | Responsive |
| αIR-1 | HB-175 | mouse/mouse | MAb | Anti human insulin receptor |
| DII 33.1 | CRL-1827 | mouse/mouse | MAb | Anti human placental insulin receptor |
| nsulin receptor: Insr, 16337 | 22 1027 | | | , |
| 3T3-L1 | CL-173 | mouse | R+ | |
| nsulin receptor: Insr, 24954 | CL 173 | | **1 | |
| AR42J | CRL-1492 | rat | R+ | |
| NMU | CRL-1743 | rat | R+ | |
| RBA | CRL-1743 | rat | R+ | |
| nsulin-like growth factor: Igf1 | | ιαι | NT. | |
| | | | | |
| _ | , 24483 | | D. | |
| lgf2 | CDI 1570 | | | |
| l gf2 NRK-49F | CRL-1570 | rat | R+ | |
| NRK-49F NRK-52E | CRL-1571 | rat | R+ R+ | |
| NRK-49F NRK-52E nsulin-like growth factor bind | CRL-1571 ing protein 2 (36kD): IGFBP2 | rat , 3485 | R+ | |
| NRK-49F NRK-52E | CRL-1571 ing protein 2 (36kD): IGFBP2 HTB-22 | rat | | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product of the produc$

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---|--|---|---|
| | | ., | | |
| nsulin-like growth factor binding | | | D : | |
| MCF7 | HTB-22 | human | P+ | |
| nsulin-like growth factor 1 recept | | In comment | D : | |
| SK-N-AS U-2 OS | CRL-2137 | human | R+ R+ | |
| U-2 US H19-7/IGF-IR | HTB-96 CRL-2526 | human | | |
| nsulin-like growth factor 2 (soma | | rat | R+ (human) | |
| SK-N-AS | CRL-2137 | human | P+ | |
| ารนไท-โเหล growth factor 2 recept | | numan | P+ | |
| C3A | CRL-10741 [†] | human | R+ | |
| Hep G2 | HB-8065 [†] | human | R+ | |
| NCI-H146 | HTB-173 | human | R+ | |
| NCI-H140 | CRL-5811 | human | R+ | |
| NCI-H69 | HTB-119 | human | R+ | |
| NCI-H82 | HTB-175 | human | R+ | |
| U-2 OS | | human | R+ | Responsive |
| | HTB-96 | numan | N+ | Responsive |
| ntegrin-associated protein. See C | דט. | | | |
| ntegrin, alpha1: ITGA1, 3672 | HB-245 | mouso/mouso | MAb | Anti human VLA-1 alpha, integrin |
| TS2/7.1.1 | □D-Z43 | mouse/mouse | UAIVI | |
| ntogrin alpha 2h (platalat glyssa | rotain IIb of IIb/IIIa careel | ov antigon CD/19\-ITC 430 | 2674 | alpha 1; anti CD49a |
| ntegrin, alpha 2b (platelet glycop | | | | |
| MEG-01 ntegrin, alpha 3 (antigen CD49C, | CRL-2021 | human | A+ | |
| | • | • • | ASV10). ITCD1 2600 | |
| | CRL-2190 | gen CD29 includes MDF2, N | | |
| HK-2 | CRL-2190 | human | P+ | |
| ntegrin, alpha 4: Itga4, 16401 R1-2 | LID 227 | rat/mausa | MAb | Anti mausa LDAM 1 (humphasuta |
| R1-2 | HB-227 | rat/mouse | MAD | Anti mouse LPAM-1 (lymphocyte |
| | | \ | | Peyer's patch HEV adhesion molecule) |
| ntoniin alaba 4 (anasias natust | | VLA-4 | | |
| ntegrin, alpha 4 (species not yet o | | | AAA I- | And decree to be distanced (All A. 4 |
| FW3-218-1 | HB-261 | mouse/mouse | MAb | Anti sheep alpha 4 integrin (VLA-4, |
| latariin alaba 4 ltma 4 16401 AA | ID | | | CD49d) |
| ntegrin, alpha 4: Itga4, 16401 AN | עוי | | | |
| hata 7. kmb7 16431 | | | | |
| beta 7: ltgb7, 16421 | | | Δ. | |
| TK-1 | CRL-2396 | mouse | A+ | Austinopous alpha 4 hata 7 intervin |
| TK-1 DATK32 | CRL-2396 HB-294 | rat/mouse | A+ MAb | Anti mouse alpha 4 beta 7 integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece | CRL-2396 HB-294 ptor, alpha polypeptide): I' | rat/mouse TGA5,3678 | MAb | Anti mouse alpha 4 beta 7 integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 | rat/mouse TGA5, 3678 human | MAb A+ | Anti mouse alpha 4 beta 7 integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 | rat/mouse TGA5,3678 human human | MAb A+ A+ | Anti mouse alpha 4 beta 7 integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 | rat/mouse TGA5,3678 human human human | MAb A+ A+ A+ | Anti mouse alpha 4 beta 7 integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 | rat/mouse TGA5,3678 human human | MAb A+ A+ | Anti mouse alpha 4 beta 7 integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: Itga6, 114517 | CRL-2396 HB-294 ptor, alpha polypeptide): I' CRL-1621 CRL-1484 CCL-159 | rat/mouse TGA5,3678 human human human human | A+ A+ A+ A+ A+ | Anti mouse alpha 4 beta 7 integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: Itga6, 114517 YPEN-1 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 | rat/mouse TGA5, 3678 human human human human rat | MAb A+ A+ A+ | Anti mouse alpha 4 beta 7 integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: Itga6, 114517 YPEN-1 ntegrin, alpha D: ITGAD, 3681 (hu | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 | rat/mouse TGA5, 3678 human human human human rat | A+ A+ A+ A+ A+ | |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: ltga6, 114517 YPEN-1 ntegrin, alpha D: lTGAD, 3681 (ht | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse | A+ A+ A+ A+ A+ MAb | Anti rat alpha D integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: ltga6, 114517 YPEN-1 ntegrin, alpha D: lTGAD, 3681 (htga6) | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12593† | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse | A+ A+ A+ A+ A+ MAb MAb | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 Integrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 Integrin, alpha 6: Itga6, 114517 YPEN-1 Integrin, alpha D: ITGAD, 3681 (hu 226H 236L Integrin, alpha L (antigen CD11A) | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alg | A+ A+ A+ A+ A+ MAb MAb MAb sha polypeptide): ITGA | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: ltga6, 114517 YPEN-1 ntegrin, alpha D: lTGAD, 3681 (htgas) 226H 236L ntegrin, alpha L (antigen CD11A) | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alg | A+ A+ A+ A+ A+ MAb MAb MAb ha polypeptide): ITGA | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 Integrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 Integrin, alpha 6: Itga6, 114517 YPEN-1 Integrin, alpha D: ITGAD, 3681 (hotal) 226H 236L Integrin, alpha L (antigen CD11A) ARH-77 Farage | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human | MAb A+ A+ A+ A+ MAb MAb MAb wha polypeptide): ITGA A+ A+ | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 Integrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 Integrin, alpha 6: Itga6, 114517 YPEN-1 Integrin, alpha D: ITGAD, 3681 (htgae) 226H 236L Integrin, alpha L (antigen CD11A) ARH-77 Farage HS-Sultan | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human human human | MAb A+ A+ A+ A+ MAb MAb MAb wha polypeptide): ITGA A+ A+ A+ | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 Integrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 Integrin, alpha 6: Itga6, 114517 YPEN-1 Integrin, alpha D: ITGAD, 3681 (hu 226H 236L Integrin, alpha L (antigen CD11A (ARH-77 Farage HS-Sultan IM-9 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human | MAb A+ A+ A+ A+ MAb MAb MAb wha polypeptide): ITGA A+ A+ | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 Integrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 Integrin, alpha 6: Itga6, 114517 YPEN-1 Integrin, alpha D: ITGAD, 3681 (hu 226H 236L Integrin, alpha L (antigen CD11A (ARH-77 Farage HS-Sultan IM-9 MC/CAR | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 CRL-8083† | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human human human | MAb A+ A+ A+ A+ MAb MAb MAb wha polypeptide): ITGA A+ A+ A+ A+ A+ | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 Integrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 Integrin, alpha 6: Itga6, 114517 YPEN-1 Integrin, alpha D: ITGAD, 3681 (htgas) 126H 236L Integrin, alpha L (antigen CD11A) ARH-77 Farage HS-Sultan IM-9 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse bon-associated antigen 1; algo human human human human human | MAb A+ A+ A+ A+ MAb MAb MAb sha polypeptide): ITGA A+ A+ A+ A+ | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: Itga6, 114517 YPEN-1 ntegrin, alpha D: ITGAD, 3681 (htgas) 226H 236L ntegrin, alpha L (antigen CD11A) ARH-77 Farage HS-Sultan IM-9 MC/CAR | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 CRL-8083† | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alg human human human human human human human | MAb A+ A+ A+ A+ MAb MAb MAb wha polypeptide): ITGA A+ A+ A+ A+ A+ | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: Itga6 , 114517 YPEN-1 ntegrin, alpha D: ITGAD , 3681 (hr 226H 236L ntegrin, alpha L (antigen CD11A (ARH-77) Farage HS-Sultan IM-9 MC/CAR NK-92 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cur HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-8083† CRL-2407 | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human | MAb A+ A+ A+ A+ MAb MAb MAb sha polypeptide): ITGA A+ A+ A+ A+ A+ A+ | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: Itga6, 114517 YPEN-1 ntegrin, alpha D: ITGAD, 3681 (hr 226H 236L ntegrin, alpha L (antigen CD11A (ARH-77) Farage HS-Sultan IM-9 MC/CAR NK-92 NK-92CI | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-8083† CRL-2407 CRL-2409 | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human | MAb A+ A+ A+ A+ MAb MAb MAb sha polypeptide): ITGA A+ A+ A+ A+ A+ A+ A+ A+ | Anti rat alpha D integrin Anti rat alpha D integrin |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: Itga6, 114517 YPEN-1 ntegrin, alpha D: ITGAD, 3681 (hr 226H 236L ntegrin, alpha L (antigen CD11A (ARH-77) Farage HS-Sultan IM-9 MC/CAR NK-92 NK-92CI NK-92MI | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-8083† CRL-2407 CRL-2409 CRL-2408 | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human | MAb A+ A+ A+ A+ MAb MAb MAb Sha polypeptide): ITGA A+ | Anti rat alpha D integrin Anti rat alpha D integrin AL, 3683 |
| TK-1 DATK32 ntegrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 ntegrin, alpha 6: Itga6 , 114517 YPEN-1 ntegrin, alpha D: ITGAD , 3681 (hr 226H 236L ntegrin, alpha L (antigen CD11A (ARH-77) Farage HS-Sultan IM-9 MC/CAR NK-92 NK-92CI NK-92MI TS1/22.1.1.13 TS2/4.1.1 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cur HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-8083† CRL-2407 CRL-2409 CRL-2408 HB-202 | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human | MAb A+ A+ A+ A+ MAb MAb MAb Sha polypeptide): ITGA A+ | Anti rat alpha D integrin Anti rat alpha D integrin AL, 3683 Anti human CD11a |
| TK-1 DATK32 Integrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 Integrin, alpha 6: Itga6, 114517 YPEN-1 Integrin, alpha D: ITGAD, 3681 (hr 226H 236L Integrin, alpha L (antigen CD11A (ARH-77) Farage HS-Sultan IM-9 MC/CAR NK-92 NK-92CI NK-92MI TS1/22.1.1.13 TS2/4.1.1 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cur HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-8083† CRL-2407 CRL-2409 CRL-2408 HB-202 | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human | MAb A+ A+ A+ A+ MAb MAb MAb Sha polypeptide): ITGA A+ | Anti rat alpha D integrin Anti rat alpha D integrin AL, 3683 Anti human CD11a |
| TK-1 DATK32 Integrin, alpha 5 (fibronectin rece ARH-77 HS-Sultan IM-9 RPMI 8226 Integrin, alpha 6: Itga6, 114517 YPEN-1 Integrin, alpha D: ITGAD, 3681 (hr 226H 236L Integrin, alpha L (antigen CD11A (ARH-77) Farage HS-Sultan IM-9 MC/CAR NK-92 NK-92CI NK-92MI TS1/22.1.1.13 TS2/4.1.1 Integrin alpha L: Itga1, 16408 | CRL-2396 HB-294 ptor, alpha polypeptide): I CRL-1621 CRL-1484 CCL-159 CCL-155 CRL-2222 uman; rat gene not yet cui HB-12592† HB-12593† (p180), lymphocyte function CRL-1621 CRL-2630 CRL-1484 CCL-159 CRL-8083† CRL-2407 CRL-2407 CRL-2409 CRL-2408 HB-202 HB-244 | rat/mouse TGA5, 3678 human human human human rat rated) mouse/mouse mouse/mouse on-associated antigen 1; alp human | MAb A+ A+ A+ A+ MAb MAb MAb Sha polypeptide): ITGA A+ | Anti rat alpha D integrin Anti rat alpha D integrin AL, 3683 Anti human CD11a Anti human CD11a |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|-----------------------------|-------------------------------|--------------------------|---|
| ntegrin, alpha M (complement co | omponent receptor 3, alpl | ha; also known as CD11b (p170 | 0), macrophage ant | igen alpha polypeptide): |
| DMS 114 | CRL-2066 | human | A+ | |
| DMS 153 | CRL-2064 | human | A+ | |
| 17aba | HB-248 | mouse/mouse | MAb | Anti human CD11b |
| 44aacb | HB-249 | mouse/mouse | MAb | Anti human CD11b |
| LM2/1.6.11 | HB-204 | mouse/mouse | MAb | Anti human CD11b, anti human Mac-1 antigen, alpha chain |
| MY904 | HB-9510 [†] | mouse/mouse | MAb | Anti human CD11b |
| OKM 1 | CRL-8026 [†] | mouse/mouse | MAb | Anti human CD11b |
| tegrin alpha M: Itgam, 16409 | C.1.2 0020 | | | , |
| AMJ2-C11 | CRL-2456 | mouse | A+ | |
| AMJ2-C8 | CRL-2455 | mouse | A+ | |
| MH-S | CRL-2019 | mouse | A+ | |
| NFS-70 C-10 | CRL-1694 | mouse | A+ | |
| PMJ2-PC | CRL-2457 | | | |
| WEHI-274.1 | CRL-2457 CRL-1679 | mouse | A+ A+ | |
| PMJ2-R | CRL-1679 CRL-2458 | mouse | A+ A+ | |
| | | mouse rat/mouse | | Anti mouse CD11b |
| 5C6 Clone 1 | CRL-1969 | rat/mouse | MAb | |
| M1/70.15.11.5.HL | TIB-128 | rat/mouse | MAb | Anti mouse Mac-1, alpha chain |
| tegrin alpha M: Itgam, 16409 A | חמו | | | |
| beta 2: ltgb2, 16414 | CD1 0.1 | | A : | |
| EOC 13.31 | CRL-2468 | mouse | A+ | |
| EOC 2 | CRL-2467 | mouse | A+ | |
| EOC 20 | CRL-2469 | mouse | A+ | |
| I-11.15 | CRL-2470 | mouse | A+ | |
| I-13.35 | CRL-2471 | mouse | A+ | |
| ntegrin, alpha V (vitronectin rece | ptor, alpha polypeptide, a | ntigen CD51): ITGAV, 3685 AN | ID | |
| beta 1 (fibronectin recep | otor, beta polypeptide, ant | igen CD29 includes MDF2, MS | K12): ITGB1, 3688 | |
| 293 | CRL-1573 | human | R+ | |
| itegrin alpha X: Itgax, 16411 | | | | |
| N418 | HB-224 | Armenian hamster/ mouse | MAb | Anti mouse CD11 |
| tegrin, beta 1 (fibronectin recep | stor heta nolynentide ant | | K12)-ITGR1 3688 | |
| Farage | CRL-2630 | human | A+ | |
| TS2/16.2.1 | HB-243 | mouse/mouse | MAb | Anti human VLA-1 beta, integrin beta 1; |
| 132/10.2.1 | ПБ-243 | anti CD29 | IVIAD | Anti numan vea-i beta, integrin beta 1, |
| to avia hata 1 (Ehvanastia vasaa | 4 b4-\- | anti CD29 | | |
| tegrin beta 1 (fibronectin recep | <u> </u> | mauss | | Three conies of the both 4 into mile |
| F9 | CRL-1720 | mouse | | Three copies of the beta 1 integrin |
| I/A A I/C | CDL 2172 | | | gene |
| KMI6 | CRL-2179 | rat/mouse | MAb | Anti mouse integrin beta 1 subunit (CD29) |
| tegrin beta 1 (fibronectin recep | tor beta) (species not yet | curated) | | |
| FW4-101-1-1 | HB-289 | mouse/mouse | MAb | Anti sheep beta 1 integrin (CD29) |
| tegrin, beta 2 (antigen CD18 (ps | | | | |
| IB4 | HB-10164 [†] | mouse/mouse | MAb | Anti human CD18 |
| TS1/18.1.2.11 | HB-203 | mouse/mouse | MAb | Anti human CD18 |
| ntegrin beta 2: ltgb2, 16414 | 1.15 2.00 | | 111110 | , |
| 2E6 | HB-226 | Armenian hamster/ | MAb | Anti mouse CD18 |
| | | mouse | | |
| M18/2.a.12.7 | TIB-218 | rat/mouse | MAb | Anti mouse CD18 |
| tegrin, beta 3 (platelet glycopro | <u> </u> | GB3, 3690 | | |
| MEG-01 | CRL-2021 | human | A+ | |
| AP-3 | HB-242 | mouse/mouse | MAb | Anti human integrin, beta 3 |
| LK-4 | CRL-2345 | mouse/mouse | MAb | Anti human platelet glycoprotein GPIlla |
| tegrin beta 3 (Cd61): Itgb3, 293 | 302 | | | Gi iliu |
| YPEN-1 | CRL-2222 | rat | A+ | |
| tegrin beta 7: ltgb7, 16421 | CNL-ZZZZ | ιαι | ΛΤ | |
| | | | | |
| | LID 202 | va+/m | N A A I | Antimouso bata 7 into |
| FIB504.64 FIB21 | HB-293 HB-295 | rat/mouse rat/mouse | MAb MAb | Anti mouse beta 7 integrin Anti mouse beta 7 integrin |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product is a product of the product$

* Part of the NBL collection; see page 12. $\,^+$ Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|--|-------------|------------|---|
| | | органи | | |
| ntegrin, leukocyte. See Integrin alph | | | | |
| ntercellular adhesion molecule 1 (C | | | | |
| BC-3 | CRL-2277 | human | A+ | |
| Farage | CRL-2630 | human | A+ | |
| LS1034 | CRL-2158 | human | A+ | |
| LS411N | CRL-2159 | human | A+ | |
| LS513 | CRL-2134 | human | A+ | |
| NK-92 | CRL-2407 | human | A+ | |
| NK-92CI | CRL-2409 | human | A+ | |
| NK-92MI | CRL-2408 | human | A+ | |
| R6.5.D6.E9.B2 | HB-9580 [†] | mouse/mouse | MAb | Anti human ICAM-1 |
| tercellular adhesion molecule: Ica | m1,15894 | | | |
| bEnd.3 | CRL-2299 | mouse | A+ | |
| BE29G1 | HB-233 | rat/mouse | MAb | Anti mouse ICAM-1 |
| YN1/1.7.4 | CRL-1878 | rat/rat | MAb | Anti mouse ICAM-1 |
| terferon | CILL 1070 | Ιαζιαί | IVIAU | A THE THOUSE TEAMY I |
| HT-1376 | CRL-1472 | human | P+ | |
| MG-63 | CRL-1472 CRL-1427 | human | P+ P+ | |
| Mo-63 | CRL-1427 CRL-8066 [†] | | P+ | |
| | CUT-9000, | human | r+ | |
| terferon, alpha (over 20 loci) | CDL 0001+ | | D . | |
| KG-1 | CRL-8031 [†] | human | P+ | |
| terferon (alpha, beta, and omega) | | | | |
| Hs 294T | HTB-140 | human | R+ | Responsive |
| terferon, gamma: IFNG, 3458 | | | | |
| Jurkat, Clone E6-1 | TIB-152 | human | P+ | |
| TALL-104 | CRL-11386 [†] | human | P+ | |
| IFGCP-F1BA10 | HB-8291 [†] | mouse/mouse | MAb | Anti human gamma interferon |
| gamma3-11.1 | HB-8700 [†] | mouse/mouse | MAb | Anti human gamma interferon |
| terferon, gamma: Ifng, 15978 | | | | <u> </u> |
| R4-6A2 | HB-170 | rat/mouse | MAb | Anti mouse gamma interferon |
| terferon, gamma, receptor: Ifngr, ' | 15979 | | | |
| GR-20 | CRL-2024 | rat/mouse | MAb | Anti mouse receptor for gamma |
| GN 20 | CHE ZOZ I | rat/mouse | 111110 | interferon |
| GR-96 | CRL-2013 | rat/mouse | MAb | Anti mouse receptor for gamma |
| GN-90 | CNL-2013 | rat/mouse | MAD | interferon |
| nterleukin 1 alpha: Il1a, 16175 OR | | | | IIIterreron |
| | | | | |
| 1 beta: II1b, 16176 | TID 67 | | D. | |
| J774A.1 | TIB-67 | mouse | P+ | |
| MH-S | CRL-2019 | mouse | P+ | |
| NCTC 3749 | CCL-46.1 | mouse | P+ | |
| P388D1 (IL-1) | TIB-63 | mouse | P+ | |
| nterleukin 1 alpha: II1a, 24493 OR | | | | |
| 1 beta: II1b, 24494 | | | | |
| NR8383 | CRL-2192 | rat | P+ | |
| terleukin 1, alpha: IL1A, 3552 | | | | |
| HS-5 | CRL-11882 [†] | human | P+ | |
| iterleukin 1, beta: IL1B, 3553 | | | | |
| HS-5 | CRL-11882 [†] | human | P+ | |
| ILB1-H21 | HB-10220 [†] | mouse/mouse | MAb | Anti human IL-1 beta |
| ILB1-H34 | HB-10221 [†] | mouse/mouse | MAb | Anti human IL-1 beta |
| ILB1-H6 | HB-10219 [†] | mouse/mouse | MAb | Anti human IL-1 beta |
| ILB1-H67 | HB-10222 [†] | mouse/mouse | MAb | Anti human IL-1 beta |
| IED I 1107 | 110 10222 | mouse/mouse | MIAD | , and manuffile 1 Deta |
| | | | MAb | Anti bovine IL-1 beta (rbolL-1 beta |
| nterleukin 1, beta: IL1B, 281251 | CDI 2052 | | IVIALI | AUII DOVIDE II - L DEIZ (IDOII - L DEIZ |
| sA22 | CRL-2052 | mouse/mouse | 1417.05 | , 501c.12 1 50ta (15012 1 50ta |
| sA22 sterleukin 1, beta: IL1B, 281251 SA22 sterleukin 1 receptor, type I: II1r1, | 16177 OR | mouse/mouse | 111110 | , |
| sA22 nterleukin 1 receptor, type I: Il1r1, type II:Il1r2, | 16177 OR 16178 | | | |
| nterleukin 1, beta: IL1B, 281251 SA22 nterleukin 1 receptor, type l: II1r1, type ll: II1r2, D10.G4.1 | 16177 OR 16178 TIB-224 | mouse | R+ | Responsive |
| terleukin 1, beta: IL1B, 281251 SA22 terleukin 1 receptor, type I: II1r1, type II: II1r2, | 16177 OR 16178 | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|--|--------------------------------------|-----------------------|---|
| | 7.7.00 110. | 2400102 | _Api 03363 | |
| Interleukin 2: IL2, 3558 | 1170 474 | | | |
| H9 | HTB-176 | human | P+ | |
| HuT 78 | TIB-161 | human | P+ | |
| J45.01 | CRL-1990 | human | P+ | |
| Jurkat, Clone E6-1 | TIB-152 | human | P+ | |
| NK-92 | CRL-2407 | human | P- | |
| NK-92MI | CRL-2408 | human | P+ | |
| nterleukin 2: II2, 16183 | | | | |
| EL4.IL-2 | TIB-181 | mouse | P+ | |
| LBRM-33-1A5 | CRL-8079 [†] | mouse | P+ | |
| LBRM-33 clone 4A2 | TIB-155 | mouse | P+ | |
| LBRM TG6 | CRL-1778 | mouse | P+ | |
| 4B6-1 | HB-10968 [†] | rat/mouse | MAb | Anti mouse IL-2 |
| nterleukin 2 receptor, alpha: IL2RA | | rat/mouse | IVIAD | Antimodae IL 2 |
| beta: IL2RB , | | | | |
| | | leficiency): IL2RG, 3561 : mu | Ilticomponent recepto | r |
| H9 | HTB-176 | human | R+ | |
| HuT 102 | TIB-162 | human | R+ | Responsive |
| HuT 78 | TIB-161 | human | R+ | Responsive |
| MJ | CRL-8294 [†] | human | R+ | |
| TALL-104 | CRL-11386 [†] | human | R+ | Responsive (cells dependent for |
| | J.12 11500 | | ••• | optimal growth) |
| 2A3A1H | HB-8555 [†] | mouse/mouse | MAb | Anti human IL-2 receptor |
| 7G7B6 | HB-8784 [†] | mouse/mouse | MAb | Anti human IL-2 receptor |
| nterleukin 2 receptor, alpha chain: | | mouse/mouse | IVIAD | Anti numari il 2 receptor |
| | 12rb, 16185 AND | | | |
| | | | | |
| | n: II2rg, 16186 | | D : | |
| CTLL-2 | TIB-214 | mouse | R+ | |
| HT-2 clone A5E | CRL-1841 | mouse | R+ | Responsive (cells dependent for growth) |
| 7D4 | CRL-1698 | rat/mouse | MAb | Anti mouse IL-2 receptor |
| PC 61 5.3 | TIB-222 | rat/mouse | MAb | Anti mouse IL-2 receptor |
| nterleukin 2 receptor (species not | vet curated) | | <u> </u> | |
| MYA-1 | CRL-2417 | cat | R+ | Responsive (cells dependent for growth) |
| nterleukin 2 receptor, alpha: IL2RA | . 3550 | | | growth |
| 29SR | CRL-2262 | human | Λ. | |
| | | human | A+ | |
| DB | CRL-2289 | human | A- | |
| HH | CRL-2105 | human | A- | |
| HT | CRL-2260 | human | A- | |
| RL | CRL-2261 | human | A- | |
| SUP-T1 [VB] | CRL-1942 | human | A- | |
| 7G7B6 | HB-8784 [†] | mouse/mouse | MAb | Anti human CD25 |
| nterleukin 2 receptor, alpha chain: | Il2ra, 16184 | | | |
| 7D4 | CRL-1698 | rat/mouse | MAb | Anti mouse CD25 |
| PC 61 5.3 | TIB-222 | rat/mouse | MAb | Anti mouse CD25 |
| nterleukin 2 receptor, beta: IL2RB, | | | - | |
| HH | CRL-2105 | human | R+ | Functional p70 beta chain (IL-2R beta) |
| nterleukin 3 (colony-stimulating fa | | | *** | |
| Hs-5 | CRL-11882 [†] | human | P+ | |
| nterleukin 3: II3, 16187 | CIL 11002 | Human | 1.1 | |
| · · · · · · · · · · · · · · · · · · · | CRL-8179 [†] | mouso | P+ | |
| Cl. Ly1+2-/9 | | mouse | | |
| WEHI-3 | TIB-68 | mouse | P+ | |
| nterleukin 3 receptor, alpha chain: | | | | |
| 32D Clone 3 | CRL-11346 [†] | mouse | R+ | Responsive (cells dependent for |
| nterleukin 4: II4, 16189 | | | | growth) |
| | | | | |
| · | CDI 0170† | mouro | | |
| Cl. Ly1+2⁻/9 | CRL-8179 [†] | mouse | P+ | |
| · · · · · · · · · · · · · · · · · · · | CRL-8179 [†] TIB-224 HB-188 | mouse mouse rat/mouse | P+ P+ MAb | Anti mouse IL-4 |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

^{*} Part of the NBL collection; see page 12. $\,^+$ Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|----------------------------------|------------------------------------|---------------------------------|--|
| Cell Lille Naille | AICC NO. | 3pecies | Expresses | Comments |
| nterleukin 4 receptor: IL4R, 3566 | | | | |
| · · · | | leficiency): IL2RG, 3561 Mu | | |
| Ramos (RA 1) | CRL-1596 | human | R+ | Sensitive |
| Ramos.2G6.4C10 | CRL-1923 | human | R+ | Sensitive (greater sensitivity than CRL-1596 |
| interleukin 5: II5, 16191 | | | | |
| D10.G4.1 | TIB-224 | mouse | P+ | |
| Interleukin 5 receptor, alpha: IL5R | | | | |
| Clone 15 HL-60 | CRL-1964 | human | R+ | |
| nterleukin 6 (interferon, beta 2): IL | <u> </u> | | | |
| HS-5 | CRL-11882 [†] | human | P+ | |
| LS 180 | CL-187 | human | P+ | |
| LS 174T | CL-188 | human | P+ | |
| U266B1 | TIB-196 | human | P+ | |
| nterleukin 6: II6, 16193 | | | | |
| AMJ2-C11 | CRL-2456 | mouse | P+ | |
| EOMA | CRL-2586 | mouse | P+ | |
| MPC-11 | CCL-167 | mouse | P+ | |
| Sp2/mIL-6 | CRL-2016 | mouse/mouse | P+ | |
| Interleukin 6 (interferon, beta 2): II | | | | |
| NR8383 | CRL-2192 | rat | P+ | |
| Interleukin 6 receptor: IL6R, 3570 | | | | |
| | | or): IL6ST, 3572: multicom | ponent receptor | |
| DS-1 | CRL-11102 [†] | human | R+ | |
| nterleukin 7 receptor: II7r, 16197 | AND | | | |
| 2 receptor, gamma cha | in: II2rg, 16186 Multicon | nponent receptor | | |
| 2E8 | TIB-239 | mouse | R+ | Responsive (cells dependent for growth) |
| Interleukin 8: IL8, 3576 | | | | |
| HS-5 | CRL-11882 [†] | human | Р | |
| EL-NC-1S | HB-9647 [†] | mouse/mouse | MAb | Anti IL-8 (species unknown) |
| Interleukin 8 receptor, beta: IL8RB , | 3579 | | | |
| 10H2.12.1 | HB-11494 [†] | mouse/mouse | MAb | Anti human IL-8 receptor, type B |
| 4D1.5.7 | HB-11495 [†] | mouse/mouse | MAb | Anti human IL-8 receptor, type B |
| Interleukin 10: IL10, 3586 | | | | |
| COLO 205 | CCL-222 | human | P+ | |
| LS 174T | CL-188 | human | P+ | |
| LS 180 | CL-187 | human | P+ | |
| JES3-19F1.1.1 | HB-10487 [†] | rat/mouse | MAb | Anti human IL-10 |
| Interleukin 10: II10, 16153 | | | | |
| H36.12j | CRL-2449 | mouse | P+ | |
| Interleukin 11: IL11, 3589 | | | | |
| HS-5 | CRL-11882 [†] | human | P+ | |
| Interleukin 12A (natural killer cell s | timulatory factor 1, cyto | toxic lymphocyte maturatio | on factor 1, p35): IL12A | , 3592 AND |
| 12B (natural killer cell s | timulatory factor 2, cytot | oxic lymphocyte maturation | n factor 2, p40): IL12B, | 3593 |
| 20C2 | CRL-2382 | rat/mouse | MAb | Anti human IL-12 p75 |
| Interleukin 12a: Il12a, 16159 AND | | | | |
| 12b: Il12b, 16160 | | | | |
| R2-9A5 | CRL-2357 | rat/mouse | MAb | Anti mouse IL-12 p75 |
| Interleukin 12b: II12b , 16160 | | | | · |
| R2-10F6 | CRL-2358 | rat/mouse | MAb | Anti mouse IL-12 p40 |
| R1-5D9 | CRL-2360 | rat/mouse | MAb | Anti mouse IL-12 p40 |
| nterleukin 12 receptor, beta 1: IL1 | 2RB1, 3594 | | | · |
| HIL12R1.2B10 | CRL-2359 | rat/mouse | MAb | Anti human IL-12 receptor beta 1 |
| | | | • | (hulL-12Rbeta1) subunit |
| Interleukin 15: IL15, 3600 | | | | |
| hIL-15-M110 | HB-12061 [†] | mouse/mouse | MAb | Anti human IL-15 |
| hIL-15-M111 | HB-12062 [†] | mouse/mouse | MAb | Anti human IL-15 |
| Involucrin: IVL, 3713 | | | - | |
| NCI-H596 | HTB-178 | human | P+ | |
| SCC-15 | CRL-1623 | human | P+ | |
| | | | | |
| SCC-25 | CRL-1628 | human | P+ | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name: Symbol, GeneID | ATCC® N - | C | F | Camananta |
|--|------------------------|------------------------------|---------------------------------------|-------------------------|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| Keratin 4: KRT4, 3851 | | | | |
| NCI-H128 | HTB-120 | human | P– | |
| NCI-H23 | CRL-5800 | human | P- | |
| NCI-H524 | CRL-5831 | human | P- | |
| NCI-H69 | HTB-119 | human | P- | |
| NCI-H82 | HTB-175 | human | P- | |
| NCI-N417 | CRL-5809 | human | P- | |
| Keratin 5 (epidermolysis bullosa simpl | ex, Dowling-Meara/K | obner/Weber-Cockayne ty | oes): KRT5, 3852 | |
| CA-HPV-10 | CRL-2220 | human | P+ | |
| PZ-HPV-7 | CRL-2221 | human | P+ | |
| Keratin 5 (epidermolysis bullosa simpl | ex, Dowling-Meara/K | Cobner/Weber-Cockayne ty | pes): KRT5, 3852 AND, | /OR |
| 8: KRT8, 3856 | | | | |
| NCI-H128 | HTB-120 | human | P+ | |
| NCI-H23 | CRL-5800 | human | P+ | |
| NCI-H524 | CRL-5831 | human | P- | |
| NCI-H69 | HTB-119 | human | P+ | |
| NCI-H82 | HTB-175 | human | P- | |
| NCI-N417 | CRL-5809 | human | P– | |
| Keratin 7: KRT7, 3855 | | | | |
| NCI-H128 | HTB-120 | human | P– | |
| NCI-H23 | CRL-5800 | human | P+ | |
| NCI-H524 | CRL-5831 | human | P- | |
| NCI-H69 | HTB-119 | human | P- | |
| NCI-H82 | HTB-175 | human | P- | |
| NCI-N417 | CRL-5809 | human | P- | |
| Panc 02.03 | CRL-2553 | human | P+ | |
| Panc 02.13 | CRL-2554 | human | P+ | |
| Panc 03.27 | CRL-2549 | human | P+ | |
| Panc 08.13 | CRL-2551 | human | P+ | |
| Panc 10.05 | CRL-2547 | human | P+ | |
| Keratin 8: KRT8, 3856 | | | | |
| CA-HPV-10 | CRL-2220 | human | P+ | |
| MCF-12A | CRL-10782 [†] | human | P+ | |
| MCF-12F | CRL-10783 [†] | human | P+ | |
| PWR-1E | CRL-11611 [†] | human | P+ | |
| PZ-HPV-7 | CRL-2221 | human | P+ | |
| RWPE-1 | CRL-11609 [†] | human | P+ | |
| RWPE-2 | CRL-11610 [†] | human | P+ | |
| UCD/AB 6.01 | HB-8693 [†] | mouse/mouse | MAb | Anti human CK8 |
| Keratin 8: Krt8, 25626 | | | | |
| RLE-6TN | CRL-2300 | rat | P+ | |
| RMC | CRL-2573 | rat | P- | |
| Keratin 8 (species not yet curated) | | | | |
| vEPT | CRL-2087 | rabbit | P+ | |
| Keratin 8: KRT8, 3856 AND | | | | |
| 18: KRT18, 3875 | | | | |
| UCD/PR 10.11 | HB-8694 [†] | mouse/mouse | MAb | Anti human CK8 and CK18 |
| Keratin 10 (epidermolytic hyperkerato | sis; keratosis palmari | s et plantaris): KRT10, 3858 | 3 | |
| HEK001 | CRL-2404 | human | P- | |
| NCI-H128 | HTB-120 | human | P- | |
| NCI-H23 | CRL-5800 | human | P- | |
| NCI-H524 | CRL-5831 | human | P- | |
| NCI-H69 | HTB-119 | human | P- | |
| NCI-H82 | HTB-175 | human | P- | |
| NCI-N417 | CRL-5809 | human | P- | |
| Keratin 10 (species not yet curated) | C 5507 | | · · · · · · · · · · · · · · · · · · · | |
| vEPT | CRL-2087 | rabbit | P- | |
| Keratin 11: cytokeratin 11 (CK11) | S 2007 | | <u> </u> | |
| vEPT | CRL-2087 | rabbit | P+ | |
| VEPT | CKL-2087 | rabbit | Ρ+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--------------------------------|------------------------|-------------|-----------|-----------------|
| | Arec no. | эрсско | Expresses | Comments |
| ratin 13: KRT13, 3860 | | | | |
| NCI-H128 | HTB-120 | human | P- | |
| NCI-H23 | CRL-5800 | human | P- | |
| NCI-H524 | CRL-5831 | human | P- | |
| NCI-H69 | HTB-119 | human | P- | |
| NCI-H82 | HTB-175 | human | P- | |
| NCI-N417 | CRL-5809 | human | P- | |
| atin 14 (epidermolysis bullosa | | | | |
| HEK001 | CRL-2404 | human | P+ | |
| MCF-12A | CRL-10782 [†] | human | P+ | |
| MCF-12F | CRL-10783 [†] | human | P+ | |
| ratin 18: KRT18, 3875 | | | | |
| MCF-10-2A | CRL-10781 [†] | human | P+ | |
| MCF-12A | CRL-10782 [†] | human | P+ | |
| MCF-12F | CRL-10783 [†] | human | P+ | |
| NCI-H128 | HTB-120 | human | P+ | |
| NCI-H23 | CRL-5800 | human | P+ | |
| NCI-H524 | CRL-5831 | human | P– | |
| NCI-H69 | HTB-119 | human | P+ | |
| NCI-H82 | HTB-175 | human | P– | |
| NCI-N417 | CRL-5809 | human | P- | |
| Panc 02.03 | CRL-2553 | human | P+ | |
| Panc 02.13 | CRL-2554 | human | P+ | |
| Panc 03.27 | CRL-2549 | human | P+ | |
| Panc 08.13 | CRL-2551 | human | P+ | |
| Panc 10.05 | CRL-2547 | human | P+ | |
| RWPE-1 | CRL-11609 [†] | human | P+ | |
| RWPE-2 | CRL-11610 [†] | human | P+ | |
| PWR-1E | CRL-11611 [†] | human | P+ | |
| THLE-3 | CRL-11233 [†] | human | P+ | |
| UCD/AB 6.11 | HB-8458 [†] | mouse/mouse | MAb | Anti human CK18 |
| eratin 19: KRT19, 3880 | | | | |
| HCC1008 | CRL-2320 | human | P+ | |
| HCC1143 | CRL-2321 | human | P+ | |
| HCC1187 | CRL-2322 | human | P+ | |
| HCC1395 | CRL-2324 | human | P+ | |
| HCC1419 | CRL-2326 | human | P+ | |
| HCC1428 | CRL-2327 | human | P+ | |
| HCC1500 | CRL-2329 | human | P+ | |
| HCC1569 | CRL-2330 | human | P+ | |
| HCC1599 | CRL-2331 | human | P+ | |
| HCC1806 | CRL-2335 | human | P+ | |
| HCC1937 | CRL-2336 | human | P+ | |
| HCC1954 | CRL-2338 | human | P+ | |
| HCC202 | CRL-2316 | human | P+ | |
| HCC2157 | CRL-2340 | human | P+ | |
| HCC2218 | CRL-2343 | human | P+ | |
| HCC38 | CRL-2314 | human | P+ | |
| HCC70 | CRL-2315 | human | P+ | |
| MCF-10-2A | CRL-10781 [†] | human | P+ | |
| MCF-12A | CRL-10782 [†] | human | P- | |
| MCF-12F | CRL-10783 [†] | human | P- | |
| NCI-H128 | HTB-120 | human | P+ | |
| NCI-H23 | CRL-5800 | human | P- | |
| NCI-H524 | CRL-5831 | human | P- | |
| NCI-H69 | HTB-119 | human | P+ | |
| NCI-H82 | HTB-175 | human | P- | |
| NCI-N417 | CRL-5809 | human | P- | |
| SCC-15 | CRL-1623 | human | P+ | |
| JCC 13 | CILL IUZJ | Haman | P+ | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|--|----------------------------------|----------------|--|
| | | • | • | Comments |
| THLE-3 | CRL-11233† | human | P+ | |
| Keratin 19 (species not yet curated) | CDI 2007 | | D. | |
| vEPT | CRL-2087 | rabbit | P+ | |
| Keratin complex 1, acidic, gene 19: K RLE-6TN | CRL-2300 | vo+ | P+ | |
| | CRL-2300 | rat | P+ | |
| Kidney-specific esterase-2 (ES-2) RAG | CCL-142 | maura | P+ | |
| KAG Killer cell lectin-like receptor, subfan | | mouse | P+ | |
| 4D11 | HB-240 | rat/mouse | MAb | Anti mouse LGL-1 |
| Kinase insert domain protein recept | | Tat/Tilouse | IVIAD | Aliti Illouse Ede-1 |
| MS1 (MILE SVEN 1) | CRL-2279 | mouse | R+ | |
| SVR (SVEN 1 ras) | CRL-2280 | mouse | R+ | |
| DC101 | HB-11534 [†] | rat/mouse | MAb | Anti mouse VEGF receptor-2 (Flk-1/KDR) |
| Kininogen: KNG, 3827 | 110 11554 | rat/mouse | 1417 (15) | Allti modde v Edi Teceptor 2 (Fik 17 kom |
| 2B5 | HB-8963 [†] | mouse/mouse | MAb | Anti human kininogen heavy chain |
| C11C1 | HB-8964 [†] | mouse/mouse | MAb | Anti human kininogen light chain |
| -kit Hardy-Zuckerman 4 feline sarco | | | IVII NO | 7.1.3 Haman Allinogen light chall |
| NCI-H187 | CRL-5804 | human | 0+ | c-kit |
| NCI-H378 | CRL-5808 | human | O+ | c-kit |
| NCI-H526 | CRL-5811 | human | O+ | c-kit |
| NCI-N417 | CRL-5809 | human | 0- | c-kit |
| BA7.3C.9 | HB-10716 [†] | mouse/mouse | MAb | Anti human stem cell factor (hSCF) |
| 5,0,50,5 | 110 107 10 | mouse/mouse | WITNO | receptor (CD117) |
| Kit ligand: KITLG, 4254 | | | | receptor (eb 117) |
| HS-5 | CRL-11882 [†] | human | P+ | |
| SI/SI4 hSCF220 | CRL-2453 | mouse | P+ (human) | Membrane-bound protein |
| SI/SI4 hSCF248 | CRL-2454 | mouse | P+ (human) | Secreted |
| Kit ligand: Kitl, 17311 | CILL Z-15-1 | mouse | T T (Haman) | Secreted |
| 15P-1 | CRL-2618 | mouse | P+ | |
| L3T4. See CD4. | CILL ZOTO | mouse | 1 1 | |
| LAM-1. See Selectin L. | | | | |
| _aminin (about 60 forms of laminin) | | | | |
| A2058 | CRL-11147 [†] | human | R+ | Responsive |
| EHS | CRL-2108 | mouse | P+ | espe.isive |
| M2-10B4 | CRL-1972 | mouse | P+ | |
| NE NE | CRL-2070 | mouse | P+ | |
| L2-RYC | CRL-2180 | rat | P+ | |
| RL-65 | CRL-10354 [†] | rat | P+ | |
| 2AB1-IA10 | HB-8210 [†] | rat/mouse | MAb | |
| _aminin-1 | | | | |
| PFHR 9 | CRL-2423 | mouse | P+ | |
| _atent transforming growth factor b | | | | |
| 33 | | LTBP2, 4053 | | |
| HT-29 | HTB-38 | human | P+ | |
| -dopa-decarboxylase. See Dopa de | | | | |
| _e3 | , | | | |
| SW756 | CRL-10302 [†] | human | A+ | |
| _e4 | | | | |
| SW756 | CRL-10302 [†] | human | A+ | |
| _e5 | | <u> </u> | | |
| SW756 | CRL-10302 [†] | human | A+ | |
| | <u> </u> | | | |
| .ECAM. See Selectin L. | Lgals3, 16854 | | | |
| | | mouso | A+ | |
| ectin, galactose binding, soluble 3: | | mouse | | |
| ectin, galactose binding, soluble 3: AMJ2-C8 | CRL-2455 | mouse mouse | A+ | |
| ectin, galactose binding, soluble 3: AMJ2-C8 AMJ2-C11 | CRL-2455 CRL-2456 | mouse | A+ A+ | |
| ectin, galactose binding, soluble 3: AMJ2-C8 AMJ2-C11 EOC 13.31 | CRL-2455 CRL-2456 CRL-2468 | mouse mouse | A+ | |
| ectin, galactose binding, soluble 3: AMJ2-C8 AMJ2-C11 EOC 13.31 EOC 2 | CRL-2455 CRL-2456 CRL-2468 CRL-2467 | mouse mouse mouse | A+ A+ | |
| ectin, galactose binding, soluble 3: AMJ2-C8 AMJ2-C11 EOC 13.31 EOC 2 EOC 20 | CRL-2455 CRL-2456 CRL-2468 CRL-2467 CRL-2469 | mouse mouse mouse mouse | A+ A+ A+ | |
| AMJ2-C11 EOC 13.31 EOC 2 | CRL-2455 CRL-2456 CRL-2468 CRL-2467 | mouse mouse mouse | A+ A+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product is a product of the product$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|---|---|--|--|
| Cen Line Hanc | 711 CC 110. | эрсско | Expresses | Commence |
| Leptin receptor: LEPR, 3953 | | | | |
| HP75 | CRL-2506 | human | R+ | Leptin receptor protein and mRNA |
| eu-1. See CD5. | | | | |
| _eu-2a. See CD8. | | | | |
| _eu-3. <i>See</i> CD4. | | | | |
| _eu-4. <i>See</i> CD3. | | | | |
| _eu-5. <i>See</i> CD2. | | | | |
| _eu-6. <i>See</i> CD1a. | | | | |
| _eu-7. <i>See</i> CD57. | | | | |
| ₋eu-8. <i>See</i> Selectin L. | | | | |
| _eu-9. <i>See</i> CD7. | | | | |
| eucyl/cystinyl aminopeptidase: L | .NPEP , 4012 | | | |
| HK-2 | CRL-2190 | human | P+ | |
| eukemia inhibitory factor (cholin | nergic differentiation facto | or): LIF, 3976 | | |
| HS-5 | CRL-11882 [†] | human | P+ | |
| eukocyte function antigen 1. See | Integrin, alpha L. | | | |
| _eukotrienes | | | | |
| MC/9 | CRL-8306 [†] | mouse | P+ | |
| -GL-1. See Killer cell lectin-like rece | | | | |
| _ipopolysaccharide binding prote | ein·I RP. 3929 | C1 /. | | |
| Mab 1E8 | HB-11490 [†] | mouse/mouse | MAb | Anti human LPS binding protein (LBP) |
| Mab 2B5 | HB-11491 [†] | mouse/mouse | MAb | Anti human LPS binding protein (LBP) Anti human LPS binding protein (LBP) |
| Lipoprotein, beta | ПО-11491 | mouse/mouse | IVIAU | And numan Er3 binding protein (EBF) |
| C3A | CRL-10741 [†] | human | P+ | |
| | | | | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| ipotropin. See Proopiomelanocor | | (50004) | | |
| Low affinity IgE (CD23). See Fc frag | | | | |
| Low density lipoprotein receptor | | | | |
| B1B3 | CRL-2249 | mouse/mouse | MAb | Anti human LDL receptor |
| B1B6 | CRL-2248 | mouse/mouse | MAb | Anti human LDL receptor |
| IgG-4A4 | CRL-1898 | mouse/mouse | MAb | Anti human LDL receptor |
| Low density lipoprotein receptor: | | | | |
| SVEC4-10 | CRL-2181 | mouse | R+ | High affinity |
| | | mouse | R+ | High affinity |
| SVEC4-10EE2 | CRL-2167 | | | |
| | | | | |
| SVEC4-10EE2 | | mouse/mouse | MAb | Anti bovine LDL receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: | :LDLR, 281276 | | MAb MAb | Anti bovine LDL receptor Anti bovine LDL receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: C7 9D9 | : LDLR, 281276 CRL-1691 CRL-1703 | mouse/mouse mouse/mouse | | |
| SVEC4-10EE2 Low density lipoprotein receptor: C7 9D9 | : LDLR, 281276 CRL-1691 CRL-1703 | mouse/mouse mouse/mouse | | Anti bovine LDL receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: C7 9D9 Low density lipoprotein receptor- MEF-1 | :LDLR, 281276 | mouse/mouse mouse/mouse 5971 mouse | MAb | Anti bovine LDL receptor Wild type |
| SVEC4-10EE2 Low density lipoprotein receptor: C7 9D9 Low density lipoprotein receptor- | :LDLR, 281276 CRL-1691 CRL-1703 related protein 1: Lrp1, 10 | mouse/mouse mouse/mouse 5971 mouse mouse | MAb P+ | Anti bovine LDL receptor Wild type Heterozygous deletion |
| SVEC4-10EE2 Low density lipoprotein receptor: C7 9D9 Low density lipoprotein receptor- MEF-1 PEA 10 PEA 13 | CRL-1691 CRL-1703 related protein 1: Lrp1, 1 0 CRL-2214 CRL-2215 CRL-2216 | mouse/mouse mouse/mouse 5971 mouse mouse mouse | MAb P+ P- | Anti bovine LDL receptor Wild type |
| SVEC4-10EE2 Low density lipoprotein receptor: C7 9D9 Low density lipoprotein receptor- MEF-1 PEA 10 PEA 13 Low density lipoprotein receptor- | CRL-1691 CRL-1703 related protein 1: Lrp1, 10 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) | MAb P+ P- P- | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion |
| SVEC4-10EE2 Low density lipoprotein receptor: C7 9D9 Low density lipoprotein receptor- MEF-1 PEA 10 PEA 13 Low density lipoprotein receptor- IgG-11H4 | CRL-1691 CRL-1703 related protein 1: Lrp1, 16 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse | P+ P- P- MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) |
| SVEC4-10EE2 Low density lipoprotein receptor: | CRL-1691 CRL-1703 related protein 1: Lrp1, 16 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse mouse/mouse | P+ P- P- MAb MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit |
| SVEC4-10EE2 Low density lipoprotein receptor: | CRL-1691 CRL-1703 related protein 1: Lrp1, 16 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse | P+ P- P- MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) |
| SVEC4-10EE2 Low density lipoprotein receptor: | CRL-1691 CRL-1703 related protein 1: Lrp1, 16 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse mouse/mouse | P+ P- P- MAb MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit |
| SVEC4-10EE2 Low density lipoprotein receptor: | CRL-1691 CRL-1703 related protein 1: Lrp1, 10 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse mouse/mouse mouse/mouse | P+ P- P- MAb MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit |
| SVEC4-10EE2 Low density lipoprotein receptor: | CRL-1691 CRL-1703 related protein 1: Lrp1, 16 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse mouse/mouse mouse/mouse | P+ P- P- MAb MAb MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit |
| SVEC4-10EE2 Low density lipoprotein receptor: | CRL-1691 CRL-1703 related protein 1: Lrp1, 10 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 dotropin receptor: LHCGI | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse mouse/mouse mouse/mouse mouse/mouse mouse/mouse | P+ P- P- MAb MAb MAb MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: | CRL-1691 CRL-1703 related protein 1: Lrp1, 10 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 dotropin receptor: LHCGI CRL-2687 CRL-2685 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse mouse/mouse mouse/mouse mouse/mouse mouse/mouse | P+ P- P- MAb MAb MAb MAb MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor Anti human LH/hCG receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: | CRL-1691 CRL-1703 related protein 1: Lrp1, 16 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 dotropin receptor: LHCGI CRL-2687 CRL-2685 CRL-2686 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse mouse/mouse mouse/mouse mouse/mouse mouse/mouse mouse/mouse mouse/mouse mouse/mouse mouse/mouse | P+ P- P- MAb MAb MAb MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: | CRL-1691 CRL-1703 related protein 1: Lrp1, 16 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 dotropin receptor: LHCGI CRL-2687 CRL-2685 CRL-2686 dotropin receptor: Lhcgr, | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse | P+ P- P- MAb MAb MAb MAb MAb MAb MAb MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor Anti human LH/hCG receptor Anti human LH/hCG receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: | cRL-1691 CRL-1703 related protein 1: Lrp1, 10 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 dotropin receptor: LHCGI CRL-2687 CRL-2685 CRL-2686 dotropin receptor: Lhcgr, | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse | P+ P- P- MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: | cRL-1691 CRL-1703 related protein 1: Lrp1, 10 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 dotropin receptor: LHCGI CRL-2687 CRL-2685 CRL-2686 dotropin receptor: Lhcgr, CRL-2065 CRL-1714 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse | P+ P- P- MAb MAb MAb MAb MAb MAb MAb MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor Anti human LH/hCG receptor Anti human LH/hCG receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: | cRL-1691 CRL-1703 related protein 1: Lrp1, 10 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 dotropin receptor: LHCGI CRL-2687 CRL-2685 CRL-2686 dotropin receptor: Lhcgr, CRL-2065 CRL-1714 ptide: LHB, 3972 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse | MAb P+ P- P- MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor Anti human LH/hCG receptor Anti human LH/hCG receptor Anti human LH/hCG receptor Responsive Responsive |
| SVEC4-10EE2 Low density lipoprotein receptor: | cRL-1691 CRL-1703 related protein 1: Lrp1, 10 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 dotropin receptor: LHCGI CRL-2687 CRL-2685 CRL-2686 dotropin receptor: Lhcgr, CRL-2065 CRL-1714 ptide: LHB, 3972 CRL-2506 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse | P+ P- P- MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor |
| SVEC4-10EE2 Low density lipoprotein receptor: | cRL-1691 CRL-1703 related protein 1: Lrp1, 10 CRL-2214 CRL-2215 CRL-2216 related protein 1 (species CRL-1936 CRL-1937 CRL-1938 dotropin receptor: LHCGI CRL-2687 CRL-2685 CRL-2686 dotropin receptor: Lhcgr, CRL-2065 CRL-1714 ptide: LHB, 3972 CRL-2506 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse mouse/mouse mouse/mouse mouse/mouse 16867 mouse | MAb P+ P- P- MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor Anti human LH/hCG receptor Anti human LH/hCG receptor Responsive Responsive Luteinizing hormone beta (LH) |
| SVEC4-10EE2 Low density lipoprotein receptor: | :LDLR, 281276 | mouse/mouse mouse/mouse 5971 mouse mouse mouse not yet curated) mouse/mouse mouse mouse mouse nouse mouse mouse | MAb P+ P- P- MAb | Anti bovine LDL receptor Wild type Heterozygous deletion Homozygous deletion Anti LRP, carboxy terminal (various species) Anti rabbit LRP, 85 kDa subunit Anti rabbit LRP, 515 kDa subunit Anti human LH/hCG receptor Anti human LH/hCG receptor Anti human LH/hCG receptor Anti human LH/hCG receptor Responsive Responsive |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|--|--|----------------------|--------------------|
| | | - Petitos | =xp:csscs | |
| y-6C; Ly6.2C. See Lymphocyte antiq | gen 6 complex, locus C. | | | |
| yb-2; Lyb-2.1. See CD72 antigen. | | | | |
| yb 8.2. See CD22 antigen. | | | | |
| ymphocyte antigen 6 complex, loc | | . / | | A 11 C 1 |
| E13 161-7 | HB-215 | rat/mouse | MAb | Anti mouse Sca-1 |
| mphocyte antigen 6 complex, loc | | | | |
| EOC 13.31 | CRL-2468 | mouse | A+ | |
| EOC 2 | CRL-2467 | mouse | A+ | |
| EOC 20 | CRL-2469 | mouse | A+ | |
| 143-4-2 | CRL-1790 | mouse/mouse | MAb | Anti mouse Ly 6.2C |
| mphocyte antigen 75: LY75, 406 | | | | A DEC |
| MG38 | CRL-2640 | mouse/mouse | MAb | Anti human DEC-205 |
| mphocyte antigen 75: Ly75, 170 | | | | |
| DEC-205 | HB-290 | rat/mouse | MAb | Anti mouse DEC-205 |
| nphocyte function antigen 1 (LF | | and/or integrin, beta 2. | | |
| mphocyte function antigen 2 (LF | | | | |
| mphocyte function antigen 3 (LF | | | | |
| nphotoxin alpha (TNF superfam | | | | |
| RPMI 1788 | CCL-156 | human | P+ | |
| SK-N-FI | CRL-2142 | human | R+ | Responsive |
| sozyme | | | | |
| GDM-1 | CRL-2627 | human | P+ | |
| THP-1 | TIB-202 | human | P+ | |
| U-937 | CRL-1593.2 | human | P+ | |
| I-11.15 | CRL-2470 | mouse | P+ | |
| I-13.35 | CRL-2471 | mouse | P+ | |
| IC-21 | TIB-186 | mouse | P+ | |
| J774A.1 | TIB-67 | mouse | P+ | |
| LADMAC | CRL-2420 | mouse | P+ | |
| P388D1 (IL-1) | TIB-63 | mouse | P+ | |
| P815 | TIB-64 | mouse | P+ | |
| PU5-1.8 (PU5-1R) | TIB-61 | mouse | P+ | |
| RAW 264.7 | TIB-71 | mouse | P+ | |
| RAW 264.7γNO(-) | CRL-2278 | mouse | P+ | |
| RAW 309 Cr.1 | TIB-69 | mouse | P+ | |
| WEHI-3 | TIB-68 | mouse | P+ | |
| WR19M.1 | TIB-70 | mouse | P+ | |
| t 1; Lyt 1.1; Lyt 1.2. See CD5 antige | | | • • | |
| : 2; Lyt 2.1; Lyt 2.2. See CD3 antige | (000 02). | | | |
| AC-1. See Integrin, alphaM and int | tegrin heta 2 | | | |
| AC-2. <i>See</i> Lectin, galactose-bindin | | | | |
| AC-3 | 19, 3014516, 3. | | | |
| EOC 13.31 | CRL-2468 | mouse | A+ | |
| EOC 13.31 | CRL-2467 | | A+ A+ | |
| EOC 20 | CRL-2467 CRL-2469 | mouse | | |
| EUC ZU | | mouse rat/mouse | A+ MAb | Anti mouso Mas 2 |
| | TIB-168 | rat/mouse | | Anti mouse Mac-3 |
| M3/84.6.34 | tor (M CSE) Con Colores | timulating tactor 1 /m = | | |
| M3/84.6.34 crophage colony stimulating fac | | stimulating factor 1 (macro | priage). | |
| M3/84.6.34 crophage colony stimulating fac crophage-inhibitory protein-1 al | lpha | • | | |
| M3/84.6.34 crophage colony stimulating fac crophage-inhibitory protein-1 al HS-5 | lpha CRL-11882 [†] | human | P+ | |
| M3/84.6.34 crophage colony stimulating fac crophage-inhibitory protein-1 al HS-5 D, mothers against decapentapl | lpha CRL-11882 [†] legic homolog 4 (<i>Drosop</i> i | human hila): MADH4,4089 | P+ | |
| M3/84.6.34 crophage colony stimulating fac crophage-inhibitory protein-1 al HS-5 D, mothers against decapentapl PL45 | lpha CRL-11882 [†] legic homolog 4 (<i>Drosopi</i> CRL-2558 | human hila): MADH4,4089 human | | |
| M3/84.6.34 crophage colony stimulating fac crophage-inhibitory protein-1 al HS-5 AD, mothers against decapentapl PL45 ADCAM1. See Mucosal vascular ac | lpha CRL-11882 [†] legic homolog 4 <i>(Drosopi</i> CRL-2558 ddressin cell adhesion m | human hila): MADH4, 4089 human olecule 1. | P+ | |
| M3/84.6.34 Icrophage colony stimulating factorophage-inhibitory protein-1 all HS-5 AD, mothers against decapentapl PL45 ADCAM1. See Mucosal vascular actor (SC35). Standard SC35. | lpha CRL-11882† legic homolog 4 (<i>Drosopi</i> CRL-2558 ddressin cell adhesion m See Splicing factor, argini | human hila): MADH4, 4089 human olecule 1. ne/serine-rich 2. | P+ O+ | |
| M3/84.6.34 acrophage colony stimulating factorophage-inhibitory protein-1 all HS-5 AD, mothers against decapentapl PL45 ADCAM1. See Mucosal vascular actor (SC35). Set cell growth factor 2 (MCGF2). | Ipha CRL-11882† legic homolog 4 (Drosopi CRL-2558 ddressin cell adhesion m See Splicing factor, argini See Growth factor recept | human hila): MADH4, 4089 human olecule 1. ne/serine-rich 2. or bound protein 2-associa | P+ O+ | |
| M3/84.6.34 crophage colony stimulating factorophage-inhibitory protein-1 all HS-5 AD, mothers against decapentapl PL45 ADCAM1. See Mucosal vascular adammalian splicing factor (SC35). Sist cell growth factor 2 (MCGF2). Strix metalloproteinase 3 (strome | Ipha CRL-11882† legic homolog 4 (Drosopi CRL-2558 ddressin cell adhesion mose Splicing factor, argini See Growth factor recept | human hila): MADH4, 4089 human olecule 1. ne/serine-rich 2. or bound protein 2-associa | P+ O+ | |
| M3/84.6.34 acrophage colony stimulating factorophage-inhibitory protein-1 all HS-5 AD, mothers against decapentapl PL45 ADCAM1. See Mucosal vascular actor (SC35). Set cell growth factor 2 (MCGF2) atrix metalloproteinase 3 (strome metalloproteinase 10 (strome | Ipha CRL-11882† legic homolog 4 (Drosopi CRL-2558 ddressin cell adhesion mose Splicing factor, argini See Growth factor recept elysin 1, progelatinase): Malelysin 2): MMP10, 4319 | human hila): MADH4, 4089 human olecule 1. ne/serine-rich 2. or bound protein 2-associa | P+ O+ ted protein 2. | |
| M3/84.6.34 acrophage colony stimulating fac acrophage-inhibitory protein-1 al HS-5 AD, mothers against decapentapl PL45 ADCAM1. See Mucosal vascular ac ammalian splicing factor (SC35). S ast cell growth factor 2 (MCGF2) atrix metalloproteinase 3 (strome metalloproteinase 10 (strome | Ipha CRL-11882† legic homolog 4 (Drosopi CRL-2558 ddressin cell adhesion mose Splicing factor, argini See Growth factor recept elysin 1, progelatinase): Malelysin 2): MMP10, 4319 nelysin 3): MMP11, 4320 | human hila): MADH4, 4089 human olecule 1. ne/serine-rich 2. or bound protein 2-associal MP3, 4314 OR OR (human; rabbit gene not ye | P+ O+ ted protein 2. | |
| M3/84.6.34 acrophage colony stimulating fac acrophage-inhibitory protein-1 al HS-5 AD, mothers against decapentapl PL45 ADCAM1. See Mucosal vascular ac ammalian splicing factor (SC35). S ast cell growth factor 2 (MCGF2) atrix metalloproteinase 3 (strome metalloproteinase 10 (strome | Ipha CRL-11882† legic homolog 4 (Drosopi CRL-2558 ddressin cell adhesion mose Splicing factor, argini See Growth factor recept elysin 1, progelatinase): Malelysin 2): MMP10, 4319 | human hila): MADH4, 4089 human olecule 1. ne/serine-rich 2. or bound protein 2-associa | P+ O+ ted protein 2. | |
| M3/84.6.34 acrophage colony stimulating facacrophage-inhibitory protein-1 al HS-5 AD, mothers against decapentapl PL45 ADCAM1. See Mucosal vascular acammalian splicing factor (SC35). Sast cell growth factor 2 (MCGF2)atrix metalloproteinase 3 (strome metalloproteinase 10 (strome metalloproteinase 11 (strome | Ipha CRL-11882† legic homolog 4 (Drosopi CRL-2558 ddressin cell adhesion mose Splicing factor, argini See Growth factor recept elysin 1, progelatinase): Malelysin 2): MMP10, 4319 nelysin 3): MMP11, 4320 CRL-1832 | human hila): MADH4, 4089 human olecule 1. ne/serine-rich 2. or bound protein 2-associal MP3, 4314 OR OR (human; rabbit gene not ye | P+ O+ ted protein 2. | |
| M3/84.6.34 acrophage colony stimulating factorophage-inhibitory protein-1 al HS-5 AD, mothers against decapentapl PL45 ADCAM1. See Mucosal vascular actor (SC35). Sast cell growth factor 2 (MCGF2) atrix metalloproteinase 3 (strome metalloproteinase 11 (strom HIG-82) | Ipha CRL-11882† legic homolog 4 (Drosopi CRL-2558 ddressin cell adhesion mose Splicing factor, argini See Growth factor recept elysin 1, progelatinase): Malelysin 2): MMP10, 4319 nelysin 3): MMP11, 4320 CRL-1832 | human hila): MADH4, 4089 human olecule 1. ne/serine-rich 2. or bound protein 2-associal MP3, 4314 OR OR (human; rabbit gene not ye | P+ O+ ted protein 2. | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product of the produc$

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|------------------------------------|--------------------------------|--------------------------------|-------------|---------------------------------------|
| | | | =xp:esses | |
| 1-CSF. See Colony stimulating fact | or 1 (macrophage) (CSF1 |). | | |
| ADNCF. See Interleukin 8 (IL8). | | | | |
| Melanin | CDL 1424 | In comment | D. | |
| G-361 SH-4 | CRL-1424 CRL-7724 | human | P+ P+ | |
| SK-MEL-1 | HTB-67 | human human | P+ | |
| Clone M-3 | CCL-53.1 | mouse | P+ | |
| RPMI 1846 | CCL-33.1 | Syrian golden | P+ | |
| INFIVIT 1040 | CCL-45 | hamster | ГТ | |
| Melanoma, proteoglycan antigen | | Hamster | | |
| WM-115 | CRL-1675 | human | P+ | |
| WM-266-4 | CRL-1676 | human | P+ | |
| 1embrane metallo-endopeptidas | | | | |
| Farage | CRL-2630 | human | A+/- | |
| GA-10 | CRL-2392 | human | A+ | |
| JM1 | CRL-10423 [†] | human | A+ | |
| MV-4-11 | CRL-9591 [†] | human | A+/- | |
| NCI-H929 | CRL-9068 [†] | human | A- | |
| NK-92 | CRL-2407 | human | A- | |
| NK-92CI | CRL-2409 | human | A- | |
| NK-92MI | CRL-2408 | human | A- | |
| Pfeiffer | CRL-2632 | human | A+ | |
| Reh | CRL-8286 [†] | human | A+ | |
| RS4;11 | CRL-1873 | human | A- | |
| SUP-B15 | CRL-1929 | human | A+ | |
| SUP-T1 [VB] | CRL-1942 | human | A- | |
| Toledo | CRL-2631 | human | A+ | |
| Membrane-spanning 4-domains, s | ubfamily A, member 1: N | IS4A1,931 | | |
| 29SR | CRL-2262 | human | A- | |
| ARH-77 | CRL-1621 | human | A+ | |
| BC-3 | CRL-2277 | human | A- | |
| DB | CRL-2289 | human | A+ | |
| DS-1 | CRL-11102 [†] | human | A- | |
| Farage | CRL-2630 | human | A+ | |
| GA-10 | CRL-2392 | human | A+ | |
| HS-Sultan | CRL-1484 | human | A- | |
| HT | CRL-2260 | human | A+ | |
| IM-9 | CCL-159 | human | A+ | |
| MC/CAR | CRL-8083 [†] | human | A+ | |
| NK-92 | CRL-2407 | human | A- | |
| NK-92CI | CRL-2409 | human | A- | |
| NK-92MI | CRL-2408 | human | A- | |
| OML, clone 13C | CRL-2312 | human | A+ | |
| Pfeiffer | CRL-2632 | human | A+ | |
| RL | CRL-2261 | human | A+ | |
| RPMI 8226 | CCL-155 | human | A- | |
| SML, clone 4D8 | CRL-2311 | human | A+ | |
| Toledo | CRL-2631 | human | A+ | A (1) (5000 P. 1) (5 1000 P. 1) |
| 1F5 | HB-9645 [†] | mouse/mouse | MAb | Anti human CD20 B cell antigen (Bp35) |
| C273 | HB-9303 [†] | mouse/mouse | MAb | Anti human CD20 |
| Nilk fat globule membrane antige | | In comme | D : | |
| MCF-12A | CRL-10782 [†] | human | P+ | |
| MCF-12F | CRL-10783 [†] | human | P+ | |
| Mink cell focus-forming retrovirus | | | D. | |
| NFS-5 C-1 | CRL-1693 | mouse | P+ | |
| Moloney murine leukemia virus | TID CO | maure | D · | |
| WR19L | TIB-52 | mouse | P+ | |
| Monocyte Fc receptor (high affinit | y, rcki). See rc tragment (| or igo, nigh ainnity ia, recep | tor (CD64). | |
| Mucin | CDI 1602 | human | D : | |
| AsPC-1 | CRL-1682 CRL-1687 | human human | P+ P+ | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Call Lina Nama | ATCC® No | Cmasiss | F.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | Comments |
|--------------------------------------|----------------------------|--------------|--|---------------------------------------|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| Capan-1 | HTB-79 | human | P+ | |
| HT-29 | HTB-38 | human | P+ | |
| LS123 | CCL-255 | human | P+ | |
| LS 174T | CL-188 | human | P+ | |
| LS 180 | CL-187 | human | P+ | |
| MES-SA | CRL-1976 | human | P- | |
| NCI-H498 | CCL-254 | human | P+ | |
| NCI-H661 | HTB-183 | human | P- | |
| NCI-H676B | HTB-179 | human | P+ | |
| RF-1 | CRL-1864 | human | P+ | |
| RF-48 | CRL-1863 | human | P- | |
| DSL-6B/C2 | CRL-2133 | rat | P+ | |
| ucin 1, transmembrane: MUC1 , | | Tut | 11 | |
| BC-1 | CRL-2230 | human | A+ | |
| BC-2 | CRL-2231 | human | A+ | |
| | | | | |
| BC-3 | CRL-2277 | human | A+ | |
| Capan-2 | HTB-80 | human | P+ | |
| ChaGo-K-1 | HTB-168 | human | P+ | |
| HCC2218 | CRL-2343 | human | A+ | |
| HPAF-II | CRL-1997 | human | P+ | |
| VA-ES-BJ | CRL-2138 | human | A+ | |
| ZR-75-1 | CRL-1500 | human | P+ | |
| UC7 | HB-9753 [†] | mouse/mouse | MAb | Anti human colonic mucin glycoprotein |
| ucin 2, intestinal/tracheal: MUC | | | | |
| Capan-2 | HTB-80 | human | P+ | |
| ChaGo-K-1 | HTB-168 | human | P+ | |
| ZR-75-1 | CRL-1500 | human | P+ | |
| lucin 3A, intestinal: MUC3A, 458 | 34 | | | |
| ChaGo-K-1 | HTB-168 | human | P- | |
| ZR-75-1 | CRL-1500 | human | P- | |
| lucin 4, tracheobronchial: MUC4 | , 4585 | | | |
| HPAF-II | CRL-1997 | human | P+ | |
| ucin 5, subtypes A and C, trache | | | | |
| Capan-2 | HTB-80 | human | P+ | |
| ChaGo-K-1 | HTB-168 | human | P+ | |
| ZR-75-1 | CRL-1500 | human | P+ | |
| ucin 13, epithelial transmembra | | Haman | 11 | |
| MCF-12A | CRL-10782 [†] | human | P+ | |
| MCF-12F | CRL-10783 [†] | human | P+ | |
| | CRL-10/03 | numan | P+ | |
| ucoid | CCL 20 | L | D . | |
| RPMI 2650 | CCL-30 | human | P+ | |
| ucosal vascular addressin cell ad | | | | |
| bEnd.3 | CRL-2299 | mouse | A+ | |
| C166 | CRL-2581 | mouse | A+ | |
| EOMA | CRL-2586 | mouse | A+ | |
| MECA-367 | HB-9478 [†] | rat/mouse | MAb | Anti mouse MAdCAM-1 |
| MECA-89 | HB-292 | rat/mouse | MAb | Anti mouse MAdCAM-1 |
| lultiplication stimulating activity | (MSA). See Insulin-like gr | owth factor. | | |
| y23 | | | | |
| DMS 114 | CRL-2066 | human | A+ | |
| DMS 153 | CRL-2064 | human | A+ | |
| DMS 53 | CRL-2062 | human | A+ | |
| DMS 79 | CRL-2049 | human | A+ | |
| myb myeloblastosis viral oncog | | | | |
| COLO 201 | CCL-224 | human | 0+ | |
| | | | O+ O+ | |
| DLD-1 | CCL-221 | human | | |
| HT-29 | HTB-38 | human | 0+ | |
| LoVo | CCL-229 | human | 0+ | |
| LS 174T | CL-188 | human | 0+ | |
| MSTO-211H | CRL-2081 | human | 0+ | c-myb |
| NCI-H146 | HTB-173 | human | 0+ | c-myb |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product is a product of the product$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|-----------------------|--------------|------------|--|
| | | | | |
| myb myeloblastosis viral oncoge | | | | |
| NCI-H526 | CRL-5811 | human | 0+ | c-myb |
| NCI-H69 | HTB-119 | human | 0+ | c-myb |
| NCI-H82 | HTB-175 | human | 0- | |
| NCI-N417 | CRL-5809 | human | 0- | c-myb |
| SK-CO-1 | HTB-39 | human | 0+ | |
| SW1116 | CCL-233 | human | 0+ | |
| SW1417 | CCL-238 | human | 0- | |
| SW480 | CCL-228 | human | 0+ | |
| SW620 SW948 | CCL-227 CCL-237 | human | O+ | |
| | | human | 0+ | |
| yeloblastosis oncogene: Myb, 1 7 M-NFS-60 | | | 0. | Turn sate dia marih |
| | CRL-1838 | mouse | 0+ | Truncated c- <i>myb</i> |
| YB (species not yet curated) | CDL 1720 | | NA N In | Andi abiatan MVD (V MVD) |
| MYB 2-3.76 | CRL-1728 | mouse/mouse | MAb | Anti chicken MYB (V-MYB) |
| MYB 2-37.63 | CRL-1726 | mouse/mouse | MAb | Anti chicken MYB (V-MYB) |
| MYB 2-7.77 | CRL-1724 | mouse/mouse | MAb | Anti chicken MYB (V-MYB) |
| myc myelocytomatosis viral onc | | | | |
| DT40 | CRL-2111 | chicken | 0+ | с-тус |
| DT95 | CRL-2112 | chicken | 0+ | c-myc |
| COLO 201 | CCL-224 | human | 0+ | |
| D341 Med | HTB-187 | human | 0+ | c- <i>myc</i> (amplified) |
| DLD-1 | CCL-221 | human | 0+ | c-myc+; N–myc- |
| DMS 79 | CRL-2049 | human | 0+ | c-myc+; N–myc+ |
| HL-60 | CCL-240 | human | 0+ | |
| HT-29 | HTB-38 | human | 0+ | c-myc+; N–myc– |
| LoVo | CCL-229 | human | 0+ | c-myc+; N–myc– |
| LS 174T | CL-188 | human | 0+ | c-myc+; N–myc+ |
| MSTO-211H | CRL-2081 | human | 0+ | c-myc+; L–myc–; N-myc– |
| NCI-H146 | HTB-173 | human | 0+ | c- <i>myc</i> |
| NCI-H187 | CRL-5804 | human | 0+ | N-myc (not amplified) |
| NCI-H23 | CRL-5800 | human | 0+ | c-myc+ (amplified); L-myc+ |
| NCI-H378 | CRL-5808 | human | 0+ | L- <i>myc</i> (not amplified) |
| NCI-H446 | HTB-171 | human | 0+ | c- <i>myc</i> (amplified) |
| NCI-H526 | CRL-5811 | human | 0+ | N-myc+ (amplified); c-myc–; L-myc– |
| NCI-H69 | HTB-119 | human | O+ | N-myc+ (amplified); c-myc+ |
| NCI-H82 | HTB-175 | human | 0+ | c- <i>myc</i> (amplified) |
| NCI-H929 | CRL-9068 [†] | human | 0+ | с-тус |
| NCI-N417 | CRL-5809 | human | 0+ | c-myc+ (amplified); N-myc+ |
| NCI-N87 | CRL-5822 | human | 0+ | c-myc+; L-myc–; N-myc– |
| SNU-1 | CRL-5971 | human | 0+ | c-myc+; L-myc-; N-myc- |
| SNU-16 | CRL-5974 | human | 0+ | c-myc+; L-myc–; N-myc– |
| SNU-5 | CRL-5973 | human | 0+ | c-myc+; L-myc–; N-myc– |
| NTERA-2 cl.D1 | CRL-1973 | human | O+ | N-myc |
| SJRH30 [RMS 13] | CRL-2061 | human | 0+ | N-myc (not amplified) |
| SK-CO-1 | HTB-39 | human | 0+ | c-myc+; N-myc+ |
| SW1116 | CCL-233 | human | 0+ | c-myc+; N-myc- |
| SW1417 | CCL-238 | human | 0+ | c-myc+; N-myc- |
| SW480 | CCL-228 | human | 0+ | c-myc+; N-myc- |
| SW620 | CCL-227 | human | 0+ | c-myc+; N-myc- |
| SW948 | CCL-237 | human | 0+ | c-myc+; N-myc- |
| MYC CT 9-B7.3 | CRL-1725 | mouse /mouse | MAb | Anti human <i>myc</i> (c- <i>myc</i>) protein |
| MYC CT 14-G4.3 | CRL-1727 | mouse /mouse | MAb | Anti human <i>myc</i> (c- <i>myc</i>) protein |
| MYC 1-9E10.2 | CRL-1727 CRL-1729 | mouse /mouse | MAb | Anti human <i>myc</i> (c- <i>myc</i>) protein |
| | | mouse/mouse | IVIAU | And Human myc (c-myc) protein |
| yelocytomatosis oncogene: Myo | | chickon | D. () | Overpreduces manage a management of |
| DUKX B1 | CRL-9010 [†] | chicken | P+ (mouse) | Overproduces mouse c- <i>myc</i> protein |
| hyalaid laukersis (CD33) Co. CD3 | 22 | | | when heated |
| yeloid leukemia (CD33). See CD3 |)). | | | |
| yeloid leukemia antigen (M-1) | CDL 2627 | la | Λ . | |
| GDM-1 | CRL-2627 | human | A+ | |
| | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Name: Symbol, GeneID | | | _ | |
|---|---------------------------------------|-----------------------------------|-----------|--|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| Nyeloperoxidase: MPO, 4353 | 3 | | | |
| GDM-1 | CRL-2627 | human | P+ | |
| MEG-01 | CRL-2021 | human | P- | |
| RS4;11 | CRL-1873 | human | P- | |
| Nyoglobin: MB, 4151 | | | | |
| RD | CCL-136 | human | P+ | |
| 1yokinase | | | | |
| A-10 | CRL-1476 | rat | P+ | |
| A7r5 | CRL-1444 | rat | P+ | |
| H9c2(2-1) | CRL-1446 | rat | P+ | |
| lyosin | | | | |
| RD | CCL-136 | human | P+ | ATPase |
| G-8 | CRL-1456 | mouse | P+ | |
| A-10 | CRL-1476 | rat | P+ | |
| A7r5 | CRL-1444 | rat | P+ | |
| H9c2(2-1) | CRL-1446 | rat | P+ | |
| L6 | CRL-1458 | rat | P+ | |
| L8 | CRL-1769 | rat | P+ | |
| QM7 | CRL-1962 | Japanese quail | P+ | Light chain 2; heavy chain |
| A4.74 | CRL-2041 | mouse/mouse heavy chain | MAb | Anti human fast and rat fast IIa myosin |
| A4.840 | CRL-2043 | mouse/mouse heavy chain (MyHC) | MAb | Anti adult human and rat slow myosin |
| A4.951 | CRL-2046 | mouse/mouse | MAb | Anti human and rat slow myosin heavy chain (MyHC) |
| BA-D5 | HB-287 | mouse/mouse | MAb | Anti rat type 1 myosin heavy chain |
| BA-G5 | HB-276 | mouse/mouse | MAb | Anti rat cardiac alpha myosin heavy chain |
| BF-45 | HB-278 | mouse/mouse | MAb | Anti rat embryonic myosin heavy chain |
| BF-F3 | HB-283 | mouse/mouse | MAb | Anti rat type 2B myosin heavy chain |
| F1.652 | CRL-2039 | mouse/mouse heavy chain (MyHC) | MAb | Anti human and rat embryonic myosin |
| N1.551 | CRL-2040 | mouse/mouse | MAb | Anti rat fast Ila myosin heavy chain (MyHC) |
| N2.261 | CRL-2047 | mouse/mouse myosin heavy chain | | Anti slow and fast IIa human and rat |
| N3.36 | CRL-2042 | mouse/mouse | MAb | Anti neonatal and adult human and rat fast myosin heavy chain (MyHC) |
| SC-71 | HB-277 | mouse/mouse | MAb | Anti rat type 2A myosin heavy chain |
| | A/guanylate cyclase A (atriona | | | |
| | B/guanylate cyclase B (atrional | | | |
| NCI-H660 | CRL-5813 | human | R+ | Functional, but no change in growth pattern. |
| NCI-H82 | HTB-175 | human | R+ | Functional, but no change in growth pattern. |
| latriuretic peptide receptor (| · · · · · · · · · · · · · · · · · · · | | | |
| OK (A) | CRL-1840 | opossum | R+ | |
| ephroblast growth factor (N | | | | |
| G-401 | CRL-1441 | human | P+ | |
| | r (TNFR superfamily, member 1 | | D : | |
| A2058 | CRL-11147 [†] | human | R+ | |
| Hs 294T | HTB-140 | human | R+ | |
| erve growth factor receptor SCA-9 clone 15 | r: Ngfr, 18053 CRL-1734 | mouse | R+ | |
| lerve growth factor receptor | | | | |
| PC-12 | CRL-1721 | rat | R+ | Responsive |
| lerve growth factor receptor | | | • | **P * |
| 200-3-G6-4 (20.4) | HB-8737 [†] | mouse/mouse | MAb | Anti NGF receptor of primates |
| leural cell adhesion molecul | | | | The state of the s |
| NK-92 | CRL-2407 | human | A+ | |
| | | | | |
| NK-92 NK-92Cl | CRL-2407 CRL-2409 | human human | A+ A+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product of the produc$

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| ame: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Evnrossos | Comments |
|--|------------------------------|----------------------------|---------------------|------------------------------------|
| Cell Line Name | AICC® NO. | Species | Expresses | Comments |
| eural cell adhesion molecule 1 c | | | | |
| NK-92MI | CRL-2408 | human | A+ | |
| SHP-77 | CRL-2195 | human | A+ | |
| TALL-104 | CRL-11386 [†] | human | A+ | |
| eural cell adhesion molecule 1: | | | | |
| | NCAM2, 4685 | | | |
| SHP-77 | CRL-2195 | human | P+ | |
| euroblastoma. See ras viral (v-ras | s) oncogene homolog. | | | |
| eurofilament protein | 1170 105 | | | |
| D283 Med | HTB-185 | human | P+ | |
| D341 Med | HTB-187 | human | P+ | |
| HCN-1A | CRL-10442 [†] | human | P+ | |
| HCN-2 | CRL-10742 [†] | human | P+ | |
| euromedin B: NMB, 4828 | CDI 5010 | L | D.: | |
| NCI-H1155 | CRL-5818 | human | P+ | |
| NCI-H1299 | CRL-5803 | human | P+ | |
| NCI-H187 | CRL-5804 | human | P- | |
| NCI-H522 | CRL-5810 | human | P- | |
| NCI-H727 | CRL-5815 | human | P+ | |
| NCI-H810 | CRL-5816 | human | P- | |
| NCI-N417 | CRL-5809 | human | P+ | |
| UMC-11 | CRL-5975 | human | P+ | |
| euron-specific enolase. See Enol | ase 2 (gamma, neuronai) | | | |
| eurotensin: NTS, 4922 | CDL 2001 | h | D. | |
| MSTO-211H | CRL-2081 | human | P- | |
| eurotensin/neuromedin N gene 6-23 (Clone 6) | CRL-1607 | ro+ | P+ | |
| | | rat | r+ | |
| eurotensin receptor: Ntsr, 1821 receptor 2: Ntsr2, 18 | | | | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| eurotransmitter | ChL-2203 | mouse | N± | |
| T84 | CCL-248 | human | R+ | |
| eutrophil attractant/activation p | | | ΝΤ | |
| eutrophil migration inhibitory fa | | | locyte-macronhage) | |
| dogen 1: Nid1, 18073 | actor (Wil 1) See Colorly 30 | timulating factor 2 (grand | locyte macrophage). | |
| EHS | CRL-2108 | mouse | P+ | |
| NE NE | CRL-2070 | mouse | P+ | |
| PFHR 9 | CRL-2423 | mouse | P+ | Entactin-1 |
| dogen: Nid, 25494 | CITE ZHZS | mouse | 1 1 | Littactiii i |
| L2-RYC | CRL-2180 | rat | P+ | |
| K cell antigen (LGL-1). See Killer | | | | |
| myc. See myc. | zzeete receptor, su | , , ,ciiibci , , | | |
| orepinephrine | | | | |
| COLO 320DM | CCL-220 | human | P+ | |
| COLO 320HSR | CCL-220.1 | human | P+ | |
| CATH.a | CRL-11179 [†] | mouse | P+ | |
| PC-12 | CRL-17721 | rat | P+ | |
| uclear receptor subfamily 3, gro | | | | |
| HPAC | CRL-2119 | human | R+ | Sensitive |
| MCF-10-2A | CRL-10781 [†] | human | R+ | |
| MCF 10F | CRL-10318 [†] | human | R+ | Responsive |
| MDA-kb2 | CRL-2713 | human | R+ | Programme and the second |
| T-47D | HTB-133 | human | R+ | |
| H19-7/IGF-IR | CRL-2526 | rat | R+(human) | Insulin-like growth factor (IGF-IF |
| ucocorticoid receptor: Grl, 244 | | | () | |
| AR42J | CRL-1492 | rat | R+ | Responsive |
| C ₆ | CCL-107 | rat | R+ | ·p - · · · · · · · |
| McA-RH7777 | CRL-1601 | rat | R+ | Responsive |
| | | | R+ | Sensitive |
| | CRL-1602 | rat | n± | |
| McA-RH8994 NMU | CRL-1602 CRL-1743 | rat rat | R+ | Sensitive |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Call Lina Nama | ATCC® No. | Species | Expresses | Comments |
|---|----------------------------------|--------------------------|--------------|---|
| Cell Line Name | AICC® NO. | Species | Expresses | Comments |
| Glucocorticoid receptor (species not y | et curated) | | | |
| DDT ₁ MF-2 | CRL-1701 | Syrian golden | R+ | Sensitive |
| | | hamster | | |
| HIT-T15 | CRL-1777 | Syrian golden hamster | R+ | Sensitive |
| luclear receptor subfamily 3, group C | , member 1: Nr3c1, 1 | 4815 AND | | |
| glucocorticoid receptor: Grl, 24413 | | | | |
| FIGR | CRL-2173 | mouse/mouse | MAb | Anti mouse and rat glucocorticoid receptor |
| lucleosome assembly protein 1-like 1 | | | | |
| EL-NC-1S | HB-9647 [†] | mouse/mouse or IL-8 | MAb | Anti NAP-1, also known as interleukin 8 |
| I-ras. See ras. | | | | |
| OKT10. See CD38. | | | | |
| Osteoblast specific factor 2 (fasciclin I- | | | | |
| 5H8 | CRL-2646 | mouse/mouse | MAb | Anti human periostin |
| Osteoblast specific factor 2 (fasciclin I- | | 50706 AND | | |
| runt related transcription factor 2: R | | | | |
| MC3T3-E1 Subclone 14 | CRL-2594 | mouse | P+ | |
| MC3T3-E1 Subclone 24 | CRL-2595 CRL-2596 | mouse | P+ | |
| MC3T3-E1 Subclone 30 | | mouse | P+ | |
| MC3T3-E1 Subclone 4 Dsteonectin. See Secreted protein, acid | CRL-2593 | mouse | P+ | |
| Oxysterol binding protein: OSBP, 5007 | | | | |
| lgG-B16 | CRL-1899 | mouse/mouse | MAb | Anti hamster oxysterol binding protein |
| IgG-11H9 | CRL-1899 CRL-2213 | mouse/mouse | MAb | Anti namster oxysteror binding protein Anti rabbit oxysterol binding protein |
| Osteocalcin (OCN). See Bone gamma-c | | | IVIAD | Anti Tabbit Oxysteror binding protein |
| Osteosacoma derived growth factor (C | | u, protein. | | |
| U-2 OS | HTB-96 | mouse | P+ | |
| Ovalbumin, chicken | 1110 00 | mouse | 1 1 | |
| E.G7-OVA | CRL-2113 | mouse | P+ (chicken) | |
| Oxytocin, prepro- (neurophysin I): OX1 | | | · · (emenen) | |
| DMS 114 | CRL-2066 | human | P+ | |
| DMS 153 | CRL-2064 | human | P+ | |
| DMS 53 | CRL-2062 | human | P+ | |
| DMS 79 | CRL-2049 | human | P+ | |
| Oxcytocin: Oxt, 25504 | | | | |
| PS 38 | CRL-1950 | mouse/mouse | MAb | Anti rat NP-OT |
| PS 60 | CRL-1800 | mouse/mouse | MAb | Anti rat NP-OT |
| PS 67 | CRL-1797 | mouse/mouse | MAb | Anti rat NP-OT |
| glycoprotein. See ATP binding casset | te. | | | |
| o27 protein | | | | |
| HP75 | CRL-2506 | human | P+ | |
| 53. See Tumor protein p53 (Li-Fraum | eni syndrome). | | | |
| Pancreas-associated antigen | | <u> </u> | | |
| AsPC-1 | CRL-1682 | human | P+ | |
| ancreas cancer-specific antigen | CDL 1607 | 1 | D : | |
| | CRL-1687 | human | P+ | |
| BxPC-3 | | | | |
| BxPC-3 Pancreas-specific antigen | CDL 1603 | human | D. | |
| BxPC-3 ancreas-specific antigen AsPC-1 | CRL-1682 | human | P+ | |
| BxPC-3 ancreas-specific antigen AsPC-1 ancreastatin | | | | |
| BxPC-3 ancreas-specific antigen AsPC-1 ancreastatin HP75 | CRL-1682 CRL-2506 | human human | P+ P+ | |
| BxPC-3 ancreas-specific antigen AsPC-1 ancreastatin HP75 ancreatic oncofetal antigen (POA) | CRL-2506 | human | P+ | |
| BxPC-3 lancreas-specific antigen AsPC-1 lancreastatin HP75 lancreatic oncofetal antigen (POA) CFPAC-1 | CRL-2506 CRL-1918 | | | |
| BxPC-3 Pancreas-specific antigen AsPC-1 Pancreastatin HP75 Pancreatic oncofetal antigen (POA) CFPAC-1 Parathormone. See Parathyroid hormo | CRL-2506 CRL-1918 | human | P+ | |
| BxPC-3 Pancreas-specific antigen AsPC-1 Pancreastatin HP75 Pancreatic oncofetal antigen (POA) CFPAC-1 Parathormone. See Parathyroid hormo | CRL-2506 CRL-1918 ne. | human human | P+ P+ | |
| BxPC-3 Pancreas-specific antigen AsPC-1 Pancreastatin HP75 Pancreatic oncofetal antigen (POA) CFPAC-1 Parathormone. See Parathyroid hormo Parathyroid hormone: PTH, 5741 COLO 320DM | CRL-2506 CRL-1918 ne. CCL-220 | human human human | P+ P+ | |
| BxPC-3 Pancreas-specific antigen AsPC-1 Pancreastatin HP75 Pancreatic oncofetal antigen (POA) CFPAC-1 Parathormone. See Parathyroid hormo | CRL-2506 CRL-1918 ne. | human human | P+ P+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---|---|----------------------------|---------------------------------|
| | | • | • | |
| arathyroid hormone/parathyroid horn | | e receptor: Pthr, 24696 OR | | |
| hormone receptor 2: Pthr2 | • | | D. | Danis and the |
| UMR-106 | CRL-1661 | rat | R+ | Responsive |
| UMR-108 | CRL-1663 | rat | R+ | Responsive |
| arathyroid hormone (PTH) receptor: P ⁻ OK | CRL-1840 | • | R+ | |
| arathyroid hormone-like hormone: PT | | opossum | N+ | |
| 786-O | CRL-1932 | human | P+ | |
| arathyroid hormone-like peptide: Pth l | | Human | ГТ | |
| MC3T3-E1 Subclone 14 | CRL-2594 | mouse | P+ | |
| MC3T3-E1 Subclone 24 | CRL-2595 | mouse | P- | |
| MC3T3-E1 Subclone 30 | CRL-2596 | mouse | P- | |
| MC3T3-E1 Subclone 4 | CRL-2593 | mouse | P+ | |
| CA-1. See Ectonucleotide pyrophosph | | | | |
| eptide hormone | | | | |
| T84 | CCL-248 | human | R+ | |
| eptide hydrolase | | | | |
| SCA-9 clone 15 | CRL-1734 | mouse | P+ | |
| eriostin. See Osteoblast specific factor | 2 (fasciclin I-like). | | | |
| erlecan. See Heparan sulfate proteogly | | | | |
| ETA-3 (CD151). See CD151. | <u> </u> | | | |
| eyer's patch endothelial cells, human. | See CD44. | | | |
| eyer's patch endothelial cells, mouse. | | addressin cell adhesion me | olecule 1 | |
| gp-1. See CD44 | | | | |
| hosphatase and tensin homolog (mut | tated in multiple adv | anced cancers 1): PTEN, 57 | 28 | |
| LN-18 | CRL-2610 | human | 0+ | Wild type |
| LN-229 | CRL-2611 | human | 0+ | Wild type |
| hospholipase C, gamma 1 (formerly su | ubtype 148): PLCG1, | 5335 | | |
| J.γ1 | CRL-2678 | human | P- | |
| J.γ1.WT | CRL-2679 | human | P+ | |
| Jurkat, Clone E6-1 | TIB-152 | human | P+ | |
| hosphoserine aminotransferase: PSA, | 29968 | | | |
| 22Rv1 | CRL-2505 | human | A+ | |
| CA-HPV-10 | CRL-2220 | human | A- | |
| DU 145 | HTB-81 | human | A- | |
| LNCaP clone FGC | CRL-1740 | human | A+ | |
| MDA PCa 2b | CRL-2422 | human | A+ | |
| PWR-1E | CRL-11611 [†] | human | A+ | |
| PZ-HPV-7 | CRL-2221 | human | A- | |
| RWPE-1 | CRL-11609 [†] | human | A+ | |
| RWPE-2 | CRL-11610 [†] | human | A+ | |
| F5-A-1/22.8.13 | HB-8051 [†] | mouse/mouse | MAb | Anti human prostate antigen (PA |
| RLSD06 | HB-8527 [†] | mouse/mouse | MAb | Anti human prostate antigen (PA |
| RLSD09 | HB-8525 [†] | mouse/mouse | MAb | Anti human prostate antigen (PA |
| ituitary adenylate cyclase-activating p | | | | p gen (17) |
| HP75 | CRL-2506 | human | R+ | |
| ituitary adenylate cyclase-activating p | | | | |
| HP75 | CRL-2506 | human | R+ | |
| lacental lactogen. See Chorionic soma | | | *** | |
| | | | | |
| | | | A+ | |
| asma cell antigen (PCA) | CRI -11102† | human | | |
| asma cell antigen (PCA) DS-1 | CRL-11102 [†] | human | Al | |
| lasma cell antigen (PCA) DS-1 lasminogen: PLG , 5340 | | | | |
| lasma cell antigen (PCA) DS-1 lasminogen: PLG , 5340 C3A | CRL-10741 [†] | human | P+ | |
| lasma cell antigen (PCA) DS-1 lasminogen: PLG , 5340 C3A Hep 3B2.1-7 | CRL-10741 [†] HB-8064 [†] | human human | P+ P+ | |
| lasma cell antigen (PCA) DS-1 lasminogen: PLG , 5340 C3A Hep 3B2.1-7 Hep G2 | CRL-10741 [†] | human | P+ | |
| lasma cell antigen (PCA) DS-1 lasminogen: PLG , 5340 C3A Hep 3B2.1-7 Hep G2 lasminogen activator | CRL-10741 [†] HB-8064 [†] HB-8065 [†] | human human human | P+ P+ P+ | |
| lasma cell antigen (PCA) DS-1 lasminogen: PLG , 5340 C3A Hep 3B2.1-7 Hep G2 lasminogen activator HE-LU(Rifkin) | CRL-10741 [†] HB-8064 [†] HB-8065 [†] CRL-7717* | human human human human | P+ P+ P+ | |
| lasma cell antigen (PCA) DS-1 lasminogen: PLG , 5340 C3A Hep 3B2.1-7 Hep G2 lasminogen activator HE-LU(Rifkin) HT-29 | CRL-10741 [†] HB-8064 [†] HB-8065 [†] CRL-7717* HTB-38 | human human human human human | P+ P+ P+ P+ P- | |
| lasma cell antigen (PCA) DS-1 lasminogen: PLG , 5340 C3A Hep 3B2.1-7 Hep G2 lasminogen activator HE-LU(Rifkin) | CRL-10741 [†] HB-8064 [†] HB-8065 [†] CRL-7717* | human human human human | P+ P+ P+ | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|--|---------------------|------------|----------------------------|
| | | · | • | |
| CL-S1 | CRL-1615 | mouse | P+ | |
| F9 | CRL-1720 | mouse | P+ | |
| TM4 | CRL-1715 | mouse | P+ | |
| PK(15) | CCL-33 | pig | P+ | |
| LLC-PK1 | CL-101 | pig | P+ | |
| LLC-PK1A | CL-101.1 | pig | P+ | |
| NMU | CRL-1743 | rat | P+ | |
| LLC-RK, | CCL-106 | rabbit | P+ | |
| LLC-MK, | CCL-7 | Rhesus monkey | P+ | |
| LLC-MK | CCL-7.1 | Rhesus monkey | P+ | |
| sminogen activator, tissue: PLAT, 5 | | ····esus ····erimey | | |
| CHL-1 | CRL-9446 [†] | human | P+ | |
| HMCB | CRL-9607 [†] | human | P+ | |
| | | | | |
| CHO 1-15 ₅₀₀ | CRL-9606 [†] | Chinese hamster | P+ (human) | |
| sminogen activator, urokinase rec | | In comment | D. | |
| HT-29 | HTB-38 | human | R+ | |
| RKO | CRL-2577 | human | R+ | |
| elet-activating factor (five variant | | | | |
| HEC-1-A | HTB-112 | human | P+ | |
| telet-activating factor receptor: P | TAFR, 5724 | | | |
| HEC-1-A | HTB-112 | human | R+ | Responsive |
| telet-derived growth factor alpha | polypeptide: PDGFA, | 5154 | | · |
| NCI-H23 | CRL-5800 | human | P+ | |
| NCI-H661 | HTB-183 | human | P+ | |
| NCI-H69 | HTB-119 | human | P- | |
| NCI-H82 | HTB-175 | human | P– | |
| | | | <u> </u> | IEE |
| telet-derived growth factor beta p | | | | 155 |
| COLO 201 | CCL-224 | human | 0+ | |
| DLD-1 | CCL-221 | human | 0+ | |
| HT-29 | HTB-38 | human | 0+ | |
| LoVo | CCL-229 | human | 0- | |
| LS 174T | CL-188 | human | 0- | |
| MSTO-211H | CRL-2081 | human | 0– | v-sis |
| NCI-H23 | CRL-5800 | human | O+ | |
| NCI-H661 | HTB-183 | human | 0+ | |
| NCI-H69 | HTB-119 | human | 0- | |
| NCI-H82 | HTB-175 | human | 0- | |
| SK-CO-1 | HTB-39 | human | O+ | |
| SW1116 | CCL-233 | human | 0+ | |
| SW1417 | CCL-238 | human | 0+ | |
| SW480 | CCL-238 | | 0+ 0+ | |
| | | human | | |
| SW620 | CCL-227 | human | 0+ | |
| SW948 | CCL-237 | human | 0- | A CODEST |
| 116 | HB-9367 [†] | mouse/mouse | MAb | Anti PDGF beta, v-sis form |
| 232 | HB-9372 [†] | mouse/mouse | MAb | Anti PDGF beta, v-sis forn |
| 52 | HB-9361 [†] | mouse/mouse | MAb | Anti PDGF beta, v-sis form |
| elet-derived growth factor recep | tor, alpha polypeptide | : PDGFRA, 5156 | | |
| NCI-H23 | CRL-5800 | human | R- | |
| NCI-H661 | HTB-183 | human | R- | |
| NCI-H69 | HTB-119 | human | R+ | |
| NCI-H82 | HTB-175 | human | R– | |
| elet-derived growth factor recep | | | | |
| NCI-H23 | CRL-5800 | human | R- | |
| NCI-H661 | HTB-183 | human | R- | |
| NCI-H69 | HTB-119 | | R– | |
| NCI-H82 | | human | | |
| NV 1-007 | HTB-175 | human | R– | |
| | alaania. Dagaan 40111 | | | |
| et/endothelial cell adhesion mo EOMA | olecule: Pecam, 18613 CRL-2586 | mouse | A+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|---|-----------------|-----------|--------------------------------------|
| | DOLA 5400 OD | <u> </u> | • | |
| olymerase (DNA directed), alpha | POLA, 5422 OR (70kD): POLA2, 23649 | | | |
| SJK-132-20 | CRL-1640 | mouse/mouse | MAb | Anti human DNA polymerase alpha |
| SJK-237-71 | CRL-1645 | mouse/mouse | MAb | Anti human DNA polymerase alpha |
| SJK-287-38 | CRL-1644 | mouse/mouse | MAb | Anti human DNA polymerase alpha |
| STK 1 | CRL-1652 | mouse/mouse | MAb | Anti human DNA polymerase alpha |
| Polymerase (DNA directed), epsilo | | mouse/mouse | WIND | 7 THE HAMILE DIVIN POLYMETUSE dipha |
| 3C5.1 | CRL-2284 | mouse/mouse | MAb | Anti human DNA polymerase epsilon |
| olypyrimidine tract binding prote | | 1110435,1110435 | 111110 | , and manian Brus polymeruse epsilon |
| mAb BB7 | CRL-2501 | mouse/mouse | MAb | Anti PTB |
| RB. See Retinoblastoma 1. | | | | |
| -Pregnen-3-one(20-hydroxy) | | | | |
| I-10 | CCL-83 | mouse | P+ | |
| reproenkephalin 1: Penk1, 1861 | | | | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| Procollagen. See Collagen. | | | | |
| rogesterone receptor: PGR, 5241 | | | | |
| HCC1008 | CRL-2320 | human | R- | |
| HCC1143 | CRL-2321 | human | R- | |
| HCC1187 | CRL-2322 | human | R– | |
| HCC1395 | CRL-2324 | human | R– | |
| HCC1419 | CRL-2326 | human | R- | |
| HCC1500 | CRL-2329 | human | R+ | |
| HCC1569 | CRL-2330 | human | R- | |
| HCC1599 | CRL-2331 | human | R– | |
| HCC1806 | CRL-2335 | human | R– | |
| HCC1937 | CRL-2336 | human | R– | |
| HCC1954 | CRL-2338 | human | R– | |
| HCC202 | CRL-2316 | human | R– | |
| HCC2157 | CRL-2340 | human | R+ | |
| HCC2218 | CRL-2343 | human | R+ | |
| HCC38 | CRL-2314 | human | R– | |
| HCC70 | CRL-2315 | human | R– | |
| NIH:OVCAR-3 | HTB-161 | human | R+ | |
| T-47D | HTB-133 | human | R+ | Responsive |
| UACC-812 | CRL-1897 | human | R– | |
| Progesterone receptor: Pgr, 1866 | | | | |
| TM3 | CRL-1714 | mouse | R+ | |
| TM4 | CRL-1715 | mouse | R+ | |
| Progesterone, product | | | | |
| BeWo | CCL-98 | human | P+ | |
| ChaGo-K-1 | HTB-168 | human | P+ | |
| JAR JEG 2 | HTB-144 | human | P+ | |
| JEG-3 | HTB-36 | human | P+ | |
| I-10 | CCL-83 | mouse | P+ | |
| MLTC-1 | CRL-2065 | mouse | P+ | |
| R2C | CCL-97 | rat | P+ | |
| Prohormone convertases PC1/3 ar | | human | D: | |
| HP75 Prolactin: Prl, 19109 | CRL-2506 | human | P+ | |
| CW13.20-3B3 | CDL 1660 | maura | D. | |
| | CRL-1669 | mouse | P+ | |
| Prolactin: Prl, 24683 | CCI 02 | rat | D : | |
| GH ₁ | CCL-82 | rat | P+ | |
| GH ₃ | CCL-82.1 | rat | P+ | |
| GH ₄ C ₁ | CCL-82.2 | rat | P+ | |
| MMQ RC-4B/C | CRL-10609 [†] CRL-1903 | rat | P+ P+ | |
| Prolactin receptor: PRLR, 5618 | CUL-1303 | rat | ГТ | |
| | | | | |

hormone/beta-endorphin): POMC, 5443

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|----------------------------------|---------------------------------|-----------------------------|--------------------------------|-------------------|
| DMS 79 | CRL-2049 | human | P+ | |
| protein convertase subtilisin/k | | | | |
| ectonucleotide pyrophosphata | * * | | | |
| C1.18.4 | TIB-11 | mouse | A+ | |
| J558 | TIB-6 | mouse | A+ | |
| P1.17 | TIB-10 | mouse | A+ | |
| P3.6.2.8.1 | TIB-8 | mouse | A+ | |
| S194/5.XXO-1 | TIB-19 | mouse | A+ | |
| \$194/5.XXO.BU.1 | TIB-20 | mouse | A+ | |
| ostaglandin E receptor 1 (subty | | | | |
| | pe EP2): Ptger2, 19217 O | | | |
| | pe EP3): Ptger3, 19218 O | | | |
| | pe EP4): Ptger4, 19219 | | | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| staglandin E | CIL 2203 | mouse | 111 | |
| GCT | TIB-223 | human | P+ | |
| staglandin E2 (PGE2) | 110-223 | numan | 1 T | |
| HSDM ₁ C ₁ | CCL-148 | mouse | P+ | |
| HIG-82 | | mouse | P+ P+ | |
| | CRL-1832 | rabbit | r+ | |
| staglandin F2a | CDI 1714 | mayee | D · | |
| TM3 | CRL-1714 | mouse | P+ | |
| ostaglandins | CD1 4740 | | | |
| NMU | CRL-1743 | rat | P+ | |
| tein tyrosine phosphatase, rece | | | | |
| BC-1 | CRL-2230 | human | A+ | |
| BC-2 | CRL-2231 | human | A+ | |
| BC-3 | CRL-2277 | human | A+ | |
| DS-1 | CRL-11102 [†] | human | A- | |
| GA-10 | CRL-2392 | human | A+ | |
| J45.01 | CRL-1990 | human | A- | |
| NK-92 | CRL-2407 | human | A+ | |
| NK-92CI | CRL-2409 | human | A+ | |
| NK-92MI | CRL-2408 | human | A+ | |
| 4B2 | HB-196 | mouse/mouse | MAb | Anti human CD45 |
| 9.4 | HB-10508 [†] | mouse/mouse | MAb | Anti human CD45 |
| GAP 8.3 | HB-12 | mouse/mouse | MAb | Anti human CD45 |
| ein tyrosine phosphatase, rece | eptor type, C: Ptprc, 1926 | 4 | | |
| AMJ2-C11 | CRL-2456 | mouse | A+ | |
| AMJ2-C8 | CRL-2455 | mouse | A+ | |
| BW5147(T200 ⁻ a)5.2 | TIB-233 | mouse | A- | |
| EOC 13.31 | CRL-2468 | mouse | A+ | |
| EOC 2 | CRL-2467 | mouse | A+ | |
| EOC 20 | CRL-2469 | mouse | A+ | |
| EOMA | CRL-2586 | mouse | A+ | |
| NFS-25 C-3 | CRL-2566 CRL-1695 | | A+ A+ | |
| NFS-5 C-1 | | mouse | | |
| | CRL-1693 | mouse | A+ | |
| NFS-70 C-10 | CRL-1694 CRL-2457 | mouse | A+ | |
| PMJ2-PC | | mouse | A+ | |
| PMJ2-R | CRL-2458 | mouse | A+ | 4 60.450.4 |
| 14.8 | TIB-164 | rat/mouse | MAb | Anti mouse CD45RA |
| I/24.D6 | HB-251 | rat/mouse | MAb | Anti mouse CD45RC |
| M1/89.18.7.HK | TIB-124 | rat/mouse | MAb | Anti mouse CD45 |
| M1/9.3.4.HL.2 | TIB-122 | rat/mouse | MAb | Anti mouse CD45 |
| MB23G2 | HB-220 | rat/mouse | MAb | Anti mouse CD45 |
| MB4B4 | HB-223 | rat/mouse | MAb | Anti mouse CD45 |
| RA3-3A1/6.1 | TIB-146 | rat/mouse | MAb | Anti mouse CD45R |
| tein tyrosine phosphatase, rece | eptor type, C (species not | yet curated) | | |
| 74-9-3 | HB-156 | mouse/mouse | MAb | Anti pig CD45 |
| eoglycan 2, bone marrow (nat | ural killer cell activator, e | osinophil granule major bas | sic protein): PRG2, 555 | 3 |
| Clone 15 HL-60 | CRL-1964 | human | P+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product of the produc$

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| ame: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---------------------------------------|---------------------------|----------|---------------|---------------------------|
| | | | | |
| ectin. See Selectin P. | | | | |
| f-1 murine leukemia viral onc | | | | |
| DMS 79 | CRL-2049 | human | 0+ | v-raf |
| MSTO-211H | CRL-2081 | human | 0+ | c-raf-1 |
| NCI-H146 | HTB-173 | human | 0+ | c-raf 1 |
| NCI-H23 | CRL-5800 | human | 0+ | c-raf-1 |
| NCI-H526 | CRL-5811 | human | 0+ | c-raf 1 |
| NCI-H69 | HTB-119 | human | 0+ | c-raf 1 |
| NCI-H82 | HTB-175 | human | 0+ | c-raf 1 |
| NCI-N417 | CRL-5809 | human | 0+ | c-raf 1 |
| ras Harvey rat sarcoma vira | | \S, 3265 | | |
| COLO 201 | CCL-224 | human | 0+ | ras + |
| DLD-1 | CCL-221 | human | 0+ | H-ras +; K-ras +; N-ras - |
| DMS 79 | CRL-2049 | human | 0+ | H-ras +; K-ras +; N-ras |
| HT-29 | HTB-38 | human | O+ | H-ras +; K-ras +; N-ras |
| J82 | HTB-1 | human | O+ | H-ras + |
| LoVo | CCL-229 | human | 0+ | H-ras +; K-ras +; N-ras |
| LS 174T | CL-188 | human | 0+ | H-ras +; K-ras -; N-ras + |
| MSTO-211H | CRL-2081 | human | 0+ | H-ras +; K-ras +; N-ras |
| NCI-H146 | HTB-173 | human | 0+ | H-ras +; K-ras +; N-ras |
| NCI-H23 | CRL-5800 | human | 0+ | H-ras +; K-ras +; N-ras - |
| NCI-H526 | CRL-5811 | human | 0+ | H-ras +; K-ras +; N-ras - |
| NCI-H69 | HTB-119 | human | 0+ | H-ras +; K-ras +; N-ras - |
| NCI-H82 | HTB-175 | human | 0+ | H-ras +; K-ras +; N-ras - |
| NCI-N417 | CRL-5809 | human | 0+ | H-ras +; K-ras +; N-ras - |
| SK-CO-1 | HTB-39 | human | 0+ | H-ras +; K-ras +; N-ras - |
| SW1116 | CCL-233 | human | 0+ | H-ras +; K-ras +; N-ras |
| SW1417 | CCL-238 | human | 0+ | H-ras +; K-ras –; N-ras |
| SW480 | CCL-228 | human | O+ | H-ras +; K-ras +; N-ras - |
| SW620 | CCL-227 | human | 0+ | H-ras +; K-ras +; N-ras - |
| SW948 | CCL-237 | human | 0+ | H-ras +; K-ras +; N-ras - |
| T24 | HTB-4 | human | O+ | H-ras + |
| WR21 | CRL-2189 | mouse | O+ (human) | c-H-ras + (human) |
| | ciated gene): SSPN, 8082 | | O+ (Hulliali) | C-11-703 + (Hulliall) |
| | arcoma 2 viral oncogene h | | | |
| Calu-1 | HTB-54 | human | 0+ | K-ras + |
| DMS 79 | | | | H-ras +; K-ras +; N-ras - |
| | CRL-2049 | human | 0+ | |
| HT-29 | HTB-38 | human | 0+ | H-ras +; K-ras +; N-ras |
| LoVo | CCL-229 | human | 0+ | H-ras +; K-ras +; N-ras |
| MSTO-211H | CRL-2081 | human | 0+ | H-ras +; K-ras +; N-ras |
| NCI-H146 | HTB-173 | human | 0+ | H-ras +; K-ras +; N-ras |
| NCI-H23 | CRL-5800 | human | 0+ | H-ras +; K-ras +; N-ras |
| NCI-H526 | CRL-5811 | human | 0+ | H-ras +; K-ras +; N-ras - |
| NCI-H69 | HTB-119 | human | 0+ | H-ras +; K-ras +; N-ras |
| NCI-H82 | HTB-175 | human | 0+ | H-ras +; K-ras +; N-ras |
| NCI-N417 | CRL-5809 | human | 0+ | H-ras +; K-ras +; N-ras |
| Panc 02.03 | CRL-2553 | human | 0+ | K-ras + |
| Panc 02.13 | CRL-2554 | human | 0+ | K-ras + |
| Panc 03.27 | CRL-2549 | human | 0+ | K-ras + |
| Panc 08.13 | CRL-2551 | human | 0+ | K-ras + |
| Panc 10.05 | CRL-2547 | human | 0+ | K-ras + |
| PL45 | CRL-2558 | human | 0+ | K-ras + |
| SK-CO-1 | HTB-39 | human | 0+ | H-ras +; K-ras +; N-ras + |
| SW1116 | CCL-233 | human | 0+ | H-ras +; K-ras +; N-ras - |
| SW1417 | CCL-238 | human | 0+ | H-ras +; K-ras –; N-ras – |
| SW480 | CCL-228 | human | 0+ | H-ras +; K-ras +; N-ras + |
| SW620 | CCL-227 | human | 0+ | H-ras +; K-ras +; N-ras + |
| SW948 | CCL-237 | human | 0+ | H-ras +; K-ras +; N-ras + |
| blastoma Ras viral (v-ras) o | | | | ,, |
| DLD-1 | CCL-221 | human | 0+ | H-ras +; K-ras +; N-ras + |
| DMS 79 | CRL-2049 | human | 0+ | H-ras +; K-ras +; N-ras + |
| | 3.12 20 12 | | <u> </u> | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Call Lina Nama | ATCC® N. | Coories | Everence | Commonts |
|--|-------------------------------|--------------|-----------|--|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| HT-1080 | CCL-121 | human | 0+ | N-ras |
| HT-29 | HTB-38 | human | 0+ | H-ras +; K-ras +; N-ras + |
| LoVo | CCL-229 | human | 0+ | H-ras +; K-ras +; N-ras + |
| MSTO-211H | CRL-2081 | human | 0+ | H-ras +; K-ras +; N-ras + |
| NCI-H146 | HTB-173 | human | 0+ | H-ras +; K-ras +; N-ras + |
| NCI-H23 | CRL-5800 | human | 0+ | H-ras +; K-ras +; N-ras + |
| NCI-H526 | CRL-5811 | human | 0+ | H-ras +; K-ras +; N-ras + |
| NCI-H69 | HTB-119 | human | 0+ | H-ras +; K-ras +; N-ras + |
| NCI-H82 | HTB-175 | human | 0+ | H-ras +; K-ras +; N-ras + |
| NCI-N417 | CRL-5809 | human | 0+ | H-ras +; K-ras +; N-ras + |
| PA-1 | CRL-1572 | human | 0+ | N-ras + |
| SK-CO-1 | HTB-39 | human | 0+ | H-ras +; K-ras +; N-ras + |
| SW1116 | CCL-233 | human | O+ | H-ras +; K-ras +; N-ras – |
| SW1417 | CCL-238 | human | 0+ | H-ras +; K-ras –; N-ras – |
| SW480 | CCL-228 | human | 0+ | H-ras +; K-ras +; N-ras + |
| SW620 | CCL-227 | human | 0+ | H-ras +; K-ras +; N-ras + |
| SW948 | CCL-237 | human | 0+ | H-ras +; K-ras +; N-ras + |
| | | | | |
| 142-24E5 | CRL-2649 | mouse/mouse | MAb | Anti ras, H/N, peptide, synthetic |
| 146-03E04 | CRL-2650 | mouse/mouse | MAb | Anti ras oncogene peptide, synthetic |
| 147-67C6 | CRL-2654 | mouse/mouse | MAb | Anti synthetic v-ras K oncogene |
| | | | | peptide |
| MX | HB-9158 [†] | mouse/mouse | MAb | Anti ras, Ha, p21 |
| Y13-238 | CRL-1741 | rat/mouse | MAb | Anti ras (v-ras) protein, p21 |
| Y13-259 | CRL-1742 | rat/mouse | MAb | Anti ras (v-ras) protein, p21 |
| nin 1 structural: Ren1, 19701 | CILE 17 12 | raymouse | 1417.65 | 7 (17 (17 (17 (17 (17 (17 (17 (17 (17 (1 |
| SCA-9 clone 15 | CRL-1734 | mouse | P+ | |
| As4.1 | CRL-2193 | mouse | P+ | |
| nin (species not yet curated) | CILL 2173 | mouse | | |
| F32 VIII C4 | CRL-1653 | mouse/mouse | MAb | Anti hog rennin |
| P-1. See Choroideremia (Rab esco | | mouse, mouse | 1417.65 | 7 that hog remini |
| inal pigment epithelium-specific | | | | |
| ARPE-19 | CRL-2302 | human | A+ | |
| ARPE-19/HPV-16 | CRL-2502 | human | A+ | |
| inaldehyde binding protein 1: R | | Haman | 7(1 | |
| ARPE-19 | CRL-2302 | human | A+ | |
| ARPE-19/HPV-16 | CRL-2502 | human | A+ | |
| inol binding protein (seven retir | | Human | A1 | |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| | HB-8065 [†] | | P+ | |
| Hep G2 | CRL-1715 | human | | |
| TM4 | | mouse | P+ | |
| inol binding protein 1, cellular: F Caco-2 | | human | D: | |
| Caco-2 nol binding protein 2, cellular: F | HTB-37 | human | P+ | |
| <u> </u> | | human | Di | |
| Caco-2 | HTB-37 | human | P+ | |
| inoblastoma 1 (including osteos | <u> </u> | h | 0: | |
| C-33 A | HTB-31 | human | 0+ | |
| HT-3 | HTB-32 | human | 0+ | |
| ME-180 | HTB-33 | human | 0+ | |
| NCI-H209 | HTB-172 | human | 0+ | |
| SiHa | HTB-35 | human | 0+ | |
| onuclease, RNase A family, 2 (live | | | | |
| Clone 15 HL-60 | CRL-1964 | human | P+ | |
| onuclease, RNase A family, 3 (eo: | | | | |
| Clone 15 HL-60 | CRL-1964 | human | P+ | |
| os UR2 sarcoma virus oncogene | homolog 1 (avian): ROS | 1,6098 | | |
| COLO 201 | CCL-224 | human | 0- | |
| DLD-1 | CCL-221 | human | 0- | |
| LIT OO | LITE 20 | h | 0 | |
| HT-29 | HTB-38 | human | 0- | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product of the produc$

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|------------------------|---------------------------------------|-----------|--------------------------------------|
| | | • | | |
| r-ros UR2 sarcoma virus oncogene ho LS 174T | CL-188 | human | 0- | |
| SK-CO-1 | HTB-39 | human | 0- | |
| SW1116 | CCL-233 | human | 0- | |
| SW1417 | CCL-233 | human | 0- | |
| SW480 | CCL-238 | human | 0- | |
| SW620 | CCL-228 | human | 0- | |
| SW948 | CCL-227 | human | 0- | |
| -100 protein (seventeen S-100 prote | | Hulliali | 0- | |
| D283 Med | HTB-185 | human | P- | |
| D341 Med | HTB-187 | human | P- | |
| | | human | P- | |
| Daoy DBTRG-05MG | HTB-186 CRL-2020 | human | P+ | |
| LN-18 | CRL-2020 CRL-2610 | human | P+ | |
| | | | | |
| C ₆ EGC/PK060399egfr | CCL-107 CRL-2690 | rat | P+ P+ | |
| | | rat | r+ | |
| arcospan. See K-ras oncogene-associ | | | | |
| cavenger receptor class F, member 1 C166 | CRL-2581 | mouso | R+ | |
| EOMA | CRL-2581 | mouse | R+ | |
| | | mouse | K+ | |
| ecreted phosphoprotein 1: Spp1, 20 MC3T3-E1 Subclone 14 | CRL-2594 | mausa | P+ | |
| | | mouse | P+ P- | |
| MC3T3-E1 Subclone 24 | CRL-2595 | mouse | P- | |
| MC3T3-E1 Subclone 30 MC3T3-E1 Subclone 4 | CRL-2596 CRL-2593 | mouse | P+ | |
| | | mouse | P+ | |
| ecreted protein, acidic, cysteine-rich NE | | | D. | |
| | CRL-2070 | mouse | P+ | |
| electin E (endothelial adhesion mole | | | 14 A A In | Anti-human F calcutin (CDC2F) |
| CL2 | CRL-2514 | mouse/mouse | MAb | Anti human E-selectin (CD62E) |
| CL3 | CRL-2515 | mouse/mouse | MAb | Anti human E-selectin (CD62E) |
| CL37 | CRL-2516 | mouse/mouse | MAb | Anti human E-selectin (CD62E) |
| H18/7 | HB-11684 [†] | mouse/mouse | MAb | Anti human E-selectin (ELAM-1, CD62E |
| electin L (lymphocyte adhesion mol | | | *** | A CD.401 |
| 1H3 | HB-284 | mouse/mouse | MAb | Anti human CD62L |
| DREG56 | HB-300 | mouse/mouse | MAb | Anti human L-selectin (CD62L, LECAM, |
| | | | | LAM-1, Leu-8) |
| DREG200 | HB-302 | mouse/mouse | MAb | Anti human L-selectin (CD62L, LECAM, |
| | | | | LAM-1, Leu-8) |
| electin L (lymphocyte adhesion mol | | | | |
| DU1-29 | HB-263 | mouse/mouse | MAb | Anti sheep and bovine CD62L |
| electin, lymphocyte: Sell, 20343 | | | | |
| MEL-14 | HB-132 | rat/mouse | MAb | Anti mouse equivalent to human L- |
| | 44010 | 0) 6818 4040 | | selectin, CD62L, Leu-8) |
| selectin P (granule membrane protei | | · · · · · · · · · · · · · · · · · · · | | |
| WAPS 12.2 | HB-299 | mouse/mouse | MAb | Anti human P-selectin (CD62P) |
| erine (or cysteine) proteinase inhibit | | · · · · · · · · · · · · · · · · · · · | | 12 |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| erotonin. See 5-Hydroxytryptamine (| serotonin). | | | |
| erum albumin. See Albumin. | | | | |
| ialomucin. See CD164 antigen. | | | | |
| is. See Platelet-derived growth factor | | | | |
| omatostatin receptor 1: Smstr1, 206 | 05 OR | | | |
| receptor 2: Smstr2, 206 | 06 OR | | | |
| receptor 3: Smstr3, 206 | 07 OR | | | |
| | 00 OD | | | |
| receptor 4: Smstr4, 206 | 08 OR | | | |
| receptor 4: Smstr4, 206 receptor 5: Smstr5, 206 | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Name: Symbol, GeneID | ATCC . | C ' | - | Comment |
|--|------------------------|------------------------------|-----------|---|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| omatostatin (hamster gene not yet | curated) | | | |
| HIT-T15 | CRL-1777 | Syrian golden | R+ | Sensitive |
| | | hamster | | |
| Somatostatin: SST, 6750 | | | | |
| DMS 53 | CRL-2062 | human | P+ | Somatostatin-like immunoreactivity (SRIF) |
| DMS 79 | CRL-2049 | human | P+ | Somatostatin-like immunoreactivity (SRIF) |
| HCN-1A | CRL-10442 [†] | human | P+ | |
| HCN-2 | CRL-10742 [†] | human | P+ | |
| omatostatin: Smst, 20604 | | | | |
| β-TC-6 | CRL-11506 [†] | mouse | P+ | |
| MTC-M | CRL-1806 | mouse | P+ | |
| N1E-115 | CRL-2263 | mouse | P+ | |
| NIT-1 | CRL-2055 | mouse | P– | |
| TGP47 | CRL-2141 | mouse | P– | |
| TGP49 | CRL-2136 | mouse | P– | |
| TGP52 | CRL-2140 | mouse | P+ | |
| TGP55 | CRL-2150 | mouse | P+ | |
| TGP61 | CRL-2135 | mouse | P+ | Not secreted |
| omatostatin: Sst, 24797 | | | | |
| RIN-14B | CRL-2059 | rat | P+ | |
| RIN-5F | CRL-2058 | rat | P- | |
| RIN-m | CRL-2057 | rat | P+ | |
| RIN-m5F | CRL-11605 [†] | rat | P- | |
| Somatotrophin. See Growth hormone | e 1. | | | |
| Spleen tyrosine kinase: SYK, 6850 | | | | |
| P116 | CRL-2676 | human | P- | |
| P116.cl39 [P116.c39] | CRL-2677 | human | P- | |
| plicing factor, arginine/serine-rich 2 | :SFRS2,6427 | | | |
| Anti-SC35 | CRL-2031 | mouse/mouse | MAb | Anti mammalian splicing factor (SC35) |
| -src sarcoma (Schmidt-Ruppin A-2) | viral oncogene homol | og (avian): SRC, 6714 | | |
| COLO 201 | CCL-224 | human | 0- | |
| DLD-1 | CCL-221 | human | 0- | |
| HT-29 | HTB-38 | human | 0- | |
| LoVo | CCL-229 | human | 0- | |
| LS 174T | CL-188 | human | 0- | |
| MSTO-211H | CRL-2081 | human | 0+ | V-SrC |
| NCI-H23 | CRL-5800 | human | 0+ | V-SrC |
| SK-CO-1 | HTB-39 | human | 0- | |
| SW1116 | CCL-233 | human | 0- | |
| SW1417 | CCL-238 | human | 0- | |
| SW480 | CCL-228 | human | 0- | |
| SW620 | CCL-227 | human | 0- | |
| SW948 | CCL-237 | human | 0- | |
| SYF | CRL-2459 | mouse | 0- | |
| 201-45E9 | CRL-2670 | mouse/mouse | MAb | Anti synthetic v-src oncogene peptide |
| 202-11A8 | CRL-2669 | mouse/mouse | MAb | Anti SRC/YES synthetic oncogene peptide |
| 203-7D10 | CRL-2651 | mouse/mouse | MAb | Anti synthetic v-src oncogene peptide |
| REBP cleavage-activating protein: S | | | | |
| IgG-9D5 | CRL-2347 | mouse/mouse | MAb | Anti hamster SCAP |
| item cell antigen 1 (Sca-1). See Lymp | hocyte antigen 6 com | | | |
| stem cell factor (SCF). See kit. | , , | | | |
| steroid hormones | | | | |
| NCI-H295 | CRL-10296 [†] | human | P+ | |
| Y-1 | CCL-79 | mouse | P+ | |
| LC-540 | CCL-43 | rat | P+ | |
| R2C | CCL-97 | rat | P+ | |
| - | | | · · · | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|--|---------------------------------|-----------|---------------------------------------|
| | | • | | |
| erol regulatory element binding | transcription factor 1: SF transcription factor 2: SF | | | |
| IgG-2A4 | CRL-2121 | mouse/mouse | MAb | Anti human SREBP |
| erol regulatory element binding | | | IVIAD | Antinuman shebr |
| lgG-3B2 | CRL-2693 | mouse/mouse | MAb | Anti <i>Drosophila</i> dSREBP |
| erol regulatory element binding | | | 11110 | 7 HILL DI OSOPI MA GOLLEDI |
| lgG-1C6 | CRL-2224 | mouse/mouse | MAb | Anti human SREBP 2 |
| lgG-1D2 | CRL-2545 | mouse/mouse | MAb | Anti human SREBP 2 |
| erol regulatory element binding | | | - | |
| IgG-7D4 | CRL-2198 | mouse/mouse | MAb | Anti hamster SREBP2 |
| urfactant, pulmonary-associated | protein A1: SFTPA1, 643 | 5 | | |
| NCI-H1404 | CRL-5819 | human | P+ | mRNA and protein |
| NCI-H358 | CRL-5807 | human | P+ | mRNA and protein |
| NCI-H441 | HTB-174 | human | P+ | mRNA and protein |
| NCI-H820 | HTB-181 | human | P+ | |
| ırfactant, pulmonary-associated | protein B: SFTPB, 6439 | | | |
| NCI-H1404 | CRL-5819 | human | P+ | mRNA and protein |
| NCI-H358 | CRL-5807 | human | P- | |
| NCI-H820 | HTB-181 | human | P+ | |
| rfactant-associated protein B: S | | | | |
| MLE 12 | CRL-2110 | mouse | P+ | |
| ırfactant, pulmonary-associated | | | | |
| | | human; canine gene not yet cura | | |
| DS-1 | HB-8906 [†] | mouse/mouse | MAb | Anti canine ASP |
| DS-3 | HB-8651 [†] | mouse/mouse | MAb | Anti canine ASP |
| DS-5 | HB-8653 [†] | mouse/mouse | MAb | Anti canine ASP |
| DS-6 | HB-8652 [†] | mouse/mouse | MAb | Anti canine ASP |
| rfactant-associated protein C: S | | | - | |
| NCI-H1404 | CRL-5819 | human | P- | |
| NCI-H358 | CRL-5807 | human | P- | |
| NCI-H820 | HTB-181 | human | P+ | |
| urfactant-associated protein C: S MLE 12 | CRL-2110 | mausa | P+ | |
| naptophysin: Syp, 20977 | CRL-2110 | mouse | P+ | |
| CATH.a | CRL-11179 [†] | mouso | P+ | |
| cell antigen receptor (TCR) | CRL-111/9 | mouse | гт | |
| 29SR | CRL-2262 | human | R- | |
| HT | CRL-2260 | human | R- | |
| J45.01 | CRL-1990 | human | R+ | |
| J.CaM1.6 | CRL-2063 | human | R+ | TCR signal transduction is defective. |
| J.RT3-T3.5 | TIB-153 | human | R– | Lacks the beta chain of the T cell |
| 3.1(15-15.5 | 110 133 | naman | 11— | antigen receptor |
| Jurkat, Clone E6-1 | TIB-152 | human | R+ | unigen receptor |
| RL | CRL-2261 | human | R- | |
| 145-2C11 | CRL-1975 | mouse/mouse | MAb | Anti mouse T cell receptor (CD3 - T3) |
| 113 2011 | CILE 1973 | complex | 111110 | And mouse received (ebs. 15) |
| (BF1) 8A3.31 | HB-9283 [†] | mouse/mouse | MAb | Anti human T cell antigen receptor, |
| (51.1) 67(3.31 | 110 7203 | mouse/mouse | WIND | major framework determinant |
| C305 | CRL-2424 | mouse/mouse | MAb | Anti beta chain of the T cell antigen |
| 2303 | CILE 2 12 1 | receptor on Jurkat cells | 111110 | 7 that beta chain of the Feen antigen |
| H57-597 | HB-218 | rat/mouse | MAb | Anti mouse T cell antigen receptor |
| TR 310 | HB-219 | rat/mouse | MAb | Anti mouse T cell antigen receptor |
| W4F.5B | HB-9282 [†] | mouse/mouse | MAb | Anti human T cell antigen receptor, |
| W-11.50 | 110 7202 | mouse/mouse | 111110 | major framework determinant |
| cell receptor alpha locus: TRA @, | .6955 AND | | | major namework determinant |
| beta locus: TRB @, | | | | |
| TALL-104 | CRL-11386 [†] | human | R+ | T cell antigen receptor alpha/beta |
| 17.22 107 | CILL 11500 | Haman | | (TCR) |
| cell receptor alpha locus: TRA @, | . 6955 OR | | | (1019 |
| | | | | |
| beta locus: TRB@, | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| lame: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|--|---|--|---|
| cell antigen receptor gamma/de | lta (TCR) | | | |
| 86D | HB-286 | mouse/mouse | MAb | Anti sheep gamma/delta T cell receptor |
| UC3-10A6 | CRL-1988 | Armenian hamster/ mouse | MAb | Anti mouse gamma/delta T cell receptor (TCR) |
| UC7-13D5 | CRL-1989 | Armenian hamster/ mouse | MAb | Anti mouse gamma/delta T cell receptor (TCR) |
| cell growth factor 2 (TCGF2) | | mouse | | receptor (TCN) |
| Cl. Ly1+2-/9 | CRL-8179 [†] | mouse | P+ | |
| cell precursor | | | | |
| OKT 10 | CRL-8022 [†] | mouse/mouse | MAb | Anti human T cell precursor |
| 200. See Protein tyrosine phospha | atase, receptor type C. | | | · |
| AG-72 | | | | |
| NCI-H498 | CCL-254 | human | A+ | |
| NCI-H508 | CCL-253 | human | A- | |
| NCI-H548 | CCL-249 | human | A- | |
| NCI-H716 | CCL-251 | human | A- | |
| NCI-H747 | CCL-252 | human | A- | |
| NCI-N87 | CRL-5822 | human | A+ | |
| SNU-1 | CRL-5971 | human | A+ | |
| SNU-16 | CRL-5974 | human | A+ | |
| SNU-5 | CRL-5973 | human | A+ | |
| SNU-C2A | CCL-250.1 | human | P+ | |
| CC 49 | HB-9459 [†] | mouse/mouse | MAb | Anti human TAG-72 |
| erminal deoxynucleotidyl transfe | rase (TdT). See Deoxynuo | | - | |
| GF. See Transforming growth factor | | , | | |
| hB. See Lymphocyte antigen 6 co | | | | |
| Thrombin. See Coagulation factor I | I (thrombin) receptor. | | | |
| Thrombospondin | · (till offisill) receptori | | | |
| EOMA | CRL-2586 | mouse | P+ | |
| Thy-1 cell surface antigen: THY1, 7 | | | | |
| K117 | HB-8553 [†] | mouse/mouse | MAb | Anti human Thy-1 |
| hymus cell antigen 1, theta: Thy1 | | | 111110 | 7.11.11.11.11.11.11.11.11.11.11.11.11.11 |
| AKR1.G.1.OVA ^R .1.26 | TIB-232 | mouse | A+ | Thy-1 |
| AMJ2-C11 | CRL-2456 | mouse | A- | Thy-1 |
| AMJ2-C8 | CRL-2455 | mouse | A- | Thy-1 |
| BW5147.3 | TIB-47 | mouse | A+ | Thy-1.1 |
| EL4 | TIB-39 | mouse | A+ | Thy-1.2 |
| EL4.BU | TIB-40 | mouse | A+ | Thy-1.2 |
| EL4.BU.1.OUA ^r .1.1 | TIB-41 | mouse | A+ | Thy-1.2 |
| FDC-P1 | CRL-12103 [†] | mouse | A+ | Thy-1.2 |
| HT-2 clone A5E | CRL-1841 | mouse | A+ | Thy-1 |
| PMJ2-PC | CRL-1641 CRL-2457 | mouse | A- | Thy-1.2 |
| PMJ2-R | CRL-2458 | | A- | Thy-1.2 |
| | TIB-42 | mouse | | Thy-1.2 |
| R1.1 R1E/TL8x.1 | TIB-43 | mouse mouse | A+ | • |
| RIE/ILOX.I | 11D- 4 3 | | A+ | Thy-1.2 |
| D1 C1 | | | Λ. | Thu 1 2 |
| R1.G1 | TIB-44 | mouse | A+ | Thy-1.2 |
| S1A.TB.4.8.2 | TIB-44 TIB-27 | mouse mouse | A+ | Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1 ⁻ b) | TIB-44 TIB-27 TIB-231 | mouse mouse mouse | A+ A- | Thy-1.2 Thy-1.1 |
| S1A.TB.4.8.2 S1A(Thy-1 ⁻ b) S49.1 | TIB-44 TIB-27 TIB-231 TIB-28 | mouse mouse mouse mouse | A+ A- A+ | Thy-1.2 Thy-1.1 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1 ⁻ b) S49.1 S49.1H.1AG.6/2 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 | mouse mouse mouse mouse mouse | A+ A- A+ A+ | Thy-1.2 Thy-1.1 Thy-1.2 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1 ⁻ b) S49.1 S49.1H.1AG.6/2 S49.1G.3 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 | mouse mouse mouse mouse mouse mouse | A+ A- A+ A+ A+ | Thy-1.2 Thy-1.1 Thy-1.2 Thy-1.2 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1·b) S49.1 S49.1H.1AG.6/2 S49.1G.3 S49.1G.3 PHA.100/0 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 TIB-35 | mouse mouse mouse mouse mouse mouse mouse mouse mouse | A+ A- A+ A+ A+ A+ | Thy-1.2 Thy-1.1 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1·b) S49.1 S49.1H.1AG.6/2 S49.1G.3 S49.1G.3 PHA.100/0 S49.1TB.2 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 TIB-35 TIB-30 | mouse | A+ A- A+ A+ A+ A+ A+ | Thy-1.2 Thy-1.1 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1·b) S49.1 S49.1H.1AG.6/2 S49.1G.3 S49.1G.3 PHA.100/0 S49.1TB.2 S49.1TB.4 DEX R.63 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 TIB-35 TIB-30 TIB-33 | mouse | A+ A- A+ A+ A+ A+ A+ A+ | Thy-1.2 Thy-1.1 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 |
| \$1A.TB.4.8.2 \$1A(Thy-1·b) \$49.1 \$49.1H.1AG.6/2 \$49.1G.3 \$49.1G.3 PHA.100/0 \$49.1TB.2 \$49.1TB.4 DEX R.63 TIMI.4 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 TIB-35 TIB-30 TIB-33 TIB-37 | mouse | A+ A- A+ A+ A+ A+ A+ A+ A+ | Thy-1.2 Thy-1.1 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1·b) S49.1 S49.1H.1AG.6/2 S49.1G.3 S49.1G.3 PHA.100/0 S49.1TB.2 S49.1TB.4 DEX R.63 TIMI.4 TIMI.4G.1.3 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 TIB-35 TIB-30 TIB-33 TIB-37 TIB-38 | mouse | A+ A- A+ A+ A+ A+ A+ A+ A+ A+ A+ | Thy-1.2 Thy-1.1 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1·b) S49.1 S49.1H.1AG.6/2 S49.1G.3 S49.1G.3 PHA.100/0 S49.1TB.2 S49.1TB.4 DEX R.63 TIMI.4 TIMI.4G.1.3 WEHI 7.1 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 TIB-35 TIB-30 TIB-33 TIB-37 TIB-38 TIB-53 | mouse | A+ A- A+ | Thy-1.2 Thy-1.1 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1·b) S49.1 S49.1H.1AG.6/2 S49.1G.3 S49.1G.3 PHA.100/0 S49.1TB.2 S49.1TB.4 DEX R.63 TIMI.4 TIMI.4G.1.3 WEHI 7.1 WEHI 22.1 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 TIB-35 TIB-30 TIB-33 TIB-37 TIB-38 TIB-53 TIB-54 | mouse | A+ A- A+ A+ A+ A+ A+ A+ A+ A+ A+ | Thy-1.2 Thy-1.1 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1·b) S49.1 S49.1H.1AG.6/2 S49.1G.3 S49.1G.3 PHA.100/0 S49.1TB.2 S49.1TB.4 DEX R.63 TIMI.4 TIMI.4G.1.3 WEHI 7.1 WEHI 22.1 WR19L | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 TIB-35 TIB-30 TIB-33 TIB-37 TIB-38 TIB-53 TIB-54 TIB-52 | mouse | A+ A- A+ | Thy-1.2 Thy-1.1 Thy-1.2 |
| S1A.TB.4.8.2 S1A(Thy-1·b) S49.1 S49.1H.1AG.6/2 S49.1G.3 S49.1G.3 PHA.100/0 S49.1TB.2 S49.1TB.4 DEX R.63 TIMI.4 TIMI.4G.1.3 WEHI 7.1 WEHI 22.1 | TIB-44 TIB-27 TIB-231 TIB-28 TIB-29 TIB-34 TIB-35 TIB-30 TIB-33 TIB-37 TIB-38 TIB-53 TIB-54 | mouse | A+ A- A+ | Thy-1.2 Thy-1.1 Thy-1.2 |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody. The product is a product of the product$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Name: Symbol, GeneID | ATCC@ N | C | F | Comments |
|--|-----------------------------------|---------------------------|--------------|---|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| Thymus cell antigen 1, theta contir | nued | | | |
| HO-13-4 | TIB-99 | mouse/mouse | MAb | Anti mouse Thy-1.2 |
| HO-22-1 | TIB-100 | rat/mouse | MAb | Anti mouse Thy-1 |
| J1j.10 | TIB-184 | rat/mouse | MAb | Anti mouse Thy-1.2 |
| M5/49.4.1 | TIB-238 | rat/mouse | MAb | Anti mouse Thy-1 |
| T11D7e2 | TIB-103 | mouse/mouse | MAb | Anti mouse Thy-1.1 |
| Thyroglobulin: Tg, 24826 | | | | |
| FRTL | CRL-1468 | rat | P+ | |
| Thyrotropin-releasing hormone: TF | | | | |
| DMS 53 | CRL-2062 | human | P+ | |
| hyroid stimulating hormone (TSH | | coprotein hormones, alpha | polypeptide. | |
| hyroid stimulating hormone, beta | | , | **** | A TOU |
| TSHR-R5T-34 | CRL-2683 | mouse/mouse | MAb | Anti human TSH receptor beta |
| TSHR-T3-365 | CRL-2684 | mouse/mouse | MAb | Anti human TSH receptor beta |
| hyroid stimulating hormone, beta | | | | |
| RC-4B/C | CRL-1903 | rat | P+ | |
| ight junction protein 1 (zona occl | | | | |
| RPE-J | CRL-2240 | rat | P+ | |
| issue inhibitor of bioreactive mat | rix metalloproteinase CRL-2279 | maura | D. | |
| MS1 (MILE SVEN 1) | | mouse | P+ | |
| SVR (SVEN 1 ras) | CRL-2280 | mouse | P+ | |
| Γissue plasminogen activator (t-PA ΓL antigen | j. see Plasminogen activ | ator, tissue. | | |
| | TID 42 | | Λ. | |
| R1.1 | TIB-42 | mouse | A+ | |
| R1.G1 | TIB-44 | mouse | A+ | |
| S49.1 | TIB-28 | mouse | A+ | |
| S49.1G.3 | TIB-34 | mouse | A+ | |
| S49.1G.3 PHA.100/0 | TIB-35 | mouse | A+ | |
| S49.1H.1AG.6/2 | TIB-29 | mouse | A+ | |
| S49.1TB.2 | TIB-30 | mouse | A+ | |
| S49.1TB.4 DEX R.63 | TIB-33 | mouse | A+ | |
| S49 (Thy-1-a) | TIB-36 | mouse | A+ | |
| HD168 | HB-252 | rat/mouse | MAb | Anti mouse TL antigen |
| I(TL.m9) | HB-131 | mouse/mouse | MAb | Anti mouse TL antigen |
| Fransducing vector | CD1 4050 | | | |
| CRE BAG 2 | CRL-1858 | mouse | P+ | Beta-galactosidase transducing vector (BAG) |
| ψ 2 DAP | CRL-1949 | mouse | P+ | Placental alkaline phosphatase transducing vector |
| Ψ 2 BAG alpha | CRL-9560 [†] | mouse | P+ | Beta-galactosidase transducing vector (BAG) |
| PG13/LN c8 | CRL-10685 [†] | mouse | P+ | GaLV-based neomycin resistance transducing vector |
| ransferrin: TF, 7018 | | | | - |
| C3A | CRL-10741 [†] | human | P+ | |
| Hep 3B2.1-7 | HB-8064 [†] | human | P+ | |
| Hep G2 | HB-8065 [†] | human | P+ | |
| ransferrin: Trf, 22041 | | | | |
| AML12 | CRL-2254 | mouse | P+ | |
| TM4 | CRL-1715 | mouse | P+ | |
| ransferrin: Tf, 24825 | | | | |
| CTX TNA2 | CRL-2006 | rat | P+ | |
| DITNC, | CRL-2005 | rat | P+ | |
| H4-II-E-C3 | CRL-1600 | rat | P+ | |
| ransferrin receptor (p90, CD71): TI | | | | |
| 8E5 | CRL-8993 [†] | human | R+ | |
| BC-3 | CRL-2277 | human | A+ | |
| NCI-H929 | CRL-9068 [†] | human | R+ | |
| SUP-B15 | CRL-1929 | human | A+ | |
| SUP-T1 [VB] | CRL-1942 | human | R- | |
| 301-111401 | | | | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|---|---------------------------------|---------------------------------|---|---------------------------------|
| L5.1 | HB-84 | mouse/mouse | MAb | Anti human transferrin receptor |
| OKT 9 | CRL-8021 [†] | mouse/mouse | MAb | Anti human transferrin receptor |
| ansferrin receptor: Trfr, 22042 | | | | |
| R17 208.2 | TIB-220 | rat/mouse | MAb | Anti mouse transferrin receptor |
| R17 217.1.3 | TIB-219 | rat/mouse | MAb | Anti mouse transferrin receptor |
| nsforming growth factor, alpha: | | | | |
| AML12 | CRL-2254 | mouse | P+ (human) | |
| NCI-H23 | CRL-5800 | human | P+ | |
| SW620 | CCL-227 | human | P+ | |
| ansforming growth factor, alpha: | | Haman | | |
| FAT 7 | CRL-2109 | rat | P+ | |
| ansforming growth factor, alpha: | | Tut | | |
| MDA-MB-231 | HTB-26 | human | R+ | |
| MDA-MB-468 | HTB-132 | human | R+ | |
| NCI-H23 | CRL-5800 | human | R+ | |
| NCI-H661 | HTB-183 | human | R- | |
| ansforming growth factor, beta1 (| | | n- | |
| beta2: | TGFB2, 7042 OR | isease): IUFD I, /U4U OK | | |
| | TGFB3, 7043 | | | |
| SW480 | CCL-228 | human | P+ | |
| WiDr | CCL-218 | human | P+ | |
| ansforming growth factor, beta1: | | | | |
| | : Tgfb2,81809 OR | | | |
| | : Tgfb3, 25717 | | | |
| NR8383 | CRL-2192 | rat | P+ | |
| nsforming growth factor, beta1 (| (Camurati-Engelmann d | isease): TGFB1, 7040 | | |
| HCT 116 | CCL-247 | human | P+ | |
| HP75 | CRL-2506 | human | P+ | |
| LS1034 | CRL-2158 | human | P- | |
| LS411N | CRL-2159 | human | P+ | |
| LS513 | CRL-2134 | human | P+ | |
| ansforming growth factor, beta 2: | TGFB2, 7042 | | | |
| HCT 116 | CCL-247 | human | P+ | |
| HP75 | CRL-2506 | human | P+ | |
| ansforming growth factor, beta 2 | | | | |
| 1D11.16.8 | HB-9849 [†] | mouse/mouse | MAb | Anti bovine transforming growth |
| .5 | | | 111110 | factor beta 2 (TGF-beta 2) |
| ansforming growth factor, beta 3: | TGFB3, 7043 | | | idetor beta 2 (1-Gr beta 2) |
| HP75 | CRL-2506 | human | P+ | |
| ansforming growth factor, beta re | | | | |
| | ceptor II (70-80kD): TGF | | ,. 1 C 1 D 1(1) 7 C 1 C C N | |
| | ceptor III (beta glycan, 3 | | | |
| DMS 53 | CRL-2062 | human | R+ | |
| NCI-H23 | CRL-5800 | human | R+ | |
| NCI-H661 | HTB-183 | human | R+ | |
| nsforming growth factor, beta re | | | | |
| MG-63 | CRL-1427 | | | |
| HP75 | CRL-1427 CRL-2506 | human | R+ | |
| Saos-2 | | human | R+ | |
| | HTB-85 | human | R+ | |
| insforming growth factor, beta re | | | D. | |
| HP75 | CRL-2506 | human | R+ | |
| MG-63 | CRL-1427 | human | R+ | |
| Saos-2 | HTB-85 | human | R+ | |
| ansforming growth factor, beta re | | | | |
| HP75 | CRL-2506 | human | R+ | |
| ansforming growth factor, beta b | | | or beta binding protei | n. |
| ppomyosin 1 (alpha): TPM1, 716 8 | | | | |
| QM7 | CRL-1962 | Japanese quail | P+ | |
| pomyosin 2 (beta): TPM2, 7169 | | | | |
| 162-46.2 | HB-187 | mouse/mouse | MAb | Anti human trop-2 antigen |
| | | | | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Cell Line Nam | elD e ATCC® No. | Species | Expresses | Comments |
|----------------------------------|--|------------------------|-----------|--|
| | | <u> </u> | Expresses | Comments |
| | , 7134 (human; quail gene not yet | | | |
| QM7 | CRL-1962 | Japanese quail | P+ | |
| | NT2, 7139 (human; quail gene not y | | | |
| QM7 | CRL-1962 | Japanese quail | P+ | |
| roponin I, skeletal, slow | | | | |
| | TNNI2, 7136 (human; quail gene no | | | |
| QM7 | CRL-1962 | Japanese quail | P+ | |
| roponin T1, skeletal, slo | | | | |
| | t: TNNT3, 7140 (human; quail gene | | D : | |
| QM7 | CRL-1962 | Japanese quail | P+ | |
| ubulin | CDL 10442† | la como a se | D.: | |
| HCN-1A | CRL-10442 [†] | human | P+ | |
| HCN-2 | CRL-10742 [†] | human | P+ | |
| MDA-MB-330 | | human | P+ | |
| MDA-MB-435 | | human | P+ | |
| MDA-MB-436 | | human | P+ | |
| Neuro-2a RL-65 | CCL-131 | mouse | P+ | |
| | CRL-10354 [†] | rat | P+ | |
| umor-associated antige Ca Ski | CRL-1550 | human | P+ | |
| | m signal transducer 1: TACSTD1, 4 0 | | P+ | |
| HCC1008 | CRL-2320 | human | P+ | |
| HCC1143 | CRL-2320 CRL-2321 | human | P+ | |
| HCC1187 | CRL-2321 | human | P+ | |
| HCC1395 | CRL-2324 | human | P+ | |
| HCC1419 | CRL-2324 | human | P+ | |
| HCC1419 | CRL-2327 | human | P+ | |
| HCC1500 | CRL-2329 | human | P+ | |
| HCC1569 | CRL-2330 | human | P+ | |
| HCC1599 | CRL-2331 | human | P+ | |
| HCC1806 | CRL-2335 | human | P+ | |
| HCC1937 | CRL-2336 | human | P+ | |
| HCC1954 | CRL-2338 | human | P+ | |
| HCC202 | CRL-2316 | human | P+ | |
| HCC2157 | CRL-2340 | human | P+ | |
| HCC2218 | CRL-2343 | human | P+ | |
| HCC38 | CRL-2314 | human | P+ | |
| HCC70 | CRL-2315 | human | P+ | |
| | NF superfamily, member 2): TNF, 71 | | | |
| HL-60 | CCL-240 | human | P+ | |
| HuT 78 | TIB-161 | human | P+ | |
| SK-N-FI | CRL-2142 | human | P+, R+ | Responsive |
| TALL-104 | CRL-11386 [†] | human | P+ | |
| U-937 | CRL-1593.2 | human | P+ | |
| H36.12j | CRL-2449 | mouse | P+ | Upon direct beryllium stimulation |
| | ceptor superfamily, member 1a: Tn f | | | , |
| 9TR#1 | CRL-11379 [†] | mouse | R- | Disrupted receptor (TNFR) p55 gene |
| umor necrosis factor re | ceptor superfamily, member 5: TNF | RSF5, 958 | | |
| Farage | CRL-2630 | human | A+ | |
| GA-10 | CRL-2392 | human | A+/- | 10% positive |
| 3A8 | HB-12024 [†] | mouse/mouse | MAb | Anti human CD40 |
| G28-5 | HB-9110 | mouse/mouse | MAb | Anti Bp50 (CD40, human B cell antigen) |
| | gand) superfamily, member 5 (hype | | | |
| 5c8 | HB-10916 [†] | mouse/mouse | MAb | Anti human CD40L ligand |
| hCD40L-M90 | HB-12055 [†] | mouse/mouse | MAb | Anti human CD40L ligand |
| hCD40L-M91 | HB-12056 [†] | mouse/mouse | MAb | Anti human CD40L ligand |
| | gand) superfamily, member 5: Tnfst | | | |
| MR1 | CRL-2580 | Armenian hamster/mouse | MAb | Anti mouse CD40L ligand |
| | ceptor superfamily, member 6: TNF | | | |
| | CRL-1593.2 | • | A+ | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|-----------------------------|--------------------------|-----------------------------------|------------------|--|
| VA-ES-BJ | CRL-2138 | human | A+ | |
| huFasM3 | HB-11726 [†] | mouse/mouse | MAb | Anti human Fas |
| huFasM38 | HB-11465 [†] | mouse/mouse | MAb | Anti human Fas |
| necrosis factor receptor su | perfamily, member 8: TNF | RSF8, 943 | | |
| BC-1 | CRL-2230 | human | A+ | |
| BC-3 | CRL-2277 | human | A+ | |
| DS-1 | CRL-11102 [†] | human | A- | |
| HH | CRL-2105 | human | A+ | |
| protein p53 (Li-Fraumeni s | | | | |
| AU565 | CRL-2351 | human | 0+ | |
| C-33 A | HTB-31 | human | 0+ | Point mutation at codon 273 resulting in a Arg \rightarrow Cys substitution. |
| COLO 201 | CCL-224 | human | 0+ | III a Aig → Cys substitution. |
| DLD-1 | CCL-224 | human | O+ | $C \rightarrow T$ mutation resulting in Ser \rightarrow Phe |
| | | at position 241. | | C → Findtation resulting in Ser → Prie |
| HCC38 | CRL-2314 | human | 0+ | |
| HCC70 | CRL-2315 | human | 0+ | Overexpressed |
| HCC1008 | CRL-2320 | human | 0+ | |
| HCC1143 | CRL-2321 | human | 0+ | |
| HCC1187 | CRL-2322 | human | 0+ | Overexpressed |
| HCC1395 | CRL-2324 | human | 0+ | |
| HCC1419 | CRL-2326 | human | O- | |
| HCC1428 | CRL-2327 | human | O- | |
| HCC1500 | CRL-2329 | human | 0+ | |
| HCC1569 | CRL-2330 | human | 0- | |
| HCC1599 | CRL-2331 | human | 0- | |
| HCC1806 | CRL-2335 | human | 0- | |
| HCC1937 | CRL-2336 | human | 0- | |
| HCC202 | CRL-2316 | human | 0- | |
| HCC2157 | CRL-2340 | human | 0+ | |
| HCC2218 | CRL-2343 | human | 0+ | |
| HP75 | CRL-2506 | human | 0+ | Overexpressed |
| HT-29 | HTB-38 | human | 0+ | $G \rightarrow A$ mutation in codon 273 resulting |
| => | | in an Arg \rightarrow His subst | | 2 //atation codo 2/ 0 / codining |
| HT-3 | HTB-32 | human | 0+ | Point mutation at codon 245 resulting in a Gly \rightarrow Val substitution. |
| LN-18 | CRL-2610 | human | 0+ | TGT (Cys) → TCT (Ser) mutation at codon 238 |
| LN-229 | CRL-2611 | human | 0+ | CCT (Pro) \rightarrow CTT (Leu) mutation at |
| LNZTA3WT11 | CRL-11544 [†] | human | 0+ | codon 98 Wild type |
| LNZTA3WT1 | | | | ,, |
| | CRL-11543† | human | O+ O+ | Wild type |
| Loucy | CRL-2629 | human | | Overexpressed; mutated, GTG → ATG mutation at codon 272 |
| LoVo | CCL-229 | human | 0+ | |
| LS1034 | CRL-2158 | human | 0+ | Gly \rightarrow Ser mutation at position 245 |
| LS 174T | CL-188 | human | 0+ | mRNA expression |
| LS 180 | CL-187 | human | 0– | |
| LS513 | CRL-2134 | human | 0+ | Wild type |
| MDA-MB-468 | HTB-132 | human | O+ | $G \rightarrow A$ mutation in codon 273 gene |
| | | resulting in an Arg $ ightarrow$ | His substitution | |
| ME-180 | HTB-33 | human | 0+ | |
| MOLT-4 | CRL-1582 | human | 0+ | Not expressed; $G \rightarrow A$ mutation at codon 248 |
| NCI-H1299 | CRL-5803 | human | 0- | Homozygous partial deletion of the p53 protein; lacks expression of p53 protein. |
| | | | | h l |
| NCI-H187 | CRL-5804 | human | 0+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

* Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Name: Symbol, GeneID | | | | |
|---|------------------------|------------------------------------|----------------------|---|
| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
| umor protein p53 (Li-Fraumeni syndro | me) continued | | | |
| NCI-H23 | CRL-5800 | human | 0+ | Mutation in codon 246 (ATC \rightarrow ATG, Ile \rightarrow Met) |
| NCI-H345 | HTB-180 | human | 0+ | |
| NCI-H378 | CRL-5808 | human | O+ | |
| NCI-H460 | HTB-177 | human | 0+ | |
| NCI-H520 | HTB-182 | human | O+ | Underexpressed |
| NCI-H522 | CRL-5810 | human | O+ | Mutation in codon 191 |
| NCI-H526 | CRL-5811 | human | 0+ | |
| NCI-H596 | HTB-178 | human | 0+ | |
| NCI-H661 | HTB-183 | human | O+ | |
| NCI-H676B | HTB-179 | human | O+ (2.3 kb) as we | Produces an abnormally sized p53 mRNA Il as the normal size |
| mRNA (2.8 kb) | | | | |
| NCI-H727 | CRL-5815 | human | 0+ | |
| NCI-H82 | HTB-175 | human | 0+ | Produces an abnormally sized p53 mRNA (3.7 kb) |
| NCI-H889 | CRL-5817 | human | 0+ | Underexpressed |
| NCI-N417 | CRL-5809 | human | 0+ | Underexpressed |
| OV-90 | CRL-11732 [†] | human | 0+ | Ser \rightarrow Arg mutation at exon 6, codon 215 |
| PL45 | CRL-2558 | human | 0+ | Mutation at codon 255 where an ATC |
| | | → AAC mutation re | sulted in | |
| substitution of Asx for Ile. | | | | |
| RKO | CRL-2577 | human | 0+ | Wild type |
| RKO-AS45-1 | CRL-2579 | human | 0+ | Underexpressed |
| RKO-E6 | CRL-2578 | human | 0- | Lacks appreciable functional p53 |
| TOV-112D | CRL-11731 [†] | human | 0+ | Arg \rightarrow His mutation at exon 6, codon 175 |
| TOV-21G | CRL-11730 [†] | human | 0+ | Wild type |
| SiHa | HTB-35 | human | 0+ | |
| SK-CO-1 | HTB-39 | human | 0+ | |
| SW1116 | CCL-233 | human | 0+ | |
| SW1417 | CCL-238 | human | 0- | |
| SW480 | CCL-228 | human | 0+ | Mutation in codon 273 and codon 309 |
| SW620 | CCL-227 | human | 0+ | Mutation in codon 273 resulting in an |
| | | $Arg \rightarrow His substitution$ | on | |
| SW837 | CCL-235 | human | O+ | $C \rightarrow T$ mutation in codon 248 resulting |
| | | in an Arg \rightarrow Trp sub | stitution | |
| SW948 | CCL-237 | human | 0+ | |
| VA-ES-BJ | CRL-2138 | human | 0+ | |
| WiDr | CCL-218 | human | 0+ | $G \rightarrow A$ mutation resulting in Arg \rightarrow His at position 273 |
| ransformation related protein 53: Trp5 | | | | |
| 7F2 | CRL-12557† | mouse | 0- | p53 knockout mouse |
| FAK-/- | CRL-2644 | mouse | 0- | |
| FAK+/+ | CRL-2645 | mouse | 0- | |
| p53NiS1 | CRL-2619 | mouse | 0+ | Deletion in exon 5 |
| umor-specific antigen T24 | HTB-4 | human | P+ | |
| yrosine aminotransferase: Tat, 24813 H4-II-E-C3 | CRL-1600 | rat | P+ | |
| yrosine hydroxylase: Th, 21823 | | | | |
| NB41A3 | CCL-147 | mouse | P+ | |
| N1E-115 | CRL-2263 | mouse | P+ | |
| yrosine hydroxylase: Th, 25085 | 601 611-61 | | | |
| CATH.a | CRL-11179 [†] | mouse | P+ (rat) | |
| Ubiquitin cross-reactive protein (UCRP) | | | | |
| BEND | CRL-2398 | bovine | P+ | |
| racil-DNA glycosylase: UNG, 7374 | LID costs! | | *** | 100 |
| 37.04.12 | HB-9312 [†] | mouse/mouse | MAb | Anti human UDG |
| 40.10.09 | HB-9311 [†] | mouse/mouse | MAb | Anti human UDG |
| 42.08.07 | HB-9313 [†] | mouse/mouse | MAb | Anti human UDG |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---|---|---|--------------------------------------|
| | | • | | |
| Urokinase receptor (u-PAR). See P | lasminogen activator, urol | inase receptor. | | |
| v-abl. See abl. | 1 11 1 1 1 1 | | | |
| Vascular addressin. See Mucosal v | | esion molecule 1. | | |
| Vascular cell adhesion molecule 1 | | In community | Δ. | |
| HS-27A | CRL-2496 | human | A+ | A-4:VCAAA 1 - f |
| VIII-6G10 Vascular cell adhesion molecule 1 | HB-10519 [†] | mouse/mouse | MAb | Anti VCAM-1 of human and macaque |
| 2F-2B | CRL-2168 | | Λ. | |
| | | mouse | A+ | |
| 2H-11 3B-11 | CRL-2163 CRL-2160 | mouse | A+ A+ | |
| bEnd.3 | CRL-2100 | mouse mouse | A+ | |
| C166 | CRL-2581 | mouse | A+ | |
| IP-1B | CRL-2361 CRL-2162 | mouse | A+ | |
| IP2-E4 | CRL-2171 | mouse | A+ | |
| SVEC4-10 | CRL-2171 | mouse | A+ | |
| SVEC4-10EE2 | CRL-2167 | mouse | A+ | |
| SVEC4-10EHR1 | CRL-2161 | mouse | A+ | |
| M/K-1.9 | CRL-2101 | rat/mouse | MAb | Anti mouse VCAM-1 |
| M/K-1.9 | CRL-1910 | rat/mouse | MAb | Anti mouse VCAM-1 |
| Vascular endothelial growth factor | | | 111110 | , and model vertiff i |
| /asoactive intestinal peptide rece | | . ac.nam recepton | | |
| NCI-N87 | CRL-5822 | human | R+/- | |
| SNU-1 | CRL-5971 | human | R+ | |
| SNU-16 | CRL-5974 | human | R+ | |
| SNU-5 | CRL-5973 | human | R+ | |
| Vasoactive intestinal peptide rece | | | | |
| N1E-115 | CRL-2263 | mouse | R+ | |
| Vasopressin-neurophysin (VP-NT |). See Arginine vasopressir | | | |
| v-erb B. See erb. | , , | | | |
| Very low density lipoprotein rece | ptor: VLDLR, 7436 | | | |
| IgG-6A6 | CRL-2197 | mouse/mouse | MAb | Anti VLDL receptor (various species) |
| v-fes. See Feline sarcoma oncoger | ne. | | | |
| v-fms. See Colony stimulating fact | or 1 receptor. | | | |
| Vimentin: VIM, 7431 | | | | |
| COLO 320DM | CCL-220 | human | P+ | |
| COLO 320HSR | CCL-220.1 | human | | |
| DBTRG-05MG | CC2 220 | Hallian | P+ | |
| סואוכט סווויסים | CRL-2020 | human | P+ P+ | |
| HCN-1A | | | | |
| | CRL-2020 | human | P+ | |
| HCN-1A | CRL-2020 CRL-10442 [†] | human human | P+ P+ | |
| HCN-1A HCN-2 | CRL-2020 CRL-10442 [†] CRL-10742 [†] | human human human | P+ P+ P+ | |
| HCN-1A HCN-2 HPAC | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 | human human human human | P+ P+ P+ P- | |
| HCN-1A HCN-2 HPAC MeT-5A | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] | human human human human human | P+ P+ P+ P- P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 | human human human human human human | P+ P+ P+ P- P+ P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 | human human human human human human human | P+ P+ P+ P- P+ P+ P- | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 | human human human human human human human human | P+ P+ P+ P- P+ P+ P- P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 | human | P+ P+ P+ P- P+ P+ P- P+ P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 | human | P+ P+ P+ P- P+ P- P+ P- P+ P- P+ P+ P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H460 NCI-H520 NCI-H522 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 HTB-182 CRL-5810 | human | P+ P+ P+ P- P+ P- P+ P- P+ P+ P+ P+ P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H460 NCI-H520 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 | human | P+ P+ P+ P- P+ P- P+ P+ P+ P+ P+ P+ P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H460 NCI-H520 NCI-H522 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 HTB-182 CRL-5810 | human | P+ P+ P+ P- P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H292 NCI-H292 NCI-H200 NCI-H520 NCI-H522 NCI-H524 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 HTB-182 CRL-5810 CRL-5831 | human | P+ P+ P+ P- P+ P- P+ P+ P+ P+ P+ P+ P+ P+ P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H292 NCI-H460 NCI-H520 NCI-H524 NCI-H596 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 HTB-182 CRL-5810 CRL-5831 HTB-178 | human | P+ P+ P+ P- P+ P- P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H292 NCI-H460 NCI-H520 NCI-H524 NCI-H596 NCI-H661 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 HTB-182 CRL-5810 CRL-5831 HTB-178 HTB-178 | human | P+ P+ P+ P- P+ P- P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H292 NCI-H460 NCI-H520 NCI-H520 NCI-H524 NCI-H596 NCI-H661 NCI-H69 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 HTB-182 CRL-5810 CRL-5831 HTB-178 HTB-178 HTB-183 HTB-119 | human | P+ P+ P+ P- P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H292 NCI-H460 NCI-H520 NCI-H520 NCI-H524 NCI-H596 NCI-H661 NCI-H69 NCI-H82 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 HTB-182 CRL-5810 CRL-5831 HTB-178 HTB-178 HTB-183 HTB-119 HTB-175 | human | P+ P+ P+ P- P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H292 NCI-H460 NCI-H520 NCI-H520 NCI-H524 NCI-H524 NCI-H596 NCI-H661 NCI-H69 NCI-H82 NCI-H82 | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 HTB-182 CRL-5810 CRL-5831 HTB-178 HTB-178 HTB-178 HTB-183 HTB-119 HTB-175 CRL-5809 | human | P+ P+ P+ P- P+ | |
| HCN-1A HCN-2 HPAC MeT-5A NCCIT NCI-H128 NCI-H146 NCI-H23 NCI-H292 NCI-H460 NCI-H520 NCI-H520 NCI-H524 NCI-H524 NCI-H596 NCI-H661 NCI-H69 NCI-H82 NCI-H82 NCI-H82 NCI-H817 VA-ES-BJ | CRL-2020 CRL-10442 [†] CRL-10742 [†] CRL-2119 CRL-9444 [†] CRL-2073 HTB-120 HTB-173 CRL-5800 CRL-1848 HTB-177 HTB-182 CRL-5810 CRL-5831 HTB-178 HTB-178 HTB-178 HTB-183 HTB-119 HTB-175 CRL-5809 | human | P+ P+ P+ P- P+ | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

* Part of the NBL collection; see page 12. $\,^+$ Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.



| Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---|---|---|--|
| | 711 44 1101 | - Species | =xp:coses | |
| Vimentin: Vim, 81818 | CD1 0.000 | | | |
| EGC/PK060399egfr | CRL-2690 | rat | P+ | |
| NMU | CRL-1743 | rat | P- | |
| RBA | CRL-1747 | rat | P- | |
| RL-65 | CRL-10354 [†] | rat | P+ | |
| RMC | CRL-2573 | rat | P+ | |
| /itamin D (1,25- dihydroxyvitamin D3 | | | | |
| HT-29 | HTB-38 | human | R+ | |
| /itamin D receptor: Vdr, 24873 | | | | |
| UMR-106 | CRL-1661 | rat | R+ | Responsive |
| UMR-108 | CRL-1663 | rat | R+ | Responsive |
| Vitamin D receptor (species not yet c | urated) | | | |
| XVI E6E6G10 | HB-9496 [†] | mouse/mouse | MAb | Anti porcine receptor for 1,25- |
| | | | | dihydroxy vitamin D3 |
| /itronectin receptor: VTNR, 7449 | | | | |
| 293 | CRL-1573 | human | R+ | |
| CMVα1 WSS-1 | CRL-2029 | human | R+ | |
| B6H12. | HB-9771 [†] | mouse/mouse | MAb | Anti human integrin associated |
| | | | | protein (CD47) and vitronectin |
| | | | | receptor (VnR) |
| /LA-1. See Integrin, alpha 1. | | | | |
| /LA-4. See Integrin, alpha 4. | | | | |
| ı-myb. See myb. | | | | |
| on Willebrand factor: VWF, 7450 | | | | |
| HK-2 | CRL-2190 | human | A- | |
| on Willebrand factor homolog: Vwf, | | | | |
| EOMA | CRL-2586 | mouse | A+ | |
| MS1 (MILE SVEN 1) | CRL-2279 | mouse | A+ | |
| SV40 MES 13 | CRL-1927 | mouse | A- | |
| SVEC4-10 | CRL-2181 | mouse | A+ | |
| SVEC4-10 SVEC4-10EE2 | CRL-2167 | mouse | A+ | |
| von Willebrand factor product | CNL-2107 | mouse | АТ | |
| bEnd.3 | CRL-2299 | mouse | P+ | |
| v-sis. See Platelet-derived growth fact | | | ГТ | |
| · · · · · · · · · · · · · · · · · · · | tor receptor, beta poryp | Deptide. | | |
| v-src. See src. Wingless-related MMTV integration s | ita 2 A . W. +2 - 22416 | | | |
| wingless-related wiwi v integration s | CRL-2647 | | O+ | C . I' I . II M 2A |
| | | | | Secretes biologically active Wnt-3A protien |
| L Wnt-3A | | mouse | UΤ | secretes storogram, active time six protier. |
| L Wnt-3A Wingless-type MMTV integration site | family member 2: WN | T2,7472 | | p. o.c. |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA | e family member 2: WN HTB-111 | T2,7472 human | 0- | beauties moneycain, earne mees, process |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 | e family member 2: WN HTB-111 HTB-19 | T2,7472 human human | 0- 0- | beauties shoregrean, earlier me six promeir |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A | e family member 2: WN HTB-111 HTB-19 HTB-112 | T2, 7472 human human human | 0- 0- 0- | beauties shoregreatly technic fire on protection |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 | T2,7472 human human human human | 0- 0- 0- 0- | beauties shoregreatly technic fire on protection |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 | T2,7472 human human human human human human | 0- 0- 0- 0- 0- | beauties shoregreatly technic time st. protection |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 | T2,7472 human human human human human human human | 0- 0- 0- 0- 0- 0- | beauties shoregreatly technic three strains and the |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 | T2,7472 human human human human human human | 0- 0- 0- 0- 0- 0- 0- | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 | T2,7472 human human human human human human human | 0- 0- 0- 0- 0- 0- 0- 0- | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- | beauties shoughtup teeting the street of the |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D Wingless-type MMTV integration site | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 e family, member 3: WN | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D Wingless-type MMTV integration site AN3 CA | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 e family, member 3: WN | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D Wingless-type MMTV integration site AN3 CA BT-20 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 e family, member 3: WN HTB-111 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 e family, member 3: WN HTB-111 HTB-19 HTB-19 HTB-112 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 e family, member 3: WN HTB-111 HTB-19 HTB-19 HTB-112 HTB-24 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0 | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-157 MDA-MB-231 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 e family, member 3: WN HTB-111 HTB-19 HTB-112 HTB-12 HTB-24 HTB-24 HTB-24 HTB-24 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0 | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-157 MDA-MB-231 MDA-MB-231 MDA-MB-231 MDA-MB-231 MDA-MB-361 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 e family, member 3: WN HTB-111 HTB-19 HTB-112 HTB-24 HTB-24 HTB-24 HTB-24 HTB-24 HTB-26 HTB-26 HTB-27 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0 | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-231 MDA-MB-361 MDA-MB-415 RL95-2 T-47D Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-157 MDA-MB-231 MDA-MB-231 MDA-MB-361 MDA-MB-361 MDA-MB-361 MDA-MB-361 MDA-MB-415 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 e family, member 3: WN HTB-111 HTB-19 HTB-112 HTB-24 HTB-24 HTB-24 HTB-24 HTB-24 HTB-24 HTB-26 HTB-27 HTB-128 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0 | |
| L Wnt-3A Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-361 MDA-MB-415 RL95-2 T-47D Wingless-type MMTV integration site AN3 CA BT-20 HEC-1-A MCF7 MDA-MB-157 MDA-MB-157 MDA-MB-157 MDA-MB-231 MDA-MB-231 MDA-MB-231 MDA-MB-361 | e family member 2: WN HTB-111 HTB-19 HTB-112 HTB-22 HTB-24 HTB-26 HTB-27 HTB-128 CRL-1671 HTB-133 e family, member 3: WN HTB-111 HTB-19 HTB-112 HTB-24 HTB-24 HTB-24 HTB-24 HTB-24 HTB-26 HTB-26 HTB-27 | T2,7472 human | 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0 | |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

 $[\]textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---------------------------------------|-------------------|----------------------|---------------------------------------|
| | | · · | Expresses | Comments |
| Wingless-type MMTV integration | | | | |
| BT-20 | HTB-19 | human | 0- | |
| MCF7 | HTB-22 | human | 0+ | |
| MDA-MB-157 | HTB-24 | human | 0- | |
| MDA-MB-231 | HTB-26 | human | 0- | |
| MDA-MB-361 | HTB-27 | human | 0- 0- | |
| MDA-MB-415 | HTB-128 | human | | |
| NTERA-2 cl.D1 T-47D | CRL-1973 | human | 0+ | |
| | HTB-133 | human | 0- | |
| /ingless-type MMTV integration : AN3 CA | HTB-111 | human | 0- | |
| BT-20 | HTB-11 | | 0- | |
| HEC-1-A | HTB-112 | human human | 0- | |
| MCF7 | HTB-22 | human | 0- | |
| | | | 0- | |
| MDA-MB-157 | HTB-24 | human | 0- | |
| MDA-MB-231 MDA-MB-361 | HTB-26 | human | 0- | |
| | HTB-27 | human | | |
| MDA-MB-415 | HTB-128 | human | 0+ | |
| RL95-2 T-47D | CRL-1671 HTB-133 | human | O+ O- | |
| /ingless-type MMTV integration | | human | 0- | |
| | · · · · · · · · · · · · · · · · · · · | | 0- | |
| AN3 CA | HTB-111 | human | 0- | |
| HEC-1-A | HTB-112 CRL-1671 | human | O+/- | |
| RL95-2 | | human | U+/- | |
| Vingless-type MMTV integration : AN3 CA | HTB-111 | | 0- | |
| BT-20 | HTB-11 | human | 0- | |
| | | human | 0 - 0+ | |
| HEC-1-A | HTB-112 HTB-22 | human | 0+ | |
| MCF7 | | human | 0- | |
| MDA-MB-157 | HTB-24 | human | 0- | |
| MDA-MB-231 | HTB-26 | human | 0- | |
| MDA-MB-361 | HTB-27 | human | 0- | |
| MDA-MB-415 | HTB-128 | human | | |
| RL95-2 T-47D | CRL-1671 HTB-133 | human | 0+ 0- | |
| | | human | 0- | |
| /ingless-type MMTV integration | • | | | |
| AN3 CA | HTB-111 | human | 0- | |
| BT-20 | HTB-19 | human | 0+ | |
| HEC-1-A | HTB-112 | human | 0+ | |
| MCF7 | HTB-22 | human | 0+ | |
| MDA-MB-157 | HTB-24 | human | 0+ | |
| MDA-MB-231 | HTB-26 | human | 0+ | |
| MDA-MB-361 | HTB-27 | human | 0+ | |
| MDA-MB-415 | HTB-128 | human | 0+ | |
| RL95-2 | CRL-1671 | human | 0+ | |
| T-47D | HTB-133 | human | 0+ | |
| /ingless-type MMTV integration | · · · · · · · · · · · · · · · · · · · | | | |
| AN3 CA | HTB-111 | human | 0+ | |
| HEC-1-A | HTB-112 | human | 0- | |
| RL95-2 | CRL-1671 | human | 0+ | |
| -yes-1 Yamaguchi sarcoma viral o | | | | |
| 240-13D10 | CRL-2672 | mouse/mouse | MAb | Anti c-yes synthetic oncogene peptide |
| amaguchi sarcoma viral (v-yes) o | | | | |
| SYF | CRL-2459 | mouse | 0- | |
| eta-chain (TCR) associated protei | | | | |
| P116 | CRL-2676 | human | P- | |
| P116.cl39 [P116.c39] | CRL-2677 | human | P+ | |
| O-1 (tight junction protein). See T | <u> </u> | ona occludens 1). | | |
| ona pellucida glycoprotein 1: Zp | | | | |
| M1.4 | CRL-2464 | rat/mouse | MAb | Anti mouse ZP1 glycoprotein |
| | | | | |

 $\textbf{Expresses:} \ P = product, A = antigen, O = oncogene, R = receptor, MAb = monoclonal \ antibody.$

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics. The ATCC catalogue marks (e.g. ATCC® No. CRL-1647 $^{\text{TM}}$) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



| Name: Symbol, GeneID Cell Line Name | ATCC® No. | Species | Expresses | Comments |
|--|---------------------------------|-------------|-----------|-----------------------------|
| Zona pellucida glycoprotein 2 (sp | erm receptor): ZP2, 7783 | | | |
| H2.8 | CRL-2568 | mouse/mouse | MAb | Anti human ZP2 glycoprotein |
| Zona pellucida glycoprotein 2: Zp | 2,22787 | | | |
| IE-3 | CRL-2463 | rat/mouse | MAb | Anti mouse ZP2 glycoprotein |

^{*} Part of the NBL collection; see page 12. † Patent item; see page 12. See the ATCC online catalogue for the complete description of a cell line.



Notes



Notes

Section IV: Technical Information



Getting started with an ATCC cell line $\,$

Cell growth and propagation

Complete growth media

Culture vessels and surfaces

Cryopreservation

Contamination

Biosafety

Glossary

Formulations of media not available

from ATCC

References

Cooperation partners

Disclaimers

Material Transfer Agreement



Getting Started with an ATCC Cell Line

ATCC cell lines and hybridomas are shipped frozen on dry ice in cryopreservation vials or as growing cultures in flasks at ambient temperature. Upon receipt of frozen cells, it is important to immediately revive them by thawing and removing the DMSO and placing them into culture. If this is not possible, store the cells in liquid nitrogen vapor (below –130°C). Do not store frozen cells at temperatures above –130°C as their viability will decline rapidly.

Product Information Sheet

ATCC cell lines come with a Product Information Sheet that contains detailed information for handling the cells. An abbreviated version may be found at the ATCC website or call ATCC Technical Service Department to request a copy. The Product Information Sheet also contains batch-specific information such as the number of cells per vial, the recommended split or subcultivation ratio, and the passage number when known.

Preparation of medium

Prepare for reviving cell lines by assembling the appropriate medium, serum, and additional reagents required for growth. Many of these products are available from ATCC and can be ordered with the cell lines (see page 19 for a complete listing). These are the same reagents used by ATCC for cell growth and preservation.

NOTE: While most cell lines can replicate in more than one culture medium, their characteristics may alter when the medium is changed. For this reason, starting cell cultures in the same medium used by ATCC is recommended for the best results (see the Product Information Sheet and ATCC website). For details on adapting a cell line to a new medium, see page 262.

Initiating frozen cultures

- Prepare a culture vessel so that it contains the recommended volume of the appropriate culture medium as listed on the Product Information Sheet, equilibrated for temperature and pH (CO₃).
- Thaw the vial by gentle agitation in a water bath at 37°C or the normal growth temperature for that cell line. Thawing should be rapid, approximately 2 minutes or until ice crystals have melted.
- Remove the vial from the water bath and decontaminate it by dipping in or spraying with 70% ethanol. Follow strict aseptic conditions in a laminar flow tissue culture hood for all further manipulations.
- 4. Unscrew the top of the vial and transfer the contents to a sterile centrifuge tube containing 9 ml of the recommended medium. Remove the cryoprotectant agent (DMSO) by gentle centrifugation (10 minutes at $125 \times g$). Discard the supernatant, and resuspend the cells in 1 or 2 ml of complete growth medium. Transfer the cell suspension into the culture vessel containing the complete growth medium and mix thoroughly by gentle rocking.
- 5. Examine the cultures after 24 hours. Subculture as needed.

NOTE: Some cell lines, such as hybridomas, take several days before fully recovering from cryopreservation. Some hybridomas have poor viability the first day in culture and will generate cellular debris. After this point, the cells will begin to recover and enter exponential growth.

Processing flask cultures

Some ATCC cell lines, primarily those from the NBL collection (page 12), are shipped as growing cultures in culture vessels. These vessels are seeded with cells, incubated to ensure cell growth and then filled completely with medium for shipping.

Upon receiving a flask culture, visually examine the medium for macroscopic evidence of microbial contamination. This includes unusual pH shifts (yellow or purple color from the phenol red), turbidity, or particles. With an inverted microscope at low power (100×) check the medium for evidence of microbial contamination as well as the morphology of the cells. See page 262 for more details on examining cell cultures.

If the cells are attached and growing in a monolayer:

- Aseptically remove all but 5 to 10 ml of the shipping medium.
 The shipping medium can be saved for reuse and should be stored at 4°C.
- Incubate the flask at the temperature and CO₂ concentration recommended on the Product Information Sheet (37°C with 5% CO₂ for most cell lines) until the cells are subcultured.

If the cells are not attached or are growing in suspension:

- Aseptically transfer the entire contents of the flask to a centrifuge tube.
- 2. Centrifuge at $125 \times g$ for 5 to 10 minutes.
- Remove all but 10 ml of the shipping medium supernatant and resuspend the cells. Store the remainder of this medium at 4°C for later use.
- Aseptically transfer the resuspended cells to a 25-cm² flask or 75-cm² flask, depending upon the cell line (see the Product Information Sheet).
- Incubate the cells at the temperature and CO₂ concentration recommended on the Product Information Sheet until cells are subcultured.



Most cell lines begin as primary cultures originating from a piece of minced or enzyme-dispersed tissue. Primary cultures, as mixtures of several cell types, retain the characteristics of their source tissue.

After a period of time, primary cultures will reach confluency, the state when all available space of the culture vessel is covered due to cellular expansion. At this point, the culture will need to be disaggregated (usually with proteolytic enzymes like trypsin) into individual cells and subcultured (split, passaged, or transferred). Following this first passage, the culture is generally referred to as a cell line. With each subsequent subculture, the cellular population becomes more homogeneous as the faster growing cells predominate. Cells with desired properties can also be selected out of the culture by cloning.

Diploid cell lines rarely progress beyond a few population doublings. They have a finite replicative capacity and begin to slow down and eventually stop dividing after 20 to 80 population doublings.¹ Recent evidence suggests that some of the observed cellular senescence in cell culture may be due to inappropriate culture conditions as opposed to a predetermined replicative senescence.² Still other data support replicative senescence for the cells of some species (notably human) even when grown in improved culture conditions. This senescence is mediated by the shortening of the ends of the chromosomes (telomeres) with each cell division.³

In contrast, continuous (or immortalized) cell lines have infinite replicative capacity. These lines are derived from cell lines through immortalization or transformation by any one of a number of means. Many continuous cell lines were derived from tumor tissue. Most of the cell lines in the ATCC collection are continuous, though a few, such as CCD-1117Sk human skin fibroblast (ATCC® CRL-2465) or CCD-18Co human colon (ATCC® CRL-1459™) are finite. For more information about ATCC immortalized cell lines see the website.

As noted in the section on culture vessels, cell lines grow either attached to a surface (anchorage dependent) or in suspension (anchorage independent). As cells grow and divide in a monolayer or in suspension, they usually follow a characteristic growth pattern composed of four phases: Lag, log or exponential, stationary or plateau and decline.

- Lag phase Immediately after seeding of the culture vessel, the cells grow slowly while recovering from the stress of subculturing.
- Log or exponential phase The cells enter a period of exponential growth that lasts until the entire growth surface is occupied or the cell concentration exceeds the capacity of the medium.
- Stationary phase Cell proliferation slows and stops.
- Decline phase If the culture medium is not replaced and the cell number is not reduced, the cells lose viability and their number decreases.

To ensure viability, genetic stability, and phenotypic stability, cell lines need to be maintained in the exponential phase. This means that they

need to be subcultured on a regular basis before they enter the stationary growth phase, before a monolayer becomes 100% confluent or before a suspension reaches its maximum recommended cell density. Generating a growth curve for each cell line is useful to determine the growth characteristics of the cell line (see Figure 1).

For detailed information on the growth and propagation of any ATCC cell line, see the specific cell line Product Information Sheet which is included with every shipment. An abbreviated version may also be found on the ATCC website, or call ATCC Technical Service to have one sent to you. The Product Information Sheet contains valuable information about growth medium, subculturing procedure, split ratio, and any requirements for feeding the culture between passages.

Passage number and population doubling level

Primary cultures are generally subcultured at a 1 to 2 ratio (they are split in half with each passage). Most continuous cell lines replicate at higher rates and are subcultured at a much higher split ratio. **Passage number** is generally the number of times the cells have been subcultured into a new vessel. For diploid cultures, passage number is roughly equal to the number of population doublings (or **population doubling level**, PDL) since the culture was started. This is not the case for continuous cell lines as they are passaged at higher split ratios. Consequently the PDL is not determined for continuous cell lines. In most cases, the PDL is an estimate as it does not account for any cells that were lost due to death from necrosis or apoptosis or cells which are nearing senescence and no longer divide.




Figure 1. Growth curve for cells grown in culture. Cells should be subcultured while still in the exponential phase.



Calculate the population doubling level with the following formula:

PDL = 3.32 (log Xe - log Xb) + S

Xb is the cell number at the beginning of the incubation time. Xe is the cell number at the end of the incubation time. S is the starting PDL.

Calculate the population doubling time, or the time required for a culture to double in number, with the following formula:

DT=T In2/In(Xe/Xb)

T is the incubation time in any units.

Xb is the cell number at the beginning of the incubation time. Xe is the cell number at the end of the incubation time.

NOTE: Cells grow at different rates in each of the different phases of the growth cycle and the calculated doubling time may be a composite of growth during more than one of these phases. Growth during exponential growth or log phase is fairly constant and reproducible for a given set of growth conditions.

ATCC tracks the PDL and passage number for many adherent cell lines when the depositor supplies this information at the time of deposit. See the Product Information Sheet for the specific cell line for the passage number and/or PDL as part of the batch-specific information supplied.

Adapting to a new medium or serum

To ensure that the characteristics of your cell line remain constant, maintain your cells in the same medium, serum, and supplements with the same subculturing regimen used to establish the culture. Any change to the culturing conditions has the potential to change the characteristics of the cell line.

Be particularly cautious when working with a new cell line as media formulations vary among suppliers, even for media with similar or identical names. Read descriptions, formulations, and labels carefully to ensure that the appropriate medium is used or the cell line may be inadvertently adapted to a new medium. All ATCC cell lines come with information on their growth medium. In most cases, the recommended medium and serum can be purchased from ATCC along with the cell line.

Use the following procedure to adapt a cell line to a new medium:

Subculture the line at a 1:2 split ratio (split the culture in half) into two vessels. Maintain one with the original medium and continue to subculture these cells for the entire adaptation process. Use a 1:1 mix of the original and new medium in the second vessel. The culture grown in the original medium serves as a reference point as well as a safeguard in case the adapting cells do not survive the process. The low split ratio helps

- mitigate the stress associated with subculturing as well as with the new medium.
- 2. Monitor cell growth in the two media and watch for any change in morphology or growth rate. If they are identical, subculture the adapting cells at the next passage with a 1:2 split ratio in a 1:3 medium mix (25% original, 75% new).
- Monitor the growth rate and morphology of the original and adapting cultures. At the next passage, split the adapting cultures 1:2 in a 1:7 medium mix (12.5% original, 87.5% new).
- 4. Monitor the growth rate and morphology of the original and adapting cultures. If the cells are identical, then at the next passage split the adapting cells 1:2 in 100% new medium. At this point, the culture should be adapted to the new medium.

To confirm complete adaptation to the new medium, perform functional tests on cells derived from the original and new medium. If at any point in the process the adapting culture fails to perform as well as the reference culture, then allow the adapting culture more time and a few more passages in their current medium mix (e.g., 1:3, 1:7, etc.) until they match the reference cells.

The same approach can be used to adapt cells to serum-free medium; simply decrease the serum level in the medium by half with each passage until a 0.06% (or lower) serum level is reached. At this point, the cells can be maintained in serum-free medium. If at any point the growth rate declines, then the serum level should be increased to the level where the cells grew normally. In this procedure, start with the "serum-free" medium supplemented with serum so that only the level of serum changes with each passage.

Temperature

Most animal cell lines require 37°C for optimum growth. Insect and amphibian cells require lower temperatures (such as 28°C) as do some animal cell lines which are temperature sensitive for their phenotypic characteristics. While cultured cells can withstand considerable drops in temperature and most can survive for several days at 4°C, few can tolerate even a few hours at more than 2°C above their optimal temperature.

NOTE: Regularly calibrate the temperature control system of incubators and use an alarm system when possible to warn against temperature increases above the optimum setting.

Examination of cultures

Observe the morphology and viability of cultures regularly and carefully. Examine the medium in the vessel for macroscopic evidence of microbial contamination. This includes unusual pH shifts (yellow or purple color from the phenol red), turbidity, or particles. Also, look for small fungal colonies that float at the medium-air interface. Specifically check around the edges of the vessel as these may not be readily visible through the microscope.

With an inverted microscope at low power (40×), check the medium for evidence of microbial contamination and the morphology of the

cells. Bacterial contamination will appear as small, shimmering black dots within the spaces between the cells. Yeast contamination will appear as rounded or budding particles, while fungi will have thin filamentous mycelia. For nonadherent cells grown in flasks, such as hybridomas, this is a simple matter of viewing the flask directly on the microscope. For cells grown in spinner flasks or bioreactors, a sample of the cell suspension will need to be withdrawn and loaded into a microscope slide or hemocytometer for observation.

Most adherent cells should be attached firmly to the surface. In some cases, healthy cells will round up and detach somewhat during mitosis and appear very refractile. Following mitosis, they will reattach. Some of these will float free if the culture vessel is physically disturbed. In contrast, dead cells often round up and detach from the monolayer and appear smaller and darker (not refractile) than healthy cells.

Cells in suspension culture grow either as single cells or as clusters of cells. Viable cells appear round and refractile whereas dead cells appear smaller and darker. Occasionally, a portion of the cells will attach and grow on the side of the culture vessel and appear round or flattened. The percentage of attached cells varies with the culture conditions and the cell density. Cellular debris may also be observed in healthy cell populations. Some cell lines grow as mixed adherent and suspension cultures.

As a reference, photomicrographs for some ATCC cell lines are available on the website. Cells are shown at two different densities: just after subculturing (low) and just before they need to be subcultured (high).

In addition to daily examinations, periodically test a sample of the culture for the presence of fungi, bacteria, and mycoplasma. There are several methods that can be used to check for these contaminants. For additional information, refer to the section on microbial contamination (page 277).

Cell counting

Cell counts are necessary in order to establish or monitor growth rates as well as to set up new cultures with known cell numbers. Hemocytometers (also spelled *hemacytometers*) are commonly used to estimate cell number and determine cell viability. A hemocytometer is a fairly thick glass slide with two counting chambers, one on each side. Each counting chamber has a mirrored surface with a 3×3 mm grid of 9 counting squares (see Figure 2). The chambers have raised sides that will hold a coverslip exactly 0.1 mm above the chamber floor. Each of the 9 counting squares holds a volume of 0.0001 ml.

Hemocytometers are excellent for determining cell viability, but are not precise for determining cell number due to the relatively low number of cells actually counted. An automated counter will generate the most reliable data, particularly when used in combination with the viability data from a hemocytometer.




Figure 2. Hemocytometer grid with Neubauer ruling

Count cells as follows:

- 1. Clean, thoroughly dry, and assemble the hemocytometer with the cover slip.
- Transfer a small amount of cell suspension to the edge of each
 of the two counting chambers. Allow the cell suspension to be
 drawn into the counting chamber by capillary action.
- 3. Place the hemocytometer under an inverted microscope and view the cells at 100× magnification.
- 4. Focus on the squares on each of four corners, labeled 1, 2, 3, and 4 in Figure 2.
- 5. Record the number of cells in each square. Average the number of cells, and multiply by the dilution factor. If the cells have not been diluted, this factor will be 10⁴ cells/ml. Any dilution of the sample after it was removed from the cell suspension, such as using vital stain, needs to be included in the calculation.

For example, if the four counts are 60, 66, 69, and 75, the concentration would be 68×10^4 cells/ml for the sample that was loaded into the hemocytometer. For best results, adjust the concentration of the suspension so that 50 to 100 cells are in each of the five counting squares.

Most cultures will grow at an initial inoculum cell concentration ranging from 10³ to 10⁴ cells/cm². Faster-growing cultures are usually set up at lower concentrations. Some cultures do not grow well unless a minimum concentration of cells is initially added; see the product sheet for details.



Cell viability

Viability assays measure the number of viable cells in a population. When combined with the total number of cells, the number of viable cells provides an accurate indication of the health of the cell culture. The most common and rapid methods rely upon the integrity of the cell membrane as an indicator of cell viability. Both trypan blue (ATCC® No. 30-2502) and erythrosin B (ATCC® No. 30-2504) stains are actively excluded by viable cells but are taken up and retained by dead cells, which lack an intact membrane.

While both stains are used in the same way, ATCC recommends erythrosin B in place of trypan blue for hematopoetic cells. When using trypan blue, incubate cells for two to five minutes prior to use. If not counted within this time, the cells will begin to deteriorate and take up the dye. Erythrosin B does not require an incubation period.

Erythrosin B stain generates more accurate results with fewer false negatives and false positives. Erythrosin B stain solution provides a clear background and does not bind serum proteins as avidly as trypan blue, making stained cells more distinct and easier to identify. Also, microbial contamination or precipitates in the cell culture are more readily apparent. Finally, trypan blue is toxic and a potential carcinogen.

For either stain use the following directions:

- 1. Mix the cell suspension 1:1 with a 0.1% erythrosin B solution in PBS or 0.4% trypan blue solution in PBS.
- Load the cells in the erythrosin B solution directly into a clean, dry hemocytometer, but incubate the trypan blue solution for two to five minutes before loading.
- Nonviable cells will be stained red (erythrosin B) or dark blue (trypan blue). Cell viability is calculated as the number of unstained or viable cells divided by the total number of cells and expressed as a percentage.

Subculturing monolayer cells

Anchorage-dependent cell lines growing in monolayers need to be subcultured at regular intervals to maintain them in exponential growth. When the cells are near the end of exponential growth (roughly 70 to 90% confluent), they are ready to be subcultured. The subculturing procedure, including recommended split-ratios and medium replenishment (feeding) schedules, for each ATCC cell line is provided on the Product Information Sheet.

Subcultivation of monolayers involves the breakage of both intercellular and intracellular cell-to-surface bonds. For some cells that are loosely attached, a sharp blow with the palm of your hand against the side of the flask can dislodge them. Many require the digestion of their protein attachment bonds with proteolytic enzymes such as trypsin/EDTA. For some cell lines mechanical forces such as scraping to dislodge the cells is preferred. After the cells have been dissociated and dispersed into a single-cell suspension, they are diluted to the appropriate concentration and transferred into fresh culture vessels with the appropriate growth medium where they will reattach, grow and divide.

The procedure below is appropriate for most adherent cell lines. However, since every cell line is unique, incubation times and temperature, number of washes or the solution formulations may vary. In all cases, continually observe the cells with a microscope during the dissociation process to prevent damage by the dissociation solution. The amounts used in this procedure are for a 75-cm² flask. Adjust volumes as appropriate for different sized vessels.

Monolayer subculturing

- . Bring the trypsin-EDTA solution (ATCC® No.30-2101), balanced salt solution [Dulbecco's Phosphate Buffered Saline without calcium or magnesium, ATCC® No. 30-2200], and complete growth medium to the appropriate temperature for the cell line. In most cases, this is the temperature used to grow the cells (usually 37°C). For some sensitive cells, the trypsin-EDTA solution may need to be used at room temperature or 4°C.
- 2. Remove and discard the cell culture medium from the flask.
- 3. Rinse the cell monolayer with Dulbecco's PBS without calcium or magnesium and remove.
- 4. Add 2 to 3 ml of the trypsin-EDTA solution and incubate at the appropriate temperature. Check the progress of cell dissociation by microscopy. To avoid clumping, do not agitate the cells by hitting or shaking the flask while waiting for them to detach.
- 5. Once the cells appear to be detached (5 to 15 minutes for most cell lines; they will appear rounded and refractile under the microscope), add 6 to 8 ml of complete growth medium with a pipette to the cell suspension to inactivate the trypsin. Gently wash any remaining cells from the growth surface of the flask. Check the cells with the microscope to be sure that most (>95%) are single cells. If cell clusters are apparent, continue to disperse the cells with gentle pipetting.

NOTE: For serum-free or low-serum medium, remove the tryp-sin-EDTA solution by gentle centrifugation (10 minutes at 125 \times g) and then resuspend the cells in 6 to 8 ml of fresh medium. In some cases, the trypsin will need to be inactivated with a trypsin inhibitor.

- Add 12 to 15 ml of fresh culture medium to a new flask and equilibrate this medium to the appropriate pH and temperature.
- 7. Count the cells in suspension and determine their viability or simply divide them according to a routine split ratio and dispense them into the medium of the newly prepared flask. Do not add a concentrated cell suspension to an empty culture vessel as this can result in uneven cell attachment and growth.
- Place the flask back into the incubator. Examine the culture the following day to ensure the cells have reattached and are actively growing. Change the medium as needed; for most actively growing cultures two to three times per week is typical.



Toubleshooting monolayer cell subculturing

Cells are difficult to remove.

- Inhibitors in the medium (such as serum) have inactivated the dissociating agents. Rinse the cell monolayer twice with Dulbecco's PBS without calcium or magnesium before adding the dissociating solution. Or use the trypsin-EDTA solution in place of the Dulbecco's PBS for the first rinse of the monolayer.
- The dissociating solution was too weak. Use higher enzyme concentrations, higher EDTA concentrations, or different and/or additional enzymes (e.g., dispase, collagenase). Or incubate the cells at 37°C to increase the activity of the dissociating solution.
- The cells have been confluent for too long and the cell-to-cell junctions are so tight they prevented the dissociation agents from reaching the substrate-cell interface. In the future, subculture the cells before they become as confluent.

Cells form clumps after dissociation.

- The dissociation procedure was too harsh and genomic DNA was released from lysed cells. Either the pipetting was too vigorous or the dissociating solution was too strong or too toxic (i.e., the pH or osmolality of the buffer was incorrect). Add a drop of sterile DNAse (1 mg/ml in water) to the cell suspension to break down the DNA strands. In the future, treat the cells more gently during pipetting, shorten the incubation period, use a weaker dissociation solution (lower the enzyme concentration or remove the EDTA), or incubate at a lower temperature.
- The cells aggregated before dilution and dispersion into the medium. Hold the cell suspension on ice if there will be a delay between removing the cells from the flask growth surface and seeding a new flask.
- The cells were centrifuged too hard or too long when removing excess dissociation solution. Be sure to use gentle centrifugation (10 minutes at 125 × q).

Cells have difficulty reattaching to the flask.

- The dissociation procedure was too long and stripped away necessary attachment proteins from the cell membrane.
- Insufficient serum or attachment factors were present in the medium (common with serum-free medium). Add attachment factors to the medium and/or use a protein-coated flask (collagen, poly-L-lysine, fibronectin, gelatin, etc.).
- The dissociating solution was not inactivated or removed by centrifugation. Add additional serum or specific enzyme inhibitors (e.g., soybean trypsin inhibitor) to the neutralizing medium or centrifuge (5 minutes at 125 × g) the cells down from the dissociation solution and resuspend in fresh medium.

Viability is lower than expected.

- The dissociating procedure was too harsh.
- The pH or osmolality of the balanced salt solution containing

- the dissociation agents is incorrect. Check these directly and/or use a fresh bottle.
- The dispersed cell suspension was left too long at too high a cell concentration prior to reseeding. Keep the cells on ice.
- The medium was faulty. Use the recommended formulation and make sure it contains all of the required additives.

Suspension cells

Most primary cultures, finite cell lines, and continuous cell lines are anchorage dependent and thus grow in monolayers attached to a surface. Other cells, particularly those derived from hematopoietic or certain tumor tissues, are anchorage independent and grow in suspension.

Cell propagation in suspension has several advantages over propagation in monolayer. Subculturing is a simple matter of dilution. There is little or no growth lag after splitting a suspension culture as there is with a monolayer culture, because there is none of the trauma associated with proteolytic enzyme dispersal. Suspension cultures require less lab space per cell yield, and scale-up is straightforward. Cells can be propagated in bioreactors similar to the fermentors used for yeast or bacteria cultures.

Depending upon the cell type, suspension cultures are seeded at densities from 2×10^4 to 5×10^5 viable cells/ml and can attain densities of 2×10^6 cell/ml. If cells are seeded at too low a density they will go through a lag phase of growth, grow very slowly, or die out completely. If cell densities are allowed to become too high, the cells may exhaust the nutrients in the medium and die abruptly. Recommended seeding and subculturing densities, media replenishment (feeding) schedules, and medium formulations for each ATCC cell line are provided on the Product Information Sheet as well as in the catalogue description on the website.

Suspension cell subculturing

- Bring the complete growth medium to the appropriate temperature (usually 37°C) in a water bath.
- Thoroughly mix the cell/medium suspension; use a pipette to suspend cells grown in stationary flasks. Remove a small amount of the cell suspension to determine the cell density and viability using a hemocytometer and vital stain (page 263).
- Calculate the volume of cells required to re-seed the flask at the minimum density for that cell line, taking into consideration the amount of fresh medium that will be used.
- 4. Add the appropriate volume of medium to the culture vessel and then add the cell suspension. Do not add the concentrated cell suspension to an empty flask. The same culture vessel can be reused, but the chances of contamination increase with each reseeding due to the buildup of small spills of medium on the flask opening.
- 5. If necessary, "gas" the atmosphere of the flask with sterile-filtered CO₂, seal the flask, and then incubate at the appropriate temperature.



It is generally not necessary to completely change the medium unless the cells attain a very high density or the medium has an acidic pH (yellow in color from the phenol red). To completely replace the medium, centrifuge the cells gently (10 minutes at 125 $\times g$), decant the medium, and then resuspend the cells in fresh medium at the lower seeding density.

Troubleshooting suspension cell subculturing

Viability is lower than expected.

- The cell suspension was left too long at too high a cell concentration prior to subculture. In this case, the medium will have a low pH and be yellow in color. Completely change the medium by gently centrifuging the cells and resuspend in fresh medium at the lower seeding density.
- The cell suspension was diluted below the recommended cell density range. Recover the cells by centrifugation and resuspend in fresh medium at the appropriate cell density.
- The harvesting procedure was too harsh (pipetting too vigorous, cells were centrifuged too hard or too long, cells damaged during scraping or banging).
- The medium was faulty. Use the recommended formulation and make sure it contains all of the required additives.

Adapting a monolayer cell line to grow in suspension

Some cell lines such as L-929 (ATCC® CCL-1™), HeLa (ATCC® CCL-2™) and BHK-21 (ATCC® CCL-10™) can be adapted to grow in suspension. With time, a population of cells can be selected that does not selfaggregate or adhere to a growth surface as readily as the parental line. However, the newly selected line may have lost or acquired characteristics that are different from the original cell population. In most cases it will be necessary to maintain the culture in suspension with mechanical stirring. Keep in mind that most anchorage-dependent cells will grow in suspension only with the use of microcarrier beads.

The procedure below was developed for BHK-21 cells,4 but can be used as a starting point for most cell lines.

- Dissociate the cell monolayer using standard procedures. Centrifuge and resuspend the cell suspension in an appropriate spinner medium such as Joklik's modified Eagle's Minimum Essential Medium (EMEM). Spinner media have reduced levels of calcium and magnesium.
- Count the cell suspension, and then seed two or more spinner flasks with 5×10^5 cells/ml. This density may need to be adjusted for your particular cell line. The sides of the culture flask may need to be siliconized to prevent the cells from sticking to the glass.
- Observe the cultures daily. Remove samples and record the number of viable cells for each flask.
- Every three days, collect the cells growing in suspension by centrifugation (10 minutes at $125 \times q$). Count, and re-seed a fresh flask with fresh medium at 2.5 × 10⁵ cells/ml. Depending

- on how well (or not) the cells adapt to growth in suspension, they may need to be combined with cells from different flasks to achieve the necessary cell density.
- If there is a significant amount of cells attached to the walls of the culture vessel, particularly at the surface of the medium, remove them with trypsin-EDTA and discard them. If the cells in suspension are badly clumped, they can be dispersed with the trypsin-EDTA solution, collected by centrifugation, and then reseeded into the flask as the appropriate density. This treatment may be necessary for the first few subcultures.
- Continue to monitor the cells and subculture them every three days. Over time, they should adapt to growth in suspension and attain a constant growth rate.



A complete growth medium consists of a basal cell culture medium supplemented with ingredients such as sera, growth factors, trace elements, and hormones. There are numerous formulations ranging from simple, basic mixtures containing the minimum requirements for growing many cell lines to complex serum-free mixtures specific for growing a single fastidious cell line. The choice of a medium for a particular cell line is somewhat empirical.

Many medium formulations are available commercially in powder or liquid form.

NOTE: Formulations can vary widely among suppliers, even for media with similar or identical names. Be sure to read catalogue descriptions, formulations, and medium labels carefully to ensure that the appropriate medium is used. For best results start cell cultures in the same medium used and distributed by ATCC (listed on the Product Information Sheet).

ATCC lists complete medium formulations, plus all handling and passage information, for all ATCC cell lines both in the online catalogue description and on the Product Information Sheet that accompanies the cell line when shipped. Additionally, ATCC offers a full line of media, sera, and reagents for culturing cells. These are the same reagents used at ATCC for cell growth and propagation. See pages 17-26 for descriptions of ATCC cell culture products.

Cell culture media

Cell culture media are complex mixtures of salts, carbohydrates, vitamins, amino acids, metabolic precursors, growth factors, hormones, and trace elements. The requirements for these components vary among cell lines, and these differences are partly responsible for the extensive number of medium formulations. Carbohydrates are supplied primarily in the form of glucose. In some instances, glucose is replaced with galactose to decrease lactic acid build-up, as galactose is metabolized at a slower rate. Other carbon sources include amino acids (particularly L-glutamine) and pyruvate.

In addition to nutrients, the medium helps maintain the pH and osmolality in a culture system. The pH is maintained by one or more buffering systems; ${\rm CO_2}/{\rm sodium}$ bicarbonate, phosphate, and HEPES are the most common. Sera will also buffer a complete medium. Phenol red, a pH indicator, is added to medium to colorimetrically monitor changes in pH.

Commonly used culture media include the following:

Eagle's Minimum Essential Medium (EMEM) was among the first widely used media and was formulated by Harry Eagle from his earlier and simpler basal medium (BME). BME was developed for culturing mouse L cells (ATCC® CCL-1™) and HeLa cells (ATCC® CCL-2™). Over time, there have been numerous variations on the EMEM formula for different applications.

ATCC EMEM (ATCC® No.30-2003) contains Earle's balanced salt solution, nonessential amino acids, and sodium pyruvate. It is formulated with

a reduced sodium bicarbonate concentration (1,500 mg/l) for use with 5% $\rm CO_2$ (see Sodium Bicarbonate and Buffering, page 268). Because EMEM is a simple medium, it is often fortified with additional supplements or higher levels of serum.

Dulbecco's Modified Eagle's Medium (DMEM) has roughly twice the concentration of amino acids and four times the amount of vitamins as EMEM, as well as ferric nitrate, sodium pyruvate, and some supplementary amino acids (though not all nonessential amino acids). The original formulation contained 1,000 mg/l of glucose, but in the more commonly used variations this amount was increased to 4,500 mg/l.

ATCC DMEM (ATCC® No. 30-2002) has 4,500 mg/l of glucose and a reduced sodium bicarbonate concentration (1,500 mg/l) for use with 5% CO₂.

Iscove's Modified Dulbecco's Medium (IMDM) was formulated for growth of lymphocytes and hybridomas. Compared to DMEM, it has additional amino acids, vitamins and inorganic salts. Potassium nitrate was substituted for ferric nitrate. It also contains HEPES and selenium

ATCC IMDM (ATCC® No. 30-2005) has a reduced sodium bicarbonate concentration (1,500 mg/l) for use with 5% CO₃.

Hybri-Care Medium (ATCC® No.46-X) is a combination and modification of DMEM and NCTC 135 medium supplemented with insulin, oxalacetic acid, and HEPES. It is based on the formulation used by David H. Sachs and collaborators⁵ for the propagation of hybridomas and other fastidious cell lines.

McCoy's 5A and **RPMI-1640** were developed at Roswell Park Memorial Institute (RPMI) in Buffalo, New York. McCoy's 5A (ATCC® No. 30-2007) was originally used to grow Novikoff hepatoma cells and will support the growth of primary cultures.

RPMI-1640 is a modification of McCoy's 5A and was developed for the long-term culture of peripheral blood lymphocytes. RPMI-1640 will support the growth of a wide variety of cells in suspension as well as a number of cells grown as monolayers.

ATCC RPMI-1640 (ATCC® No. 30-2001) was modified to contain higher amounts of glucose (4,500 mg/l), sodium pyruvate, and HEPES buffer. It also contains a reduced concentration of sodium bicarbonate (1,500 mg/l) for use with 5% $\rm CO_2$.

Ham's Nutrient Mixtures were originally developed to support the clonal outgrowth of Chinese hamster ovary (CHO) cells (ATCC® CCL-61™). As with EMEM, there have been numerous modifications to the original formulation including Ham's F-12 medium, a more complex formulation than the original F-10 suitable for serum-free propagation.

Kaighn's modification of Ham's F-12 (Ham's F-12K) was designed to support the growth and differentiation of primary cells with or without serum. F-12K has increased amounts of amino acids, pyruvate, biotin, calcium, magnesium, putrescine, and phenol red in addition to other modifications from the F-12 formula.

ATCC Ham's F-12K (ATCC® No.30-2004) has a reduced sodium bicarbonate concentration (1,500 mg/l) for use with 5% CO₂.

DMEM/F12 Medium is a 1:1 mixture of Dulbecco's modified EMEM and Ham's F-12. It is an extremely rich and complex medium and will support the growth of a broad range of cell types in both serum and serum-free formulations.

ATCC DMEM/F12 medium (ATCC® No. 30-2006) has a reduced sodium bicarbonate concentration (1,500 mg/l) for use with 5% CO₃.

Leibovitz's L-15 Medium (ATCC® No.30-2008) is formulated for use without CO₂ incubation as is found in teaching laboratories or when collecting biopsy samples. The standard sodium bicarbonate/CO₂ buffering system is replaced by a combination of phosphate buffers, free-base amino acids, higher levels of sodium pyruvate, and galactose. Cell cultures can be grown in CO₂ incubators with L-15 medium provided there is no exchange between the air in the culture vessel with that of the incubator (i.e., caps of flasks are tightly closed).

Media formulations

Formulations of media available from ATCC can be found online. There are cell lines in the collection that require media not currently sold by ATCC. Some of these media formulations have been provided on page 282.

Media ingredients

Sodium bicarbonate and buffering

Cells produce and require small amounts of carbon dioxide for growth and survival. In culture media, dissolved $\rm CO_2$ is in equilibrium with bicarbonate ions and many medium formulations take advantage of this $\rm CO_2$ /bicarbonate reaction to buffer the pH of the medium. $\rm CO_2$ dissolves freely into the medium and reacts with water to form carbonic acid. As the cells metabolize and produce more $\rm CO_2$, the pH of the medium decreases as the chemical reaction below is driven to the right:

$$H_2O + CO_2 \leftrightarrow H_2CO_3 \leftrightarrow H^+ + HCO_3^-$$

The optimal pH range of 7.2 to 7.4 can be maintained by supplementing the medium with sodium bicarbonate and regulating the level of CO_2 in the atmosphere above the medium as shown by the reaction below:

$$H_2O + CO_2 + NaHCO_3 \leftrightarrow H^+ + Na^+ + 2HCO_3^-$$

In tissue culture, cells are grown either in open systems (where there is free exchange of the atmosphere immediately above the medium with the atmosphere of the incubator) or in closed systems (where the two atmospheres are kept separate). The buffering system employed in the medium needs to be matched to the culture system. Otherwise the cells may be subject to metabolic stress which will impair their performance.

In closed systems the level of CO_2 is regulated by the metabolism of the cells. The culture vessel must be sealed (flasks tightly capped) to retain any CO_2 generated by the cells. Consequently, closed systems provide additional protection against contamination and have simpler incubator requirements than open systems. Closed systems usually require media with buffers based on Hanks' balanced salt solution having relatively low levels of sodium bicarbonate.

In open systems, humidity (to reduce evaporation) and a means of regulating CO_2 levels (if the culture medium contains sodium bicarbonate) are required during incubation to maintain the pH of the culture medium. Open systems usually require the higher levels of sodium bicarbonate found in Earle's salt solution combined with a 5 to 10% CO_2 atmosphere supplied by the incubator. In general, 1.2 to 2.2 g/l of sodium bicarbonate is used with 5% CO_2 whereas 3.7 g/l sodium bicarbonate is used with 10% CO_2 . The exact amount will depend upon the medium formulation.

In some cases, researchers "gas" the atmosphere of the culture vessel with a stream of sterile-filtered 5% $\rm CO_2/95\%$ air mixture and then tightly seal the flask prior to incubation in a nonhumidified and non- $\rm CO_2$ incubator. While these culture vessels work with simpler nonhumidified, non- $\rm CO_2$ incubators, the medium requirements are those of an open system.

All ATCC media, with the exception of Leibovitz's L-15 (ATCC® No. 30-2008), are designed to be used with 5% CO $_2$ levels. Most have a sodium bicarbonate concentration of 1.5 g/l and are supplemented with extra sodium pyruvate. ATCC modification of McCoy's 5A (ATCC® No.30-2007) has a slightly higher levels of sodium bicarbonate (2.2 g/l) and does not contain sodium pyruvate.

While most commercial formulations of liquid media do contain the appropriate amount of sodium bicarbonate, it is generally omitted from the powdered form and needs to be added before use.

Some medium formulations incorporate other buffering systems such as phosphate or HEPES in addition to $\rm CO_2$ /sodium bicarbonate. These media have the advantage of maintaining optimal pH in an open system when the culture vessel is removed from the enriched $\rm CO_2$ atmosphere of the incubator.

HEPES buffer

HEPES and other organic buffers can be used with many cell lines to effectively buffer the pH of the medium.⁸ Indeed, some standard medium formulations include HEPES. However, this compound can be toxic, especially for some differentiated cell types, so evaluate its effects before use.⁹ HEPES has been shown to greatly increase the sensitivity of media to the phototoxic effects induced by exposure to fluorescent light.^{10,11}

Phenol red

Phenol red is used to monitor the pH of media. During cell growth, the



medium changes color as it changes pH due to metabolites released by the cells. At low pH levels, phenol red turns the medium yellow, while at higher pH levels it turns the medium purple. For most tissue culture work (pH 7.4), the medium should be bright red.

Unfortunately, phenol red can mimic the action of some steroid hormones, particularly estrogen. For studies with estrogen-sensitive cells, such as mammary tissue, use media without phenol red. Additionally, the sodium-potassium ion homeostasis is upset when phenol red is included in some serum-free formulations; this effect is neutralized by the inclusion of serum or bovine pituitary hormone in the medium. Phenol red is frequently omitted from studies with flow cytometry as its color interferes with detection.

L-Glutamine

L-Glutamine (ATCC® No. 30-2214) is an essential amino acid required by virtually all mammalian and insect cells grown in culture. It is used for protein production, as an energy source, and in nucleic acid metabolism. It is also more labile in liquid cell culture media than other amino acids. The rate and extent of L-glutamine degradation are related to storage temperatures, age of the product, and pH.

Because L-glutamine is so labile, it is often omitted from commercial liquid medium preparations to lengthen the product shelf life. In these cases, it must be aseptically added prior to use. L-Glutamine is not as labile in dry form and most powdered medium formulations do include it.

In some cases, the addition of L-glutamine to complete cell culture medium can extend the usable life of the medium. If L-glutamine is suspected to be a limiting factor during cell culture, a simple test of 'spiking' the medium with a small amount of L-glutamine will determine whether or not more is required. Simply add a small amount of L-glutamine (~2 mM final concentration) to the culture medium. If the cell growth rate increases, L-glutamine is most likely deficient and more should be added. Alternately, the concentration of L-glutamine can be measured directly by standard analytical means such as HPLC (High Performance Liquid Chromatography).

L-Glutamine concentrations for mammalian cell culture media can vary from 0.68 mM in Medium 199 to 4 mM in Dulbecco's Modified Eagle's Medium. Invertebrate cell culture media, such as Schneider's Drosophila medium, may contain as much as 12.3 mM L-glutamine.

Use caution when adding more L-glutamine than is called for in the original medium formulation. L-Glutamine degradation results in the build-up of ammonia which can have a deleterious effect on some cell lines. For most cell lines, ammonia toxicity is more critical for cell viability than L-glutamine limitation.

Nonessential amino acids

All medium formulations contain the ten essential amino acids as well as cysteine, glutamine, and tyrosine. The inclusion of the other non-

essential amino acids (alanine, asparagine, aspartic acid, glycine, glutamic acid, proline, and serine) in some medium formulations reduces the metabolic burden on the cells allowing for an increase in cellular proliferation.

Sodium pyruvate

Pyruvate is an intermediary organic acid metabolite in glycolysis and the first component of the Embden-Meyerhof pathway. It can pass readily into or out of the cell. Its addition to tissue culture medium provides both an energy source and a carbon skeleton for anabolic processes. Pyruvate may help in maintaining certain specialized cells, in clonal selection, in reducing the serum concentration of the medium, and in reducing fluorescent light-induced phototoxicity. Cellular metabolism of pyruvate produces carbon dioxide which is given off into the atmosphere and becomes bicarbonate in the medium. Sodium pyruvate is added to give a final concentration of 1 mM in most media, but is increased to 5 mM in Leibovitz's L-15 medium primarily to facilitate use in CO₃-free environments.

Media supplements

The complete growth media recommended for some cell lines requires the addition of components not already available in the base media and serum. These components include hormones, growth factors and signaling substances that sustain proliferation and maintain normal cell metabolism.

Supplements are usually prepared as $100\times$ (or higher) stock solutions in serum-free medium. Some supplements may need to be dissolved in a solvent prior to subsequent dilution in serum-free medium to the stock concentration. Stock concentrations should be aliquoted into small volumes and stored at an appropriate temperature; most stock concentrations can be stored at $-80\,^{\circ}$ C, but check with your supplier prior to storing.

The addition of supplements can change the final osmolality of the complete growth medium, which may have a negative effect on the growth of cells in culture. It is best to recheck the osmolality of the complete growth medium after small volumes of supplement stock solutions are added; optimal osmolality for most vertebrate cell lines should fall between 260 and 320 mOSM/kg.

After supplements have been added to a base medium, the shelf life of the complete growth medium should be determined on a case-by-case basis. Complete media containing protein supplements (e.g., epidermal growth factor, bovine serum albumin, etc.) tend to degrade faster than base media alone. Most complete growth media can be stored in aliquots at 2 to 8°C for about a month. However, if any supplement is expected to expire before the one-month period has passed, the expiration date for the complete growth media should follow suit. Some fastidious cell lines may require that components be added immediately before use. Do not freeze complete growth medium. Freezing cell culture media at -70°C or below causes some of the



growth factors and/or vitamins to precipitate out of solution. It can be very difficult to get these components to go back into solution after thawing, even if warmed to 37°C. ATCC recommends storing media between 2 and 8°C, away from light.

For additional information regarding the preparation, storage, or usage of specific supplements, contact your local supplier or consult with the manufacturer's Product Information Sheet.

Osmolality

The osmolality of cell culture media for most vertebrate cells is kept within a narrow range from 260 to 320 mOsm/kg, even though most established cell lines will tolerate a rather large variation in osmotic pressure.In contrast, the osmolality requirements for some invertebrate cell lines fall outside of this range.For example, the snail embryo (ATCC° CRL-1494™) requires medium of about 155 mOsm/kg, while some insect cells prefer 360 to 375 mOsm/kg. Most commercially available liquid media report osmolality and it is advisable to check the osmolality of any medium after the addition of saline solutions, drugs or hormones dissolved in an acid or base solution, or large volumes of buffers (e.g., HEPES).

Antibiotics and antimycotics

Antibiotics and/or antimycotic agents are added to cell culture media as a prophylactic to prevent contamination, as a cure once contamination is found, to induce the expression of recombinant proteins, or to maintain selective pressure on transfected cells.

Routine use of antibiotics or antimycotics for cell culture is not recommended unless they are specifically required, such as G418 for maintaining selective pressure on transfected cells. Antibiotics can mask contamination by mycoplasma and resistant bacteria. Further, they can interfere with the metabolism of sensitive cells. Avoid antimycotics as they can be toxic to many cell lines.

While cell lines can be cured of microbial contamination with antibiotics and/or antimycotics, this is not recommend unless the cell line is irreplaceable; the process is lengthy and there is no guarantee contamination will be eliminated. Even if the contamination is eliminated, there is no way of ensuring that the resulting cell line will have the same characteristics as the initial one due to the stress of the treatment. It is best to discard the cell line and start over with new stocks. Mycoplasma contamination in particular is very difficult to eliminate (see p. 277).

In some cases, antibiotic use for short periods of time can serve as a valuable prophylactic. For example, antibiotic use is recommended when developing and working with primary culture and when using flow cytometry to isolate subpopulations.

If an antibiotic is used in medium, penicillin-streptomycin solution (ATCC® No. 30-2300) can be added at 0.5 to 1 ml of solution per 100

ml of cell culture medium for a final concentration of 50 to 100 IU/ml penicillin and 50 to 100 μ g/ml streptomycin. Gentamicin sulfate, another antibiotic (ATCC® No.30-2303), is used at 50 to 100 μ g/ml.The antimycotic amphotericin B (ATCC® No.30-2301) is used at 2.5 μ g/ml.¹³ These concentrations apply to media that contain serum. For serum-free media, reduce the concentrations by at least 50%.

Animal sera

Sera serve as a source for amino acids, proteins, vitamins (particularly fat-soluble vitamins such as A, D, E, and K), carbohydrates, lipids, hormones, growth factors, minerals, and trace elements. Additionally, serum buffers the culture medium, inactivates proteolytic enzymes, increases medium viscosity (which reduces shear stress during pipetting or stirring), and conditions the growth surface of the culture vessel. The exact composition is unknown and varies from lot to lot, although lot-to-lot consistency has improved in recent years.

Sera from fetal and calf bovine sources are commonly used to support the growth of cells in culture. Fetal serum is a rich source of growth factors and is appropriate for cell cloning and for the growth of fastidious cells. Calf serum, because of its lower growth-promoting properties, is used in contact-inhibition studies with NIH/3T3 cells (ATCC® CRL-1658™). In contrast to fetal or calf sera, horse serum is collected from a closed herd of adult animals ensuring lot-to-lot consistency. Horse serum is less likely to carry the contaminants found in bovine sera such as viruses and less likely to metabolize polyamines which may be mitogenic for some cells. Horse and bovine calf sera are less expensive and more readily available than fetal bovine serum. The pricing and availability of fetal serum fluctuates considerably.

Unfortunately, naturally derived products from bovine sources may contain adventitious viruses such as bovine viral diarrhea virus (BVDV), bovine parvovirus, bovine adenovirus, and blue tongue virus. All reputable suppliers test their products for infectious virus by several methods including fluorescent antibody, cytopathic effect, and hemad-sorption. These products are also screened for the standard microbial contaminants such as bacteria, fungi, and mycoplasma.

BVDV, in contrast to the other virus contaminants, is present in nearly all bovine serum at very low levels even when tests for infectious virus are negative. Fortunately, very few cell lines (except those of bovine origin) are susceptible to this virus. For the few sensitive cell lines, use non-bovine sera or irradiated bovine sera. Several ATCC cell lines were tested for BVDV contamination¹⁴ and the results of this study are indicated in the cell line description on the website.

Bovine-derived products also may contain the agent responsible for bovine spongiform encephalopathy (BSE). Unfortunately, there is no test for the presence of this agent and we highly recommend that you obtain all bovine products (including sera) from countries not affected by BSE such as the United States, Australia and New Zealand.

At one time animal serum was a major source of mycoplasma con-



tamination of tissue culture cells. However, nearly all sera today are filtered through several 0.1- μ m pore (or smaller) filters which effectively remove this organism.

ATCC offers the following four types of animal sera:

- Fetal Bovine Serum (also known as fetal calf) ATCC® No. 30-2020
- Fetal Bovine Serum qualified for embryonic stem cells ATCC® No. SCRR-30-2020
- Iron-supplemented Calf Bovine Serum ATCC® No. 30-2030
- Horse Serum ATCC® No. 30-2040

These products are rigorously tested for adventitious infective agents and sourced from only U.S. herds. Further, each lot is tested for its ability to support cell growth and is the same sera used in ATCC labs.

Storage

Store sera at -20° C or colder for storage over 30 days. ATCC sera are routinely stored at -70° C. Do not store sera at temperatures above -20° C for any length of time. Avoid repeated freeze-thaws by dispensing and storing in aliquots.

Thawing

The following procedure is used to thaw serum:

- 1. Place frozen serum in a refrigerator at 2 to 8°C overnight.
- Put the bottles in a 37°C water bath and gently agitate from time to time to mix the solutes that tend to concentrate at the bottom of the bottle.

Do not keep the serum at 37° C any longer than necessary to thaw it, and do not thaw the serum at higher temperatures. Thawing serum in a bath above 40° C without mixing may lead to the formation of a precipitate inside the bottle.

Turbidity and precipitates

All sera may retain some fibrinogen. Because external factors may initiate the conversion of fibrinogen to fibrin, flocculent material or turbidity may be observed after serum is thawed. The presence of this material does not alter the serum's performance. If the presence of flocculent material or turbidity is a concern, it can be removed by filtration through a 0.45-µm filter.

A precipitate can form in serum when incubated at 37°C or higher for prolonged periods of time which may be mistaken for microbial contamination. This precipitate may include crystals of calcium phosphate, but does not alter the performance of the serum as a supplement for cell culture. Heat inactivation of sera can also cause the formation of precipitates.

Heat inactivation

ATCC does not routinely use heat-inactivated serum unless specifically required for a particular cell line. Heat inactivation is usually unnecessary and can be detrimental to the growth of some cells. It will reduce or destroy growth factors present in the serum.

Heat inactivation was originally performed to inactivate complement (a group of proteins present in sera that are part of the immune response) as well as to destroy mycoplasma contaminants. Today, mycoplasma contamination, if any, is removed by filtration. Removal of complement is usually unnecessary, but can be important when preparing or assaying viruses or in cytotoxicity tests. According to a study by HyClone,¹⁵ warming serum to 37°C inactivates heat-labile complement factors. A few types of cell lines grow better in heat-inactivated sera such as embryonic stem cells¹⁶ and many insect cell lines.¹⁷

The following procedure can be used to heat-inactivate serum:

- 1. Thaw serum.
- 2. Preheat a water bath to 56°C. Use sufficient water to immerse the bottle above the level of serum.
- 3. Mix thawed serum by gentle inversion and place in the 56°C bath. The temperature of the water bath will drop.
- 4. When the temperature of the water bath reaches 56°C again, continue to heat for an additional 30 minutes. Mix gently every 5 minutes to insure uniform heating.
- Remove serum from water bath, cool quickly (slow cooling can sometimes reverse the inactivation of complement activity), and store at -20°C or colder.



Culture Vessels and Surfaces

Vessels

Culture vessels provide a contamination barrier to protect the cultures from the external environment while maintaining the proper internal environment. For anchorage-dependent cells, the vessels provide a suitable and consistent substrate for cell attachment. Other characteristics of vessels include easy access to the cultures and optically clear viewing surfaces.¹⁸

Originally all culture vessels were glass. Drawbacks for glass include the heavy weight, expense, labor-intensive cleaning, and poor microscopic viewing compared to plastic. By the 1960s, surface treatment techniques were developed for polystyrene, allowing plastic vessels to replace glass for most cell culture applications.

The information below focuses on standard culture vessels used by many researchers. Large-scale culture equipment is not included.

Selecting the right vessel

First, match the characteristics of the cells to be grown with the characteristics of the different culturing systems. There are three basic types of cell cultures:

- Anchorage dependent, which must become attached to a surface to grow (for example, human diploid fibroblasts).
- Anchorage independent, which grow in suspension (most blood-derived cell cultures).
- Cells that can grow either attached or in suspension (many transformed cell lines such as HeLa and BHK-21).

Understand the growth requirements of the cultures to help select the best culture system. There are four basic culture systems:

- Stationary monolayer cultures which are grown in undisturbed flasks, dishes, and multiwell plates. These are the easiest culture systems to use and require the least amount of equipment. However, these systems are very labor intensive for producing large quantities of cells.
- Moving monolayer cultures which are grown primarily in roller bottles. These vessels are slowly rotated (approximately 0.5 to 1 rpm) on motorized racks or drums and are widely used for producing large quantities of cells. Roller bottles employ simple technology but require an investment in the appropriate equipment.
- Stationary suspension cultures which are grown without agitation in untreated dishes and flasks. These are best for growing small volumes of anchorage-independent cells that grow poorly in traditional stirred suspension cultures.
- Moving suspension cultures which are grown in mechanically stirred vessels (spinner flasks), bioreactors, or fermentors. These systems are the most economical in terms of space, labor and media; as a result, stirred suspension cultures are usually the method of choice for producing large volumes of cells both in

the lab and in industry. Many anchorage-dependent cells can be adapted to grow on microcarriers to take advantage of these systems.

Next, decide whether the cells will be grown as an open system or as a closed system (see the section on sodium bicarbonate, page 268). Open-system plastic dishes are less expensive than closed-system flasks, but require more expensive incubators that can regulate the CO_2 and humidity in the atmosphere. Closed systems provide additional protection against contamination and have simpler incubator requirements.

All dishes and multiwell plates are open systems. All other culture vessels can be used in either mode by leaving caps loose for an open system or tightened for a closed system. The plastic walls of culture vessels are slightly permeable to carbon dioxide and oxygen, permitting a very small amount of gas exchange. This is not a problem in most culture applications, but may interfere with anoxia experiments or long-term storage of media. ¹⁹ Caps that allow gas exchange when the cap is fully tightened are available to reduce opportunities for flask spills and contamination in open systems.

The last step is matching the desired cell yield with an appropriately sized culture vessel. For monolayer cultures, the yield is limited by the area of treated growth surface. Approximately 0.5×10^5 to 1×10^5 cells/cm² of treated surface is a typical yield for confluent continuous mammalian cell lines. For suspension cultures the total cell yield is determined by the working volume of the vessel. In stirred systems, cell concentrations can easily reach between 1×10^6 and 2×10^6 cells/ml of medium. However, the exact yields will need to be determined empirically for each cell line. ATCC strongly recommends that cells be maintained in the logarithmic phase of growth, and not be allowed to enter the stationary phase. Anchorage-dependent cell lines are routinely passaged or split before they reach confluency.

Flasks

Alexis Carrel developed the first glass flasks in the 1920s. Harry Earle developed the more traditional straight neck rectangular (also hexagonal) glass T-flasks in the 1940s. Today, plastic flasks are available with a range of growing areas, a variety of shapes, with several different neck designs. Choice of design depends on the cell culture techniques used as well as personal preference. The more common sizes are listed below.

| Description | Growth | Recommended working | Cell yield* |
|-------------|------------|---------------------|----------------------|
| | area (cm²) | volume (ml) | |
| T-25 | 25 | 5 to 10 | 2.5×10^{6} |
| T-75 | 75 | 15 to 25 | 7.5×10^{6} |
| T-150 | 150 | 30 to 50 | 15.0×10^{6} |
| T-175 | 175 | 35 to 60 | 17.5×10^{6} |
| T-225 | 225 | 45 to 75 | 22.5×10^{6} |

*Cell line dependent. Based upon a density of 1×10^5 cells/cm².



Culture Vessels and Surfaces

Cell culture dishes

Cell culture dishes offer the best economy and access to the growth surface. This makes them the vessels of choice for cloning or other manipulations such as scraping that require direct access to the cell monolayer. They must be used with incubators that control CO_2 and humidity. Most manufacturers offer dishes in four diameters: 35 mm, 60 mm, 100 mm, and 150 mm. These are nominal diameters and may not be the actual diameter of the growth surface. Cell culture dishes are available with either specially treated surfaces for growing anchorage-dependent cells, or untreated (native) surfaces for growing suspension cultures where attachment is not desired.

| Diameter (mm) | Growth area (cm ²) | Working volume (ml) | Cell yield* |
|---------------|--------------------------------|---------------------|----------------------|
| 35 | 8 | 1 to 2 | 0.8×10^{6} |
| 60 | 21 | 4 to 5 | 2.1×10^{6} |
| 100 | 55 | 10 to 12 | 5.5×10^{6} |
| 150 | 148 | 28 to 32 | 14.8×10^{6} |

^{*}Cell line dependent. Based upon a density of 1×10^5 cells/cm².

Multiwell plates

These widely used vessels were originally designed for virus titration, but have since become popular in many other applications, especially hybridoma production, high-throughput screening, and toxicity testing. Multiwell plates offer significant savings in space, media, and reagents when compared to an equal number of dishes. They are more convenient to handle, especially if the pipettors, plate washers, readers, and other equipment for processing these plates are used. They must be used with incubators that control humidity and CO₂ levels.

| Description | Growth area/ well (cm²) | Working volume/ well (ml) | Cell yield* |
|-------------|----------------------------|------------------------------|-----------------------|
| 96-well | 0.32 | 0.1 to 0.2 | 0.32×10^{5} |
| 48-well | 1.0 | 0.3 to 0.6 | 0.8×10^{5} |
| 24-well | 1.88 | 0.5 to 1.2 | 1.9 × 10 ⁵ |
| 12-well | 3.83 | 1.0 to 2.4 | 3.8×10^{5} |
| 6-well | 9.40 | 2.0 to 3.0 | 9.5 × 10 ⁵ |

^{*}Cell line dependent. Based upon a density of 1×10^5 cells/cm².

Roller bottles

The roller bottle was developed for cultivating large numbers of anchorage-dependent cells. ²⁰ Today they provide a more economical means for cultivating large volumes of cells using essentially the same culture techniques as with flasks but with considerably less labor. Besides the traditional smooth wall design, roller bottles are available with small ridges that approximately double the surface area available for growing cells without increasing the dimensions of the bottles.

| Description | Growth area (cm ²) | Working volume (ml) | Cell yield* |
|----------------|--------------------------------|---------------------|---------------------|
| Small | 490 | 100 to 150 | 4.9×10^{7} |
| Standard | 850 | 170 to 250 | 8.5×10^{7} |
| Pharmaceutical | 1750 | 340 to 500 | 17.5×10^7 |

^{*}Cell line dependent. Based upon a density of 1×10^5 cells/cm².

Surface coatings and feeder cells

Most tissue culture work uses disposable polystyrene vessels. The vessel surface is treated to render it hydrophilic (wettable). Most cell lines in the ATCC collection are cultivated on treated plastic surfaces in dishes, flasks, or roller bottles. Since the properties of tissue culture plastic can vary among manufacturers, samples should be evaluated for their ability to support cell growth and propagation prior to use. ATCC routinely uses the SelecT™ fully automated cell culture system.

Some fastidious cell lines require further treatment of the growth surface before they will attach and proliferate. The most common techniques include coating the surface with serum, collagen (ATCC® No. 30-2511), laminin (ATCC® No. 30-2505), gelatin, poly-L-lysine, or fibronectin.

Beyond simple attachment, some cells require specialized surface treatment in order for them to differentiate into more tissue-like formations. For example, endothelial cells will form tubules and neuronal cells will extend neurite processes when cultured on a surface of extracellular matrix (ECM) proteins (ATCC® No.30-2501 and 30-2503). These ECM proteins closely resemble the basal lamina membrane surrounding cells in tissue and not only provide attachment points, but modulate signal transduction from external growth factors and hormones, influence the permeability of ions and nutrients, and actively "communicate" with intracellular processes through integrins.

Finally, some cells, particularly when seeded at low densities as for cloning, require the support of living cells. Most cells are "happier in a crowd." Feeder layer cells supply a crowd by conditioning the medium through metabolic leakage and/or the active secretion of growth and other factors. They also provide a support matrix for cell attachment and proliferation. To prevent feeder layer cells from overgrowing the cells of interest, they are treated to prevent division. Common methods include irradiation with X-rays or gamma rays or treatment with mitomycin C. Each of these treatments damages cellular DNA so that the cells continue to metabolize but can no longer proliferate. ATCC offers a variety of well-characterized feeder cells. See page 179 for the complete list.



Cryopreservation

Most cell cultures can be stored for many years, if not indefinitely, at temperatures below -130°C (cryopreservation). ATCC has recovered cells from cultures cryopreserved for more than 40 years. The many advantages of cryopreservation far outweigh the required investment in equipment and reagents. These advantages include:

- Generation of safety stocks to ensure against loss of the culture from equipment failures or contamination by microorganisms or other cell lines.
- Elimination of the time, energy, and materials required to maintain cultures not in immediate use.
- Preservation of cells with finite population doublings (that will ultimately senesce).
- Insurance against phenotypic drift in the culture due to genetic instability and/or selective pressure.
- Creating a standard reagent to be used for a series of experiments.

Overview

As the cell suspension is cooled below the freezing point, ice crystals form and the concentration of the solutes in the suspension increases. Intracellular ice can be minimized if water within the cell is allowed to escape by osmosis during the cooling process. A slow cooling rate, generally –1°C per minute, facilitates this process. However, as the cells lose water, they shrink in size and will quickly lose viability if they go beyond a minimum volume. The addition of cryoprotectant agents such as glycerol or dimethylsulfoxide (DMSO) will mitigate these effects.

The standard procedure for cryopreservation is to freeze cells slowly until they reach a temperature below –70°C in medium that includes a cryoprotectant. Vials are transferred to a liquid-nitrogen freezer to maintain them at temperatures below –130°C.

The recovery of cryopreserved cells is straightforward: Cells are thawed rapidly in a water bath at 37°C, removed from the freezemedium by gentle centrifugation and/or diluted with growth medium, and seeded in a culture vessel in complete growth medium.

There are numerous factors which affect the viability of recovered cells. Modify the procedure for each cell line to attain optimal cell viability upon recovery. Some of the critical parameters for optimization include the composition of the freeze medium, the growth phase of the culture, the stage of the cell in the cell cycle, and the number and concentration of cells within the freezing solution.

ATCC provides information on cryopreservation for all cell lines on the Product Information Sheet. Most ATCC cell lines are frozen with a cryopreservation medium consisting of 5% DMSO and complete growth medium.

Freeze medium

Glycerol and DMSO at 5 to 10% are the most common cryoprotectant agents. While DMSO can be toxic to cells, it penetrates them much faster than glycerol and yields more reproducible results. Unfortunately, DMSO can cause some cells to differentiate (e.g., HL-60 promyeloblast cells) and may be too toxic for some cells (e.g., HBE4-E6/E7 lung epithelial cells). Glycerol should be used in these instances. Glycerol can be sterilized by autoclaving whereas DMSO must be sterilized by filtration. Care should be used when handling any DMSO solution as it will rapidly penetrate intact skin and may carry toxic contaminants along with it.

Use only reagent-grade (or better, such as cell culture-grade) DMSO or glycerol. Store both in aliquots protected from light. ATCC offers DMSO (ATCC® No. 4-X) that has been thoroughly tested for cell culture use.

For cells grown in serum-free medium, adding 50% conditioned medium (serum-free medium in which the cells were grown for 24 hours) to both the cell freezing and the recovery medium may improve recovery and survival. The addition of 10 to 20% cell culture-grade bovine serum albumin to serum-free freezing medium may also increase postfreeze survival.

Other variations of freeze medium formulations include high (up to 90%) concentrations of serum which presumably supplies some cryoprotection as well as additional growth factors; use of a balanced salt solution designed for hypothermal conditions in place of medium designed for 37°C incubation; and the addition of apoptotic inhibitors which may prevent delayed onset cell death following recovery.²¹ Optimum formulations for individual cell lines need to be determined empirically.

Equipment

Cryopreservation vials

There are two materials to choose from for cryopreservation vials: glass or plastic. Glass vials are more difficult to work with; they need to be sterilized before use, they do not come with labels (information is imprinted into the glass), they need to be sealed with a hot flame, and they can be difficult to open. However, they are preferred for long-term storage (many years) of valuable cultures and are considered fail-safe once properly sealed. ATCC uses glass vials for the storage of seed stocks which are placed in the lower level of the liquid nitrogen tank. Plastic vials are used for the storage of distribution stocks.

Plastic vials come in two varieties: those with an internal thread and silicone gasket and those with an external thread. The internal-thread version was the first commercially available, but has some disadvantages over the external-thread version. For example, while the silicone gasket provides an excellent seal, it needs to be tightened just right; too tight or too loose and the vial will leak.



Cryopreservation

Controlled-rate freezing chambers

There are several means to achieve a cooling rate of -1°C per minute. The best is with a computer controlled, programmable electronic freezing unit (such as CryoMed Freeze) which rigorously maintains this rate of cooling. This is the method used exclusively at ATCC. Such equipment is relatively expensive and absolutely necessary for only the most sensitive cells.

A less costly approach is to place the cryopreservation vials into an insulated chamber and cool for 24 hours in a mechanical freezer at -70°C or lower. There are several commercially available freezing chambers which achieve a cooling rate very close to the ideal -1°C per minute (Mr. Frosty, Nalgene ATCC® No. 5100-0001; or StrataCooler, Stratagene ATCC® No. 400005). Alternately, the vials can be placed into a polystyrene box with 15-mm (3/4 inch) thick walls and 1-liter capacity packed with paper, cotton wool, or foam peanuts for insulation.

Liquid nitrogen freezer storage

The ultra-low temperatures (below -130°C) required for long-term storage can be maintained by specialized electric freezers or more commonly by liquid nitrogen freezers. There are two basic types of liquid nitrogen storage systems: immersing vials in the liquid and holding vials in the vapor phase above the liquid. The liquid-phase system holds more nitrogen and thus requires less maintenance. However, there is always a chance that some liquid will enter improperly sealed vials which may explode when retrieved. For this reason ATCC strongly recommends storage in vapor-phase systems.

Vapor-phase systems create a vertical temperature gradient within the container. The temperature in the liquid nitrogen at the bottom will be -196° C, whereas the temperature at the top will vary depending upon the amount of liquid nitrogen at the bottom as well as the amount of time the container is opened. To ensure safe storage of cells, be sure to keep enough liquid nitrogen in the container so that the temperature at the top is -130° C or lower. All storage systems should be equipped with temperature alarms.

Cryopreservation procedure

The procedure below will work for most cell cultures and should be modified as needed. Freeze medium formulations for all ATCC cell lines are provided on the Product Information Sheet. Harvest cells in exponential growth.

- Check your cell culture for contamination from bacteria, fungi, mycoplasma, and viruses (see Contamination, page 277) immediately before cryopreservation. In most cases, the results of the contamination screen will be available some time after the cultures are cryopreserved (10 to 14 days). If contamination is confirmed, then destroy the frozen material.
- Prepare a freeze medium consisting of complete growth medium and 5% DMSO (ATCC® No. 4-X). Do not add undiluted DMSO to a cell suspension as dissolution of DMSO in aqueous

- solutions gives off heat.
- 3. Collect cells by gentle centrifugation (10 minutes at $125 \times g$) and resuspend them in the freeze medium at a concentration of
 - 1×10^6 to 5×10^6 viable cells/ml. Continue to maintain the cells in culture until the viability of the recovered cells is confirmed (see Step 9).
- Label the appropriate number of vials with the name of the cell line and the date. Then add 1 to 1.8 ml of the cell suspension to each of the vials (depending upon the volume of the vial) and seal.
- Allow cells to equilibrate in the freeze medium at room temperature for a minimum of 15 minutes but no longer than 40.
 This time is usually taken up in dispensing aliquots of the cell suspension into the vials. After 40 minutes, cell viability may decline due to the DMSO.
- 6. Place the vials into a pre-cooled (4°C), controlled-rate freeze chamber and place the chamber in a mechanical freezer at -70°C (or colder) for at least 24 hours. Alternately, use a pre-cooled (4°C) programmable freezer unit set to cool the vials at -1°C per minute until a temperature below -40°C is achieved and then set to abruptly drop to -130°C.
- 7. Quickly transfer the vials to a liquid nitrogen or –130°C freezer. Frozen material will warm up at a rate of 10°C per minute and cells will deteriorate rapidly if warmed above –50°C.
- 8. Record the location and details of the freeze.
- 9. After 24 hours at –130°C, remove one vial, restore the cells in culture medium, and determine their viability and sterility.

Recovery of cryopreserved cells

The cell solution in the frozen vial needs to be warmed as rapidly as possible and then immediately combined with complete culture medium and seeded into an appropriate flask. While cells grown in monolayers can be recovered from cryopreservation in multiwell plates, the results are not as consistent as with flasks.

Some cell lines, such as hybridoma cultures, take several days before they fully recover from cryopreservation. Some hybridomas show low viability on the first day in culture and will generate cellular debris. Viability for most cells declines and reaches a nadir at 24 hours post-thaw. Most, if not all, of this decline appears to be due to apoptosis (as opposed to necrosis) induced by the stress of the cryopreservation process.²² After this time point, cells begin to recover and enter exponential growth.

- Prepare a culture vessel (T-75 flask) so that it contains at least 10 ml of the appropriate culture medium equilibrated for temperature and pH.
- 2. Remove the vial from the liquid nitrogen freezer and thaw by gentle agitation in a 37°C water bath (or a bath set at the normal growth temperature for that cell line). Thaw rapidly until ice crystals have melted (approximately 2 minutes).
- 3. Remove the vial from the water bath and decontaminate it by dipping in or spraying with 70% ethanol. Follow strict aseptic conditions in a laminar flow tissue culture hood for all further



Cryopreservation

manipulations.

- 4. Unscrew the top of the vial and transfer the contents to a sterile centrifuge tube containing 9 ml complete growth medium. Remove the cryoprotectant agent by gentle centrifugation (10 minutes at $125 \times g$). Discard the supernatant, taking care not to disturb the soft pellet, and resuspend the cells in 1 or 2 ml of complete growth medium. Pipette gently to loosen the pellet and break apart clumps. (If the cells normally grow as clusters, avoid over-pipetting during resuspension.) Transfer the cell suspension into the medium in the culture vessel and mix thoroughly.
- 5. Examine the cultures after 24 hours and subculture as needed.



Contamination

Contamination of cells in culture can arise from many sources including other cell lines, reagents, supplies such as pipettes and culture vessels, equipment such as tissue culture hoods and incubators, and laboratory personnel. While the potential for contamination is constant, the risk can be reduced or eliminated by proper precautions: using only reagents of known quality and sterility, quarantining new cell lines until they are tested to be free from contamination, performing routine maintenance and cleaning of all equipment, and properly training cell culture personnel.

Checking for microbial contamination

When most bacterial contamination occurs, it usually occurs within a few days and is typically obvious to the naked eye: Distinct changes to the medium such as turbidity, presence of particles visible in suspension, and a rapid decline in pH (yellow color, indicating acidity) are all indicators of bacterial contamination. Fastidious bacteria species that grow very slowly can be difficult to detect.

Fungal contaminants may or may not cause a change in the pH of the medium and can be distinguished from bacteria by checking for the presence of filamentous structures in the suspension. Yeast cells are larger than bacteria, but may not appreciably change the pH of the medium, and will appear as separate round or ovoid particles.

Microbacterial media which can be used to test for bacterial and fungal contamination include blood agar, thioglycollate broth, tryptic soy broth, BHI broth, Sabouraud broth, YM broth, and nutrient broth with 2% yeast extract.²³ However, some microbial contamination is not apparent. For example, the use of antibiotics can suppress bacterial growth and thus mask contamination. Some viral infections do not alter the morphology of the cells, and detection of mycoplasma contamination requires specific assays.

Mycoplasma contamination

Cell lines are screened for mycoplasma contamination by direct (agarose and broth culture) and indirect (Hoechst) methods. ^{24,25} For example, the fluorochrome Hoechst DNA stain will bind to the DNA of mycoplasma and the organisms can be detected easily when examined using a microscope equipped with appropriate fluorescence optics. The direct culture method requiring both broth and agar will permit isolation of cultivable strains as apparent by appearance of characteristic mycoplasma colonies on the agar medium.

Both direct and indirect methods for detection of mycoplasma are used at ATCC several times while a cell line is expanded for the preparation of the token, seed and distribution stocks.

Cell cultures can be submitted to the ATCC Mycoplasma Testing Service. See the ATCC Services section of the website for details.

Treating for microbial contamination

Eliminating contamination from a cell line is time consuming and does not always work. Discarding the culture and starting over is preferred. However, if the cells are unique and irreplaceable, one should first identify the contaminant and select a suitable antibiotic for treatment. It is best to test the contaminating microbe for its antibiotic sensitivity prior to treatment; this allows for a shorter treatment time and limits exposure of the cell line to potentially damaging reagents.

The cells are cultured for 1 to 2 weeks in the presence of the antibiotic, and then cultured without antibiotic for 1 to 2 months. At this point, the line should be retested with a very sensitive test method to make sure that the culture is clean. Periodic retesting should be employed to make sure that the contaminant does not reappear. Since antibiotics may be toxic to cells, a selected population that no longer exhibits qualities of the parental line may result. It may be necessary to examine the cured culture to determine if it is sufficiently similar to the original line.

Cellular cross-contamination

Cross-contamination of one cell line with another can sometimes lead to the replacement of the original cell with the contaminant, particularly when the contaminant grows faster than the original line. HeLa cells are perhaps the most famous example of a cross-contaminating cell line overtaking and then masquerading as the original.

In the 1950s and 1960s, many continuous lines were unknowingly cross-contaminated with other cell lines including HeLa cells. In the 1970s and 1980s, as many as one in three cell lines deposited in cell repositories were imposters. ²⁶ This cross-contamination was only uncovered with the development of suitable genetic markers beginning in 1967. ²⁷ Indeed, several "unique" cell lines in ATCC's collection turned out to be HeLa cells upon further study. Despite the confirmation of their HeLa cell origin, cytogenetic analysis suggests that there are differences among these HeLa-derived cell lines. Several of them possess unique properties. However, these cell lines should not be used as functional models of their claimed tissues of origin.

More recently, ATCC and other cell repositories have used DNA polymorphisms in addition to enzyme polymorphisms, HLA typing, and karyotyping to confirm the identity of their cell lines. One of the most reliable methods to study DNA polymorphisms is the profiling of short tandem repeats (STR) by PCR amplification followed by capillary electrophoresis.²⁸ STR profiles for all ATCC human cell lines are available on the website in the catalogue descriptions.

Routine testing

Test cell cultures on a regular basis to ensure the absence of contamination from both microorganisms as well as from other cell lines. If contamination is found, discard the culture and start fresh with a new stock.

Biosafety

The need for precautions when experimenting with cells in culture depends upon the source and nature of the biological material, the experimental procedure, and the laboratory/containment conditions. Since every situation is different, the risks need to be identified and appropriate precautions need to be taken before any work begins.

More information on risk assessment and precautions can be found in the Center for Disease Control (CDC) publication Biosafety in Microbiological and Biomedical Laboratories, (BMBL) 4th Edition.²⁹ The text of this publication is available in its entirety online (www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm). Information on agent risk assessment and a description of the four biosafety levels can be found in this publication.

ATCC assigns a biosafety level (BSL) to each cell line for purposes of packaging for safe shipment. When a cell line is known to contain an etiologic agent, ATCC classification is at least comparable to the BSL assigned to the agent by the CDC and in some cases the ATCC designation is more restrictive. ATCC follows federal biosafety guidelines and takes several factors into consideration when assessing potential hazard.

Biosafety Level 1

 Cell lines with animal origin not included under Biosafety Level 2

Biosafety Level 2

- Cell lines that harbor mycoplasma or any other BSL 2 agent*
- Cell lines exposed to or transformed by a primate oncogenic virus
- Primate cell lines that contain viruses
- Cell lines carrying a part of certain viral genomes, even if whole virus is not released from the cell ³⁰

As the recipient of a cell line, take into account not only the nature of the material but also the manipulations employed during its handling when assessing the potential laboratory risk. For example, procedures involving large volumes of cell lines that contain HIV or that include manipulation of HIV in high concentration should be conducted under BSL 3 conditions.²⁹

Note: It is not possible to screen cell lines for the presence of every agent. For added precaution, ATCC handles all cell lines under BSL 2 practices, even those classified as BSL 1. It is prudent to treat all mammalian cell lines as potentially hazardous.

*Some patent cell lines at ATCC are known to be contaminated with mycoplasma and are noted as such in the catalog.



Glossary

The following glossary was originally published by the Tissue Culture Association Terminology Committee in 1990.31

Anchorage-dependent cells or cultures. Cells, or cultures derived from them, which will grow, survive, or maintain function only when attached to a surface such as glass or plastic. The use of this term does not imply that the cells are normal or that they are not neoplastically transformed.

Aneuploid. The situation in which the nucleus of a cell does not contain an exact multiple of the haploid number of chromosomes, one or more chromosomes being present in greater or lesser number than the rest. The chromosomes may or may not show rearrangements.

Aseptic technique. Procedures used to prevent the introduction of fungi, bacteria, viruses, mycoplasma, or other microorganisms in cell, tissue, and organ cultures. Although these procedures are used to prevent microbial contamination of cultures, they also prevent crosscontamination of cell cultures as well.

Attachment efficiency. The percentage of cells plated (seeded, inoculated) which attach to the surface of the culture vessel within a specified period of time. The conditions under which such a determination is made should always be stated.

Autocrine cell. In animals, a cell which produces hormones, growth factors, or other signaling substances for which it also expresses the corresponding receptors. (See also *endocrine* and *paracrine*.)

Cell culture. Term used to denote the maintenance or cultivation of cells in vitro including the culture of single cells. In cell cultures, the cells are no longer organized into tissues.

Cell generation time. The interval between consecutive divisions of a cell. This interval can best be determined, at present, with the aid of cinephotomicrography. This term is not synonymous with *population doubling time*.

Cell hybridization. The fusion of two or more dissimilar cells leading to the formation of a synkaryon.

Cell line. A *cell line* arises from a primary culture at the time of the first successful subculture. The term implies that cultures from it consist of lineages of cells originally present in the primary culture. The terms *finite* or *continuous* are used as prefixes if the status of the culture is known. If not, the term *line* will suffice. The term *continuous line* replaces the term *established line*. In any published description of a culture, one must make every attempt to publish the characterization or history of the culture. If such has already been published, a reference to the original publication must be made. In obtaining a culture from another laboratory, the proper designation of the culture, as originally named and described, must be maintained and any deviations in cultivation from the original must be reported in any publication.

Cell strain. A cell strain is derived either from a primary culture or a cell line by the selection or cloning of cells having specific properties or markers. In describing a cell strain, its specific features must be defined. The terms *finite* or *continuous* are to be used as prefixes if the status of the culture is known. If not, the term *strain* will suffice. In any published description of a cell strain, one must make every attempt to publish the characterization or history of the strain. If such has already been published, a reference to the original publication must be made. In obtaining a culture from another laboratory, the proper designation of the culture, as originally named and described, must be maintained and any deviations in cultivation from the original must be reported in any publication.

Chemically defined medium. A nutritive solution for culturing cells in which each component is specifiable and, ideally, is of known chemical structure.

Clone. In animal cell culture terminology, a population of cells derived from a single cell by mitoses. A clone is not necessarily homogeneous and therefore the terms *clone* and *cloned* do not indicate homogeneity in a cell population, genetic or otherwise.

Cloning efficiency. The percentage of cells plated (seeded, inoculated) that form a clone. One must be certain that the colonies formed arose from single cells in order to properly use this term. (See *colony forming efficiency*.)

Colony forming efficiency. The percentage of cells plated (seeded, inoculated) that form a colony.

Contact inhibition of locomotion. A phenomenon characterizing certain cells in which two cells meet, locomotory activity diminishes and the forward motion of one cell over the surface of the other is stopped.

Continuous cell culture. A culture which is apparently capable of an unlimited number of population doublings, often referred to as an immortal cell culture. Such cells may or may not express the characteristics of in vitro neoplastic or malignant transformation. (See also *immortalization*.)

Crisis. A stage of the in vitro transformation of cells. It is characterized by reduced proliferation of the culture, abnormal mitotic figures, detachment of cells from the culture substrate, and the formation of multinucleated or giant cells. During this massive cultural degeneration, a small number of colonies usually, but not always, survives and gives rise to a culture with an apparent unlimited in vitro lifespan. This process was first described in human cells following infection with an oncogenic virus (SV40). See also *cell line, in vitro transformation*, and *in vitro senescence*.

Cryopreservation. Ultra-low temperature storage of cells, tissues, embryos, or seeds. This storage is usually carried out using temperatures below –100°C.



Glossary

Density-dependent inhibition of growth. Mitotic inhibition correlated with increased cell density.

Differentiated. Cells in culture that maintain all or much of the specialized structure and function typical of the cell type in vivo.

Diploid. The state of the cell in which all chromosomes, except sex chromosomes, are two in number and are structurally identical with those of the species from which the culture was derived.

Electroporation. Creation by means of an electrical current of transient pores in the plasmalemma usually for the purpose of introducing exogenous material, especially DNA, from the medium.

Embryo culture. In vitro development or maintenance of isolated mature or immature embryos.

Embryogenesis. The process of embryo initiation and development.

Endocrine cell. In animals, a cell which produces hormones, growth factors or other signaling substances for which the target cells, expressing the corresponding receptors, are located at a distance. (See also *autocrine* or *paracrine*.)

Epithelial-like. Resembling or characteristic of, or having the form or appearance of, epithelial cells. In order to define a cell as an epithelial cell, it must possess characteristics typical of epithelial cells. Often one can be certain of the histologic origin and/or function of the cells placed into culture and, under these conditions, one can be reasonably confident in designating the cells as epithelial. The individual reporting on such cells should use as many parameters as possible in assigning this term to a culture. Until a rigorous definition is possible, it is more correct to use the term *epithelial-like*.

Euploid. The situation in which the nucleus of a cell contains exact multiples of the haploid number of chromosomes.

Feeder layer. A layer of cells (usually irradiated or mitomycin-C treated) that are nondividing but metabolically active, upon which a fastidious cell type is cultured.

Finite cell culture. A culture which is capable of only a limited number of population doublings after which the culture ceases proliferation. (See *in vitro senescence*.)

Heterokaryon. A cell possessing two or more genetically different nuclei in a common cytoplasm, usually derived as a result of cell-to-cell fusion.

Heteroploid. A culture whose cells contain chromosome number other than the diploid number. This is a term used only to describe a culture and is not used to describe individual cells. Thus, a heteroploid culture would be one which contains an euploid cells.

Histiotypic. The in vitro resemblance of cells in culture to a tissue in form, function, or both. For example, a suspension of fibroblast-like cells may secrete a glycosaminoglycan-collagen matrix and the result is a structure resembling fibrous connective tissue, which is, therefore, histiotypic. This term is not meant to be used along with *culture*. Thus, a tissue culture system demonstrating form and function typical of the cells in vivo would be said to be histiotypic.

Homokaryon. A cell possessing two or more genetically identical nuclei in a common cytoplasm, derived as a result of cell-to-cell fusion.

Hybridoma. The cell which results from the fusion of an antibody-producing tumor cell (myeloma) and an antigenically stimulated normal plasma cell. Such cells are constructed because they produce a single antibody directed against the antigen epitope which stimulated the plasma cell. This antibody is referred to as a *monoclonal antibody*.

Immortalization. The attainment by a cell culture, whether by perturbation or intrinsically, of the attributes of a continuous cell line. An immortalized cell is not necessarily one which is neoplastically or malignantly transformed.

In vitro senescence. The inability of a vertebrate cell culture to grow beyond a finite number of population doublings. Neither invertebrate nor plant cell cultures exhibit this property.

In vitro transformation. A heritable change occurring in cells in culture, either intrinsically or from treatment with chemical carcinogens, oncongenic viruses, irradiation, transfection with oncogenes, etc., which leads to the acquisition of altered morphological, antigenic, neoplastic, proliferative, or other properties. This expression is distinguished from in vitro neoplastic transformation in that the alterations occurring in the cell population may not always include the ability of the cells to produce tumors in appropriate hosts. The type of transformation should always be specified in any description.

Organ culture. The maintenance or growth of organ primordia or the whole or parts of an organ in vitro in a way that may allow differentiation and preservation of the architecture and/or function.

Paracrine. In animals, a cell which produces hormones, growth factors or other signaling substances for which the target cells, expressing the corresponding receptors, are located in its vicinity, or in a group adjacent to it. (See also *autocrine* and *endocrine*.)

Passage. The transfer or transplantation of cells, with or without dilution, from one culture vessel to another. It is understood that any time cells are transferred from one vessel to another, a certain portion of the cells may be lost, and therefore dilution of cells, whether deliberate or not, may occur. This term is synonymous with *subculture*.



Glossary

Passage number. The number of times the cells in the culture have been subcultured or passaged. In descriptions of this process, the ratio or dilution of the cells should be stated so that the relative cultural "age" can be ascertained.

Plating efficiency. This term originally encompassed the terms attachment efficiency, cloning efficiency, and colony forming efficiency; it is now better to use one or more of them in its place because plating is not sufficiently descriptive. (See attachment efficiency, cloning efficiency, and colony forming efficiency.)

Population density. The number of cells per unit area or volume of a culture vessel, or the number of cells per unit volume of medium in a suspension culture.

Population doubling level. The total number of population doublings of a cell line or strain since its initiation in vitro. This term is synonymous with *cell generation time*.

Population doubling time. The interval, calculated during the logarithmic phase of growth in which cells double in number; for example, 1.0×10^6 cells increase to 2.0×10^6 cells. This term is not synonymous with *cell generation time*.

Primary culture. A culture started from cells, tissues, or organs taken directly from organisms. A primary culture may be regarded as such until it is successfully subcultured for the first time. It then becomes a *cell line*.

Pseudodiploid. The condition in which the number of chromosomes in a cell is diploid but, as a result of chromosomal rearrangements, the karyotype is abnormal and linkage relationships may be disrupted.

Saturation density. The maximum cell number attainable, under specified culture conditions, in a culture vessel. This term is usually expressed as the number of cells per square centimeter in a monolayer culture or the number of cells per cubic centimeter in a suspension culture.

Suspension culture. A type of culture in which cells, or aggregates of cells, multiply while suspended in liquid medium.

Synkaryon. A hybrid cell which results from the fusion of the nuclei it carries.

Tissue culture. The maintenance or growth of tissues in vitro in a way that may allow differentiation and preservation of the architecture and/or function.

Transfection. The transfer, for the purpose of genomic integration, of foreign DNA into cells in culture. The traditional microbiological usage of this term implied that the DNA being transferred was derived from a virus. The definition as stated here describes the general transfer of DNA irrespective of its source.

Undifferentiated. With animal cells, this is the state wherein the cell in culture lacks the specialized structure and/or function of the cell type in vivo.



Formulations of Media Not Available from ATCC

There are cell lines in the collection that require media which are not currently sold by ATCC. Some media may require the addition of serum or other supplements. Refer to the Product Information Sheet for specific recommendations for each cell line.

ACL-4

A medium for the cultivation of human tumor cell lines with or without serum.³² It consists of a 1:1 mixture of RPMI 1640 or Ham's F12 or F12K and Dulbecco's Modification of Eagle's Medium plus the following:

| Insulin | 20 µg/ml |
|----------------------------------|----------|
| Transferrin | 10 µg/ml |
| Sodium selenite | 25 nM |
| Hydrocortisone | 50 nM |
| Epidermal growth factor | 1 ng/ml |
| Ethanolamine | 10 µM |
| Phosphorylethanolamine | 10 µM |
| Triiodothyronine | 100 pM |
| Bovine serum albumin | |
| 4-(2-Hydroxyethyl)-1-piperazine- | _ |
| ethanesulfonic acid buffer | 10 mM |
| Sodium pyruvate | 0.5 mM |
| Glutamine | 2 mM |

Eagle's Basal Medium (BME)

A simple synthetic medium in routine use. Not adequate for more fastidious cell types.^{34,35}

| L-Amino Acids | mg/l |
|------------------|--------|
| Arginine | |
| Cystine | 12.0 |
| Glutamine | 292.0 |
| Histidine | 7.75 |
| Isoleucine | 26.0 |
| Leucine | 26.0 |
| Lysine | 29.0 |
| Methionine | 7.5 |
| Phenylalanine | 16.0 |
| Threonine | 24.0 |
| Tryptophan | 4.0 |
| Tyrosine | |
| Valine | 23.0 |
| Vitamins | |
| Biotin | 0.24 |
| Choline | 0.12 |
| Folic acid | 0.44 |
| Nicotinamide | 0.12 |
| Pantothenic acid | 0.20 |
| Pyridoxal HCI | 0.20 |
| Riboflavin | |
| Thiamine HCI | 0.34 |
| Inorganic Salts | |
| NaCl | 5845.0 |
| KCI | 373.0 |
| Na,HPO,·H,O | 138.0 |
| MgCl, · 6H, Ó | |
| CaCl | |
| 4 | |

| NaHCO,1680.0 |
|------------------|
| Other Components |
| Glucose900.0 |
| Phenol red 5.0 |

Ham's MCDB 105 and 107

The formulation for MCDB 107 is given below. For MCDB 105, change glycine to 7.51 mg/liter and omit KCl.

| glycine to 7.51 mg/liter and omit KCl. | |
|--|-------------|
| L-Amino Acids | mg/l |
| Alanine | |
| Arginine HCI | 211.7 |
| Asparagine · H ₃ O | 15.0 |
| Aspartic acid | 13.3 |
| Cysteine HCI · H ₂ O | 8.8 |
| Glutamic acid | |
| Glutamine | 365.3 |
| Glycine | 22.5 |
| Histidine HCI · H ₂ O | |
| Isoleucine ² | |
| Leucine | |
| Lysine HC | |
| Methionine | |
| Phenylalanine | |
| Proline | |
| Serine | |
| Threonine | |
| Tryptophan | |
| Tyrosine, 2Na · 2H ₂ O | |
| Valine | |
| Vitamins | |
| d-Biotin | 0.007 |
| D-Ca pantothenate | |
| Choline chloride | |
| Folinic acid, calcium salt | |
| i-Inositol | |
| Niacinamide | |
| Pyridoxine HCI | |
| Riboflavin | |
| Thiamine HCI | |
| Vitamin B ₁₂ | |
| Inorganic Salts | |
| CaCl ₂ (anhyd) | 110.99 |
| KCI | |
| KH,PO ₄ | |
| $MgSO_4$ (anhyd) | 120.38 |
| NaCl | 6546.00 |
| CuSO ₄ · 5H ₂ O | |
| FeSO ₄ · 7H ₂ O | |
| MnSO ₄ · 5H ₂ O | |
| (NH ₄) ₆ Mo ₂ O ₂₄ ·4H ₂ O | |
| | |
| NiCl ₂ · 6H ₂ O H ₂ SeO ₃ | 0.00387 |
| Na ₂ SiO ₃ ·9H ₂ O | n 147 |
| SnCl ₂ · 2H ₂ O | 0 00011 |
| NH ₄ VO ₃ | 0.00011 |
| $ZnSO_4 \cdot 7H_2O$ | 1 1 / λ |
| Other Components | |
| o the components | |
| | |



Formulations of Media Not Available from ATCC

| Adenine HCI | 1.72 |
|------------------------------------|---------|
| Linoleic acid | 0.0028 |
| DL-a-Lipoic acid | 0.0021 |
| Putrescine 2HC | 0.00016 |
| Thymidine | 0.0727 |
| Glucose | 720.64 |
| HEPES | 7149.00 |
| Phenol red, sodium salt | 1.242 |
| Sodium pyruvate | 110.0 |
| Adjust pH to 7.6. Use $2\% CO_2$. | |

HITES

A medium for the selective cultivation of small cell lung carcinomas, adenocarcinomas, and tumors from other organ sites with and without serum.³⁶ It can be formulated using either RPMI 1640 or a 1:1 mixture of DMEM:F12K and supplemented with the following components:

| Insulin | 5 µg/ml |
|-----------------|--------------------------|
| Transferrin | 10 μg/ml |
| Sodium selenite | 3.0 x 10 ⁻⁸ M |
| Hydrocortisone | 1.0 x 10 ⁻⁸ M |
| β-Estradiol | 1.0 x 10 ⁻⁸ M |
| HEPES | 10 mM |
| L-Glutamine | 2 mM |

Mitsuhashi and Maramorosch Medium for Insect Tissue Culture

M and M medium is no longer available commercially. Consult reference 37 for additional information on this formulation.

| Inorganic Salts | mg/l |
|---------------------------------------|--------|
| CaCl ₃ · 2H ₃ O | 200.0 |
| KCI | 200.0 |
| MgCl ₃ · 6H ₃ O | 100.0 |
| NaCI | |
| NaHCO ₃ | 120.0 |
| $NaH_2PO_4 \cdot H_2O$ | 200.0 |
| Other Components | |
| D-Glucose | 4000.0 |
| Lactalbumin hydrolysate | 6500.0 |
| Yeastolate | 5000.0 |
| Adjust pH to 6.5 with 2N KOH. | |

Waymouth's MB 752/1

Capable of supporting growth of several cell lines in the absence of serum. $^{\rm 34,38}$

| L-Amino Acids | mg/l |
|---------------|-------|
| Arginine HCI | 75.0 |
| Aspartic acid | 60.0 |
| Cysteine HCI | 90.0 |
| Cystine | 15.0 |
| Glutamic acid | 150.0 |
| Glutamine | 350.0 |
| Glycine | 50.0 |
| Histidine HCI | 150.0 |
| Isoleucine | 25.0 |
| Leucine | 50.0 |
| Lysine HCI | 240.0 |
| Methionine | |

| Phenylalanine | 50.0 |
|---|--------|
| Proline | 50.0 |
| Threonine | 75.0 |
| Tryptophan | 40.0 |
| Tyrosine | 40.0 |
| Valine | 65.0 |
| Vitamins | |
| Ascorbic acid | 17.5 |
| Biotin | 0.02 |
| Ca-pantothenate | 1.0 |
| Choline HCI | |
| Cyanocobalamin (Vitamin B ₁₂) | 0.2 |
| Folic acid | |
| m-Inositol | 1.0 |
| Nicotinamide | 1.0 |
| Pyridoxine HCI | 1.0 |
| Riboflavin | 1.0 |
| Thiamine HCI | 10.0 |
| Inorganic Salts | |
| NaCl | 6000.0 |
| KCI | 150.0 |
| Na ₃ HPO ₄ | 300.0 |
| KH,PO, | |
| MgCl, · 6H,O | 240.0 |
| MgSO ₄ · 7H̄ ₂ O | 200.0 |
| CaCl, · 2H, O | |
| NaHCO, | 2240.0 |
| Other Components | |
| Glucose | 5000.0 |
| Hypoxanthine | 25.0 |
| Glutathione | 15.0 |
| Phenol red | 10.0 |
| | |



References

- 1. Hayflick L and Moorhead PS. Exp. Cell Res. 25: 585-621, 1961.
- 2. Rubin H. Mech. Aging Devel. 98: 1-35, 1997.
- 3. Wright WE and Shay JW. Nat. Biotechnol. 20: 682-688, 2002.
- 4. Capstick PB et al. Exp. Cell Res. 44: 119-128, 1966.
- Osato et al. J. Immunology 124: 533-540, 1980.
- 6 McLimans WF. Chapter 5. In: Growth, Nutrition and Metabolism of Cells in Culture, Vol.1. Rothblat GH and Cristofalo VJ, eds. New York: Academic Press; 1972.
- Freshney RI. Chapter 8. In: Culture of Animal Cells, 5th ed. New York: Wiley-Liss; 2005.
- 8. Shipman C. Proc. Soc. Exp. Biol. Med. 130: 305, 1969.
- 9. People CA et al. In Vitro 18: 755, 1982.
- 10. Spierenberg GT et al. Cancer Res. 44: 2253, 1984.
- 11. Zigler JS et al. In Vitro 21: 282, 1985.
- Karmiol S. Development of serum free media. In: Master JRW, ed. Animal Cell Culture, 3rd ed. Oxford: Oxford University Press; 2000
- Jacoby WB and Pasten IH, eds. Chapter 7. In: Methods in Enzymology: Cell Culture, Vol. 58. New York: Academic Press; 1979.
- 14. Bolin SR et al. J. Virol. Methods 48: 211, 1994.
- 15. Hyclone, Inc. Art to Science 15(1): 1-6, 1996.
- Rudnicki MA and McBurney MW.Teratocarcinomas and Embryonic Stem Cells - A Practical Approach. Oxford: IRL Press Ltd.; 1987: p. 75.
- 17. Weiss SA et al. Meth. Mol. Biol. 39: 65, 1995.
- Gabridge MG. Vessels for Cell and Tissue Culture. In: Setting Up and Maintenance of Tissue and Cell Cultures. Shannon: Elsevier Scientific Publishers; 1985: pp. 1-19.
- Balin A.K et al. Atmospheric Stability in Cell Culture Vessels. In Vitro 12:687-692, 1977.
- 20. Gey GO. Am. J. Cancer 17: 752-756, 1933.
- 21. Baust JM et al. Cell Preservation Technology 1:17-31, 2002.
- 22. Baust JM et al. Cell Preservation Technology 1:63-80, 2002.
- Quality Control Methods for Cell Lines, 2nd edition. Rockville, MD: ATCC: 1992.
- Freshney RI. Culture of Animal Cells, 5th ed. New York: Wiley-Liss;
 2005.
- 25. Lincoln CK and Gabridge MG. Cell culture contamination: Sources, consequences, prevention and elimination. In: Mather JP and Barnes D, eds. Animal Cell Culture Methods. San Diego: Academic Press; 1998: p. 49.
- 26. O'Brien SJ. Science 98: 7656-7658, 2001.
- 27. Gartler SM. NCI Monograph 26: 167-195, 1967.
- 28. Master JR. et al. Proc. Natl. Acad. Sci. USA 98:8012-8017, 2001.
- U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories, 4th ed. HHS Publication No. (CDC) 93-8395. Washington DC: U.S. Government Printing Office; 1999. Available online at www.cdc.gov/od/ohs/biosfty/bmbl4/ bmbl4toc.htm.
- 30. Weiss RA. NCI Monograph 48: 183-189, 1978.
- 31. Schaeffer Wl. In Vitro Cell. Dev. Biol. 26: 97-101, 1990.
- 32. Gazdar AF and Oie HB. Cancer Res. 46: 798-806 and 6011-6012, 1986.
- 33. Macy ML and Shannon JE. Preparation of medium ATCC-CRCM30.TCA Manual 3:617-622, 1977.

- 34. Morton HJ. In Vitro 6:89-108, 1970.
- 35. Eagle H. Science 122: 501-504, 1955.
- 36. Carney DN et al. Proc. Natl. Acad. Sci. USA 78:3185-3189, 1981.
- 37. Mitsuhashi J. Adv. Cell Culture 2: 133-196, 1982.
- 38. Waymouth C. J. Natl. Cancer Inst. 22: 1003-1017, 1959.



Cooperation Partners

Increasing success

Regarded as standard experimental reagents, cell lines of the highest quality are recommended to ensure reproducible and reliable results of life science products. Manufacturers of quality kits and reagents routinely and exclusively use ATCC cell lines for product development and optimization. Performance of an optimized product can suffer when used with cell lines of inferior quality.


To make it easier to determine the quality of reagents and applications using cell lines, ATCC is working with other life science companies to promote the use of authenticated, quality-tested cell lines by providing access to references, protocols and detailed information about cell cultures and applications.

amaxa Nucleofector® technology is a well established method for the transfer into cells of various substrates (e.g., DNA, siRNA, peptides). Novel electrical parameters in combination with cell-type-specific solutions allow the manipulation of cell lines, including primary cells and lines that previously were not amenable to gene transfer. Optimized protocols (e.g., for specific ATCC cell lines) guarantee high transfer efficiencies along with superior cell survival and minimal impact on cell metabolism.

"It is our goal to enable researchers to genetically manipulate the cell types they consider the best experimental model. In looking for a partner, we needed a large collection of cell lines that came with reliable authentication. ATCC was the obvious choice."

> Rainer Christine CEO amaxa

Transfection efficiency 24h [%]





Roche Applied Science set the standard for transfection with FuGENE® 6 Transfection Reagent. With the launch of FuGENE® HD Transfection Reagent, Roche again takes transfection to a higher level, enabling the results needed to advance your research. An extensive database of cell lines transfected using these reagents is available at www.roche-applied-science.com/transfection with links to protocols and information regarding the successful transfection of hundreds of ATCC cell lines. Choose transfection reagents from Roche Applied Science combined with fresh, authenticated cell lines from ATCC to move closer to discovery.

"Combining the strengths of our organizations through this agreement creates a powerful offering for life sciences research."

Lonnie Shoff Senior Vice President Roche Applied Science

HeLa cells (ATCC® CRL-2™)





(A) FuGENE® HD Transfection Reagent

(B) L2K

References and optimized protocols are available for many ATCC cell lines for both amaxa Nucleofector® and Roche FuGENE® Transfection Reagents. See the cell-specific Product Information Page on the ATCC website for more information.

The ATCC catalogue marks (e.g. ATCC® No. CRL-1647™) are trademarks owned by the American Type Culture Collection. ATCC retains all right, title and interest in these trademarks.

These products are for laboratory research use only. Not intended for use in humans, animals or for diagnostics.



Disclaimers

Product use and warranty

Purchasers of ATCC products must accept the terms of a Material Transfer Agreement (MTA) before the items can be shipped. ATCC products are distributed for research purposes only for use only in the purchaser's laboratory. They are not intended for human, clinical, or diagnostic use. Some materials, such as items from the Wistar and Johns Hopkins Special Collections, may require completion of special use agreements before shipment.

The viability of ATCC cultures is guaranteed for 30 days from the date of shipment. A culture that was handled according to the instructions on the Product Information Sheet and which is found to be unsatisfactory during the 30-day period following shipment will be replaced. Products other than cell lines and hybridomas are guaranteed to meet or exceed specifications on the Product Information Sheet or certificate of analysis until the expiration date on the product label, provided the product is stored and handled properly. In case of damaged shipments notify ATCC as soon as possible. The responsibility of ATCC is limited to the purchase price of the product. ATCC is not liable for any claims or damages arising from the use of the product.

Information about the sources and applications for ATCC cell lines was supplied by the depositor at the time of deposit or may have been published in the scientific literature. Most of this information has not been verified by ATCC beyond routine quality control tests for characterization and contamination. While ATCC uses reasonable efforts to include accurate and up-to-date information in both the online and print catalogs, we make no warranties or representations as to its accuracy. ATCC is not responsible for any errors or omissions or for the results obtained from the use of this information.

For complete details regarding the use and warranty of ATCC products, see the MTA on page 287 or on the website.

Regulatory compliance

Information about permits is provided as a courtesy to ATCC customers. Anyone purchasing ATCC cultures is ultimately responsible for obtaining permits. Contact the appropriate regulatory agency for current requirements.

The distribution of material derived from endangered wildlife or a marine mammal is conditional on the issuance of a valid permit by the U.S. Fish and Wildlife Service or the National Marine Fisheries Service and will not be consummated until a permit is obtained from the appropriate agency.

Trademarks

ATCC trademarks and trade-names: UNIPLUS®, EXPRESS-CHECK™ YOUR DISCOVERIES BEGIN WITH US®, THE GLOBAL BIORESOURCE CENTER™, ATCC CULTURES™, ATCC BIOPRODUCTS™, ATCC SPECIAL COLLECTIONS™, ATCC SERVICES™, ATCC Genuine Cultures™, ATCC Licensed Derivative®, BioEscrow™, ATCC Reference Material™, ATCC Fungal Allergen Standard™, ATCC Proficiency Standard™, ATCC Standard Reference Material™ and any and all ATCC Catalogue Marks (example ATCC® CRL-1740™) or ATCC specific designations of ATCC Materials sold by ATCC, or other trademarks registered or owned by the ATCC.You expressly agree not to use the ATCC trademark, the ATCC trade-name, or the ATCC Catalogue numbers in any way in connection with any offering, marketing, promotion or sale without ATCC′s prior written agreement.

SelecT™ is a trademark of The Automation Partnership.
CryoMed® is a trademark of Thermo Electron Corp.
Nalgene® is a trademark of Nalge Nunc International.
StrataCooler® is a trademark of Stratagene.
ELF® and Molecular Probes are trademarks of Molecular Probes, Inc.
Netscape™ is a trademark of Netscape.
Firefox® is a trademark of Mozilla Corporation.
Amaxa®, Nucleofector® and Nucleofection® are registered trademarks of amaxa GmbH.
FuGENE® is a registered trademark of Fugent, L.L.C., USA.



MATERIAL TRANSFER AGREEMENT ("MTA")

Last updated September 8, 2003

IMPORTANT! PLEASE READ CAREFULLY BEFORE SUBMITTING ORDER. THIS IS A CONTRACT.

This MTA is between you ("Purchaser" or "you") and American Type Culture Collection, a not-for-profit organization ("ATCC" or "we" or "us"). You must have an approved, current ATCC account to place an order.

Scope of Use

YOU MAY MAKE AND USE THE MATERIAL ("MATERIAL") PROVIDED TO YOU BY ATCC AND ALL REPLICATES AND DERIVATIVES FOR RESEARCH PURPOSES IN YOUR LABORATORY ONLY. THE MATERIAL IS NOT INTENDED FOR USE IN HUMANS. PURCHASER AGREES THAT MATERIAL DESIGNATED AS BIOSAFETY LEVEL 2 OR 3 CONSTITUTES KNOWN PATHOGENS AND THAT OTHER MATERIAL NOT SO DESIGNATED AND REPLICATES OR DERIVATIVES MAY BE PATHOGENIC UNDER CERTAIN CONDITIONS. PURCHASER ASSUMES ALL RISK AND RESPONSIBILITY IN CONNECTION WITH THE RECEIPT, HANDLING, STORAGE, DISPOSAL, TRANSFER AND USE OF THE MATERIAL INCLUDING WITHOUT LIMITATION TAKING ALL APPROPRIATE SAFETY AND HANDLING PRECAUTIONS TO MINIMIZE HEALTH OR ENVIRONMENTAL RISK. PURCHASER AGREES THAT ANY ACTIVITY UNDERTAKEN WITH THE MATERIAL AND REPLICATES OR DERIVATIVES WILL BE CONDUCTED IN COMPLIANCE WITH ALL APPLICABLE GUIDELINES, LAWS AND REGULATIONS.

The Purchaser shall not distribute, sell, lend or otherwise transfer the Material or Replicates for any reason. Any commercial use of the Material, Replicates, and Derivatives is prohibited without ATCC's prior written authorization. Your use of the Materials may require a license from a third party or be subject to third party restrictions ("Third Party Terms"), which you may learn about in the catalogue description for the particular Material and which are either set forth below or available at www.atcc.org. If there is a conflict between this MTA and Third Party Terms, the latter shall govern. Use of the Materials may be subject to the intellectual property rights of a third party not listed in the ATCC catalogue or website, and ATCC makes no representation or warranty that such rights do not exist. Purchaser shall have the sole responsibility for obtaining any intellectual property licenses necessitated by its possession and use of Materials.

"Replicate" means any biological or chemical material that represents a substantially unmodified copy of the Material such as, but not limited to, material produced by growth of cells or microorganisms or amplification of Material. "Derivative" means material created from the Material that is substantially modified to have new properties such as, but not limited to, recombinant DNA clones made using a vector purchased from ATCC.

Warranty; Warranty Disclaimer

ATCC warrants that cells and microorganisms shall be viable upon shipment from ATCC for a period of thirty (30) days ("Warranty Period"). ATCC warrants that any Material other than cells and microorganisms shall meet the specifications on the product information sheet, certificate of analysis, and/or catalogue description until the expiration date on the product label. The exclusive remedy for breach of this warranty is, at ATCC's option, (a) refund of the fee paid to ATCC for such Material (exclusive of shipping and handling charges), or (b) replacement of the Material. The exclusive remedy applies under the condition that Purchaser handles and stores Material as described in the product sheet. To obtain the exclusive remedy, Purchaser must report the lack of viability to ATCC's Technical Service Department within the Warranty Period. Any expiration date specified on the Material shipment documentation states the expected remaining useful life, but does not constitute a warranty or extend any applicable warranty period. EXCEPT AS EXPRESSLY PROVIDED ABOVE, THE MATERIAL AND ANY TECHNICAL INFORMATION AND ASSISTANCE PROVIDED BY ATCC ARE PROVIDED AS-IS, WITHOUT WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TYPICALITY, SAFETY, ACCURACY AND NON-INFRINGEMENT.

Compliance With Laws

PURCHASER IS SOLELY RESPONSIBLE FOR COMPLIANCE WITH ALL APPLICABLE FOREIGN AND DOMESTIC, FEDERAL, STATE AND LOCAL STATUTES, ORDINANCES AND REGULATIONS. Without limiting the generality of the foregoing, any shipment of the Material to countries outside the United States must comply with all applicable U.S. laws, including the U.S. export control laws and related regulations.

Indemnification

Purchaser hereby agrees to indemnify, defend and hold harmless ATCC and its contributors against all third party claims, losses, expenses and damages (including reasonable attorneys' fees) arising out of or relating to the use, receipt, handling, storage, transfer, disposal and other activities relating to the Material, Replicates or Derivatives. All non-monetary settlements will be subject to ATCC's consent.

Limitation of Liability

IN NO EVENT WILL ATCC OR ITS CONTRIBUTORS BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAM-



AGES OF ANY KIND IN CONNECTION WITH OR ARISING OUT OF THE MTA, MATERIALS, REPLICATES OR DERIVATIVES (WHETHER IN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, STATUTE OR OTHERWISE) EVEN IF ATCC HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL ATCC'S CUMULATIVE LIABILITY EXCEED THE FEES PAID BY PURCHASER UNDER THIS MTA FOR THE TWELVE (12) MONTH PERIOD PRECEDING THE DATE OF THE EVENT GIVING RISE TO THE CLAIM. Purchaser agrees that the limitations of liability set forth in this Agreement shall apply even if a limited remedy provided hereunder fails of its essential purpose.

Intellectual Property; Identification

ATCC and/or its contributors shall retain ownership of all right, title and interest in the Material and Replicates. The Material, Replicates and Derivatives are subject to the restrictions noted in the "Scope of Use" section above. Purchaser agrees to acknowledge ATCC and any contributor indicated by ATCC as the source of the Material in all publications and patent applications that reference the Material. If required by the contributor of the Material, ATCC may inform the contributor of Purchaser's identity. ATCC retains all right, title and interest in the trademarks registered or owned by the ATCC and any and all ATCC catalogue numbers or ATCC specific designations of Material sold by the ATCC.

Payment; Taxes; Shipping

Payments may be made by check, wire transfer or credit card. Unless payment in advance is required by ATCC or its exclusive distributors, payments due to ATCC or its exclusive distributors shall be invoiced to Purchaser and due within thirty (30) days after the date of invoice. Any payments not made within such thirty (30) day period will be subject to an interest charge of one percent (1%) per month or the maximum rate allowed by applicable law, whichever is less. Purchaser is responsible for all taxes, duties, tariffs and permit fees assessed in connection with this MTA and the Material. Purchaser shall, upon demand, pay to ATCC or its exclusive distributors an amount equal to any such tax(es), duties, tariffs and permit fees actually paid or required to be collected or paid by ATCC or its exclusive distributors. ATCC and/or its exclusive distributors shall have no obligation hereunder to accept an order from Purchaser unless Purchaser has satisfied the requirements of ATCC's applicable credit approval process and has satisfied any additional credit requirements imposed by ATCC, which may include providing ATCC with a deposit, letter of credit, or payment in advance, as requested.

ATCC will package the Material for shipping in accordance with applicable laws and regulations. Purchaser is responsible for ensuring that all permits required for Purchaser to receive its order are obtained and that sufficient proof of such permits is provided to ATCC. ATCC will notify Purchaser when orders are submitted without the necessary permits, and Purchaser will have a two (2) month period after such notification to supply proof of the necessary permit(s) before an order will be cancelled. A processing fee will be charged if special processing or packaging is necessary. All Materials are shipped Free on Board (FOB) point of shipment, freight prepaid via carrier of our choice and added to your invoice. If the Material is lost or damaged during shipment, ATCC will replace such Material at no additional charge, provided that you have reported lost or damaged shipments to the applicable carrier and notified ATCC's Customer Service Department or exclusive distributor within fourteen (14) days from invoice date. Each invoice will be mailed the following day after Material is shipped from the point of shipment.

Miscellaneous

This Agreement shall be governed by the laws of the Commonwealth of Virginia, without reference to its choice of law rules. Purchaser may not assign or otherwise transfer this Agreement or any rights or obligations under this Agreement, whether by operation of law or otherwise. Any attempted assignment or transfer will be void and of no force or effect. This MTA and all documents incorporated herein by reference constitute the entire agreement between ATCC and Purchaser with respect to the Material and supersede all previous agreements or representations. ATCC may revise this MTA at any time. The revisions will be effective immediately upon posting the revised MTA on ATCC's Website available at www.atcc.org, or otherwise making available the revised MTA to Purchaser. The version of the MTA applicable to any Materials ordered by Purchaser shall be the version in effect at the time of order placement.

The following additional provisions are Third Party Terms which apply to the purchase of I.M.A.G.E. cDNA clones: **Agreement in Good Faith Concerning Use and Distribution of Arrayed cDNA Clones (revised 09/00)**

You are being provided with I.M.A.G.E. Consortium [LLNL] cDNA clones ("CLONES") and/or associated products ("PRODUCTS") (referred to collectively as "IMAGE MATERIALS"), in order to advance the public interest and to advance the objectives of the institutions that developed the original libraries from which these clones were derived ("Originators"). The Originators are the beneficiaries of, and may independently enforce, this Agreement.

Use of IMAGE Materials

By accepting IMAGE MATERIALS you are agreeing in good faith to the following terms. If you are unable to agree to these terms, you must immediately return IMAGE MATERIALS along with all copies and replicas thereof.

- (a) You will use the IMAGE MATERIALS in compliance with all applicable laws, governmental regulations and guidelines, including National Institutes of Health guidelines or their equivalent, and any regulations or guidelines pertaining to research with humans, or animals, or with recombinant DNA.
- (b) You may use CLONES to produce PROGENY, and to create DERIVATIVE PRODUCTS. You may use IMAGE MATERIALS, PROGENY, and DERIVATIVE PRODUCTS for commercial or non-commercial purposes, except for the purpose of redistribution of CLONES or PROGENY. Accordingly, you may transfer CLONES or PROGENY to additional parties only if 1) this document in its entirety accompanies CLONES or PROGENY, and 2) you transfer CLONES or PROGENY at no cost to such additional parties. "PROGENY" means an unmodified descendant from CLONES or any comparable bacterial stock derived from CLONES (STOCK). "DERIVATIVE PRODUCTS" means any modification or product of CLONES or PRODUCTS that is not a PROGENY or a STOCK.
- (c) You will include the unique and specific identifier of each arrayed clone (which was initially assigned by Lawrence Livermore National Laboratory, Livermore, California, and accompanies the IMAGE MATERIALS) in data pertaining to the IMAGE MATERIALS submitted to public databases and in resulting publications. This nomenclature consists of the term "I.M.A.G.E. Consortium CloneID" followed by a five to seven digit number. You will refer publicly (including but not limited to electronic and print versions of articles and databases) to these arrayed cDNA clones as the "I.M.A.G.E. Consortium [LLNL] cDNA Clones," and will reference the following publication: "The I.M.A.G.E. Consortium: An Integrated Molecular Analysis of Genomes and their Expression," Lennon, G.G., Auffray, C., Polymeropoulos, M., and Soares, M.B. [1996] Genomics 33, pgs. 151-152. In INTERNET/World Wide Web publications and databases, you agree to provide electronic referencing (e.g. 'anchors' and/or 'hotlinks') to the I.M.A.G.E. Consortium homepage, currently located at URL http://image.llnl.gov.
- (d) You agree that the IMAGE MATERIALS are experimental in nature and are being provided without warranty, express or implied, including any implied warranty of merchantability or fitness for a particular purpose or freedom from infringement of any patent or other proprietary right of a third party.
- (e) You agree to hold harmless and indemnify the Regents of the University of California, Lawrence Livermore National Laboratory, the Department of Energy, the U.S. Government, the originators of the library from which clones were arrayed, the provider of the IMAGE MATERIALS and persons acting on their behalf, for any claim asserted by a third party related to your possession, use, storage or disposal of the IMAGE MATERIALS.
- (f) You understand that the ownership of the unarrayed cDNA libraries from which clones were arrayed is retained by the Originators of those libraries. Any new patentable developments or inventions first made by any party using the arrayed clones will remain the property of the inventing party. This Agreement does not constitute the Originators waiver of any patent rights.
- (g) Any correspondence concerning the I.M.A.G.E. Agreement should be addressed to: The Regents of the University of California Industrial Partnerships and Commercialization Program Attn: I.M.A.G.E. Consortium P.O. Box 808, L-795 Livermore, CA 94550 Phone: (925) 422-6416 Fax: (925) 423-8988.

Any correspondence concerning the ATCC Material Transfer Agreement should be addressed to ATCC, Attention: Office of Licensing, Contracts and Compliance, P.O. Box 1549, Manassas, VA 20108 U.S.A., Phone: (703) 365-2700 or contact us at licensing@atcc.org.